{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/descartesmbogning/Deciphering_Bacteriophage_Revolution/blob/main/Patent_TopicModeling.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "j7nUM_BMRY1D"
      },
      "outputs": [],
      "source": [
        "import pandas as pd\n",
        "import numpy as np\n",
        "import matplotlib.pyplot as plt\n",
        "import seaborn as sns"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "Gdy8NI_lSZEb"
      },
      "outputs": [],
      "source": [
        "import spacy\n",
        "import codecs\n",
        "import re\n",
        "from wordcloud import STOPWORDS\n",
        "\n",
        "import nltk\n",
        "from nltk.corpus import stopwords\n",
        "from nltk.stem import WordNetLemmatizer\n",
        "\n",
        "from sklearn.feature_extraction.text import TfidfVectorizer, CountVectorizer\n",
        "from sklearn import decomposition\n",
        "from nltk.stem.porter import PorterStemmer"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "3m_8ZWnbL0Et",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "d5f510b8-bca9-4417-f561-65a7ec6389e1"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Drive already mounted at /content/drive; to attempt to forcibly remount, call drive.mount(\"/content/drive\", force_remount=True).\n"
          ]
        }
      ],
      "source": [
        "from google.colab import drive\n",
        "drive.mount('/content/drive')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 660
        },
        "id": "_yRRTyNvSZFv",
        "outputId": "61bc2026-5dd7-4b78-964a-08727ccfe5bb"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "6427\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "      # Jurisdiction Kind        Display Key              Lens ID  \\\n",
              "0  6343           FR   A1      FR 2878165 A1  088-886-194-310-021   \n",
              "1  4170           EP   A2      EP 0174810 A2  114-080-007-142-359   \n",
              "2  4522           EP   A3      EP 0192033 A3  145-504-884-019-37X   \n",
              "3  2680           WO   A1  WO 2007/083793 A1  147-331-231-570-922   \n",
              "4   111           WO   A1  WO 2007/114139 A1  148-164-161-664-368   \n",
              "\n",
              "  Publication Date  Publication Year Application Number Application Date  \\\n",
              "0       26/05/2006              2006       FR 0412364 A       22/11/2004   \n",
              "1       19/03/1986              1986      EP 85306331 A       05/09/1985   \n",
              "2       04/05/1988              1988      EP 86100279 A       10/01/1986   \n",
              "3       26/07/2007              2007    JP 2007050890 W       22/01/2007   \n",
              "4       11/10/2007              2007    JP 2007056579 W       28/03/2007   \n",
              "\n",
              "            Priority Numbers Earliest Priority Date  \\\n",
              "0               FR 0412364 A             22/11/2004   \n",
              "1  CA 489897 A;;GB 8422819 A             10/09/1984   \n",
              "2              US 69200185 A             14/01/1985   \n",
              "3            JP 2006014314 A             23/01/2006   \n",
              "4            JP 2006105143 A             06/04/2006   \n",
              "\n",
              "                                               Title  \\\n",
              "0  New (mutant) netrin-4, netrin-1, netrin-3, ant...   \n",
              "1  Multidrug resistance in mammalian cell lines a...   \n",
              "2             CHLAMYDIA MAJOR OUTER MEMBRANE PROTEIN   \n",
              "3  PANNING METHOD UTILIZING PHOTOREACTIVE GROUP A...   \n",
              "4   PHAGE DISPLAY BY NOVEL FILAMENTOUS BACTERIOPHAGE   \n",
              "\n",
              "                                            Abstract  \\\n",
              "0  (Mutant) netrin-4 protein (I) comprising at le...   \n",
              "1  @ A method for isolating a cDNA specific for P...   \n",
              "2  @ Methods and compositions are provided for th...   \n",
              "3  [PROBLEMS] To provide a method for ensuring th...   \n",
              "4  [PROBLEMS] To provide a phage display vector w...   \n",
              "\n",
              "                                          Applicants  \\\n",
              "0  CENTRE NAT RECH SCIENT;;I V S INST DES VAISSEA...   \n",
              "1                                   HSC RES DEV CORP   \n",
              "2                  CHIRON CORP;;WASHINGTON RES FOUND   \n",
              "3  UNIV TOYAMA NAT UNIV CORP;;HATANAKA YASUMARU;;...   \n",
              "4                                   UCHIYAMA FUMIAKI   \n",
              "\n",
              "                                           Inventors  \\\n",
              "0                        PLOUET JEAN;;ALEMANY MONICA   \n",
              "1                                     RIORDAN JOHN R   \n",
              "2  AGABIAN, NINA;;STEPHENS, RICHARD;;KUO, CHO-CHO...   \n",
              "3                 HATANAKA YASUMARU;;SADAKANE YUTAKA   \n",
              "4                                   UCHIYAMA FUMIAKI   \n",
              "\n",
              "                                              Owners  \\\n",
              "0                                                NaN   \n",
              "1  HSC RESEARCH DEVELOPMENT CORPORATION (1993-03-24)   \n",
              "2  CHIRON CORPORATION (1999-10-13);;CHIRON CORPOR...   \n",
              "3                                                NaN   \n",
              "4                                                NaN   \n",
              "\n",
              "                                    URL       Document Type Has Full Text  \\\n",
              "0  https://lens.org/088-886-194-310-021  Patent Application            no   \n",
              "1  https://lens.org/114-080-007-142-359  Patent Application           yes   \n",
              "2  https://lens.org/145-504-884-019-37X       Search Report           yes   \n",
              "3  https://lens.org/147-331-231-570-922  Patent Application           yes   \n",
              "4  https://lens.org/148-164-161-664-368  Patent Application           yes   \n",
              "\n",
              "   Cites Patent Count  Cited by Patent Count  Simple Family Size  \\\n",
              "0                   1                      7                   1   \n",
              "1                   0                     31                   6   \n",
              "2                   2                      0                   7   \n",
              "3                   1                      2                   2   \n",
              "4                   1                      0                   5   \n",
              "\n",
              "   Extended Family Size  Sequence Count  \\\n",
              "0                    21               0   \n",
              "1                    10               0   \n",
              "2                    10               2   \n",
              "3                     2               4   \n",
              "4                     5              38   \n",
              "\n",
              "                                 CPC Classifications  \\\n",
              "0          A61K38/18;;A61P9/00;;A61P19/00;;A61P25/00   \n",
              "1       C07K14/705;;C12N15/65;;C12N15/65;;C07K14/705   \n",
              "2  A61K39/00;;C12Q1/689;;C07K14/295;;C07K2319/00;...   \n",
              "3                 C07D229/02;;G01N33/582;;G01N33/554   \n",
              "4  C07K14/005;;C12N15/1037;;C12N2795/14122;;C12N1...   \n",
              "\n",
              "                                IPCR Classifications US Classifications  \\\n",
              "0  A61K38/17;;A61K39/395;;A61K48/00;;A61P9/00;;A6...                NaN   \n",
              "1                    C07K14/705;;C12N1/21;;C12N15/65                NaN   \n",
              "2        A61K39/00;;C07K14/295;;C12Q1/68;;G01N33/569                NaN   \n",
              "3  G01N33/53;;C07D229/02;;G01N33/15;;G01N33/543;;...                NaN   \n",
              "4  C12N15/09;;C07K14/005;;C12N1/21;;C12N7/00;;C12...                NaN   \n",
              "\n",
              "   NPL Citation Count  NPL Resolved Citation Count  \\\n",
              "0                   1                            1   \n",
              "1                   0                            0   \n",
              "2                   5                            4   \n",
              "3                   2                            1   \n",
              "4                  24                           22   \n",
              "\n",
              "                             NPL Resolved Lens ID(s)  \\\n",
              "0                                085-906-838-714-934   \n",
              "1                                                NaN   \n",
              "2  010-400-221-345-21X;;015-638-157-208-094;;030-...   \n",
              "3                                016-994-266-998-256   \n",
              "4  050-417-296-901-112;;051-984-368-264-261;;058-...   \n",
              "\n",
              "                         NPL Resolved External ID(s)  \\\n",
              "0        11038171;;pmc2192657;;10.1083/jcb.151.2.221   \n",
              "1                                                NaN   \n",
              "2  pmc263342;;6469350;;10.1128/iai.45.3.637-641.1...   \n",
              "3                 10.2174/1568026023394182;;11944820   \n",
              "4  16277371;;10.1021/cr000261r;;10.1006/jmbi.1999...   \n",
              "\n",
              "                                       NPL Citations  Legal Status  \n",
              "0  KOCH M ET AL: \"A NOVEL MEMBER OF THE NETRIN FA...  DISCONTINUED  \n",
              "1                                                NaN       EXPIRED  \n",
              "2  INFECTION AND IMMUNITY, vol. 45, no. 3, Septem...       EXPIRED  \n",
              "3  HATANAKA Y. ET AL.: \"Photoaffinity Labeling in...       PENDING  \n",
              "4  KEHOE J.W. ET AL.: \"Filamentous phage display ...       PENDING  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-e53276c5-4155-4f32-8ca7-c2b81420af2e\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>#</th>\n",
              "      <th>Jurisdiction</th>\n",
              "      <th>Kind</th>\n",
              "      <th>Display Key</th>\n",
              "      <th>Lens ID</th>\n",
              "      <th>Publication Date</th>\n",
              "      <th>Publication Year</th>\n",
              "      <th>Application Number</th>\n",
              "      <th>Application Date</th>\n",
              "      <th>Priority Numbers</th>\n",
              "      <th>Earliest Priority Date</th>\n",
              "      <th>Title</th>\n",
              "      <th>Abstract</th>\n",
              "      <th>Applicants</th>\n",
              "      <th>Inventors</th>\n",
              "      <th>Owners</th>\n",
              "      <th>URL</th>\n",
              "      <th>Document Type</th>\n",
              "      <th>Has Full Text</th>\n",
              "      <th>Cites Patent Count</th>\n",
              "      <th>Cited by Patent Count</th>\n",
              "      <th>Simple Family Size</th>\n",
              "      <th>Extended Family Size</th>\n",
              "      <th>Sequence Count</th>\n",
              "      <th>CPC Classifications</th>\n",
              "      <th>IPCR Classifications</th>\n",
              "      <th>US Classifications</th>\n",
              "      <th>NPL Citation Count</th>\n",
              "      <th>NPL Resolved Citation Count</th>\n",
              "      <th>NPL Resolved Lens ID(s)</th>\n",
              "      <th>NPL Resolved External ID(s)</th>\n",
              "      <th>NPL Citations</th>\n",
              "      <th>Legal Status</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>6343</td>\n",
              "      <td>FR</td>\n",
              "      <td>A1</td>\n",
              "      <td>FR 2878165 A1</td>\n",
              "      <td>088-886-194-310-021</td>\n",
              "      <td>26/05/2006</td>\n",
              "      <td>2006</td>\n",
              "      <td>FR 0412364 A</td>\n",
              "      <td>22/11/2004</td>\n",
              "      <td>FR 0412364 A</td>\n",
              "      <td>22/11/2004</td>\n",
              "      <td>New (mutant) netrin-4, netrin-1, netrin-3, ant...</td>\n",
              "      <td>(Mutant) netrin-4 protein (I) comprising at le...</td>\n",
              "      <td>CENTRE NAT RECH SCIENT;;I V S INST DES VAISSEA...</td>\n",
              "      <td>PLOUET JEAN;;ALEMANY MONICA</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/088-886-194-310-021</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>1</td>\n",
              "      <td>7</td>\n",
              "      <td>1</td>\n",
              "      <td>21</td>\n",
              "      <td>0</td>\n",
              "      <td>A61K38/18;;A61P9/00;;A61P19/00;;A61P25/00</td>\n",
              "      <td>A61K38/17;;A61K39/395;;A61K48/00;;A61P9/00;;A6...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>085-906-838-714-934</td>\n",
              "      <td>11038171;;pmc2192657;;10.1083/jcb.151.2.221</td>\n",
              "      <td>KOCH M ET AL: \"A NOVEL MEMBER OF THE NETRIN FA...</td>\n",
              "      <td>DISCONTINUED</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>4170</td>\n",
              "      <td>EP</td>\n",
              "      <td>A2</td>\n",
              "      <td>EP 0174810 A2</td>\n",
              "      <td>114-080-007-142-359</td>\n",
              "      <td>19/03/1986</td>\n",
              "      <td>1986</td>\n",
              "      <td>EP 85306331 A</td>\n",
              "      <td>05/09/1985</td>\n",
              "      <td>CA 489897 A;;GB 8422819 A</td>\n",
              "      <td>10/09/1984</td>\n",
              "      <td>Multidrug resistance in mammalian cell lines a...</td>\n",
              "      <td>@ A method for isolating a cDNA specific for P...</td>\n",
              "      <td>HSC RES DEV CORP</td>\n",
              "      <td>RIORDAN JOHN R</td>\n",
              "      <td>HSC RESEARCH DEVELOPMENT CORPORATION (1993-03-24)</td>\n",
              "      <td>https://lens.org/114-080-007-142-359</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>yes</td>\n",
              "      <td>0</td>\n",
              "      <td>31</td>\n",
              "      <td>6</td>\n",
              "      <td>10</td>\n",
              "      <td>0</td>\n",
              "      <td>C07K14/705;;C12N15/65;;C12N15/65;;C07K14/705</td>\n",
              "      <td>C07K14/705;;C12N1/21;;C12N15/65</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>EXPIRED</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>4522</td>\n",
              "      <td>EP</td>\n",
              "      <td>A3</td>\n",
              "      <td>EP 0192033 A3</td>\n",
              "      <td>145-504-884-019-37X</td>\n",
              "      <td>04/05/1988</td>\n",
              "      <td>1988</td>\n",
              "      <td>EP 86100279 A</td>\n",
              "      <td>10/01/1986</td>\n",
              "      <td>US 69200185 A</td>\n",
              "      <td>14/01/1985</td>\n",
              "      <td>CHLAMYDIA MAJOR OUTER MEMBRANE PROTEIN</td>\n",
              "      <td>@ Methods and compositions are provided for th...</td>\n",
              "      <td>CHIRON CORP;;WASHINGTON RES FOUND</td>\n",
              "      <td>AGABIAN, NINA;;STEPHENS, RICHARD;;KUO, CHO-CHO...</td>\n",
              "      <td>CHIRON CORPORATION (1999-10-13);;CHIRON CORPOR...</td>\n",
              "      <td>https://lens.org/145-504-884-019-37X</td>\n",
              "      <td>Search Report</td>\n",
              "      <td>yes</td>\n",
              "      <td>2</td>\n",
              "      <td>0</td>\n",
              "      <td>7</td>\n",
              "      <td>10</td>\n",
              "      <td>2</td>\n",
              "      <td>A61K39/00;;C12Q1/689;;C07K14/295;;C07K2319/00;...</td>\n",
              "      <td>A61K39/00;;C07K14/295;;C12Q1/68;;G01N33/569</td>\n",
              "      <td>NaN</td>\n",
              "      <td>5</td>\n",
              "      <td>4</td>\n",
              "      <td>010-400-221-345-21X;;015-638-157-208-094;;030-...</td>\n",
              "      <td>pmc263342;;6469350;;10.1128/iai.45.3.637-641.1...</td>\n",
              "      <td>INFECTION AND IMMUNITY, vol. 45, no. 3, Septem...</td>\n",
              "      <td>EXPIRED</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>2680</td>\n",
              "      <td>WO</td>\n",
              "      <td>A1</td>\n",
              "      <td>WO 2007/083793 A1</td>\n",
              "      <td>147-331-231-570-922</td>\n",
              "      <td>26/07/2007</td>\n",
              "      <td>2007</td>\n",
              "      <td>JP 2007050890 W</td>\n",
              "      <td>22/01/2007</td>\n",
              "      <td>JP 2006014314 A</td>\n",
              "      <td>23/01/2006</td>\n",
              "      <td>PANNING METHOD UTILIZING PHOTOREACTIVE GROUP A...</td>\n",
              "      <td>[PROBLEMS] To provide a method for ensuring th...</td>\n",
              "      <td>UNIV TOYAMA NAT UNIV CORP;;HATANAKA YASUMARU;;...</td>\n",
              "      <td>HATANAKA YASUMARU;;SADAKANE YUTAKA</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/147-331-231-570-922</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>yes</td>\n",
              "      <td>1</td>\n",
              "      <td>2</td>\n",
              "      <td>2</td>\n",
              "      <td>2</td>\n",
              "      <td>4</td>\n",
              "      <td>C07D229/02;;G01N33/582;;G01N33/554</td>\n",
              "      <td>G01N33/53;;C07D229/02;;G01N33/15;;G01N33/543;;...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>2</td>\n",
              "      <td>1</td>\n",
              "      <td>016-994-266-998-256</td>\n",
              "      <td>10.2174/1568026023394182;;11944820</td>\n",
              "      <td>HATANAKA Y. ET AL.: \"Photoaffinity Labeling in...</td>\n",
              "      <td>PENDING</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>111</td>\n",
              "      <td>WO</td>\n",
              "      <td>A1</td>\n",
              "      <td>WO 2007/114139 A1</td>\n",
              "      <td>148-164-161-664-368</td>\n",
              "      <td>11/10/2007</td>\n",
              "      <td>2007</td>\n",
              "      <td>JP 2007056579 W</td>\n",
              "      <td>28/03/2007</td>\n",
              "      <td>JP 2006105143 A</td>\n",
              "      <td>06/04/2006</td>\n",
              "      <td>PHAGE DISPLAY BY NOVEL FILAMENTOUS BACTERIOPHAGE</td>\n",
              "      <td>[PROBLEMS] To provide a phage display vector w...</td>\n",
              "      <td>UCHIYAMA FUMIAKI</td>\n",
              "      <td>UCHIYAMA FUMIAKI</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/148-164-161-664-368</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>yes</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>5</td>\n",
              "      <td>5</td>\n",
              "      <td>38</td>\n",
              "      <td>C07K14/005;;C12N15/1037;;C12N2795/14122;;C12N1...</td>\n",
              "      <td>C12N15/09;;C07K14/005;;C12N1/21;;C12N7/00;;C12...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>24</td>\n",
              "      <td>22</td>\n",
              "      <td>050-417-296-901-112;;051-984-368-264-261;;058-...</td>\n",
              "      <td>16277371;;10.1021/cr000261r;;10.1006/jmbi.1999...</td>\n",
              "      <td>KEHOE J.W. ET AL.: \"Filamentous phage display ...</td>\n",
              "      <td>PENDING</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-e53276c5-4155-4f32-8ca7-c2b81420af2e')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-e53276c5-4155-4f32-8ca7-c2b81420af2e button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-e53276c5-4155-4f32-8ca7-c2b81420af2e');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-12414ab2-bb22-4c1e-82ea-bcb7c38f1d46\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-12414ab2-bb22-4c1e-82ea-bcb7c38f1d46')\"\n",
              "            title=\"Suggest charts.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-12414ab2-bb22-4c1e-82ea-bcb7c38f1d46 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ]
          },
          "metadata": {},
          "execution_count": 4
        }
      ],
      "source": [
        "df = pd.read_csv ('/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/patent_phage_lens_12072023.csv')\n",
        "pd.set_option('display.max_columns', None)\n",
        "print(len(df))\n",
        "df.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "GYfiUBxrStTX",
        "outputId": "d78a8d37-2f07-4f55-c9de-2ca8e75fde65"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "5145"
            ]
          },
          "metadata": {},
          "execution_count": 5
        }
      ],
      "source": [
        "# Convert 'Publication Year' to integers\n",
        "df['Publication Year'] = df['Publication Year'].astype(int)\n",
        "\n",
        "# Filter based on 'Publication Year' column\n",
        "df = df[df['Publication Year'] >= 2003]\n",
        "len(df)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "WBPCsGRMKnto"
      },
      "outputs": [],
      "source": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "bN_vhjVQfN47",
        "outputId": "ff632cfb-3e56-4d74-b345-604607361344"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "5145"
            ]
          },
          "metadata": {},
          "execution_count": 6
        }
      ],
      "source": [
        "df = df[(~pd.isnull(df['Abstract'])) & (~pd.isnull(df['Title']))]\n",
        "len(df)"
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "taAS0BuOLE4B"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df = df.set_index(['Lens ID','Publication Year'])\n",
        "df"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "QZW6MAnWJb-U",
        "outputId": "c118f258-85cf-410b-ba7c-97279f73c37e"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                         # Jurisdiction Kind  \\\n",
              "Lens ID             Publication Year                           \n",
              "088-886-194-310-021 2006              6343           FR   A1   \n",
              "147-331-231-570-922 2007              2680           WO   A1   \n",
              "148-164-161-664-368 2007               111           WO   A1   \n",
              "161-684-752-020-329 2004              3085           JP    A   \n",
              "089-102-410-621-069 2004              3892           JP    A   \n",
              "...                                    ...          ...  ...   \n",
              "179-151-089-030-564 2019              6156           CZ   U1   \n",
              "014-594-233-943-253 2020              6024           CZ   U1   \n",
              "115-179-292-453-581 2006              6234           AU   A1   \n",
              "069-774-923-021-970 2005              6214           AU   A1   \n",
              "125-476-374-578-517 2017              4736           GB   D0   \n",
              "\n",
              "                                            Display Key Publication Date  \\\n",
              "Lens ID             Publication Year                                       \n",
              "088-886-194-310-021 2006                  FR 2878165 A1       26/05/2006   \n",
              "147-331-231-570-922 2007              WO 2007/083793 A1       26/07/2007   \n",
              "148-164-161-664-368 2007              WO 2007/114139 A1       11/10/2007   \n",
              "161-684-752-020-329 2004                JP 2004097032 A       02/04/2004   \n",
              "089-102-410-621-069 2004                JP 2004099465 A       02/04/2004   \n",
              "...                                                 ...              ...   \n",
              "179-151-089-030-564 2019                    CZ 33381 U1       12/11/2019   \n",
              "014-594-233-943-253 2020                    CZ 33918 U1       14/04/2020   \n",
              "115-179-292-453-581 2006              AU 2006/201041 A1       06/04/2006   \n",
              "069-774-923-021-970 2005              AU 2005/227384 A1       24/11/2005   \n",
              "125-476-374-578-517 2017                GB 201709104 D0       19/07/2017   \n",
              "\n",
              "                                     Application Number Application Date  \\\n",
              "Lens ID             Publication Year                                       \n",
              "088-886-194-310-021 2006                   FR 0412364 A       22/11/2004   \n",
              "147-331-231-570-922 2007                JP 2007050890 W       22/01/2007   \n",
              "148-164-161-664-368 2007                JP 2007056579 W       28/03/2007   \n",
              "161-684-752-020-329 2004                JP 2002260418 A       05/09/2002   \n",
              "089-102-410-621-069 2004                JP 2002260419 A       05/09/2002   \n",
              "...                                                 ...              ...   \n",
              "179-151-089-030-564 2019                 CZ 201936608 U       09/09/2019   \n",
              "014-594-233-943-253 2020                 CZ 202037223 U       06/02/2020   \n",
              "115-179-292-453-581 2006               AU 2006/201041 A       10/03/2006   \n",
              "069-774-923-021-970 2005               AU 2005/227384 A       27/10/2005   \n",
              "125-476-374-578-517 2017                 GB 201709104 A       07/06/2017   \n",
              "\n",
              "                                                        Priority Numbers  \\\n",
              "Lens ID             Publication Year                                       \n",
              "088-886-194-310-021 2006                                    FR 0412364 A   \n",
              "147-331-231-570-922 2007                                 JP 2006014314 A   \n",
              "148-164-161-664-368 2007                                 JP 2006105143 A   \n",
              "161-684-752-020-329 2004                                 JP 2002260418 A   \n",
              "089-102-410-621-069 2004                                 JP 2002260419 A   \n",
              "...                                                                  ...   \n",
              "179-151-089-030-564 2019                                  CZ 201936608 U   \n",
              "014-594-233-943-253 2020                                  CZ 202037223 U   \n",
              "115-179-292-453-581 2006              AU 2001/027834 A;;AU 2006/201041 A   \n",
              "069-774-923-021-970 2005              AU 2000/077021 A;;AU 2005/227384 A   \n",
              "125-476-374-578-517 2017                                  GB 201709104 A   \n",
              "\n",
              "                                     Earliest Priority Date  \\\n",
              "Lens ID             Publication Year                          \n",
              "088-886-194-310-021 2006                         22/11/2004   \n",
              "147-331-231-570-922 2007                         23/01/2006   \n",
              "148-164-161-664-368 2007                         06/04/2006   \n",
              "161-684-752-020-329 2004                         05/09/2002   \n",
              "089-102-410-621-069 2004                         05/09/2002   \n",
              "...                                                     ...   \n",
              "179-151-089-030-564 2019                         09/09/2019   \n",
              "014-594-233-943-253 2020                         06/02/2020   \n",
              "115-179-292-453-581 2006                         12/01/2001   \n",
              "069-774-923-021-970 2005                         14/09/2000   \n",
              "125-476-374-578-517 2017                         07/06/2017   \n",
              "\n",
              "                                                                                  Title  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              New (mutant) netrin-4, netrin-1, netrin-3, ant...   \n",
              "147-331-231-570-922 2007              PANNING METHOD UTILIZING PHOTOREACTIVE GROUP A...   \n",
              "148-164-161-664-368 2007               PHAGE DISPLAY BY NOVEL FILAMENTOUS BACTERIOPHAGE   \n",
              "161-684-752-020-329 2004              METHOD FOR MONITORING BACTERIUM UTILIZING CHIT...   \n",
              "089-102-410-621-069 2004              METHOD FOR CONTROLLING INSECT PEST WITH ALGINA...   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019              System for preparing samples and identifying a...   \n",
              "014-594-233-943-253 2020              Test kit to determine the antimicrobial biolog...   \n",
              "115-179-292-453-581 2006              The parenteral use of bacterial phage associat...   \n",
              "069-774-923-021-970 2005              The use of bacterial phage associated lysing e...   \n",
              "125-476-374-578-517 2017              Use of Bacteriophages to control blackleg and ...   \n",
              "\n",
              "                                                                               Abstract  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              (Mutant) netrin-4 protein (I) comprising at le...   \n",
              "147-331-231-570-922 2007              [PROBLEMS] To provide a method for ensuring th...   \n",
              "148-164-161-664-368 2007              [PROBLEMS] To provide a phage display vector w...   \n",
              "161-684-752-020-329 2004              <P>PROBLEM TO BE SOLVED: To develop a method f...   \n",
              "089-102-410-621-069 2004              <P>PROBLEM TO BE SOLVED: To develop a new defo...   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                                              .   \n",
              "014-594-233-943-253 2020                                                              .   \n",
              "115-179-292-453-581 2006                                                              .   \n",
              "069-774-923-021-970 2005                                                              .   \n",
              "125-476-374-578-517 2017                                                              .   \n",
              "\n",
              "                                                                             Applicants  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              CENTRE NAT RECH SCIENT;;I V S INST DES VAISSEA...   \n",
              "147-331-231-570-922 2007              UNIV TOYAMA NAT UNIV CORP;;HATANAKA YASUMARU;;...   \n",
              "148-164-161-664-368 2007                                               UCHIYAMA FUMIAKI   \n",
              "161-684-752-020-329 2004                                                      UNIV KOBE   \n",
              "089-102-410-621-069 2004                                                      UNIV KOBE   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                                UNIV MASARYKOVA   \n",
              "014-594-233-943-253 2020                                                MB PHARMA S R O   \n",
              "115-179-292-453-581 2006              NEW HORIZONS DIAGNOSTICS CORPORATION;;UNIV ROC...   \n",
              "069-774-923-021-970 2005                                   NEW HORIZONS DIAGNOSTICS INC   \n",
              "125-476-374-578-517 2017                                 AGRI-FOOD AND BIOSCIENCES INST   \n",
              "\n",
              "                                                                              Inventors  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006                                    PLOUET JEAN;;ALEMANY MONICA   \n",
              "147-331-231-570-922 2007                             HATANAKA YASUMARU;;SADAKANE YUTAKA   \n",
              "148-164-161-664-368 2007                                               UCHIYAMA FUMIAKI   \n",
              "161-684-752-020-329 2004              MAYAMA SHIGEYUKI;;TOSA YUKIO;;OTSU YASUNARI;;T...   \n",
              "089-102-410-621-069 2004              MAYAMA SHIGEYUKI;;TOSA YUKIO;;OTSU YASUNARI;;T...   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019              PANTŮČEK ROMAN;;ŠTVERÁKOVÁ DANA;;ŠEDO ONDREJ;;...   \n",
              "014-594-233-943-253 2020                                     MOŠA MAREK;;BENEŠÍK MARTIN   \n",
              "115-179-292-453-581 2006                             FISCHETTI VINCENT;;LOOMIS LAWRENCE   \n",
              "069-774-923-021-970 2005                             LOOMIS LAWRENCE;;FISCHETTI VINCENT   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                     Owners  \\\n",
              "Lens ID             Publication Year          \n",
              "088-886-194-310-021 2006                NaN   \n",
              "147-331-231-570-922 2007                NaN   \n",
              "148-164-161-664-368 2007                NaN   \n",
              "161-684-752-020-329 2004                NaN   \n",
              "089-102-410-621-069 2004                NaN   \n",
              "...                                     ...   \n",
              "179-151-089-030-564 2019                NaN   \n",
              "014-594-233-943-253 2020                NaN   \n",
              "115-179-292-453-581 2006                NaN   \n",
              "069-774-923-021-970 2005                NaN   \n",
              "125-476-374-578-517 2017                NaN   \n",
              "\n",
              "                                                                       URL  \\\n",
              "Lens ID             Publication Year                                         \n",
              "088-886-194-310-021 2006              https://lens.org/088-886-194-310-021   \n",
              "147-331-231-570-922 2007              https://lens.org/147-331-231-570-922   \n",
              "148-164-161-664-368 2007              https://lens.org/148-164-161-664-368   \n",
              "161-684-752-020-329 2004              https://lens.org/161-684-752-020-329   \n",
              "089-102-410-621-069 2004              https://lens.org/089-102-410-621-069   \n",
              "...                                                                    ...   \n",
              "179-151-089-030-564 2019              https://lens.org/179-151-089-030-564   \n",
              "014-594-233-943-253 2020              https://lens.org/014-594-233-943-253   \n",
              "115-179-292-453-581 2006              https://lens.org/115-179-292-453-581   \n",
              "069-774-923-021-970 2005              https://lens.org/069-774-923-021-970   \n",
              "125-476-374-578-517 2017              https://lens.org/125-476-374-578-517   \n",
              "\n",
              "                                           Document Type Has Full Text  \\\n",
              "Lens ID             Publication Year                                     \n",
              "088-886-194-310-021 2006              Patent Application            no   \n",
              "147-331-231-570-922 2007              Patent Application           yes   \n",
              "148-164-161-664-368 2007              Patent Application           yes   \n",
              "161-684-752-020-329 2004              Patent Application            no   \n",
              "089-102-410-621-069 2004              Patent Application            no   \n",
              "...                                                  ...           ...   \n",
              "179-151-089-030-564 2019                  Limited Patent            no   \n",
              "014-594-233-943-253 2020                  Limited Patent            no   \n",
              "115-179-292-453-581 2006              Patent Application            no   \n",
              "069-774-923-021-970 2005              Patent Application            no   \n",
              "125-476-374-578-517 2017              Patent Application            no   \n",
              "\n",
              "                                      Cites Patent Count  \\\n",
              "Lens ID             Publication Year                       \n",
              "088-886-194-310-021 2006                               1   \n",
              "147-331-231-570-922 2007                               1   \n",
              "148-164-161-664-368 2007                               1   \n",
              "161-684-752-020-329 2004                               0   \n",
              "089-102-410-621-069 2004                               0   \n",
              "...                                                  ...   \n",
              "179-151-089-030-564 2019                               0   \n",
              "014-594-233-943-253 2020                               0   \n",
              "115-179-292-453-581 2006                               0   \n",
              "069-774-923-021-970 2005                               0   \n",
              "125-476-374-578-517 2017                               0   \n",
              "\n",
              "                                      Cited by Patent Count  \\\n",
              "Lens ID             Publication Year                          \n",
              "088-886-194-310-021 2006                                  7   \n",
              "147-331-231-570-922 2007                                  2   \n",
              "148-164-161-664-368 2007                                  0   \n",
              "161-684-752-020-329 2004                                  1   \n",
              "089-102-410-621-069 2004                                  0   \n",
              "...                                                     ...   \n",
              "179-151-089-030-564 2019                                  0   \n",
              "014-594-233-943-253 2020                                  1   \n",
              "115-179-292-453-581 2006                                  1   \n",
              "069-774-923-021-970 2005                                  0   \n",
              "125-476-374-578-517 2017                                  0   \n",
              "\n",
              "                                      Simple Family Size  \\\n",
              "Lens ID             Publication Year                       \n",
              "088-886-194-310-021 2006                               1   \n",
              "147-331-231-570-922 2007                               2   \n",
              "148-164-161-664-368 2007                               5   \n",
              "161-684-752-020-329 2004                               2   \n",
              "089-102-410-621-069 2004                               2   \n",
              "...                                                  ...   \n",
              "179-151-089-030-564 2019                               1   \n",
              "014-594-233-943-253 2020                               1   \n",
              "115-179-292-453-581 2006                               1   \n",
              "069-774-923-021-970 2005                               1   \n",
              "125-476-374-578-517 2017                               1   \n",
              "\n",
              "                                      Extended Family Size  Sequence Count  \\\n",
              "Lens ID             Publication Year                                         \n",
              "088-886-194-310-021 2006                                21               0   \n",
              "147-331-231-570-922 2007                                 2               4   \n",
              "148-164-161-664-368 2007                                 5              38   \n",
              "161-684-752-020-329 2004                                 2               0   \n",
              "089-102-410-621-069 2004                                 2               0   \n",
              "...                                                    ...             ...   \n",
              "179-151-089-030-564 2019                                 1               0   \n",
              "014-594-233-943-253 2020                                 1               0   \n",
              "115-179-292-453-581 2006                                 1               0   \n",
              "069-774-923-021-970 2005                                 1               0   \n",
              "125-476-374-578-517 2017                                 1               0   \n",
              "\n",
              "                                                                    CPC Classifications  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006                      A61K38/18;;A61P9/00;;A61P19/00;;A61P25/00   \n",
              "147-331-231-570-922 2007                             C07D229/02;;G01N33/582;;G01N33/554   \n",
              "148-164-161-664-368 2007              C07K14/005;;C12N15/1037;;C12N2795/14122;;C12N1...   \n",
              "161-684-752-020-329 2004                                                      Y02A50/30   \n",
              "089-102-410-621-069 2004                                                            NaN   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                             C12N7/02;;C12Q1/70   \n",
              "014-594-233-943-253 2020                              C12N1/205;;C12Q1/70;;C12R2001/445   \n",
              "115-179-292-453-581 2006                                                      Y02A50/30   \n",
              "069-774-923-021-970 2005                                                      Y02A50/30   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                                                   IPCR Classifications  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              A61K38/17;;A61K39/395;;A61K48/00;;A61P9/00;;A6...   \n",
              "147-331-231-570-922 2007              G01N33/53;;C07D229/02;;G01N33/15;;G01N33/543;;...   \n",
              "148-164-161-664-368 2007              C12N15/09;;C07K14/005;;C12N1/21;;C12N7/00;;C12...   \n",
              "161-684-752-020-329 2004                                  C12N15/09;;C12Q1/04;;C12Q1/34   \n",
              "089-102-410-621-069 2004              C12N15/09;;A01N25/28;;A01N63/00;;C12N1/20;;C12...   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                             C12Q1/70;;C12N7/02   \n",
              "014-594-233-943-253 2020                                             C12Q1/70;;C12R1/44   \n",
              "115-179-292-453-581 2006                                                      A61K38/00   \n",
              "069-774-923-021-970 2005                                                      A61K38/00   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                     US Classifications  NPL Citation Count  \\\n",
              "Lens ID             Publication Year                                          \n",
              "088-886-194-310-021 2006                            NaN                   1   \n",
              "147-331-231-570-922 2007                            NaN                   2   \n",
              "148-164-161-664-368 2007                            NaN                  24   \n",
              "161-684-752-020-329 2004                            NaN                   0   \n",
              "089-102-410-621-069 2004                            NaN                   0   \n",
              "...                                                 ...                 ...   \n",
              "179-151-089-030-564 2019                            NaN                   0   \n",
              "014-594-233-943-253 2020                            NaN                   0   \n",
              "115-179-292-453-581 2006                            NaN                   0   \n",
              "069-774-923-021-970 2005                            NaN                   0   \n",
              "125-476-374-578-517 2017                            NaN                   0   \n",
              "\n",
              "                                      NPL Resolved Citation Count  \\\n",
              "Lens ID             Publication Year                                \n",
              "088-886-194-310-021 2006                                        1   \n",
              "147-331-231-570-922 2007                                        1   \n",
              "148-164-161-664-368 2007                                       22   \n",
              "161-684-752-020-329 2004                                        0   \n",
              "089-102-410-621-069 2004                                        0   \n",
              "...                                                           ...   \n",
              "179-151-089-030-564 2019                                        0   \n",
              "014-594-233-943-253 2020                                        0   \n",
              "115-179-292-453-581 2006                                        0   \n",
              "069-774-923-021-970 2005                                        0   \n",
              "125-476-374-578-517 2017                                        0   \n",
              "\n",
              "                                                                NPL Resolved Lens ID(s)  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006                                            085-906-838-714-934   \n",
              "147-331-231-570-922 2007                                            016-994-266-998-256   \n",
              "148-164-161-664-368 2007              050-417-296-901-112;;051-984-368-264-261;;058-...   \n",
              "161-684-752-020-329 2004                                                            NaN   \n",
              "089-102-410-621-069 2004                                                            NaN   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                                            NaN   \n",
              "014-594-233-943-253 2020                                                            NaN   \n",
              "115-179-292-453-581 2006                                                            NaN   \n",
              "069-774-923-021-970 2005                                                            NaN   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                                            NPL Resolved External ID(s)  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006                    11038171;;pmc2192657;;10.1083/jcb.151.2.221   \n",
              "147-331-231-570-922 2007                             10.2174/1568026023394182;;11944820   \n",
              "148-164-161-664-368 2007              16277371;;10.1021/cr000261r;;10.1006/jmbi.1999...   \n",
              "161-684-752-020-329 2004                                                            NaN   \n",
              "089-102-410-621-069 2004                                                            NaN   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                                            NaN   \n",
              "014-594-233-943-253 2020                                                            NaN   \n",
              "115-179-292-453-581 2006                                                            NaN   \n",
              "069-774-923-021-970 2005                                                            NaN   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                                                          NPL Citations  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              KOCH M ET AL: \"A NOVEL MEMBER OF THE NETRIN FA...   \n",
              "147-331-231-570-922 2007              HATANAKA Y. ET AL.: \"Photoaffinity Labeling in...   \n",
              "148-164-161-664-368 2007              KEHOE J.W. ET AL.: \"Filamentous phage display ...   \n",
              "161-684-752-020-329 2004                                                            NaN   \n",
              "089-102-410-621-069 2004                                                            NaN   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                                            NaN   \n",
              "014-594-233-943-253 2020                                                            NaN   \n",
              "115-179-292-453-581 2006                                                            NaN   \n",
              "069-774-923-021-970 2005                                                            NaN   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                      Legal Status  \n",
              "Lens ID             Publication Year                \n",
              "088-886-194-310-021 2006              DISCONTINUED  \n",
              "147-331-231-570-922 2007                   PENDING  \n",
              "148-164-161-664-368 2007                   PENDING  \n",
              "161-684-752-020-329 2004                   EXPIRED  \n",
              "089-102-410-621-069 2004                   EXPIRED  \n",
              "...                                            ...  \n",
              "179-151-089-030-564 2019                    ACTIVE  \n",
              "014-594-233-943-253 2020                    ACTIVE  \n",
              "115-179-292-453-581 2006              DISCONTINUED  \n",
              "069-774-923-021-970 2005              DISCONTINUED  \n",
              "125-476-374-578-517 2017              DISCONTINUED  \n",
              "\n",
              "[5145 rows x 31 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-224ded23-12cd-4cb5-952f-97d6ee2a85c7\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th>#</th>\n",
              "      <th>Jurisdiction</th>\n",
              "      <th>Kind</th>\n",
              "      <th>Display Key</th>\n",
              "      <th>Publication Date</th>\n",
              "      <th>Application Number</th>\n",
              "      <th>Application Date</th>\n",
              "      <th>Priority Numbers</th>\n",
              "      <th>Earliest Priority Date</th>\n",
              "      <th>Title</th>\n",
              "      <th>Abstract</th>\n",
              "      <th>Applicants</th>\n",
              "      <th>Inventors</th>\n",
              "      <th>Owners</th>\n",
              "      <th>URL</th>\n",
              "      <th>Document Type</th>\n",
              "      <th>Has Full Text</th>\n",
              "      <th>Cites Patent Count</th>\n",
              "      <th>Cited by Patent Count</th>\n",
              "      <th>Simple Family Size</th>\n",
              "      <th>Extended Family Size</th>\n",
              "      <th>Sequence Count</th>\n",
              "      <th>CPC Classifications</th>\n",
              "      <th>IPCR Classifications</th>\n",
              "      <th>US Classifications</th>\n",
              "      <th>NPL Citation Count</th>\n",
              "      <th>NPL Resolved Citation Count</th>\n",
              "      <th>NPL Resolved Lens ID(s)</th>\n",
              "      <th>NPL Resolved External ID(s)</th>\n",
              "      <th>NPL Citations</th>\n",
              "      <th>Legal Status</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Lens ID</th>\n",
              "      <th>Publication Year</th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>088-886-194-310-021</th>\n",
              "      <th>2006</th>\n",
              "      <td>6343</td>\n",
              "      <td>FR</td>\n",
              "      <td>A1</td>\n",
              "      <td>FR 2878165 A1</td>\n",
              "      <td>26/05/2006</td>\n",
              "      <td>FR 0412364 A</td>\n",
              "      <td>22/11/2004</td>\n",
              "      <td>FR 0412364 A</td>\n",
              "      <td>22/11/2004</td>\n",
              "      <td>New (mutant) netrin-4, netrin-1, netrin-3, ant...</td>\n",
              "      <td>(Mutant) netrin-4 protein (I) comprising at le...</td>\n",
              "      <td>CENTRE NAT RECH SCIENT;;I V S INST DES VAISSEA...</td>\n",
              "      <td>PLOUET JEAN;;ALEMANY MONICA</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/088-886-194-310-021</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>1</td>\n",
              "      <td>7</td>\n",
              "      <td>1</td>\n",
              "      <td>21</td>\n",
              "      <td>0</td>\n",
              "      <td>A61K38/18;;A61P9/00;;A61P19/00;;A61P25/00</td>\n",
              "      <td>A61K38/17;;A61K39/395;;A61K48/00;;A61P9/00;;A6...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>085-906-838-714-934</td>\n",
              "      <td>11038171;;pmc2192657;;10.1083/jcb.151.2.221</td>\n",
              "      <td>KOCH M ET AL: \"A NOVEL MEMBER OF THE NETRIN FA...</td>\n",
              "      <td>DISCONTINUED</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>147-331-231-570-922</th>\n",
              "      <th>2007</th>\n",
              "      <td>2680</td>\n",
              "      <td>WO</td>\n",
              "      <td>A1</td>\n",
              "      <td>WO 2007/083793 A1</td>\n",
              "      <td>26/07/2007</td>\n",
              "      <td>JP 2007050890 W</td>\n",
              "      <td>22/01/2007</td>\n",
              "      <td>JP 2006014314 A</td>\n",
              "      <td>23/01/2006</td>\n",
              "      <td>PANNING METHOD UTILIZING PHOTOREACTIVE GROUP A...</td>\n",
              "      <td>[PROBLEMS] To provide a method for ensuring th...</td>\n",
              "      <td>UNIV TOYAMA NAT UNIV CORP;;HATANAKA YASUMARU;;...</td>\n",
              "      <td>HATANAKA YASUMARU;;SADAKANE YUTAKA</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/147-331-231-570-922</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>yes</td>\n",
              "      <td>1</td>\n",
              "      <td>2</td>\n",
              "      <td>2</td>\n",
              "      <td>2</td>\n",
              "      <td>4</td>\n",
              "      <td>C07D229/02;;G01N33/582;;G01N33/554</td>\n",
              "      <td>G01N33/53;;C07D229/02;;G01N33/15;;G01N33/543;;...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>2</td>\n",
              "      <td>1</td>\n",
              "      <td>016-994-266-998-256</td>\n",
              "      <td>10.2174/1568026023394182;;11944820</td>\n",
              "      <td>HATANAKA Y. ET AL.: \"Photoaffinity Labeling in...</td>\n",
              "      <td>PENDING</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>148-164-161-664-368</th>\n",
              "      <th>2007</th>\n",
              "      <td>111</td>\n",
              "      <td>WO</td>\n",
              "      <td>A1</td>\n",
              "      <td>WO 2007/114139 A1</td>\n",
              "      <td>11/10/2007</td>\n",
              "      <td>JP 2007056579 W</td>\n",
              "      <td>28/03/2007</td>\n",
              "      <td>JP 2006105143 A</td>\n",
              "      <td>06/04/2006</td>\n",
              "      <td>PHAGE DISPLAY BY NOVEL FILAMENTOUS BACTERIOPHAGE</td>\n",
              "      <td>[PROBLEMS] To provide a phage display vector w...</td>\n",
              "      <td>UCHIYAMA FUMIAKI</td>\n",
              "      <td>UCHIYAMA FUMIAKI</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/148-164-161-664-368</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>yes</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>5</td>\n",
              "      <td>5</td>\n",
              "      <td>38</td>\n",
              "      <td>C07K14/005;;C12N15/1037;;C12N2795/14122;;C12N1...</td>\n",
              "      <td>C12N15/09;;C07K14/005;;C12N1/21;;C12N7/00;;C12...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>24</td>\n",
              "      <td>22</td>\n",
              "      <td>050-417-296-901-112;;051-984-368-264-261;;058-...</td>\n",
              "      <td>16277371;;10.1021/cr000261r;;10.1006/jmbi.1999...</td>\n",
              "      <td>KEHOE J.W. ET AL.: \"Filamentous phage display ...</td>\n",
              "      <td>PENDING</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>161-684-752-020-329</th>\n",
              "      <th>2004</th>\n",
              "      <td>3085</td>\n",
              "      <td>JP</td>\n",
              "      <td>A</td>\n",
              "      <td>JP 2004097032 A</td>\n",
              "      <td>02/04/2004</td>\n",
              "      <td>JP 2002260418 A</td>\n",
              "      <td>05/09/2002</td>\n",
              "      <td>JP 2002260418 A</td>\n",
              "      <td>05/09/2002</td>\n",
              "      <td>METHOD FOR MONITORING BACTERIUM UTILIZING CHIT...</td>\n",
              "      <td>&lt;P&gt;PROBLEM TO BE SOLVED: To develop a method f...</td>\n",
              "      <td>UNIV KOBE</td>\n",
              "      <td>MAYAMA SHIGEYUKI;;TOSA YUKIO;;OTSU YASUNARI;;T...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/161-684-752-020-329</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>2</td>\n",
              "      <td>2</td>\n",
              "      <td>0</td>\n",
              "      <td>Y02A50/30</td>\n",
              "      <td>C12N15/09;;C12Q1/04;;C12Q1/34</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>EXPIRED</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>089-102-410-621-069</th>\n",
              "      <th>2004</th>\n",
              "      <td>3892</td>\n",
              "      <td>JP</td>\n",
              "      <td>A</td>\n",
              "      <td>JP 2004099465 A</td>\n",
              "      <td>02/04/2004</td>\n",
              "      <td>JP 2002260419 A</td>\n",
              "      <td>05/09/2002</td>\n",
              "      <td>JP 2002260419 A</td>\n",
              "      <td>05/09/2002</td>\n",
              "      <td>METHOD FOR CONTROLLING INSECT PEST WITH ALGINA...</td>\n",
              "      <td>&lt;P&gt;PROBLEM TO BE SOLVED: To develop a new defo...</td>\n",
              "      <td>UNIV KOBE</td>\n",
              "      <td>MAYAMA SHIGEYUKI;;TOSA YUKIO;;OTSU YASUNARI;;T...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/089-102-410-621-069</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>2</td>\n",
              "      <td>2</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>C12N15/09;;A01N25/28;;A01N63/00;;C12N1/20;;C12...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>EXPIRED</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>179-151-089-030-564</th>\n",
              "      <th>2019</th>\n",
              "      <td>6156</td>\n",
              "      <td>CZ</td>\n",
              "      <td>U1</td>\n",
              "      <td>CZ 33381 U1</td>\n",
              "      <td>12/11/2019</td>\n",
              "      <td>CZ 201936608 U</td>\n",
              "      <td>09/09/2019</td>\n",
              "      <td>CZ 201936608 U</td>\n",
              "      <td>09/09/2019</td>\n",
              "      <td>System for preparing samples and identifying a...</td>\n",
              "      <td>.</td>\n",
              "      <td>UNIV MASARYKOVA</td>\n",
              "      <td>PANTŮČEK ROMAN;;ŠTVERÁKOVÁ DANA;;ŠEDO ONDREJ;;...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/179-151-089-030-564</td>\n",
              "      <td>Limited Patent</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>C12N7/02;;C12Q1/70</td>\n",
              "      <td>C12Q1/70;;C12N7/02</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>ACTIVE</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>014-594-233-943-253</th>\n",
              "      <th>2020</th>\n",
              "      <td>6024</td>\n",
              "      <td>CZ</td>\n",
              "      <td>U1</td>\n",
              "      <td>CZ 33918 U1</td>\n",
              "      <td>14/04/2020</td>\n",
              "      <td>CZ 202037223 U</td>\n",
              "      <td>06/02/2020</td>\n",
              "      <td>CZ 202037223 U</td>\n",
              "      <td>06/02/2020</td>\n",
              "      <td>Test kit to determine the antimicrobial biolog...</td>\n",
              "      <td>.</td>\n",
              "      <td>MB PHARMA S R O</td>\n",
              "      <td>MOŠA MAREK;;BENEŠÍK MARTIN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/014-594-233-943-253</td>\n",
              "      <td>Limited Patent</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>C12N1/205;;C12Q1/70;;C12R2001/445</td>\n",
              "      <td>C12Q1/70;;C12R1/44</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>ACTIVE</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>115-179-292-453-581</th>\n",
              "      <th>2006</th>\n",
              "      <td>6234</td>\n",
              "      <td>AU</td>\n",
              "      <td>A1</td>\n",
              "      <td>AU 2006/201041 A1</td>\n",
              "      <td>06/04/2006</td>\n",
              "      <td>AU 2006/201041 A</td>\n",
              "      <td>10/03/2006</td>\n",
              "      <td>AU 2001/027834 A;;AU 2006/201041 A</td>\n",
              "      <td>12/01/2001</td>\n",
              "      <td>The parenteral use of bacterial phage associat...</td>\n",
              "      <td>.</td>\n",
              "      <td>NEW HORIZONS DIAGNOSTICS CORPORATION;;UNIV ROC...</td>\n",
              "      <td>FISCHETTI VINCENT;;LOOMIS LAWRENCE</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/115-179-292-453-581</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>Y02A50/30</td>\n",
              "      <td>A61K38/00</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DISCONTINUED</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>069-774-923-021-970</th>\n",
              "      <th>2005</th>\n",
              "      <td>6214</td>\n",
              "      <td>AU</td>\n",
              "      <td>A1</td>\n",
              "      <td>AU 2005/227384 A1</td>\n",
              "      <td>24/11/2005</td>\n",
              "      <td>AU 2005/227384 A</td>\n",
              "      <td>27/10/2005</td>\n",
              "      <td>AU 2000/077021 A;;AU 2005/227384 A</td>\n",
              "      <td>14/09/2000</td>\n",
              "      <td>The use of bacterial phage associated lysing e...</td>\n",
              "      <td>.</td>\n",
              "      <td>NEW HORIZONS DIAGNOSTICS INC</td>\n",
              "      <td>LOOMIS LAWRENCE;;FISCHETTI VINCENT</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/069-774-923-021-970</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>Y02A50/30</td>\n",
              "      <td>A61K38/00</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DISCONTINUED</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>125-476-374-578-517</th>\n",
              "      <th>2017</th>\n",
              "      <td>4736</td>\n",
              "      <td>GB</td>\n",
              "      <td>D0</td>\n",
              "      <td>GB 201709104 D0</td>\n",
              "      <td>19/07/2017</td>\n",
              "      <td>GB 201709104 A</td>\n",
              "      <td>07/06/2017</td>\n",
              "      <td>GB 201709104 A</td>\n",
              "      <td>07/06/2017</td>\n",
              "      <td>Use of Bacteriophages to control blackleg and ...</td>\n",
              "      <td>.</td>\n",
              "      <td>AGRI-FOOD AND BIOSCIENCES INST</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/125-476-374-578-517</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DISCONTINUED</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>5145 rows × 31 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-224ded23-12cd-4cb5-952f-97d6ee2a85c7')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-224ded23-12cd-4cb5-952f-97d6ee2a85c7 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-224ded23-12cd-4cb5-952f-97d6ee2a85c7');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-99b5b77c-1412-4c28-b82e-f600b5f2af4d\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-99b5b77c-1412-4c28-b82e-f600b5f2af4d')\"\n",
              "            title=\"Suggest charts.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-99b5b77c-1412-4c28-b82e-f600b5f2af4d button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ]
          },
          "metadata": {},
          "execution_count": 7
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "9Ma8jUgsStU2",
        "outputId": "5cfb002b-f471-4077-8ecd-72733311a035"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "5145"
            ]
          },
          "metadata": {},
          "execution_count": 8
        }
      ],
      "source": [
        "data = [str(df['Title'][i])+str(df['Abstract'][i]) for i in df.index] #Title and Abstract\n",
        "len(data)"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#data"
      ],
      "metadata": {
        "id": "70xjrXWmK_hQ"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "AlFC9BAghud5",
        "outputId": "938847b4-70f2-45c6-e9b7-c50f58417890"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "2023-09-14 16:23:15.935713: W tensorflow/compiler/tf2tensorrt/utils/py_utils.cc:38] TF-TRT Warning: Could not find TensorRT\n",
            "Collecting en-core-web-md==3.6.0\n",
            "  Downloading https://github.com/explosion/spacy-models/releases/download/en_core_web_md-3.6.0/en_core_web_md-3.6.0-py3-none-any.whl (42.8 MB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m42.8/42.8 MB\u001b[0m \u001b[31m8.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: spacy<3.7.0,>=3.6.0 in /usr/local/lib/python3.10/dist-packages (from en-core-web-md==3.6.0) (3.6.1)\n",
            "Requirement already satisfied: spacy-legacy<3.1.0,>=3.0.11 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (3.0.12)\n",
            "Requirement already satisfied: spacy-loggers<2.0.0,>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (1.0.4)\n",
            "Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (1.0.9)\n",
            "Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (2.0.7)\n",
            "Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (3.0.8)\n",
            "Requirement already satisfied: thinc<8.2.0,>=8.1.8 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (8.1.12)\n",
            "Requirement already satisfied: wasabi<1.2.0,>=0.9.1 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (1.1.2)\n",
            "Requirement already satisfied: srsly<3.0.0,>=2.4.3 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (2.4.7)\n",
            "Requirement already satisfied: catalogue<2.1.0,>=2.0.6 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (2.0.9)\n",
            "Requirement already satisfied: typer<0.10.0,>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (0.9.0)\n",
            "Requirement already satisfied: pathy>=0.10.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (0.10.2)\n",
            "Requirement already satisfied: smart-open<7.0.0,>=5.2.1 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (6.4.0)\n",
            "Requirement already satisfied: tqdm<5.0.0,>=4.38.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (4.66.1)\n",
            "Requirement already satisfied: numpy>=1.15.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (1.23.5)\n",
            "Requirement already satisfied: requests<3.0.0,>=2.13.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (2.31.0)\n",
            "Requirement already satisfied: pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (1.10.12)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (3.1.2)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (67.7.2)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (23.1)\n",
            "Requirement already satisfied: langcodes<4.0.0,>=3.2.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (3.3.0)\n",
            "Requirement already satisfied: typing-extensions>=4.2.0 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (4.5.0)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (3.2.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (3.4)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (2.0.4)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (2023.7.22)\n",
            "Requirement already satisfied: blis<0.8.0,>=0.7.8 in /usr/local/lib/python3.10/dist-packages (from thinc<8.2.0,>=8.1.8->spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (0.7.10)\n",
            "Requirement already satisfied: confection<1.0.0,>=0.0.1 in /usr/local/lib/python3.10/dist-packages (from thinc<8.2.0,>=8.1.8->spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (0.1.2)\n",
            "Requirement already satisfied: click<9.0.0,>=7.1.1 in /usr/local/lib/python3.10/dist-packages (from typer<0.10.0,>=0.3.0->spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (8.1.7)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->spacy<3.7.0,>=3.6.0->en-core-web-md==3.6.0) (2.1.3)\n",
            "\u001b[38;5;2m✔ Download and installation successful\u001b[0m\n",
            "You can now load the package via spacy.load('en_core_web_md')\n"
          ]
        }
      ],
      "source": [
        "!python -m spacy download en_core_web_md"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "ADJ4guaGStYx"
      },
      "outputs": [],
      "source": [
        "import en_core_web_md\n",
        "nlp = en_core_web_md.load()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "AVWSWIUljCxr",
        "outputId": "19affe19-59b7-4064-b7b7-c48b09f495e4"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package punkt to /root/nltk_data...\n",
            "[nltk_data]   Package punkt is already up-to-date!\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "True"
            ]
          },
          "metadata": {},
          "execution_count": 12
        }
      ],
      "source": [
        "import nltk\n",
        "nltk.download('punkt')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "1gZFkHOfStaS",
        "outputId": "63f22f4b-4300-4fb1-e622-7b5ea2383391"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package wordnet to /root/nltk_data...\n",
            "[nltk_data]   Package wordnet is already up-to-date!\n",
            "[nltk_data] Downloading package stopwords to /root/nltk_data...\n",
            "[nltk_data]   Package stopwords is already up-to-date!\n"
          ]
        }
      ],
      "source": [
        "from wordcloud import WordCloud, STOPWORDS\n",
        "import plotly.express as px\n",
        "import nltk\n",
        "from nltk.corpus import stopwords\n",
        "from nltk.stem import WordNetLemmatizer\n",
        "\n",
        "nltk.download('wordnet')\n",
        "nltk.download('stopwords')\n",
        "s = set(STOPWORDS)\n",
        "sw = stopwords.words('english')\n",
        "sw += s\n",
        "sw.append ('amp')"
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "mVxitGDjVJiW"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "waTKGoC0SZJM",
        "outputId": "10e7164e-68e2-4fea-8a7d-9a0001eed888"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "5108"
            ]
          },
          "metadata": {},
          "execution_count": 14
        }
      ],
      "source": [
        "# Read the texts and remove the stopwords :\n",
        "#Build the text list:\n",
        "txt = []\n",
        "idx = []\n",
        "t1 = ''\n",
        "t2 = []\n",
        "for i in range(len(data)):\n",
        "        t1 = str(data[i]).lower()\n",
        " #       t1 = re.sub ('#','',t1)\n",
        "        #t1 = re.sub ('.','',t1)\n",
        " #       t1 = re.sub (',','',t1)\n",
        " #       t1 = re.sub (\"'\",'',t1)\n",
        "#        t1 = t1.replace('.','')\n",
        "        t2 = t1.split()\n",
        "        t1 = ''\n",
        "        for item2 in t2:\n",
        "            if item2 not in sw:\n",
        "                t1 += item2\n",
        "                t1 += ' '\n",
        "        if t1[:-1] not in txt and t1[:-1] != '':\n",
        "            txt.append (t1[:-1])\n",
        "            idx.append (i)\n",
        "len (txt)"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "txt"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "mbAVUEHnbFFL",
        "outputId": "d38f41b5-1e95-4b7c-fc03-71435d2dfae6"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['new (mutant) netrin-4, netrin-1, netrin-3, anti-idiotypic netrin-4 antibodies, fab fragments nucleotide sequences useful preventing treating tumoral non-tumoral disorders (of angiogenesis)(mutant) netrin-4 protein (i) comprising least 230 amino acids seq id. nos 522 524, fragment, derivative homologue, new. (mutant) netrine-4 protein (i) comprising contains one following sequences; seq id no. 522 524, fragment 522/524 anti-angiogenic activity and/or perictye activation activity, fragment comprises 40 450 amino acids, preferably 40 230 amino acids represented seq id no: 2q, q variant 187 248 seq id 526 528. included sequences substitutions, suppression addition one amino acids providing sequences anti-angiogenic perictye activation activity. active homologues included least approximiately 50 % sequence identity region amino acids 261 515 seq id no: 522. sequence information fully defined specification. independent claims included for: (1) nucleotide sequence (ii) encoding proteins (i); (2) recombinant vector (iv), plasmid, cosmid, phage dna virus comprising (ii) comprising necessary elements expression suitable host cell expression (i); (3) host cell (iv), chosen bacteria, viruses, yeast, mushrooms, plants mammalian cells, transformed (iv); (4) antibody (v), specific (i); (5) anti-idiotypic antibody (vi) specific (i); activity : cytostatic; opthalmological; antiangiogenic; immunosuppressive; vasotropic; hypotensive; antiarthritic; cardiant; anorectic; cerebroprotective; dermatological; antiarteriosclerotic. biological data given. mechanism action : none given.',\n",
              " 'panning method utilizing photoreactive group kit method[problems] provide method ensuring screening protein peptide capable interacting ligand. [means solving problems] disclosed method screening protein peptide capable interacting photoreactive ligand, wherein method comprises mixing photoreactive ligand protein display phage peptide display phage liquid phase, irradiating mixed solution active ray photoreactive group photoreactive ligand, immobilizing photoreactive ligand solid phase utilizing immobilization function photoreactive ligand, washing solid phase photoreactive ligand immobilized thereon, collecting protein display phage peptide display phage bound photoreactive ligand immobilized solid phase.',\n",
              " 'phage display novel filamentous bacteriophage[problems] provide phage display vector fused inside piii phage display method using vector. [means solving problems] disclosed phage display method characterized using mutant piii protein amino acid residue inserted proline residue position 11 histidine residue position 12 m13 phage piii protein depicted seq id no:1. method enables produce random peptide high efficiency provide novel source peptide conformation.',\n",
              " 'method monitoring bacterium utilizing chitinous substance degrading enzyme gene labeling<p>problem solved: develop method monitoring labeled bacterium utilizing genes chitinase chitosanase chitinous substance degrading enzymes reporters. <p>solution: provided method detecting bacterium chitinous substance degrading gene transduced comprises following. step bringing bacterium chitinous substance degrading gene transduced contact bacteriophage specific bacterium, step reacting lysate bacterium lysed infection bacteriophage substrate chitinous degrading enzyme step detecting degradation substrate. <p>copyright: (c)2004,jpo',\n",
              " 'method controlling insect pest alginate microbead encapsulating bacterium defoliator pest-suppressing effect<p>problem solved: develop new defoliator pest control means. <p>solution: alginate microbeads characterized encapsulating bacterium defoliator pest-suppressing effect. further, alginate microbeads characterized encapsulating bacterium defoliator pest-suppressing effect bacteriophage capable infecting bacterium. method controlling insect pests alginate microbeads. <p>copyright: (c)2004,jpo',\n",
              " 'kit forming double-stranded rna lactobacillus use thereof<p>problem solved: easily stably form rnai (rna interference) human animal intestine. <p>solution: kit forming double-stranded rna lactobacillus comprises vector containing promoter derived phage. <p>copyright: (c)2009,jpo&inpit',\n",
              " 'method producing multicopy displaying phage<p>problem solved: obtain phage controls number copies objective polypeptide displayed head part phage used phage display displays desired number copies. <p>solution: expression amount fusion protein phage coat protein objective peptide controlled using suppressor trna stop codon, obtained inserting stop codon dna encoding phage coat protein dna encoding objective polypeptide temperature-sensitive suppressor activity. <p>copyright: (c)2004,jpo',\n",
              " 'staphylococcus aureus bacteriolytic bacteriophage<p>problem solved: provide bacteriophage bacteriolytic character plurality staphylococcus aureus (s. aureus) strains, method effectively removing s. aureus using bacteriophage. <p>solution: disclosed bacteriophage bacteriolytic character s. aureus strain selected accession no. nite bp-693 accession no. nite bp-694, bacteriophage composition containing bacteriophage, method preventing s. aureus proliferation characterized applying bacteriophage composition. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'autolysis-resistant cell method producing material using same<p>problem solved: provide cell resistivity lysis occurring without direct stimulation outside infection phage chemical/enzyme treatment prokaryotic cell, provide method producing material using cell. <p>solution: autolysis-resistant cell obtained transforming procaryote extraneous gene base sequence encoding active oxygen species-responsive protein. method producing material using cell provided. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'clathrin-bonding peptide derivative<p>problem solved: provide clathrin-bonding peptide derivative indwells solely cell, competitively inhibits bonding grp78 clathrin thereby exhibiting excellent anticancer action administered together anticancer agent, safe, causes little side effects even applied combination anticancer agent, low molecular weight mass-productively manufactured inexpensively good yield, drug-transporting material comprising same. <p>solution: clathrin-bonding peptide derivative contains amino acid sequence thr-pro-val-leu-glu-thr-pro-lys-leu-leu-leu-trp. drug-transporting material includes colloid particle contains clathrin-bonding peptide derivative peptide-incorporated phage clathrin-bonding peptide derivative chemically bonded extendedly end coat protein phage, clathrin-bonding peptide derivative exposed surface thereof. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'molecular antigen array<p>problem solved: provide composition comprising bacteriophage ap205 virus particle (vlp) antigen, provide process producing antigen antigenic determinant bound vlp. <p>solution: provided vlp associated coat protein bacteriophage ap205 protein, composition organic molecules bind vlp core particles. composition useful induce immune responses useful prevention treatment diseases, disorders conditions including infectious diseases, allergies, cancer, efficiently induce self-specific immune responses, particular antibody responses. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'drug treating bacterial infectious disease comprising bacteriophage<p>problem solved: provide drug treatment prophylaxis edwardsiellosis and/or streptococcus iniae infections fishes. <p>solution: drug obtained including bacteriophage specifically infected edwardsiella tarda bacteriophage specifically infected streptococcus iniae. bacteriophage obtained concentrated method double agar method using edwardsiella tarda streptococcus iniae indicating bacterium. <p>copyright: (c)2007,jpo&inpit',\n",
              " 'genotype classification method staphylococcus aureus primer set use same<p>problem solved: provide genotype classification method staphylococcus aureus, obtained improving technique described publication no.2006-141249 suitable actual industry (medical spot) primer set use same. <p>solution: genotype classification method staphylococcus aureus includes step detecting presence/absence (1) phage-derived open reading frame (orf), (2) orf derived genomic islands except staphylococcal cassette chromosome mec; sccmec, (3) transposon-derived orf, (4) sccmec-derived orf, (5) orf constituting genomic islet staphylococcus aureus genome arbitrary order performing genotype classification combination orf presence/absence. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'method producing albumin variant high ligand affinity<p>problem solved: provide high br-affinity albumin variant usable preparing albumin dialyzing fluid containing efficiently decreased amount albumin-binding toxin (abt) bilirubin (br). <p>solution: provided method screening albumin variant high ligand affinity comprising step preparing prepare phage library present human serum albumin variant phage surface; step contacting phage library ligand measure quantity ligand bound phage; step selecting phage high binding quantity ligand. human serum albumin variant amino acid sequence human serum albumin amino acid sequence first 585th sequence number 2 sequence table, wherein 195th 199th amino acids lysine arginine 240th amino acid lysine. <p>copyright: (c)2010,jpo&inpit',\n",
              " 'inspection container detection device organism-related substance<p>problem solved: provide inspection container bubbles unlikely occur liquid containing organism-related substance. <p>solution: inspection container 101 solid phase carrier 102 probe detecting organism-related substance made solid phase flow passage 103 storing sample solution liquid containing organism-related substance. solid phase carrier 102 consists porous object permits sample solution permeate. flow passage 103 large diameter part 103a extending downward opening upper face cross solid phage carrier 102 small diameter part 103b extending sidewise large diameter part 103a side face. solid carrier 102, hydrophilic processing performed. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'bacteriophage bacteriolytic action ralstonia solanacearum<p>problem solved: provide means effectively controlling ralstonia solanacearum. <p>solution: method controlling ralstonia solanacearum includes spraying bacteriophage exhibiting bacteriolytic action ralstonia solanacearum plant soil soil-improving method includes adding bacteriophage soil. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'ralstonia solanacearum infective bacteriophage<p>problem solved: provide means effectively controlling ralstonia solanacearum. <p>solution: bacteriophage isolated ralstonia solanacearum showing bacteriolytic action strains c-319, m4s, ps29, ps65, ps72, ps74, maff106603, maff106611, maff211270, maff211271, naff211272, maff301556, maff301558, maff730138 maff730139 ralstonia solanacearum. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'method labeling nucleic acid<p>problem solved: provide means efficiently obtaining labeled nucleic acid product long base pair increasing formation labeled nucleic acid. <p>solution: method efficiently obtaining labeled nucleic acid product long base pair increasing formation labeled nucleic acid comprises, labeling reaction nucleic acid, using one kinds proteins (single-stranded dna-binding protein, t4 phage gene 32, 41, 44, 45 61 protein, replication protein radiation protein) associated dna recombinational repair. labeling reaction uses either random primer method pcr method. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'means specifying cell type using virus<p>problem solved: provide means specifying cell type capable solving defects immunization methods polymerase chain reaction methods complicated, require long times, decide lives death cells. <p>solution: means specifying cell type uses specific infection ability specified virus specified cell. preliminarily, fluorescent bacteria 1 dyed fluorescent reagent infected lambda phages 2 recovered membrane filter 3. preliminary image recovered compared post image b infected fluorescent bacteria 4 lysed (5) passage time, whereby presence absence escherichia coli specifically infected lambda phages 2 rapidly detected. also, live bacteria proliferate, presence live escherichia coli detected. <p>copyright: (c)2010,jpo&inpit',\n",
              " 'medicament treating bacterial cold water disease using bacteriophage<p>problem solved: provide medicament treating preventing bacterial cold water disease fish. <p>solution: bacteriophage specifically infecting flavobacterium psychrophilum carrying bacteriolysis thereof contained medicament. bacteriophage obtained, example, concentrated culture method double agar method using flavobacterium psychrophilum indicator bacterium. <p>copyright: (c)2004,jpo&ncipi',\n",
              " 'spike g protein pentamer derived bacteriophage method producing same<p>problem solved: provide method proliferation escherichia coli c strain specifically controlled escherichia coli c strain detected among samples comprising various species escherichia coli present therein. <p>solution: chisg (pentamer g protein) obtained adding histidine tag spike g protein derived bacteriophage φx174. pentamer formed thereby bound escherichia coli c strain. result, chisg used controlling proliferation escherichia coli c strain detecting escherichia coli c strain. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'method amplifying nucleic acid reagent kit amplifying nucleic acid<p>problem solved: provide method amplifying nucleic acid desired nucleic acid amplified suppressing amplification by-product pcr reaction provide reagent kit amplification nucleic acid desired nucleic acid amplified suppressing amplification by-product pcr reaction. <p>solution: method amplifying nucleic acid comprises mixing first protein containing least one selected t. th. reca protein reca modified protein obtained modifying protein functions similar protein second protein containing least one selected phage t4 gene 32 protein phage t4 gene 32-modified protein obtained modifying 32 protein function similar protein reaction solution carrying pcr. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'method analyzing molecular interaction using phage display method<p>problem solved: provide method analyzing three-dimensional structure target molecule-polypeptide ligand complex high precision rapid simple process. <p>solution: method analyzing three-dimensional structure target molecule-polypeptide ligand complex comprises first process exhibiting polypeptide combined target molecule phage surface phage display method, second process obtaining polypeptide ligand cleaving polypeptide exhibited phage surface, third process forming target molecule-polypeptide ligand complex fourth process analyzing three-dimensional structure complex. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'phage method controlling bacterial disease damage terrestrial part plant using nonpathogenic bacterium plant<p>problem solved: provide method controlling bacterial disease damage plant, reduction environmental loading aimed using phages. <p>solution: bacterial disease damage terrestrial part plant controlled applying phages pathogenic bacterium terrestrial part plant nonpathogenic bacterium common hosts nonpathogenic bacterium terrestrial part plant keeping high number phages. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'method detecting mutation genetic polymorphism using mu phage transposase<p>problem solved: provide method detecting mismatch dna:rna double strand, detail, method detecting mutation genetic polymorphism using method detection. <p>solution: method detecting mutation genetic polymorphism comprises (11) step bringing double-stranded nucleic acid contact mu-terminal nucleic acid mu phage transposase (12) step judging mutation genetic polymorphism detecting transposition double-stranded nucleic acid specific site mu-terminal nucleic acid. method detection, double-stranded nucleic acid dna:rna double strand. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'method detecting igg using peptide bindable lgg phage presented peptide surface<p>problem solved: provide method detecting igg using detective means new peptide bindable fc fragment igg phage presented peptide surface. <p>solution: using fc fragment igg derived various animals target substance, screening carried phage display method amino acid sequence peptide bindable target substance identified. peptide thus obtained specific amino acid sequence amino acid sequence selected modified, amino acid residue-substituted, inserted and/or deleted amino acid sequence condition bindability igg fc fragment impaired, phage presented peptide surface, used detective means igg. <p>copyright: (c)2004,jpo&ncipi',\n",
              " 'method detecting material causing damage dna metabolic system utilizing phage lysogenic bacterium<p>problem solved: provide method evaluating activities causing damage dna metabolic system compound, provide method screening antimicrobial agent anticancer agent targeting metabolic system utilizing method. <p>solution: prophage induced damage dna metabolic system cleavage dna double strand phage lysogenic bacterium accompanying bacteriolysis. method evaluating presence absence activities causing damage dna metabolic system specimen comprises expressing reporter gene phage lysogenic bacterium, using activities reporter gene product released bacteriolysis accompanied induction prophage indicator. screening antimicrobial agent anticancer agent enabled utilizing evaluation method. <p>copyright: (c)2003,jpo',\n",
              " 'method identifying antibody specific sugar chain structure<p>problem solved: provide method identifying antibody specifically bonding sugar chain certain specific structure using phage presentation type antibody library sugar chain. <p>solution: method identifying antibody bonding specifically sugar chain comprises process bringing phage presentation type antibody contact sugar chain. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'antigen-specific antibody given using extracorporeally immunized peripheral hemolymphocyte<p>problem solved: provide method inducing antibody production response, extracorporeally immunizing peripheral hemolymphocyte, provide method rapidly efficiently preparing human monoclonal antibody specific arbitrary antigen, provide method acquiring antigen-specific antibody gene highly efficiently short period compared conventional phage display methods, especially, phage display method unprimed human peripheral hemolymphocyte used. <p>solution: antigen-specific human monoclonal antibody mass-produced separating human peripheral hemolymphocytes, removing cd11c-positive cells using cd11c-specific antibody magnetic beads, conducting extracorporeal immunization induce antigen-specific human antibody production response, supplying phage display method lymphocytes subjected extracorporeal immunization acquire antigen-specific human monoclonal antibody variable region gene, inserting acquired human monoclonal antibody variable region gene animal cell expression vector, introducing obtained vector highly heterologous protein-expressing host cell line express antigen-specific human monoclonal antibody. <p>copyright: (c)2004,jpo',\n",
              " 'coat protein gene phage vector<p>problem solved: provide method producing heat-resistant protein high efficiency using thermophilic phage. <p>solution: method production heat-resistant protein contains (1) step integrate gene encoding heat-resistant protein dna thermophilic phage, (2) step introduce recombinant dna obtained step 1 host cell (3) step proliferate thermophilic phage heat-resistant protein coat protein host cell. <p>copyright: (c)2004,jpo&ncipi',\n",
              " 'method producing ligand high association rate ligand production system carrying same<p>problem solved: provide method producing ligands effectively screening ligands (antibodies, like) practical level ligand library provide ligand production system realizing method. <p>solution: method sets screening conditions either one comprising association time contacting proper antigen obtained immobilizing phage library, washing time washing removing phage antibody unassociated antigen, effective concentration immobilized antigen using mathematical formula model including constants expressing recovery rate phage antibody assuming apparent association rate constant dissociation rate constant dissociation constant prescribed specific phage antibody, screening step, screening specific phase antibody associates specific antigen phage library biopanning treatment. <p>copyright: (c)2004,jpo',\n",
              " 'isolation production catalytic antibody using phage technology<p>problem solved: provide method producing isolating catalytic antibody catalytically increasing chemical reaction velocity exhibited bacteriophage. <p>solution: recombinant cloning vector containing antibody, 6his residue, part myc gene phage gene iii, method increasing rate bond cutting forming specific molecule vivo provided, method activating prodrug vivo method activating inactivating biological functions animal increasing rate bond cutting forming specific molecule vivo provided. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'analysis method sugar bonding phage presenting antibody<p>problem solved: provide method qualitatively quantitatively analyzing sugar bonding specificity phage presenting antibody. <p>solution: bonding specificity antibody sugar chain analyzed, bringing phage presenting antibody contact sugar chain immobilized carrier comprising inorganic material. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'method screening new biotin-containing protein<p>problem solved: provide method refining high purity dna removing foreign material environmental sample provide method preparing phage display library using environmental dna (dna obtained environmental sample) efficiently screening gene encoding protein display library. <p>solution: environmental dna extracted soil refined prepare phase display library bound clone group concentrated enriched solidified streptavidin avidin biopanning procedure membrane blot plaqueses carried plaqueses dyed enzyme-labeled streptavidin avidin display clone biotin-containing protein detected thereby biotin-containing protein screened. <p>copyright: (c)2007,jpo&inpit',\n",
              " 'new expression vector<p>problem solved: provide method screening replication-starting region used expression vector using genus rhodococcus microorganism host, provide expression vector expressing target protein using genus rhodococcus microorganism host. <p>solution: method making expression vector genus rhodococcus microorganism utilizing replication-starting region bacteriophage, expression vector provided. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'method screening organism mismatch target gene<p>problem solved: provide method selecting individual organism mutation transduced target gene individual organism group prepared random mutagenesis, etc., high efficiency low cost. <p>solution: method selecting organism mismatch target gene contains (a) step prepare test mu transposition product bringing nucleic acid (test nucleic acid) containing target gene target organism contact (i) mu-terminal nucleic acid (ii) phage mu transposase condition enable transposition mu-terminal nucleic acid mismatch part thereabout target gene target gene contains mismatch, (b) step detect transposition mu-terminal nucleic acid test mu transposition product target gene (c) step select test organism test nucleic acid detected remarkable transposition mu-terminal nucleic acid specific position target gene organism mismatch near specific position target gene. <p>copyright: (c)2007,jpo&inpit',\n",
              " 'method detecting bacteriophage<p>problem solved: provide method simply, rapidly specifically detecting bacteriophage infecting lactococcus lactis high sensitivity sample containing kinds lactic bacteria. <p>solution: method detecting bacteriophage infecting lactococcus lactis sample containing lactococcus lactis lactic bacteria except lactococcus lactis includes coating sample agar plate medium containing 2 mass% sodium chloride, culturing sample, observing resultant agar plate medium naked eye. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'method screening peptide o-bound sugar chain added thereto<p>problem solved: provide method totally analyzing peptides o-bound sugar chain added thereto. <p>solution: method identifying peptide o-bound sugar chain added thereto comprises steps (a) producing peptide capable substrate transglucosylation enzyme expression system protein sugar chain added, (b) adding o-bound sugar chain reacting peptide transglucosylation enzyme, (c) selecting peptide o-bound sugar chain added, (d) analyzing structure sugar chain-added peptide. preferably, production peptide step (a) carried displaying peptide surface phage. preferably, analysis peptide structure step (d) carried analyzing sequence dna inserted phage. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'method suppressing multiplication filamentous microorganism using bacteriophage<p>problem solved: provide method suppressing multiplication filamentous microorganism causing bulking. <p>solution: method suppressing multiplication filamentous microorganism performed adding bacteriophage property infected filamentous microorganism causing bulking activated sludge carrying bacteriolysis. <p>copyright: (c)2004,jpo',\n",
              " 'peptide<p>problem solved: provide new antibacterial/bactericidal compound exhibiting antibacterial and/or bactericidal properties pseudomonas aeruginosa. <p>solution: antibacterial/bactericidal compound quaternary ammonium salt-peptide compound obtained binding thiol group l-cysteine residue introduced n-terminal c-terminal peptide specific amino acid sequence quaternary ammonium salt covalent bond, determined effective phage display method using pseudomonas aeruginosa. <p>copyright: (c)2010,jpo&inpit',\n",
              " \"genotype classification method methicillin-resistant staphylococcus aureus primer set use method<p>problem solved: provide new genotype classification method methicillin-resistant staphylococcus aureus (mrsa) alternative pfge (pulse field gel electrophoresis), provide primer set use method. <p>solution: new genotype classification method comprises following procedure: presence/absence (1) phage-derived open reading frame(orf), (2) orf derived genomic islands except staphylococcal cassette chromosome mec:sccmec (3) transposon-derived orf genome mrsa detected order, objective genotype classification conducted based combination orf presence/absence. method, genotype classification mrsa conducted easily, quickly, objectively high sensitivity without need special devices operator's skill, route hospital infection determined quickly, preventing spread hospital infection. <p>copyright: (c)2006,jpo&ncipi\",\n",
              " 'new lytic enzyme, method producing use thereof<p>problem solved: provide new lytic enzyme high lytic activity wide lytic spectrum. <p>solution: protein composed gene composed dna comprising 933 nucleotide sequences obtained lactobacillus gasseri jcm1131<sp>t</sp>which one species lactic acid bacillus holding temperate phage phigay amino acid sequence encoded same. recombinant plasmid contains dna host cell transformed recombinant plasmid. method producing protein comprises culturing host cell recovering protein. composition comprising protein active ingredient, especially reagent research, food additive, preservative, industrial fungicide bactericide, agricultural fungicide bactericide medical antibiotic provided. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'bacteriophage-originated lysis gene composition gene therapy plasmid incorporated lysis gene<p>problem solved: provide new medicinal composition infection diseases improving defects using phage good use advantage conventional phage treatment, obtain plasmid same. <p>solution: medicinal composition prepared using plasmid combined lysis gene phage without using whole phage. microorganisms bacteria lysed expressing lysis gene combined plasmid, pathogenic microorganisms. gene structure containing lysis gene bacteriophage, medicinal composition containing pharmaceutically permissible support, gene structure plasmid like, microorganism lysis agent using same, method lysing pathogenic microorganisms using lysis agent treating humans provided. <p>copyright: (c)2004,jpo&ncipi',\n",
              " 'method detecting escherichia coli bacteriophage<p>problem solved: provide new method detecting escherichia coli. <p>solution: method detecting escherichia coli characterized bringing bacteriophage labeled coat protein contact sample judging whether bacteria, etc., binding label cell surface present sample. reagent detecting escherichia coli comprises bacteriophage specifically adsorbing cell surface escherichia coli labeled coat protein. label bound coat protein bacteriophage specifically adsorbing surface cell escherichia coli directly detected, escherichia coli simply accurately detected high sensitivity short time. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'peptide protein affinity il-2, il-2 absorbent, il-2 testing reagent il-2 neutralizing agent, using peptide protein<p>problem solved: provide new peptide protein affinity il-2 capable obtained easily inexpensively; provide il-2 absorbent, il-2 testing reagent il-2 neutralizing agent, using peptide protein. <p>solution: screening carried using il-2 target material phage display method, amino acid sequence peptide affinity il-2 determined. peptide specific amino acid sequence obtained thus, amino acid sequence obtained carrying decoration, substitution, insertion and/or deletion amino acid residues, amino acid sequence within range losing affinity il-2 easily chemically synthesized, utilized example il-2 absorbent, il-2 testing reagent, il-2 neutralizing agent like. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'peptide protein bondability tnf-alpha tnf-alpha adsorbent, tnf-alpha test reagent tnf-alpha neutralizing agent use peptide protein<p>problem solved: provide new peptide protein bondability tnf-α obtained ease low cost, tnf-α adsorbent, tnf-α test reagent tnf-α neutralizing agent use peptide protein. <p>solution: amino acid sequence peptide bondability tnf-α identified screening phage display method use tnf-α target substance. amino acid sequence represented one sequence nos. 1-7 thus obtained amino acid sequences, possible easily chemically synthesize peptide amino acid sequence obtained modification substitution insertion amino acid residue and/or defective amino acid sequence far bondability tnf-α adversely affected, peptide utilized, example, tnf-α adsorbent, tnf-α test reagent, tnf-α neutralizing agent. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'intracellular delivery biological effector new transporter peptide sequence<p>problem solved: provide new peptide transporter comprising least one amino acid sequences selected group consisting (a) (x<sb>m</sb>rx<sb>o</sb>rx<sb>n</sb>), (b) (x<sb>m</sb>rrrx<sb>n</sb>), (c) (x<sb>m</sb>rrxrx<sb>n</sb>), (d) (x<sb>m</sb>rxrrx<sb>n</sb>), wherein x non-basic amino acid, integer zero 14, n integer, independent m, zero 14, integer, independent n, zero 5, wherein transporter peptide capable translocating across biological membrane. <p>solution: provided method screening phage library specific peptide transporter. <p>copyright: (c)2009,jpo&inpit',\n",
              " 'expression fused polypeptide surface filamentous phage particle<p>problem solved: provide novel surface recombination technology expressing heterodimeric recombinant gene products surface filamentous phage containing recombinant gene. <p>solution: disclosed filamentous phage containing genome encoding ligand-binding heterodimeric receptor, wherein ligand-binding heterodimeric receptor contains first second polypeptide, wherein first polypeptide fused carboxy-terminal filamentous phage membrane cpiii anchor domain cpviii anchor domain, wherein first second polypeptide independently expressed separate polypeptide reconstituted surface filamentous phage ligand-binding heterodimeric receptor. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'hepatitis b virus inhibitor<p>problem solved: provide peptide composition specific diagnosis, treatment prophylaxis hepatitis b virus infection. <p>solution: present invention provides peptides molecules, inhibiting assembly hepatitis b virus, obtained selecting peptides inhibit assembly hepatitis b virus binding virus core antigen prevent binding core antigen surface antigen fused phage library presented fibrous phage, method treating pharmaceutical composition comprising them. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'peptide reactivity substrate transglutaminase utilization same<p>problem solved: provide peptide reactivity substrate transglutaminase. <p>solution: peptide provided reactivity substrate transglutaminase consisting blood coagulation xiiith factor and/or tissue type transglutaminase specific amino acid sequence transglutaminase inhibitor activity. method searching compound transglutaminase inhibitory activity utilizing peptide presented phage-displaying method compound containing primary amine provided. <p>copyright: (c)2007,jpo&inpit',\n",
              " 'cellulose-binding peptide method producing same<p>problem solved: provide peptide slight amino acid residue specifically binding cellulose provide method producing peptide. <p>solution: cellulose-binding peptide comprises amino acid 7 numbers amino acid residues least one positive hydropathy index amino acid hydroxy group amino group least one side chain. method producing cellulose-binding peptide comprises steps amplifying, separating, washing eluting phage cellulose-binding peptide phage display peptide library. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'tumor invading cyclic peptide<p>problem solved: provide peptide vector composed cyclic peptide repetitively systemically administrable advanced solid cancer hepatic cancer pancreatic cancer, useful drug delivery system, taken tumor cell transferred cytoplasm provide tumor trophic peptide vector using cyclic peptide. <p>solution: phage library peptide 9 amino acid sequences cysteine terminals displayed surface brought contact pancreatic cancer cell line tumor formed inoculating pancreatic cancer cell line. thereby, phage actually taken tumor cell amplified. dna extracted subjected sequencing cyclic peptide taken tumor cell transferred cytoplasm identified determined base sequence. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'phage acinetobacter baumannii<p>problem solved: provide phage used uses reducing amount acinetobacter baumannii, specifically infecting acinetobacter baumannii. <p>solution: phage isolated acinetobacter baumannii, four kinds isolated phages include one genome sequences selected group consisting sequences sequence similarity ≥80%. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'phage/virus inactivator water-soluble paint<p>problem solved: provide phage/virus inactivator comprising anatase-type titanium oxide containing copper effective phage/virus inactivation, water-soluble paint using same. <p>solution: phage/virus inactivator comprises anatase-type titanium oxide containing copper, wherein mass% ratio cuo/tio<sb>2</sb>ranges 1.0 3.5 relative phage titer irradiation ultraviolet intensity 10 μw/cm<sp>2</sp>for 60 min 1×10<sp>-2</sp>to 1×10<sp>-5</sp>. water-soluble paint contains paint binder phage/virus inactivator. inactivator capable inactivating phage/virus fluorescent lamp weakly emitting ultraviolet radiation. painting, water-soluble paint exerts excellent effect various applications sanitary environments required, e. g. suppresses viral growth indoor environment. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'plasmid, ralstonia solanacearum, method monitoring, method evaluation, method screening<p>problem solved: provide plasmid reinforcing expression labeling material ralstonia solanacearum, rastonia solanacearum reinforcing expression labeling material, method monitoring various pathogenic bacteria including rastonia solanacearum, method evaluating sensitivity resistance various pathogenic bacteria including rastonia solanacearum, method screening test substances effective various pathogenic bacteria including rastonia solanacearum. <p>solution: plasmid replication module genome phage ϕrss1 infective capacity rastonia solanacearum expression cassette labeling substance. expression cassette phage ϕrsb2-originated mcp (major coat protein) promotor region, gene encoding labeling material, phage ϕrsb2-originated mcp terminator region. method monitoring performed culturing plant elongate root and/or stem along agar medium surface made inclined, observing labeling substance. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'plasmid containing replicative module phage rss1 method using same<p>problem solved: provide plasmid affinity ralstonia solanacearum, simply easily taken ralstonia solanacearum, stably exists ralstonia solanacearum contains gene express ralstonia solanacearum, ralstonia solanacearum transformed plasmid, system simply monitors dynamic state ralstonia solanacearum wide strain real time using plasmid, method using system. <p>solution: plasmid contains replicative module genome phage rss1 infectious ability ralstonia solanacearum, detail, plasmid contains gene express labeled substance. method labeling ralstonia solanacearum plasmid provided. ralstonia solanacearum transformed plasmid provided. method measuring dynamic state ralstonia solanacearum plant body comprises using plant body containing ralstonia solanacearum. method screening substance effectiveness ralstonia solanacearum provided. <p>copyright: (c)2009,jpo&inpit',\n",
              " 'process recovering polypeptide unfold reversibly polypeptide repertoire<p>problem solved: provide polypeptide improved property capable producing polypeptide high yield using biological production system. <p>solution: method producing antibody variable domain library variable domain resistant thermal coagulation concentrated includes following steps of: (a) providing phage display system including plurality displayed antibody variable domains least part displayed variable domain unfolded refolded, unfolding temperature 80-100°c; (b) selecting least one phage unfolded refolded phage display system displays variable region whose connecting function recovered; (c) obtaining nucleic acid encoding cdr1 optionally cdr2 variable domain displayed selected phage; (d) preparing, nucleic acid library encoding antibody variable domain. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'cell separation method using hydrophobic solid support<p>problem solved: provide rapid ready method separating cells viruses. <p>solution: method separating cells viruses using hydrophobic solid support comprises step contacting solution containing cells viruses hydrophobic solid support water contact angle 70 90 degrees. viruses selected group consisting bacteria, bacteriophages, plant cells, animal cells, plant viruses animal viruses, hydrophobic solid support selected group consisting various kinds structures plane, pillar, bead sieve. <p>copyright: (c)2010,jpo&inpit',\n",
              " 'recognition probe sugar chain marker, nerve projection elongation inhibitor using same, neuron-dyeing agent, tumor cell dyeing agent, immunological system dyeing agent, pharmacological composition, medicine<p>problem solved: provide recognition probe sugar chain marker, capable recognizing e disaccharide unit ie disaccharide unit. <p>solution: antibody, produced phage display method, gd3g7 used recognize ie [idoua-galnac (4s, 6s)] disaccharide unit (disaccharide unit) e [glcua-galnac (4s, 6s)] disaccharide unit ie [idoua-galnac (4s, 6s)] disaccharide unit (disaccharide unit). according constitution, example, effect intensively dyeing high metastatic cells low metastatic cells obtained. recognition probe sugar chains applied widely nerve projection elongation inhibitors, neuron-dyeing agent, tumor cell dyeing agent, immunological system dyeing agent, etc. brings significant advance basic medicine, applied medicine, drug discovery field sugar-chain engineering. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'method specifying classifying target bacterium phage specific genus, species serum type<p>problem solved: provide relative-entropy algorithm genomic fingerprinting capturing host-phage similarity. <p>solution: method comprises classification target bacterium phage following steps; (a) step specify target genome sequence; (b) step form randomized background genome derived target genome; (c) step specify oligonucleotide influencing difference background genome target genome executing iterative argorithm; (d) step compare oligonucleotide sequence selected step (c) known bacterium phage sequence. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'immuno-chromatography method using single-chain variant-part antibody<p>problem solved: provide sandwich type immunoassay using recombination protein bonding property antigen, especially immuno-chromatography method, recombination protein suitable use this. <p>solution: sandwich type immunoassay using first bonding material second bonding material antigen measured, least one first bonding material second bonding material made recombination protein heavy chain variant-part light chain variant-part antibody antigen. preferably, recombination protein single-chain variant-part fragment type antibody (scfv antibody) obtained phage displaying method. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'transformant screening method using transformant<p>problem solved: provide screening method generally used enzymes without limited characteristics, sizes properties, enzymes, enables easy display products enzyme-substrates reaction surfaces phages, enables highly accurate screening. <p>solution: transformant characterized infecting protein-encoding phagemid helper phage host. phage phagemid phage characterized produced transformant. furthermore, screening method characterized using phage phagemid phage. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'sequence specific dna recombination eukaryotic cell<p>problem solved: provide simple controllable recombination system practical means carrying stable targeted integration desired dna sequence provide method affording improved protein expression system. <p>solution: method sequence specific recombination dna eukaryotic cell provided. method comprises step introducing first dna comprising nucleotide sequence containing least one recombination sequence cell, introducing second dna comprising nucleotide sequence containing least one recombination sequence cell step performing sequence specific recombination bacteriophage lambda integrase int. <p>copyright: (c)2004,jpo&ncipi',\n",
              " 'site-specific genetic recombination method<p>problem solved: provide site-specific genetic recombination method using tg1 integrase method modifying microbial genome site-specific genetic recombination method. <p>solution: provided: site-specific genetic recombination method using actinomyces proteobacteria having, genome, base sequence high homology specific site (attb<sb>tg1</sb>) host strain s. avermitilis corresponding specific site (attp<sb>tg1</sb>) tg1 phage utilizing tg1 integrase; method modifying microbial genome site-specific genetic recombination method. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'protein adsorption-inhibiting substrate use<p>problem solved: provide substrate protein adsorption-inhibiting surfaces useful wide medical material, provide use thereof. <p>solution: substrate characterized self-tissue membrane comprising peptide derivative prepared introducing polyalkylene oxide chain one end side peptide specifically affinity hydrophobic organic polymer surface support comprising hydrophobic organic polymer. peptide selected phage display method. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'system selecting delta-endotoxin variant improved effect target insect<p>problem solved: provide system selecting δ-endotoxin variant improved effect target insect. <p>solution: method selecting toxin protein variant increased insecticidal activity target insect comprises preparation toxin presentation phage express insecticidal toxin protein t7 phage form bindable receptor, selection toxin presentation phage binding affinity carrier using carrier bound receptor, selection variant increased binding affinity receptor using system. insecticidal composition contains variant active body, vermin-resisting plant contains gene encoding variant introduced plant expressible manner. <p>copyright: (c)2007,jpo&inpit',\n",
              " 'thermostable lysozyme<p>problem solved: provide thermostable lysozyme exhibiting activity high temperatures. <p>solution: thermostable lysozyme specific amino acid sequence derived bacteriophage φin93 infected thermophilic bacterium thermus aquaticus thermostable lysozyme amino acid sequence one plurality amino acids substituted, deleted added sequence exhibits thermostable activity. furthermore, gene specified base sequence encoding amino acid sequence enzyme. thermostable lysozyme exhibits good activity high temperature conditions 60-120°c reaction optimum temperature suitably used sterilization, etc., high-temperature environment. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'transformer excitation rush current supression control method, device therefor<p>problem solved: provide transformer excitation rush current suppression control method device capable suppressing excitation rush current generated connecting three-phase alternate current transformer electric power system including higher harmonic wave closing breaker. <p>solution: residual magnetic flux three-phase alternate current transformer 2 time shut-down measured, minimum phase absolute value residual magnetic flux three phases made controlling phase, two phase angles θ give residual magnetic flux controlling phase calculated, furthermore, virtual rush current respective phases time first phase angle θ virtual rush current respective phases time second phase angle θ acquired, making phase angle θ absolute value virtual rush currents becomes 1 less closing phage angle, closing transformer primary side breaker 6 controlled. <p>copyright: (c)2009,jpo&inpit',\n",
              " 'construction vector constructing expression vector host vegetable, application same<p>problem solved: provide vector constructing expression vector capable rapidly recombining vegetable transformation vector cloning target gene vector constructing expression vector good cloning efficiency sequence efficiency. <p>solution: vector constructing expression vectors constructed inserting two att sites, promotor terminator two sites cloning site put promotor terminator puc-based cloning vector, inserting gene coding functional peptide changing arbitrary transcription factor transcription control factor. vectors rapidly recombined vegetable transformation vectors using phage-derived integrase/att-system. <p>copyright: (c)2005,jpo&ncipi',\n",
              " \"vector cell-free protein synthesis system baculovirus expression system<p>problem solved: provide vector used cell-free protein synthesis system baculovirus expression system. <p>solution: baculovirus transfer vector comprises baculovirus late gene promoter sequence (a), baculovirus late gene 5' untranslated region sequence (b), sequence (c) inserting desired structural gene upstream side downstream side, comprises phage-derived rna polymerase recognition sequence (d) upstream side sequence (a) downstream side sequence (a) upstream side sequence (b). method preparing protein baculovirus expression system and/or cell-free protein synthesis system recombinant baculovirus transfer vector obtained inserting desired structural gene baculovirus transfer vector provided. <p>copyright: (c)2010,jpo&inpit\",\n",
              " 'single-stranded antibody recognizing t-antigen sugar chain derived phage library<p>problem solved: provide antibody recognizing t-antigen sugar chain function analysis sugar chain associated cancer, nucleic acid encoding antibody. <p>solution: provided antibody containing specific amino acid sequence, recognizing t-antigen sugar chain produced screening phage-presentation library present human scfv using t-antigen containing hexaethylene glycol producing t-antigen specific single-stranded antibody, method producing recombinant antibody recognizing t-antigen sugar chain using nucleic acid encoding antibody, recombinant antibody composed single-stranded antibody. <p>copyright: (c)2009,jpo&inpit',\n",
              " 'anti-suminori disease bacteriophage method preventing suminori disease cultured laver<p>problem solved: provide anti-suminori disease bacteriophage provide method preventing suminori disease cultured laver using anti-suminori disease bacteriophage. <p>solution: anti-suminori disease bacteriophage liquid b added mixed treating liquid w treating bath 1 order 1×10<sp>5</sp>to 1×10<sp>8</sp>pfu. seeded, frozen, preserved net 10 laver culture frozen preserved -20°c directly dipped thawed dipped treating liquid w treating bath 1. net 10 laver culture directly extended washed seawater extended culture farm. <p>copyright: (c)2009,jpo&inpit',\n",
              " 'encryption method decryption method<p>problem solved: provide encryption method decryption method encrypted information easily held transported. <p>solution: encrypted dna fragment dna sequence corresponding information encrypted prepared, prepared encrypted dna fragment integrated dna λ phage, λ phage 4 integrated encrypted dna fragment integrated colon bacillus 10. <p>copyright: (c)2003,jpo',\n",
              " 'variant rna polymerase<p>problem solved: provide improved t7rna polymerase increases specific activity bacteriophage t7rna polymerase improve reactivity high temperature range. <p>solution: provided variant t7rna polymerase obtained replacing tryptophan residue corresponding 344-position amino acid sequence wild t7rna polymerase derived bacteriophage t7 valine residue. <p>copyright: (c)2009,jpo&inpit',\n",
              " 'intestinal tract immunity induction type vaccine exhibiting phage head shell<p>problem solved: provide intestinal tract immunity induction type vaccine capable inexpensively efficiently inducing intestinal tract immunity. <p>solution: intestinal tract immunity induction type vaccine comprises bacteriophage infected intestinal tract contagium. vaccine, antigen protein derived intestinal tract contagium exhibited surface head shell bacteriophage. <p>copyright: (c)2007,jpo&inpit',\n",
              " 'phage treatment pseudomonas aeruginosa<p>problem solved: provide bacteriophage mpk6 progeny bacteriophage thereof. <p>solution: bacteriophage mpk6 (accession number kccm 11044p) lytic activity pseudomonas aeruginosa progeny bacteriophage thereof rflp (restriction fragment length polymorphism) dna profile bacteriophage mpk6 provided. new bacteriophage mpk6 progeny bacteriophage thereof capable treating pseudomonas aeruginosa infectious disease provided present antibacterial efficacy bacteriophage mpk6 progeny bacteriophage thereof using mammalian non-mammalian infection model. <p>copyright: (c)2010,jpo&inpit',\n",
              " 'kunitz domain library<p>problem solved: provide libraries, vectors, phage particles, host cells, methods displaying kunitz domain. <p>solution: provided library comprising plurality filamentous phage particles, phage particle includes (i) display protein comprises kunitz domain, (ii) nucleic acid comprising (a) phage genes sufficient produce infectious phage particle (b) sequence encoding display protein, wherein kunitz domain includes least varied one amino acid position two interaction loops, positions respective loops varied among plurality particles, wherein average number copies kunitz domain per phage particle less 2.0. <p>copyright: (c)2010,jpo&inpit',\n",
              " 'method constructing display library genetic package member diverse family peptides<p>problem solved: provide methods useful constructing libraries collectively display members diverse families peptides, polypeptides, proteins, libraries produced using methods. <p>solution: methods cleaving single-stranded nucleic acids selected locations, cleaved nucleic acids encodes, least part, peptides, polypeptides, proteins displayed genetic packages libraries. genetic packages filamentous phage phagemids. peptides, polypeptide, proteins identified screening provided. also, sequences may deleterious expression removed amplified dna cloning displaying. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'opsonic monoclonal chimeric antibody specific lipoteichoic acid gram positive bacterium<p>problem solved: provide monoclonal antibodies binding lipoteichoic acid (lta) gram positive bacteria. <p>solution: present invention encompasses monoclonal antibodies, least part variable regions antibodies obtained phage display library containing human antibody sequences, specifically binding lipoteichoic acid (lta) gram-positive bacteria fragments. antibodies bind whole bacteria enhance phagocytosis killing bacteria vitro. invention disclose antibodies human sequences (chimeric, humanized human antibodies). invention discloses three variable regions contained antibodies. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'gene cluster if1a11 expressing human fab antibody fabif1a11 effectively neutralizing influenza virus type h3n2 subtype<p>problem solved: solve problems effect oseltamivir specific therapeutic preparation influenza infectious diseases exhibited administration initial stage infection preparation administered infants specific treating method case symptom caused influenza infectious disease becomes serious established time required exhibiting effect inoculation influenza vaccine prophylaxis. <p>solution: present inventors separated gene cluster if1a11 expressing human fab using combinatorial chemistry method phage display method found fabifia11 gene product gene cluster activity effectively neutralize influenza virus type h3n2 subtype. if1a11 gene product human fab believed if1a11 molecule possibility compensate defects prophylaxis vaccine influenza infectious diseases specific therapeutic preparations present. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'human fab antibody gene cluster effectively neutralizing rabies virus<p>problem solved: solve problems equine serum neutralizing rabies comprises heterologous protein human antiserum rabies danger contraction infectious diseases mediated blood. <p>solution: gene product fabtc3g7 produced gene cluster tc3g7, wherein fabtc3g7 proven effectively neutralization activity rabies virus 3 strain, result separation gene cluster tc3g7 expresses human fab, using combinatorial science procedure phage display procedure. gene product fabtc3g7 comprises human fab seems molecule possibility covering defect caused administration equine antiserum administration human antiserum presently recommended preventive measure onset rabies exposure rabies virus. <p>copyright: (c)2006,jpo&ncipi',\n",
              " \"method down-regulating gdf-8 activity1. method vivo down-regulation growth differentiation factor 8 (gdf-8) activity animal, including human being, method comprising effecting presentation animal's immune system immunogenically effective amount least one gdf-8 analogue wherein introduced least one modification gdf-8 amino acid sequence results - immunization animal analogue induces production antibodies gdf-8 polypeptide, - substantial fraction gdf-8 b-cell epitopes preserved, - foreign helper epitope (th epitope) introduced corresponding one residues 18-41, 49-69, 79-104 seq id no: 11 12 means addition, deletion, insertion substitution, introduced corresponding equivalent sequence gdf-8 polypeptide different origin human, bovine, porcine, chicken turkey, foreign th epitope inserted substituted one loop areas flexible termini gdf-8 polypeptide, wherein number aminoacid additions, deletions, insertions substitutions 60. 2. method according claim 1, comprises - least one first moiety introduced effects targeting modified molecule antigen presenting cell (apc) b-lymphocyte, and/or - least one second moiety introduced stimulates immune system, and/or - least one third moiety introduced optimises presentation modified gdf-8 polypeptide immune system. 3. method according claim 1 2, wherein modification includes introduction side groups, covalent non-covalent binding suitable chemical groups gdf-8 subsequence thereof, foreign th epitope and/or first and/or second and/or third moiety. 4. method according one claims 1-3, wherein modification includes amino acid substitution and/or deletion and/or insertion and/or addition. 5. method according claim 4, wherein modification results provision fusion polypeptide. 6. method according claim 4 5, wherein introduction amino acid substitution and/or deletion and/or insertion and/or addition results substantial preservation overall tertiary structure gdf-8. 7. method according one claims 1-6, wherein modification includes duplication least one gdf-8 b-cell epitope and/or introduction hapten. 8. method according one claims 1-7, wherein foreign th epitope immunodominant animal. 9. method according one claims 1-8, wherein foreign th epitope promiscuous, natural promiscuous th epitope artificial mhc-ii binding peptide sequence. 10. method according claim 9, wherein natural th epitope selected tetanus toxoid epitope p2 p30, diphtheria toxoid epitope, influenza virus hemagluttinin epitope, p. falciparum cs epitope. 11. method according one claims 2-10, wherein first moiety substantially specific binding partner b-lymphocyte specific surface antigen apc specific surface antigen, hapten carbohydrate receptor b-lymphocyte apc, mannan mannose. 12. method according one claims 2-11, wherein second moiety selected cytokine, hormone, heat-shock protein. 13. method according claim 12, wherein cytokine selected from, effective part of, interferon gamma (ifngamma), flt3l, interleukin 1 (il-1), interleukin 2 (il-2), interleukin 9 (il-4), interleukin 6 (il-6), interleukin 12 (il-12), interleukin 13 (il-13), interleukin 15 (il-15), granulocyte-macrophage colony stimulating factor (gm-csf), wherein heat-shock protein selected group consisting hsp70, hsp90, hsc70, grp94, calreticulin (crt), effective part thereof. 14. method according one claims 2-13, wherein third moiety lipid nature, palmitoyl group, myristyl group, farnesyl group, geranyl-geranyl group; gpi-anchor, n-acyl diglyceride group. 15. method according one preceding claims, wherein gdf-8 subsequence gdf-8 analogue derived c-terminal, active form gdf-8, subsequence analogue derived bovine, porcine, human, chicken, sheep, turkey gdf-8 polypeptide. 16. method according claim 15, wherein gdf-8 polypeptide modified substituting least one amino acid sequence seq id no: 11 12 least one amino acid sequence equal different length contains foreign th epitope, wherein substituted amino acid sequences comprised residues 1-12, 18-91, 43-48, 49-69, 79-104 seq id no: 11 12, wherein gdf-8 polypeptide modified inserting least one amino acid sequence contains foreign th epitope, wherein insertion performed anywhere positions 1-12, 18-30, 42-51, 82-86, 105-109 seq id no: 11 12. 17. method according one preceding claims, wherein presentation immune system effected least two copies gdf-8 polypeptide, subsequence thereof modified gdf-8 polypeptide covalently non-covalently linked carrier molecule capable effecting presentation multiple copies antigenic determinants. 18. method according one preceding claims, wherein effective amount gdf-8 polypeptide gdf-8 analogue administered animal via route selected parenteral route intradermal, subdermal, intracutaneous, subcutaneous, intramuscular routes; peritoneal route; oral route; buccal route; sublinqual route; epidural route; spinal route; anal route; intracranial route. 19. method according claim 18, wherein effective amount 0.5 mug 2,000 mug gdf-8 polypeptide, subsequence thereof analogue thereof. 20. method according claim 18 19, includes least one administration gdf-8 polypeptide analogue per year, least 2, least 3, least 4, least 6, least 12 administrations per year. 21. method according one claims 18-20, wherein gdf-8 polypeptide, subsequence thereof, modified gdf-8 polypeptide optionally formulated pharmaceutically immunologically acceptable carrier and/or vehicle formulated adjuvant facilitates breaking autotolerance autoantigens, adjuvant selected group consisting immune targeting adjuvant; immune modulating adjuvant toxin, cytokine mycobacterial derivative: oil formulation; polymer; micelle forming adjuvant; saponin; immunostimulating complex matrix (an iscom matrix); particle; dda; aluminium adjuvants; dna adjuvants; gamma-inulin: encapsulating adjuvant. 22. method according one claims 19-21, wherein gdf-8 polypeptide analogue contained virtual lymph node (vln) device. 23. method according one claims 1-17, wherein presentation modified gdf-8 immune system effected introducing nucleic acid(s) encoding modified gdf-8 animal's cells thereby obtaining vivo expression cells nucleic acid(s) introduced. 24. method according claim 23, wherein nucleic acid(s) introduced is/are selected naked dna, dna formulated charged uncharged lipids, dna formulated liposomes, dna included viral vector, dna formulated transfection-facilitating protein polypeptide, dna formulated targeting protein polypeptide, dna formulated calcium precipitating agents, dna coupled inert carrier molecule, dna formulated chitin chitosan, dna formulated adjuvant. 25. method according claim 23 24, wherein nucleic acids administered intraarterially, intravenously, routes defined claim 18. 26. method according claim 24 25, wherein nucleic acid(s) is/are contained vln device and/or formulated defined claim 21. 27. method according one claims 24-26, includes least one administration nucleic acids per year, least 2, least 3, least 4, least 6, least 12 administrations per year. 28. method increasing muscle mass animal, method comprising down-regulating gdf-8 activity according method one claims 1-27 extent muscle mass increased least 5% compared animals exhibit normal gdf-8 activity, least 10, 15, 20, 25, 30, 35, 40, 45%. 29. gdf-8 analogue derived animal gdf-8 polypeptide wherein introduced modification defined one claims 1-17. 30. immunogenic composition comprising immunogenically effective amount gdf-8 analogue according claim 29, composition comprising pharmaceutically immunologically acceptable carrier and/or vehicle optionally adjuvant. 31. immunogenic composition according claim 30, wherein adjuvant selected group consisting adjuvants claim 21. 32. nucleic acid fragment encodes gdf-8 analogue according claim 29. 33. vector carrying nucleic acid fragment according claim 32, vector capable autonomous replication. 34. vector according claim 33 selected group consisting plasmid, phage, cosmid, minichromosome, virus. 35. vector according claim 33\",\n",
              " 'method device simultaneous detection multiple components mixture1. method simultaneous detection multiple components mixture, said method comprises reacting mixture components analysis specific receptors immobilized surfaces microcarriers type specific receptor bound marked microcarrier, wherein completion reacting separation microcarriers reacted non-reacted receptors judged mobility influence physical field provided, availability non-availability components analysis mixture detected identification markers separated microcarriers. 2. method claim 1, wherein physical field gravitation field, electric field, magnetic field combination thereof. 3. method claim 1, wherein microcarriers produced microscopic biological subjects, synthetic, semi-synthetic natural substances mixtures microincapsulated markers bound nucleus surface said microcarriers. 4. method claim 3, wherein microcarriers produced protysta, bacteria, viruses, phages, spores plants, bacteria fungi, flower pollen plants, erythrocytes, microscopic algae, magnetite, maghemite, iron, nickel, chrome, gold, silicagel, zeolite, carbon, polystyrene, divinyl benzene, polyacrylamide, polysulfone, polyamide, polyethylene glycol, glucans [alpha] [beta] conformations, including aminoglucans, polyuronic acids, polyacrolein, polyglutaraldehide, polymethyl(hydroxymethyl)acrylate, polychloromethylsterene, polyvinyl alcohol, polyvinyl [epsilon]-amino acids, polyvinyl isotronium, polyacrylic acid, polylactate, polyalkylcyanoacrylate mixtures combinations above. 5. method claim 3, wherein microcarriers used one analysis identical shape, dimensions differ max. 20%. 6. method claim 3, wherein shape microcarriers looks hemisphere, cone, polyhedron, rod strand. 7. method claim 3, wherein microcarriers marked symbol relief surface viewed microscope. 8. method claim 3, wherein microcarriers marked substance mixture substances included said microcarriers affixed surface. 9. method claim 8, wherein identifying features marker absorption spectra, emission spectra, reflection spectra, dispersion spectra, birefringence spectra, circular dichroism spectra energy spectra radioactive decay characteristics given substance mixture substances well intensity said spectra. 10. method claim 8, wherein markers organic complexes cations lantanum group, natural synthetic porphyrins, natural synthetic quinones, natural synthetic alkaloids with/or without paramagnetic markers, with/or without radioactivity well mixtures thereof. 11. method claim 1, wherein characteristics particles changed mobility influence physical field evaluated either visually means registering means. 12. method claim 11, wherein registering means spectrometers electromagnetic radiation radio, infra-red, visible x-ray ranges taken individually combinations thereof. 13. method claim 11, wherein evaluation provided either visually help magnifying devices. 14. method claim 13, wherein microscope, magnifying glass, projector, slide projector computer display used magnifying devices. 15. method reacting components analysis specific receptors immobilized surfaces microcarriers, said method comprising combination microcarriers mixture one chamber, wherein ordered motion microcarriers medium containing components analysis provided. 16. method claim 15, wherein counter motion medium containing components analysis provided. 17. method claims 15 16, wherein motion microcarriers provided linear path, circular path helix path. 18. method claims 15-17, wherein motion microcarriers provided influence physical field. 19. method claim 18, wherein physical field gravitation field, electric field, magnetic field combinations thereof. 20. method claim 19, wherein physical field magnetic field electric field, motion microcarriers provided counter movement medium field. 21. method claim 20, wherein microcarriers passed two times whole volume medium analysis. 22. device simultaneous detection multiple components mixture, said device comprised reacting chamber reacting mixture components analysis specific receptors immobilized surfaces microcarriers, type specific receptor bound marked microcarrier, analyzing means, wherein said device additionally supplied separating chamber inlet said chamber coupled outlet reacting chamber, said separating chamber supplied unit generating physical field separation microcarriers non-reacted reacted receptors judged mobility influence physical field, separating chamber equipped means supplying separated microcarriers and/or information latter analyzing means. 23. reacting chamber mixture components analysis specific receptors immobilized surfaces microcarriers, latter made paramagnetic, said reacting chamber comprising mixture container form channel, unit generating physical field form least one magnet generating physical field possibility movement relation said channel, wherein magnet adapted move substantially along channel constant distance therefrom. 24. reacting chamber claim 23, wherein channel made form helix. 25. reacting chamber claim 23, channel made elastic tube coiled form helix. 26. reacting chamber claim 23, wherein channel formed baffle plate made form helix cylindrical surface. 27. reacting chamber claim 23, wherein channel formed baffle plate made form helix disk plate. 28. reacting chamber claim 23, wherein least two magnets positioned sides helix channel shift relation one another. 29. reacting chamber claims 23-28, wherein said chamber additionally supplied means supplying motion mixture analysis counter direction relation motion microcarriers, supplied fittings supply collection microcarriers. 30. separating chamber comprising unit generating physical field form permanent magnet working chamber, inlet outlet fittings mixture analysis washing fluid, wherein said working chamber made two removable sterile cylindrical cases disposable ones, case presents cylindrical cover fittings, said cover groove sealed disk inserted, said disk provided possibility rotation around axis means drive. 31. separating chamber claim 30, wherein said separating chamber fixedly secured permanent magnet means projections grooves positioned magnet ring internal surface cases. 32. separating chamber claim 31, wherein magnet made form disk half two built parts form sectors truncated 90 degree half depth magnetic field orientation along central axis said disk. 33. separating chamber claim 30, wherein disk rotation drive made form friction wheel contiguous surfaces two movable disks. 34. separating chamber claim 33, wherein disks made possibility rotation counter directions equal speed. 35. separating chamber claim 30, wherein inlet outlet fittings separated fluid located median level case, fittings washing fluid supply located top part case. 36. separating chamber claim 30, wherein outlet fitting washing fluid located slightly median level case. 37. separating chamber claim 30, wherein rotating disk assembly cylindrical cover provides self-contained volume separated baffle plate falculate shape formed interior part case cover. 38. separating chamber claim 37, wherein baffle plate tight contact along full length surface rotating disk. 39. separating chamber claim 37, wherein arch-shaped central part baffle plate forms cavity, circumferential direct part located radial small angle median forms inclined channel along lower half rotating disk. 40. separating chamber claim 39, wherein bottom cavity thus formed installed fitting exhaust washing fluid microcarriers. 41. separating chamber claim 40, wherein end inclined channel installed fitting exhaust microcarriers reacted.',\n",
              " 'hbv core antigen particles multiple immunogenic components attached via peptide ligands1. hbv core antigen particle comprising least one capsid binding immunogen, said capsid binding immunogen comprising least one hbv capsid binding peptide component least one immunogenic component. 2. hbv core antigen particle according claim 1, wherein said capsid binding immunogen oriented said particle permits said immunogenic component elicit immune response said particle administered individual. 3. hbv core antigen particle according claim 1, wherein said capsid binding immunogen linked said particle amino acid residue said hbv capsid-binding peptide component. 4. hbv core antigen particle according claim 1, wherein said capsid binding immunogen linked said particle amino acid residue residue said immunogenic component. 5. hbv core antigen particle according claim 4, wherein said residue said immunogenic component carbohydrate. 6. hbv core antigen particle according claim 1, wherein said capsid binding immunogen linked said particle amino terminus said hbv capsid-binding peptide component. 7. hbv core antigen particle according claim 1, wherein said capsid binding immunogen linked said particle carboxy terminus said hbv capsid-binding peptide component. 8. hbv core antigen particle according claim 1, wherein said capsid binding immunogen crosslinked said particle crosslinker. 9. hbv core antigen particle according claim 1, wherein said immunogenic component linked said hbv capsid-binding peptide component directly linker sequence. 10. hbv core antigen particle according claim 1, wherein said immunogenic component linked amino terminus said hbv capsid-binding peptide component directly linker sequence. 11. hbv core antigen particle according claim 1, wherein said immunogenic component linked carboxy terminus said hbv capsid-binding peptide component directly linker sequence. 12. hbv core antigen particle according one claims 9-11, wherein said immunogenic component linked said hbv capsid-binding peptide component crosslinker. 13. hbv core antigen particle according claim 8, wherein said crosslinker multifunctional crosslinker. 14. hbv core antigen particle according claim 12, wherein said crosslinker multifunctional crosslinker. 15. hbv core antigen particle according claim 14, wherein said multifunctional crosslinker selected group consisting 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide hydrochloride n-hydroxy-sulphosuccinimide. 16. hbv core antigen particle according claim 1, wherein said immunogenic component comprises one epitopes selected group consisting immunologic epitopes, immunogenic epitopes antigenic epitopes. 17. hbv core antigen particle according claim 16, wherein said epitopes selected group consisting linear epitopes, conformational epitopes, single epitopes mixed epitopes. 18. hbv core antigen particle according claim 1, wherein said immunogenic component selected group consisting antigens, allergens, antigenic determinants, proteins, glycoproteins, antibodies, antibody fragments, peptides, peptide mimotopes mimic antigen antigenic determinant, polypeptides, glycopeptides, carbohydrates, oligosaccharides, polysaccharides, oligonucleotides polynucleotides. 19. hbv core antigen particle according claim 1, wherein said immunogenic component targeted derived pathogenic agent selected group consisting viruses, parasites, mycobacteria, bacteria, bacilli, fungi, protozoa, plants, phage, animal cells plant cells. 20. hbv core antigen particle according claim 19, wherein said virus selected group consisting retroviruses, herpesviruses, orthomyoxoviruses, paramyxoviruses, hepadnaviruses, flaviviruses, picornaviruses, papoviruses, adenoviruses, baculoviruses, hantaviruses, parvoviruses, enteroviruses, rhinoviruses, tumor viruses, dna viruses, rna viruses, togaviruses, rhabdoviruses poxviruses. 21. hbv core antigen particle according claim 20, wherein said virus selected group consisting human immunodeficiency type 1 virus, human immunodeficiency type 2 virus, cell-leukemia virus, herpes simplex type 1 virus, herpes simplex type 2 virus, varicella-zoster virus, cytomegalovirus, epstein-barr virus, influenza virus, influenza b virus, influenza c virus, respiratory syncytial virus, measles-like virus, mumps virus, parainfluenza virus, hepatitis b virus, hepatitis c virus, hepatitis virus, hepatitis e virus, yellow fever virus, malaria, dengue virus, tick-borne encephalitis virus, oncovirus, poliomyelitis virus, papillomavirus, rubella virus, rabies virus vaccinia virus. 22. hbv core antigen particle according claim 19, wherein said immunogenic component targeted derived bacillus, enterobacteria, clostridium, listeria, mycobacterium, pseudomonas, staphylococcus, eubacteria, mycoplasma, chlamydia, spirochetes, neisseria salmonella. 23. hbv core antigen particle according claim 19, wherein said immunogenic component targeted diptheria, tetanus, acellular pertussis, haemophilus influenza, polio, measles, mumps, rubella, varicella, hepatitis b virus, hepatitis virus, pneumococcal pneumonia, yellow fever, malaria, hepatitis b virus, hepatitis virus, typhoid fever, meningococcal encephalitis cholera. 24. hbv core antigen particle according claim 18, wherein said immunogenic component selected group consisting animal allergens, insect allergens, plant allergens, atmospheric allergens inhalant allergens. 25. hbv core antigen particle according claim 1, wherein said hbv core antigen hbv core antigen fusion protein. 26. hbv core antigen particle according claim 25, wherein said hbv core antigen fusion protein comprises immunologic epitope, immunogenic epitope antigenic epitope. 27. hbv core antigen particle according claim 26, wherein said hbv core antigen fusion protein comprises immunologic epitope, immunogenic epitope antigenic epitope fused hbv core antigen directly linker sequence. 28. hbv core antigen particle according claim 26, wherein said hbv core antigen fusion protein comprises immunologic epitope, immunogenic epitope antigenic epitope fused carboxy terminus said hbv core antigen directly linker sequence. 29. hbv core antigen particle according claim 26, wherein said hbv core antigen fusion protein comprises immunologic epitope, immunogenic epitope antigenic epitope fused amino terminus said hbv core antigen directly linker sequence. 30. hbv core antigen particle according claim 25, wherein said hbv core antigen fusion protein comprises truncated hbv core antigen. 31. hbv core antigen particle according claim 25, wherein said hbv core antigen fusion protein comprises hbv surface antigen portions thereof. 32. hbv core antigen particle according claim 31, wherein said hbv core antigen fusion protein comprises sequence selected group consisting pre-s1 region hbv surface antigen, pre-s2 region hbv surface antigen, immunodominant region hbv surface antigen portions thereof. 33. hbv core antigen particle according claim 1, wherein said hbv core antigen full length hbv core antigen polypeptide, portions, truncates, mutations derivatives thereof capable assembling particulate form. 34. hbv core antigen particle according claim 1, wherein said hbv capsid-binding peptide component selected group consisting of: sllgrmkga (seq id no: 6), gsllgrmkga (seq id no: 36), dgsllgrmkgaa (seq id no: 37), adgsllgrmkgaag (seq id no: 38), sllgrmkg(beta-a)c (seq id no: 8), rsllgrmkga (seq id no: 9), hrsllgrmkga (seq id no: 10), allgrmkg (seq id no: 12), mhrsllgrmkga (seq id no: 40), rsllgrmkga(beta-a)c (seq id no: 11) mhrsllgrmkgag(beta-a)gc (seq id no: 41). 35. vaccine comprising prophylactically effective amount hbv core antigen particle according claim 1. 36. pharmaceutical composition comprising therapeutically effective amount hbv core antigen particle according claim 1. 37. method producing immune response individual comprising step administering said individual hbv core antigen particle according claim 1 amount effective produce immune response. 38. method according claim 37, wherein said hbv core antigen particle administered said individual parenteral route. 39. method increasing immunogenicity immunogen linking said immunogen hbv core antigen particle hbv capsid-binding peptide, characterized claim 34. 40. hbv core antigen particle according claim 1, wherein said capsid binding immunogen comprises diagnostic label chemical marker. 41. method detecting presence antibodies immunogen sample comprising steps of: (a) contacting sample hbv core antigen particle according claim 40, time sufficient permit antibodies said sample form complex said capsid binding immunogen and; (b) using detection means detect complex formed capsid binding immunogen said antibodies said sample. 42. hbv capsid-binding peptide immunogen comprising least one capsid-binding peptide component least one immunogenic component. 43. hbv capsid-binding peptide immunogen according claim 42, wherein sa',\n",
              " 'method storing food agricultural products1. technical result improvement products quality, increase duration shelf life reduce net cost. 2. essence food agricultural products and/or materials packing treated homologous bacteriophage causing putrefaction. 3. field application food industry',\n",
              " 'means exposure neutralization ralstonia solanacearum bacteria water, soil, plant materials1. technical result increase efficiency exposure ralstonia solanacearum bacteria causing disease bacterial wilting (wilt) brown putrefaction, extermination development propagation disease widening assortment means biological control. 2. essence means comprises mixture specific polyvalent bacteriophages equal proportion. 3. field application agriculture, environmental protection.',\n",
              " 'bandage treatment wounds burns1. technical result increase efficiency treatment prophylaxis. 2. essence bandage comprises collagen plate impregnated bacteriophage homologous microbes infecting wounds and/or burns. 3. field application medicine, surgery.',\n",
              " 'medicinal paste filling tooth root1. technical result intensification anti-inflammatory effect, prevention side-effects widening assortment medicinal pastes filling tooth root. 2. essence medicinal paste filling tooth root comprises hydro apatite (ha), zinc oxide, combined preparation bacteriophage eugenol. 3. field application medicine, stomatology.',\n",
              " 'method water air refinement1. technical result refinement water air bacteria. 2. essence water air passed filters, pores mass bacteriophage. 3. field application ecology.',\n",
              " 'combined antimicrobial antimycotic preparation enteric infection1. technical result widening spectrum preparation effect increase efficiency treatment. 2. essence combined preparation enteric infection comprises phage lysates bacteria: shigellae, salmonellae, e.coli, proteus, pseudomo¬nas aeruginosa, staphylococcus enterococcus antimycotic preparation: nystatin, levorine, nizoral, diflukan, pimafucine, klotrimazole therapeutically effective amount. 3. field application medicine, pharmacology.',\n",
              " 'combined antimicrobial antimycotic preparation purulent infection1. technical result widening spectrum preparation effect increase efficiency treatment/ 2. essence preparation purulent infection comprises phage lysates aerobian bacteria: staphylo¬coccus, streptococcus, pathogenic esche¬richia coli, pseudomo¬nas, proteus, entero¬coc¬cus, klebseiellae и anaerobian bacteria clostri¬dium, antimycotic preparation: nystatin, levorine, nixoral, diflukan, pimafucine, klotrimazole therapeutically effective amount. 3. field application medicine, veterinary.',\n",
              " \"human nucleic acid ovarian tumor tissue123 nucleic acid (cdna) sequences (a), fully defined specification, highly expressed ovarian tumor tissue (and testis breast cancer tissue), new. independent claims included following: (a) subset (a') 56 (a) encode least part gene product, allelic variants (a') complements (a') allelic variants; (b) bacterial phage artificial chromosomes cosmid clones containing functional genes, chromosome region containing them, corresponding (a') use gene transfer vehicles; (c) nucleic acid sequences containing part (a) sufficiently long hybridize (a); (d) expression cassette (ec) comprising (a), fragments, plus control regulatory sequences; (e) dna fragments containing gene isolated using (a); (f) host cells containing (a) heterologous component; (g) recombinant production polypeptides (b), fragments, culturing cells (f); (h) antibody (ab) directed (b), fragments, encoded (a); (j) 134 partial polypeptide sequences, fully defined specification, sequences least 80% homology them; (k) pharmaceutical composition containing least one partial sequences; (l) genomic genes, promoters, enhancers, silencers, exon intron structures, splice variants obtained using (a).\",\n",
              " 'phage ?29 dna polymerase chimera597884 disclosed dna polymerase chimera comprising: a) amino acid sequence encoding ?29 type dna polymerase, bound c-terminal end b) connecting amino acid sequence bound c-terminal end c) amino acid sequence comprising least one helixhairpin-helix (hhh) domain.',\n",
              " 'method device bacterial samplinga bacterial detection sampling device comprising: sampling medium receiving bacterial sample; plurality bacteriophage. bacteriophage located sampling medium. bacteriophage comprises nucleic acid encoding protein capable emitting light output wavelength.',\n",
              " 'bacterial strain streptococcus thermophilus used production bacterial concentrates fermented milk productsa bacterial strain streptococcus thermophilus imb b-7247 used production bacterial concentrates fermented milk products. strain ability generation capsule exopolysaccharides, providing formation viscous texture fermented milk, characterized cholesterin-reducing activity, antagonistic action towards wide range pathogenic opportunistic microorganisms, moderate acid formation energy milk, resistant towards bacteriophages, providing high quality functional activity fermented milk products using thereof.',\n",
              " 'bacterium reduced sensitivity bacteriophagea bacterial strain modified reduce activity and/ expression autolysin, wherein said modified strain reduced sensitivity bacteriophage, bacterial compositions comprising bacterial strain use strain composition manufacture food feed product.',\n",
              " 'bacteriophage belonging siphoviridae bacteriocidal composition comprising samea bacteriophage belonging siphoviridae annihilating escherichia coli salmonellae infected escherichia coli salmonellae provided control antibiotic resistant bacteria cure diseases caused escherichia coli salmonellae infection. bacteriophage eps7(kctc 11121bp) belonging siphoviridae separated sewage shows host susceptibility escherichia coli salmonellae. salmonellae salmonella typhimurium salmonella enteritidis. composition bacteria extinction microbe form comprise bacteriophage eps7 (kctc 11121bp).',\n",
              " 'bacteriophage composition application inactivating antibiotic-resistant pathogenic bacteriaa bacteriophage composition application inactivating antibiotic-resistant pathogenic bacteria, comprising three bacteriophages deposited china typical culture collection aug. 1, 2018,respectively phi. yszka, accession number cctcc 2018513; phage [phi] yszkp, deposited cctcc 2018514; phage [phi] yszpa, preservation number cctcc 2018515. method apparatus treat contaminated soil adding specific bacteriophage solution plant system, directionally infecting inactivating system resistant pathogenic bacteria combined pollution remove resistance gene. restoration, diversity stability soil ecological environment function significantly restored.',\n",
              " 'bacteriophage composition, bacteriostat, use thereofa bacteriophage composition comprising clostridium perfringens phage cctcc no: 2020047, salmonella phage cctcc no: 2020710, escherichia coli phage cctcc no: 2020711, shigella flexneri phage cctcc no: 209029. bacteriophage composition present disclosure strong lytic effects clostridium perfringens, salmonella, escherichia coli, shigella flexneri, used inhibit and/or clear bacterial infections inhibiting overgrowth. bacteriophage composition effectively controls pathogenesis animal intestinal diseases; provides safe, non-toxic, side effect-free phage bacteriostat source controlling animal intestinal diseases.',\n",
              " 'bacteriophage, bacterial wilt disease control agent, bacterial wilt disease control methoda bacteriophage effective wider variety bacterial wilt diseases, bacterial wilt disease control method uses provided. bacteriophage characterized infecting bacterial wilt diseases, gene encodes lysozyme fused-type darb, gene encodes three lytic enzymes, namely endolysin, aforementioned darb, rz/rz1, gene encodes csra, gene encodes two different tail fiber proteins; bacterial wilt disease control agent characterized said bacteriophage active component; bacterial wilt disease control method plants, characterized administering said bacterial wilt disease control agent plant plant growth medium.',\n",
              " 'novel bacteriophage killing activity specific salmonella selected infectious bacteriophages salmonella enteritidisa bacteriophage selectively annihilating salmonella selected infectious bacteriophages salmonella enteritidis provided prevent cure diseases caused salmonella. bacteriophage(kctc 11173bp) killing activity specific salmonella selected infectious bacteriophages salmonella enteritidis. bacteriophage genome represented part gene sequence seq id no:1 seq id no:25. pharmaceutical composition preventing disease caused salmonella genus bacteria comprises bacteriophage killing activity specific salmonella. disease caused salmonella genus bacteria sitotoxism, lymphocytic enteritis, salmonellosis, fowl typhoid bacteremia.',\n",
              " \"bacteriophage, bacterial wilt disease control agent, method controlling bacterial wilt diseasea bacteriophage genome size 200,000 bp longer, wherein protein constituting phage particles bacteriophage contains β-subunit virion-associated rna polymerase β'-subunit virion-associated rna polymerase. bacteriophage transmitted ralstonia solanacearum.\",\n",
              " 'novel bacteriophage killing activity specific salmonella selected infectious bacteriophages salmonella gallinaruma bacteriophage killing activity specific salmonella main cause bacillus infectious disease, specifically, salmonella gallinarum provided effectively prevent cure disease caused salmonella. bacteriophage(kctc 11174bp) killing activity specific salmonella selected bacteriophage infected salmonella gallinarum. salmonella genus bacteria salmonella enteritidis, salmonella pullorum salmonella typhimuriun. bacteriophage represented part gene sequence seq id no:1 seq id no:21.',\n",
              " 'bacteriophage killing activity specific staphylococcus aureusa bacteriophage provided kill pathogenic bacteria staphylococcus aureus specifically, thereby widely used agent preventing treating infectious diseases caused staphylococcus aureus, antibiotics, antibacterial agent cosmetics preservative derived nature, various disinfectants. myoviridae family t4-like phage genus bacteriophage killing activity specific staphylococcus aureus, comprises genetic body including nucleic acid molecule described sequences consisting seq id : nos. 1 26 deposited deposition no. kacc 97001p. pharmaceutical composition preventing treating diseases induced staphylococcus aureus comprises bacteriophage effective ingredient. antibiotic disinfectant comprises bacteriophage effective ingredient.',\n",
              " 'method detecting pathogen using virusa bacteriophage linked enzyme replace antibody system detecting presence bacteria sample. specifically brucella abortus (a pathogen causes brucellosis cattle) detected using brucella bacteriophage virus, urease enzyme linked bacteriophage, m-maleimidobenzoyl-n-hydrosysuccimide ester coupling reagent, sera mice immunized brucella bacteriophage detector antibody, urease conjugated anti-mouse sheep antibody indicator, urea bromcresol purple substrate. materials used indirect (sandwich) direct enzyme-linked viral assays (elvira).',\n",
              " 'bacteriophage preparations methods usea bacteriophage preparation generally includes preparation heterogeneous bacteriophages obtained fermentative process. bacteriophage preparation may formulated pharmaceutic composition. bacteriophage preparation may used treat dysbiosis administering bacteriophage preparation subject having, risk having, dysbiosis. bacteriophage preparation may used prepare prime gut environment healthy subject prior administering source bacteria subject.',\n",
              " 'bacteriophage preparation form gel prevent treat bacterial infections dairy cattle, manufacturing method bacteriophage strainsa bacteriophage preparation form gel prevent treat bacterial infections dairy cattle, including limited infections caused e.coli and/or s. aureus, intended intramammary administration lactation dry period, particular, treat prevent mastitis dairy cattle, manufacturing method bacteriophage strains especially useful preparation manufacturing, characterised detail enclosed patent claims, revealed.',\n",
              " 'bacteriophage preparation treatment intracellular bacterial infectiona bacteriophage preparation provided comprising bacteriophage adapted enter eukaryotic cell and/or eukaryotic cellular compartment, bacteriophage lytic towards least one strain pathogenic bacteria may infect said cell compartment, bacteriophage fused to, linked to, adapted express annihilation moiety, annihilation moiety adapted presence least one specific pathogen cause stimulate death inactivation said cell; said bacteriophage preparation capable causing stimulating death inactivation cells infected said pathogen. invention comprehends pharmaceutical composition comprising bacteriophage preparation, formulated administration patient need thereof; method producing death inactivation cell infected pathogen administration bacteriophage preparation thereto; use bacteriophage preparation manufacture pharmaceutical composition, optionally use treatment and/or prophylaxis disease mediated characterised intracellular infection pathogen, including particular tuberculosis, aids, hiv infection, malaria.',\n",
              " 'thermostable variants t7 rna polymerasea bacteriophage rna polymerase variant provided. embodiments, variant may increased thermostability relative corresponding wild type bacteriophage rna polymerase and/or wildtype t7 rna polymerase. compositions, kits methods employ variant provided.',\n",
              " 'highly ordered phage structures uses thereof stem cell differentiationa bacteriophage structure, method making structure, uses structure described. structure substrate surface ordered arrangement parallel microridges thereon. microridge composed plurality nanoridges longitudinal axis. nanoridge contains bundle phage nano fibers longitudinal axes. phage nanofibers nanoridge bundle arranged substantially smectic alignment. longitudinal axis microridge perpendicular longitudinal axes phage nanofibers make nanoridges microridge. structure may used growth surface inducing differentiation stem cells neural progenitor cells.',\n",
              " 't7 phage peptide display system uses thereofa bacteriophage t7 display vector expressing displaying exogenous peptide, wherein display vector comprises polynucleotide encoding bacteriophage t7 tail fiber protein p17 hepatocyte-targeting determinant sequence inactivated, wherein cloning site contained coding sequence tail fiber protein p17 coding sequence capsid protein p10b. provided host cell containing display vector described above, bacteriophage t7 particle comprising least one copy p17 protein comprises exogenous peptide displayed thereon, least one copy p10 protein exogenous peptide displayed thereon, wherein hepatocyte-targeting determinant sequence bacteriophage t7 tail fiber protein p17 inactivated. present invention provides viral lysate containing assembled bacteriophage t7 particle described above, method determining candidate peptide liver-targeting peptide, screening liver targeting peptides.',\n",
              " 'bacteriophage methods making usinga bacteriophage defined endolysin gene provided, inhibit growth bacteria tobacco. addition, isolation bacteriophage tobacco shown. methods making using bacteriophages provided.',\n",
              " 'bacteriophage, agent preventing xanthomonas campestris disease, method preventing xanthomonas campestris diseasea bacteriophage, phage particles linear structure, infects xanthomonas campestris pv. citri. bacteriophage may genome size 7,000-8,000 b. bacteriophage may genome configuration including dna replication module, structural protein module, assembly secretion module, regulatory region.',\n",
              " 'bacteria reduced genomea bacterium genome genetically engineered least 5% smaller genome native parent strain. bacterium preferably escherichia coli strain. described methods deleting genes dna sequences bacterial genome preferably introduce scars. genes dna sequences selected group consisting flagella gene, restriction modification system gene, lipopolysaccharide surface gene, insertion sequence, rhs element, toxin gene, pathogenicity gene, fimbrae gene, invasin gene, periplasmic protein gene, membrane protein gene, prophage, pseudogene, island, bacteriophage receptor, non-transcribed region genome native parent strain gene dna sequence present two bacteria strains related species native parent strain.',\n",
              " 'antibody specificity colon cancera binding structure binds in, and/or surface of, tumour cells; target structure displayed and/or expressed in, surface of, tumour cells; binding structure recognises blocks said target structure; substance binds blocks expression said target structure; pharmaceutical compositions comprising said binding structure, target structures substance active principles; vaccine compositions comprising said target structures active principles; method phage selection; methods vitro vivo diagnosis prognosis, treatment human malignant diseases comprising use subject matters, described.',\n",
              " 'biomaterial dyeing method utilizing pipa biomaterial dyeing method utilizing pip disclosed. method includes dyeing biomaterial utilizing pip pip-containing agent complete biomaterial dyeing. chemical structure pip shown formula i. biomaterial microbes bacteriophages, viruses bacteria, animal plant cells, tissues, organs sections thereof. experiments prove pip used dyeing plurality biomaterials, pip dangerous compound, physical chemical danger, harmless health environment, easily available water-soluble, replace uranyl acetate used biomaterial dyeing.',\n",
              " 'method apparatus target detection using electrode-bound virusesa biosensor capable detecting presence and/or concentration analyte biomarker includes least one electrically conductive electrode operatively coupled impedance analyzer measuring change resistive impedance electrode response applied alternating current plurality frequencies. one embodiment, least one electrode covered self-assembled monolayer chemically bonded surface. plurality virus particles phage viruses immobilized self-assembled monolayer may exposed test sample solution. virus particles may obtained phage-displayed libraries detect wide variety targets including, example, dna, rna, small molecules, proteins polypeptides. another embodiment, virus particles electrostatically bound substrate pair elongated electrodes disposed substrate.',\n",
              " 'bacteriophage-based biosensor microbial detectiona biosensor detecting microorganism sample includes polymer matrix immobilized layer bacteriophages surface polymer matrix, wherein interaction bacteriophage microorganism causes detectable physicochemical change polymer matrix. method detecting microorganism sample using biosensor includes steps contacting sample biosensor; allowing bacteriophage bind microorganism sample; detecting physicochemical change polymer matrix, change indicative presence microorganism.',\n",
              " 'bacteriophage-based electrochemical biosensora biosensor detecting bacteria may use bacteriophages sandwich-assay system. biosensor may include capture element detection element. capture element may include substrate bacteriophage. detection element may include bacteriophage signal amplification element. biosensor may utilized target bacterium sandwiched capture element detection element, quantifiable signal may generated measure amount bacteria sample. biosensor present invention utilizes direct sensing detect bacteria sample opposed indirect sensing methods.',\n",
              " 'canine parvovirus nanobody cpv-vhh-d4 application thereofa canine parvovirus (cpv) nanobody cpv-vhh-d4 includes heavy chain variable region amino acid sequence shown seq id no: 1, nucleotide sequence gene encoding nanobody cpv-vhh-d4 shown seq id no: 2. present application constructs nanobody immune library cpv phage-display technology, obtains specific anti-cpv nanobody cpv-vhh-d4 screening, verified specifically bind cpv experiments, applicable develop nanobody preparation clinical diagnosis treatment cpv, providing certain theoretical support application nanobodies field veterinary biological products',\n",
              " 'therapeutic agent pruritusa clone bm095 potent proliferation-inhibiting activity obtained human antibody phage library il-31-dependent ba/fc cell proliferation assay system. anti-mouse nr10 neutralizing antibody administered pruritus model mouse, significant effect preventing conditions disease observed. revealed anti-nr10 neutralizing antibody useful therapeutic agent pruritus.',\n",
              " 'method generating high affinity, bivalent binding agentsa combined kunkel mutagenesis phage-display method producing bivalent binding agents provided.',\n",
              " 'method kit generating high affinity binding agentsa combined ribosome-display phage-display method kit carrying method provided. method includes screening ribosome-display library binding agents identify binding agents interact one target molecules interest, converting rna encoding binding agents phage-display format amplification primer extension, screening phage-display library enrich binding agents interact one target molecules interest.',\n",
              " 'complex bacteriophage liposomes inhibiting activity staphylococcal infectiona complex inhibiting activity staphylococcal infection contains bacteriophage base liposomes added 1:1-2:1 ratio.',\n",
              " 'composition method treating mastitisa composition method treating mastitis use effective amount least one lytic specific bacteria causing disease. lytic enzyme genetically coded bacteriophage may specific said bacteria. enzyme may least one lytic protein peptides natural modified form.',\n",
              " 'treatment bacterial infections aquaculturea composition comprises bacteriophage covalently attached edible particle use treating bacterial infection fish crustaceans. infections fish crustaceans caused vibrio, aeromonas, yersinia, moritella, rickettsia, piscirickettsia, lactococcus, pseudomonas, flavobacterium photobacterium bacteria species treated. bacteria infected lysogenic bacteriophage used treating disease fish crustaceans caused similar infections bacteria carrying lysogenic bacteriophage express toxin gene.',\n",
              " 'conjugate photosensitiser bacteriophage.a composition comprising conjugate photosensitiser bacteriophage provided. conjugate may used kill bacteria, particularly mrsa, emrsa, vrsa, hetero-vrsa ca-mrsa targeted method photodynamic therapy.',\n",
              " 'klebsiella bacteriophage uses thereofa composition comprising least two different strains isolated bacteriophages, capable infecting bacteria species klebsiella pneumoniae, wherein least one said least two different strains isolated bacteriophages genomic nucleic acid sequence least 90 % identical one nucleic acid sequence set forth seq id nos: 1-30. uses thereof disclosed.',\n",
              " 'pseudomonas bacteriophage uses thereofa composition comprising least two different strains isolated bacteriophages, capable infecting bacteria species pseudomonas aeruginosa, wherein least one said least two different strains isolated bacteriophages genomic nucleic acid sequence least 90% identical one nucleic acid sequence set forth seq id nos: 1-10. uses thereof disclosed.',\n",
              " 'staphylococcus bacteriophage uses thereofa composition comprising least two different strains isolated bacteriophages, capable infecting bacteria species staphylococcus aureus, wherein least one said least two different strains isolated bacteriophages genomic nucleic acid sequence least 90% identical one nucleic acid sequence set forth seq id nos: 1-7. uses thereof disclosed.',\n",
              " 'gastric inhibtory polypeptide (gip) antigen arrays vlps uses thereofa composition comprising: (a) virus-like particle (vlp) least one first attachment site; wherein said vlp vlp rna-phage; (b) least one antigen least one second attachment site, wherein said least one antigen gastric inhibitory peptide (glp) protein gip fragment, wherein said antigen selected ability induce immune response gip linked said vlp; wherein (a) (b) linked said least one first said least one second attachment site.',\n",
              " 'broad spectrum bacteriocin control unwanted bacteriaa composition containing newly identified bacteriocin produced lactobacillus plantarum strain, isolated natural corn mash used commercial fermentation process production ethanol. bacteriocin composition effective broad range killing vast majority lactic acid bacteria (lab) isolates ethanol fermentation mash, include multiple species lactobacillus, lactococcus, weissella, leuconostoc, pediococcus, enterococcus, streptococcus well killing activity non-lab isolates, strains staphylococcus, enterobacter, bacillus, clostridium. bacteriocin combined broad range bacteriophage provide synergistic effectiveness unwanted bacteria industrial biofuel fermentation process human animal bacterial infections.',\n",
              " 'bacteriophage particle agglutinationa composition detecting one species, classes, and/or types bacteriophage present sample. embodiments, disclosed composition includes plurality detection particles, wherein plurality detection particles includes one binding molecules complexed therewith, specifically binds one species bacteriophage. provided methods employing disclosed compositions testing and/or direct indirect identification indicators presence bacteria, viruses, microbes sample testing and/or identification desired.',\n",
              " 'agent use bacteriophagea composition lysing least one type staphylococcus bacteria selected group consisting staphylococcus hyicus, staphylococcus chromogenes, staphylococcus simulans, staphylococcus schleiferi, staphylococcus felis, prevention treatment diseases caused said bacteria, said composition containing, active ingredients: least one bacteriophage selected group consisting bacteriophages identified accession number nite bp-693 bacteriophages identified accession number nite bp-694; endolysin, protein specified amino acid sequence seq id no: 1.',\n",
              " 'bacteriophage compositiona composition lysing staphylococcus aureus composition preventing treating disease caused staphylococcus aureus, said composition comprising, active ingredients, least one bacteriophage selected group consisting bacteriophage identified accession number nite bp-693 bacteriophage identified accession number nite bp-694, endolysin least one protein selected group consisting (a) protein amino acid sequence represented seq id no: 1, (b) protein amino acid sequence least 80% identity amino acid sequence represented seq id no: 1, (c) protein amino acid sequence substitution, deletion, addition and/or insertion one amino acids amino acid sequence represented seq id no: 1.',\n",
              " 'composition making milk products prophylactic propertiesa composition making milk products prophylactic properties comprises milk base biologically active additive. comprises intesti-bacteriophage inducing virulence lytic activity 10by apelman biologically active additive.',\n",
              " 'compositions methods inhibiting proliferation pathogenic escherichia colia composition preventing treating infection disease caused pathogenic escherichia coli includes myoviridae bacteriophage (esc-cop-23) ability lyse pathogenic escherichia coli pharmaceutically acceptable carrier. method preventing treating infection disease caused pathogenic escherichia coli includes administering subject myoviridae bacteriophage lysing pathogenic escherichia coli myoviridae bacteriophage.',\n",
              " 'compositions methods inhibiting proliferation pathogenic escherichia colia composition preventing treating infection disease caused pathogenic escherichia coli includes myoviridae bacteriophage esc-cop-18 ability lyse pathogenic escherichia coli pharmaceutically acceptable carrier. method preventing treating infection disease caused pathogenic escherichia coli includes administering subject myoviridae bacteriophage lysing pathogenic escherichia coli myoviridae bacteriophage.',\n",
              " 'compositions methods inhibiting proliferation pathogenic escherichia colia composition preventing treating infection disease caused pathogenic escherichia coli includes podoviridae bacteriophage (esc-cop-30) ability lyse pathogenic escherichia coli pharmaceutically acceptable carrier. method preventing treating infection disease caused pathogenic escherichia coli includes administering subject podoviridae bacteriophage lysing pathogenic escherichia coli podoviridae bacteriophage.',\n",
              " 'compositions methods inhibiting proliferation enterotoxigenic bacteroides fragilisa composition preventing treating infection disease caused enterotoxigenic bacteroides fragilis includes siphoviridae bacteriophage (bac-frp-3) ability lyse enterotoxigenic bacteroides fragilis cells pharmaceutically acceptable carrier. method preventing treating infection disease caused enterotoxigenic bacteroides fragilis includes administering subject siphoviridae bacteriophage lysing enterotoxigenic bacteroides fragilis cells siphoviridae bacteriophage.',\n",
              " 'compositions methods inhibiting proliferation enterotoxigenic bacteroides fragilisa composition preventing treating infection disease caused enterotoxigenic bacteroides fragilis includes siphoviridae bacteriophage (bac-frp-4) ability lyse enterotoxigenic bacteroides fragilis cells pharmaceutically acceptable carrier. method preventing treating infection disease caused enterotoxigenic bacteroides fragilis includes administering subject siphoviridae bacteriophage lysing enterotoxigenic bacteroides fragilis cells siphoviridae bacteriophage.',\n",
              " 'compositions methods inhibiting proliferation enterotoxigenic bacteroides fragilisa composition preventing treating infection disease caused enterotoxigenic bacteroides fragilis includes siphoviridae bacteriophage (bac-frp-5) ability lyse enterotoxigenic bacteroides fragilis cells pharmaceutically acceptable carrier. method preventing treating infection disease caused enterotoxigenic bacteroides fragilis includes administering subject siphoviridae bacteriophage lysing enterotoxigenic bacteroides fragilis cells siphoviridae bacteriophage.',\n",
              " 'compositions methods inhibiting proliferation pathogenic escherichia colia composition preventing treating infections diseases caused pathogenic escherichia coli, comprising bacteriophage muscular tail bacteriophage family ability lyse pathogenic escherichia coli pharmaceutically acceptable carrier. method preventing treating infection disease caused pathogenic escherichia coli comprises administering subject bacteriophage family muscapulobacteriophage family lysing pathogenic escherichia coli bacteriophage family muscapulobacteriophage family.',\n",
              " 'bacteriophage lytic protein derived bacteriophage effective treatment staphylococcus aureus biofilma composition removing pellicle formed owing staphylococcus aureus provided improve antibiotic treatment effect disease caused staphylococcus aureus forming pellicle. composition removing pellicle formed owing staphylococcus aureus staphylococcus aureus extinction ability includes bacteriophage ability removing pellicle formed staphylococcus aureus active ingredient. bacteriophage myoviridae sp. t4-similarity phage sp. bacteriophage( accession number kctc 11153bp, sap-1) podoviridae sp. phi29-similarity phage sp. bacteriophage( accession number kctc11154bp, sap-2).',\n",
              " 'composition method preventing infections vegetable tissues caused erwinia amylovoraa composition treating preventing infections vegetable tissues caused erwinia amylovora comprises phage m9, deposited number dsm 27111; method treating preventing infections vegetable tissues caused erwinia amylovora comprises administering said phage m9 said vegetable tissues.',\n",
              " 'topical treatment streptococcal infections using lysin enzyme coded c1 bacteriophagea composition treating dermatological streptococcal infections comprises effective amount therapeutic agent. therapeutic agent produced obtaining lysin enzyme genetically coded fro c1 bacteriophage mixing lysin enzyme pharmaceutically acceptable carrier topical application lysin enzyme. described time-release patch liquid absorbed wipe comprising therapeutic agent.',\n",
              " 'composition comprising group c streptococcal phage associated lysin enzyme, use composition preventing treating streptoccocal infectionsa composition use therapeutic prophylactic treatment streptococcal infection, comprising effective amount group c streptococcal phage associated lysine enzyme carrier delivering enzyme mouth, throat, nasal passage, wherein lysine enzyme kills bacteria responsible infection. above-described composition useful therapeutic prophylactic treatment streptococcal infections alleviation symptoms thereof.',\n",
              " 'method prevention treatment streptococcus parauberis infectionsa composition includes isolated bacteriophage str-pap-1 ability kill streptococcus parauberis cells specifically infecting same, may used prevent treat streptococcus parauberis infections. bacteriophage str-pap-1 active ingredient composition ability kill streptococcus parauberis cells characteristically genome represented nucleotide sequence seq. id. no: 1.',\n",
              " 'plant vascular disease treatment compositiona composition including lyophilized bacteriophage expression thereof present amount effective elimination xylella fastiodisa xanthomonas plant. lyophilized bacteriophage expression thereof combined bacteriophage nutrient water soluble polymer.',\n",
              " 'compositions comprising rankl peptide attached core virus-like particle treatment bone disease immunizationa composition described comprises virus-like particle (vlp) least one antigen antigenic determinant wherein antigen antigenic determinant rankl protein, rankl fragment rankl peptide, antigen bound vlp. preferably vlp selected recombinant proteins of: hepatitis b virus, measles virus, sindbis virus, rotavirus, foot-and-mouth-disease virus, retrovirus, norwalk virus, alphavirus, human papilloma virus, polyoma virus, bacteriophages, rna-phages ty. composition useful treating preventing bone diseases. described method immunizing non-human animals using composition.',\n",
              " 'computer implemented method analysing host phage response dataa computer implemented method analyzing host phage response data comprises fitting sequence sigmoidal functions time point start time end time selecting best fit point. best fit time points selected, search performed time point similar coefficient determination, closer time minimum time point indicative end lag phase. lag time best fit time point obtained fitted model. best fit fails threshold test dataset considered flat lag time set end time.',\n",
              " 'computer implemented method system optimizing phage selectiona computer implemented method optimizing selection bacteriophage (phage) grow advance order target large range bacteria comprising performing multiple phage susceptibility assays susceptibility n bacteria assessed phage. efficacy measures obtained assay efficacy summary measure obtained phage assessed n bacteria. possible phage combination, coverage value overall efficacy value determined coverage percent n bacterial combination phage efficacious. filtered ranked enable selection best phage combinations manufacture use treating patient.',\n",
              " 'machine learning system interpreting host phage responsea computer implemented method generating machine learning model interpreting host phage response data comprising receiving datasets labels host phage response, training machine learning model using model estimate efficacy test phage inhibiting growth test bacteria.',\n",
              " 'methods compositions controlled release bioactive compoundsa controlled release pharmaceutical dosage form bacteriophage presented. dosage form prepared drying active ingredient together dispersion solution polymethacrylate copolymer lyprotectant using mild, entirely aqueous conditions.',\n",
              " 'cross-species cleavable xanthomonas phage composition, kit use thereofa cross-species cleavable xanthomonas phage composition, kit use thereof. xanthomonas axonopodis phage xanthomonas phage gj19p1 accession number cctcc no: 2020805; composition least contains one strain xanthomonas phage gj19p1; kit contains xanthomonas phage gj19p1 composition containing xanthomonas phage gj19p1; composition containing xanthomonas phage gj19p1 used for, limited to, killing xanthomonas.',\n",
              " 'phage culturing device, method preparing phages, filtration device samea device method clinically providing preparation autologous phages, namely, verifiably traced back originating specific person preferably intended use one specific person includes phage culturing device fluid line system sealed respect outside environment phages fluid line system obtained least one-time culturing separated bacteria way filtration, preferably way tangential flow filtration. phages separated way filtration transferred collection vessel connected fluid line system preferably removed fluid line system, using collection vessel, usable, preferably autologous preparation.',\n",
              " 'detecting bacteria using fluorescently-labeled phage immobilized optically transparent surfacea device method detecting bacteria sample include optically transparent substrate phage known react bacteria detected. phage tagged fluorescent tag dapi sbyr® gold cyanine dye. fluorescently tagged, phage-substrate combination illuminated light source, wavelength corresponds excitation wavelength fluorescent tag establish baseline intensity device. device exposed sample illuminated establish test intensity. bacteria detected deemed present test intensity less baseline intensity.',\n",
              " 'optical method detecting bacteriaa device method determining total bacteria count sample include step removing eukaryotes sample filtering sample 0.45 μm pore size syringe filter made low protein binding material. next, sample tagged fluorescent tag illuminated light source excitation wavelength fluorescent tag. resulting fluorescent intensity compared calibration curve determine total bacteria count. cases total bacteria count specific bacteria desired, phage known react bacteria interest fluorescently tagged mixed sample, combination illuminated establish test intensity said sample, used obtain total bacteria count bacteria species interest.',\n",
              " 'diagnostic reagent, containing bioparticles, method production thereof use thereof internal standard nucleic acid preparation nucleic acid detection methodsa diagnostic reagent form composition dimensionally stable standard conditions, comprising bioparticles customary pharmaceutical excipients, wherein bioparticles selected group consisting bacteria, viruses, fungi, protozoa, bacteriophages, yeasts, spores, parasites, plant cells, animal human cells, gametes, plasmids, viroids.',\n",
              " 'method preparing immunobiological composition form foam aerosol treating dermatological diseases infectious etiologya diseases infectious etiology comprises mixing basic components preserving agent aqueous solution bacteriophages. mixtures emulsifier first class preserving agent emulsifier second class vegetable oil produced followed mixing together adding aqueous solution bacteriophages. composition obtained packed aerosol balloons propellant added.',\n",
              " 'dna polymerase possessing continuous catalytic capacity salt tolerancea dna polymerase, amino acid sequence represented seq id no. 2, derivative amino acid sequence substitution, deletion, addition least one amino acid residue. dna polymerase hybrid dna polymerase prepared inserting thioredoxin binding domain (tbd) bacteriophage t7 dna polymerase dna polymerase (sau) staphylococcus aureus. method preparing dna polymerase includes: 1) determining corresponding position target substitution sequence sau protein tbd bacteriophage t7 dna polymerase; 2) devising synthesizing primer according gene sequence sau sequence tbd published genbank; 3) cloning sau-tbd segment acquired (2) expression vector ptrc99a construct recombinant vector ptrc99a-sau-tbd; 4) transforming escherichia coli recombinant vector ptrc99a-sau-tbd inducing protein expression.',\n",
              " \"vaccine diabetes type i, constructing methoda dna vaccine able express antisense peptide diabetes preventing diabetes disclosed prepared. configuration method features coding genes diabetes a's early-phase antigen (insulin, preinsulin, ia-2 beta, igrg gad 65) specific epitopes t, b ctl inserted eukaryon expression plasmid terminal 3' t7 phage dna capsid protein b10 coding gene.\",\n",
              " 'open-reading-frame (orf) phage displaya dual display phage system identification protein interaction networks therapeutic targets.',\n",
              " 'fimh vaccine urinary tract infections (uti)a engineered bacteriophage herein described, displaying surface multiple copies polypeptide, comprises domain bacterial adhesion protein fimh fused coat protein pviii. domain preferably region 45-159aa mature protein fimh. polypeptide beingantigenic, raises desired immunological response, particular urinary tract infections (uti) human animal. engineered bacteriophage suitable preparation vaccinesfor therapy, diagnosis and/or prevention urinary tract infections (uti) human animal.',\n",
              " 'combinatorial libraries proteins scaffold structure c-type lectin-like domainsa family protein libraries comprising ctlds (c-type lectin-like domains) internal polypeptide loop-regions lining ligand binding sites ctlds replaced ensembles completely partially randomised polypeptide segments. tetranectin ctlds chosen framework preferred embodiment; versatile phagemid vectors useful generation manipulation human murine tetranectin ctld libraries disclosed. tetranectin ctlds monomeric well trimeric form efficiently displayed gene iii fusions fully functional form recombinant fd phage display vector. ctld derivatives affinity new ligands may readily isolated libraries vectors displaying ctlds, loop-regions randomised, using one rounds enrichment screening selection followed amplification enriched subpopulation round. efficiency protein products containing ctlds new binding properties produced, e.g. bacterial expression vitro refolding, mono-, tri-, multimeric formats provides important advantages terms simplicity, cost efficiency generation, production diagnostic therapeutic applications comparison recombinant antibody derivatives.',\n",
              " 'utilization bacteriophage control bacterial contamination fermentation processesa fermentation process production ethanol natural sources, corn, comprising introducing fermentable sugar inoculant, bacteriophage cocktail fermentation system introducing cocktail comprising one lytic bacteriophage added one fermentable sugar, inoculant, fermentation system. bacteriophages infect lyse bacteria contaminate fermentable sugars selected. bacteriophage cocktail added amount effective substantially prevent growth bacteria.',\n",
              " 'abiz phage resistance genea first aspect present invention isolated nucleic acid encoding phage abortive defense protein, isolated nucleic acid selected group consisting of: (a) isolated nucleic acid sequence coding sequence given seq id no: 1 (by \"coding sequence\" meant nucleotides 373 1668 therein); (b) isolated nucleic acid encoding phage abortive defense protein hybridizes nucleic acid sequence coding sequence given seq id no: 1, and/or sequence least 60, 70, 80, 90, 92 95 percent identical sequence coding sequence given seq id no: 1; (c) isolated nucleic acid encoding phage abortive defense protein encoded isolated nucleic acid (a) (b) above, differing sequence therefrom due degeneracy genetic code (e.g., nucleic acid encoding protein given seq id no: 2).',\n",
              " 'food save couragea food storage container provided prevent foods going bad allow maintaining freshness foods good long time inhaling purifying gases surrounding environment. food storage container comprises: storage container(100); sealing cover(200) close upper part storage container, includes assembly groove part(20) leaning phage grooves(21) established sides top part cover; medium pack(30) containing medium inhaling purifying gases, received combined assembly groove part removably. medium contained medium pack comprises one activated charcoal, activated charcoal mixture, zeolite, porous ceramic material.',\n",
              " 'preparation containing bacteriophage kctc 11120bp inhibit kill bacteriaa formulation provided inhibit bacteria genesistasis induce apoptosis due bacteriophage kctc 11120bp effects reducing pathogenicity host inhibiting growth host. formulation comprises bacteriophage kctc 11120bp separated cheonggyecheon(one korean streams) active ingredient. bacteriophage kctc 11120bp dissolve salmonella escherichia coli. bacteriophage kctc 11120bp susceptibility salmonella enteritidis separated human organs salmonella typhimurium separated animals. formulation containing bacteriophage kctc 11120bp inhibits bacteria genesistasis induce apoptosis. bacteria represent salmonella escherichia coli.',\n",
              " 'fusion protein method detecting bacteria pseudaminic acida fusion protein including phage tail-spike protein φab6tsp signal indicator provided. also, method detecting bacteria pseudaminic acid (pse) provided, including steps contacting sample phage tail-spike protein φdab6tsp; detecting signal sample. fusion protein method detecting bacteria applied set practical diagnosis therapeutic alternative pse-coated antibiotic resistant pathogenic bacteria.',\n",
              " 'antibody proteina genera! method recombinant nucleic acid sequences, means method selects recombinant protein containing fha domain binding target molecule library proteins high-throughput method creating protein variations within fha domain non-conserved non-structural sequences fha scaffold, library may form phagemid phage library wherein alp nucleic acid sequence inserted vector capable allowing vector expressed alp protein virally packaged, recombinant nucleic acid sequences randomly mutated varying non-conserved non- structural fha domain sequences.',\n",
              " 'general strategy antibody library screening.a generally applicable method selective covalent attachment reporter molecule replicating entity allows one obtain specific binders single round library screening disclosed. example, selective biotinylation phage particles yeast cells displaying binder given target achieved via application coupled enzyme reaction includes peroxidase, oxidase catalase.',\n",
              " 'm13 bacteriophage high cysteine content genetically engineerable hydrogelsa genetically engineered bacteriophage crosslinked form solid material, example, hydrogel.',\n",
              " 'genetically engineered bacterium producing tetrahydropyrimidine induction using xylosea genetically engineered bacterium producing tetrahydropyrimidine induction using xylose, construction method therefor, application thereof. strain obtained heterologously expressing ectabc gene cluster halomonas elongatus chromosome e. coli, reconstructing tetrahydropyrimidine synthesis pathway, constructing plasmid-free system, using promoter xylose transporter encoding gene control rna polymerase t7 phage, utilizing t7 strong promoter system initiate efficient expression target gene, yield tetrahydropyrimidine reaches 12-16 g/l shake-flask fermentation 20-28 h, yield tetrahydropyrimidine reaches 35-50 g/l fermentation 5 l fermentation tank 24-40 h.',\n",
              " 'bacteriophages reducing toxicity bacteriaa genetically modified bacteriophage disclosed comprises: (i) exogenous polynucleotide encodes agent reduces toxicity bacterium; (ii) exogenous polynucleotide encodes selectable marker. uses thereof kits comprising disclosed.',\n",
              " \"genotoxic substance detection vector detection method thereofa genotoxic substance detection vector detection method thereof provided. vector escherichia coli expression vector sequentially having, 5' end 3' end, genotoxic response promoter, bacteriophage lysis gene, escherichia coli terminator. detection method includes introducing genotoxic substance response vector escherichia coli obtain recombinant bacteria, incubating recombinant bacteria genotoxic substances, lysing escherichia coli. recombinant escherichia coli genotoxic response vector, self-cell lysis initiated recombinant bacteria contacts genotoxic substances. detection method quantitates genotoxic substances means lysis efficiency. method consumes little time, high detection sensitivity, easy implement, low cost, easy promote.\",\n",
              " 'method screen selecting polypeptides excitomotor glucagon-like peptide-1 receptor vitroa glucagon peptide-1 receptor (glp-1 receptor) one nowadays recognized, important anti-diabetic drug targets. invention relates multi- peptide agonist vitro screening method glucagon peptide-1 receptor screened multi- peptide. invention discloses multi-peptide agonist method vitro screening glucagon peptide-1 receptor, screening method regards restructure glp-1 receptor membrane protein n-terminal fragment (n-glp-1r) target, method established utilizing vitro combining capacity combining phage display technology phage-elisa technology. invention discloses multi- peptide sequences acquired screening method. screening method disclosed invention simple convenient, appropriate vitro high flux screening glp-1 receptor multi-peptide agonist, invention provides novel method idea development treatment diabetes multi- peptide drugs, saves screening time reduces development cost.',\n",
              " 'healing promotion coated bandagea healing promotion coated bandage belongs medical appliance, comprises surface layer, medical adhesive, wound protecting layer piece adhesion-proof isolation paper, wherein, wound protecting layer contains enough sugar. ideal compatibility sugar solution osmotic pressure human tissue important biochemical action grapesugar wound tissue, utility model outstanding effect wound hemostasia, acesodyne, inflammation diminish healing promotion. utility model advantages anaphylaxis drug-resistance, low cost less use bacteriophage wound, thereby important product trauma care.',\n",
              " 'helical antennaa helical antenna comprises dielectric frame, matching board, quadri-filar radiating element assembly excite coaxial cables balancing loops, phasing bridge strong rings provided high-frequency connectors. phase bridge performed one high-frequency connector. strong rings made metal discs holes fixing protection cylindrical antenna body, inside diameter less than, made internal ring flange upper external flange. internal flange fixed strong rings phage bridge. external upper flange protection body protective dielectric cover fixed through-holes antenna fixing made.',\n",
              " 'human bladder cancer specific antigen binding peptidea human bladder cancer specific antigen binding peptide belongs field bio-medicines, characterized human bladder cancer specific antigen binding peptide composed 12 amino acids sequence mpmfkhrmfhth, wherein methionine residue, p proline residue, f phenylalanine residue, lysine residue, h histidine residue, arginine residue, threonine residue. human bladder cancer specific antigen binding peptide molecular weight 2024.0, specifically bound bladder cancer antigen human urine. human bladder cancer specific antigen binding peptide beneficial effects follows: polypeptide fragment derivatives thereof important application value early diagnosis, screening targeted therapy bladder cancer tumors. compared traditional screening method, phage display technology simple application, convenient operation easy large-scale production. human bladder cancer specific antigen binding peptide lays foundation targeted development targeted drug selection due advantages small relative molecular weight, weak immunogenicity, high activity, etc.',\n",
              " 'human monoclonal antibody targeting tnfer2 cancer immunotherapya human monoclonal antibody specifically binds tumor necrosis factor receptor 2 (tnfr2), defucosylated form antibody, described. tnfr2-specific antibody isolated human scfv phage display antibody library. disclosed antibodies promote antibody-dependent cell-mediated cytotoxicity (adcc) human tnfr2',\n",
              " \"heteroprotein melanoma epi (mage-1, hla-al) bacteriophage coat protein applicationa hybrid protein melanoma epitope (mage-1, hla-al) bacteriophage's coat protein application disclosed. melanoma epitope (mage-1, hla-al) gene fragment inserted carrier integrated main coat protein gene filamentous bacteriophage dna recombination technique configure new recombinant carrier. host, epitope gene product secreted outside cell assembled coat protein bacteriophage form said hybrid protein. used antigen generate immunore sponse antibody serum tumor patient, used prepare medicines diagnosing, preventing treating tumor.\",\n",
              " 'tumour vascular-targeting novel recombinant human tumour necrosis factor fusion protein preparationa kind amalgamation albumen combined peptide hrn tnf specificity knub neconatal vein preparation method disclosed invention. knub necro-gene kind multi-functional cell gene, participates immunity metabolizating modulation economy, restriant cell poison action growth cancer cells. invention wipes 1-7 bit amino acid amido end knub necro-gene, changes 8-10 bit amino acid arg-lys-arg 157 bit amino acid carboxyl end phe, composes new type high effect low poison knub necro-gene nrhtnf. basis, prepared amalgamation albumen combined peptide nrhtnf specificity ofthe knub neonatal vein enrich place knub neonated vein use cyclopeptide crgdc containing five amino acids elected phage revelation library.',\n",
              " 'method rapid detection enumeration viruses, bacteriophage and/or bacteriaa kit method rapid cost-effective culturing and/or detecting viruses, bacteriophage and/or bacteria provided. viruses, bacteriophage and/or bacteria cultured and/or detected within, on, absorptive fibrous matrix, cellulose fibre absorbent pad, allows growth detection viruses, bacteriophage and/or bacteria. detection may qualitative, semi-quantitative quantitative.',\n",
              " 'methods kits determine sensitivity strains lactococcus lactis bacteria phage infectiona kit useful determining phage susceptibility one strains lactococcus lactis means multiplex polymerase chain reaction (pcr) described. kit comprises: (a) first primer pair adapted generate first amplicon correlating region cwps operon unique l. lactis strains mg1363 sk11; (b) second primer pair adapted generate second amplicon correlating region cwps operon unique l. lactis strains il1403 kf147; (c) third primer pair adapted generate third amplicon correlating region cwps operon uniqueto l. lactis strains uc509.9 cv56; (d) optionally, control primer pair adapted amplify sequence conserved l.lactis. methods kits invention may employed type strains l. lactis phage-sensitivity groups, sub-type phage-sensitivity groups according phage sensitivity. invention described methods formulation mixed defined starter cultures using strains different phage sensitivity groups.',\n",
              " 'method apparatus enhanced bacteriophage-based diagnostic assaya labeled first bacteriophage (112) capable selectively attaching target microorganism (110) combined sample sample incubated sufficiently allow bacteriophage attach target microorganism. labeled first bacteriophage/target microorganism complex (136, 436) bound substrate (125) using second bacteriophage (104) selective target microorganism, substrate assayed detect presence absence label determine presence absence target microorganism. antibiotic may added least portion sample determine antibiotic susceptibility target microorganism.',\n",
              " 'bacteriophage resistant lactic acid bacteriaa lactic acid bacterium (lab) wherein yjae protein essentially inactive lab thereby improved resistance bacteriophages, starter culture composition comprising lactic acid bacterium use starter culture manufacturing food feed product.',\n",
              " 'phage display librarya library replicating entities, entity comprises recombinant vector comprising randomized nucleic acid sequence, reading frame structure [nxx]n [coraa] [nxx]m [nzz]o, [nzz]o [nxx]m [coraa] [nxx]n. nxx independently codon encoding amino acid except cysteine, coraa codon encoding cysteine least one amino acid, nzz independently codon encoding amino acid, n integer 0 40, integer 1 20, integer 1 40, least 20 percent coraa encode cysteine. invention relates set recombinant vectors set randomized oligonucleotides, oligonucleotide said structure, well method generating library replicating entities method identifying amino acid polymer.',\n",
              " 'light green balloon bacteriophage avp use thereofa light green balloon bacteriophage avp brought forward, deposited china typical culture preservation center deposit number cctcc no:m 2018155, deposited 25 march 2018. new light green balloon bacteriophage avp lyse bacteriophage avp lysate aeromonas aeruginosa, bacteriophage wide lysis spectrum, lyse pale green balloon bacteria, lyse staphylococcus aureus staphylococcus epidermidis. lyse standard strains clinical strains isolated environment diseased animal feces. used alone combination substances provide safe non-toxic bacteriophage sterilization product disinfection purification environment.',\n",
              " 'targetted polypeptide specificity liver cancer blood vessela liver cancer blood vessel specific target polypeptide lci-x7 able specific binding liver cancer blood vessel extracted naked mouse model human liver cancer showing technique phage random peptide library body microscopic laser cutting technique. provides important theory practical basis diagnosis liver cancer transfer recurrence target therapy.',\n",
              " 'methods isolating phage controlling microorganism populations phagea lytic virus specific target strain microorganism substantially free undesirable genes may utilized processes including control populations microorganisms. virus may include host-range mutant, \"h-mutant.\" method generating virus includes growing virus-resistant variants target strain microorganism presence viruses specific target strain. h-mutant viruses proliferate. wild-type virus-resistant virus-resistant variants microorganism disclosed, methods generating variants. methods controlling target strain microorganisms include introducing virus treatment site control population target strain microorganism desired introducing virus-resistant variants microorganism treatment sites presence microorganism desired.',\n",
              " 'medical devices coating promoting endothelial cell adhesiona medical device coating cell adhesion polypeptides enhance endothelial cell adhesion onto medical device. cell adhesion polypeptides may proteins extracellular matrix known play role cell adhesion derivative peptides rgd yigsr. polypeptides may incorporated backbone polymer polyurethane, grafted onto polymer polybisphosphonate. polypeptides may carried antibodies displayed bacteriophages. polypeptides may modified adhesive amino acid sequences. certain embodiments, medical device comprises temporary barrier protects polypeptides biofouling. temporary barrier may formed biodegradable polymer constructed coating polypeptides plurality micelles encapsulating polypeptides. certain embodiments, polypeptides may coated onto medical device manner form monolayer polypeptides.',\n",
              " 'plasma immobilization bacteriophages applications thereofa medical device, medical device including substrate defining surface; plasma polymer layer bound coating surface; bactericide layer bound plasma polymer layer, plasma polymer layer substrate bactericide layer. also, method coating surface substrate medical device bactericide layer, method including: exposing surface plasma form plasma polymer layer bound surface; binding bactericide layer plasma polymer layer.',\n",
              " 'means treatment colibacillosis birdsa medical means contains phage lysate e.coli o111 e.coli o26 therapeutically effective amount. tables: 1',\n",
              " 'means treatment salmonellosis birdsa medical means contains phage lysate s. typhimurium, s. gallinarum s. enteritidis therapeutically effective amount. tables: 1',\n",
              " 'means treatment salmonellosis pigsa medical means contains phage lysate s. typhimurium, s.cholerae suis s. enteritidis therapeutically effective amount. tables: 1',\n",
              " 'bacteriophage medical meansa medical means contains therapeutically effective amount phage lysates salmonella enteritidus.',\n",
              " 'bacteriophage medical meansa medical means contains therapeutically effective amount phage lysates xanthomonas campestris pv. malvaceum strains.',\n",
              " 'bacteriophage medical meansa medical means contains therapeutically effective amount phage lysates xanthomonas campestris pv. orizae strains.',\n",
              " 'method site-directed immunisationa method phage used producing antibodies selective (specific) certain antigen. antigen expressed surface phage presented immune system produce antibodies said antigen, phage used screening specific antibodies sample form immunised individual. further, specific antibodies may isolated.',\n",
              " 'methods composition production sequence specific antimicrobialsa method composition production sequence specific antimicrobials capable overcoming inefficient delivery, narrow host range, potential transfer virulence genes generalized transduction phage-based delivery systems integrating crispr/cas9 system phage genome, removing major virulence genes host chromosome, expanding host specificity phage complementing tail fiber protein significantly improves efficacy safety crispr/cas9 antimicrobials alternative therapeutics. method composition provide efficacious safe crispr/cas9 antimicrobial, broadly applicable mrsa.',\n",
              " 'bacteriophage-encoded antibacterial enzyme treatment prevention gingivitis root surface cariesa method composition treatment prevention gingivitis root surface caries using actinomyces naeslundii bacteriophage av-1 encoded anti-bacterial enzyme (av-1 lysin) remove inhibit establishment cariogenic pathogenic bacteria oral cavity disclosed, along amino acid sequence enzyme used therein isolated dna molecule encoding same.',\n",
              " 'identification phage associated lytic enzyme rapidly specifically detect kill bacillus anthracisa method composition treating bacillus anthracis infection disclosed comprises steps of: administering site infection colonization effective amount least one lytic enzyme genetically coded bacteriophage specific bacillus anthracis, wherein said least one said lytic enzyme specific ability digest cell wall said bacillus anthracis. lytic enzyme may chimeric shuffled, holin protein may used. sequence lytic enzyme gamma bacteriophage disclosed.',\n",
              " 'method kit identifying antimicrobial agents effective concentrations thereofa method kit determining effective concentration antimicrobial agent inhibiting bacterial growth provided. method kit involve use first second multiwell receptacle. fluid sample containing suspected contain one microbial organisms dispensed wells first multiwell receptacle containing range dilutions antimicrobial agent, growth medium bacteriophage form assay mixtures wells. assay mixtures transferred corresponding wells second multiwell receptacle detection.',\n",
              " 'method system high throughput screening antibacterial phagea method system high throughput screening antibacterial phage. method comprises: 1) spotting, plate containing host bacteria, multiple phages detected performing cultivation; 2) capturing image cultivation plate obtain plaque image; 3) performing binarization plaque image convert phage image binary image; 4) filtering binary image basis appearance transmittance plaque binary image obtain phage antibacterial phenotype data; 5) screening, basis phage antibacterial phenotype data, phages detected, obtain antibacterial phage. method system used identifying phage infection capacity, selecting phage monoclones, preparing phage cocktail preparation phage therapy, performing phage function verification, reversely screening anti-phage host bacteria, performing phage lysin function verification.',\n",
              " 'method manipulating phages within body attack infectious target cellsa method system disclosed regulating, manipulating inducing change activity, lysogenic lytic activities native naturally occurring phages within subject treat bacterial, viral, fungal, parasitic infection, pathological biologically-physiologically advantageous target subject, method including steps identifying target within subject exposing subject treatment electromagnetic signature suitable induce native phages subject attack target, advantageously modify target pathology substance. method include implanting treatment electromagnetic signature within ingestible carrier medium providing ingestible carrier medium subject.',\n",
              " 'method production mono combined dry bacteriophage preparationa method comprises concentrating separate united phage lysates centrifuging following adding fillers lyophilization.',\n",
              " 'method capable auto rejecting marking gene trans gene planta method autonomously rejecting marker gene transgenic plant includes using lambda bacteriophage attp-specific recombinant site recombinant enzyme gene int configure plant transfer carrier pamf containing int, target gene marker gene, preparing transgenic plants, selfing cutting marker gene, screening plants without marker gene, determining pcr southern molecule test.',\n",
              " 'method detecting bacteria bacteriophagea method detecting bacterium measurement, including steps of: allowing bacteriophage bind bacterium, bacteriophage capable specifically binding bacterium growing bacterium, whereby gene within bacteriophage expresses light-emission protein introduced bacterium protein produced within bacterium product gene; providing external factor non-invasive manner outside bacterium, thereby causing actually-present bacterium emit light specific manner.',\n",
              " \"method detection mitigation compound producing microbiota aquaculture systema method detecting mitigating compound producing microbiota aquaculture system. method detecting mitigating off-flavor producing microbiota includes, taking least one sample water portion aquaculture system contains aquaculture, extracting genetic material microbiota sample taken, quantifying extracted genetic material creating least one bacteriophage relation microbiota's genetic material, introducing bacteriophage(s) aquaculture system.\",\n",
              " 'method apparatus detecting bacteriaa method detecting bacteria enables detection judgement specific bacterias simple operation, shortened measurement time, improved efficiency, excellent detection accuracy labelling bacteria per se simple specific manner without resort color tone changes caused metabolism fermentation substrate. bacteriophage nucleic add labelled fluorescent substance subjected bacterial contact host cell judge whether specific bacterias present absent utilizing fact significant difference fluorescence intensity fluorescence-labelled nucleic acid present phage fluorescence intensity state fluorescence-labelled nucleic add introduced bacteria.',\n",
              " 'apparatus method detecting microscopic living organisms using bacteriophagea method detecting one target bacteria (14) raw sample where: bacteriophage(s) (18, 102) specific target bacterium added raw sample, test sample incubated, test sample applied substrate (64, 220) changes color either bacteriophage biological substance associated bacteriophage present. substrate contains antibodies (44, 228) bind specifically phage. bacteria test sample may lysed adding microbial lysozyme (22) bacteriophage exposed sample. parent phages (102) tagged (105) way separated progeny phage (106) prior detection process. phage dissociated (94, 124) incubation process sample tested (99, 116) presence individual capsid proteins (97, 72) phage nucleic acids (74). invention used (140) test target bacteria antibiotic resistance.',\n",
              " \"method detection coagulant's anti-virus activity water conditioninga method detection coagulants antivirus activity consists determination intestinal bacteriophages number eluent treatment ofprecipitate therewith. determination antivirus activity made according decrease bacteriophages number eluent treatment explored coagulant precipitate statically valid value (p<0,05) compared eluent treatment control coagulant precipitate.\",\n",
              " 'method detection low-molecular inhibitors biosynthesis nucleic acidsa method detection low-molecular inhibitors biosynthesis nucleic acids using combination model dna-containing enzymatic complexes comprises using reaction transcription using dna-dependent rna-polymerase phage t7, polymerase chain reaction using tag-polymerase reaction relaxation superhelicited dna topoisomerase test systems.',\n",
              " 'method detection pathogens pileate fungi (basidiomicetes)a method detection pathogenes pileate fungi (basidiomicetes) preparing preparation mycelium layer thereof 2- mixed phosphotungstic acid (pta) ph 5.5-6.5 prepared mixture contracts prepared mixture exposure 150-180 seconds, coated onto grid-substrate, dried, photograph taken electronic microscope; assessing external characters carried basis images (photographs) contrasted mycelium preparation; preparing fungal fruiting body preparation sample taken pileus fruiting body shaped triangle side 2.5- contrasting treatment pta ph 5.5-6.5 exposure 90-180 seconds, applying mixture onto grid-substrate drying. final assessment contrasted preparation fungal fruiting body external characters carried basis images (photographs). structure-morphological objects bacteria, microscopic fungi viruses detected whole preparation short period time. addition bacteria, phages thereof (viruses), microscopic fungi fragments thereof (organelles) preparations mycelium (fruiting body) pileate fungi (basidiomicetes) detected fixed images magnification 10000-25000 times, viruses rod, bacillary isometric form detected photographs thereof taken magnification 25000-45000 times.',\n",
              " 'method determination antiviarl action preparations based fluorenesa method determination antiviarl action preparations based fluorenes, described themes, characterized test tube investigated preparation based fluorenes entered equal quantities certain concentration well staphylococcal bacteriophage intestiphage. incubated thermostate temperature 37 ° c 30 minutes, drop put agar surface sowing staphylococcal culture incubated thermostate 24 hours, registration - absence lysis zones site drop application evidence antiviral action preparation.',\n",
              " 'method determination electromagnetic radiation influence biological objectsa method determination electromagnetic radiation influence biological objects comprises selection radiation parameters. bacteriophage used biological object, irradiations carried polarized electromagnetic field power 2 mw 15 minutes, influence radiation determined quantitative indices infectious titres prior irradiation.',\n",
              " 'autonomous inducible directed evolution complex pathwaysa method directed evolution microbe, method comprising: introducing first host cell propagation deficient phage genome vector comprising target gene sequence mutated phage propagation component responsive induce lysis first host cell provide propagation phage genome; exposing first host cell mutagenesis agent; inducing lysis first host cell phage propagation produce lysate comprising phage particles comprising target gene sequence; infecting second host cell lysate. systems kits practicing method disclosed.',\n",
              " 'method vivo directed evolution target proteina method directed evolution target protein cell provided perform treatment, culture screening repetitive mutant-inducing agent. hybrid helper phage fusion genome comprises: genome dna first phage origin replication removed; genome dna second phage origin replication different first phage. directed evolution method target protein cell comprises: step preparing carrier plasmid contains origin replication polynucleotide encoding target protein; step selection plasmid containing antibiotics-resistance gene promoter; step preparing first transformant second transformant; step infecting hybrid helper phage second transformant; step producing mutant carrier phage; step collecting mutant carrier phage; step preparing third transformant; step infecting mutant carrier phage third transformant; step culturing third transformant; step screening single colony.',\n",
              " 'peroral pharge display process, enterocyte-transcytotic peptide identified thereby peroral drug delivery system using samea method displaying peroral phage provided identify peptide showing optimum absorption efficiency passing small intestine mucosa highest frequency. peroral administration system identified peptide introduced provided increase absorption efficiency protein drug bio-membrane significantly, thereby enlarging usability protein drug. method displaying peroral phage comprises steps of: (a) forming phage-peptide library; (b) perorally injecting library rat; (c) blood-irrigating rat; (d) taking organs rat taking tissue sample therefrom, washing homogenizing sample, neutralizing titrating it; (e) quantifying phage sample; (f) titrating separated phage separate phage dna therefrom, analyzing sequence dna identify peptide functional group characterized steps (b) (e) repeated 3 times perform biopanning, phage passing small intestine mucosa biopanning identified various tissues organs liver, lung, heat, spleen blood, acid elution step homogenization step(d) added identify organ targeting peptide specifically bound specific tissue passing small intestine mucosa. peptide identified method inducing absorption promotion small intestinal epithelium includes amino acid sequence cskssdyqc. peroral administration system characterized peptide inducing absorption promotion small intestinal epithelium introduced protein-based drug.',\n",
              " 'selection system phagemids using proteolytically sensitive helper phagea method effecting helper phage rescue phagemid comprising fusion polypeptide form progeny bacteriophage wherein <sl> <li>(a) helper phage encodes viral coat protein comprising protease sensitive cleavage site <li>(b) phagemid comprises fusion polypeptide <li>(c) progeny phage exposed protease capable cleaving proteolytically cleavable site cleavage protein derived helper phage impairs ability mediate infection <li>(d) progeny propagated infection. </sl> helper phage protease sensitive site within p3 coat protein filamentous bacteriophage m13, fd related species.',\n",
              " 'methods testing integrity membranes optically electrochemically detectable nanoprobes thereofa method evaluating integrity microf iltration, ultrafiltration nanof iltration membranes, method comprises passing liquid contains substantially mono-dispersed population nano-probes selected gold nanoparticles, viruses bacteriophages labled fluorescent marker reaction catalyzing group said membrane form permeate testing said permeate presence said nano-probes, wherein non-detection said nano-probes said permeate indicates said membrane substantially intact.',\n",
              " 'sensitive preparation amplification eukaryotic derived nucleic acid fortranscriptional profilinga method global amplification c dna rna template described. c dna produced retains relative abundance across sample rna transcripts produced. embodiments method sensitive enough produce c dna samples equivalent single cell amounts rna. method comprises steps of: a) reverse transcription template rna population, produce global c dna population; b) homopolymer tailing c dna population, produce c dna molecules homopolymer tail; c)amplifying tailed global c dna; wherein least one steps (a) (b), preferably both, is/are effected presence acetate buffer. preferred embodiments, step (a) carried presence non specific rna template (nsrt) comprise sequences found target; example, target may mammalian rna nsrt may lambda phage rna. preferred embodiments, step (b) carried presence co cl2..',\n",
              " 'method pegylating human monoclonal antibody antibody methoda method glycolating human monoclonal antibody provided stabilize scfv(single chain fv fragment) antibody glycolated polyethylene trypsin, extend half life scfv antibody maintaining biological function resistance. human monoclonal antibody specifically bound duffy-binding protein plasmodium bovis stabilized glycolation polyethylene, wherein antibody sfdbii-12 clone, sfdbii-58 clone sfdbii-92 clone derived scfv phage expression library human body.',\n",
              " 'phage antibodies radiation-inducible neoantigensa method identifying molecule binds irradiated tumor subject molecules identified thereby. method includes steps of: (a) exposing tumor ionizing radiation; (b) administering subject library diverse molecules; (c) isolating tumor one molecules library diverse molecules, whereby molecule binds irradiated tumor identified. provided therapeutic diagnostic methods using targeting ligands bind irradiated tumor.',\n",
              " 'method sorting vesicle-entrapped, coupled nucleic acid-protein displaysa method identifying sorting variants chosen enzyme disclosed. enzyme variants chosen enzyme obtained linked corresponding genetic code family suitable surface display methods. enzyme variants, displayed surface biological particle phage, virus, yeast, bacterium encapsulated vesicle containing enzyme activity-sensitive assay reagent. enzyme variant thus exposed assay reagent, displays signal using enzyme activity-sensitive assay reagent manner proportionate levels activity enzyme, thus rendering vesicles suitable mechanical sorting based levels. vesicles sorted using methods known art isolate variants exhibiting possibly beneficial variations enzyme function.',\n",
              " 'method identifying interaction partners using phage displaya method identifying/selecting interaction partners interact target molecule, aid support anchor molecules applied form polymer-free surface affinity ligands covalently bonded, said ligands brought contact viruses plurality peptides proteins interaction partners surface described. method described guarantees accumulation viruses present specific interaction partners optionally cyclic repetition selection. optionally, selected specific interaction partners expressed recombinantly coding nucleotide identified. furthermore, surface use phage display method described.',\n",
              " 'magnetic nanoparticlesa method making composition magnetic nanoparticles, includes step forming magnetic nanoparticles, within protein template, wherein liquid composition said protein template subunits thereof subjected microporous membrane filtration step prior formation magnetic nanoparticles. protein template may comprise flagellar l-p rings, microtubules, bacteriophages, chaperonins, virus capsids preferably members ferritin family, preferably apoferritin. magnetic nanoparticles preferably comprise ferri- ferro-magnetic materials, metal alloys, m-type spinel ferrite. claimed method treating liquid composition magnetic nanoparticles, formed within macromolecular template, method including subjecting composition microporous membrane filtration step. claimed composition encapsulated magnetic nanoparticles, wherein least 70% weight nanoparticles agglomerated form wherein composition comprises 30% free encapsulating material, based total weight encapsulating material composition.',\n",
              " 'detection infectious agents using antigen mimics.a method making diagnosis antigen, comprising identifying binding specificity anti-antigen antibody molecules serum antibody detection antigen mimics (adam) methodology, comprising screening phage libraries using sera antigen-infected patients non-infected individuals, identifying peptides binding antibodies (ligands) specifically associated said antigen. improvements method given vitro maturation strategies; linking ligands common core, map. particular method applies hcv.',\n",
              " 'modifying bacteriophagea method modifying genome lytic target phage, uses method products thereof described. compositions comprising phage described. compositions may formulated medicament, useful human treatment may treat various conditions, including bacterial infections.',\n",
              " 'modifying bacteriophage using beta-galactosidase selectable markera method modifying genome target phage described. compositions comprising modified phage described. compositions may formulated medicament, useful human treatment may treat various conditions, including bacterial infections.',\n",
              " 'bacteriophage activity pathogenic strains salmonellaa method obtaining strain bacteriophage specific selected strain bacteria found well bacteriophage strains obtained way. moreover, application bacteriophages manufacturing preparation preventing fighting infections farm animals, especially poultry, pathogenic strains bacteria sensitive phages described.',\n",
              " 'method liberating bacteriophages uses thereofa method obtaining bacteriophages stressing bacteria. method involves isolating bacteria, propagating bacteria, exposing bacteria least one environmental stressing agent induce excision bacteriophage present bacterial genome. multiple individual environmental stressing agents may applied. liberated bacteriophages may collected purposes treating pathogenic infections, protecting plants agricultural products general sterilization sanitation.',\n",
              " 'site-specific serine recombinases mycobacterium tuberculosis phage phirv1 m. smegmatis phage bxb1and methods usea method obtaining site-specific recombination isolated eukaryotic cell comprising: - providing isolated eukaryotic cell comprises first recombination site second recombination site; - contacting first second recombination site prokaryotic recombinase polypeptide resulting recombination two sites; -the first recombination site either phage genomic recombination attachment site (attp) bacterial genomic recombination attachment site (attb) second recombination either attp attb, provided first recombination site attp second recombination site attb vice versa; - recombinase mycobacterium tuberculosis phage recombinase m. smegmatis phage recombinase particular recombinases phirv1 bxb1 recombinase. method encompasses use pseudo attp attb recombination sites well third fourth, fifth sixth recombination site.',\n",
              " 'method potentiating effects antibiotics fluoroquinolone groupa method potentiating effects antibiotics fluoroquinolone group comprises combination antibiotic coli-proteus phage.',\n",
              " 'method predicting relationship bacteriophage bacterial infectiona method predicting relationship bacteriophage bacterial infection, comprising learning model bacteriophage-host infection relationship construction method therefor. method constructing learning model bacteriophage-host infection relationship comprises: training learning model using data training set bacteriophages bacterial strains, data training set bacteriophages bacterial strains comprising genome data phenotypic assay data. method using learning model bacteriophage-host infection relationship predict bacteriophage infect bacteria method predicting bacteria infected bacteriophage, computer-executable medium comprising computer program performing methods.',\n",
              " 'method preparing bacteriophage preparation, pharmaceutical composition, applicationa method preparing bacteriophage preparation, pharmaceutical composition, application. method comprises: percolating bacteriophage mixed culture solution using tangential flow system obtain bacteriophage original solution; concentrating bacteriophage original solution using tangential flow system concentration 7-10 times concentration bacteriophage original solution obtain bacteriophage concentrate; performing cesium chloride density gradient centrifugation bacteriophage concentrate using cesium chloride solution obtain bacteriophage density gradient solution; dialyzing bacteriophage density gradient solution using 20 kd membrane obtain bacteriophage preparation. way, endotoxin bacteriophage preparation removed quickly, low cost high efficiency.',\n",
              " 'bioactive peptide-based probesa method preparing site-specific peptide probe, wherein peptide specific receptor, includes modifying marker include tether molecule covalently binding tether molecule peptide. present invention provides labeled probe, comprising peptide specific receptor marker. marker modified include tether molecule capable covalently binding peptide. peptide typically derived bacteriophage synthetic analog derivative peptide. receptor typically found surface bacterial cell. method probe invention suitable rapid assay bacteria complex mixture.',\n",
              " 'frame-shifting pcr germline immunoglobulin genes retrieval antibody engineeringa method preparing antigen-specific antibody constructing library phage-displayed single chain variable fragment antibody novel frame-shifting pcr disclosed. disclosed method preparing clone producing antigen-specific antibody.',\n",
              " 'bacteriophage composition useful treating food products prevent bacterial contaminationa method preventing growth e. coli microorganisms food product comprising contacting food product microbial growth inhibiting effective amount bacteriophage composition comprising bacteriophage isolate 119u, wherein application time said bacteriophage composition least fraction second prevent growth microorganisms food product',\n",
              " 'method producing antigen-binding molecule using modified helper phagea method producing bacteriophage presenting antigen-binding molecule, method characterized including step brings helper phage capable expressing first polypeptide contact bacterium capable expressing second polypeptide, first polypeptide second polypeptide associating forming antigen-binding molecule.',\n",
              " 'process production bacteriophage compositions methods phage therapy fielda method producing bacteriophage stock compositions including (a) incubating culture medium including least one bacterial strain, least one bacteriophage strain infect bacterial strain, least one antibiotic, wherein concentration antibiotic medium range causes 0.1% 99.9% inhibition growth bacterial strain absence bacteriophage strain; (b) continuing incubation culture medium bacterial lysis occurs, thereby obtaining bacteriophage lysate; preparing crude bacteriophage extract culture medium.',\n",
              " 'method producing new medicinesa method producing new medicines wherein organisms cells 1 known producer medicines exposed offending medicine resistant organisms cells 3 almost destroyed 4 offending organisms cells killed organism cell killing substance radiation 5 kill offending organisms cells organisms cells enable surviving organisms cells reproduce 6 enabling inherited resistance harvested steps repeated sufficient number times organisms cells kill offending organisms cells without help. organisms cells may fungi mould offending organisms cells may bacteria organism cell killing substance may bleach phages. method may used develop new antibiotics, antifungals, antivirals, antiparasitics anticancer drugs.',\n",
              " 'modifying bacteriophagea method producing one hybrid bacteriophage host range determinant (hrd) sequences, comprises: (1) identifying least two dna sequences, encoding hrd series regions dna sequence, wherein hrds different one another, (2) incorporating region vector region flanked recognition site restriction enzyme capable cutting dna specific cleavage site outside recognition sequence, cleavage site restriction enzyme situated boundary region, wherein cleavage site sequences regions individual series different one another wherein cleavage site sequences boundaries corresponding regions different series same; (3) treating vectors restriction enzyme capable cutting dna specific cleavage site outside recognition sequence generate mixture regions; (4) treating mixture regions ligase ligate form array dna sequences encoding array hybrid hrds.',\n",
              " 'methods profiling extracellular vesicles combinatorial phage display librariesa method profiling extracellular vesicles (ev) provided. method includes: (a) incubating isolated ev one sources phage display library conditions suitable forming ev-bound phage, wherein phage display library comprises one types phage, type phage displayed proteinaceous display binding moieties capable recognizing one epitopes surface ev, wherein type phage comprises nucleic acids encoding displayed proteinaceous display binding moieties, wherein displayed proteinaceous display binding moieties type phage different; (b) isolating ev-bound phage; (c) extracting nucleic acids ev-bound phage; (d) amplifying extracted nucleic acids; (e) sequencing amplified nucleic acids identify specific nucleic acid sequences associated type phage library enriched isolated ev; (f) comparing specific nucleic acid sequences (output) nucleic acid sequences phage display library (input) nucleic acid sequences control identify sequences distinguish ev one sources.',\n",
              " 'high density growth t7 expression strains auto-induction optiona method promoting suppressing auto-induction transcription cloned gene 1 bacteriophage t7 cultures bacterial cells grown batchwise disclosed. transcription control promoter whose activity induced exogenous inducer whose ability induce said promoter dependent metabolic state said bacterial cells.',\n",
              " 'method protecting plants black stem disease using lactobacilli erwinia autolysatea method protecting plants black stem disease using lactobacilli erwinia autolysate lies fact treating roots vegetable seedlings lactic acid bacteria lactobacillus plantarum, grown 48 hours liquid medium mrs concentrationcfu/ml, used. roots treated complex mixture, composition supplemented autolysate bacterium erwinia carotovora subsp. carotovora, comprises bacteriophages macromolecular bacteriocines allows controlling pathogens plant black stem disease.',\n",
              " 'method protecting roots tubers soft rot using lactobacilli erwinia autolysatea method protecting roots tubers soft rot lies fact treating roots bulbs lactic acid bacteria lactobacillus plantarum, grown 48 hours liquid mrs medium concentration ofcfu/ml, used. composition bacterial suspension supplemented autolysate bacteria erwinia carotovora subsp. carotovora, comprises bacteriophages macromolecular bacteriocines specifically killing phytopathogenic bacteria.',\n",
              " 'method protection short-circuit currents power supply network asynchronous motora method protection short-circuit currents asynchronous motor power supply circuit comprises measuring time slot passing currens preset low upper levels, comparison said time slot pulse length, corresponds short-circuit failure, shaping command network voltage protection turn off, said time slot exceed maximum allowable time slot. time slot measuring, control pulse length 90 electrical degrees shaped case presence time phase current semi-wave pulse preset maximum permissible length, leading edge coincides beginning voltage wave phase corresponding polarity. shaped command protection supply voltage turn used, control pulse present. momentary values phage current used current parameter measured.',\n",
              " 'method quantitative detecting fusion protein affiliation object fusion protein using display technique bacteriophagea method quantitative-detecting quantity external source protein applies bacteriophage demonstration technique expression qualitative detection external source protein applies bacteriophage demonstration technique carry quantitative detection external source protein.',\n",
              " 'method rapidly preparing antigen-specific antibodya method rapidly preparing antigen-specific antibody provided. method includes establishing antibody-polypeptide corresponding relationship antibody-motif corresponding relationship; finding polypeptide amino acid sequence target protein searching antibody-polypeptide corresponding relationship, antibody corresponding polypeptide antigen-specific antibody; calculating similarity degree motifs antibody modules target protein antibody-motif corresponding relationship, antibody corresponding motif similarity degree greater 0.4 antigen-specific antibody. phage display technology high throughput sequencing technology combined method, information polypeptide motif recognized given antibody efficiently acquired overall manner, antibody-polypeptide corresponding relationship antibody-motif corresponding relationship established, relationship, specific antibody corresponding target protein rapidly determined. method wide application prospect.',\n",
              " 'method treating food surfaces bacteriophagesa method reducing bacterial contamination food surface. method comprises applying food surface bacteriophage methylcellulose. methylcellulose anhydroglucose units joined 1-4 linkages wherein hydroxy groups anhydroglucose units substituted methyl groups s23/s26 0.36 less, wherein s23 molar fraction anhydroglucose units wherein two hydroxy groups 2- 3-positions anhydroglucose unit substituted methyl groups wherein s26 molar fraction anhydroglucose units wherein two hydroxy groups 2- 6-positions anhydroglucose unit substituted methyl groups.',\n",
              " 'location-specific bacterial managementa method reducing population pathogenic bacteria animal reared animal rearing facility provided. method involves using one one naturally-occurring location-specific bacteriophages selected highly specific strains one one pathogen present facility, phage component derived one one naturally-occurring location-specific bacteriophages, combination thereof, produce location-specific bacteriophage preparation. preparation administered animal, reduce one one pathogenic bacteria. method may involve step identifying location-specific isolates one one pathogenic bacteria near animal rearing facility.',\n",
              " 'method rejecting marking gene trans gene planta method rejecting marker gene transgenic plant order increase safety includes using lambda bacteriophage attp-specific recombinant site recombinant enzyme gene int configure plant transfer carriers pmfc containing int pmfb containing target gene marker gene, preparing transferred plants respectively, crossing specifically cutting marker gene, screening transgenic plants without said marker gene, determinating.',\n",
              " 'methods compositions remediating microbial induced corrosion environmental damage improving wastewater treatment processesa method remediating bacterially-induced corrosion, environmental damage, and/or process inefficiencies industrial process includes identifying industrial process target bacteria adversely affect corrosion, environmental impact, and/or process efficiencies. process includes identifying strains target bacteria, obtaining bacteriophage virulent one strains target bacteria, exposing target bacteria bacteriophage. method utilize aqueous composition comprising bacteriophage encapsulated least one selected group consisting of: liposomes, foam, gel.',\n",
              " 'methods nucleic acid manipulationa method replicating amplifying target nucleic acid sequence described. method invention involves formation recombination intermediate without prior denaturing nucleic acid duplex use recombination factor. recombination intermediate treated high fidelity polymerase permit replication amplification target nucleic acid sequence. preferred embodiments, polymerase comprises polymerase holoenzyme. preferred embodiments, recombination factor bacteriophage t4 uvsx protein homologs species, polymerase holoenzyme comprises polymerase enzyme, clamp protein clamp loader protein, derived viral, bacteriophage, prokaryotic, archaebacterial, eukaryotic systems.',\n",
              " 'method revealing pathogens pileate mushrooms (basidiomicetes)a method revealing pathogens pileate mushrooms (basidiomicetes), which, preparing preparation mycelium, layer latter 2-4 mm mixed phosphoric-tungstic acid (phta) ph 5,5-6,5, prepared mixture contrasted exposure 150-180 seconds, coated onto liner net, dried photographed electron microscope. assessment outward signs carried basis images contrasted mycelium preparation; and, compounding preparation fruit body mushroom, sample taken pileus fruit body mushroom contrasting thereof phta ph 5,5-6,5 exposure 90-180 seconds, coating mixture onto liner net dried, final assessment preparation outward signs carried basis images thereof. structural-morphological objects bacteria, microscopic fungi viruses revealed integrated manner one preparation short time; addition bacteria, phages thereof (viruses), microscopic fungi fragments thereof (organelles) preparations mycelium (fruit body) pileate mushrooms (basidiomicetes) revealed fixed images magnification 10000-25000 times, viruses rod-like, bacillus isometric shape revealed photographed magnification 25000-45000 times.',\n",
              " 'inhibitors viral infection targeting integrase n-terminal regiona method screening novel integrase inhibitor completely different conventional integrase inhibitors drug function point hiv-infection inhibited reverse transcription step; novel integrase inhibitors obtained using screening method; medicinal compositions containing integrase inhibitors dna encoding highly expected novel remedies aids. peptide inhibiting infection proliferation retrovirus (hiv-1, etc.) reverse transcription obtained screening phage display method peptide binding specifically n-terminal region retrovirus integrase.',\n",
              " 'method screening catalytic peptides using phage display technologya method screening catalytic peptides using phage display technology disclosed. compound exposed phage library. peptide library catalyzes reaction, gel formed phage displays peptide. gel, including first phage, separated un-reacted phages released gel. phage replicated analyzed determine composition peptide functioned catalyst.',\n",
              " \"method screening αβ-tcr heterodimer mutantsa method screening αβ-tcr mutants, method comprising construction phagemid. construction, gene encoding a1 polypeptide gene encoding b1 polypeptide inserted 3' ends genes encoding constant regions α chain β chain tcr respectively, ribosome binding site molecular chaperone gene integrated phage vector, wherein amino acid sequence a1 polypeptide shown seq id no: 1 represented variant a1 polypeptide; amino acid sequence b1 polypeptide shown seq id no: 2 represented variant b1 polypeptide; variants least retain function polypeptides mutation. a1 peptide b1 peptide used promoting correct pairing folding αβ heterodimer tcr, efficiency displaying correctly folded tcr surface phage improved. method efficiently complete screening αβ heterodimer tcr mutants.\",\n",
              " 'vector method screening functional antigen-binding proteina method selecting functional antigen-binding protein. method comprises step constructing expression vector, means phage display technique and/or cell display technique, using light chain fragment thereof reference antigen-binding protein known sequence function, heavy chain fragment thereof reference antigen-binding protein, thereby selecting functional antigen-binding protein binds epitope reference antigen-binding protein. provided functional antigen-binding protein obtained means method.',\n",
              " 'use native epitope selecting evolved binding members library mutants protein capable binding said epitopea method selecting mutant molecule (such antibody) capable binding epitope (such ep-cam), comprising: (a) generating phage display library mutants molecule, said molecule capable binding epitope; (b) incubating phage display library cell crude cellular extract thereof, said cell crude cellular extract thereof displaying epitope; (c) selecting least phages binding cell crude cellular extract thereof displaying epitope, and; (d) separating recovering phages binding cell crude cellular extract thereof displaying epitope.',\n",
              " 'method selecting peptide polypeptide binds targeta method selecting peptide polypeptide binds target provided. method based protein splicing phage display.',\n",
              " 'method selecting method sanitization abdominal cavity generalized peritonitisa method selecting method sanitization abdominal cavity generalized peritonitis comprises washing abdominal cavity antiseptic solutions followed studying morphometric parameters parietal peritoneum. specific volume 0.1314 ± 0.0546 neutrophilic polymorphonuclear leukocytes (npml), 0.0145 ± 0.0038 lymphocytes, 0.0046 ± 0.0013 macrophages, abdominal cavity washed antiseptic solutions irrigated bacteriophage. specific volume 0.2614 ± 0.0431 npml, 0.0126 ± 0.0023 lymphocytes, 0.0039 ± 0.0010 macrophages, washing antiseptic solutions irrigation bacteriophage supplemented infiltration mesenteric root small intestine, purulent foci omentum parietal peritoneum bacteriophage.',\n",
              " \"optical mapping genomic dnaa method single-molecule optical dna profiling using exceptionally dense, yet sequence-specific coverage dna fluorescent probe, using dna methyltransferase enzyme direct dna labeling, followed molecular combing dna onto polymer-coated surface subsequent sub-diffraction limit localization fluorophores. result 'dna fluorocode'; simple description dna sequence, maximum achievable resolution less 20 bases, read analyzed barcode. method generates fluorocode genomic dna lambda bacteriophage using dna methyltransferase direct fluorescent labels four-base sequences reading 5'-gcgc-3'. consensus fluorocode constructed allows study dna sequence level individual labeling site generated handful molecules entirely independently reference sequence.\",\n",
              " 'method synthesis gold nanostructures using dodecamer peptides midas-1 midas-12a method synthesizing nanosturecture gold using dodecamer peptides midas-1 midas-12 provided synthesize nanosturecture gold environment-friendly easily without using high temperature, pressure high toxic chemicals. method synthesizing nanosturecture gold using dodecamer peptides midas-1 midas-12 comprises following steps of: eluting phage combined metallic gold powder adding glycine-hcl cultivating metallic gold powder solution phage; amplifying eluted phage infection e.coli neutralizing supernatant including phage tris hydrochloride; separating phage combined surface metallic gold powder polyethylene glycol/nacl; repeating first third step 2 times; acquiring dodeca peptide midas-2 synthesizing gold; substituting amino acid glycine midas-2.',\n",
              " 'mycobacteria detection using bacteriophagesa method testing target mycobacteria reaction mixture comprising steps of: providing reaction mixture; admixing bacteriophage reaction mixture conditions suitable allow bacteriophage infect target mycobacteria present reaction mixture; allowing time bacteriophage lyse infected live target mycobacteria; analysing said reaction mixture dna lysed mycobacteria identify signature dna sequence occurs target mycobacteriumspedes.',\n",
              " 'modifying bacteriophagea method genetic modification, mutation, homologous recombination recombineering naturally obligate lytic phage bacteriophage disclosed wherein variant usually lytic phage lacking endolysin gene introduced first host cell together vector comprising target nucleic acid modified trans endolysin gene. target nucleic acid incorporates genome endolysin deficient phage, endolysin gene comes it. thus phage subsequently propagated usual host cell (also endolysin deficient), presence endolysin gene within phage genome facilitates lytic cycle enabling ready selection phages comprising recombinant nucleic acid.',\n",
              " 'method isolation unicellar algae algoviruses, e.g., platymonas viridis rouch (chlorophita)a method isolation algoviruses unicellar algae, e.g, platymonas viridis rouch (chlorophita), consists revealing interaction bacterial sensitive (indicative bacteriophage) culture predictable bacteriophage. revealing culture microalga p.viridis cultural medium logarithmic stage used, culture contaminated equal volumes material tested. availability pathogenic microorganisms material tested determined according changes test compared control. that, effect inhibition fixed subsequent subinoculations revealed suppressing material culture microalgae. .',\n",
              " 'phage display librariesa method preparation phage display library selection high affinity binding phage (shaved phage) comprising: providing library phage expressing proteinaceous ligand plurality phage surfaces wherein ligand attached phage coat protein wherein cleavable site located within expressed ligand-coat protein; treating library cleaving agent proportion phage monovalent proteinaceous ligand. claimed method selection phage library, phage particle comprising ligand attached phage gene iii coat protein wherein particle cleavable site within said surface-expressed ligand-coat protein shaved phage library.',\n",
              " 'antibody anthraxa method production antibody specific b. anthracis comprising steps i) generating immune scfv phage-display library ii) panning library immobilised b. anthracis spore presence spore one bacillus species.',\n",
              " 'affinity separation means, uses thereof separate, purify concentrate target moleculea method purification target molecule sample containing, suspected containing, target molecule, employs filamentous phage functionalised magnetic particle filamentous phage genetically engineered express least one coat protein form fusion protein comprising foreign peptide specific binding affinity binding partner selected target molecule surface magnetic particle. method comprising steps incubating affinity separation means sample period time sufficient allow filamentous phage bind target molecule present sample, separating affinity separation means sample, eluting bound target molecule affinity separation means.',\n",
              " 'method sanitization abdominal cavity generalized peritonitisa method sanitization abdominal cavity generalized peritonitis comprises washing abdominal cavity decaxan solution followed infiltration mesenteric root small intestine, purulent foci omentum parietal peritoneum bacteriophage.',\n",
              " 'semiconductor nanoparticlesa method synthesis semiconductor nanoparticles within protein template, wherein semiconductor selected cdse, cdte, znse, zns znte, method comprising forming reaction mixture combining liquid medium cation source selected cadmium zinc ions anion source selected sulfur, selenium tellurium ions presence source protein capable acting template formation nanoparticles maintaining liquid medium temperature least 24{c time sufficient permit nanoparticle formation within protein template, proviso cation source cadmium, anion source sulfur. protein template may comprise flagellar l-p rings, microtubules, bacteriophages, chaperonins, virus capsids preferably members ferritin family, preferably apoferritin. encapsulated nanoparticle may subjected membrane filtration. independently claimed composition protein-encapsulated semiconductor nanoparticles wherein semiconductor selected cdse, cdte, znse, zns znte.',\n",
              " 'method preventing spoilage food bacteriophagea method treatment prevention dental caries periodontal diseases using bacteriophages phage-encoded anti-bacterial enzymes inhibit establishment bacteria oral cavity provided. provided methods studying cell wall oral bacterium, method preventing spoilage perishable items method removing dextrans surfaces utilized sugar manufacture. purified enzymes isolated dna fragments encoding provided.',\n",
              " 'microbiome byproducts uses thereofa method treating microorganism-related condition patient may include detecting microorganisms set samples collected population comparing relative abundance co-occurrence different microbial taxa set samples. method includes associating change relative abundance co-occurrence microbial taxa samples people, among population, microorganism-related condition samples people, among population, without microorganism-related condition determine target taxa. blend bacteriophages identified, blend configured remove target taxa community microorganisms. therapeutic composition comprising blend administered patient microorganism-related condition.',\n",
              " 'method treating acute cholecystitis complicated peritonitis elderly patients heart failure ischemic origina method treating acute cholecystitis complicated peritonitis elderly patients heart failure ischemic origin includes laparoscopy, aspiration peritoneal fluid, laparoscopic cholecystectomy, sanitization inflammatory focus, drainage abdominal cavity. following sanitization inflammatory foci physiological saline, irrigation therapeutic bacteriophage volume 50-100 ml provided. abdominal cavity drained. postoperatively, bacteriophage administered fractionally volume 20 ml every 8 hours drainages pinching drainages one hour followed passive aspiration.',\n",
              " 'method treating individual suffering bladder cancera method treating individual suffering bladder cancer employs crispr system selectively kill reduce numbers pathogenic bacteria within individual individual administered immune checkpoint inhibitor. particular embodiments, pathogenic bacteria one e. coli, pseudomonas aeruginosa klebsiella bacteria, checkpoint inhibitor selected group consisting nivolumab, pembrolizumab, dostarlimab, pidilizumab, amp-224, amp-514, sti-a1110, tsr-042, rg-7446, bms-936559, medi-4736, msb-0020718c, aur-012 sti-a1010. embodiments include enhancing growth second bacteria individual, bacteria including akkermansia, bacteroides, bifidobacterium, clostridium, enterococcus, fusobacterium, coprococcus, lactobacillus, propionibacterium, ruminococcus, veillonella, prevotella, escherichia streptococcus. crispr system may include cas9, cpf1 cas3, may delivered using bacteriophage.',\n",
              " 'method treatment atopic dermatitis children first year lifea method treatment atopic dermatitis children first year life comprises use antihistamine drugs, topical compositions, hypoallergenic mixtures prebiotic additives, bacteriophages. bacteriophage strain selected depending conditionally pathogenic bacteria isolated patient. bacteriophage prescribed age-related dosage. bifidumbacterin lactobacteria used normalization laboratory parameters.',\n",
              " 'systems methods specimen processing storagea method including receiving specimen comprising carrier, first target species, first component storing least portion carrier first target species storage media self-driven filtering specimen storage media, wherein storage media comprises porous superabsorbent polymer (psap) beads. psap beads provide fast self-driven microfiltration biofluid samples. treatment effectively separates small analytical targets (e.g., glucose, catalase, bacteriophage) large undesired components (e.g., bacteria blood cells) biofluids capturing former inside excluding latter outside psap beads. treatment reduce sample volume, self-aliquot liquid sample, avoid microbial contamination, separate plasma blood cells, stabilize target species inside beads, enable long-term storage room temperature.',\n",
              " 'identification specific tumour antigens means selection cdna libraries sera use said antigens diagnostic imaging techniques.a method described identification specific tumour antigens means selection cdna display libraries using sera characterised said selection accomplished phage display technique, particular said selection accomplished means serex technique (serological analysis autologous tumour antigens expression recombinant cdna). method according invention described herein advantageously combines serex approach potency phage display technique defined above, time avoiding drawbacks characteristic serex technique.',\n",
              " 'identification specific tumor antigens means selection cdna libraries sera use said antigena treatment tumorsa method described identification specific tumour antigens means selection cnd display libraries using sera, characterised said selection accomplished phage display technique, particular said selection accomplished means serex technique (serological analysis autologous tumor antigens expression recombinant cdna). method according invention described herein advantageously combines serex approach potency phage display technique defined above, time avoiding drawbacks characteristic serex technique. identified antigens useful preparation medicaments treatment tumors.',\n",
              " 'bacteriophage immobilization biosensorsa method disclosed anchoring bacteriophage substrate, bacteriophage phage amine moiety, method comprising: producing free amine terminal moiety substrate chemical modification substrate; activating free amine terminal moiety cross-linking agent produce active functional group couple phage amine moiety; anchoring bacteriophage substrate using active functional group. sensor disclosed comprising: substrate; anchor group attached chemical modification substrate active functional group produced activation free amine terminal moiety; bacteriophage phage amine moiety coupled active functional group anchor bacteriophage substrate.',\n",
              " 'method prevention and/or biological control bacterial wilt caused ralstonia solanacearum, via use bacteriophages suitable purpose compositions thereofa method prevention and/or biological control wilt caused ralstonia solanacearum, use suitable bacteriophages. addition method uses structural characterisation, genome sequence activity three specific lytic bacteriophages r. solanacearum. podovirus presents elevated stability 4° c. 30° c. aqueous medium absence host. result high level stability, lytic activity, elevated specificity towards r. solanacearum absence activity microbiota associated plants protected, bacteriophages used biological control r. solanacearum river courses irrigation water, well method preventing and/or controlling wilt produced bacteria, least one bacteriophages, combinations thereof, delivered plants and/or soil irrigation water.',\n",
              " 'method isolating binding peptides combinatorial phage display library peptides produced therebya method provided identifying isolating peptides capable binding inorganic materials silica, cobalt, iron, oxides thereof using combinatorial phage display peptide library. method invention, combinatorial phage display library used isolate select desired binding peptides series steps target binding phage inorganic material interest, elution purification bound phages, amplification determine sequences phages producing desired binding peptides. binding peptides invention particularly advantageous may used templates guide development useful structures nanometric scale.',\n",
              " 'peptide templates nanoparticle synthesis obtained pcr-driven phage display methoda method provided identifying isolating peptides capable binding inorganic materials silica, silver, germanium, cobalt, iron, oxides thereof, materials nanometric scale carbon nanotubes, using combinatorial phage display peptide library polymerase-chain reaction (pcr) step obtain specific amino acids sequences. method invention, combinatorial phage display library used isolate select desired binding peptides series steps target binding phage nanometric material interest, elution purification bound phages, amplification using pcr determine sequences phages producing desired binding peptides. binding peptides invention particularly advantageous may used templates guide development useful structures nanometric scale.',\n",
              " 'method screening peptides diagnostic probe anthrax infection resulting novel peptides specifically recognizing anthrax protective antigena method provided screen peptide recognizes anthrax toxin protein specifically bonded thereto diagnose anthrax infection. screened peptide provided used low molecular weight probe diagnosing anthrax infection. method screening peptide diagnostic probe anthrax infection comprises steps of: (a) mass-producing protective antigen anthrax toxin proteins genetic recombination; (b) bonding mass-produced protective antigen 96-well plate certain directivity; (c) screening specific peptide bonded protective antigen using library phage display. peptide probe characterized specifically bonded protective antigen anthrax toxin proteins screened method act low-molecular weight picomole probe diagnosing anthrax infection, wherein amino acid sequence peptide consists amino acid described seq id : no. 1, 2, 3, 4, 5, 6, 7, 8.',\n",
              " 'nucleic acid sequencing-based methods analyzing affinities libraries binding compoundsa method analysing affinities library binding compounds one ligands disclosed comprising steps reacting one ligands library binding compounds (e.g. antibodies), binding compound consisting encoded nucleotide sequence, determining nucleotide sequences binding compounds forming complexes ligands binding compounds free ligand determining affinities respective binding compounds comparing number times nucleotide sequence identified among binding compounds forming complexes ligands number times nucleotide sequence identified among binding compounds free ligand. library may phage display system expressing antibody. methods identifying binding compounds increased stability utilising aforementioned steps claimed.',\n",
              " 'multiple virus reaction assaya method assay outcome reaction comprises conducting reaction first reactant second reactant produce first reactant product least one new structural feature present first reactant second reactant, e.g. cleaving first reactant adding it, producing multiple-phage tagged complex comprising least two different viruses said product said first reactant, complex least one said viruses connected said product using said new structural feature lost said first reactant upon formation said new structural feature, determining presence amount said complex dual-phage assay.',\n",
              " 'particle bindinga method binding bacteriophage particles. method comprising steps exposing particles electrical discharge mixing activated particles bacteriophage. bacteriophage bound particles.',\n",
              " 'method cleaning implement handling plurality samplesa method cleaning pin head implements handling plurality samples nucleic acid subject amplification process using biochemical amplification product. method comprises exposing pin head implement ultraviolet (uv) preferably infrared (ir) illumination handling different samples order suppress cross-contamination non-specific amplification. biochemical amplification product may obtained rolling circle amplification (rca) procedure, catalyzed bacteriophage phi29, polymerase chain reaction (pcr) amplification product. <image>',\n",
              " 'method use nitrate reducing bacteria phages mitigating biogenic sulfide productiona method controlling deleterious bacteria fluid including injecting nitrite nitrate fluid, identifying phage capable infecting deleterious bacteria, injecting phage fluid.',\n",
              " 'method control deleterious microbes oil gas industrial fluids.a method controlling deleterious bacteria oil gas production, oil gas completion fluids industrial fluids described includes identifying phage capable infecting deleterious bacteria, identifying biocide compatible phage effective deleterious bacteria injecting biocide phage oil gas production, oil gas completion industrial fluid.',\n",
              " 'methods compositions controlling body odora method controlling body odor disclosed. method comprises topically administering subject effective amount least one species lytic bacteriophage capable killing odor-generating bacteria. deodorant compositions comprising bacteriophages disclosed.',\n",
              " 'control filamentous bacteria induced foaming wastewater systemsa method controlling filamentous bacteria responsible foaming bulking wastewater systems virulent bacteriophage. method includes, optionally, identification problematic filamentous bacteria matching virulent bacteriophage, use bacteriophage phage libraries concentration filamentous bacteria bacteriophage wastewater treated.',\n",
              " 'control unwanted bacteria fermentation systems bacteriocina method controlling unwanted bacteria fermentation processes comprising contacting reactants process effective amount bacteriocin. bacteriocin, indigenous produced independent sources, optionally bacteriocin plus bacteriophages virulent unwanted bacteria used reduce control unwanted bacteria.',\n",
              " 'artificial cellulosome bacteriophage scaffold, method decomposing cellulose manufacturing alcohol using samea method decomposing cellulose provided, including building recombinant bacteriophage, wherein genome bacteriophage modified express linking peptide affinity decomposing enzyme anchoring peptide affinity anchoring site surface cell, applying decomposing enzyme contact recombinant bacteriophage, applying cellulose contact decomposing enzyme.',\n",
              " 'delivery active proteins central nervous system using phage vectors.a method delivering protein central nervous system active form comprises: (1) preparing single-stranded filamentous bacteriophage vector comprising nucleic acid construct protein delivered central nervous system encoded fusion protein coat protein filamentous phage; (2) preparing phage particles incorporating nucleic acid construct phage genome fusion protein expressed coat protein; (3) delivering phage particles mammal route phage particles reach central nervous system protein delivered central nervous system active form. protein delivered antibody, enzyme, reporter protein, receptor, another type protein. method wide diagnostic therapeutic application. invention encompasses nucleic acid constructs, bacteriophage particles including protein delivered, pharmaceutical compositions.',\n",
              " 'detection bacteria using bacteriophagea method detecting species, strain type bacteria includes mixing labeled bacteriophage including label detectible via detection system bacterial culture including species, strain type bacteria labeled bacteriophage selectively binds using detection system detect labeled bacteriophage bound species, strain type bacteria.',\n",
              " 'method detecting escherichia coli phage detecting escherichia colia method detecting escherichia coli contained test sample bringing sample contact specific phage infected e. coli comprises using phage expressing fluorescent protein form fused protein together phage coat protein coat phage defect lytic enzyme. particular, method comprises detecting fluorescence strong level emitted fluorescent protein phage adsorbed e. coli and/or detecting fluorescence strong level emitted fluorescent protein expressed e. coli caused adsorption phage.',\n",
              " 'bacteriophage-based microorganism diagnostic assay using speed acceleration bacteriophage reproductiona method determining presence absence target microorganism sample tested, method comprising: combining sample amount bacteriophage capable infecting target microorganism create bacteriophage-exposed sample; measuring time rate change amount said bacteriophage change rate change amount said bacteriophage indication presence absence target microorganism function time.',\n",
              " 'brain tumor targeting peptides methodsa method diagnosing treating human glioblastoma multiforme (gbm) brain tumor subject disclosed. method includes administering subject, effective amount composition peptide 12-20 amino acid residues length selected ability bind preferentially subtype human gbm cells identified brain tumor initiating cells (btics) highly invasive glioma cells (higcs). disclosed phage-display screening method identifying therapeutic peptides, peptides hind specifically btics higcs.',\n",
              " 'disinfection foodstuffsa method disinfection livestock provided. method comprises administering least one bacteriophage effective amount said livestock reduce number campylobacter spp present gastro-intestinal tract said livestock. bacteriophage selected cp8 (ncimb accession no. 41184) cp34 (ncimb accession no. 41185).',\n",
              " 'bacterial control dispersion bacteriophage powdersa method eliminating, reducing preventing bacterial contamination surface, method comprising dispersing bacteriophage containing composition air proximity surface. embodiments, bacteriophage containing composition powder dispersed pressurizing load chamber containing powder powder expelled outlet. also, devices performing method powder used method.',\n",
              " 'genetically engineered bacteriophagea method engineering bacteriophages comprising isolating bacteriophage; removing attachment genes genome said bacteriophage; inserting first unique open reading frame encoding one attachment genes inserting second unique open reading frame encoding one genes useful overcoming bacterial defenses; inserting non-natural attachment gene said first open reading frame, wherein said non-natural attachment gene specific attaching selected bacteria.',\n",
              " 'anti-sialic acid antibody moleculesa method generating isolating recombinant high affinity anti-sialic acid antibody molecules comprises steps immunising avian host immunogen comprising conjugate sialic acid carrier protein generate anti-sialic acid polyclonal serum, isolating sample rna immunised avian host, using phage display generation screening library recombinant avian antibody molecules rna sample, isolating recombinant high affinity anti-sialic acid antibody molecules. antibody molecule selected group consisting of: whole antibodies; scfv fragments; fab fragments, avian host gallus domesticus. recombinant avian antibody fragment high binding affinity sialic acid obtainable method invention, anti-sialic acid polyclonal serum obtainable immunising avian host conjugate sialic acid carrier protein, described.',\n",
              " 'identification gene editing gene excising (cas9-like argonaute-like) proteins organismsa method identifying gene editor gene excisor nuclease (cas9-like argonaute-like) protein assay, stressing microbial strain bacteriophage infection, separating nuclease proteins non-nuclease proteins, identifying nuclease proteins. method identifying cas9 nuclease activity nuclease protein, verifying sgrna (and/or sgdna) nuclease activity nuclease protein, determining pam sequence nuclease protein. method identifying argonaute nuclease activity nuclease protein, verifying sgrna (and/or sgdna) nuclease activity nuclease protein. molecule gene editing and/or gene excising capabilities obtained isolated methods described above. gene excisor obtained isolated methods described above.',\n",
              " 'method high throughput screening inhibitors inhibit interaction attachment protein cell receptors using recombinant phage displaya method identifying potential reagent inhibit reaction target polypeptides recombinant protein comprises steps providing plurality target polypeptides attached solid platform; bringing plurality potential reagent contact bind onto recombinant protein expressed displayed phage; bringing plurality recombinant protein potential reagent contact target polypeptides; removing unbound recombinant protein phage; adding plurality bacterial cells capable infected phage solid platform; determining presence number infected bacterial cells; whereby binding potential reagent onto recombinant protein inhibits binding interaction target polypeptides recombinant protein well subsequent infection bacterial cells, incapability potential reagent bind onto recombinant protein allows subsequent infection bacterial cells recombinant phage.',\n",
              " 'identification useful bacteriophagea method identifying particular bacteriophage provided.',\n",
              " 'bacteriophage displaying abeta epitopes method usea method immunizing plaque forming diseases using display technology provided. method utilize novel agents, pharmaceutical compositions vaccination plaque forming diseases rely upon presentation antigen epitope display vehicle. method includes agents, pharmaceutical compositions vaccination plaque forming diseases, rely upon presentation antibody, active portion thereof, display vehicle. whether antigens antibodies employed, disaggregation plaques results immunization.',\n",
              " 'method treating drug resistant eskape pathogens using therapeutic bacteriophagesa method improving immunological response human subject suffering pseudomonas aeruginosa wound comprising step of: (i) administering one isolated purified strains pseudomonas aeruginosa one pharmaceutically acceptable carriers adjuvants wounded area human subject, said genomic phages interacting innate adaptive immune system human subject, providing biological protection and/or wound recovery stimulation; (ii) co-administering one additional genomic phages selected genomic phages selected myoviridae, podoviridae siphoviridae interacts one pharmaceutically acceptable carriers adjuvants wounded area human subject.',\n",
              " 'tagging microorganismsa method labelling microorganism comprises introducing label first microorganism, wherein phenotype labelled first microorganism second microorganism strain first labelled and, separately, mutating first microorganism. one method, label introduced phage integration site genome microorganism. another label istron. gene identification assays gene function carried using microorganisms labelled way, invention provides vectors carrying labelling.',\n",
              " 'modification nucleic acid-containing biological entitiesa method modifying surface nucleic acid-containing biological entity comprising growing polymer chains one initiation points said surface, presence one catalysts, wherein nucleic acid-containing biological entity optionally virus, bacteriophage, prokaryotic cell, bacterium, archaeum, eukaryotic cell, fungus, spore, nucleic acid-containing viral core outer membrane(s) and/or capsids removed, membrane-stripped virus, viral core, eukaryotic cell nucleus, mitochondrion, mammalian cell nucleus, complex comprising nucleic acid condensing agent complex comprising sirna condensing agent; preferably virus bacterium; preferably adenovirus, adenovirus core, pox virus, pox virus core, herpes virus.',\n",
              " 'methods analyzing microbiome, immunoglobulin profile physiological statea method predicting microbiome profile subject provided. method comprising: (a) providing phage display library comprising phages displaying surface peptides microbiome mammalian host, wherein phage display library comprises peptides frequency predetermined threshold; (b) contacting library biological sample subject, biological sample comprising immunoglobulins, wherein contacting performed conditions allow specific immunocomplexation immunoglobulins peptides; (c) isolating immunecomplexes resultant immunocomplexation; (d) identifying peptides immunocomplexes, peptides indicative microbiome subject.',\n",
              " 'purified bacteriophage, preparation applicationa method preparation purified bacteriophage increased antibacterial activity, bacterial lysate phages obtained, advantageously presence lysozyme, chelating factor detergent, continuous manner ultrafiltration membranes, phage containing high molecular mass preparation, devoid bacterial cell wall contaminants, free toxins endotoxins, active tests bacterial lysis, characterized chromatography hplc, sds-page electrophoresis, immunoblotting, biological tests bacterial lysis, dedicated phage therapy bacterial infections tumors production phage deriving pharmaceutical preparations.',\n",
              " 'use recombinant antibacterial enzyme lyssap26 effectively killing pathogenic bacteriaa method preventing treating pathogenic bacterial infectious diseases, includes: providing pharmaceutical composition comprising lyssap26 protein, wherein lyssap26 protein recombinant protein composed amino acid sequence derived bacteriophage genome includes amino acid sequence represented seq id no: 1 active ingredient; administering pharmaceutical composition subject.',\n",
              " 'method preventing wound pyoinflammatory complications laparoscopic cholecystectomy acute destructive cholecystitis complicated formsa method preventing wound pyoinflammatory complications laparoscopic cholecystectomy acute destructive cholecystitis, including laparoscopic cholecystectomy, gallbladder removal sub-xyphoid wound container, introduction medication wound closure skin. removal container gallbladder closure skin sub-xyphoid wound irrigated polyvalent bacteriophage (sekstafage) volume 3-5 ml; container damaged extraction, deferred sutures applied sub-xyphoid wound, wound swabbed tampon, dipped sekstafage every 8 hours bandage tampon irrigated, alternating one following bacteriophages: coliproteous, sekstafage, intest-bacteriophage.',\n",
              " 'bacterial ghost (bg) production process using betapropiolactone (blp) final inactivationa method producing bacterial ghost preparation using betapropiolactone inactivate bacteria. method performed 0.01-1% (v/v) betapropiolactone 26-50 degrees celsius bacteria inactivated 10-60 min. bacterial ghosts obtained expressing lytic protein encoded bacteriophage phix174 gene e. bacterial ghosts used human veterinary medicine vaccination adjuvant.',\n",
              " 'bacteriophage production methoda method producing bacterial replication host bacteriophage provided, including selecting bacterial species, strain, serotype isolate different pathogenic bacterium host replication bacteriophage. bacterial replication host provides safe, efficient non-toxic vehicle propagating bacteriophage capable infecting pathogenic bacterium different bacterial species, strain, serotype isolate replication host. pathogenic bacterium may genus vibrio, aeromonas pseudomonas. particular vibrio bacteria pathogens shrimps prawns, vibrio parahaemolyticus. invention may particular applicability aquaculture.',\n",
              " 'methods expanding bacteriophage host-range bacteriophage produced methodsa method producing novel bacteriophages expanded host-range bacteriophages expanded host ranges disclosed. method produces mutant phage strains infectious second host infectious natural host natural state. method includes repeatedly passaging selected phage strain bacterial cultures contain varied ratios natural host bacterial strain bacterial strain phage interest unable infect; target-host. passage resulting phage purified screened activity target-host via double-overlay assays. mutant phages shown infect target-host discovered, propagated culture contains target-host produce stock resulting mutant phage.',\n",
              " 'phage display assaya method producing specific binding members cell surface antigen, wherein cells antigen surface control cells without antigen surface immobilised solid surface, without fixation, contacted phage display library blocking non-specific binding, population phage displaying specific binding members cell surface antigen identified, method comprising obtaining nucleic acid nucleotide sequence encoding specific binding members displayed phage population producing one specific binding members cell surface antigen recombinant expression nucleic acid nucleotide sequence derivative nucleotide sequence produce product specific binding member.',\n",
              " 'method purification bacteriophage particlesa method recovering viable phage from, example, crude phage preparation lysate resulting amplification phage bacterial cell culture disclosed. method may \"universal\"; is, applicable purification broad range phage species strains. phage product resulting method may acceptably low endotoxin titer (e.g. less 500 eu/ml) sufficiently high phage titer (e.g. > 1 x 10',\n",
              " 'application bacteriophages control unwanted bacteria biofuel production mediated non-bacterial reactive agentsa method reducing process interruptions biofuel production systems reducing amount unwanted bacteria biofuel production system reduction effected use effective amount one types bacteriophages virulent least strains unwanted bacteria.',\n",
              " 'application bacteriophages control unwanted bacteria biofuel production mediated bacterial reactive agentsa method reducing process interruptions biofuel production systems mediated bacterial reactive agents reducing amount unwanted bacteria without reduction wanted useful bacteria. method comprises applying phage panel(s) containing phage virulent unwanted bacteria contain phage phages virulent wanted bacteria. method includes, optionally, selective production solutions phage unwanted bacteria phages wanted bacteria screened out.',\n",
              " 'system method select phage therapy based time locationa method selecting phage formulation described wherein method comprises storing bacterial infection/contamination data one treatment locations spatio-temporal infection database, database comprising least one following data fields: (1) clinical indication, (2) bacteria identification, (3) clinical outcome, (4) phage resistance status, (5) phage susceptibility profile, (6) antibiotic susceptibility profile, and/or (7) lab test result relating one (1)-(6); identifying one phage suitable inclusion phage formulation analyzing data fields (1)-(7) database identify one infections associated treatment location historical time period based least one frequency infections/contamination, geographic clustering infections/contamination, and/or phage usage data; generating selected list phage included phage formulation. uses formulations described.',\n",
              " 'bacteriophage selection breedinga method selectively breeding bacteriophages comprises incubating phage obtained natural sources bacterial host, removing host cells plating phages bacterial lawn, assessing plaques isolating phage plaques showing greatest activity, culturing isolated phage host bacteria adding viricidal medium remove free phage, plating viricidally-treated culture onto host bacterial lawn, identifying selecting plaques showing virulent phage activity. methods described use genetic manipulation techniques. viricidal medium preferably comprises pomegranate rind extract, iron salt (preferably ferrous sulphate), polysorbate surfactant (preferably tween (rtm) 20). method modifying phage host sensitivity disclosed, phages incubated one chelating agent (such edta), detergent (preferably tween (rtm) 20), lantibiotic nisin a, enzyme lysozyme and/or cell wall-destroying agent.',\n",
              " 'sequence specific dna recombination eukaryotic cellsa method sequence-specific recombination dna eukaryotic cells, comprising introducing first dna comprising attb, attp, attl attr, comprising introducing second dna comprising attb, attp, attl attr performing sequence specific recombination bacteriophage lambda integrase int.',\n",
              " 'method sterilizing object comprising gold nanorod home electronic products employing methoda method sterilizing object comprising gold nano-rod home electronic products employing method provided perform sterilization efficiently using light harmful human. method sterilizing object comprising gold nano-rod includes irradiating light wavelength absorbed gold nano-rod gold nano-rod, includes steps of: applying gold nano-rod material solid phase sterilized; irradiating light wavelength absorbed gold nano-rod material solid phage coated gold nano-rod. gold nano-rod contained material solid phase permeated light. material solid phase consists silicone, metal, glass polymer.',\n",
              " 'fusobacterium bacteriophage uses thereofa method treating disease associated fusobacterium nucleatum infection subject need thereof disclosed. method comprises administering subject therapeutically effective amount least one isolated bacteriophage capable infecting fusobacterium nucleatum bacterial species, wherein said least one bacteriophage genomic nucleic acid sequence least 85 % identical nucleic acid sequence set forth seq id nos: 1-7 15-20. compositions treating disease disclosed.',\n",
              " 'composition comprising amino acid polymers bioactive agent method preparing thereofa method treating, reducing preventing bacterial infection wound, method comprising: applying film wound, film including biodegradable polymer bacteriophages dispersed therein, wherein polymer poly (ester amide urea).',\n",
              " 'methodology detection, enumeration, propagation manipulation bacteriophagesa method propagate, enumerate quantify bacteriophage(s) water sample aqueous sample designed contains ingredients stimulate growth select bacterial species susceptible infection specific bacteriophage(s), interfering background organisms either inhibited inconsequential. important features medium include oxidation-reduction compounds producing colored and/or fluorescent products, chromogenic and/or fluorogenic enzyme substrates, temperature-independent gelling agent(s). preferred combination growth medium containing 2,3,5-triphenyl tetrazolium chloride, 5-bromo-4-chloro-3-indolyl-b-d-galactoside, appropriate gelling agents, (when properly used) produces dark red bacterial lawn containing teal blue-green, irregularly circular spots representing individual phage plaque, discernible eye visible light. procedure readily applied towards automatic counting systems artificial illumination. procedure employed water samples elution buffers retain bacteriophages suspension following contact buffer foods, soils, hard surfaces solids may contaminated bacteriophages.',\n",
              " 'method determining order food product cultureda method, process, computer program determining order food product successively cultured set bacterial cultures process producing fermented food product, bacterial culture set bacterial cultures including least one bacterial strain, wherein set bacterial cultures comprises first subset one bacterial cultures comprising one unknown bacterial strain, second subset one bacterial cultures comprising one known bacterial strains, wherein bacterial strains second subset known; wherein process carried initial order set bacterial cultures; wherein culturing bacterial culture first subset process sample collected, wherein culture sample bacterial culture second subset exposed collected process samples order determine bacteriophage sensitivities one bacterial cultures second subset bacteriophages present collected process sample, wherein adapted order set bacterial cultures determined based determined bacteriophage sensitivities reduce common bacteriophage sensitivities successive bacterial cultures.',\n",
              " 'rotation scheme bacterial cultures food product fermentationa method, system computer program selecting consecutive bacterial cultures culturing food product process producing fermented food product, method comprising steps of: culturing food product first bacterial culture comprising least one bacterial strain; isolating sample culturing first bacterial culture; determining least one value indicative number bacteriophages sample, e.g. using pcr, plaque assay, ph; selecting second bacterial culture culturing food product value larger predetermined threshold, wherein second bacterial culture comprises least one bacterial strain, wherein second bacterial culture differs first bacterial culture, wherein sensitivities first second bacterial culture bacteriophages sample known wherein second bacterial culture selected reduce common bacteriophage sensitivities first second bacterial culture, culturing food product second bacterial culture.',\n",
              " 'particulate labelsa methodology bioassays diagnostics particulate label (ranging size nm-scale molecular assemblages organisms scale tens hundreds microns), as, limited to, nanoparticles, bacteria, bacteriophage, daphnia, magnetic particles, serve carriers analytes bound molecular recognition elements antibodies, aptamers, etc. described methodology generally applicable pathogen assays molecular diagnostics leads enhanced sensitivity convenience use.',\n",
              " 'microarray kit diagnosing cmt1aa microarray kit diagnosis cmt1a(charcot-marie-tooth neuropathy 1a) syndrome provided detect chromosome disorder resulting cmt1a syndrome, especially chromosome 17 dna duplication total human genomic dna rapidly accurately. microarray diagnosis cmt1a syndrome comprises least one probe selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-235, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, wherein content ratio repeated sequence nucleotide sequence probe 85%; nucleotide sequence probe single locus chromosome; probe produced inserting genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid, immobilized microarray concentration 2-100 pg per spot; least two kinds probes immobilized per one spot. kit diagnosis cmt1a syndrome comprises microarray marker material-detecting tool, determines chromosome disorder testing sample reacting total genomic dna testing sample labeled first probe detectable marker material standard dna labeled second probe detectable marker material, measuring hybridization ratio testing sample dna standard dna, wherein first second marker materials independently radioactive isotope, fluorescent material, chemiluminescent enzyme.',\n",
              " \"microarray kit diagnosing down's syndromea microarray kit diagnosis syndrome provided analyze chromosome disorder total human genomic dna, improve rapidness accuracy diagnosis, diagnose health status subject examined. microarray diagnosis syndrome comprises least one probe selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-34 bac8_g15, bac11_l10, bac29_l21, bac36_d16, bac37_m17, bac42_o16, bac56_c18, bac65_n02, bac82_f19, bac88_n11, bac88_n19, bac96_c04, bac109_e20, bac117_h13, bac141_f01, bac145_k01, bac147_a13, bac182_i05, bac190_j11, bac203_b21, bac203_m13, bac207_b17, bac213_c09, bac1_c02, bac84_o06, bac88_n19, bac100_h22, bac155_l05, bac165_i10, bac166_i08, bac183_c22, bac46_a15, bac65_c07, bac136_d13, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, wherein content ratio repeated sequence nucleotide sequence probe 85%; nucleotide sequence probe single locus chromosome; probe produced inserting genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid, immobilized microarray concentration 2-100 pg per spot; least two kinds probes immobilized per one spot.\",\n",
              " 'microarray kit diagnosing hnpp diseasea microarray kit diagnosis hnpp(hereditary neuropathy liability pressure palsies) syndrome provided detect chromosome disorder, especially deletion chromosome 17p11.2 total human genomic dna resulting hnpp syndrome, rapidly accurately using immobilized probe specific hnpp syndrome. microarray diagnosis hnpp syndrome comprises least one probe selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-165 listed, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, wherein probe produced inserting genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid, immobilized microarray concentration 2-100 pg per spot, 85% content ratio repeated sequence nucleotide sequence; least two kinds probes immobilized per one spot; nucleotide sequence probe single locus chromosome. kit diagnosis hnpp syndrome comprises microarray marker material-detecting tool, determines chromosome disorder testing sample reacting total genomic dna testing sample labeled first probe detectable marker material standard dna labeled second probe detectable marker material, measuring hybridization ratio testing sample dna standard dna, wherein first second marker materials independently radioactive isotope, fluorescent material, chemiluminescent enzyme; kit determines (i) none chromosome disorder, (ii) increase chromosome (iii) deletion chromosome hybridization ratio testing dna (i) identical to, (ii) higher (iii) lower standard dna, respectively.',\n",
              " \"microarray kit diagnosing klinefelter's syndromea microarray kit diagnosis klinefelter syndrome provided detect chromosome disorder, especially sex chromosome disorder containing addition one x chromosome results klinefelter syndrome total human genomic dna rapidly accurately. microarray diagnosis klinefelter syndrome comprises least one probe selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-10 bac10-i08, bac52_l18, bac126_d02, bac147_n13, bac170_j12, bac194_k10, bac37_g04, bac41_i24, bac202_c09 bac220_p01, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, wherein content ratio repeated sequence nucleotide sequence probe 85%; nucleotide sequence probe single locus chromosome; probe produced inserting genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid, immobilized microarray concentration 2-100 pg per spot; least two kinds probes immobilized per one spot. kit diagnosis klinefelter syndrome comprises microarray marker material-detecting tool, determines chromosome disorder testing sample reacting total genomic dna testing sample labeled first probe detectable marker material standard dna labeled second probe detectable marker material, measuring hybridization ratio testing sample dna standard dna, wherein first second marker materials independently radioactive isotope, fluorescent material, chemiluminescent enzyme.\",\n",
              " 'microarray kit diagnosing miller-dieker syndromea microarray kit diagnosis miller-dieker syndrome provided detect chromosome disorder resulting miller-dieker syndrome, especially deletion chromosome 17p13.3 total human genomic dna, rapidly accurately using immobilized probe specific miller-dieker syndrome. microarray diagnosis miller-dieker syndrome comprises least one probe selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-137, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, wherein nucleotide sequence probe single locus chromosome; probe produced introducing genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid, 85% content ratio repeated sequence nucleotide sequence, immobilized microarray concentration 2-100 pg per spot; least one two kinds probes immobilized per one spot. kit diagnosis miller-dieker syndrome comprises microarray marker material-detecting tool, determines chromosome disorder testing sample reacting total genomic dna testing sample labeled first probe detectable marker material standard dna labeled second probe detectable marker material, measuring hybridization ratio testing sample dna standard dna, wherein kit determines (i) none chromosome disorder, (ii) increase chromosome (iii) deletion chromosome hybridization ratio testing dna (i) identical to, (ii) higher (iii) lower standard dna, respectively.',\n",
              " \"microarray kit diagnosing patau's syndromea microarray kit diagnosis patau syndrome provided easily diagnose health status subject examined identify disease specific chromosome disorder detecting chromosome disorder total human genomic dna resulting patau syndrome rapidly accurately. microarray diagnosis patau syndrome comprises least one probe selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-34 bac27_o11, bac123_j22, bac145_o09, bac155_b10, bac157_j18, bac199_l02, bac232_g07, bac235_d20, bac29_d09, bac29_k13, bac60_f12, bac63_i22, bac73_o17, bac77_m02, bac80_f19, bac84_e11, bac88_k22, bac91_o18, bac92_j05, bac96_a02, bac96_n17, bac97_a19, bac143_b05, bac147_i15, bac154_e21, bac166_a03, bac168_m20, bac171_b19, bac175_n19, bac193_h21, bac233_l22, bac29_c16, bac66_b10 bac122_p16, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, wherein content ratio repeated sequence nucleotide sequence probe 85%. nucleotide sequence probe single locus chromosome. probe produced inserting genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid, immobilized microarray concentration 2-100 pg per spot, least two kinds probes immobilized per one spot.\",\n",
              " 'microarray kit diagnosing rubinstein-taybi syndromea microarray kit diagnosis rubinstein-taybi syndrome provided detect chromosome disorder resulting rubinstein-taybi syndrome caused deletion chromosome 16p13.3 total human genomic dna rapidly accurately. microarray diagnosis rubinstein-taybi syndrome comprises least one probe immobilized therein selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-141, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, wherein probe 85% content ratio repeated sequence nucleotide sequence produced inserting genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid; concentration immobilized prove 2-100 pg per spot; least two kinds probes immobilized per one spot; nucleotide sequence probe single locus chromosome. kit diagnosis rubinstein-taybi syndrome comprises microarray marker material-detecting tool determines (i) none chromosome disorder, (ii) increase chromosome (iii) deletion chromosome hybridization ratio testing dna (i) identical to, (ii) higher (iii) lower standard dna, respectively.',\n",
              " 'microarray kit diagnosing rubinstein-taybi syndromea microarray kit diagnosis smith-magenis syndrome provided detect chromosome disorder caused interstitial deletion p11.2 region chromosome 17 total human genomic dna rapidly accurately. microarray diagnosis smith-magenis syndrome comprises least one probe (i) immobilized microarray concentration 2-100 pg per spot, (ii) selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-165, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, (iii) produced inserting genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid, (iv) 85% content ratio repeated sequence nucleotide sequence, wherein least two kinds probes immobilized per one spot; nucleotide sequence probe single locus chromosome.',\n",
              " \"microbe pesticidea microbe pesticide disclosed. microbe pesticide comprises bdellovibrio bacteriovorus powder, phage powder, oceanospirillales powder, hirsutella thompsonii fisher powder, chinaberry seeds, macleaya cordata, tobacco stems, sanqi flower, sichuan chinaberry bark, herba houttuyniae, herb named chinese characters 'layecao' inventor, synergist, nux vomica, camphor, anemone vitifolia, dalbergia hupeana, dandelion, lightyellow sophora root, common andrographis herb water. microbe pesticide adopts natural microbes microbe pesticide free side toxic effects crops microbe pesticide used killing pests, agricultural products eaten safely persons without safe toxic effects human body health, quality agricultural products significantly improved, microbe pesticide suitable large-scale popularization application.\",\n",
              " 'microfluidic platform concentration detection bacterial populations liquida microfluidic device concentrating detecting bacteria liquids, related methods described. device includes first filter chamber capturing bacteria performing incubations bacteria one reagents, second filter chamber capturing concentrating detectable material, little binding detectable material first filter. aspect, bacteria incubated growth media engineered phage cause bacteria produce enzyme. aspect, enzyme capture second filter chamber exposed substrate produce detectable signal.',\n",
              " 'regulated antigen delivery system (rads) comprising two origin replicationsa microorganism comprising regulated antigen delivery system (rads) described. rads comprises (a) vector comprising (1) site insertion gene encoding desired gene product (2) first origin replication (ori) conferring vector replication using dna polymerase iii (3) second ori conferring vector replication using dna polymerase i, wherein second ori operably linked first control sequence repressible first repressor wherein runaway vector comprise phage lysis gene; (b) gene encoding first repressor operably lined first activatible control sequence. preferably microorganism salmonella sp., vector plasmid, repressor laci c2 repressor desired gene product antigen. described vaccine immunization comprising attenuated derivative pathogenic bacterium microorganism use microorganism manufacture medicament delivering desired gene product vertebrate.',\n",
              " 'mimic antigen epitope her-2 composition comprise epitopea mimic antigen epitope (formula i) isolated screening phage display library. derivatives antigenic epitope immunogenic activity identified mutative modification research. peptides comprising epitope derivatives related compositions including proteins used vaccines inducing immune response her-2 prevent treat malignancies. prevent invention synthesized oligonucleotides encode peptides constructed expression vectors comprising oligonucleotides fusion nucleotides gene transferred cells. present invention provided methods pharmaceutical compositions oligonucleotides, vectors, cells treating malignancies.',\n",
              " 'polypeptide activity targeting intestine inflammation, use thereofa model animal inflammation small intestine prepared ischemic reperfusion. search peptide specifically adsorbing onto inflammation site intestine made conducting ex vivo panning using small intestine tissue collected model animal respect phage library displays peptide comprising randomly arranged seven amino acid residues surface particle. result, peptide capable causing phage particle specifically bind intestine inflammation found, sequence peptide found.',\n",
              " 'modified antibody comprising substitution mutation confers increased stabilitya modified antibody selectively binds specific target, antibody modified least one amino acid residue determines antigen binding selectivity/affinity characterised antibody molecule exhibits great stability unmodified parent antibody. mutation may variable heavy domain position vh71 comprises substitution smaller amino acid native residue. antibody molecule, eg scfv, diabody, may derived humanised hmfg-1 antibody raised cancer specific glycoprotein antigen, muc-1. conjugation antibody drugs, toxins, radionucleides, nucleases use fusion molecules pharmaceutical compositions treatment cancer, particularly adenocarcinoma, described. use antibody phage display system identify target molecules described. host cells vectors comprising nucleic acid figure 8, encoding mutated antibody, described.',\n",
              " 'modified bacteriophagea modified bacteriophage capable infecting target bacterium, bacteriophage comprises bacteriophage phi33 includes toxin gene encoding toxin protein toxic target bacteria; wherein bacteriophage lytic.',\n",
              " 'porea modified portal protein bacteriophage dna packaging motor, wherein modified portal protein capable direct insertion membrane wherein portal protein modified compared wild type portal protein one amino acid residues outer surface portal protein substituted one amino acid residue, and/or wherein one amino acid residue inserted outer surface portal protein alter outer surface hydrophobicity modified portal protein compared wild type portal protein.',\n",
              " 'nasally-administered vaccinesa molecular complex comprising bacteriophage displaying peptide targets nasal-associated lymphoid tissue (nalt) antigen use vaccine intranasal administration. gene encoding antigen inserted coat protein phage. claimed method selecting phage comprising peptide targets nalt.',\n",
              " 'chimeric phage tail proteins uses thereofa multi-protein pyocin-like structure derived bacteriophage bacteriocin includes chimeric tail fiber protein receptor binding domain capable recognizing lipid a. multiprotein pyocin-like structure, derived bacteriophage bacteriocin includes chimeric tail fiber capable recognizing binding murnac-l-ala-d-glu. phage including chimeric tail fiber binds lipid a. plasmid encoding chimeric ail fiber binds murnac-l-ala-d-glu. plasmid encoding chimeric tail fiber binds lipid a. chimeric bacteriocin bacteriophage derived tail fiber includes amino terminal human bactericidal/permeability-increasing protein (bpintd)- chimeric bacteriophage bacteriocin derived tail fiber includes binding domain encoding mammalian nod2ctd- antibacterial agent includes bacteriocidal/permeability-increasing protein receptor domain binds lipid a. antibacterial agent includes nod2 carboxyl-terminus receptor domain binds murnac-l-ala-d-glu.',\n",
              " 'application bacteriophages transplantationa new application bacteriophages preparation pharmaceuticals administration patients undergoing transplantation and/or invoke immunosuppression revealed.',\n",
              " 'new lytic phage specific klebsiella pneumoniaea new lytic phage specific klebsiella pneumoniae, deposited number: bcrc 970052, strong infectious lytic effects vivo vitro klebsiella pneumoniae selected taiwan area.',\n",
              " 'methods apparatus whole cell panninga new method apparatus whole cell panning employs homegenous populations cells separated membrane(s) permeable phage/phagemid particles.',\n",
              " 'rna ligase bacteriophage rm 378a novel bacteriophage rm 378 rhodothermus marinus, nucleic acids genome, nucleic acids comprising nucleotide sequences open reading frames (orfs) genome, polypeptides encoded nucleic acids, described.',\n",
              " 'circular dna molecule conditional origin replication, method preparing use thereof gene therapya novel circular dna molecule (i), useful gene therapy, comprises >= 1 sequence interest, replication controlled origin replication (ori) plasmid bacteriophage, active host cell presence one specific proteins foreign cell.',\n",
              " 'conformation type peptide library based insect alexins, constitute method applicationa novel conformational peptide library random phage display uses fragment terminal c insect phylacin basic protein skeleton. random region introduced configure random peptide library simple two-class structure. used protein engineering research developing novel medicines vaccines.',\n",
              " 'scattering interference correlation spectroscopy (sics)a novel fluctuation spectroscopy technique based interferometry described. technique, termed scattering interference correlation spectroscopy (sics), autocorrelates signal forward scattered transmitted laser light nanoparticles (nps) solution. sics two important features: firstly, unlabeled nps known refractive index, analyses diffusion coefficient, effective cross-section concentration, single measurement. secondly, combined fluorescence correlation spectroscopy (fcs) simultaneous analysis labeled unlabeled nps. sics demonstrated unlabeled m13 phages unlabeled nps 210 nm 26 nm diameter. shown combination sics fcs determine fraction fluorescent nps mixture, estimate kd single binding measurement.',\n",
              " 'new inducible vector system coryneform bacteriaa novel induced expression system provided usefully used effectively expressing green fluorescence protein(gfp) coryne-form bacteria corynebacterium glutamicum corynebacterium ammoniagenes. promoter induced expression obtained linking bacteriophage lambda(ol1) promoter nucleotide sequence described seq id : no. 27(cj1) derived corynebacterium ammoniagenes nucleotide sequence described seq id : no. 1(cj10g), wherein induced expression protein achieved increasing temperature. shuttle vector able reproduced escherichia coli corynebacterium genus bacteria includes promoter induced expression. transformant microorganism selected group consisting escherichia, brevibacterium, corynebacterium, serattia providentia genera, includes shuttle vector.',\n",
              " 'novel cell target peptidea novel cell target peptide provided induce absorption macromolecular materials mucosal immune response passing cell mucous membrane small intestine without passage epithelia cell layer small intestine, peptide useful improvement absorption efficiency oral vaccines biomembrane. vitro phage display method comprises steps of: forming phage display peptide library; establishing vitro cell model; screening cell target peptides; analyzing vitro phage transcytosis; identifying peptide sequence screened cell target peptides; retesting cell target candidate peptides; selecting cell target peptide amino acid sequence cksthplsc. oral vaccine transfer system contains cell target peptide capable passing cell mucous membrane small intestine.',\n",
              " 'method detecting endotoxina novel method detecting endotoxin described. sample containing endotoxins contacted surface coated endotoxin binding substance. p12 bacteriophage tail proteins incubated endotoxin immobilised surface. p12 bacteriophage tail proteins detected means spectroscopic methods, enzyme-linked immunosorbent assay (elisa), chemical enzymatic detection reaction endotoxins cleaved-of endotoxin components, means capacitance measurements.',\n",
              " 'peptide protein capable binding lipid lps, dna coding peptide protein, utilizing peptide protein, lps adsorbent lps poison neutralizera novel peptide protein capable binding lipid lps, highly safe obtained low cost; dna coding peptide protein; utilizing peptide protein, lps adsorbent lps poison neutralizer. screening carried accordance phage display method use lipid lps target substance thereby identify amino acid sequence peptide capable binding lipid lps dna coding amino acid sequence. peptides amino acid sequence thus obtained seq id nos. 1 6 amino acid sequences resulting modification, amino acid residue substitution, insertion and/or deletion amino acid sequences performed without detriment capability binding lipid easily produced chemical synthesis. example, lps adsorbent obtained immobilizing peptides support. lps poison neutralizer obtained containing peptides active ingredient.',\n",
              " \"pseudo-rabies virus proteina novel recombinant dna molecule comprises dna sequence coding polypeptide displaying pseudorabies virus (prv) glycoprotein gp50, gp63 gi immunogenicity, dna sequence operatively linked expression control sequence. prv genomic dna derived prv rice strain isolated cytoplasm prv-infected vero cells (atcc ccl 81). genomic dna fragmented sonication cloned lambda gt11 produce lambda/prv recombinant (lambda prv) dna library. antisera screening lambda prv library produced inoculating mice proteins isolated cells infected prv (infected cell proteins icp's) segregated according size sds gels isolating antibodies. lambda prv phages screened plated lawn e.coli foreign dna's inserted unique cloning site 3' end lacz gene proper orientation reading frame produce, expression, polypeptides fused beta-galactosidase.\",\n",
              " 'phage-derived vectors methods protein expressiona novel system, including vectors, phage particles, host cells methods use, expressing one polypeptides interest prokaryotes described.',\n",
              " 'novel virus-like particle expression vector, construction method application thereofa novel virus-like particle expression vector ptmsca2c provided. firstly, apply gene mutation technique plasmid ptrchis-ms2, mutate fifth base 19mer pack site genetic sequence ms2 bacteriophage c obtain plasmid ptmsc; mutate amino acid corresponding start codon maturation protein coding ms2 bacteriophage plasmid ptmsc valine methionine, order obtain plasmid ptmsca; finally, apply gene cloning technique remove stop codon genetic coding sequence capsid protein wildtype ms2 bacteriophage, use form tandem array genetic coding sequence capsid protein his-tagged ms2 bacteriophage pseudo viral vector ptrcms, insert genetic sequences tandem plasmid ptmsca construct obtain expression vector ptmsca2c.',\n",
              " 'bacteriophage lysina nucleic acid comprising nucleotide sequence encoding lysin, nucleotide sequence comprises sequence shown seq idno. 1 variant, homologue derivative thereof. novel lysin obtainable bacteriophage capable colonising clostridium perfringens, use thereof medicament treatment disorder associated pathogenic clostridium bacteria, example.',\n",
              " 'baculovirus-based gene librariesa nucleotide molecule comprising selectable gene flanked anl1 anl2 attachment sites bacteriophage additionally comprising origin replication. used create baculovirus-based gene library.',\n",
              " 'bacteriophages useful therapy prophylaxis bacterial infectionsa panel bacteriophages comprising first vir mutant bacteriophage capable infecting lysing first strain bacteria, second vir mutant capable infecting lysing second strain bacteria. pharmaceutical composition including panel bacteriophages disclosed above. method identifying bacteriophage suitable killing bacterium obtaining sample bacterium patient site infected bacterium, identifying one phage sensitivity characteristics bacterium, comparing characteristics identification step known host range library bacteriophages, library bacteriophages including first vir mutant bacteriophage capable infecting lysing first strain bacteria, second vir mutant capable infecting lysing second strain bacteria, identifying one bacteriophages panel suitable killing bacterium.',\n",
              " 'peptides enhance transport across tissuesa peptide permits facilitates transport active agent human animal tissue. predetermined amount phage random phage library preselected phage library administered vivo s6itu site animal, gastro-intestinal tract. predetermined time, phage transported across tissue barrier harvested harvesting site separated site administration tissue barrier select transported phage. transported phage amplified host. cycle events repeated (using transported phage produced recent cycle) predetermined number times obtain selected phage library containing phage transported site administration harvesting site. identity least one peptide coded phage selected phage library determined identify peptide permits facilitates transport active agent human animal tissue.',\n",
              " 'permanent magnet synchronous excitation generatora permanent magnet synchronous excitation generator, magnetic steel distributed fixed according polarity 16 polars surface rotor core permanent magnet synchronous excitation generator, rotor core welded rotating shaft via front back stuffy board; 1,2,3 tooth disposed among grooves rotor core permanent magnet synchronous excitation generator winded centralization coil windings belong a,b,c three phages separately, 16 polars 8 pair polars, 8 pair coil windings, three-phase coil windings formed connectng them; winding rotor core containing centralization coil windings, front end embedded installation mouth generator front end cover, front back rotor core rotating shaft covered bearings, fromt bearing disposed bearing chamber front end cover, back bearing disposed bearing chamber back end cover, front back end covers fixed tightly pin screws. invention features high efficieny, high turning frequency width accuracy, great improvement every frequencies pressure drop generator.',\n",
              " 'evaluation different delivery strategies therapeutic applications klebsiella pneumoniae phages burn wound modela phage cocktail composition comprises five different strains bacteriophages alongwith phosphotidylcholine (pc), tween 80 stearylamaine.',\n",
              " 'phage dispensing systema phage dispensing method, phage dispensing apparatus phage dispensing system configured dispense phage prescription. dose calculation performed using patient weight, target phage dose, titer phage vial contaminant level phage vial determine dispensing set associated dispensing volumes phage vials stored phage storage apparatus. storage locations dose preparation instructions including respective dispensing volumes provided pharmacist verification vials performed check correct vials removed phage storage apparatus.',\n",
              " 'phage dispensing systema phage dispensing system comprises user interface, phage treatment computing system, phage laboratory, phage dispensing apparatus, including dispensing kiosk. user interface allowsa treating physician request testing patient sample phage laboratory identify phage mixture treatment. phage computing system arranges shipping sample provision identified phage mixture treatment dispensing apparatus located near patient. dispensing apparatus stock phage vials used prepare dispense doses identified phage mixture treatment.',\n",
              " 'randomized humanized antibody libraries engineered sequence insert diversitya phage display library formed plurality recombinant phages; plurality recombinant phages comprising m13-derived expression vector; m13-derived expression vector comprising polynucleotide sequence encoding randomized peptide, wherein randomized peptide variable region human igg1 heavy chain; randomized peptide expressed absence immunoglobulin light chain protein outer surface recombinant phage phage display antibody library; protein product expressed recombinant phage phage display antibody library fuses human immunoglobulin constant region form full human igg1 heavy chain molecule. phage display library utilized identify candidate antibodies bind receptor axl receptors.',\n",
              " 'single-domain antigen-binding antibody fragments derived llama antibodiesa phage display library variable heavy domain (vhh vh) fragments (sdab fragments) derived antibody repertoire non-immunized llama disclosed. sdab fragments library characterized absence cysteine residues complementarity determining regions (cdrs) low presence residues glutamic acid, arginine glycine positions 44, 45 47, respectively, vl interface variable heavy domain vhh. large size library (in order 109) makes source antigen-binding fragments high affinity almost antigen interest. library preferably generated using modified fd-tet phage growing plaques absence tetracycline.',\n",
              " 'phage display method detecting low molecule target materiala phage display method according present invention fixed substrate high binding force even low molecular weight target material poor binding force substrate, excellent binding force target phage phage-peptide library, excellent selectivity precision.',\n",
              " 'phage display systema phage display system provided comprising mutant phage-infected host cell adapted express peptide interest fused phage capsid protein, wherein mutant phage includes nonsense mutation prevents expression capsid protein functional protein, wherein expression peptide interest controlled inducible repressor suppressor suppresses nonsense mutation.',\n",
              " 'phage display vector application thereofa phage display vector comprises ampicillin resistance gene open reading frame containing phage capsid protein p6 gene, wherein exogenous gene inserted downstream phage capsid protein p6 gene open reading frame, upstream phage capsid protein p6 gene connected protein secretion signal peptide gene, upstream open reading framecontains promoter sequence ribosome binding site, e-tag arranged phage capsid protein p6 gene exogenous gene, downstream exogenous gene histidinetag, c-myc tag gene amber codon. exogenous gene antibody gene, protein gene polypeptide gene, anti-hiv virus antibody gene, anti-influenza virus antibody gene like. protein gene gene various enzymes, polypeptide gene gene antimicrobial polypeptide gene physiologically functional polypeptide.',\n",
              " 'phage staphylococcus aureus application thereofa phage staphylococcus aureus, preservation number cctcc m2011409, effective splitting effect staphylococcus aureus; storage condition phage filtered degermed, phage culture solution stored two months 4 deg c, stored two years glycerin tube 70 deg c zero; concentration stored phage culture solution 1011pfu/ml; application phage staphylococcus aureus, phage culture solution directly sprayed surface solid food mixed bacteria-containing food inhibit staphylococcus aureus food. dosage phage bacteria-containing material 0.0001pfu/cfu 100pfu/cfu. phage effectively control contamination staphylococcus aureus food system, relative antibiotics chemical preservatives, phage characteristics high specificity, residues safety.',\n",
              " 'novel 88 phage vectorsa phage genome engineered include novel restriction site one two different positions. first embodiment, restriction site inserted phage genome end gene iv mos hairpin serves phage packaging signal newly synthesized single strands phage dna. second embodiment, restriction site inserted phage genome mos hairpin prior minus strand origin. phage genome modified contain new restriction site, vector engineered \"88\" vector inserting new restriction site nucleotide sequence encoding least functional domain pviii least first cloning site receiving gene encoding polypeptide displayed and, optionally second cloning site receiving displayed. particularly useful embodiments, novel vectors engineered produce phage particles display antibodies.',\n",
              " 'novel 33 phage vectorsa phage genome engineered include novel restriction site one two different positions. first embodiment, restriction site inserted phage genome end gene iv mos hairpin serves phage packaging signal newly synthesized single strands phage dna. second embodiment, restriction site inserted phage genome mos hairpin prior minus strand origin. phage genome modified contain new restriction site, vector engineered \"33\" vector inserting new restriction site nucleotide sequence encoding least functional domain piii least first cloning site receiving gene encoding polypeptide displayed and, optionally second cloning site receiving second gene encoding polypeptide capable dimerizing polypeptide displayed. particularly useful embodiments, novel vectors engineered produce phage particles display antibodies.',\n",
              " 'phage application thereofa phage phage-hy19 separated farm environment, characteristic wide host range main pathogen etec-k88ac causing animal diarrhea phage product nontoxic, sothe phage safely used preventing treating animal diarrhea, used specifically crack etec-k88acin order avoid etec-k88ac evolution drug-resistant strains caused use antibiotics avoided, used killing breeding environment keeping foods fresh.',\n",
              " 'pathogenic escherichia coli phage oral preparation preparation method thereofa phage phage-hy19 strong cracking effect pathogenic escherichia coli etec-k88ac separated farm environment, processed oral preparation, oral preparation thecharacteristic wide host range main pathogen etec-k88ac causing animal diarrhea, phage product nontoxic, phase product safely applied prevention treatment animal diarrhea; etec-k88ac specifically cracked phage, etec-k88ac evolution drug-resistant strains caused use process antibiotics avoided.',\n",
              " 'detection phage amplification sers nanoparticlesa phage specific antibody presenting particle, devices methods related detection phage amplification provided.',\n",
              " 'pathogen detection sers nanoparticlesa phage specific antibody presenting particle, devices methods related detection phage amplification provided. specifically, described herein compositions methods detecting listeria bacteria using antibody recognized a511 anti-listeria phage, wherein antibody conjugated nanoparticle detected surface-enhanced raman scattering (sers).',\n",
              " 'phage-based limulus amoebocyte lysate assay rapid detection bacteriaa phage-based limulus amoebocyte lysate (lal) assay able detect low levels viable bacteria water vegetable samples described.',\n",
              " 'pharmaceutical composition based bacteriophages f. nucleatum; use treatment diseases associated pathogena pharmaceutical composition comprising: a) effective amount one lytic bacteriophages specific fusobacterium nucleatum selected fnpφ02-14, fnpφ11 fnnφ107 mixtures them; b) one pharmaceutically acceptable carrier and/or excipients. method preventing and/or treating diseases associated fusobacterium nucleatum use pharmaceutical composition treating disease associated fusobacterium nucleatum oral cavity periodontal disease, among others.',\n",
              " 'polyclonal antibody composition treating allergya pharmaceutical composition treating allergy described. composition comprises active ingredient recombinant polyclonal antibody mixture different monoclonal antibodies capable reacting binding allergen together one pharmaceutically acceptable excipients. composition may used topically solution, dispersion, powder, form microspheres. polyclonal antibody preferably recombinant polyclonal antibody produced phage display technology. pairing specific immunoglobulin variable region light chain heavy chain maintained original polyclonal immune response selected panning using allergen question preferably maintained bulk transfer pairs expression vector.',\n",
              " \"virus-like particle compositions methods using samea pharmaceutical composition includes preparation virus-like particles (vlps) obtained gastrointestinal tract subject pharmaceutically-acceptable carrier. vlps include bacteriophages, eukaryotic viruses, gene transfer agents. vlp composition may administered subject having, risk dysbiosis, amount effective ameliorate least one symptom clinical sign dysbiosis. vlp composition may administered subject preparation administering source bacteria, improve receptivity subject's gut source bacteria.\",\n",
              " 'podoviridae bacteriophage killing activity specific staphylococcus aureusa podoviridae bacteriophage provided specifically kill staphylococcus aureus, useful therapeutic agent preventing treating infectious disease caused staphylococcus aureus, antibiotic, cosmetic antibiotics, antiseptic disinfectant. podoviridae bacteriophage(kctc 11154bp) killing activity specific staphylococcus aureus, gene nucleotide sequence seq id no:1. pharmaceutical composition preventing treating infectious disease caused staphylococcus aureus comprises podoviridae bacteriophage(kctc 11154bp).',\n",
              " 'nano-antibody capable binding sftsv application thereofa polypeptide capable binding sftsv, comprising 3 complementarity determining regions (cdrs) 1-3, cdr1 sequence comprising one sequences shown seq id nos: 1-74, cdr2 sequence comprising one sequences shown seq id nos: 75-151, cdr3 sequence comprising one sequences shown seq id nos: 152-232. means preparation gn protein, immunization two-humped camel, use phage library display platform technology nano-monoclonal antibodies, etc., nano-antibody vhh specifically binds gn screened, cdr sequence thereof identified, humanized antibody snb constructed; addition, humanized mouse model used evaluate efficacy snb treatment sftsv infection. present solution provides potential novel nano-antibody drugs clinical treatment sfts, provides corresponding detection kits diagnosis sfts.',\n",
              " \"novel allergen diagnostic method ectoparasite infestationa polypeptide derived louse parasitic, preferably bovicola ovis, provokes humoral and/or cellular immunological response, allergen designated bo1 amino acid sequence seq id no:2. nucleic acid comprises nucleotide sequence seq id no:1. antibodies phage display molecules bind polypeptide uses ligands antigen present ectoparasite's faeces diagnosing ectoparasite infestation animal described. described vaccines prevent reduce bo1 hypersensitivity, methods treating preventing non-human animals exhibiting allergic hypersensitivity bo1 polypeptide test kits methods assaying samples presence ligands bind bo1. (62) divided 504096\",\n",
              " 'preparation method polypeptide inhibiting gelatin enzyme activity applicationa polypeptide m204c4 suppressing activity gelatinase (mmp-2) composed amino acid sequence shown hnwtrwllhpdrgggs disclosed. suppress invasion transfer external pancreas cancer cells panc01 cfpac-1. preparing process includes steps affinity screening reproduction bacteriophage several times obtain bacteriophage specific binding mmp-2, coating, cloning monoclonal screening fluorescent screening reagent kit.',\n",
              " 'polypeptide inhibiting gelatin enzyme activity preparation method applicationa polypeptide m205c4 suppressing activity gelatinase (mmp-2) composed amino acid sequence shown hnwtrwllhpdrgggs disclosed. suppress invasion transfer external pancreas cancer cells panc01 cfpac-1. preparing process includes steps affinity screening reproduction bacteriophage several times obtain bacteriophage specific binding mmp-2, coating, cloning monoclonal screening fluorescent screening reagent kit.',\n",
              " 'method apparatus determining level microorganisms using bacteriophagea predetermined amount parent bacteriophage capable infecting target microorganism added sample create bacteriophage-exposed sample; sample incubated defined incubation time assayed determine level bacteriophage bacterial marker sample; measured marker level increased, initial concentration microorganism exceeds specific threshold value. antibiotic different concentrations added different separate portions sample tested determine bacteriophage marker present thereby determine minimum inhibitory concentration (mic) given antibiotic. antibiotic preferably antibiotic inhibits dna replication protein synthesis.',\n",
              " 'probe combination detection cancera probe combination detecting cancer includes one sets partial hepatitis b virus (hbv) targeting probes. sequences sets partial hbv targeting probes aligned,an overall sequence aligned set probes matches reference sequence genome hbv genotype direct repeat (dr) region genome. aligned set probes, probes overlap one two adjacent probes portion length probe. probe combination may includes one sets hotspot gene targeting probes targeting cancer hotspotgenes ctnnb1, tert, tp53 genes, one sets exogenous gene targeting probes targeting portions lambda phage genome, endogenous gene targeting probes targeting endogenous genes gapdh gdx genes.',\n",
              " 'preparation peptide mixtures protease catalysis designed provide useful biological physical propertiesa process preparing unique peptide mixtures broad range uses using combinations natural non-natural amino acid alkyl ester monomers specific combinations monomers dimers, trimers higher oligomers selected large group structural motifs lead useful physical and/or biological properties may identified solid state peptide synthesis, isolation peptides natural sources, production peptides recombinant dna methods, identification peptides recombinant methods phage display, method peptide synthesis comprising a) admixing one natural non-natural amino acid alkyl ester monomer, dimer, trimer higher oligomers one proteases reaction medium; b) heating mixture 5° c. 90° c. 5 minutes 24 hours; c) recovering formed oligopeptide.',\n",
              " 'staged bacteriophage remediation target bacteriaa process remediation target bacteria, particularly sulfur reducing bacteria (srb), waters (“target water”) multiplicity diverse host target bacteria employing serial staged bacteria culturing lysing dominant bacteria. remediation sulfur reducing bacteria (srb) effected application series bacteriophage isolated staged culturing bacteriophage lysing successive aliquots waters containing multiplicity srb.',\n",
              " 'process separation prokaryotic dna eukaryotic dna whole blood samplea process separating prokaryotic dna eukaryotic dna whole blood sample infected pathogen provided. process includes extracting prokaryotic eukaryotic dna whole blood sample, contacting prokaryotic dna whole blood sample motif specifically binds prokaryotic dna, generating bound pair. process includes separating bound pair. whole blood sample transfected bacteriophages genetically modified contain defined dna sequence selectable marker dna. dna sequence integrates prokaryotic dna, motif oligonucleotide specific defined dna sequence engineered bacteriophages.',\n",
              " 'processes preparation highly pure plasmid compositions enzymatic digestion colanic acida process purification plasmid dna, process comprising treating aqueous composition containing plasmid dna polypeptide obtained nst1 phage digest colanic acid separating plasmid dna treated aqueous composition.',\n",
              " 'viral-based antimicrobial agent use ethanol productiona process controlling unwanted microorganism contamination fermentation mash form ethanol, particularly control lactobacilli contamination, achieved adding viral agents adapted destroy deactivate lactobacilli and/or selected microorganisms. amount viral agents added sufficient amount keep presence undesired microorganisms, particularly lactic acid bacteria family particularly lactobacilli, level 5 times 106 viable cells per milliliter mash, example level 1 times 106 viable cells per milliliter mash, fermentation. treatment may include bacteriophages one stabilizers trehalose, sucrose, maltose, glycerol, divalent alkaline earth metal salt, salts gluconic acid.',\n",
              " 'medicinal preparation form antistaphylococcal phage lysate, process preparation usea process production medicinal product form antistaphylococcal phage lysate, including following successive steps: revival bacterial strain, passaging bacterial strain, preparation cell sub-cultures, preparation phage starter via double-layer agar method, preparation phage starter liquid medium, preparation bacterial suspension, preparation phage lysate, filtration phage lysate lysate mixture, filling filtered lysate lysate mixture vials, lyophilisation lysate lysate mixture vials; whereas final medicinal product lyophilized powder preparation solution (lyophilisate) produced via sterile filtration lyophilisation mixture antistaphylococcal phage lysate containing active phage particles polyvalent staphylococcal bacteriophage. medicinal product local use contains high-potent virulent phage particles polyvalent effect.',\n",
              " 'peptide antagonists inhibiting heat shock protein (hsp 16.3) mycobacterium tuberculosisa process identify peptide antagonists hsp16.3, chaperon protein necessary survival mycobacterium tuberculosis dormant phase described. affinity selection 7-mer 12-mer random peptide libraries displayed bacteriophage m13 performed using recombinant hsp16.3 template two peptide phage clones, bind hsp16.3 protein identified. synthetic peptides corresponding peptide sequences displayed phage clones able specifically bind inhibit chaperone function hsp16.3 vitro dose dependent manner. corresponding inhibitory effect peptides chaperon activity alphab-crystallin, constituent human eye lens homologue hsp16.3, found substantially less. peptide inhibitors, similar inhibitors generated process described, specifically target hsp16.3, used lead compounds obtain better therapeutics latent tuberculosis.',\n",
              " 'treating & preventing microbial infectionsa programmable nuclease use method durable treating microbial infection subject. infection caused microbes first species strain. nuclease programmed cut target site within genome microbes, thereby durably killing reducing growth proliferation microbes. method comprises reducing infection 100 fold least 60 minutes exposing subject nuclease. subject immunosuppressant medication. method comprise use rna complexes nuclease target nuclease target site. infection vaginosis, meningitis, pneumonia, urinary tract infection, cystitis, nephritis, gastroenteritis, skin infection, impetigo, erysipelas, cellulitis, septicaemia sepsis. subject cancer patient. nuclease cas nuclease, meganuclease, talen, zinc finger nuclease. aspects invention viruses, phages, phagemids, compositions, vectors, viriophages, plasmids transposons comprising copy nucleic acid encoding nuclease. aspect crispr/cas system comprising nuclease guide rna. microbes e. coli (e.g., ehec), c. difficile, klebsiella, pseudomonas bacteria.',\n",
              " 'expression systema protein expression system use prokaryotic host provided, expression system comprising: a) expression cassette comprising nucleic acid sequence encoding protein interest operably linked t7 rna polymerase-dependent promoter; b) expression cassette comprising nucleic acid sequence encoding t7 rna polymerase operably linked host polymerase-dependent λ phage promoter single perfect palindrome operator sequence; wherein expression cassette t7 rna polymerase located chromosome host cell.',\n",
              " 'phi 15 dna polymerasea purified recombinant dna polymerase high processivity strand-displacement activity. isolated nucleic acid encodes bacteriophage dna polymerase. kit method amplifying dna disclosed.',\n",
              " 'methods evaluation bacteriophage preparationa quality assurance/quality control paradigm bacteriophage provided.',\n",
              " 'rapid simplified developing antibodies fabs molecules consisting amino acids recognizing natural antigens non-natural molecular targets using special blocking agenta rapid simplified method developing antibodies monoclonal antigen-recognizing polypeptides comprised amino acids (polypeptides capable forming complexes targeted antigens, comprised natural non-natural molecular targets), using bioparticle display library approach, bioparticle bioparticle display library containing gene coding polypeptide capable multiplying presence particular multiplication limiting factor. polypeptide-carrying bioparticle insulated complex mixture similar bioparticles bioparticle display library using first blocking agent, said blocking agent consisting bioparticle strain lacks resistant multiplication limiting factor (for example phage display library multiplication limiting factor antibiotic, blocking agent phage strain lacks resistance particular antibiotic).',\n",
              " 'production recombinant protein pap 31 diagnosis prevention bartonella bacilliformis infectiona recombinant dna polypeptide sequence immuno-dominant phage particle associated protein bartonella bacilliformis. recombinant protein easily produced permitting conduct accurate rapid diagnositic assays detection b. bacilliformis infection reduced reagent equipment requirements required currently available methods diagnosis. dna polypeptide sequence useful vaccine preparations b. bacilliformis.',\n",
              " 'recombinant double-stranded rna phage, use samea recombinant double stranded rna (dsrna) phage expresses dsrna-encoded genes eukaryote cells. recombinant dsrna phage useful expression dsrna expression cassettes encoding passenger genes, as, restricted to, vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense rnas, catalytic rnas eukaryotic cells tissues. methods provided deliver recombinant dsrna phage eukaryotic cells tissues, either direct administration, formulated lipid polylactide-coglycolide, utilizing bacterial vaccine vector.',\n",
              " 'bioreporter detection microbesa recombinant phage system developed rapid detection bacteria, particularly fecal coliform indicator bacteria. systems invention link phage infection events quorum sensing signal molecule biosynthesis bioluminescent bioreporter induction, facilitating detection pathogens may present low numbers. phage-based systems invention maintain specificity pathogen still producing significant signal amplification sensitive quantitative detection. systems require combination sample phage bioreporter organisms; extraneous addition substrates user intervention kind necessary, making approach significantly less technical standard molecular immunological methods.',\n",
              " 'recombinant plasmid dna pspaa(tr) coding surface spaa antigen erysipelothrix rhusiopathiaea recombinant plasmid dna pspaa(tr) coding surface spaa antigen erysipelothrix rhusiopathiae contains fragment spaa gene gram-positive erysipelothrix rhusiopathiae, regulatory elements expression target protein (t7/lac promoter t7 terminator), ori – site origin replication coiei plasmids, selective marker – kan gene kanamycin resistance, ori fl – site origin replication fl phage providing synthesis recombinant protein spaa erysipelothrix rhusiopathie upon transformation cells escherichia coli strain b121 (de3).',\n",
              " 'human mini-antibody cytotoxic tumor cells express erbb2 receptora recombinant single chain anti-erbb2 antibody human origin able inhibit growth cells expressing erbb2 receptor; nucleotide sequences encoding recombinant antibody; vector bacteriophage comprising nucleotide sequences; pharmaceutical composition comprising antibody; use composition preparation anti-proliferative anti-tumor drugs; process preparation bacteriophage.',\n",
              " 'reporter mycobacteriophage, assays methods comprising reporter mycobacteriophagea reporter mycobacteriophage comprising heterologous nucleic acid comprising promoter-reporter construct encoding promotor operably linked nucleotide sequence encoding fusion protein, wherein fusion protein comprises luciferase protein linked fluorescent protein. methods utilizing reporter mycobacteriophage detection viable target microbe sample, screening test substance treatment tuberculosis, detecting drug-resistant mycobacterium subject provided.',\n",
              " 'bacteriophage compositions treatment bacterial infectionsa respirable composition treatment bacterial infection includes one active bacteriophages combination pharmaceutically acceptable respirable carrier. composition includes carbohydrate carrier, prepared fine powder. another aspect, bacteriophages provided liquid carrier administration nebulization. one aspect, bacteriophages anti-bacterial activity one species strains burkholderia cepacia complex (bcc) bacteria. invention relates use bcc bacteriophage treat bcc infection, particular individual suffering cystic fibrosis.',\n",
              " 'sequence natural synthetic retroelements enabling nucleotide sequence insertion eukaryotic cella retroviral vector eliminates cis-acting retroviral elements, useful may cause problems for, integrated provirus utilizes recombination system, bacteriophage p1 cre-lox recombination system. gene interest loxp site inserted long terminal repeat, duplicated. enzyme cre inserted long terminal repeats combines them. structure resulting provirus host genome single, long terminal repeat carrying single copy gene interest. following infection, retrovirus produces proviral structures single long terminal repeat.',\n",
              " 'method apparatus identification microorganisms using bacteriophagea sample tested presence bacteria, automatic blood culturing apparatus. bacteria determined present, bacteriophage-based bacteria identification process performed identify bacteria present. plurality bacteria detection processes, blood culture test gram stain test may carried prior bacteria identification process. bacteriophage-based antibiotic resistance test antibiotic susceptibility test conducted sample.',\n",
              " 'preservation phage concentration clinical samplesa simple method kit preserving clinical specimens biological samples, particularly purpose preserving concentration bacteriophage and/or bacteria present sample, described. method involves rapidly lowering temperature sample (e.g. freezing) temperature -50°c lower (especially -78°c) presence suitable cryoprotectant (e.g. 20% glycerol). one application, method used clinical samples (e.g. urine) taken patient undergoing phage therapy bacterial infection, wherein method permits samples transported and/or stored following collection viability phage and/or bacteria present maintained inhibiting potential interactions phage bacteria. thawing samples, samples may analyzed phage and/or bacterial concentration provide information effectiveness phage therapy.',\n",
              " 'scfv antibody fragments grp78 used cancer treatmenta single chain variable fragment (scfv) antibody glucose-regulated protein 78 (grp78, bip) provided. antibody fragment may used diagnosis cancer tumour cells, upregulated response increased nitric oxide synthase activity higher concentrations. anti-grp78 fragment may used treatment cancer, possibly combination another radiotherapeutic chemotherapeutic etoposide. particular antibody defined amino acid seqid no:i dna seqid no: 2 provided. antibody fragments isolated phage libraries recombinant grp78 protein. treatment cells antibody abolished no-mediated cytoprotection increased apoptosis prostate cancer colon cancer cell lines, enhanced combination etoposide.',\n",
              " 'human monoclonal antibodies block invasion duffy binding protein plasmodium vivax human erythrocyte using antibody phage displaya single chain variable fragment(scfv) recombinant antibody provided able inhibit binding duffy receptor erythrocyte duffy binding protein(dbp), thereby utilized developing therapeutic agent vaccine plasmodium vivax. scfv recombinant antibody includes nucleotide sequence light-chain variable portion one kind selected seq id : nos. 9, 10 11 heavy-chain variable portion one kind selected seq id : nos. 12, 13 14, specifically bound dbp antigen plasmodium vivax merozoite. recombinant antibody characterized encoded nucleotide sequence described seq id : no. 21, 22 23.',\n",
              " \"apparatus method targeted biodetection using phage carrying single electron transistora single electron transistor conjugated bacteriophage form detectable probe rf signal identify location probe site specific biological matrix provide unique electronic signal coulomb staircase signal act diagnostic beacon probe detector form mesoscopic detector. detector uses: bioprobe containing phage conjugated set properties phage specificity; phage mobility within biological environment phage ability act carrier set; set's ultimate use beacon detection.\",\n",
              " 'parathyroid hormone related protein antagonistsa single-chain triple-stranded alpha-helical coiled coil polypeptide binds parathyroid hormone related protein (pthrp) act antagonist it. pthrp-binding \"alpha-body\" may used treatment cancer, hypercalcemia associated cancer cancer metastasis. nucleic acids encoding said alpha-bodies, host cells comprising said nucleic acids, well pharmaceutical compositions comprising said alpha-bodies provided. alpha-bodies preferably selected phage display coiled-coil scaffold.',\n",
              " 'strain bacteria streptococcus thermophilus, used production bacterial preparations fermented milk products functional actiona strain bacteria streptococcus thermophilus imb b-7179 used production bacterial preparations fermented milk products functional action, characterized number probiotic properties: resistance products human alimentary system metabolism, adhesiveness, expressed antagonistic action wide range pathogenic opportunistic microorganisms, high cholesterase activity. strain streptococcus thermophilus imb b-7179 phage-resistant, moderate energy acid formation milk, forms clots high viscosity. strain enables prepare fermented milk products functional action.',\n",
              " 'modified streptococcus bacteriuma streptococcus bacterium auxotrophic least one amino acid normally present milk, normally present low concentrations. bacterium preferably dependent upon one glutamine, tryptophan proline, capable growing production medium containing one amino acids upon dependent. bacterium may reduced susceptibility bacteriophage multiplication, preferably streptococcus thermophilus. starter cultures comprising bacterium disclosed, methods preparing starter cultures comprising admixing bacterium dairy medium milk provided. bacterium invention may used decontamination equipment contaminated bacteriphage.',\n",
              " 'surface acoustic wave biosensor employing analog front end dna encoded libraries improved limit detection (lod) exemplary apparatus samea surface acoustic wave (saw) performs rapid, label-free detection biological species. biosensing detection multiple analytes multiplexed array sensing lanes configured enable bio-amplification using engineered dna encoded libraries probe phage display procedure enhance specificity, capture statistics detection, screening analyzing analyte vitro. biochemical formulation minimizes limit detection (lod) threshold magnitude order femtomolar concentration. additional enhancement apparatus achieved use analog front end amplify biochemical events.',\n",
              " 'process preparation synergistic herbal preparation extracts picrorhiza kurroa glycyrrhiza glabra medicinal valuea synergistic herbal preparation extracts picrorhiza kurroa royle close species family picrorhiza scrophulariflora pennel neopicrorhiza scrophulariiflora, glycyrrhiza glabra medicinal values antiviral immune boosting activity dna virus -bacteriophage pi 300 mug/ml plaque reduction assay',\n",
              " 'cancer stem cell targeting peptide use thereofa synthetic peptide targets cancer stem cells provided. peptide consists amino acid sequence anyone seq id no: 1 seq id no: 15. provided composition comprising said synthetic peptide therapeutic agent fused thereto, pharmaceutically acceptable carrier diluent. provided method screening peptide specifically targeting cancer stem cell. method comprises steps establishing oligopeptide library using phage expression system, contacting library culture bulk tumor cells cancer cell line, contacting phages bind bulk tumor cells culture cancer stem cells said cancer cell line, screening peptide specifically targeting cancer stem cell phages bind cancer stem cells.',\n",
              " 'bacteriophage treatment reducing preventing bacterial contaminationa system method reducing preventing bacterial contamination food includes application bacteriophage treatment type food product stage processing food product. bacteriophage treatment may applied non-food surfaces water systems, may susceptible bacterial contamination subsequent spread bacteria. bacteriophage treatment comprises least one bacteriophage concentration sufficient reduce prevent bacterial contamination pathogenic bacteria and/or spoilage bacteria. embodiments, bacteriophage able reduce eliminate bacteria introduced food product bacteriophage treatment applied food product. embodiments, bacteriophage treatment includes buffering agent maintain bacteriophage ph level sustains bacteriophage. embodiments, bacteriophage treatment includes surfactant and/or thickener aid applying bacteriophage. additional adjuvants enhancers may used embodiments stabilize bacteriophage enhance performance antibacterial agent.',\n",
              " 'systems method electrophoretic fractionation microbiomea system methods characterizing population virus, bacteriophage, microbes microbiome includes steps separating sample microbiota one fraction continuous capillary zone electrophoresis based physiochemical properties microbes microbiota using constant voltage applied sample continuous zone electrophoresis. least one separated fraction includes intact virus, bacteriophage, microbe may visualized and/or directly sequenced characterize population virus, bacteriophage, microbe microbiome.',\n",
              " 'automatic phagograma system measuring sensitivity bacterium plurality phages, system comprising: microwell plate comprising plurality wells, said plurality wells configured contain one plurality phages, wherein said microwell plate configured sample comprising said bacterium dispensed said plurality wells; least one reagent and/or additive, configured added mixtures said sample comprising said bacterium phage said plurality phages; control unit configured interpret present results measurements form phagogram, said measurements provided least one analytical device, said least one analytical device configured measure interaction said plurality phages said bacterium. invention relates corresponding method use same.',\n",
              " 'methods compositions identifying peptide intermolecular interaction target interesta system recombinant bacteriophage library target interest complex, wherein recombinant bacteriophage peptide library includes plurality peptides expressed surface recombinant bacteriophages wherein recombinant bacteriophage includes (a) pill protein; wherein pill protein includes (b) peptide polypeptide involved intermolecular interaction, differs least one amino acid peptides polypeptides library; (c) modified protease cleavage site proximal peptide, wherein modified protease cleavage site bacteriophage, modified cleavage site reduced binding affinity protease, compared non-modified cleavage site, wherein target interest complex includes protease, flexible linker attached protease, target interest attached flexible linker, wherein target interest participates intermolecular interaction.',\n",
              " 'carrier construction methoda carrier higher ta cloning efficiency includes gene sequence pblue script ii sk(-), colei ori sequence pblue script ii sk (-), flori sequence pblue script ii sk(-), lacz gene sequence pblue script iisk (-), t3 bacteriophage promoter sequence pblue script ii sk (-), t7 bacteriophage promoter sequence pblue script ii sk(-), two polycloning site sequences ends. process preparing carrier disclosed.',\n",
              " 't4 bacteriophage teaching demonstration modela t4 bacteriophage teaching demonstration model comprises head portion, support pedestal, iron wires, iron nails spring. t4 bacteriophage teaching demonstration model solves abstractness hard understanding problem previous teaching process, vividly demonstrate structure t4 bacteriophage, help students better understand t4 bacteriophage, simple structure convenient carry.',\n",
              " 'bacteriophage t4 nanoparticles eukaryotic deliverya t4 nanoparticle non-infectious, tail-less variant t4 bacteriophage. one embodiment, eukaryotic cells labeled dyed t4 nanoparticles, wherein dyed t4 nanoparticle comprises least 350 dye molecules covalently bound thereto. another embodiment, t4 nanoparticles used deliver exogenous dna eukaryotic cells protein expression therein. contemplated t4 nanoparticles may used deliver exogenous material eukaryotic cells.',\n",
              " 't7 bacteriophage display fabsa t7 bacteriophage vector displays fab fragments disclosed. host cells methods making bacteriophage described.',\n",
              " 'high-affinity target peptidyl ligands tumor biomarker, grp-78, screening method thereofa target peptidyl ligands revealed. peptidyl ligands high-affinity. peptidyl ligands tumor biomarker, grp-78. phage display libraries coordinated panning used screening peptidyl ligands. peptidyl ligands labeled fluorescent substance laser used probes tumors.',\n",
              " 'drug delivery nanocarriers targeted landscape phagea targeted drug delivery nanocarrier method forming disclosed herein. targeted drug delivery nanocarrier includes plurality amphipathic molecules forming carrier particle plurality drug molecules contained therein. targeted landscape phage protein assembly complexed carrier particle preferably using unique method disclosed herein. targeted landscape phage protein assembly displays binding peptide selected specifically selectively bind target site. method forming targeted drug delivery nanocarriers includes steps obtaining plurality bacteriophage displaying binding peptide desired target site, treating bacteriophage denaturing agent, mixing treated bacteriophage plurality carrier particles purifying mixture obtain plurality targeted drug delivery nanocarriers.',\n",
              " 'technique orienting binding phage bacteria detectiona technique orienting binding head end phage substrate disclosed. tail end phage thereby made readily available bacteria sensing.',\n",
              " 'use phage displaying peptide adhesion protein treating disease associated intracellular formation protein fibrillar inclusions aggregatesa therapeutic agent carries peptide sequence containing mammalian cell adhesion sequence used inhibit treat diseases associated intracellular formation protein fibrillar inclusions aggregates, inhibit intracellular formation protein fibrillar inclusions aggregates, disaggregate pre-formed intracellular protein fibrillar inclusions aggregates. filamentous bacteriophage displays non-filamentous bacteriophage rgd cell adhesion sequence surface, antibody non-filamentous bacteriophage antigen said rgd cell adhesion sequence, preferred embodiment therapeutic agent.',\n",
              " 'therapy prophylaxis klebsiella pneumoniae infections lytic bacteriophage specifically k. pneumoniaea therapy prophylaxis k. pneumoniae infections lytic bacteriophage specifically k. pneumoniae, provides lytic bacteriophage (dsm 24329) k. pneumoniae infected organism sake relieving serious complications liver abscesses bacteremia, high mortality rate k. pneumoniae infections taiwan.',\n",
              " 'methods vaccination using icosahedral phagea transdermal membrane comprising non-infectious icosahedral phage vaccine displaying antigen described wherein membrane stable room temperature greater 3 months uses thereof vaccinate subject antigen.',\n",
              " 'transformation method actinoplanes teichomyceticus conjugal transfera transformation method actinoplanes teichomyceticus using vector containing bacteriophage c31 att/int system provided improve transformation rate. method transforming conjugal transfer actinoplanes teichomyceticus comprises: step inducing vector e.coli et12567/puz8002 culturing strain produce 1.2î 10^8 donor; step culturing actinoplanes teichomyceticus atcc31121 medium collecting 1î 10^5 receptor; step mixing donor receptor.',\n",
              " 'novel tricistronic vectors uses therefora tricistronic vector (i.e., vector capable expressing three exogenous genet, fused together, control one promoter) effectively encode immunoglobulin-presenting polypeptide two immunoglobulin (ig) polypeptides. encoded ig-presenting polypeptide able associate least one ig polypeptides via co-expressed associating agents. vector according present invention particularly suited phage display technology, e.g., ig-presenting polypeptide phage coat protein ig polypeptides associate form fab.',\n",
              " 'triple vector expressing antibody molecules full therapeutic formata triple expression vector disclosed expressing antibody molecule comprising fc domain prokaryotic cells eukaryotic cells. triple expression vector comprises polynucleotide encoding fc domain; polynucleotide encoding phage coat protein; cloning site cloning genes encoding antibody molecule part thereof wherein antibody molecule part thereof comprise fc domain; prokaryotic secretion signal sequence eukaryotic secretion signal sequence, secretion signal sequence drives efficient secretion prokaryotic eukaryotic cells; promoter mediating expression eukaryotic cells; stop codon preventing expression phage coat protein eukaryotic cells. triple expression vector used expressing antibody molecule phage display format; producing antibody molecule prokaryotic cell, example periplasm prokaryotic cell; producing antibody molecule eukaryotic cell, example mammalian cell, particularly human cell. antibody molecule contains fc domain, may example vhh-fc molecule scfv-fc molecule vh-fc vl-fc. phage display libraries produced vector present antibody molecule therapeutic format. use vector avoids need repeated cloning moving one expression medium another.',\n",
              " 'phage displayed cell binding peptidesa tryptophan cage binding domain polypeptide containing part amino acid sequence aaadx<sub>1</sub>yx<sub>2</sub>qwlx<sub>3</sub>x<sub>4</sub>x<sub>5</sub>gpx<sub>6</sub>sgrpppx<sub>7 </sub>(seq id no: 4), wherein x<sub>n </sub>represents amino acid found position n, polypeptide comprising tryptophan cage (trp cage). cell binding domain polypeptide amino acid sequence produced phage display.',\n",
              " 'temporal traumatic brain injury biomarkers methods use thereofa unique pipeline employed biomarker discovery entailed domain antibody phage display, next generation sequencing analysis, nanotechnology strategies generate antibody mimetics disclosed. disclosed temporal biomarkers traumatic brain injury methods use. embodiments, temporal biomarkers synthetic peptides comprising hcdr3 sequences identified using disclosed pipeline. aspects, synthetic peptides less 30 amino acid residues comprise biotin scaffold linked hcdr3 sequences.',\n",
              " 'use tail fiber protein prevention acinetobacter baumannii infectionsa use tail fiber protein prevention acinetobacter baumannii infections disclosed. tail fiber protein bacteriophages coated sprayed carriers (such pipelines medical devices hospitals) inhibit biofilm formation acinetobacter baumannii prevent acinetobacter baumannii infections.',\n",
              " 'functional proteomics using double phage display screeninga use identifying protein double phage screening.',\n",
              " 'schistosoma recombinant fusion protein vaccinea vaccine eliciting immunity schistosoma parasites, comprises recombinant fusion protein capable comprising 27/28 kda cercarial elastase sequence ofs. mansoni active fragment, homologue variant thereof, fused suitable bacterial, phage viral protein, together pharmaceutically acceptable excipient carrier. vaccine used combat s. mansoni, s. japonicum and/or s. haematobium mammals, especially humans.',\n",
              " 'vibrio parahaemolyticus phage separation methoda vibrio parahaemolyticus phage separation method provided invention comprises steps culture medium reagent treatment, water sample treatment, phage enrichment phage separation.through observation, large transparent spots appear double-layer flat plate, thereby proving vibrio parahaemolyticus phage successfully separated out. method beneficial effects phage separation quicker accurate, experiment period short, experiment operation requirement high, phage separation success rate greatly improved, themethod quite high practical applicability application prospect.',\n",
              " 'waterless toilet system fece-urine separation, odor vermin seal, thermal biological disinfection, gas ozonationa waterless toilet system fece urine separation, odor vermin seal, thermal biological disinfection, gas ozonation includes system components. feces urine kept separate ridge separating urine bowl fece chute. seat forms temporary seal platform, lid forms temporary seal seat closed. rest components sealed keep vermin outside odors inside, exception gas vent hose screened opening. biological disinfection achieved phage focused human pathogens. thermal disinfection human pathogens achieved insulating fece receptacle containing metabolic heat. air toilet ozonated electrical discharges hand operated device.',\n",
              " 'skin care wipes comprising added natural antibacterial agentsa wet wipe product including fibrous porous substrate material combined aqueous personal care lotion, lotion including preservative added bacteriophage composition, methods making same, disclosed. bacteriophage composition may include one bacteriophages selected effective one respective bacteria strains.',\n",
              " 'differential phage capture proteomicsabstract disclosure disclosed herein methods identifying, isolating comparing proteins biomolecules differing two complex biological samples using affinity chromatography phage display techniques. 3224244_1 (ghmatter) p49917.au.2',\n",
              " 'method isolation soluble polypeptidesabstract polypeptides desirable biophysical properties solubility, stability, high expression, monomericity, binding specificity non-aggregation, including monomeric human vhs vls, identified using high throughput method screening polypeptides, comprising steps obtaining phage display library, allowing infection bacterial lawn library phage, identifying phage form larger average plaques bacterial lawn. sequences monomeric human vhs vls identified, may useful immunotherapy diagnostic agents. multimer complexes human vhs vls identified. vhs vls identified may used create libraries identifying additional polypeptides. further, vhs vls may subjected dna shuffling select improved biophysical properties.',\n",
              " 'anti-bacteria compositionsabstract invention relates anti-bacterial compositions comprising bacteriophage (phage) sufficiently high concentrations induce lysis without bacteria. uses compositions disclosed. phage and/or p68 especially preferred.',\n",
              " 'phage display fmd particle preparation method vaccineabstract present invention belongs field veterinary biological products discloses fmd (foot-and-mouth disease) particle phage display technique preparation method vaccine. phage display fmd particles either type phage display fmd particles type 0 phage display fmd particles. type phage display fmd particles consist structural protein vp1 type fmd virus combined phage capsid, type 0 phage display fmd particles consist structural protein vp1 type 0 fmd virus combined phage capsid. stable structure, phage foot-and-mouth disease particle invention composed structural protein vp1 foot-and-mouth disease virus phage. temperature stability acid-base environment stability increased, prepared foot-and-mouth disease phage particle quickly induce production specific antibody, prolong duration immunity, reduce production cost usage adjuvant.',\n",
              " 'method producing polypeptide displayed phage display system conjugated molecular scaffoldabstract present invention relates method producing polypeptide displayed phage display system conjugated molecular scaffold. method comprises following steps: (a) combining polypeptides displayed phage display system purification resin phage display system bound resin treating bound phage display system reducing agent; (b) exposing bound phage display system molecular scaffold; (c) removing unreacted molecular scaffold bound phage display system; (d) eluting phage display system purification resin thereby producing polypeptide displayed phage display system conjugated molecular scaffold. date recue/date received 2020-06-01',\n",
              " \"composition comprising amyloid beta 1-6 peptide coupled virus-like particle adjuvantabstract present invention relates compositions comprising construct comprising ap1-6 peptide pharmaceutically acceptable adjuvant, treatment patients suffering dementia, particular dementia alzheimer's type. one embodiment, construct containing ap1-6 peptide consists virus-like particle (vlp) rna bacteriophage qp chemically coupled said ap1-6 peptide.\",\n",
              " \"native phage enrichment combat bacterial proliferation critical non-food-contact surface areas food industriesabstract: phage therapy applied means selective phage introduction desired spot. unfortunately, successful phage treatment wastewater bacterial pathogens dependent prevalence diversity pathogen species within wastewater microbial community structure vary substantially processing sites. therefore, attempt enrich native phages selective bacteria present respective industry combat pathogenic bacterial proliferation. effluent treated using mf contain none bacteria, fungi protozoan's contains phages. therefore, treated water circulated infect bacteria proliferating drainage system used hosing down/dripping floor prewashing utensils. approach actually increases effectiveness increase time exponential manner high degree safety associated phage treatment suggests low risk-to-benefit ratio uv treatment kill bacteria facilitates conversion lysogenic lytic phages. thus, phage left lysogenic normal operation.\",\n",
              " 'phage-based method detecting biomarkersaccording example aspect present invention, provided method determining presence biomarker disease pretreated biological sample comprising steps diluting sample, contacting sample europium label, terbium label samarium label, dye, contacting sample phage, incubating sample, measuring luminescence emission intensity absorption emission intensity, determining presence biomarker based measurement luminescence emission intensity absorption emission intensity.',\n",
              " 'specific single-chain antibody resisting canine pancreatic lipase, plasmid vector methodaccording anti-canine pancreatic lipase specific single-chain antibody, plasmid vector method, recombinant protein provided, amino acid sequence recombinant protein formed repeatedly connecting two dominant epitopes canine pancreatic lipase series, amino acid sequence recombinant protein converted corresponding nucleotide sequence adopting escherichia coli preferred codons; nucleotide sequence chemically synthesized, recombinant expression vector constructed, expression quantity recombinant protein escherichia coli improved. invention relates phage library established immunizing mice recombinant protein, corresponding cpl single-chain antibody scfv sequence obtained panning screening, complete mouse igg antibody sequence expression vector constructed obtained scfv sequence, monoclonal antibody expression monoclonal antibody purification transient hek293f cells, optimal monoclonal antibody pairing combination determined immunofluorescence orthogonal experiment.',\n",
              " 'semi-synthetic antibody fragment combinatorial libraryaccording invention provided semi-synthetic antibody fragment combinatorial library based avian immunoglobulin genes. avian immunoglobulin genes poultry chicken immunoglobulin genes. antibodies single chain antibody fragments library displayed large phages. least third complementarity determining region (cdr 3) variable (v) domain heavy (h) chains antibody fragments replaced synthetically randomised peptides. synthetically randomised variable heavy (vh) regions paired natural repertoire avian vh regions defined light chains, arrangement combinatorial diversity contributed variable light (vl) vh regions natural vh repertoire avian vh regions adds diversity.',\n",
              " 'fully-humanized anti-human interleukin 17a single-chain antibodyaccording present invention, constructing great-capacity natural phage antibody library, single-chain antibody specific affinity il-17a obtained biological elutriation. antibody inhibit reaction il-17a il-6 released human fibrosarcoma cell ht1080 used detecting treating rheumatoid arthritis.',\n",
              " 'enterocyte-transcytotic, tissue target cell target peptide identified phage display process drug delivery systems using sameaccording present invention, peptide specific amino acid sequence identified using phage display technique vitro phage display technique, grouped basis similarity sequence meaningful sequence selected statistical analysis grouped peptide sequence group, binding motif extracted means selected meaning sequence thereafter generalized amino acid sequence extracted means extracted binding motif. also, according present invention, peptide introduced protein group ligand vaccine efficiently, efficient drug delivery system designed absorption efficiency biological membrane significantly increased. also, optimized delivery system designed behavior drug body controlled means tissue target type peptide. accordingly, present invention increases use possibility protein drug vaccine great ripple effect medicine, pharmacy, livestock farming veterinary fields.',\n",
              " 'cancer treatment novel technology cellular molecule nuclear fission mode-regulation technologyactive carbon fiber (acf) controlling pin novel biotechnology urgently demanded current cancer treating. acf controlling pin technology irrefutable confirms special function anti-cancer medicine capturing virus biological neutrons thus treating cancers. medicine positive active effect protecting normal cells. therefore, medicine effective special anti-cancer treatment medicine. bio-energetic era, acf controlling pin technology provide significant contributions virus cancer treatments. according characteristic active carbon fiber (acf) absorb neutrons, controlling rods inserted cancer cells. adjustment depth controlling rods, cancer cell fission reaction speeds controlled. controlling pin designed cubic lattice. without actions controlling rods, cancer cells subjected self-sustaining chain reaction. therefore, human-controllable cell nuclear fission started controllable phage chain reaction. scheme utilizing active carbon fiber (acf) controlling pin cubic lattice capturing virus biological neutrons, human canceration conquered.',\n",
              " 'methods preventing adhesions following laminectomies surgical proceduresadhesions scar formation following surgical procedure controlled providing human recombinant phage antibody, introducing antibody onto area body following procedure inhibit adhesions, scar formation. according one embodiment, antibody used prevent formation scar tissue following spinal surgery. may carried placing antibody dura lining spinal nerves spinal cord. alternatively, antibody may used inhibit adhesions following abdominal surgery, placed around great vessels following anterior approach spine regions. importantly, antibody may used inhibit adhesion formation adjacent areas growth factors used stimulate healing. invention may include step protecting growth factors and/or area body stimulated healing desired antibodies growth factors. option, medications therapeutic substances may added antibody(ies) enhance healing effectiveness.',\n",
              " 'aggregation induced emission-bacteriophage bioconjugatesaggregation-induced emission-bacteriophage bioconjugate including bacteriophage covalently bonded least one aggregation-induced emission luminogen via optional linker, pharmaceutical compositions including same, methods preparation use thereof.',\n",
              " 'bacteriophages control bacterial speck diseaseagricultural compositions disclosed comprise least one isolated bacteriophage capable infecting plant pathogen pseudomonas syringae pv. tomato, least one bacteriophage genomic nucleic acid sequence least 85 % identical one nucleic acid sequence set forth seq id nos: 1-23. composition comprises 10 different strains bacteriophage. uses thereof treating bacterial speck disease disclosed.',\n",
              " 'method positioning main allergen epitopes cow milkaiming cow milk alpha-lactalbumin, specific ige igg antibodies cow milk allergy patient subjected affinity purification serve target molecules, phage random peptide library subjected affinity panning, finally cow milk alpha-lactalbumin epitope positioned network server. according invention, bacteriophage display technology adopted, positive clone simulating epitope screened bacteriophage peptide library specific target molecule, allergen epitope positioned using bioinformatics method. compared traditional analysis method, novel analysis method many advantages, simple operate relatively low cost, easily screen mimic epitope retaining antigen reactivity, wide prospect application analyzing antigen epitope food protein.',\n",
              " 'composition comprising polymer bioactive agent method preparing thereofamino acid based polymers polymer blends. compositions comprising least one amino acid based polymer polymer blend, least one bioactive agent, optionally least one filler. additionally, compositions comprising least one bacteriophage least one salt buffer, which, example, form dry powder, methods preparing thereof disclosed.',\n",
              " 'compositions methods binding agglomeration proteinsamplibody compositions methods used interact agglomeration proteins disclosed herein. compositions herein comprise one dna rna molecules affinity least one agglomeration protein. nucleic acid component naturally non-naturally occuring molecule twenty ribonucleotide bases. rna, least one nucleotide sequence portion rna molecule affinity least one consensus sequence present agglomeration rna-binding protein. portion nucleotide sequence rna affinity agglomeration proteins sequence derived either rna virus, rna agglomeration proteins sequence derived either rna virus, rna phage, messenger rna (\"mrna\"), ribosomal rna (\"rrna), transfer rna (\"trna\"), sequence received template one rna dependent rna polymerases, combination thereof. methods disclosed herein directed towards detecting presence one agglomeration proteins sample matrix using amplibody compositions described herein.',\n",
              " 'active phage-based inks, methods printing materials phage-based bioactivean active phage bio-ink composition phage-based bioactive paper, wherein phage oriented immobilized paper surface heads, phage tail fibers free capture target bacterial pathogens.',\n",
              " 'rapid detection microorganisms using acyltransferase-labeled engineered bacteriophagean acyltransferase-labeled engineered bacteriophage kit developed invention directly analyze microorganisms environmental biological sample. acyltransferase-labeled engineered bacteriophage specifically recognize pathogenic microorganisms. engineered bacteriophage recognizes combined microorganisms, genetically engineered dna injected microorganisms recombine, express amplify large amount new bacteriophage acyltransferase protein microorganisms. recognition mechanism reaction kinetics engineered bacteriophage microbiological response material designed, action rule functional modules recognition responses rapid detection microbes instant analysis microorganisms investigated. references provided solving problems \"online\", \"portable\" \"automatic\" mechanical electrical engineering biology compounding microbial detection method.',\n",
              " 'modified adenovirus containing fiber replacement proteinan adenovirus modified replacing adenovirus fibre protein fibre replacement protein. fibre replacement protein comprises amino-terminal portion comprising adenoviral fibre tail domain associates penton base protein, chimeric fibre replacement protein provides trimerization function carboxy-terminal portion comprising targeting ligand. fibre replacement protein t4 bacteriophage fibritin protein. adenovirus may comprise therapeutic gene preferably herpes simplex virus thymidine kinase gene.',\n",
              " 'affinity carrier selective uptake / separation bacteriophages method selective uptake / separation bacteriophages capillary electrophoresisan affinity carrier designated selective uptake bacteriophages / separating them. carrier consisting substrate, surface substrate adhered cells least one bacterial strain. cells infected specific bacteriophages incubated, bacteriophages released cells. isolated separated, preferably capillary electrophoresis.',\n",
              " 'rapid detection microorganisms using aminopeptidase-labeled engineered bacteriophagean aminopeptidase-labeled engineered bacteriophage kit developed invention directly analyze microorganisms environmental biological sample. aminopeptidase-labeled engineered bacteriophage specifically recognize pathogenic microorganisms. engineered bacteriophage recognizes combined microorganisms, genetically engineered dna injected microorganisms recombine, express amplify large amount new bacteriophage aminopeptidase protein microorganisms. recognition mechanism reaction kinetics engineered bacteriophage microbiological response material designed, action rule functional modules recognition responses rapid detection microorganisms instant analysis microorganisms investigated. interaction relation functionalized bacteriophage microorganisms disclosed base researches order solve problems \"online\", \"portable\" \"automatic\" mechanical electrical engineering biology compounding microbial detection method.',\n",
              " 'agonist antibody heteroreceptoran animal immunized chain b chain receptor mrna extracted spleen cells animal. next, l-chain h-chain variable regions collected rt-pcr use primers corresponding variable regions including cdr. single-strand fv synthesized assembly pcr thus phage library constructed. next, antigen-binding antibody clones concentrated cloned panning. single-strand variable region inserted signal sequence animal cells ch1-hinge-ch2-ch3 prepare scfv-ch1-fc expression vector. transferring various combinations vector cells, antibodies expressed antibody clone showing ligand-like activity selected.',\n",
              " 'bacteriophage cocktail-containing hydrogel compositions methods production use thereofan anti-bacterial coating composition use medical implant disclosed. anti-bacterial coating composition includes bacteriophage cocktail encapsulated beads embedded within hydrogel. disclosed kits containing anti-bacterial coating composition well methods producing using coating composition.',\n",
              " 'anti-cd22 fully human antibody antigen binding fragment thereof, preparation method therefor, use thereofan anti-cd22 fully human antibody antigen binding fragment thereof, preparation method therefor use thereof. anti-cd22 antibody antigen binding fragment thereof screened fully human phage display library, formed means flexible linker peptide linking heavy chain variable region light chain variable region. framework region sequences complementarity determining region (cdr) sequences heavy chain variable region light chain variable region derived humans.',\n",
              " 'anti-hgf/sf humanized antibody method preparation thereofan anti-hgf/sf humanized antibody provided show low immunity side reaction binding affinity higher mother monoclonal antibody. method preparing using phage surface expression provided. anti-hgf/sf humanized antibody comprises heavy chain variable region amino acid sequence complementarity determining region(cdr), respectively, tyyms seq id : no. 1, yigtssgttyyansvkg seq id : no. 2, glgrinl seq id : no. 3; light chain variable region light chain variable region human antibody; heavy chain invariable region heavy chain invariable region human antibody; light chain invariable region light chain invariable region human antibody. dna encodes heavy variable region humanized antibody sequence seq id : no. 7, 11, 15 19. method preparing anti-hgf/sf humanized antibody comprises steps of: (a) preparing fab library including combination heavy chain variable region light chain variable region; (b) surface-expressing library phage. composition preventing treating cancer comprises humanized antibody.',\n",
              " 'antimicrobial protein derived podoviridae bacteriophage specific staphylococcus aureusan antimicrobial protein derived podoviridae bacteriophage specific staphylococcus aureus provided selectively kill staphylococcus aureus, thereby preventing treating infectious disease caused staphylococcus aureus. antimicrobial protein derived podoviridae bacteriophage(kctc 11154bp) specific staphylococcus aureus amino acid sequence seq id no:3. gene encoding antimicrobial protein nucleotide sequence seq id no:2. transformed escherichia coli(kctc 11152bp) over-expresses gene encoding antimicrobial protein.',\n",
              " 'packaged antimicrobial medical device method preparing samean antimicrobial suture assembly comprising containment compartment comprising one surfaces antimicrobial agent disposed thereon, said antimicrobial agent selected group consisting halogenated hydroxyl ethers, acyloxydiphenyl ethers, combinations thereof, amount sufficient substantially inhibit bacterial colonization said containment compartment; suture positioned within containment compartment, suture comprising one surfaces antimicrobial agent disposed thereon, said antimicrobial agent selected group consisting halogenated hydroxyl ethers, acyloxydiphenyl ethers, combinations thereof, least one active agent selected group consisting biocide, disinfectant, antiseptic, antibiotic, antimicrobial peptide, lytic bacteriophage, surfactant; adhesion blocker; oligonucleotide, efflux pump inhibitors; photosensitive dye, immune modulator chelator.',\n",
              " 'anti-pd-1 antibody, preparation method therefor use thereofan anti-pd-1 antibody molecule comprising variable region combination, nucleic acid molecule encoding antibody molecule, corresponding expression vector, host cell, method screening antibody using phage library, immunoconjugate, bis- poly-specific antibody molecule pharmaceutical composition comprising antibody molecule. antibody molecule coupled compound, conjugate, derivative composition thereof used treating cancer diseases infectious diseases. antibody molecule used detect pd-1.',\n",
              " 'surface-effect sensor formulationan area sensor chip (700) coating contains fiber bundles (622) including phage bioengineered interact target analyte. quartz crystal microbalance (qcm) surface acoustic wave (saw) sensing circuit, may connected integrated sensor chip (700), measures effects result interaction coating target analyte. spin coating spray coating may produce coating suitable qcm sam sensing techniques.',\n",
              " 'article storage bacteriophages method thereofan article, kit method. article includes composition comprising phage, gelling agent thickening agent, disaccharide, trisaccharide polysaccharide; nonwoven; wherein composition adsorbed onto nonwoven. kit includes article present disclosure; solid support; wherein article embedded solid support. method includes immobilizing composition comprising phage, gelling agent, disaccharide, trisaccharide polysaccharide onto nonwoven; wherein phage immobilized onto nonwoven stored room temperature 180 days, least 60% phages remain viable.',\n",
              " 'bacterial identification assay using bacteriophages colony growth measurementsan assay typing bacterial strains comprising: (a) providing isolated colony bacteria; (b) combining said isolated colony selected bacteriophage container, incubating medium containing nutrients required bacterial growth, enables phage/bacteria interaction; (c) determining extent bacterial growth compared control sample, comparing value obtained predetermined growth data known bacteria said bacteriophage, thereby identifying bacteria. method using said assay select bacteriophages work specific bacterial species covered.',\n",
              " 'preparation method gfp (green fluorescent protein) antibody gfp antibodyan embodiment invention provides preparation method gfp (green fluorescent protein) antibody gfp antibody. preparation method comprises steps follows: gerbu-lq mixed emulsified antigen serve immunogen, immunogen injected alpaca, wherein antigen gfp label; peripheral blood lymphocytes immunized alpaca extracted; phage library constructed peripheral blood lymphocytes; target phage screened phage library, wherein phage plasmid target phage contains gene segments gfp antibody; phage plasmid target phage expressed. method standardized batched whole antibody preparation process, prepared antibodies smalldifference batches high stability.',\n",
              " 'microencapsulation bacteriophages related productsan encapsulated bacteriophage formulation method encapsulating bacteriophages bacteriophage-related products polymeric microcapsules provided. embodiments method producing encapsulated bacteriophages involves water-in-oil-in-water double emulsion.',\n",
              " 'genetically encoded system constructing detecting biologically active agentsan engineered bacterial cell, comprising: bacterial two-hybrid system linking expression reporter protein production inhibitor protein phosphatase engineered bacterial cell; isoprenoid pathway producing inhibitor protein phosphatase. bacterial two-hybrid system may comprise one components encode: substrate recognition domain sh2 domain coupled dna-binding protein 434 phage ci repressor; substrate domain coupled subunit rna polymerase (rna polymerase omega); protein kinase (src); protein phosphatase; operon comprising: operator dna-binding protein; binding site rna polymerase; reporter gene encoding reporter protein. methods producing two-hybrid system claimed.',\n",
              " 'm13 phage based gene therapy platforman engineered phage-derived particle (pdp) expressing transgene target cell transduced bacteriophage, pdp includes (i) less 500 bp dna bacteriophage genome, (ii) itr-flanked therapeutic gene 20 kb, (iii) endosomal escape sequence, (iv) nuclear localization sequence, (v) cell-specific targeting moiety. pdp may escape lysosomal degradation, traffic across nuclear envelope expressed therapeutic gene mammalian cell.',\n",
              " 'igy purification methodan igy purification method comprises following steps: obtaining anti-igy nano antibody subjecting igy immunized two-humped camel phage display biocompatibility screening; fetching 2 to4 grams 4ff gel filler, washing 4ff gel filler dmso solutions volume ratios 20%, 50%, 70% sequence, washing 4ff gel filler water, drying; adding dmso, nabh4, naoh, epoxy chloropropane sequence obtain mixed filler; coupling nano antibody na2co3 solution mixed filler; coupling, adding glycine, using nacl solution wash column obtain affinity column coupled nano antibody, wherein volume ratio nacl solution column 10-20:1; adding igy sample, needs purified, intothe nano antibody affinity column carry coupling, coupling, washing column pbs; finally washing igy column using glycinate, neutralizing separated igy glycinate (ph=8) avoid situation igy inactivated acidic condition. provided method obtain high purity igy.',\n",
              " 'il-18-like peptide, fused peptide thereof, method producing use samean il-18-like peptide capable regulating/controlling interaction il-18, participates inflammation immune abnormality diseases atopic dermatitis, receptor; medicinal composition containing peptide active ingredient; physiological activity inhibitor. intended disclose method producing above-described il-18-like peptide comprises screening phage random peptide library use human anti-il-18 antibody. il-18-like peptide regulate/control interaction il-18, seemingly participates immune abnormality diseases atopic dermatitis, receptor useful il-18 activity inhibitor. thus, expected applicable various inflammatory diseases.',\n",
              " 'immunobiological agent form gel treating staphylococcus pyodermiaan immunobiological agent form gel treating staphylococcus pyodermia contains antistaphylococcus bacteriophage lytic activity least 10according appelman, carbomer constifuens, preserving agent, alkaline neutralizer, macrogol.',\n",
              " 'immunobiological composition form foam aerosol treating dermatological diseases infectious etiologyan immunobiological composition form foam aerosol treating dermatological diseases infectious etiology comprises aqueous solution bacteriophages preserving agent. mixture contains emulsifiers first second classes, vegetable oil propellant.',\n",
              " 'egfrviii immunogen methods using samean immunogen includes antigenic egfrviii peptide linked qβ bacteriophage virus-like particle (vlp) carrier. antigenic egfrviii peptide least 53%, least 61%, least 69%, least 76%, least 84%, least 92% sequence similarity amino acid similarity leekkgnyvvtdh (seq id no:1).',\n",
              " 'improved bacteriophage expression carrrieran improved expression carrier phen2 used screen phagemid single-chain antibody phage display method features enzyme severing site apal1 multiple enzyme severing sites removed replaced bssh ii, products coded light-chain gene human immunoglobulin effectively inserted single-chain antibody library ensure diversity high volume.',\n",
              " \"method simultaneous identification differentially expressed mrnas measurement relative concentrationsan improved method simultaneous sequence-specific identification mrnas mrna population allows visualization nearly every mrna expressed tissue distinct band gel whose intensity corresponds roughly concentration mrna. general, method comprises formation cdna using anchor primers fix 3'-endpoint, producing cloned inserts cdna vector containing bacteriophage-specific promoter subsequent rna synthesis, generating linearized fragments cloned inserts, preparing crna, transcribing cdna crna using set 5'-rt primers, performing pcr using 3'-pcr primer whose sequence derived vector set 5'-pcr primers derived 5'-rt primers used transcription cdna crna. method identify changes expression mrna associated administration drugs physiological pathological conditions.</ptext>\",\n",
              " 'method vitro synthesis short double stranded rnasan vitro transcription method using bacteriophage polymerases target sequence-specific single-stranded dna oligonucleotides templates disclosed. present invention finds particularly advantageous use synthesis short interfering rnas (sirnas) shown function key intermediates triggering sequence-specific rna degradation posttranscriptional gene silencing plants rna interference invertebrates vertebrate systems.',\n",
              " 'inorganic nanowiresan inorganic nanowire organic scaffold substantially removed inorganic nanowire, inorganic nanowire consisting essentially fused inorganic nanoparticles substantially free organic scaffold, methods making same. example, virus-based scaffold synthesis single crystal zns, cds free-standing l10 copt fept nanowires used, means modifying substrate specificity standard biological methods. peptides selected evolutionary screening process exhibit control composition, size, phase nanoparticle nucleation expressed highly ordered filamentous capsid m13 bacteriophage. incorporation specific, nucleating peptides generic scaffold m13 coat structure provide viable template directed synthesis variety materials including semiconducting magnetic materials. removal viral template via annealing promote oriented aggregation-based crystal growth, forming individual crystalline nanowires. unique ability interchange substrate specific peptides linear self\\xadassembled filamentous construct 13 virus introduces material tunability seen previous synthetic routes. therefore, system provides genetic tool kit growing organizing nanowires various materials including semiconducting magnetic materials.',\n",
              " 'treatment intracellular bacterial infectionan intracellular bacterial infection plant animal treated administration plant cell animal cell particle infectious bacteriophage covalently attached, wherein particle internalised cell. particles phage attached compositions comprising particles provided. formulation, treatment bacterial infection, comprises bacteriophage, liquid carrier adhesive, dries adhesive adheres bacteriophage surface, one formulation comprising liquid carrier: 85%-99.98% weight; bacteriophage: 0.01%-5% weight; adhesive: 0.01%-10% weight.',\n",
              " 'coupling borrelial protein bb0689 virus-like particles generation lyme disease vaccinean invention discloses lyme disease vaccine obtaining high immune response surface protein bb069 borrelia burgdorferi, causative agent lyme disease. present invention includes protein comprising amino acids identical least 80% modified borrelia burgdorferi bb0689 protein (as set forth seq id 5), chemically coupled bacteriophage q² virus-like particles. said invention relates method production purification protein, comprising amino acids identical least 80% modified borrelia burgdorferi bb0689 protein set forth seq id 5.',\n",
              " 'pseudomonas aeruginosa bacteriophage uses thereofan isolated bacteriophage mr299-2 nh-4 deposited ncimb deposit accession nos. 41729 41730, respectively, described. phages lytic activity p. aeruginosa strains, including mucoid cf clinical isolate strains. variant hages described, wherein said variants retain phenotypic characteristics said phage wherein said phage variants thereof lytic activity p. aeruginosa strains.',\n",
              " 'compositions methods producing single stranded dnaan isolated nucleic acid includes first sequence filamentous bacteriophage, first sequence initiator terminator functions; second sequence identical first sequence; single-strand dna sequence interest located first sequence second sequence. host cell including isolated nucleic acid method producing single-stranded dna disclosed.',\n",
              " 'brucella phage polynucleotides uses thereofan isolated polynucleotide disclosed comprises nucleic acid sequence brucella phage, nucleic acid sequence specific brucella phage comprising sequence selected group consisting seq id nos: 387-393. exemplary polynucleotide sequence one comprises least 100 consecutive nucleotides nucleic acid sequence set forth seq id no: 396. uses sequences disclosed.',\n",
              " 'bacterial anti-phage defense systemsan isolated polypeptide disclosed comprising amino acid sequence selected group consisting seq id nos: 2773-5544 11089-11094, wherein polypeptide antimicrobial activity. uses thereof treating microbial infections disclosed.',\n",
              " 'bacteriophages useful prophylaxis therapy vibrio anguillaruman isolated strain bacteriophage, specific bacteria belonging vibrio genre, particularly anguillarum species, deposited 3 oct. 2012 polish collection microorganisms (pcm) ludwik hirszfeld institute immunology experimental therapy polish academy sciences, access number f/00072, characterized said strain efficient prophylaxis, control and/or treatment infection caused vibrio anguillarum types species fish, mollusks crustaceans important aquaculture susceptible bacteria, genome size 48.6 kb, sensitive chloroform storage temperature −80° c.',\n",
              " 'isolation viruses using anionic resin beadsan isolation detection method viruses large quantities water aqueous media. technology employs charged resins isolate viral particles liquid sources water, milk, juices, homogenized food. anionic resin beads added sample liquid suspended within liquid. suspension anionic beads complex negatively charged virus particles pathogens. complexed beads removed liquid, effecting isolation virus. detection techniques performed directly complexed beads without resorting additional steps elute virus pathogen bead. methodology employed detection bacteriophage aqueous medium bacteriophage serves surrogate presence pathogen contaminant, enteric virus.',\n",
              " 'modified cre recombinase gene mammalsan object present invention provide modified gene mammals expression level, mammalian cells, tissues, organs bodies, several times high phage-derived cre recombinase. attain aforementioned object, present invention provides modified cre recombinase gene mammals consisting codons frequently used mammalian cells.',\n",
              " 'host bacterium specific nanoparticlean object present invention provide recombinant phage high safety excellent practicality usefulness. provided recombinant bacteriophage deprived proliferative capacity infect due fact bacteriophage genome part virion constituent gene deleted stored head, method preparing same. addition, provided recombinant bacteriophage deprived proliferative capacity infect due fact plasmid packaging site encoding target gene stored head, method preparing same.',\n",
              " 'fiber light emitting device using functionally characterized bacteriophagean objective present invention provide fibrous light-emitting device using bacteriophage. according present invention, silver nanowire produced mixing bacteriophage solution silver acetate, irradiating bacteriophage solution light, adsorbing silver (ag) onto bacteriophage electrophoresis photoreaction, fibrous light-emitting device produced using silver nanowire electrode, providing electron transport layer, light-emitting layer, hole transport layer, upper electrode silver nanowire, light-emitting layer coated using bacteriophage. words, electrode electron transport layer immersed bacteriophage solution pulled allow bacteriophage enclose electron transport layer self-assembling property, electrode immersed phosphorescent material (+) charge efficiently produce light-emitting layer, using fact bacteriophage (-) charge.',\n",
              " 'ointment containing bacteriophagean ointment contains bacteriophage base – vaseline, lanolin vaseline oil.',\n",
              " 'systems methods using bacteriophage-mediated lysis detection identification microorganisms fluid samplean optical measurement instrument includes optical cavity light source, plurality fluid containers, optical sensor. fluid container holds test portion fluid sample containing unknown microorganism, either distinct microorganism- attracting substance distinct growth-inhibiting substance. distinct microorganism- attracting growth-inhibiting substance configured react single type microorganism. instrument incubates test portions fluid sample within fluid containers. using microorganism-attracting substances, presence microorganism growth within one fluid containers simultaneously indicates presence identity unknown microorganism. using growth-inhibiting substances, absence microorganism growth within one fluid containers simultaneously indicates presence identity unknown microorganism. incubated test portions fluid sample compared incubated control portion fluid sample.',\n",
              " 'optical sensor methodan optical sensor waveguide core, cladding outer surface long period fiber grating. core, cladding long period fiber grating collectively provide least two resonant wavelengths. optical sensor binding sites outer surface cladding binding elements detected outer surface cladding. cladding may thinned thickness sufficiently low produce resonant wavelengths. binding sites include agents binding elements detected agents covalently bonded surface cladding. example binding sites include bacteriophages detecting e. coli bacteria, palladium detecting hydrogen, synthetic dna detecting viruses certain molecules example.',\n",
              " 'ozone disinfection filtering system swimming pool water bodyan ozone disinfection filtration system used water system swimming pool comprising water pump filtration unit, water pump connected filtration unit comprising filtering sand cylinder, connected pressure water pump, mixing pot communicated tube ozone generator, reactive pot communicated outflow tube one one pipe. water swimming pool pumped filtering sand cylinder filtrate quickly, afterwards pressurized pressure water pump sent mixing pot. ozone ozone generator sent mixing pot mix water sent reactive pot oxidative decompose bacteria, removal effectiveness distinctly especially brood-cell strong chlorine resistance f bacteriophage. water disinfection discharged cycle swimming pool. invention disinfects quickly side effect.',\n",
              " 'thermostable rna ligase thermus phagean rna ligase derived bacteriophage ts2126 infects thermus scotoductus, nucleic acids comprising nucleotide sequences open reading frame (orf) polypeptides encoded nucleic acids, described.',\n",
              " 'agonist antibody heteroreceptoranimals immunized either b chain receptor, mrna extracted spleen cells animals, variable regions l h chains isolated rt-pcr using primers variable regions comprising cdrs. single-chain fv synthesized assembly pcr construct phage library. clones antigen-bound antibodies concentrated cloned panning. expression vector scfv-ch1-fc prepared inserting single-chain variable region ch1-hinge-ch2-ch3 signal sequence animal cells. various combinations expression vectors introduced cells express antibodies, antibody clones exhibiting ligand-like activity selected.',\n",
              " \"single chain antibodies beta-amyloid peptideanti-a~p scfvs single domain antibodies generated, antibodies displayed filamentous phage soluble protein molecules, stabilized maltose binding protein, prevent fibrilization abp 1-40 disaggregate abp 1-40 fibrils generated vitro. anti-a~p scfv antibodies stained amyloid neuritic plaques slices transgenic mice. anti-a~p scfv single domain antibodies used inhibiting treating alzheimer's disease.\",\n",
              " 'antimicrobial proteins spo1 bacteriophageanti-bacterial peptides provided derived bacteriophage spo1.',\n",
              " 'antibacterial phage peptides methods use thereofantibacterial phage peptides methods use thereofthe present invention directed isolated chimeric polypeptides bacteriophage origin antibiotic activity use thereof treatment control bacterial infections. specifically, present invention directed 0 use novel antibacterial polypeptide derived bacteriophage f87s/06 chimeric constructs thereof, use ibr treatment control infections caused gram-positive bacteria, including staphylococcus ameus.figure no.',\n",
              " \"identifying affinity-matured human antibodies.antigen-specific immunoglobulin v-regions identified library nucleic acids amplified using polymerase chain reaction using leader sequence-specific forward primers. use leader sequence primers allows v-region sequences amplified (including extensive 5' end mutations) without loss original 5' v gene segment sequence. libraries screened antigen-specific v-regions using eukaryotic cells engineered express amplified v-region-encoding nucleic acids using bacterial phage display techniques. latter, second v-region library made using larger conventional set 5' v-region primers. sequence errors introduced amplification products method corrected using sequence information obtained products amplified v-region primers screen library created using leader sequence primers. amino acid sequence information fragments donor immunoglobulins used assist identification nucleic acids encoding heavy light chains donor antibodies well design primers amplify nucleic acids.\",\n",
              " 'antimicrobial composition use thereofantimicrobial composition contains bacterio¬phage strains sensitive staphylococcus aureus: dsm 32631, dsm 32629, dsm 32630, bacterio¬pha¬ge strains sensitive streptococcus pyogenes: dsm 32634, dsm 32635, bacteriophage strains sensitive escherichia coli: dsm 32612, dsm 32611, dsm 32610, bacteriophage strains sensitive proteus vulgaris: dsm 32613, dsm 32614, dsm 32615, bacteriophage strains sensitive pseudomonas aeruginosa: dsm 32616, dsm 32618, dsm 32617 optionally pharmaceuti¬cally acceptable excipient. that, said bacteriophages deposited german collection microorganisms cell cultures (dsmz). composition used treatment and/or prevention purulent-inflammatory people, animals birds, well.',\n",
              " 'colonic delivery antimicrobial agentsantimicrobial compositions oral delivery, administration colon, distal ileum, portion gastrointestinal tract stomach, bacteriophage, phage proteins, antimicrobial peptides, antimicrobial aptamers, disclosed. one embodiment, active agent capable lysing bacterial cell wall. another embodiment, active agent capable interacting receptor enzyme bacteria. embodiments, active agents selectively act one harmful bacteria, clostridium dificile, either act, act lesser extent, helpful bacteria, bifidobacteria. agents delivered directly colon, active agents ultimately enter colon affect bacteria present colon. compositions include beads pectin form cationic salt enclosing active agent, types drug delivery systems designed targeted delivery desired portion gastrointestinal tract.',\n",
              " 'anti-vegf antibodiesanti-vegf antibodies variants thereof, including high affinity 5 binding vegf, disclosed. provided methods using phage display technology naive libraries generate select anti-vegf antibodies desired binding biological activities. contemplated uses antibodies research, diagnostic therapeutic applications.',\n",
              " 'anti-vegf antibodiesanti-vegf antibodies variants thereof, including high affinity 5 binding vegf, disclosed. provided methods using phage display technology naive libraries generate select anti-vegf antibodies desired binding biological activities. contemplated uses antibodies research, diagnostic therapeutic applications. 5919798_1 (ghmatters) p59588.au.2 leownr',\n",
              " 'anti-vegf antibodies methods useanti-vegf antibodies variants thereof, including high affinity binding vegf, disclosed. provided methods using phage display technology naive libraries generate select anti-vegf antibodies desired binding biological activities, used diagnostics therapy corresponding diseases.',\n",
              " 'synthetic non-covalently self-assembling bipartite prna chimerasartificial packaging rna (prna) polynucleotides share secondary structure dsdna bacteriophage prna (e.g., phi29 prna) formed non-covalent self-assembly two rna pieces form prna monomers may include heterologous sequences form chimeric prna monomers. two rna pieces (p1 p2) made non-enzymatic chemical synthesis resulting monomer includes break single- stranded head loop corresponding positions 53-58 wild-type phi29 prna. synthetic prna monomers assembled multimeric polyvalent nanoparticles may include heterologous components payloads sirna, ribozymes, aptamers, antisense rna, detectable labels, therapeutic drugs like, well targeting moieties, endosome- disrupting agents moieties.',\n",
              " 'process continuous production bacteriophageas bacteriophage use industrial application grows need commercial quantities identified bacteriophage. invention discloses continuous flow bacteriophage proliferation process provide commercial quantities desired bacteriophage concentrations suitable industrial use. host bacteria virulent bacteriophage fed reactor vessel phage attach to, infect lyse host bacteria providing multiple replications coincidentally concentrating phage.',\n",
              " 'methods periplasmic phage-assisted continuous evolutionaspects disclosure relate compositions, systems, methods evolving nucleic acids proteins utilizing continuous directed evolution periplasm host cell. embodiments, methods comprise passing nucleic acid cell-to-cell desired, function dependent manner. linkage desired function passage nucleic acid cell-to-cell allows continuous selection mutation nucleic acid.',\n",
              " 'method vitro screening in-vivo antibacterial activity phagesaustracy present invention discloses method vitro screening in-vivo antibacterial activity phages. method includes following steps: si, selecting appropriate culture dish, sterilizing culture dish; s2, adding culture medium culture dish, wherein culture medium includes 10-15 g beef soup, 5-10 g peptone, 30-50 g sodium chloride, 10-20 g glucose 5-18 g blood, mixing substances prepare fluid, semisolid solid culture media; s3, obtaining serum experiment subjects, dividing serum four parts, without performing treatment serum b, inactivating serum c, adding sterilizing agent serum d; s4, collecting secretions infected persons discharged vitro body, wherein secretions specifically include blood, urine, feces, pus secretions; s5, selecting colonies secretions, selecting host bacteria phages; s6, respectively performing following treatments four parts serum: still performing treatment serum a, adding host bacteria phages serum b, serum c serum d. present invention high screening accuracy.',\n",
              " 'method preserving freeze-dried powder capsules phagesaustracy present invention discloses method preserving freeze-dried powder capsules phages. method includes following steps: s, performing primary treatment phages, selecting host bacteria phages, inoculating phages fluid medium, performing shake culture 10 hours, collecting phage-containing supernatant; s2, preparing phage protectant, mixing phages protectant together, fully mixng phages protectant together stirring stirring rod; s3, preparing freeze-dried powder, placing mixed solution prepared s2 freezing chamber freezing, performing primary drying vacuum condition, adding 10-20 parts glycerin phage fluid subjected primary drying, heating, performing secondary drying obtain phage freeze-dried powder; s4, preparing capsules, filling freeze-dried powder capsules sterile environment using encapsulating machine, sealing capsules, preserving sealed capsules shade. preservation effect present invention excellent.',\n",
              " 'fluorescent virus probes identification bacteriabacteria fluid systems identified using fluorescently labeled virus molecular recognition element bacteria. virus, bacteriophage, optically encoded fluorescent reporter molecules allow detection quantitation phage host/phage complex. biosensors provided molecular recognition element immobilized substrate.',\n",
              " 'bacteria sensitive endodontic pointsbacteria sensitive endodontic points modern endodontic treatment directed elimination microorganisms infected root canal tooth obturation. follow-up studies examined outcome endodontic therapy revealed high success rate negative bacterial culture prerequisite root filling (sjogren et al.). insome conditions bacteria survive biomechanical preparation ofroot canal long-term success endodontic therapy doubtful bacteria present root canal prior obturation. biomechanical preparation root canal followed complete obturation. prior that, root canal thoroughly dried using paper points (a cone variable width taper, usually made paper paper product). obturation done using gutta percha. invention endodontic point fabricated bacteria specific antibody/bacteriophage vertical strips impregnated (as shown figure). strips vertical detect result apical, middle coronal third ofthe rootcanal. points used prior obturation procedure check sterility ofthe root canal long term success endodontic therapy. detection gram-positive bacteria, endodontic points impregnated gram positive bacteria specific antibody indicator used detection gram-negative bacteria, endodontic points impregnated gram negative bacteria specific antibody indicator used. 1|pa ge bacteria sensitive endodontic points drawings endodontic point detection bacteria bacte ria pe cific antibody/bacteriophage strips endodontic 2a ge',\n",
              " 'process remediating biofouling water systems virulent bacteriophagebacterial contamination industrial water systems lead biofouling biofilms corrosion bacterial induced corrosion. invention provides method control fouling contamination industrial water systems caused bacteria. prevention reduction process interruptions general contamination, fouling corrosion achieved destruction targeted problematic bacteria naturally occurring, non-engineered bacteriophage virulent targeted bacteria. invention provides in-situ confirmation proper identification target bacteria mobile laboratory adapted implement method.',\n",
              " 'bacteriophage adhesion proteinsbacteriophage adhesion proteins binding o-antigen gram negative bacteria, lacking ability binding bacteriophage hydrolysing lipopolysaccharides, described, well nucleic acid molecules encoding proteins. addition, methods generating bacteriophage adhesion proteins use detection, purification enrichment bacteria described.',\n",
              " 'endolysin bacteriophage geobacillus methods usingbacteriophage geobacillus provided, methods making using bacteriophage provided.',\n",
              " 'culture bacteriophagebacteriophage produced continuous process comprising maintaining culture bacteriophage first vessel (16); feeding culture bacteria maintained second vessel (12a, 12b) stationary phase harvesting bacteriophage first vessel (16), wherein first vessel operated dilution rate excess 1 / (bacteriophage lysis time).',\n",
              " 'bacteriophage methods usingbacteriophage provided, methods making using bacteriophage provided.',\n",
              " 'bacteriophage treatment acne biofilmsbacteriophage compositions therapeutic uses thereof. particular, compositions lytic bacteriophages capable lysing',\n",
              " 'bacteriophage compositions.bacteriophage compositions, methods preparing bacteriophage compositions provided. method producing antibacterial composition involves adsorbing aqueous solution one bacteriophages, one phage components, onto matrix produce composition, drying composition produce antibacterial composition. antibacterial composition comprising one strain bacteriophage, one phage component, adsorbed onto matrix provided. antibacterial composition may encapsulated. antibacterial composition, encapsulated antibacterial composition, may used within cream, lotion gel, admixed pharmaceutical carrier administered topically, orally, nasally, used powdered inhalant, antibacterial composition encapsulated antibacterial composition, may added feed animal, aquatic avian uses.',\n",
              " 'treatment topical systemic bacterial infectionsbacteriophage covalently attached carrier particle average diameter 0.1 microns 15 microns, used topical treatment bacterial infection. bacteriophage covalently attached carrier particle average diameter 7 microns less used systemic treatment bacterial infection. plurality bacteriophages lytic different bacterial strains gives wide antibacterial activity. combination therapy comprises administration antibiotic bacteriophage covalently attached carrier particle.',\n",
              " 'lambdasa2 endolysin truncationbacteriophage endolysins demonstrating bactericidal peptidoglycan hydrolase activity comprise one group new candidate antimicrobials reportedly refractory antibiotic resistance development. isolated recombinant nucleic acid encoding antimicrobial truncated lambdasa2 endolysin enzyme molecule specificity exolytic endopeptidase activity peptidoglycan cell wall untreated host species streptococcus agalactiae addition, least one streptococcal species: streptococcus dysgalactiae, s. dysgalactiae subs, equisimilis, s. equi subs, zooepidemicus, group e streptococcus, group g streptococcus, streptococcus pyogenes, streptococcus uberis. lambdasa2 prophage endolysin gene isolated group b streptococcal genome, expressed e. coli plasmid, shown harbor amidase-5 (endopeptidase), amidase-4 (glycosidase) domain two cp1-7 cell wall-binding domains. isolated antimicrobial lambdasa2 truncated endolysin protein encoded nucleic acid used treatment diseases caused streptococcal staphylococcal microorganisms.',\n",
              " 'bacteriophage lambda-vaccine systembacteriophage λ disclosed herein include head, tail, lambda genome comprising nucleic acid sequence encoding fusion protein comprising protein linked heterologous antigen, wherein nucleic acid sequence inserted native gene locus adjacent gene e, lambda genome, wherein expression fusion protein results head bacteriophage λ comprising fusion protein. host bacterial cells disclosed herein infected bacteriophage λ. addition, immunogenic compositions disclosed include effective amount bacteriophage λ. methods disclosed inducing immune response heterologous antigen subject. furthermore, methods disclosed preparing bacteriophage λ.',\n",
              " 'phage insensitive streptococcus thermophilusbacteriophage insensitive mutants (bims) three streptococcus thermophilus parent strains generated characterized phage sensitivity, sedimentation rate, cell chain length, phage adsorption crispr loci alterations. several bims showed altered sedimentation phenotype well increase cell chain length, reduced phage sensitivity, reduced phage adsorption 100% identity three crispr loci. results show derived bims become phage-resistant mechanism crispr.',\n",
              " 'production immobilised bacteriophagebacteriophage covalently attached substrate (a) combining (i) substrate (ii) bacteriophage, wherein prior combining (i) (ii) (i) (ii) activated, wherein (b) combining bacteriophage contained within liquid droplet average diameter 150 microns less.',\n",
              " 'novel strains bacteriophages treatment bacterial infections, particularly strains drug-resistant bacteria genus stenotrophomonasbacteriophage strains use production preparations use treatment bacterial infections, particularly strains drug-resistant bacteria genus stenotrophomonas, particularly belonging species stenotrophomonas maltophilia',\n",
              " 'bacteriophage-based contrast agents, use thereof method production thereofbacteriophage-based contrast agents method production thereof disclosed. bacteriophages, least one embodiment, contain first fusion protein comprising phage-surface protein ligand specific identifiable target structure second fusion protein comprising phage-surface protein peptide binding signal generating molecule.',\n",
              " 'enterococcus faecalis bacteriophage uses thereofbacteriophages provided infect strains enterococcus faecalis, opportunistic bacterial pathogen causes human disease. provided methods treating enterococcus faecalis therapeutic administration bacteriophages.',\n",
              " 'bacteriophage dna vaccine vectorbacteriophages used dna delivery system vaccine pathogens glycosylation critical immunity.',\n",
              " 'phage lambda display constructsbacteriophages general lambda phage particular powerful, flexible reagents yet exploited full potential. discussed herein, lambda phage head and/or genome comprises easy use highly efficient delivery vehicle delivering expression products gene interest systemically particular tissue.',\n",
              " 'lysin bacteriophage clostridia sppbacteriophages food-contaminating pathogenic bacteria lysine thereof used kill bacteria. examples include lysins bacteriophages listeria monocytogenes clostridium tyrobutyrlcum. tests bacterial contamination made specific specific bacteria using appropriate bacteriophage lysin thereof determining whether cells lysed thereby.',\n",
              " 'method obtaining bacteriophage strain increased affinity eukaryotic cells, preparations containing it, applications bacteriophagesbacteriophages showing affinity eukaryotic cells serve diagnosis and/or treatment and/or prevention and/or developmental arrest diseases connected appearance eukaryotic cells, particular neoplastic cells.',\n",
              " 'preparation method bacteriophage lyase capable lysing escherichia coli salmonellabelonging field animal biomedical engineering, invention specifically discloses preparation method bacteriophage lyase capable lysing escherichia coli salmonella. primer design, lyase gene bacteriophage ecgd1 successfully amplified pcr, transferred expression system obtain recombinant strain. iptg induction carried recombinant strain obtain expression, strain lysed obtain soluble recombinant lyase bacteriophage ecgd1, recombinant lyase lyse plurality escherichia coli salmonella, i.e. wide lysis spectrum. addition, synergistic effect result recombinant lyase polymyxin b shows existence recombinant lyase lowers minimum inhibitory concentration polymyxin b, i.e. two synergistic bacteriostatic effect. identification lysis activity recombinant lyase identification wide lysis spectrum thereof reveal recombinant lyase bacteriophage ecgd1 potential application value prevention control escherichia coli salmonella infection.',\n",
              " 'anti-idiotypic nano antibody based zearalenone green immunoassay methodbelonging field molecular biology, invention particular relates anti-idiotypic nano antibody based zearalenone green immunoassay method. according invention, zearalenone monoclonal antibody 2d3 employed immunize alpaca, leukocyte total rna extracted construct phage displayed nano antibody library; 2d3 antibody adopted target, four rounds affinity enrichment panning conducted lower coating concentration competitive elution concentration round round, positive phage zearalenone anti-idiotypic nano antibody good specificity obtained. invention employs zearalenone anti-idiotypic nano antibody substitute zearalenone standard elisa method determine naturally polluted corn feed samples, performs comparison hplc detection result, two methods good correlation, r2 0.997, thus proving zearalenone anti-idiotypic nano antibody substitute standard method accurate reliable result effective feasible green immunoassay method.',\n",
              " 'anti-tnfalpha fully human monoclonal antibodies application thereofbelonging technical field antibody drugs, invention provides anti-tnfalpha fully human monoclonal antibodies application thereof. antibodies derived human hybrid tumors obtained cytotoxin functional test screening affinity screening phage display technology, excellent affinity specificity tnfalpha. pharmacodynamic experiments cell models, antibodies effectively neutralize nfalpha cytological effect generated thereby. animal experiments, antibodies effectively neutralize tnfalpha inhibit phenotype brought tnfalpha animal models. effect lower better humira.',\n",
              " 'cn 102268072 abelonging technical field biomedicine, invention relates sequence structure polypeptide able specifically bind influenza virus hemagglutinin protein, application polypeptide anti-influenza viruses. expressing purified influenza virus hemagglutinin protein screening random peptide library phage display technology, polypeptide specifically bound influenza virus hemagglutinin equipped sequences numbered 1-18 obtained. hemagglutinin-binding peptide hinder combination hemagglutinin host cell receptor, influenza virus inhibited infecting host cell. thus, invention conducts anti-influenza virus activity study hemagglutinin-binding peptide selected phase peptide library, finds polypeptide h17, sequence nh2-shgritfayfan-cooh, effectively inhibit influenza virus infecting host cell small toxicity. therefore, hemagglutinin-binding peptide invention h17 polypeptide therein anti-influenza virus activity expected become novel treatment medicaments treating diseases caused influenza virus infection reducing hazards diseases caused influenza viruses.',\n",
              " 'bursin bpp-ii specific binding peptide application thereofbelonging technical field protein polypeptide, invention discloses bursin bpp-ii specific binding peptide application thereof. amino acid sequence bursin bpp-ii specific binding peptide following: short peptide 1: qslpsplwiqqs, short peptide 2: drmpdsawttrk, short peptide 3: alwppnlhawvp. according invention, bpp-ii-bsa fusion protein taken target molecule, bacteriophage random 12 peptide library screening carried out, elisa identification competitive inhibition test combined obtain bpp-ii specific binding bacteriophage, sequencing performed artificial synthesis bpp-ii specific binding peptide. binding peptide obtained screening specifically bound bursin bpp-ii, inhibit activity bpp-ii mouse wehi-231b lymphoma cell proliferation certain concentration, good application prospects preparation drugs inhibiting resistance bursin bpp-ii tumor cell proliferation, thus laying foundation research, development application bpp-ii inhibitors.',\n",
              " 'cadmium ion targeted metal-binding peptide z1 application thereofbelonging technical field wastewater treatment, invention particular relates cadmium ion targeted metal-binding peptide z1 application thereof. polypeptide sequence metal-binding peptide z1 shown seq id no.1, specifically mhpnaghgslmr. invention utilizes random phage dodecapeptide library screening technology obtain specifically bound dodecapeptide high affinity cadmium ions, bound peptide coded gene integrated saccharomyces cerevisiae, saccharomyces cerevisiae lectin surface display system eby100 utilized display metal-binding peptide specific cadmium ion adsorption ability outer surface cell wall, cadmium ion targeted metal-binding peptide z1 applied asan adsorbent. preliminary test shows that: gram wet bacteria adsorb 257mg cadmium ions, gram dry bacteria adsorb 2500-3000mg cadmium ions, cadmium ion targeted metal-binding peptide z1 shows good application effect, certain industrial application prospect.',\n",
              " 'methods producing biofuels compositions use biofuel production methodsbeneficial virus, phage, used fermentation methods techniques producing biofuels. beneficial virus (e.g., phage) may targeted toward microorganisms (e.g., bacteria, etc.) undesirably affect fermentation biofuel production process. beneficial virus targeted toward microorganisms undesirably affect product by-product process, processing, results processing may incorporated fermentation biofuel production process. compositions include beneficial viruses, phage, useful processes disclosed.',\n",
              " 'dual anthrax-plague vaccines protect two tier-1 bioterror pathogens, bacillus anthracis yersinia pestisbivalent immunogenic compositions anthrax plague disclosed herein. one bivalent immunogenic composition comprises triple fusion protein containing three antigens, f1 v yersinia pestis pa antigen bacillus anthracia fused in-frame retaining structural functional integrity three antigens. another bivalent immunogenic composition comprises bacteriophage nanoparticles arrayed three antigens capsid surface bacteriophage nanoparticles. bivalent immunogenic compositions able elicit robust immune response subject administered said bivalent immunogenic compositions provide protection subject sequential simultaneous challenge anthrax plague pathogens.',\n",
              " 'breathing filter bacteriophage filtration efficiency testerbreathing filter bacteriophage filtration efficiency tester, power distribution box comprises box body, set aerosol room box respectively, test tube, first anderson sample thief inclosed detection cover, set clamp box lateral wall, clamp fixes aerosol room box middle part, one end first outlet duct connected aerosol room bottom,the end first outlet duct upper end intercommunication detects cover, one end intake pipe connected air inlet first anderson sample thief, endof intake pipe lower extreme intercommunication detects cover. beneficial effects utility model aspirate detecting cover intake pipe suckfirst anderson sample thief gaseous gauze mask awaits measuring later stage cultivation fungus fungus clear, thereby convenient directly perceived accurate measuring goes blocking bacteria performance gauze mask.',\n",
              " 'anti-idiotype antibody antifungal activity fungus carrying ß-glucan synthase utilization sameby using neutralizing antibody nmab-kt hm-1 killer toxin idiotype antigen, single-chain fv antibody successfully obtained phage display method. confirmed antibody actually hm-1 killer toxin activity exhibits antifungal activity fungus carrying ß-glucan synthase. antibody used antifungal agent highly useful.',\n",
              " 'peptides methods treating cancerby using phage display derived peptide initial template, compounds developed highly specific mdm2/mdm4. compounds exhibit greater potency p53 activation protein-protein interaction assays compound derived p53 wild-type sequence. unlike nutlin, small molecule inhibitor mdm2/mdm4, phage derived compounds arrest cells resistant p53 induced apoptosis wide concentration range without cellular toxicity, suggesting highly suitable cyclotherapy.',\n",
              " 'anti-campylobacter jejuni antibodies uses thereforcampylobacter jejuni leading cause bacterial food-borne diseases humans, ranging acute diarrheal disease neurological disorders. isolated purified antibody fragment thereof specific c. jejuni described. antibody fragment thereof binds flagellar protein reduces motility c. jejuni. antibody fragment thereof derived heavy chain igg variable domain fragment (vhh) camelid animal immunized c. jejuni flagellar protein. multivalent form, well phage format, antibody fragment thereof described. methods reducing presence c. jejuni animal animal environment, methods formulations treating c. jejuni infection, method detecting c. jejuni described.',\n",
              " 'anti-angiogenin peptides, compositions, methods usecarrier compositions, including human-safe phages, equipped one angiogenin-binding peptides, optionally tumor-homing peptides use anti-tumor therapies, described. angiogenin-binding peptides bind inactivate angiogenin molecules thereby blocking angiogenic activity thus inhibiting angiogenesis tissue compositions localized.',\n",
              " 'anti-bacterial cosmetic pharmaceutical compositions suitable deodorising body, fighting body odourcertain bacteriophages suitable incorporating certain antiperspirant deodorant compositions, effective specific fighting bacteria causing odour without irritating skin damaging germs flora skin positive effect. according invention, cosmetic pharmaceutical compositions suitable deodorising body contain, cosmetic dermatologically acceptable carrier, least one deodorant antiperspirant active substance least one representative group bacteriophages effective least one following: staphylococcus aureus and/or staphylococcus hominis and/or corynebacteriumtuberculostearicum and/or anaerococcus octavius and/or staphylococcus lugdunensis and/or finegoldia magna and/or corynebacterium amycolatum and/or corynebacterium afermentans and/or staphylococcus epidermidis and/or staphylococcus capitis and/or staphylococcus haemolyticus and/or propionibacterium avidum and/or corynebacterium kroppenstedtii and/or peptinophilus spec.',\n",
              " 'methods isolating bacterial strainscertain embodiments directed methods developing bacterial strains selected metabolism producing target molecule(s) bacterial strains bacteriophage strains comprising modified gene encoding selected agent.',\n",
              " 'system molecular imagingcharged neutral particles, photons, photonic optics, detectors sensor arrays used application molecular imaging, communication biological organisms monitoring learning biological activity inside living organisms. living organisms include among others living tissue, biological organs, cells, eukaryotes, prokaryotes, viruses phages. molecular imaging effective new tool understand mechanisms life communicate, modify control it. techniques, methods devices described achieve aims. probes used molecular imaging described include full spectrum photons; charged uncharged particles; chemicals; biological probes.',\n",
              " \"immunization and/or treatment parasites infectious agents live bacteriachimeric proteins expressed, secreted released bacterium immunize treat parasite, infectious disease malignancy. delivery vector may attenuated, non-pathogenic, low pathogenic, probiotic bacterium. chimeric proteins include chimeras of, e.g., phage coat and/or colicin proteins, bacterial toxins and/or enzymes, autotransporter peptides, lytic peptides, multimerization domains, and/or membrane transducing (ferry) peptides. active portion immunogenic chimeric proteins include antigens wide range parasites infectious agents, cancers, alzheimer's huntington's diseases, enhanced activity secreted released bacteria, and/or direct anti-parasite infectious agent activity. activity secreted proteins increased co-expression protease inhibitor prevents degradation effector peptides. addition antibody binding antibody-degrading protein prevents premature elimination vector enhances immune response.\",\n",
              " 'peptide ligands erythropoietin receptorclones isolated phage display libraries bound erythropoietin (epo) receptor probe disclosed. peptides encoded sequences clones bound epo receptor disclosed. 12-mer amino acid consensus sequence, cxxgwvgxcxxw (where x represents one many amino acids), common peptides bound epo receptor, unrelated primary structure epo, disclosed.',\n",
              " 'characterization four prophage endolysins specific clostridium perfringensclostridium perfringens cause food poisoning major agent necrotic enteritis. laws banning use antibiotics animal feed become common, need alternatives antibiotics becomes greater. peptidoglycan hydrolases target cell wall specific bacteria one alternative. genes four endolysins, plycp10, plycp18, plycp33, plycp41, found within clusters phage associated genes, likely prophages strains cp10, cp18, cp33, cp41. plycp18 plycp33 harbor l-alanine amidase catalytic domains, plycp10 plycp41 glycosyl hydrolase catalytic domains predicted blastp pfam searches. four genes synthesized e. coli codon optimization, expressed e. coli expression vectors 6×his tag nickel column purification, recombinant proteins purified. four endolysins capable lysing 66 c. perfringens strains tested bacteria tested.',\n",
              " 'protein nucleic acid delivery vehicles, components mechanisms thereofcomplex viruses assembled simple protein subunits sequential irreversible assembly. genome packaging bacteriophages, powerful molecular motor assembles special portal vertex empty prohead initiate packaging. aspect invention relates phage t4 packaging machine highly promiscuous, translocating dna finished phage heads well proheads. single motors force exogenous dna phage heads rate proheads phage heads undergo repeated initiations, packaging multiple dna molecules head. shows phage dna packaging machine unusual conformational plasticity, powering dna apparently passive capsid receptacle, including highly stable virus shell, full. features allow design novel class nanocapsid delivery vehicles.',\n",
              " 'recombinant phage methods detecting listeriacomposition methods detection one target microbe(s) provided. compositions disclosure include least one recombinant phage capable infecting target microbe, said phage comprising least capsid protein sequence, ribosome binding site, codon-optimized marker. compositions disclosure may include aqueous solution enhances ability detect marker expression upon phage infection target microbe. embodiments target microbe listeria.',\n",
              " 'methods compositions preventing infection vibrio speciescompositions methods provided preventing, ameliorating, treating disease caused species bacterial genus vibrio, example, cholera caused v. cholerae, compositions containing two strains lytic bacteriophage infect kill vibrio cells. bacteriophage virulent, replicate intracellularly lyse kill bacteria. use two strains single treatment, result rate mutation bacteria simultaneous resistance bacteriophage low negligible, reduces appearance phage-resistant bacteria statistical negligibility. normal human microbial flora species affected. alternative embodiments method composition, antibiotic agents treatment agents administered cocktail plurality bacteriophage strains.',\n",
              " 'methods compositions comprising bacteriophage nanoparticlescompositions methods comprising bacteriophages provided. particular, present invention includes novel customized t4 bacteriophages uniquely designed effective antigen foreign particle presentation. present invention provides vitro methods making customized t4 bacteriophages. compositions methods present invention may used effective vaccine delivery systems.',\n",
              " 'rna replication using transcription polymerasescompositions methods amplifying rna replication using transcription polymerases disclosed. replicated rnas used various applications rnai therapeutics, diagnostic probes, rna sequencing, directed evolution rna aptamers without intermediate conversion dna, rna vaccines. transcription polymerases comprise t7 bacteriophage rna polymerase.',\n",
              " 'bacteriophage derived methods control lactic acid bacterial growthcompositions methods protection bacterial contamination disclosed antibacterial proteins methods use thereof disclosed',\n",
              " 'compositions methods molecular memory storage retrievalcompositions methods storage, organization, access, retrieval information encoded sequence controlled polymers data storage nucleic acids provided. embodiments, organization, storage, and/or selective retrieval data facilitated hybridization barcode sequence sequence controlled polymer reverse complementary sequence oligonucleotide. plurality oligonucleotides arrayed using known organization scheme, selectively capture localize corresponding sequence controlled polymer. embodiments, compositions methods utilize recombinant bacteriophage, typically featuring minigenome bacteriophage origin replication packaging signal separated data storage sequence barcodes.',\n",
              " 'phage-based pesticide varroa destructorcompositions methods use preserving beehive bees associated beehive varroa destructor infestation-induced collapse death, supporting health, vitality, longevity beehive bees associated beehive controlling, reducing, eliminating population varroa destructor associated beehive bees associated beehive targeted, phage-based, bactericidal bacteriostatic activity bacillus sp., hafnia sp., and/or escherichia sp. present varroa destructor associated beehive bees associated beehive, specifically applying administering beehive, bees associated beehive, composition comprising one bacteriophage cellular tropism for, infectivity specific for, bacillus sp., hafnia sp., and/or escherichia sp. varroa destructor associated beehive bees associated beehive.',\n",
              " 'bacteriophages selective agentscompositions containing bacteriophages methods using bacteriophages microorganism detection assays microbial growth plating media disclosed. lytic ability phages control growth non-target populations provides superior sensitivity specificity detection assays reduces false negative false positive results. removal contaminating bacteria reduces microbial competition nutrients growth media thereby increasing efficiency productivity culture. phage treatment sample increases proportion target microorganisms sample contaminating bacteria thereby requiring less time enrichment obtain significant signal improving overall signal noise ratio assays providing higher yield end product microbiological production systems.',\n",
              " 'compositions vivo expression therapeutic sequences microbiomecompositions phage particle disclosed. phage particle non-replicating includes least one heterologous nucleic acid sequence capable expressed target bacteria. expressed heterologous nucleic acid sequence non-lethal target bacteria.',\n",
              " 'bacteriophage compositions kits related methodscompositions affecting intestinal microbiome mammalian subject include pharmaceutically-acceptable carrier greater equal 1×104 pfu/ml pfu/mg bacteriophage tropism includes obesogenic and/or inflammatory bacterium associated intestinal microbiome mammal. processes preparing disclosed compositions include isolating bacteriophage environmental source, characterizing bacteriophage, combining bacteriophage pharmaceutically acceptable carrier greater equal 1×104 pfu/ml pfu/mg. methods include administering disclosed compositions mammalian subject without co-administration disclosed probiotics. administering disclosed compositions reduce concentration obesogenic and/or inflammatory bacteria intestinal microbiome mammalian subject, promote induce weight loss, reduce inflammation, support metabolic health, and/or support healthy balance/diversity within intestinal microbiome mammalian subject.',\n",
              " 'methods creating consumable strains compositions thereofconsumable biotech strain improvement products presented, well methods preparation using them. technology based reversible, single-crossover insertion vectors, plasmids phage. single crossover event reversible absence drug selection, products maintained useful form without knowledge drug selection agent. consumable strain improvement products constructed 1st generation reverse engineering protections, least 25%-75% effectiveness equivalent traditional (permanent) strain improvement product laboratory condition.',\n",
              " 'monoclonal antibody vaccine targeting filamentous bacteriophagedescribed method reducing preventing pseudomonas aeruginosa biofilm formation human subject need thereof, comprising administering human subject first composition comprising (a) antigen-binding polypeptide binds pf-family bacteriophage, (b) vaccine pf-family bacteriophage. described antigen-binding polypeptide binds specifically coab protein pf-family bacteriophage fragment thereof.',\n",
              " 'bacteriophage therapy adherent-invasive escherichia colidescribed herein bacteriophages infect lyse adherent-invasive escherichia coli (aiec). bacteriophages useful, example, prophylactic therapeutic treatment subjects infected aiec risk infection aiec, prophylactic therapeutic treatment diseases conditions associated aiec, including inflammatory bowel disease (ibd), urinary tract infection (uti), neonatal meningitis, asthma, chronic obstructive pulmonary disease (copd), bronchitis, pneumonia, lung cancer, subject uses described herein.',\n",
              " 'bacteriophages vancomycin-resistant enterococcidescribed herein bacteriophages infect lyse vancomycin-resistant enterococci (vre). bacteriophages useful, example, prophylactic therapeutic treatment subjects infected enterococci, including vre, risk infection enterococci, including vre, uses described herein.',\n",
              " 'methods treating preventing viral infection using bacteriophagesdescribed herein compositions treating preventing viral infection comprising bacteriophages bind virus block inhibit viral entry host cell. bacteriophage libraries may screened identify bacteriophages bind virus interest, identified bacteriophages may used treat prevent infection caused virus interest. described herein methods treating preventing viral infection administering bacteriophage composition subject vivo surface vitro. bacteriophages composition may bind virus inhibit viral entry host cell, thereby reducing infectivity virus. reducing infectivity virus may treat prevent viral infection.',\n",
              " 'bacteriophage hydrogel compositions uses thereofdescribed herein hydrogel compositions comprising cross-linked bacteriophages. hydrogels typically bioactive, degradable, example biodegradable, self-healing, fluorescent, example autofluorescent, and/or birefringent. hydrogels described herein may used therapeutics diagnostics, scaffolds material synthesis, catalysts, membranes filters, biosensor substrates, example.',\n",
              " 'recombinant renewable polyclonal antibodiesdescribed herein methods combine phage yeast display create polyclonal antibodies renewable, amplified 100 million fold, maintain diversity without loss representation antibodies present. antibody representation remains essentially constant, confirmed deep sequencing. provided methods allow generation, use propagation polyclonal antibodies, without concern representation lost. furthermore, derivation polyclonal pool carried vitro using phage yeast display, possible various embodiments eliminate reactivities considered undesirable. additionally, polyclonal pool enriched higher affinity antibodies.',\n",
              " 'integrases, landing pad architectures, engineered cells comprising samedescribed herein modified bacteriophage serine integrases function mammalian cells. described herein landing pad architectures. engineered cells comprising integrases landing pads described, facilitate site-specific genomic integration pay load molecules.',\n",
              " 'synthetic bacteriophage compositions methods selection usedescribed herein novel engineered bacteriophages bacteriophage compositions, methods production thereof, therapeutic uses thereof. engineered bacteriophages may properties conferring enhanced stability subjected conditions elevated heat, extreme ph, medically relevant conditions. properties may provide advantages alternatives current reliance upon antimicrobials.',\n",
              " 'peptides antibody fusions bind sars-cov-2 methods using samedescribed herein peptides peptide-antibody fusions bind sars-cov-2 protein receptor binding domain (rbd), methods using compositions containing antibodies treatment covid-19. specifically, developed novel cov-2 protein binding peptides making use naïve phage-displayed 16mer peptide library- wherein cov-2 protein binding peptides bind epitopes rbd protein outside rbd. addition, show fusion peptides n-terminus nabs improves apparent affinity, potency breadth neutralization, without compromising developability profile. thus, peptides represent novel class sars-cov-2 protein binders, formatted various ways improve functional properties nabs used treatment many different diseases.',\n",
              " 'peptide displaying bacteriophage nanoparticles related compositions methodsdescribed herein fusion protein comprising bacteriophage protein fused cancer antigen. vaccines described, well methods treatment and/or prevention cancer methods immunizing individual.',\n",
              " 'organization polymers inovirus bacteriophagedescribed herein method organizing polymers, comprising mixing first composition comprising purified inovirus bacteriophage (e.g., pf-family bacteriophage) second composition comprising one polymers. described liquid crystal comprising inovirus bacteriophage (e.g., pf-family bacteriophage) one polymers, wherein liquid crystal substantially free bacterial strain (e.g., pseudomonas aeruginosa strain) capable producing inovirus bacteriophage.',\n",
              " 'identification antibodies specific lyssaviruses methods usedescribed herein method identifying monoclonal antibody (or antigen-binding fragment thereof) specifically binds plurality lyssaviruses use post-exposure rabies prophylaxis treatment clinical rabies. method includes using naïve antibody phage display library screen phage clones bind whole recombinant rabies virus cells expressing glycoprotein multiple lyssaviruses (such rabv, mokv wcbv) and/or specifically bind recombinant glycoprotein different lyssaviruses.',\n",
              " 'methods making unbiased phage librariesdescribed herein method preparing unbiased library phage variants, comprising (a) preparing population “acceptor phage”; (b) removing endogenous target gene inserting gene variants acceptor phage genomes; (c) enriching recombined phages; (d) expressing library selection. acceptor phage lytic phage comprising synthetic genome wherein target gene interest flanked recombinase sites. acceptor phage infects first host bacteria expressing recombination plasmid facilitating recombination. phages infect second host bacteria expressing counterselection system accumulates recombined phage variants selecting non-recombined phages. accumulated phage variants infect third host bacteria. phage library may sequenced characterized.',\n",
              " 'use spycatcher protein scaffold peptide display; spycatcher/spytag cyclised peptides displayed bacteriophagedescribed herein modified spycatcher protein (comprising amino acid sequence least 80% identity seq id no: 1) wherein modification comprises peptide inserted region protein corresponding amino acid residues 12- 22, 27-31, 38-43, 48-50 59-68 seq id no: 1. described bacteriophage particles displaying chimeric protein comprising spycatcher, peptide interest, spytag, spycatcher spytag linked via isopeptide bond.',\n",
              " 'display systems proteins interestdescribed herein protein display selection method uncouples protein interest (poi) library display selection system. display poi achieved forming covalent bond poi anchor protein post expression either enzymatic protein ligation (e.g. spyligase, snoopligase, sortase, butelase, peptiligase etc.) spontaneous covalent bond formation (e.g. spy tag/spy catcher, snooptag/snoopcatcher, etc.). poi library fused tethering sequence, example spytag, c-terminus poi forms covalent bond capture sequence found anchor protein, example, spycatcher-fused anchor protein, e.g., spycatcher-genelll protein (spycatcher-piii) fusion, common form phage display. nucleic acid constructs, host cell systems methods producing protein display systems provided.',\n",
              " 'designing soluble full-length hiv-1 gp41 trimerdescribed herein soluble hiv-1 retrovirus transmembrane glycoprotein gp41 trimer (soc-gp41m-fd) containing partial ectodomain cytoplasmic domain, fused small outer capsid (soc) protein bacteriophage t4 foldon domain bacteriophage t4 fibritin (fd). gp41 trimer prehairpin structure utilized understand mechanism viral entry candidate development hiv-1 vaccines, diagnostics therapeutics. secondary embodiments gp41 proteins containing different modifications disclosed. according one embodiment, gp41 trimer attached cell penetration peptide (cpp). methods producing gp41 trimers disclosed.',\n",
              " 'generation use fab, scfv, related binding molecules specific hiv-1 revdescribed herein identification, though phage display, chimeric rabbit/human anti-rev fab (sjs-r1) readily solubilized polymeric hiv-1 rev. fab binds high affinity conformational epitope n-terminal half hiv-1 rev. corresponding single chain antibody (scfv) prepared characterized. methods making using sjs-r1 fab sjs-r1 scfv, antibodies antibody fragments share least one cdr sjs-r1 fab, provided. specific described methods include methods preventing reversing polymerization hiv rev, methods preventing inhibiting replication lentivirus cell, methods reducing infectivity replication lentivirus, inhibiting rev function cell infected lentivirus, methods treating disease symptom associated rev expression animal.',\n",
              " 'mesothelin antibodies methods eliciting potent antitumor activitydescribed herein use phage display antibody engineering technology synthetic peptide screening identify sdl sd2, human single-domain antibodies mesothelin. sdl recognizes conformational epitope c-terminal end (residues 539-588) human mesothelin close cell surface. sd2 binds full-length mesothelin. investigate sdl potential therapeutic agent, recombinant human fc (sdl-hfc) fusion protein generated. sdl-hfc protein exhibits strong complement-dependent cytotoxicity (cdc), addition antibody- dependent cellular cytotoxicity (adcc), mesothelin-expressing tumor cells. furthermore, sdl-hfc protein causes significant tumor growth inhibition tumor xenografts nude mice. sdl sd2 first human single-domain antibodies targeting mesothelin-expressing tumors.',\n",
              " 'engineered multi-omic display constructs display systemsdescribed several embodiments herein engineered phagemids bacteriophages containing same. described several embodiments herein methods using engineered phagemids bacteriophages containing same. embodiments, engineered phagemids bacteriophages containing capable providing multi-omic information single-cell level.',\n",
              " 'bioadhesive biodegradable formulations provide sustained release antimicrobials, bacteriophages anti-inflammatory medications inactivation biofilms treatment rhinosinusitis infectionsdescribed composition comprising one active ingredients coated, dispersed, dissolved mucoadhesive polymer. although subject multiple uses, composition, embodiments, usable treating rhinosinusitis.',\n",
              " \"novel family dna polymerases accepting 2-aminoadenine rejecting adenine substratesdescribed novel family dna polymerases identified bacteriophages (mainly family siphiroviridae) able accept 2-amino-2'-deoxyadenosine 5'-triphosphate (dztp) substrate accept deoxyadenosine 5'-triphosphate (datp) substrate. described recombinant nucleic acid molecules, encoding polymerases, vectors comprising nucleic acid molecules, host cells transformed nucleic acid molecules vectors well methods producing dna molecules containing 2-amino-2'-deoxyadenosine (dz) instead 2'-deoxyadenosine (da) making use novel polymerase.\",\n",
              " 'bacteriophage-based artificial viruses human genome remodelingdescribed “artificial virus” (av) programmed biomolecules enter human cells carry precise human genome modification. avs comprise: least one viral vector, bacteriophage t4; least one therapeutic molecule, dna, rna, protein complex; lipid coating. described method human genome modification, using av, method program av.',\n",
              " 'engineered bacteriophage t4 nanoparticles potential targeted activator hiv-1 latency cd4+ human t-cellsdescribed engineered viral particle programmed cell targeting specificity. viral particles comprise: least one viral vector, bacteriophage t4; least one cd4-binding protein displayed surface viral vector. described method reactivate latent hiv-1 cure patient hiv-1 infection, using engineered viral particle.',\n",
              " 'improved method selecting desired protein librarydescribed improved method selecting member specific binding pair (sbp) desired specify, preferably antibody, library expressing said member sbp, preferably phage-display antibody library.',\n",
              " 'fabrication phage nanobioparticles burn wound methicillin-resistant staphylococcus aureus (mrsa) infectionsdespite advances field control treatment burn wounds infection main cause mortality burn patients. control treatment infected wound one main problems due increased strains mdr (multi drug resistance) methicillin-resistant staphylococcal aureus (mrsa). according increased multidrug resistance (mdr) return infections need new product treatment infection. lytic bacteriophages products endolysin suggested. order optimal using bacteriophages field nanomedicine phage display technique used. results showed phage nanobioparticles lytic activity mrsa vitro, phage nanobioparticle gel lytic activity mrsa vivo. 30 days observed reepithelization, scar formation, fibroblast maturation, collagen deposition, granulation tissue, neovascularization infected group treated phage nanobioparticle gel.',\n",
              " 'detection bacteriofagos infecting lactobacillus delbrueckii real-time quantitative polymerase chain reaction (qrt-pcr) use. (machine-translation google translate, legally binding)detection bacteriophages infect lactobacillus delbrueckii real-time quantitative polymerase chain reaction (qrt-pcr) use. present invention describes method detection, especially milk, traces destructive bacteriophages species lactobacillus delbrueckii used industrial lactic fermentations, means qrt-pcr. amplification carried using single pair oligonucleotide primers which, suitable conditions, amplify double-stranded fragment flanked said oligonucleotides. viruses one main causes failure industrial dairy fermentations, causing significant economic losses. procedure allows make decisions allocating contaminated milk processes lb intervene. delbrueckii sensitive detected phages inactivation treatments, well disinfection production plant. main advantage procedure speed, together specificity, simplicity sensitivity. (machine-translation google translate, legally binding)',\n",
              " 'method distinguishing origin crop means virus-based discoloration sensor device discriminating origin crop comprising virus-based discoloration sensordisclosed method distinguishing origin crop means virus-based discoloration sensor, device distinguishing origin crop means virus-based discoloration sensor. method distinguishing origin crop means virus-based discoloration sensor comprises steps of: preparing sample color change values original color virus-based discoloration sensor altered colors changed exposing virus-based discoloration sensor components included sample crops classified origin, wherein nanofiber bundle formed m13 bacteriophages arranged base substrate virus-based discoloration sensor; obtaining color change values analysis altered colors crop analyzed respect discoloration sensor original color discoloration sensor; distinguishing origin crop analyzed according degree similarity color change values analysis sample color change values.',\n",
              " 'cd19-targeted human antibody preparation use thereofdisclosed method screening cd19-targeted human antibody means phage display technology cd19-targeted human antibody, wherein combined single chain antibody seq1-seq5, seq1-seq6, seq2-seq7, seq3-seq8 seq4-seq9 specifically bind cd19 protein. cd19-targeted human antibody used chimeric antigen receptor technology, construction monoclonal antibody kill tumor cells adcc cdc action mechanism, combining antibodies construct bispecific antibody.',\n",
              " 'method screening identifying live attenuated influenza vaccine strainsdisclosed method screening identifying live attenuated influenza vaccine strains, method obtaining candidate viral strains live attenuated vaccines means constructing screening high density random insertion mutant library viral genes mediated mu phage transposons. present invention develops set technical systems use systematically evaluating obtained live attenuated vaccine strains.',\n",
              " 'bacteriophage pbes04 cronobacter sakazakii uses thereofdisclosed novel bacteriophage infecting cronobacter sakazakii, mutant thereof, progeny thereof, uses thereof. bacteriophage accordance present invention effectively eliminates cronobacter sakazakii strains, pathogen resistant various antibiotics becomes big problem medical world, specifically infecting opportunistic cronobacter sakazakii, thereby able used antibiotic.',\n",
              " 'bacteriophage pbes01 cronobacter sakazakii uses thereofdisclosed novel bacteriophage infecting cronobacter sakazakii, mutant thereof, progeny thereof, uses thereof. bacteriophage accordance present invention effectively eliminates cronobacter sakazakii, pathogen resistant various antibiotics becomes big problem medical world, specifically infecting opportunistic cronobacter sakazakii, thereby able used antibiotic.',\n",
              " 'bacteriophage escherichia coli uses thereofdisclosed novel bacteriophage infectious escherichia coli o157:h7, mutant thereof, progeny thereof, use thereof. according present invention, bacteriophage specifically infects pathogenic escherichia coli o157:h7, effectively eliminates pathogenic escherichia strain, thus used antibiotic. moreover, bacteriophage inhibits biofilm generated thus provide effect preventing food hygienic equipment medical equipment polluted.',\n",
              " 'bacteriophage pbes02 cronobacter sakazakii uses thereofdisclosed novel bacteriophage possessing infectious property cronobacter sakazakii, mutant thereof, progeny thereof, use thereof. bacteriophage according present invention used antibiotics specifically infecting cronobacter sakazakii infectious strain eliminating cronobacter sakazakii strains effectively.',\n",
              " 'vector expressing antibody fragments method producing recombinant phage displays antibody fragments using vectordisclosed plasmid vector (pla- 1 plt-2) producing water-soluble light chain antibody fragments (vl+cl), phagemid vector (phflg3t-l phflg3a-2) heavy chain antibody fragments (vh+chl)-?piii fusion protein expression genotype-phenotype linkage function, host transformed using vectors, method producing selecting water-soluble antibody recombinant phage displaying antibody host. also, provided method producing combinatorial phage display combinatorial fab fragment libraries dvfab-il dvfab- 13 il using dual vector system (dvs-ii) method selecting antigen- specific human fab fragment combinatorial fab fragment libraries.',\n",
              " 'endothelial-targeted adenoviral vectors, methods uses therefordisclosed adenovirus vectors comprising robo4 enhancer/promoter operatively linked transgene. disclosed adenovirus vectors comprising chimeric ad5-t4 phage fibritin shaft, trimerization domain displaying myeloid cell-binding peptide (mbp), robo4 enhancer/promoter operatively linked transgene. disclosed methods expressing transgene endothelial cell vivo, comprising administering mammal adenovirus comprising robo4 enhancer/promoter operatively linked transgene. disclosed uses adenoviral vectors, including mobilization granulocytes, monocytes lymphocytes bone marrow, mobilization cancer cells vivo, selective targeting endothelial cells, cancer treatment methods.',\n",
              " 'dendritic cell targeted adenovirus vaccinationdisclosed camelid single domain antibody (sdab) dendritic cell surface antigens clec9a cd40. disclosed chimeric adenoviruses used vaccines pathogen cancer. chimeric adenovirus targeted dendritic cells incorporates sequence encoding sdab dendritic cell surface antigen. chimeric adenovirus includes phage t4 fibritin trimerization foldon replace ad5 fiber knob. furthermore, e1a/b genetic region chimeric adenovirus replaced heterologous sequence structural gene heterologous virus sequence encoding tumor antigen. examples heterologous viruses include flaviviruses zika, chikungunya, dengue, yellow fever, west nile virus. exemplary zika sequences introduced chimeric adenovirus include full length prm, e ectodomain.',\n",
              " 'p100 bacteriophage control listeria monocytogenesdisclosed compositions methods treating preventing listeriosis using recombinant bacteriophage (p100) bacteriophage-derived endolysin (ply100).',\n",
              " 'bacteriophage compositions methods treatment bacterial infectionsdisclosed compositions, devices, kits, methods treatment enterobacteriaceae infection. aspects present disclosure directed bacteriophage compositions comprising one es17, es19, hp3, hp3.1, hp3.2. certain aspects disclosure directed compositions comprising (a) bacteriophage es17 bacteriophage es19, (b) bacteriophage hp3, (c) bacteriophage hp3.1. disclosed compositions comprising bacteriophage hp 3.2. disclosed devices kits comprising compositions methods use compositions treatment prevention pathogenic e. coli infection.',\n",
              " 'compositions, methods, systems detecting methicillin-resistant staphylococcus aureusdisclosed compositions, methods systems detecting mrsa, example mrsa nasal colonization. certain embodiments, methods use bacteriophage-based amplification signal detection bacteria microorganisms detect mrsa. methods detecting mrsa may include preparing assay comprising selective agent cocktail comprising least two different types recombinant bacteriophages, incubating sample assay, capturing indicator protein product, detecting indicator protein product produced recombinant bacteriophage, wherein positive detection indicator protein product indicates mrsa present sample.',\n",
              " 'enterococcus faecalis strains production bacteriophage preparationsdisclosed enterococcus faecalis strains obtaining monoclonal preparations lytic bacteriophages high titer, particularly devoid contamination undesired bacteriophages, strains guaranteeing production safe use bacteriophage preparations, source dissemination genes associated bacterial virulence.',\n",
              " 'phages biomarker capture methods usedisclosed genetically-modified phages, comprising first nucleic acid sequence encoding least first peptide able bind magnetic nanoparticle, second nucleic acid sequence encoding least second peptide able bind high specificity predetermined biomarker, method using genetically-modified phage displaying first peptide second peptide method analyzing fluid sample predetermined biomarker.',\n",
              " 'edwardsiella ictaluri bacteriophage uses thereofdisclosed isolated bacteriophage lytic activity species edwardsiella bacteria including edwardsiella ictaluri. disclosed bacteriophage designated “φeiau” “φeidwf.” disclosed variant bacteriophage φeiau φeidwf bacteriophage, variant bacteriophage lytic activity edw. ictaluri. disclosed isolated edwardsiella ictaluri bacteriophage polynucleotides polypeptides.',\n",
              " 'compositions methods treating nervous system injuriesdisclosed methods compositions treating traumatic brain injury (tbi). brain injury-specific 4-amino acid peptide (sequence caqk), identified vivo phage display screening mice acute brain injury, shows selective binding mouse human brain injury lesions, systemically injected, specifically homes sites injury penetrating non-penetrating (controlled cortical impact) brain injury models. significantly, peptide alone produces therapeutic effect used absence therapeutic compound.',\n",
              " 'methods compositions controlling valency phage displaydisclosed methods compositions useful, e.g., controlling valency display proteins display library screenings selections. one embodiment, applicable phage phage libraries based bacteriophage, e.g., filamentous bacteriophage.',\n",
              " 'bioluminescent biosensor devicedisclosed methods devices detection bacteria based recognition infection one selected strains bacteria bacteriophage genetically modified cause production inducer molecule bacterium following phage infection. inducer molecule released infected bacterium detected genetically modified bacterial bioreporter cells designed emit bioluminescence upon stimulation inducer. autoamplification bioluminescent signal permits detection low levels bacteria without sample enrichment. disclosed methods detection select bacteria, kits detection select bacteria based described technology.',\n",
              " 'compositions methods identification isolation cell-membrane protein specific binding moietiesdisclosed methods identifying binding moieties recognize antigens displayed cells, membrane proteins recombinant proteins display eptiopes surface cells. binding moieties capable binding membrane proteins difficult obtain proteins depend native environments structural integrity. methods scfv phage display libraries panned whole cells expressing membrane protein emulsion. certain methods permit discrimination binding moieties according affinity avidity target. approach allows rapid identification cell surface epitope specific antibodies research, diagnostics, immunotherapeutics.',\n",
              " 'methods identifying peptides compositions bind oocytes species-specific mannerdisclosed methods identifying peptides compositions bind oocytes animals species-specific manner. methods utilize phage libraries oocytes isolated target species non-target species.',\n",
              " 'methods compositions involving bacteriophage isolatesdisclosed methods increasing virulence bacteriophage, comprising contacting bacteriophage composition comprising bacterium bacterial extract; polymer. disclosed methods propagating isolating therapeutic bacteriophages involve use dilute polymer compositions. disclosed pharmaceutical compositions bacteriophage virulence increased methods set forth herein isolated methods set forth herein.',\n",
              " 'display library processdisclosed methods selecting phage encoding target binding protein. methods include forming mixture comprising plurality diverse display phage, target, support, forming phage immobilized support, comprises phage binds target target immobilized support. phage bind target separated. host cells contacted phage immobilized support via binding target host cells infected phage immobilized support. replicate phage produced infected cells presence target immobilized support, thereby forming replicate phage immobilized support via binding support. replicate phage bind target separated. host cells contacted replicate phage immobilized support.',\n",
              " 'method bacteriophage delivery amplificationdisclosed methods selecting wide host range bacteriophage capable growing plurality bacteria including pathogenic non-pathogenic bacteria bacteriophage selected methods. disclosed methods treating subject infected pathogenic bacterium using bacteriophage methods decontaminating objects using bacteriophage. disclosed methods producing vaccines. another aspect, methods determining bacterial viability methods improving sensitivity biosensor using wide host range bacteriophages disclosed.',\n",
              " 'coliphage biosensordisclosed methods, apparatuses, genetically modified bacteria may used detect bacteriophages sample. embodiments, rapid detection test disclosed test presence coliphages may indicate presence human animal waste contamination water samples.',\n",
              " 'phage constructs, sequences antigenic compositions immunocontraception animalsdisclosed methods, compositions, zona pellucida binding peptides polypeptides, expression vectors use species-specific immunocontraception animals, include landscape bacteriophage. disclosed compositions may include immunogenic compositions vaccines.',\n",
              " 'biologic machines detection biomoleculesdisclosed methods, devices systems isolation detection biomolecules sample. embodiments, detection biomolecules provides detection microorganisms. example, disclosed methods, devices systems use bacteriophage-based amplification signal detection bacteria microorganisms. devices, systems methods invention may allow detection certain biomolecules peptides ions real time using minute amounts sample.',\n",
              " 'dual-image based bioimaging devices techniquesdisclosed methods, systems, devices detecting biological analytes sample. disclosed technology used obtain readings analyte concentration sample imaging scattered light angled narrow beam illuminator. fluid sample containing one biological, organic, inorganic analytes including proteins, viruses, bacteria, phages, toxins, peptides, dna, rna, hormones, chemicals, drugs, isotopes transferred microfluidic device one channels dimensions generate capillary action sample transport. geometry microfluidic device may include reservoir sensing area, wherein immunometric reaction take place narrow beam scanning. test particle may coated specific binding member used bind binding pair member analyte sample. test particles form binding particle/analyte conjugate may scanned.',\n",
              " 'highly productive one-pot system incorporation non-standard amino acids cell-free synthesized proteinsdisclosed methods, systems, components, compositions related genomically recoded engineered organisms. disclosed genomically recoded engineered organisms may used prepare extracts use platforms methods preparing sequence defined biopolymers vitro. particular, methods, systems, components, compositions relate genomically recoded engineered organisms comprising strain deficient release factor 1 (rf-1) genetic homolog thereof, wherein genomically recoded organisms engineered express heterologous rna polymerase may utilized express target protein transcription template comprising promoter heterologous rna polymerase, bacteriophage t7 rna polymerase.',\n",
              " 'bacteriophage pseudomonas aeruginosa uses thereofdisclosed new bacteriophage contagiosity pseudomonas aeruginosa, mutant thereof, progeny thereof, use thereof. bacteriophage present invention specifically infects pseudomonas aeruginosa opportunistic strain, resistance various kinds antibiotics effectively removing pseudomonas strains pathogenic bacteria causing serious problems medical world used antibiotic. bacteriophage interferes generation biofilm provides anti-fouling effect food hygiene devices medical devices.',\n",
              " \"bacteria high efficiency cloningdisclosed novel bacterial hosts capable high efficiency transformation methylated and/or unmethylated nucleic acids, bacteriophage resistant. bacteria contain: (1) f' episome confers high efficiency transformability; (2) one mutations allow transformation methylated nucleic acids; (3) one mutations allow transformation unmethylated nucleic acids; and/or (4) one mutations confer resistance bacteriophage infection. disclosed methods transforming bacteria, kits contain bacteria (e.g., made competent transformation).\",\n",
              " 'phage displaying system expressing single chain antibodydisclosed nucleic acid libraries identifying signal peptide facilitates production disulfide-stabilized single chain antibody, facilitating production disulfide-stabilized single chain antibody. disclosed host cell libraries phage libraries including nucleic acid libraries. disclosed methods identifying signal peptide facilitates production disulfide-stabilized single chain antibody, methods producing disulfide-stabilized single chain antibody non-fusion form thereof.',\n",
              " 'peptides, especially polypeptides, phage display screening method associated means, uses research biomedical applicationsdisclosed peptides, hosts expressing peptides process producing screening peptides hosts. disclosed use peptide host expressing peptide detection disease, method constructing library hosts, particular phages expressing peptides. disclosed library hosts expressing peptides use example detecting molecules and/or cells sample, treatment disease. find application therapeutic diagnostic medical technical fields.',\n",
              " 'bacteriophages treatment tuberculosisdisclosed pharmaceutical compositions comprising combination five phages pharmaceutically acceptable carrier, well methods treating, reducing, preventing disease caused mycobacterium tuberculosis mammal, methods treating antibiotic resistant infection mammal, methods treating, reducing, preventing activation latent disease caused m. tuberculosis.',\n",
              " 'phage-peptide constructs stimulating immune response cd47disclosed recombinant bacteriophage constructs related exogenous peptide sequences generating immune responses cd47. disclosed recombinant phage constructs bind antibodies cd47 administered animal generate immune response cd47, including generating anti-cd47 antibodies. disclosed recombinant phage may comprise amino acid sequence cd47, epitopic fragments, variants, functional mimics thereof. disclosed methods making selecting recombinant phage constructs compositions comprise constructs (e.g., compositions inducing immune response cd47 including pharmaceutical veterinary compositions used vaccines). disclosed recombinant polynucleotides comprising genomic nucleic acid recombinant phage constructs disclosed herein.',\n",
              " 'phage-gnrh constructs, mimics, antigenic compositions, sequences immunocontraception animals applicationsdisclosed recombinant bacteriophage constructs related heterologous peptide sequences contraception animals. disclosed recombinant phage constructs bind antibodies gonadotropin releasing hormone (gnrh) administered animal generate immune response gnrh, including generating anti-gnrh antibodies. disclosed recombinant phage may comprise amino acid sequence gonadotropin releasing hormone (gnrh), epitopic fragments, variants, functional mimics thereof. disclosed methods making selecting recombinant phage constructs compositions comprise constructs (e.g., compositions inducing immune response gnrh including pharmaceutical veterinary compositions used vaccines). disclosed recombinant polynucleotides comprising genomic nucleic acid recombinant phage constructs disclosed herein.',\n",
              " 'phage-gnrh constructs, mimics, antigenic compositions, sequences induce anti-gnrh antibodies animalsdisclosed recombinant bacteriophage constructs related heterologous peptide sequences generating anti-gnrh immune responses animals. disclosed recombinant phage constructs heterologous peptides, bind antibodies gonadotropin releasing hormone (gnrh) administered mammal generate immune response gnrh, including generating anti-gnrh antibodies, particular anti-gnrh antibodies neutralize gnrh reduce hormone levels mammal immunocontraception treating gnrh -dependent cancers. disclosed recombinant phage may comprise amino acid sequence gonadotropin releasing hormone (gnrh), epitopic fragments, variants, functional mimics thereof. disclosed methods making selecting recombinant phage constructs compositions comprise constructs (e.g., compositions inducing immune response gnrh including pharmaceutical veterinary compositions used vaccines). disclosed recombinant polynucleotides including genomic nucleic acid recombinant phage constructs disclosed herein.',\n",
              " 'system protein inactivation recombinant phages targeted bacterial killing, infection, biodetection, means protein extractiondisclosed recombinant phages infect kill bacterial hosts response user-defined inputs. components encode user-defined inputs combined, multiple inputs maintained single recombinant phage, enabling precise control targeting strategy. phages engineered kill specific bacterial species multiple species simultaneously. recombinant phages engineered harbor fluorescent bioluminescent reporter genes enable used tracking, detection, biosensing applications. recombinant phages used lyse bacterial cells produce recombinant proteins, rapid method enable extraction high-level purification potentially valuable and/or industrially important proteins. disclosed system used control activity protein interest, taking advantage interaction qtip phage repressor protein; phage repressor protein fused protein-of-interest, controlling expression qtip, phage repressor protein fused protein-of-interest inactivated qtip expressed interacts phage repressor protein.',\n",
              " 'staphylococcus aureus strains production monoclonal phage preparations deprived contamination plasmid dnadisclosed staphylococcus aureus strains obtaining monoclonal preparations lytic bacteriophages high titer, devoid contamination undesired bacteriophages plasmid dna, guarantee production safe use bacteriophage preparations, source dissemination genes associated bacterial virulence.',\n",
              " 'targeted particles comprising landscape phage fusion proteins heterologous nucleic aciddisclosed targeted particles comprising consisting plurality landscape phage fusion proteins complexed heterologous nucleic acid, landscape phage fusion proteins displaying heterologous peptide targeted particle binding specifically target site. particles may utilized methods modulating expression genes target cells.',\n",
              " \"phage compositions comprising crispr-cas systems methods use thereofdisclosed phage compositions comprising crispr-cas systems methods use thereof. certain embodiments, disclosed herein bacteriophage comprising nucleic acid sequence encoding type crispr-cas system comprising: (a) crispr array; (b) cascade polypeptide; (c) cas3 polypeptide. embodiments, crispr array comprises spacer sequence least one repeat sequence. embodiments, least one repeat sequence operably linked spacer sequence either 5' end 3' end.\",\n",
              " 'phage compositions comprising crispr-cas systems methods use thereofdisclosed phage compositions comprising type crispr-cas systems methods use thereof. embodiments, disclosed herein nucleic acid sequence comprising (a) first crispr array designed operable first type crispr-cas system, (b) second crispr array designed operable second type crispr-cas system, wherein first type crispr-cas system second type crispr-cas system different type crispr-cas systems.',\n",
              " 'phage compositions escherichia comprising crispr-cas systems methods use thereofdisclosed phage compositions escherichia comprising crispr-cas systems methods use thereof.',\n",
              " 'phage compositions staphylococcus comprising crispr-cas systems methods use thereofdisclosed phage compositions staphylococcus comprising crispr-cas systems methods use thereof.',\n",
              " 'phage compositions pseudomonas comprising crispr-cas systems methods use thereofdisclosed phage compositions targeting pseudomonas species comprising crispr-cas systems methods use thereof.',\n",
              " 'phage display biologically active bacillus thuringiensis toxindisclosed herein activated bt toxins expressed e. coli translational fusion phage coat protein filamentous phage. phage displaying fusion protein viable, infectious, lethal pure toxin molar basis fed insects susceptible native bt toxins.',\n",
              " 'bacteriophage modulating inflammatory bowel diseasedisclosed herein bacteriophage compositions therapeutic uses thereof. disclosure relates bacteriophage capable lysing klebsiella bacterial strains, e.g., strains associated inflammatory bowel disease, thereby capable modulating disease.',\n",
              " 'crispr cas systems lysogeny modulesdisclosed herein compositions methods modifying bacterial population. embodiments, described herein bacteriophage comprising first nucleic acid sequence encoding first spacer sequence crrna transcribed therefrom, wherein first spacer sequence complementary target nucleotide sequence target gene target bacterium, provided bacteriophage rendered lytic.',\n",
              " 'bacteriophage-derived nanopore sensorsdisclosed herein compositions methods involve inserting connector protein channels bacteriophage dna packaging motors copolymeric membranes via liposome-polymer fusion, canbe used nanopore sensors biomedical applications high throughput protein sequencing cancer diagnosis. example, disclosed compositions comprising copolymeric membrane connector protein channel bacteriophage packaging motor inserted.',\n",
              " 'use specific phages treatment nontuberculosis mycobacteria (ntm) infectionsdisclosed herein compositions comprising bacteriophages methods using compositions treating ntm infections. present disclosure provides compositions screening bacteriophages effective treating ntm infections methods using same.',\n",
              " 'prebiotic compositions comprising one types bacteriophagedisclosed herein compositions comprise one types bacteriophage methods using bacteriophages prebiotic promote growth beneficial bacteria decreasing harmful bacterial populations releasing nutrients environment good bacteria digestive system individual.',\n",
              " 'devices methods detecting microorganisms using recombinant reproduction-deficient indicator bacteriophagedisclosed herein compositions, methods, kits systems rapid detection microorganisms using reproduction-deficient indicator bacteriophage. specificity reproduction-deficient indicator bacteriophage binding infecting particular microorganisms interest allows targeted sensitive detection microorganism interest.',\n",
              " 'self-contained apparatus system detecting microorganismsdisclosed herein devices, methods, systems rapid detection microorganisms using recombinant bacteriophage. specificity recombinant bacteriophages binding microorganisms allows targeted highly specific detection microorganism interest.',\n",
              " 'humanized antibodiesdisclosed herein humanized antibodies human germline residues introduces complementarity determining regions (cdrs) non-human donor antibody. described herein libraries antibody variable domains (e.g., phage-display libraries) methods screening humanized antibodies.',\n",
              " 'improved methods performing differential capture proteomicsdisclosed herein improved methods identifying, isolating, comparing proteins biomolecules differing two biological samples using affinity chromatography phage display techniques.',\n",
              " 'inhibition biofilm formation using bacteriophagedisclosed herein indwelling medical devices suitable introduction body subject, wherein indwelling medical devices comprise one surfaces bacterial biofilm form, effective amount bacteriophage composition carried one surfaces, wherein bacteriophage composition inhibits formation bacterial biofilm indwelling medical device. disclosed herein methods inhibiting formation bacterial biofilms indwelling medical devices.',\n",
              " 'novel bacteriophage antibacterial composition comprising samedisclosed herein novel bacteriophage specific bactericidal activity one salmonella bacteria selected group consisting salmonella enteritidis, salmonella typhimurium, salmonella gallinarum, salmonella pullorum without affecting beneficial bacteria. disclosed compositions, animal feeds drinking water, cleaners sanitizers preventing treating infectious diseases caused salmonella enteritidis, salmonella typhimurium, salmonella gallinarum salmonella pullorum including salmonellosis, salmonella food poisoning, fowl typhoid, pullorum disease controlling salmonella bacteria.',\n",
              " 'compositions methods manufacturing bacteriophage cancer vaccines uses thereofdisclosed herein methods compositions manufacturing nanoparticle bacteriophage-based vaccines useful anti-cancer treatments. disclosed herein methods using bacteriophage-based vaccines expressing aspartyl (asparaginyl) β-hydroxylase treating cancer.',\n",
              " 'recombinant bacteriophage detection nosocomial infectiondisclosed herein methods devices detection bacterial hai. disclosed methods may utilized continuous vivo monitoring potential bacterial infection site may utilized alert patients and/or health care providers presence pathogenic bacteria early stage infection. disclosed methods include utilization recombinant bacteriophage deliver pathogenic bacteria translatable genetic sequence encoding optically detectable marker enzyme capable producing optically detectable marker. upon detection optical signal produced marker, medical personnel may alerted presence pathogenic bacteria site inquiry. bacterial causative agent hai may detected according disclosed methods.',\n",
              " 'indicator bacteriophage selecting monitoring efficacy therapeutics methods using samedisclosed herein methods systems detection microorganisms sample utilization methods selecting monitoring therapies. specificity indicator bacteriophage, staphylococcus-specific bacteriophage, allows detection specific microorganism, staphylococcus indicator signal may amplified optimize assay sensitivity.',\n",
              " 'methods systems detection antibiotic resistancedisclosed herein methods systems rapid detection antibiotic resistance microorganism sample. modified recombinant phage disclosed comprises indicator gene late gene region. specificity infectious agents allows specific microorganism targeted, indicator signal may amplified optimize assay sensitivity.',\n",
              " 'methods systems rapid detection microorganisms using recombinant bacteriophagedisclosed herein methods systems rapid detection microorganisms sample, without culturing enrichment microorganism. modified bacteriophage disclosed comprises non-native indicator gene late gene region. indicator product fusion protein. specificity infectious agents allows specific microorganism targeted, indicator signal may amplified optimize assay sensitivity.',\n",
              " 'methods systems rapid detection bacteria using recombinant bacteriophage express indicator subunitdisclosed herein methods systems rapid detection microorganisms bacteria sample. genetically modified bacteriophage disclosed comprises indicator gene encoding one subunit indicator protein. specificity bacteriophage allows detection particular bacteria interest indicator signal may amplified optimize assay sensitivity.',\n",
              " 'methods systems rapid detection listeria using infectious agentsdisclosed herein methods systems rapid detection microorganisms listeria spp. sample. genetically modified bacteriophage disclosed comprises indicator gene late gene region. specificity bacteriophage, listeria-specific bacteriophage, allows detection specific microorganism, listeria spp. indicator signal may amplified optimize assay sensitivity.',\n",
              " 'high-throughput screening functional antibody fragments, immunoconjugate comprising same, adaptor-drug conjugate screeningdisclosed herein methods high-throughput screening functional antibody fragment immunoconjugate targets protein antigen. method combines phage-displayed synthetic antibody library high-throughput cytotoxicity screening non-covalently assembled immunotoxins cytotoxic drug identify highly functional synthetic antibody fragments delivering toxin payloads.',\n",
              " 'differential phage capture proteomicsdisclosed herein methods identifying, isolating comparing proteins biomolecules differing two complex biological samples using affinity chromatography phage display techniques.',\n",
              " 'methods producing mutant bacteriophages detection listeriadisclosed herein methods production mutant bacteriophages altered host range. additionally, disclosed herein methods systems rapid detection microorganisms listeria spp. sample. genetically modified bacteriophage disclosed comprises indicator gene late gene region. specificity bacteriophage, listeria-specific bacteriophage, allows detection specific microorganism, listeria spp. indicator signal may amplified optimize assay sensitivity.',\n",
              " 'combination therapies cancerdisclosed herein methods treating cancer administering subject composition comprising bacteriophage expressing fragment human aspartate β-hydroxylase (asph) immune checkpoint protein inhibitor.',\n",
              " 'universal method extracting nucleic acid molecules diverse population one types microbes sampledisclosed herein methods extracting genetic material diverse population one types microbes sample. microbes prokaryotes eukaryotes may include bacteria, archaea, fungi, protozoa, helminths, parasites, viruses, phages, others. extraction may single sample subsequent identification may molecular method qpcr, pcr, rflp, sscp, allele specific pcr, targeted sequencing, pull sequencing, whole shotgun sequencing, methods.',\n",
              " 'antiviral, bacteriophage-derived polypeptides use virusesdisclosed herein methods using chp peptides treating viral infection coronavirus, including, example, covid-19, subject. disclosed methods using chp peptides inhibiting growth, reducing population, neutralizing infectivity of, and/or killing virus, coronavirus, including, example, covid-19. disclosed pharmaceutical compositions comprising effective amount chp peptide; pharmaceutically acceptable carrier treating viral infection, infection caused coronavirus, covid-19.',\n",
              " 'methods systems detection microorganisms using infectious agentsdisclosed herein methods, compositions, kits, systems rapid detection microorganism interest surface, including medical devices. cocktail compositions recombinant bacteriophages used detect potentially harmful bacteria. specificity recombinant bacteriophages binding microorganisms allows targeted highly specific detection microorganism interest.',\n",
              " 'compositions methods multiplex detection microorganisms using peptide-tagged recombinant infectious agentsdisclosed herein methods, compositions, kits, systems rapid multiplex detection microorganism interest. recombinant bacteriophages encoding capture moiety-indicator protein fusion products allow capture indicator proteins surface. cocktail compositions recombinant bacteriophages used detect potentially harmful bacteria. specificity recombinant bacteriophages binding microorganisms allows targeted highly specific detection microorganism interest.',\n",
              " 'genetic systems defend foreign dna uses thereofdisclosed herein microbial defense systems, provide cells protection phage infection plasmid transformation. methods use defense systems protecting cells phage infection plasmid transformation disclosed, wherein defense systems may used individually combination. addition, disclosed herein methods making cells express defense systems.',\n",
              " 'modified phage displaying post-translationally modified proteins uses thereofdisclosed herein modified phage comprising fusion protein located surface phage wherein fusion protein comprises surface protein post-translationally modified protein. disclosed methods making using modified phage comprising post-translationally modified proteins located surface phage.',\n",
              " 'phi29 dna polymerase mutants improved primer recognitiondisclosed herein mutants bacteriophage phi29 dna polymerase improved primer recognition, compared wild-type enzyme. certain mutants comprise one mutations k64r m97k. provided mutants capable using efficiently shorter longer random synthetic dna primers wild-type phi29 dna polymerase, generating amplification product multiple displacement amplification (mda) reactions. inventive mutants amplify human genomic dna less bias better coverage comparison reactions carried wild-type phi29 dna polymerase.',\n",
              " 'methods cloning prophages producing lytic phage particlesdisclosed herein novel methodologies cloning prophage genome sequences identified target organisms dna sequencing data contain mutations decrease function prophage repressor proteins producing lytic phage particles decreased prophage repressor protein function.',\n",
              " 'synthetic bacteriophages bacteriophage compositionsdisclosed herein novel synthetic bacteriophages bacteriophage compositions, methods production thereof, therapeutic uses thereof.',\n",
              " 'phage-displayed antibody libraries usesthereofdisclosed herein phage-displayed single-chain variable fragment (scfv) libraries, comprised plurality scfvs specific sequence cdr. present scfv libraries used efficiently produce different antibodies high binding affinity h1 hemagglutinin influenza virus. accordingly, present disclosure provides potential means generate different antigen-specific antibodies promptly accordance need experimental researches and/or clinical applications.',\n",
              " 'antimicrobial, bacteriophage-derived polypeptides use gram-negative bacteria.disclosed herein pharmaceutical compositions comprising effective amount isolated chp peptide amino acid sequence selected group consisting seq id nos. 1-4, 6-26 54-66, modified chp peptide 80% sequence identity therewith, wherein modified chp peptide inhibits growth, reduces population, kills least one species gram-negative bacteria; pharmaceutically acceptable carrier. disclosed herein isolated chp peptides, well vectors comprising nucleic acid molecule encode chp peptides host cells comprising vector. disclosed herein methods inhibiting growth, reducing population, killing least one species gram-negative bacteria methods treating bacterial infection subject.',\n",
              " 'antimicrobial, bacteriophage-derived polypeptides use gram-negative acid-fast bacteriadisclosed herein pharmaceutical compositions comprising effective amount isolated chp peptide amino acid sequence selected group consisting seq id nos. 81-91 94-102, modified chp peptide 80% sequence identity therewith, wherein modified chp peptide inhibits growth, reduces population, kills least one species gram-negative acid-fast bacteria; pharmaceutically acceptable carrier. disclosed herein isolated chp peptides, well vectors comprising nucleic acid molecule encode chp peptides host cells comprising vector. disclosed herein methods inhibiting growth, reducing population, killing least one species gram-negative acid-fast bacteria, methods treating bacterial infection subject, methods prevention, disruption, treatment biofilm comprising gram-negative bacteria.',\n",
              " 'bacteriophage preparations methods use thereofdisclosed herein purified bacteriophage preparations effectively lyse plurality c. perfringens strains. one embodiment, purified bacteriophage preparation includes four c. perfringens-specific bacteriophage, wherein bacteriophage lytic activity least five clostridium species strains. another embodiment, purified bacteriophage preparation includes five c. perfringens-specific bacteriophage.',\n",
              " 'situ readout dna barcodesdisclosed herein include systems, methods, compositions, kits situ readout barcodes, dna barcodes. barcode constructs containing promoter (e.g., phage promoter) inactive live cells integrated genomes cells. cells fixed, phage rna polymerase used transcription barcode rna transcripts. rna transcripts detected using, example, fluorescent imaging used determine barcode sequences.',\n",
              " 'phi29 nanochannel early detection breast cancer biomarkersdisclosed herein biosensor detecting breast cancer biomarkers biological sample subject. biosensor based double-stranded dna bacteriophage dna-packaging motor connector protein modified 1) contain affinity domain least one breast cancer biomarker, 2) incorporated membrane layer phospholipid bilayer membrane, form aperture conductance occur electrical potential applied across membrane. embodiments, binding breast cancer biomarker affinity domain alters conductance aperture, measured disclosed herein.',\n",
              " 'phage characterization method devicesdisclosed herein method characterizing phage solution microfluidic device comprising steps mixing phage solution dilution thereof bacterial solution, thereby generating phage/bacteria solution; set microfluidic channels said microfluidics device pumping phage/bacteria solution droplet generator unit, thereby generating phage/bacteria droplets; incubating generated phage/bacteria droplets transparent incubation chamber; and; monitoring, function time, characteristics phage/bacteria droplets said incubation chamber.',\n",
              " 'bacteriophage antibacterial composition comprising samedisclosed herein novel bacteriophage specific bactericidal activity one salmonella bacteria selected group consisting salmonella enteritidis, salmonella typhimurium, salmonella gallinarum, salmonella pullorum without affecting beneficial bacteria, addition showing excellent tolerance acid, heat desiccation. novel bacteriophage present invention widely used active ingredient therapeutic agents, animal feeds drinking water, cleaners sanitizers preventing treating infectious diseases caused salmonella enteritidis, salmonella typhimurium, salmonella gallinarum salmonella pullorum including salmonellosis, salmonella food poisoning, fowl typhoid, pullorum disease controlling salmonella bacteria. present invention provides important insights prevention control strategies salmonella infection suggests use bacteriophage novel, safe, effectively plausible alternative antibiotics prevention salmonella infection poultry.',\n",
              " 'particle delivery via small-scale morphology materials antibacterial applicationsdisclosed herein particle delivery system comprising electrospun nanofiber comprised coaxial fiber microfluidic core. iron-doped apatite nanoparticles (idanps) demonstrated unique influence phage killing bacteria, whereby, idanp-exposed bacterial cultures experience 2× bacterial death controls. idanps consist hydroxyapatite (ha) doped iron. ha mineral known biocompatible analogous inorganic constituent mammalian bone teeth approved food drug administration (fda) many applications medicine dentistry. previous work shown idanps enhance antibacterial activity phage greatest extent, bacterial cultures exposed idanps 1 hr prior phage introduction. biocompatible polymer materials encase idanps and/or phage used disseminate idanps and/or phage controlled manner physiological system treatment bacterial infection. components said materials contain micro- nano-scale components, high surface-to-volume ratio treatment delivery garnered.',\n",
              " 'phage-displayed single-chain variable fragment librarydisclosed herein phage-displayed single-chain variable fragment (scfv) library, comprised plurality phage-displayed scfvs characterized (1 ) specific cs combination; (2) specific distribution aromatic residues cdr; (3) specific sequence cdr. present scfv library used efficiently produce different antibodies binding affinity different antigens. accordingly, present disclosure provides potential means generate different antigen-specific antibodies promptly accordance need experimental researches and/or clinical applications.',\n",
              " 'phage-displayed single-chain variable fragment libraries uses thereofdisclosed herein phage-displayed single-chain variable fragment (scfv) library, comprises plurality phage-displayed scfvs characterized specific cs combination specific sequence cdr. present scfv library useful efficiently producing different antibodies binding affinity different antigens. accordingly, present disclosure provides potential means generate different antigen-specific antibodies promptly accordance need experimental researches and/or clinical applications.',\n",
              " 'phage-displayed single-chain variable fragment library selecting antibody fragments specific mesothelindisclosed herein phage-displayed single-chain variable fragment (scfv) library, comprises plurality phage-displayed scfvs characterized specific sequence cdr. present phage-displayed scfv library useful selecting antibody fragment exhibiting binding affinity specificity mesothelin (msln). disclosed herein recombinant antibody specific msln, immunoconjugate comprising recombinant antibody, uses thereof treating cancers.',\n",
              " 'egfr binding moiety-presenting bacteriophages tumour treatmentdisclosed herein targeted tumour-infiltrating bacteriophage. bacteriophage engineered present epidermal growth factor receptor (egfr)-binding moiety bacteriophage cell surface. egfr-binding moiety capable binding extracellular domain egfr. disclosed compositions, kits, methods uses thereof. disclosed method treating tumour subject need thereof, method comprising: administering subject composition comprising plurality bacteriophage engineered present epidermal growth factor receptor (egfr)-binding moiety bacteriophage cell surface dose effective treat tumour, wherein tumour egfr-positive tumour egfr-binding moiety capable binding egfr extracellular domain.',\n",
              " 'methods devices related controlled delivery phages theranostic tooldisclosed herein engineered bacteriophage comprising indicator gene, wherein said indicator gene rna aptamer green fluorescent protein (gfp) gfp-like protein, wherein said indicator gene indicate presence microorganism, bacterial infection. engineered bacteriophage capable infecting killing microorganism. engineered microorganism composition delivery subject, hyaluronic acid, example. disclosed methods using engineered bacteriophage diagnose and/or treat subject bacterial infection.',\n",
              " 'phage wrappingdisclosed herein, inter alia, compositions methods useful improving detection analytes. compositions methods provided include polymer-wrapped viral particles useful, inter alia, detection psma.',\n",
              " 'bacteriophage pa7 pseudomonas aeruginosadisclosed present invention novel bacteriophage infecting pseudomonas aeruginosa, mutant same, progeny same, use same. bacteriophage according present invention specifically infects pseudomonas aeruginosa oppotunistic strain, thereby effectively removing pseudomonas aeruginsa pathogen tolerance various antibiotics major problem medical circle, used antibiotic, moreover, prevents biofilm formation, thus, provide anti-fouling effect hygienic device food medical device.',\n",
              " 'carrier conjugates gnrh-peptidesdisclosed composition comprising: (a) virus particle (vlp), wherein said vlp vlp rna-phage, (b) least one gonadotrophin releasing hormone (gnrh) peptide; wherein a) b) linked one another, wherein said vlp (a) linked least one gnrh-peptide (b) least one non-peptide covalent bond; wherein said composition comprising linker (c) said vlp said least one gnrh-peptide wherein said linker consists less 4 amino acids.',\n",
              " 'vlp-antigen conjugates uses vaccinesdisclosed composition comprising: (a) virus-like particle (vlp) comprising coat proteins, mutants fragments thereof, rna-bacteriophage least one first attachment site, wherein said vlp recombinantly produced host, said vlp essentially free host rna, wherein said mutant said fragment said coat protein said rna-bacteriophage capable assembling vlp, wherein said mutant said coat protein said rna-bacteriophage amino acid sequence identity least 80% amino acid sequence said coat protein, wherein said fragment said coat protein said rna-bacteriophage polypeptide least 70% length said coat protein (b) least one antigen least one second attachment site; wherein said least one antigen (b) linked said vlp (a) said least one first attachment site said least one second attachment site, wherein said composition comprises least one polyanionic macromolecule packaged inside said vlp, wherein said polyanionic macromolecule selected group consisting of: (a) polyanionic polypeptides; (b) polyanionic saccharides; (c) polyanionic organic polymers; (d) nucleic acids, wherein said nucleic acid toll-like receptor ligand.',\n",
              " 'compositions reducing virus infection rate aquatic crustaceans applications thereofdisclosed composition reducing virus infection rates crustaceans, applied prevention and/or treatment viral infection crustaceans, improves survival rate. composition comprises least one antibodies bind specifically virus, antibodies selected group consisting monoclonal antibody, phage display antibody antibody produced recombinant organism. monoclonal antibodies produced large scale hybridoma cells bioreactor injecting abdominal cavities mice. alternatively, two highly specific antibodies produced phage clones recombinant organisms. composition used forms therapeutic medicines, nutritious feeding supplements addition feeds. also, composition used aqueous solution expose crustaceans fulfill needs treatment and/or prevention viral infection crustaceans.',\n",
              " 'detecting plate bacterial medicine sensitivity experiment detecting minimum bacterium-inhibiting concentration antibioticsdisclosed detection plate detecting minimum antibacterial concentration bacteriophages. filtration-membrane strip quantitative concentration gradient bacteriophages fixed substrate, thus leading detection plate bacterial drug sensitivity test. concentration adjacent bacteriophages increases doubly filtration-membrane strip 8-13 grades concentration units arranged. utility model carries two-in-one detection measure including drug sensitivity minimum antibacterial concentration (mic) bacteriophages surface solid semisolid culture medium; device applied easily, function detecting minimum antibacterial concentration (mic) bacteriophages replace current expensive apparatus produced overseas, utility model applied various-level hospitals, veterinary stations food industries. utility model advantages reliability, simple easy application low cost.',\n",
              " 'methods detecting separating culturing separating/identifying target bacteriophagedisclosed method detecting target bacteriophage. method detecting target bacteriophage comprises step of: immobilizing host bacterium selectively reacts target bacteriophage outer membrane host bacterium surface substrate conductive nano-islands formed; treating surface substrate host bacterium outer membrane host bacterium immobilized detection sample; detecting whether target bacteriophage present detection sample surface plasmon resonance (spr) method.',\n",
              " 'method efficiently screening fibrinogen using phage antibody librarydisclosed method efficiently screening fibrinogen using phage antibody library, comprising steps of: coating protein, sealing flat plate, removing background phage library, combining phage like. compared phage, phage screened present invention may specifically combined human fibrinogen, strong binding force easy process. phage may added various coagulation materials, enrichment fibrinogen promoted means targeted combination human fibrinogen, blood coagulation effect enhanced. method characteristics simple easy use reagents, high success rate like.',\n",
              " 'improved bacterial two-hybrid assaydisclosed method rapidly efficiently screening substance (e.g., antibody, peptide) capable interacting target substance. specifically disclosed are: novel bacterial two-hybrid assay utilizing gene transfer phage; screening method comprising combination bacterial two-hybrid assay phage display system. bacterial two-hybrid assay screening method enable rapidly efficiently screen substance (e.g., antibody, peptide) capable interacting target substance.',\n",
              " 'real time binding analysis antigens biosensor surfacedisclosed method detecting binding binding partner phage comprising: (a) immobilizing crude phage preparation, unconcentrated phage preparation, non-homogenous phage preparation, concentrated phage preparation combination thereof biosensor, wherein crude phage preparation, unconcentrated phage preparation, non-homogenous phage preparation, concentrated phage preparation combination thereof immobilized biosensor by: (i) antibody specific phage coat protein antibody fragment specific phage coat protein; (ii) passive immobilization; (b) contacting biosensor binding partner; (c) detecting binding binding partner phage immobilized biosensor.',\n",
              " 'cocaine-and amphetamine-regulated transcript peptides single-chain antibody application thereofdisclosed new antibody used relieve addiction caused nerve active substances, including opium, cocaine, benzedrine, ketamine, etc. cocain amphetamine-regulated transcript peptide antibody gene selected phage display technology; single-chain antibody sequence cocain amphetamine-regulated transcript peptide(cart) procaryon expression vector connected induced express purified obtain single-chain antibody response cart, named cartscfv(ah1,ah4b,ah6,ah19,ah33b,ah36). injecteion cartscfv abdominal cavity mouse, together cart peripheral circulation system, leads reduction cart central nervous system mouse. animal model behavioral sensitization induced cocain proves cart single-chain antibody restrain expression behavioral sensitization mouse induced cacain, shows cart single-chain antibody great potential curing addiction particularly relapse caused nerve active.',\n",
              " 'site-specific recombination method kitdisclosed novel integrase catalyse site-specific recombination rapidly low substrate concentrations. site-specific recombination method comprises use integrase recombine first dna flanked two attb second dna flanked two attp, first dna flanked two attp second dna flanked two attb, integrase tg1 phage integrase.',\n",
              " 'novel variable lymphocyte receptor, method screening phage capable binding target antigen, method producing variable lymphocyte receptor target antigendisclosed novel variable lymphocyte receptor (vlr) recognize antigen recognized known molecules vlra vlrb. disclosed method screening phage capable binding target antigen, utilizes vlr. vlr comprises one lrrnt, one lrrct, least one lrr arranged lrrnt lrrct, wherein lrrct motif comprising either amino acid sequence (a) and/or amino acid sequence (b) shown below. (a) val-lys-x1-val-asn-(x8)-cys (b) val-lys-x1-val-x1-thr-(x7)-cys (in formulae (a) (b), x represents amino acid residue; xn represents amino acid sequence composed n amino acid residues xs different other, wherein n represents natural number.)',\n",
              " 'cosmid vector transforming plant use thereofdisclosed novel vector plant transformation. vector cosmid vector entire length 15 kb shorter following properties: 1) vector contains replication initiation point incp plasmid contain replication initiation point plasmid; 2) vector contains trfa1 gene incp plasmid; 3) vector contains orit incp plasmid; 4) vector contains incc1 gene incp plasmid; 5) vector contains cos site lambda phage cos site located outside t-dna; 6) vector contains drug-resistant gene expressed escherichia coli bacterium belonging genus',\n",
              " 'phage display intact domains high copy numberdisclosed phage display system molecules displayed (i.e., molecules interest) bound dispensable capsid polypeptides soc (small outer capsid) hoc (highly antigenic outer capsid) polypeptides are, turn, bound surface lattice protein, surface virion polyhead. disclosed methods displaying molecule interest, methods immunizing patient administering displayed antigen, methods treating patient disorder associated aberrent expression activity biological molecule. latter instance, method includes administering displayed polypeptide, immunoglobulin molecule enzyme, capable specifically interacting aberrent biological molecule.',\n",
              " 'process inhibiting formation nitrosaminesdisclosed process inhibiting formation nitrosamines bacteria tobacco, comprising contacting tobacco substance comprising plurality bacteriophages capable lysing bacteria form nitrosamines. disclosed tobacco product possessing diminished concentration nitrosamines.',\n",
              " 'process production chicken recombinant divalent antibody chicken single-chain variable fragment (scfv) antibody produced processdisclosed process simple production chicken recombinant divalent antibody dimerizing single-chain variable fragment (scfv) produced phage display method produce chicken antibody. disclosed antibody produced process. discloses representative application antibody. process producing chicken recombinant divalent antibody comprising steps amplifying light-chain variable region gene heavy-chain variable region gene using, template, polynucleotide encoding chicken single-chain variable fragment, preparing gene fragment expression light chain ligating light-chain leader sequence operable host cell, light-chain variable region gene gene light-chain constant region chicken antibody, preparing gene fragment expression heavy chain ligating heavy-chain leader sequence operable host cell, heavy-chain variable region gene gene heavy-chain constant region chicken antibody.',\n",
              " 'bacteriolysis-resistant cell method production thereofdisclosed prokaryotic cell resistance bacteriolysis induced regardless presence absence external direct stimulus infection phage treatment chemical substance/an enzyme. disclosed method producing cell. specifically disclosed cell srna gene (a bacteriolytic gene) whose expression controlled se factor disrupted acquire bacteriolysis-resistance trait. specifically disclosed method producing bacteriolysis-resistant cell, comprises steps of: inserting gene encoding protein nucleotide sequence bacteriolytic gene; causing protein expressed separate bacteriolysis-resistant cell non-bacteriolysis-resistant cell.',\n",
              " 'multivalent, drying resistant, evolution-based vaccinesdisclosed recombinant nonpermutated bacteriophage includes nucleic acid sequence least 150 kb length wherein bacteriophage made display one surface antigens heterologous polypeptides, compositions kits include recominant nonpermutated bacteriophages present invention. disclosed methods inducing immune response subject involve administration pharmaceutically effective amount composition comprising recombinant nonpermutated bacteriophages present invention.',\n",
              " 'phage-displaying single-chain antibody capable recognizing non-reduced mannose residuedisclosed antibody capable recognizing non-reduced mannose residue. antibody produced screening phage-displaying library displays human scfv, using man3-dppe (which artificial glycolipid synthesized reductive amination mannotriose dipalmitoylphosphatidylethanolamine) antigen.',\n",
              " 'anti-tnf-alpha antibodydisclosed anti-tnf-alpha antibody. according antibody, natural rabbit-derived phage antibody library subjected antigen immunostimulation constructed, tnf-alpha recombinant protein target, three rounds screening enrichment, single-chain antibody specifically combined tnf-alpha obtained. antibody applied specificity capture tnf-alpha antibody, tnf-alpha signal antibody like. meanwhile, successful natural antibody library constructed directly applied screening targets.',\n",
              " 'effect sle antigen epitope polypeptide identification sle autoimmune diseasesdisclosed effect sle antigen epitope polypeptide identification sle autoimmune diseases. according effect, sle related polypeptides screened phage display peptide technology, antigen epitope polypeptide diagnostic value obtained polypeptide chip verification elisa method verification. addition, screening carried sle patient group healthy population group, screening carried disease control group autoimmune diseases, effect antigen epitope polypeptide distinguishing sle autoimmune diseases verified comparing antigen epitope polypeptide control group autoimmune diseases multiple verification processes; results show antigen epitope polypeptide effectively distinguish sle autoimmune diseases, antigen epitope polypeptide beneficial distinguishing sle autoimmune diseases diagnosis process providing accurate diagnosis result timely formulate corresponding treatment strategy realize effective treatment.',\n",
              " 'imine-resistant bacillus pyocyaneus bacteriophage use treating infection therefromdisclosed imine-resistant bacillus pyocyaneus bacteriophage use treating infection, wherein stain broad-spectrum drug-resistant bacillus pyocyaneus bacteriophage phia392, effectively kill drug-resistant bacillus pyocyaneus vivo vitro, bacteriophage decompose multiple strains clinically segregated imipenem-resistant bacillus pyocyaneus vivo. invention proves superiority feasibility bacteriophage therapeutic substance clinical application treatment bacillus pyocyaneus resistant affection, provides novel therapeutic means clinical imipenem-resistant bacillus pyocyaneus affection.',\n",
              " 'rescue influenza virusdisclosed vitro method producing replicative influenza virus particle without use helper virus, comprising culturing cell transfected least one nucleic acid, characterized nucleic acid comprises influenza gene segment bacteriophage polymerase promoter nucleic acid comprises complement influenza gene segment bacteriophage polymerase promoter.',\n",
              " 'method determining escherichia colidisclosed information related determining escherichia coli sample urine. according method, part sample admixed reagent including lanthanide(iii) ion, transition metal ion, transition metal ion/e. coli-specific m13 phage, another part sample admixed reagent including lanthanide(iii) ion, transition metal ion wild-type m13 phage. signals derived lanthanide(iii) ions admixtures detected time-gated luminescence measurement. presence e. coli sample determined comparing lanthanide(iii) ion signal presence transition metal ion/e. coli-specific m13 phage wild type m13 phage.',\n",
              " 'sars-cov-specific b-cell epitope applications thereofdisclosed sars-cov-specific b-cell epitope applications thereof. epitopes peptides either expressed phages synthesized diagnose sars patients accurately. high sensitivity specificity serologic detection achievable using plurality sars-cov-specific b-cell epitope-based peptides. therefore, peptides applied sars diagnosis potentials immunogens producing antibodies sars.',\n",
              " 'modified peptides therapeutic agentsdisclosed fusion fc domains independently randomised il antagonist peptide sequences. linkage vehicle increases half-life peptide, quickly degraded vivo. preferred vehicle fc domain. peptide preferably selected phage display, e. coli display, ribosome display, rna-peptide screening, chemical-peptide screening. peptides useful pharmacologically active agents.',\n",
              " 'bacteriophage prophage proteins cancer gene therapydisclosed use isolated bacteriophage-derived protein manufacture medicament treatment proliferative disease disorder, wherein bacteriophage- derived protein induces cell growth inhibitory activity cell killing effect eukaryotic cells.',\n",
              " 'methods generate bacteriophage resistant bacterial strains produce bacteriophage crispr loci phage mutantsdiscloses method generating crispr (clustered regularly interspaced short palindromic repeat) escape phage mutants comprising: (i) obtaining: least one parent phage phage-resistant bacterial strain comprising least one crispr locus, crispr locus comprises bacteriophage nucleic acid sequence least 95% identical least one proto-spacer sequence genome said least one parent phage; (ii) exposing least one parent phage said phage-resistant bacterial strain, conditions least one phage variant produced; (iii) selecting least one phage variant, least one phage variant exhibits ability infect said phage-resistant bacterial strain crispr-escape phage mutant discloses method generating phage-resistant bacterial strain (i) modified crispr locus comprising least portion crispr locus least one nucleic acid sequence. methods screening said phage-resistant bacterial strain variant phages capable infecting phage-resistant bacterial strain disclosed. bacteriophage selected group virus families consisting of: corticoviridae, cystoviridae, inoviridae, leviviridae, microviridae, myoviridae, podoviridae, siphoviridae, tectiviridae. suitable phage-resistant bacterial strains may used methods disclosed. invention finds application provision methods generate screen useful phage-resistant bacterial strains use e.g. dairy manufacturing processes. invention finds application provision methods generate useful phage-resistant bacterial strains use biocontrol agents e.g. dairy manufacturing processes.',\n",
              " 'phage phimru polynucleotides polypeptides uses thereofdiscloses isolated polypeptide comprising seq id no: 63 polynucleotide comprising seq id no: 136, wherein sequence comprised residues 74-228 seq id no: 63. discloses sequences within methanobrevibacter ruminantium cell, method inhibiting methanogen cell contacting cell polypeptide.',\n",
              " 'inhibition dispersion biofilms plants imidazole-triazole derivativesdisclosure provided methods preventing, removing inhibiting microbial biofilm formation microbial infection plant plant part thereof, including applying thereto treatment effective amount active compound described herein, agriculturally acceptable salt thereof. methods enhancing microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator provided, including applying active compound described herein. compositions comprising active compound described herein agriculturally acceptable carrier provided, embodiments compositions include microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator.',\n",
              " 'inhibition biofilms plants imidazole derivativesdisclosure provided methods preventing, removing inhibiting microbial biofilm formation microbial infection plant plant part thereof, including applying thereto treatment effective amount active compound described herein, agriculturally acceptable salt thereof. methods enhancing microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator provided, including applying active compound described herein. compositions comprising active compound described herein agriculturally acceptable carrier provided, embodiments compositions include microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator.',\n",
              " 'use aryl carbamates agriculture plant-related areasdisclosure provided methods preventing, removing inhibiting microbial biofilm formation microbial infection plant plant part thereof, including applying thereto treatment effective amount aryl carbamate described herein, agriculturally acceptable salt thereof. methods enhancing microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator provided, including applying active compound described herein. compositions comprising aryl carbamate compound described herein agriculturally acceptable carrier provided, embodiments compositions include microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator.',\n",
              " 'bacteriophage based microfluidic assay bacterial detectiondisclosures herein directed detection bacteria using bacteriophage recognition element animplementation framework characteristic microfluidic devices wherein magnetic nanoparticles deployed immobilization target entities detected using fluorescent nanocrystals. figure accompany published abstract: fig. 3',\n",
              " 'method disinfection box tall internal part premises contaminated bacterium means bacteriophagesdisinfection effected means containing bacteriophages sprinkling, spraying applying another method certain distances local sites box stall premises observing conditions ventilation, relative humidity temperature.',\n",
              " 'polypeptides brain -localizing activity uses thereofdnas encoding polypeptides comprising random amino acid sequences synthesized, incorporated phage library. phage library produced used screen polypeptides brain-localizing activity. result, several polypeptides brain-localizing activity obtained. polypeptides comprise common sequences, amino acid motif sequences involved brain-localizing activity successfully identified.',\n",
              " 'pharmaceutical composition antibiotics comprising bacteriophage endolysin plant extract본 발명에 따른 여드름 치료용 조성물은 엔도라이신 및 토복령 추출물을 포함하고, 천연성분을 주성분으로 하여 피부에 자극을 주지 않으면서도 항생제 내성여드름 원인균을 살균하고 염증을 완화할 수 있는 효과가 있으며, 피부를 보호 할 수 있는 효과가 있다.',\n",
              " 'crispr-cas9 method genome editing clostridium perfringens bacteriophage crispr-cas9 system본 발명은 crispr-cas9 시스템을 활용하여 클로스트리디움 퍼프린젠스 균주 및 박테리오파지의 유전자를 제거 또는 치환할 수 있는 방법에 관한 것으로, 본 발명에서 새롭게 구축한 플라스미드 및 유전자 조작 방법은 클로스트리디움 퍼프린젠스와 이를 감염시키는 박테리오파지의 유전자를 쉽게 조작할 수 있는데, 식품, 의약 및 동물 의약 산업 등에 활용될 수 있다.',\n",
              " 'bac-anp-1 bacillus anthracis bacteriophage bac-anp-1 use preventing proliferation bacillus anthracis본 발명은 바실러스 안트라시스 균을 특이적으로 사멸시킬 수 있는 능력을 갖고 서열번호 1로 표시되는 유전체를 갖는 것을 특징으로 하는 자연으로부터 분리한 시포비리대 박테리오파지 bac-anp-1(수탁번호 kctc 12942bp), 및 이를 유효성분으로 포함하는 조성물을 이용한 바실러스 안트라시스 균의 감염을 방지 및 치료하는 방법에 관한 것이다.',\n",
              " 'lytic bacteriophage specific pseudomonas genus resistant antibiotics본 발명은 강력한 항균제인 카바페넴(carbapenem)에 대한 내성을 보이는 슈도모나스 균속을 용균시키는 박테리오파지 ymc11/06/c171 ppu bp [kctc18380p]에 관한 것이다. 본 발명에서 제공하는 신규한 박테리오파지는 강력한 항균제인 카바페넴 내성 슈도모나스 균속에 대하여 특이적 사멸능을 가지므로, 상기한 카바페넴 내성 슈도모나스 균속에 의해 유발되는 질환의 예방 및 치료 목적으로 활용할 수 있다.',\n",
              " 'lytic bacteriophage specific pseudomonas genus resistant antibiotics본 발명은 강력한 항균제인 카바페넴(carbapenem)에 대한 내성을 보이는 슈도모나스 균속을 용균시키는 박테리오파지 ymc11/07/p54 pae bp [kctc18381p]에 관한 것이다. 본 발명에서 제공하는 신규한 박테리오파지는 강력한 항균제인 카바페넴 내성 슈도모나스 균속에 대하여 특이적 사멸능을 가지므로, 상기한 카바페넴 내성 슈도모나스 균속에 의해 유발되는 질환의 예방 및 치료 목적으로 활용할 수 있다.',\n",
              " 'coating composition comprising bacteriophage antibacterial film formed using same본 발명은 박테리오파지를 포함하는 코팅 조성물 및 이를 이용하여 제조된 항균 필름에 관한 것이다. 본 발명의 코팅 조성물은 살모넬라균에 대해 사멸능을 갖는 박테리오파지를 포함하므로 이를 이용하면 항균 활성을 갖는 코팅을 제조할 수 있으며, 코팅 형성 후에도 박테리오파지가 안정적으로 생존하여 우수한 항균 활성을 지속적으로 유지할 수 있다. 본 발명을 식품 포장용 코팅 또는 필름에 적용하는 경우, 살모넬라균에 의해 식품이 오염되는 것을 효과적으로 방지하여 식품의 안전성 및 저장성을 향상시킬 수 있다.',\n",
              " 'pathogenic escherichia coli salmonella shigella-specific bacteriophage antibacterial composition comprising same본 발명은 병원성 대장균, 살모넬라균, 시겔라균에 대해 특이적인 사멸능을 갖는 신규 박테리오파지 kfs-ec3 및 이의 조성물에 관한 것이다. 본 발명의 박테리오파지 kfs-ec3는 병원성 대장균, 살모넬라균 또는 시겔라균에 특이적 사멸능을 가지는 넓은 숙주 범위를 가지는 반면, 유익균은 사멸시키지 않고 내산성 및 내열성이 우수하므로, 병원성 대장균, 살모넬라균 및 시겔라균 중 어느 하나 이상의 균에 의한 감염성 질병의 예방 또는 치료에 활용할 수 있을 뿐만 아니라, 항생용 조성물, 사료 첨가용 조성물, 소독제, 또는 세척제 등에도 광범위하게 이용될 수 있다.',\n",
              " 'novel bacteriophage effective fire blight bacteria black shoot blight disease bacteria use thereof본 발명은 과수 화상병 및 가지검은마름병 원인균에 사멸능을 갖는 신규 박 테리오파지 및 이의 용도에 관한 것이다.',\n",
              " 'bacteriophage killing activity specific escherichia coli shigella본 발명은 대장균 또는 시겔라속 균에 특이적 사멸능을 갖는 박테리오파지 및 이의 용도에 관한 것으로, 본 발명의 박테리오파지인 sme50 (기탁번호: kctc 14641bp)은 신규한 파지로서 병원성 대장균 o157과 시겔라 플렉시너리를 동시에 제어할 수 있는 우수한 숙주 세균 사멸 범위를 가지고, 고온에서의 안정성과 큰 burst size가 다른 파지들과 대비하여 가지는 것을 특징으로 하여 항균제 등으로 유용하게 활용될 수 있다.',\n",
              " 'bacteriophage e. coli specificity composition treating swine e. coli infection using same본 발명은 대장균인 e.coli sw1 및 e.coli o157:h7l에 대해 특이적 사멸능을 갖는 박테리오파아지 ecsw 및 이를 이용한 돼지 대장균 감염증 치료용 조성물에 관한 것이다.',\n",
              " 'sa11 lyssa11 endolysin novel host binding domain staphylococcus aureus bacteriophage sa11 antibiotic composition thereof본 발명은 포도상구균 바인딩 도메인을 갖는 sa11 유래 엔도라이신 lyssa11 및 이를 포함하는 세균 사멸용 조성물에 관한 것이다. 본 발명에서 새롭게 확인한 포도상구균 박테리오파지 sa11 유래의 엔도라이신인 lyssa11은 포도상구균에 특이적으로 결합하여 넓은 범위의 포도상구균 뿐만 아니라, 메티실린에 감수성 및 저항성을 갖는 포도상구균에 대해서도 용균작용을 나타내고, 적은 양으로도 강한 항균 활성을 보이기 때문에, 식품, 의약, 동물의약, 사료 산업 등에 활용될 수 있는 효과가 있다. 또한, 박테리오파지와 달리 lyssa11은 포도상구균에 특이적으로 부착하는 호스트 바인딩 도메인을 가지므로 이는 식품 내에서의 포도상구균 검출에 활용될 수 있다.',\n",
              " 'method regrowth pool culture-based bacteriophage screening본 발명은 재증식 풀 컬쳐(regrowth pool culture)를 기반으로 하는 신규한 박테리오파지 스크리닝 방법에 관한 것으로, 이는 박테리오파지를 이용한 유해균을 제어할 때 발생하는 유해균의 재증식 문제를 효과적으로 해결할 수 있는 유용한 방법으로서 다양한 세균들에 적용될 수 있다.',\n",
              " 'escalator hand rail phage easy본 고안은 파지가 용이한 에스컬레이터용 핸드레일에 관한 것으로, 더욱 상세하게는 통상 백화점, 지하철 등과 같은 대형 건축물에서 층간의 이동을 위하여 설치되는 에스컬레이터의 손잡이부분인 핸드레일을 노약자나 어린이들이 쉽고 강력하게 파지할 수 있어 급정지에 따른 넘어짐, 추락과 같은 안전재해를 방지할 수 있는 파지가 용이한 에스컬레이터용 핸드레일에 관한 것이다.',\n",
              " 'bacteriophage capable killing infectious bacteria fish plankton ingested thereof uses thereof본 출원은 어류의 감염성 박테리아에 대하여 사멸능을 가지는 박테리오파지와 이를 섭취한 플랑크톤의 용도에 관한 것으로서, 어류용 항생 조성물 및 어류의 박테리아 감염성 질병을 예방 또는 치료하는 방법 등을 제공한다.',\n",
              " 'inhibition biofilm formation genetically engineered bacteriophagesembodiments directed engineered bacteriophages produce polypeptides interfere quench quorum sensing. certain aspects quorum quenching enzyme aiia broad specificity degrading substrates, small signal molecule acyl homoserine factories (ahl) initiates quorum sensing pathway global impact diverse bacteria biofilm. certain embodiments directed engineered t7aiia phage effectively degraded ahl diverse bacteria inhibited formation mixed species biofilms containing pseudomonas aeruginosa e. coli. engineered phages used antifouling antibacterial agents industrial clinical settings lysing host bacteria stably expressing quorum quenching enzyme broad substrate specificity impacting diverse bacteria community.',\n",
              " 'malaria vaccineembodiments directed malaria vaccines comprising bacteriophage vlp displaying heterologous peptide identified affinity selection anti-malaria mimotope.',\n",
              " 'methods compositions bacteriophage therapyembodiments directed methods composition preparing using therapeutic phage.',\n",
              " 'stable mixtures related methodsembodiments include colloidal mixture comprising liquid component solid component dispersed liquid component. solid component comprises plurality fine-solid (fs) particles, plurality phage particles binding domains, binding portions thereof, selected bind plurality fs particles. embodiments include methods making colloids, method improving colloidal stability mixture, methods inhibiting growth unwanted organisms, storage shipping systems, bio-additives.',\n",
              " 'identification characterization peptide affinity reagent detection noroviruses samplesembodiments disclosure include methods and/or compositions detection viral infection, including least norovirus infection. particular embodiments, methods and/or compositions employing particular peptides and/or phage useful detecting norovirus sample. sample may environment individual. individual may mammal, including human, cow, horse, dog, cat, pig, forth. certain exemplary peptides phage express peptides identified useful binding norovirus. peptides phage provided one samples order identify whether norovirus present sample.',\n",
              " 'methods compositions related phage-nanoparticle assembliesembodiments invention include additional compositions related methods devices use phage-nanoparticle assemblies. embodiments invention include compositions, methods devices related phage-nanoparticle assemblies use variety methods including detection methods, vitro vivo diagnostic methods, direct and/or indirect therapeutic methods, combinations thereof. phage-nanoparticle assemblies invention comprise plurality nanoparticles complexed one phage particles form phage-nanoparticle assembly. certain aspects, phage-nanoparticle assembly may include agents, including limited organizing agents and/or therapeutic agents.',\n",
              " 'compositions methods related synchronous selection homing peptides multiple tissues vivo phage displayembodiments invention include methods selecting parallel (i.e., synchronously simultaneously) peptides target number organs, peptide targets distinct tissues organs. typically, methods invention provide peptide selection minimal number subjects still provides selectively binding peptide. certain aspects, methods identifying peptides bind multiple selected tissues organs organism may comprise steps administering phage display library first subject; obtaining sample two selected tissues; obtaining phage displaying peptides bind samples first subject; enriching peptides administering phage isolated samples first subject second subject; obtaining sample two selected tissues second subject; identifying peptides displayed.',\n",
              " 'engineering bacteriophages genome editing using crispr-cas9 systemembodiments invention provide systems, methods, kits crispr-based editing dna targets crispr-associated (cas) enzyme. systems include bacterial host cell adapted produce engineered bacteriophage comprising cas protein guide rna naturally occur together, i.e. engineered occur together, well dna repair template comprising donor dna desired mutation. guide rna comprises trans-activating crrna guide sequence complementary target protospacer bacteriophage genome. wild-type bacteriophage glucosylhydroxymethyl cytosine (ghmc)-unmodified mutant bacteriophage may delivered disclosed bacterial host cell create recombinants bacteriophage desired mutation provided donor dna.',\n",
              " 'methods making utilizing amber-obligated phage display librariesembodiments present disclosure pertain methods constructing phage display library least 90% combinatorial regions phage display library include least one in-frame amber codon. embodiments present disclosure pertain formed phage display libraries. additional embodiments present disclosure pertain methods selecting peptides proteins bind desired target (e.g., ligand binding site desired target) utilizing phage display libraries present disclosure. embodiments present disclosure pertain peptides screened phage display libraries methods present disclosure, inhibitors sirtuin 2, inhibitors enl.',\n",
              " 'genetically encoded, phage-displayed cyclic peptide library methods making sameembodiments present disclosure pertain methods selecting cyclic peptides bind target transforming phage display library plurality nucleic acids bacterial host cells, nucleic acids include phage coat protein genes combinatorial region encodes least one cysteine least one non-canonical amino acid. transformation results production phage particles phage coat proteins cysteine non-canonical amino acid couple one another form cyclic peptide library. phage particles screened desired target select bound cyclic peptides. amino acid sequences selected cyclic peptides identified. additional embodiments pertain methods constructing phage display library encodes cyclic peptides. embodiments present disclosure pertain produced cyclic peptides, phage display libraries phage particles.',\n",
              " 'microorganism detection method apparatusembodiments present invention relate selective organism detection, and, particularly recombinant bacteriophages use recombinant bacteriophages detect target bacteria detect specific nucleic acid sequences within said target bacteria thus allowing detection phenotypic characteristics said bacteria determining drug(s) target bacteria resistant. present invention relates sample preparation apparatuses preparing samples detection analysis using bacteriophage-based techniques, lowin cost, easy use, require technical expertise additional laboratory infrastructure perform.',\n",
              " 'systems methods amplification phage displayembodiments various aspects described herein directed amplification biological entities, example, phage display. one aspect, members library biological entities encapsulated separate compartments (e.g., separate microfluidic droplets) amplified. example, putting members phage display library microfluidic droplets droplet contains one member library, library amplified without substantial changes population distributions, artifacts created due differences growth rates amplification different members library. cases, volume compartments used control copy number biological entity amplification. advantageous, example, preserving diversity within library preventing rapidly amplifying biological entities outcompeting slowly amplifying biological entities.',\n",
              " 'sp35 antibodies uses thereofendogenous sp35 negative regulator neuronal survival, axon regeneration, oligodendrocyte differentiation myelination (negative regulator). molecules block endogenous sp35 function, anti-sp35 antibodies used therapeutics treatment neuron oligodendrocyte dysfunction. present invention provides antibodies specific sp35, methods using antibodies antagonists endogenous sp35 function. invention provides specific hybridoma phage library-derived monoclonal antibodies, nucleic acids encoding antibodies, vectors host cells comprising antibodies. invention provides methods promoting oligodendrocyte survival myelination vertebrate, comprising administering vertebrate need treatment effective amount anti-sp35 antibody.',\n",
              " 'sp35 antibodies uses thereofendogenous sp35 negative regulator neuronal survival, axon regeneration, oligodendrocyte differentiation myelination. molecules block endogenous sp35 function, anti-sp35 antibodies used therapeutics treatment neuron oligodendrocyte dysfunction. present invention provides antibodies specific sp35, methods using antibodies antagonists endogenous sp35 function. invention provides specific hybridoma phage library-derived monoclonal antibodies, nucleic acids encoding antibodies, vectors host cells comprising antibodies. invention provides methods promoting oligodendrocyte survival myelination vertebrate, comprising administering vertebrate need treatment effective amount anti-sp35 antibody.',\n",
              " 'bacteriophage-based vaccines engineered bacteriophageengineered bacteriophage methods forming bacteriophage described. multivalent bacteriophage described include multiple different exogenous polypeptides surface capsid head. vaccines methods forming using vaccines described. vaccine include engineered bacteriophage exhibits immunogenic exogenous polypeptide surface bacteriophage. multivalent bacteriophage immunogenic bacteriophage free nucleic acids encoding exogenous polypeptide(s).',\n",
              " 'bacteriophage-based antibodies bindersengineered bacteriophage methods forming bacteriophage described. multivalent bacteriophage described include multiple different exogenous polypeptides include specific binding agents proteinaceous targets surface capsid head. therapeutic compositions, e.g., antiviral compositions, methods forming described. therapeutic composition include engineered bacteriophage includes polypeptide binds pathogen binds cellular receptor pathogen surface bacteriophage. engineered bacteriophage free nucleic acids encoding exogenous polypeptide(s).',\n",
              " 'enterocyte-transcytotic peptide identified peroral pharge display process peroral drug delivery systems using sameenterocyte-transcytotic peptides identified peroral phage display process provided increase absorption efficiency macromolecular materials improve mucoadhesive properties efficiently binding small intestine epithelial cell layer oral administration, absorption efficiency peroral drug delivery systems biomembrane enhanced. enterocyte-transcytotic peptide identified peroral phage display process amino acid sequence cqpapgkqc. small intestine mucoadhesive peptide identified peroral pharge display process amino acid sequence ctadqqrqc. peroral drug delivery system contains enterocyte-transcytotic peptide protein drug.',\n",
              " \"metal-reducing enzymatic tag optical electron microscopyenzymes reduce specific metal metalloid ions insoluble form important science. peptides isolated yeast- phage-display libraries affect size morphology inorganic materials synthesis. herein, se binding peptide fused enzyme capable reducing selenite (seo32-) se0 nanoparticle (senp). fusion se binding peptide metalloid reductase provided size control resulting senp. senp product remains associated enzyme fusion. se binding peptide fusion enzyme increases enzyme's seo32- reductase activity. modification enzyme activity absent, size control particles diminished se binding peptide added exogenously reaction mixture. binding peptide attributed based ligation results conformational change peptide.\",\n",
              " 'peptidoglycan hydrolase antimicrobials eradicating lactobacilli contaminate reduce ethanol yields biofuel fermentationethanol losses due bacterial contamination fermentation cultures weakens economics biofuel production. lactobacillus species predominant contaminant. bacteriophage lytic enzymes peptidoglycan hydrolases degrade gram positive cell walls exposed externally novel source antimicrobials. streptococcal phage λsa2 endolysin construct demonstrated strong lytic activity towards 17 22 strains lactobacilli, staphylococci streptococci maintaining optimal specific activity fermentation conditions toward l. fermentum substrates. lactobacillus bacteriophage endolysin constructs lysa, lysa2 lysgay showed exolytic activity towards ˜60% lactobacilli tested including four l. fermentum isolates fuel ethanol fermentations. presence ethanol (≰5%) affect lytic activity. lysins able reduce l. fermentum l. reuteri contaminants mock fermentations corn fiber hydrolysates. recombinant lysa λsa2 expressed yeast saccharomyces cerevisiae functional; lysa shown reduce lactobacilli experimentally infected fermentations.',\n",
              " 'expression vectors encoding bacteriophage signal peptidesexpression vectors encoding bacteriophage signal peptides described. vectors may used heterologous expression secretion polypeptides antibodies bacterial host cells.',\n",
              " 'display dimeric proteins phageexpression vectors expressing multimeric polypeptides anchored surfaces genetically replicable packages disclosed. expression vectors include vector segment encoding polypeptide sequence three polypeptide segments. one segments contains cleavable peptide sequence cleavable proteolytic agent, another segment anchoring peptide sequence anchoring multimeric polypeptide surface genetically replicable package. cleavable peptide sequence cleaved proteolytic agent first segment associates third segment form multimeric polypeptide. disclosed methods, host cells, kits employing expression vectors.',\n",
              " 'winter aconite fatty acid elongase uses thereof production fatty acidsfatty acids, methods production thereof, provided. transgenic organisms, microbes, plants, seeds, cells useful production fatty acids, along related expression vectors, phages, plasmids, nucleic acids, enzymes, provided. methods production fatty acids docosadienoic acid docosatrienoic acid, involving use winter aconite (eranthis hyemalis) ehelo1 elongase, described detail.',\n",
              " 'fibrous structures comprising surface care composition bacteriophagefibrous structures containing surface care composition, particularly dry fibrous structures containing surface care composition comprising one bacteriophage, methods making same, methods treating surfaces using provided.',\n",
              " 'method preparing cultures conserving plant substratesfield: agriculture. ^ substance: invention relates fodder production farm livestock. method preparing cultures conserving plant substrates, provides selection strains mesophilic lactobacillus resistance virulent bacteriophage, circulating conserved plant substrates, strains propionate bacteria species p.freudenreichii capability ferment plant carbohydrates, actively grow plant substrates display biocompatibility chosen strains mesophilic lactobacilli, separate cultivation, mixing drying. ^ effect: invention makes possible increase output quality silage. ^ 2 cl, 2 tbl',\n",
              " 'method breeding common greenbug (schizaphis graminum rond)field: agriculture.substance: method breeding common greenbug comprises sowing seeds, growing fodder plants, greenbug infestation plants, collection accounting greenbugs. seeds sowing processed plant growth stimulant.effect: method enables improve performance mass breeding greenbug conditions large-scale production aphido-phages.1 tbl, 4 ex',\n",
              " 'method evaluating specific activity bacteriophagesfield: analytical methods microbiology. ^ substance: substance method resides performing, human embryo cell culture monolayer conditions, common 2-h culturing test strains microorganisms suitable therapeutical bacteriophage multifunctional (polyvalent) bacteriophage, includes phage corresponding test culture. specific activity bacteriophage evaluated degree adhesion test strain microorganism monolayer cells compared control (cell monolayer test strain without bacteriophage). ^ effect: speeded determination enabled evaluation therapeutical bacteriophage due approaching evaluation conditions microorganism conditions. ^ 2 tbl',\n",
              " 'non-replicative transduction particles transduction particle based reporter systemsfield: biochemistry.substance: invention relates biochemistry virology relates methods systems packaging reporter nucleic acid molecules non-replicative transduction particles use reporter molecules. bacterial cell packaging system packaging reporter nucleic acid molecule non-replicative contains lysogenised bacteriophage genome contain first bacteriophage gene encoding first sequence packaging initiation site, wherein removal said first bacteriophage gene prevents packaging bacteriophage nucleic acid molecule said non-replicative transduction particle; plasmid reporter nucleic acid molecule containing reporter gene containing second bacteriophage gene, wherein said second bacteriophage gene encodes second sequence packaging initiation site facilitates packaging copy said plasmid reporter nucleic acid molecule said non-replicative transduction particle, wherein said second bacteriophage gene capable expressing protein encoded said second gene, wherein said copy said plasmid reporter nucleic acid molecule forms replicon packaged said non-replicative transduction particle, said bacteriophage selected bacteriophage p1 enterobacteriaceae, bacteriophage ϕ80α bacteriophage ϕ11 s. aureus.effect: invention makes possible obtain non-replicative transduction particles suffer harmful effects lytic functions virus.136 cl, 35 dwg, 13 tbl, 10 ex',\n",
              " 'antiviral agent based serratia-family bacteria nucleasefield: bioengineering.substance: invention relates asubstance antiviral activity respect influenza virus, variolovaccine, mousepox virus herpes virus 2type. discloses serratia-family nucleases-based bacteria. source latter includes purified culture fluid serratia plymuthica bacteria strain pna-like activity 190.0-926 unit/ml protein content 3.6-13.5 mg/ml. said serratia plymuthica bacteria strain represent serratia plymuthica bacteria strain dg-91 dg-98, bp-868 az-372 deposited collection bacteria, bacteriophages fungi federal budget scientific centre \"state r&d centre virology biotechnology \"vector\" enumerated b-1288, b-1297, b-1296, b-1285, respectively. invention may used medicine microbiological industry.effect: higher efficiency.6 cl, 4 tbl, 22 ex',\n",
              " 'strain bacteriophage citrobacter freundii cf17 able lyse pathogenic strains citrobacter freundiifield: bioengineering.substance: invention relates strain bacteriophage citrobacter freundii able lyse pathogenic strains citrobacter freundii, containing gene coding ribonucleotide reductase iii. suggested strain bacteriophage extracted clinic sample septic wound bacterium culture test-strain citrobacter freundii atcc 8090, deposited collection bacteria, bacteriophages fungus fbis ssc vb vector no. ph-1311.effect: bacteriophage strain lytic activity relation citrobacter freundii bacteria, suitable create specimen treat diseases result said bacteria.4 dwg, 5 ex',\n",
              " 'strain bacteriophage staphylococcus aureus sa20 ensuring destruction biofilms created bacteria staphylococcus familyfield: bioengineering.substance: strain ensures destruction biofilms created bacteria staphylococcus family, contains gene coding alpha-subunit ribonucleotide reductase 1b. strain deposited collection bacteria, bacteriophages fungi fbis ssc vb vector no. ph-1312.effect: bacteriophage strain wide spectrum lytic activity relation test-strains clinic isolates bacteria staphylococcus family, used creation germicides resulting death bacteria staphylococcus family.7 dwg, 1 tbl, 8 ex',\n",
              " 'method identification bacteriophage, method isolation mammal cells, method selection bacteriophage (variants), method identification bacteriophage subgroup internalizing ligand (variants)field: biology, genetic engineering. ^ substance: invention relates technology phage display used selection bacteriophages expressing peptides proteins bound cell surface receptors internalized. bacteriophage subgroup bacteriophages identified contacting bacteriophages library expressing multiple peptides cell cells mammal wherein bacteriophage genome carries least one gene encoding product determined. invention relates method isolation mammal cells internalized bacteriophage presenting bacteriophages library involves contacting bacteriophages library expressing multiple peptides mammal cell wherein bacteriophage carried gene encoding product determined, assay product isolation mammal cells express product. invention relates method selection bacteriophage expressing heterologous peptide bound receptor mammal cell surface internalized. method carried contacting library bacteriophages expressing multiple peptides mammal cell wherein bacteriophage carried gene encoding product determined. method involves assay product isolation bacteriophage gene encoding peptide mammal cells expressing product. invention provides carrying identification peptide protein ligands vitro vivo able internalization. ^ effect: improved methods selection, identification internalization. ^ 64 cl, 8 dwg, 12 ex',\n",
              " 'method producing functionally active recombinant protein lethal factor anthrax (lf), recombinant plasmid dna petgst-lfmin, encoding active lf protein strain escherichia coli bl-gstlfmin, producing active protein lethal factor anthraxfield: biology. ^ substance: designed new recombinant plasmid petgst-lfmin (7704 nucleotide pairs), containing catalytically active fragment gene lethal factor anthrax (lf) controlled bacteriophage t7 promoter, determinant resistance ampicillin glutathione-s-transferase sequence efficient purification recombinant protein sorbent immobilised glutathione. plasmid provided efficient sythensis protein lf anthrax, chimerised sequence glutathione-s-transferase purification immobilised glutathione. escherichia coli bl-lfmingst strain obtained transformation said plasmid dna e.coli bl21 (de3) strain, provides output synthesised lf protein less 90 mg/l g raw biomass. active lf protein obtained using method involves culturing said recombinant strain, destruction bacterial cells buffer solution ph 7.4 presence triton x-100 protease inhibitor, purification sorbent immobilised glutathione. ^ effect: output proteolytic active recombinant chimeric purified protein lf anthrax amount less 70 mg/l g raw biomass. ^ 3 cl, 3 dwg, 3 ex',\n",
              " \"method synthesysing nucleoside-5'-triphosphates, labelled radioactive isotopes phosphorous alpha-positionfield: biology. ^ substance: present invention relates biotechnology, specifically obtaining nucleoside-5'-triphosphates, labelled phosphorous-32 (phosphorous-33) alpha-position, used analysis molecular biology, genetics medical biochemistry. method realised treatment labelled nucleosidephosphate buffer solution mixture deoxyribonucleoside monophosphate kinase bacteriophage t5 pyruvate kinase subsequent chromatographic purification target product. ^ effect: simple method obtaining nucleoside-5'-triphosphates stable output target product. ^ 4 ex\",\n",
              " 'method dna molecules separationfield: biology.substance: invention relates molecular biology. method separating dna molecules, providing negative selection target dna molecules solution non-target dna molecules, involves interaction non-target dna molecules, containing recombinase cre recognition site bacteriophage p1 loxp, cre recombinase bacteriophage p1, defective ability covalently modify dna, provides transfer non-target dna molecules solution solid phase. addition, proposed method require presence minimal differences lengths target non-target dna molecules effective separation.effect: application principle negative selection makes possible exclude necessity presence additional nucleotide sequences target dna molecules.15 cl, 8 dwg, 5 ex',\n",
              " \"method extraction differentiation phage vibrio mimicusfield: biotechnologies. ^ substance: indicator strain use vibrio cholerae eltor km 199. three-hour broth culture amount 0.2 ml introduced mixture incubated, filtered lysogenic microorganism: 1 ml latter joined 5 ml 0.7% martin's agar. suspension seeded onto agar plate 1.5% martin's agar cultivated 37c 20-24 hours. lytic response conclusion made availability phage vibrio mimicus f-19. time differentiation cholera phage fb 0139 serogroup carried help strain vibrio cholerae 1322-69-037 serovar. prepare 0.2 ml four-hour broth culture latter, 5 ml 0.7% agar added poured onto agar plate petri dish. congelation, one path apply phage f-19, second one - cholera phage fb. placed thermostat grown 24-48 hours temperature 37c. registration lysis one paths decide availability phage vibrio mimicus it. ^ effect: method suggested extraction differentiation phage vibrio mimicus. ^ 2 tbl\",\n",
              " 'recombinant dna, codes functionally active hybrid protein gl7aca-acylase chitin-binding domain (brdgl7aca-cbd) recombinant plasmid psvh0108, providing synthesis cells escherichia coli, recombinant strain escherichia coli bl21(de3)/psvh0108-producer brdgl7aca-cbdfield: biotechnologies. ^ substance: recombinant dna produced, codes functionally active hybrid protein (brdgl7aca-cbd), consisting amino-acid sequence acylase glutaryl-7- aminocephalosporanic acid strain brevundimonas diminuta all-russian collection industrial microorganisms b-1297 chitin-binding domain chitinase al bacillus circulans. recombinant plasmid psvh0108 constructed expression brdgl7aca-cbd cells e.coli, containing sequence recombinant dna codes hybrid protein control promotor terminator rna-polymerase phage t7. result e.coli strain tranformation recombinant plasmid selection transformed clones, new strain e.coli bl21(de3)/psvh0108 cbd produced - producer hybrid protein brdgl7aca-cbd. ^ effect: high yield recombinant ferment. ^ 4 dwg, 2 tbl, 7 ex',\n",
              " 'vibrio metschnikovii bacteria strain indicator culture specific phage detectionfield: biotechnologies. ^ substance: vibrio metschnikovii bacteria strain km-185 recovered water vibrioflora analysis. strain sensitive specific pk-85 phage recovered vibrio metschnikovii bacteria strain 15818. phage titre 108- 109 particles per ml. ^ effect: maintaining phage reproduction mentor culture. ^ 2 tbl, 1 ex',\n",
              " 'aeromonas bestiarum bacteria strain - producer alkaline ribonuclease antiviral activityfield: biotechnologies.substance: invention proposes aeromonas bestiarum bacteria strain - producer alkaline ribonuclease antiviral activity deposited collection bacteria, bacteriophages fungi federal budgetary scientific institution \"the state scientific centre virology biotechnology \"vector\" registration no. b-1270. strain high production rate alkaline ribonuclease - 921.8 u/ml activity a/h5n1 bird a/aichi/2/68 (h3n2) human flu viruses.effect: improving strain properties.2 dwg, 7 tbl, 8 ex',\n",
              " 'strain bacteriophage escherichia coli ecd4, lytic activity respect bacteria escherichia coli serotype o104:h4field: biotechnologies.substance: invention relates strain bacteriophage escherichia coli ecd4. strain bacteriophage escherichia coli ecd4 isolated faeces broiler chickens culture bacteria strain escherichia coli o104.h4 rk1no.112027 deposited state collection pathogenic microorganisms cell cultures \"gkpm-obolensk\" number ph63. proposed strain bacteriophage lytic activity respect bacteria strain escherichia coli o104:h4 rkino.112027, lyses escherichia serotype 0157:h7, suppress growth cells escherichia coli m-17, lytic activity respect several clinically significant serotypes escherichia, several types shigella. strain bacteriophage escherichia coli ecd4 propagates laboratory non-pathogenic strain escherichia coli k-12 c600f.effect: invention may used creation new preparations treatment disease caused bacteria escherichia coli elimination pathogen food products.4 ex',\n",
              " 'strain basidiomycete inonotus obliquus - producer melanin pigment possessing antiviral antitumoral activityfield: biotechnologies.substance: invention relates biotechnology. strain basidium fungus inonotus obliquus tv-18, antiviral antitumoral activity, deposited collection bacteria, bacteriophages fungi fbun state research center virology biotechnology vector registration number f-1375.effect: strain basidium fungus inonotus obliquus used production medical preparations, creams, lotions, tonic biologically active additives; invention allows increase output melanin.1 cl, 4 dwg, 3 tbl, 6 ex',\n",
              " \"plasmid expression cells bacterium belonging escherichia class, non-active predecessor dnase human muteins; bacterium belonging escherichia class, - producer non-active predecessor recombinant dnase human mutein; predecessor recombinant dnase human mutein; method obtaining recombinant dnase human mutein; method obtaining conjugates polyethylene glycol recombinant mutein human dnase i, fermentative active conjugate mutein recombinant dnase humanfield: biotechnologies.substance: invention represents method obtaining recombinant dnase human mutein, well conjugates polyethylene glycol, using bacterium belonging escherichia class, transformed expression plasmid, containing promoter functioning bacterial cell, dna fragment coding hexahistidine cluster, fragment coding enterokinase recognition sequence amalgamated frame human dnase functionally active mutein containing replacements asparagine cysteine, transcription termination section, vector pet28a(+) fragment containing initiation section replication bacteriophage fl, sequence coding aminoglycoside-3'-phosphotransferase, area beginning plasmid pbr322 replication, gene rna-organising protein rop, sequence coding lactose operon repressor.effect: invention allows obtaining recombinant human dnase mutein high yield.18 cl, 7 dwg, 1 tbl, 12 ex\",\n",
              " 'method obtaining immunogenic composition based cfp10-dbd hybrid protein dextrane; pcfp10-dbd recombinant plasmide; escherichia coli [prep4, pcfp10-dbd] strain; cfp10-dbd chimeric protein applicationfield: biotechnologies.substance: invention represents pcfp10-dbd recombinant plasmide consisting artificial bacterial operon chimeric protein including promoter region early promoter t5 bacteriophage, chimeric protein gene consisting sequence protein antigene cfp10 mycobacterium tuberculosis, merged sequence dextrane-binding domain (dbd) dextrane sucrase leuconostoc citreum km20, transcription terminator, bacterial operon beta-lactamase bacterial initiation section replication cole1 type. besides, strain escherichia coli - producer cfp10-dbd chimeric protein presented. invention describes method immobilisation, concentration cleaning obtained protein cellulose. invention describes immunogenic composition containing cfp10-dbd recombinant protein, aimed induction immunity tuberculous infection.effect: invention enlarges range devices used treatment tuberculosis.4 cl, 6 dwg, 1 tbl, 4 ex',\n",
              " 'method quantitative assessment lytic activity bacteriophagesfield: biotechnologies.substance: method quantitative assessment lytic activity bacteriophages envisions preparation bacterial suspension ephemeral microorganism culture grown pre-set conditions joined beef-extract broth specific bacteriophage. assessment lytic activity bacteriophage performed average value multiple measurements optical density deduction optical density background reaction interaction components. obtained value parameter 0.045±0.025 tested microorganism assessed sensitive bacteriophage. obtained value parameter lytic activity higher named microorganism deemed steady studied bacteriophage.effect: invention allows improving reliability result.4 tbl, 2 ex',\n",
              " 'method extracting bacteriophage bordetella bronchisepticafield: biotechnologies.substance: method relates microbiology biotechnology. method extracting bacteriophage bordetella bronchiseptica includes ultraviolet radiation inducing mutagenic action wavelength 250-260 nm cell lysogenic bacterial cultures bordetella bronchiseptica, grown solid agar medium. uv radiation exposure time equal 1 day 5-7 minutes, 2 day - 7-10 minutes, 3 day - 7-10 minutes. distance irradiated cells lysogenic bacterial cultures bordetella bronchiseptica uv emitter 1 day 1 metre, 2 day-1 3 days - 0.5 m.effect: disclosed method enables relatively short time isolating bacteriophages lysogenic bacterial cells bordetella bronchiseptica without using antibacterial preparations.1 cl, 1 tbl',\n",
              " 'pharmaceutical composition treatment prophylaxis bacterial infectionfield: biotechnologies.substance: pharmaceutical composition includes bacteriophages obtained cultivation nutritional medium containing glucose, sodium chloride, twice-substituted sodium phosphate, liquid autolysed yeast clean water specified ratio, dried filler without lyophilisation, form pills gastral-resistant coating.effect: invention allows increasing safety pharmaceutical composition.7 ex',\n",
              " 'species-specific bacteriophage strain lytic activity relation staphylococcus aureus, including multi-drug resistant strainsfield: biotechnologies.substance: strain deposited number ph 62 gkpm-obolensk collection. strain used development complex medical disinfective preparations infections caused staphylococcus aureus, well preparations sanitation food products staphylococcus aureus.effect: strain lytic activity relation staphylococcus aureus.3 dwg, 6 ex',\n",
              " 'recombinant plasmid dna encoding tul4spcbd recombinant protein synthesis, m15[prep4, ptul4spcbd] escherichia coli strain producer tul4spcbd recombinant protein, tul4spcbd recombinant protein, method production thereof, method production specific antibody tul4spcbd proteinfield: biotechnology, gene engineering, microbiology. ^ substance: invention relates tul4spcbd recombinant protein comprising tul4 francisella tulergenis protein, gly-ser spacer cellulose-binding domain celd endoglucanase gen anaerocellum thermophilus. said protein tul protein antigen properties capable spontaneous binding cellulose-containing sorbents. described recombinant plasmid ptul4spcbd dna 4388 n.p. length, encoding tul4spcbd recombinant protein. abovementioned plasmid contains: artificial bacterial operon tul4spcbd recombinant protein, including promoter region n5 bacteriophage earlier promoter (7-87 n.p.); tul4spcbd recombinant protein gene (115-1113 n.p.); transcription terminator (1134-1230 n.p.); beta-lactamase bacterial operon (4183-3323 n.p. complementary chain)), providing ampicillin resistance; cole1-type bacterial site replication initiation, providing plasmid replication e.coli strain (4388 n.p.). discoised m15[prep4, ptul4spcbd] escherichia coli strain producer tul4spcbd recombinant protein method production purified, concentrated immobilized tul4spcbd recombinant protein said strain treatment cell hydrolyzate supernatant m15[prep4, ptul4spcbd] escherichia coli cellulose-containing sorbent. method production specific antibodies tul4spcbd protein described. said method includes animal immunization tul4spcbd recombinant protein immobilized onto cellulose. ^ effect: method high yield production tul4spcbd recombinant protein; simplified method purification, concentration immobilization said protein. ^ 5 cl, 1 dwg, 4 ex',\n",
              " 'recombinant plasmid dna ptrcte-oph producer enzyme organophosphate hydrolasefield: biotechnology, genetic engineering, biochemistry. ^ substance: invention represents constructed vitro recombinant plasmid dna comprising processed form enzyme organophosphate hydrolase (oph), escherichia coli trc-promoter synthetic site enhancer translation providing biosynthesis enzyme oph, strain escherichia coli producer protein also. recombinant enzyme used producing oph-base preparations designated decomposition organophosphorus compounds analytical determination also. invention solves problem development genetic-engineering construction strain cells provide preparing significant amounts active soluble form organophosphate hydrolase cell cytoplasm inducible synthesis enzyme. problem solved construction recombinant dna ptrcte-oph encoding inducible synthesis oph strain escherichia coli dh5alpha/ptrcte-oph providing synthesis protein expression level allowing prepare 12 mg purified protein 1 g wetted biomass. high inducible level synthesis end polypeptide provided fact proposed plasmid ptrcte-oph differs known one presence e. coli trc-promoter synthetic enhancer translation bacteriophage t7 gene 10. ^ effect: valuable biological properties dna. ^ 3 cl, 2 tbl, 4 dwg, 3 ex',\n",
              " 'recombinant plasmid dna pes1-6 encoding polypeptide somatotropin strain escherichia coli bl21(de3)/pes1-6 producer recombinant somatotropinfield: biotechnology, genetic engineering, molecular biology. ^ substance: invention used preparing recombinant human growth hormone. recombinant plasmid dna pes1-6 encoding polypeptide somatotropin amino acid sequence molecular mass 3.66 mda (5949 pair bases) consists of: nde i/xho dna fragment plasmid pet22b(+) comprising transcription promoter terminator t7 rna-polymerase, translation enhancer phage t7 gene 10, beta-lactamase gene nde i/xho dna fragment comprising sequence artificial gene recombinant somatotropin comprising: genetic marker beta-lactamase gene determining resistance e. coli cells transformed plasmid pse1-6 ampicillin; unique recognition sites site-specific endonuclease restriction enzymes located following distance right site nde : xba - 38 pair bases, hpa - 1332 pair bases, pst - 4065 pair bases, pvu - 4190 pair bases, xho - 5363 pair bases. invention provides preparing strain escherichia coli bl21(de3)/pes1-6 comprising recombinant plasmid dna pes1-6 producer recombinant somatotropin. invention provides preparing recombinant somatotropin high yield simplified technology. ^ effect: improved preparing method, valuable biological properties plasmid dna. ^ 3 cl, 2 dwg, 2 ex',\n",
              " 'recombinant plasmid dna pcl1 encoding polypeptide property human light chain antibody ebola virus, recombinant plasmid dna pch1 encoding polypeptide property indicated antibody heavy chain usingfield: biotechnology, genetic engineering, virology, medicine. ^ substance: invention reports construction recombinant plasmid dnas pcl1 pch1 vitro comprising artificial genes encoding light heavy chains human full-scale antigen ebola virus prepared genetic engineering methods created basis variable fragments recombinant antibody 4d1 light heavy chains phage library human single-chain antibody, human constant genes igg1, cytomegalovirus promoter polyadenylation bgh site. combining use plasmid dna pcl1 pch1 provides biosynthesis human recombinant full-size antibodies class igg1 interacting ebola virus. using recombinant full-size antibodies raised ebola virus used basis development preparations used diagnosis treatment dangerous diseases caused infectious agent. ^ effect: valuable medicinal properties plasmid. ^ 4 cl, 7 dwg, 6 ex',\n",
              " 'nutrient medium production bacteriophages method preparingfield: biotechnology, medicinal microbiology. ^ substance: invention relates, particular, method preparing nutrient medium used production bacteriophages. nutrient medium production bacteriophages contains acidic casein hydrolyzate base hydrolysis degree 0.6-0.7 vitamins: nicotinic acid, folic acid, calcium pantothenate, riboflavin, thiamine bromide biotin, distilled water. also, invention relates method preparing nutrient medium used production bacteriophages involving hydrolysis natural casein mixed water using hydrochloric acid pressure 0.2 0.05 mpa attainment hydrolysis degree 0.6-0.7 isoprecipitation treatment carbon carried simultaneously. invention provide enhancing growth properties medium quality bacteriophages produced reducing cost. ^ effect: improved preparing method. ^ 3 cl, 1 ex',\n",
              " 'recombitant plasmid dna pet21-vp40ve containing gene matrix protein vp40 ebola virus recombitant protein vp40-ve obtained result gene expression protein vp40 ebola virus using recombitant plasmid dna pet21-vp40ve exhibiting immunogenic antigenic propertiesfield: biotechnology, medicine molecular biology.substance: invention relates particular vitro construction dna construct pet21-vp40ve containing gene matrix protein vp40 ebola virus (strain zaire, isolate mayinga) recombinant protein vp40-ve, immunogenic antigenic properties. recombinant plasmid dna pet21-vp40ve intended expression ebola virus matrix protein vp40 gene (strain zaire, mayinga isolate) thee.coliprokaryotic system production recombinant vp40-ve protein, size 6366 bp. contains: theblagene (coordinates 599 1459 bp) genetic marker determines ampicillin resistance ofe.coli(bl21/de3(+) cells transformed recombinant plasmid pet21-vp40ve; site origin replication ori (coordinates 1630 2218 bp); phage t7 promoter (coordinates 5117 5135 bp); lactose repressor (coordinates 3648 bp 4730 bp); dna-binding protein inhibits expression ofe.coligenes ensures expression target recombinant protein vp40-ve; unique recognition sites restriction endonucleases following coordinates: nhei(5204 bp) xhoi(6205 bp); vp40 gene (strain zaire, mayinga isolate) (981 bp), inserted expression cassette restriction sites nhei(5204 bp) xhoi(6205 bp) (from 4479 5459 nucleotides genomic rna), encodes 327 amino acid residues (a.a.) viral matrix protein vp40; sequence (18 bp) encoding polyhistidine (6xhis) polytract six histidines n-end encoded protein subsequent purification using method ni affinity chromatography. recombinant vp40-ve protein obtained result expression ebola virus matrix protein vp40 gene (strain zaire, mayinga isolate) bacterial expression system ofe.colias part recombinant dna construct pet21-vp40ve, molecular weight 36114.68 da amino acid sequence seq id no: 1 333 a.a. length, including 6 histidines stop codon, immunogenic antigenic properties intended induction antibodies body balb/c mice recognize viral protein vp40-be immunochemical reactions, well interacts mouse monoclonal antibodies, polyclonal goat human antibodies specific inactivated infectious ebola virus.effect: increased yield target recombinant matrix protein vp40 ve.2 cl, 14 dwg, 3 tbl, 8 ex',\n",
              " 'tumor-targeted peptidefield: biotechnology, medicine, oncology, peptides. ^ substance: invention relates method based phage display preparing peptides interacting specifically mammary ehrlich tumor used therapy diagnosis malignant neoplasm. peptides prepared affinity selection phage peptide libraries comprising ten millions different peptides size 15 amino acid residues, group nine peptides wherein peptide shows ability accumulation ehrlich tumor. practice using mimetic-peptides selected manner prepared chemical synthesis use preparing conjugates basis known cytotoxic preparations, radioactive isotopes incorporated composition liposomal preparations visualization tumor neoplasm also. ^ effect: valuable medicinal properties peptides. ^ 2 dwg, 2 ex',\n",
              " 'tumor-targeted peptidefield: biotechnology, medicine, oncology. ^ substance: invention relates peptides found selection phage peptide library feature selective binding target-cells. peptides able accumulate lung adenocarcinoma cells show following amino acid sequences: rnvppifndvywiaf, svailprsfspfxvg, pfarapvehhdvvgl. new tumor-targeted peptides allow carrying purposeful delivery preparation different designation lung adenocarcinoma cells. invention used medicine treatment diagnosis lung adenocarcinoma metastasis. ^ effect: valuable medicinal properties peptides. ^ 2 dwg, 2 ex',\n",
              " \"method preparing polybacteriophagefield: biotechnology, medicine. ^ substance: method preparing polybacteriophage involves combination single volume bacteriophages obtained culturing microorganisms phages casein-acidic medium content total nitrogen 1.96 0.10 mg/ml. bacteriophages appelman's titer 10-5, less, combined obtain single volume following sterilizing filtration membranes pores size 0.2 mcm carried out. invention provides simplifying method, reducing time technological cycle enhancing preparation quality. invention used manufacturing medicinal biological bacteriophage-base preparations. ^ effect: improved preparing method. ^ 4 cl, 2 tbl, 2 ex\",\n",
              " 'high levels constructive producing anthrax protective antigenfield: biotechnology, microbiology, genetic engineering, molecular biology. ^ substance: invention relates method preparing anthrax protective antigenic protein (pa). protective antigenic protein prepared using modified e. coli culture culturing feeding. e. coli cells transformed recombinant constitutive expression plasmid dh5alpha comprising pa gene obtain e. coli dh5alpha cells expressing protein pa. culturing high density cells selected, solubilized 6-8 urea separated centrifugation. urea-denaturated pa isolated supernatant, purified eluted. also, method describes anthrax pa 6x-histidine-fused protein prepared method. culturing method involves using primary additive chosen group consisting polythiol, carbohydrate organic acid, lb medium (luria broth) used feeding beginning middle log-phase. plasmid transformation e. coli cells method involves vector series pqe comprising phage promoter recognized e. coli cells. using invention provides enhancing level producing anthrax protective antigen wherein antigen obtained form protein fused 6x-histidine. ^ effect: improved preparing method, high level antigen. ^ 13 cl, 3 dwg, 1 tbl',\n",
              " 'recombinant plasmid expressing module polypeptide delivery photosensitizer strain escherichia coli vkpm b-8356 - producer module polypeptidefield: biotechnology, microbiology, genetic engineering. ^ substance: invention proposes new recombinant plasmid pr752 (5269 pair bases) comprising genetic construction control bacteriophage t5 promoter encoding module polypeptide consisting 6 histidine residues, hemoglobin-like protein e. coli, modified fragment large t-antigen sv-40, translocation domain diphtheria toxin, spacer sequence (gly-ser)5 human epidermal growth factor (6 his-hmp-nls-dtox-(gly-ser)5-egf) designated directed transfer photosensitizers target-cell nuclei. transformation strain e. coli m15 (rep 4) plasmid pr752 recombinant strain e. coli vkpm b-8356 producer new polypeptide vector prepared. usage new strain able enhance effectiveness effect photosensitizers orders. invention used medicinal-biological industry preparing agents providing directed transport photosensitizing agents tumor cell nuclei. ^ effect: valuable biological medicinal properties polypeptide. ^ 3 dwg, 4 ex',\n",
              " 'method indication microorganismsfield: biotechnology, microbiology. ^ substance: method involves sampling specimen environment addition bacteriophage sample able multiplicate analyzed microorganism. inoculate kept definite time bacteriophage titer determined. presence microorganism proved increase bacteriophage titer value measuring degree light diffusion sample. except for, increase light diffusion sample contacted either immunosorbent radioactivity immunosorbent determined piezoelectric resonator electrodes covered antiphage ig presence piezoeffect assayed. invention used carrying analysis presence microorganisms air liquid medium, monitoring environment periodic regime closed compartments mainly places human mass. ^ effect: improved method indication. ^ 3 cl',\n",
              " 'bacteriophage n15 replicon-base vector recombinant vector regulated expression target gene escherichia coli cells, strain escherichia coli providing possibility regulation vector copy number expression systemfield: biotechnology, molecular biology, genetic engineering. ^ substance: invention relates creature expression system target proteins escherichia coli cells combines high level biosynthesis end product large range regulation. invention proposes constructed expression systems representing strain e. coli comprising phage n15 anti-repressor gene integrated chromosome cells wherein gene control functionally active promoter induced e. coli, sop-operon phage n15 transformed recombinant vector based phage n15 replicon comprising dna fragment encoding end protein control promoter chromosome another induced promoter. proposed vectors inherited stably growing microorganisms antibiotic-free medium based correct distribution replicated plasmid copies daughter cells. using invention provides broad range regulation yield end product possibility using single expression system preparing large assortment protein products independently functional activity. ^ effect: valuable biological properties vector. ^ 20 cl, 7 dwg, 2 tbl, 8 ex',\n",
              " 'combinatorial fragmid library human single-stranded antibodies enriched antibodies variolovaccine virus, recombinant fragmid phen-2a8 dna containing unique gene human single-stranded antibody, capable neutralizing variolovaccine virus cowpox virus, artificial human single-stranded 2a8 antibody capable neutralizing variolovaccine virus cowpox virusfield: biotechnology, protein engineering. ^ substance: claimed library represents e.coli tgi cells wherein cell contains fragmid dna providing biosynthesis filamentous bacteriophages exposing unique human single-stranded antibody surface thereof. disclosed recombinant fragmid phen-2a8 dna containing artificial gene human single-stranded antibody control lactose operon promoter providing synthesis human single-stranded antibody composition chimerical protein membrane piii protein m13 bacteriophage e.coli cells. disclosed method production artificial human single-stranded 2a8 antibody using fragmid dna. ^ effect: fragmid library useful medicine. ^ 3 cl, 7 dwg, 10 ex',\n",
              " 'bacteriophage-base biopreparation prophylaxis treatment colibacillosis (eshcerichiosis)in animalsfield: biotechnology, veterinary medicine. ^ substance: invention relates development biological preparation prophylaxis treatment colibacillosis (escherichiosis) control carriage escherichious infections pathogens animals poultries also. also, invention used producing curative fodders ecologically pure human foodstuffs. biopreparation prophylaxis treatment escherichiosis animals poultries comprises strains bacteriophages phagum escherichia coli ec022-dep and/or phagum escherichia coli ec021-dep, and/or phagum escherichia coli ex0782-dep, and/or phagum escherichia coli ec0781-dep, and/or phagum escherichia coli epz-1-dep, and/or phagum escherichia coli epz-2-dep, and/or phagum escherichia coli eg-5-dep, and/or phagum escherichia coli bc-1-dep, and/or phagum escherichia coli m78-dep, and/or phagum escherichia coli sheksna 2k-dep taken effective amount. biopreparation comprises antiseptic, example, quinosol stabilizing agent. protein (for example, soybean protein), vegetable meal, organic polymer, milk, serum, albumin used stabilizing agent. among organic polymers used: dextran, polyglucin, starch, polyvinylpyrrolidone. biopreparation dried lyophilization, granulated placed polymeric matrix. biopreparation toxic properties animals, shows good hygroscopicity good dispersed water. biopreparation used liquid dry prescription formulations different methods administrations: subcutaneous, intraperitoneal, intramuscular injections aerosol, administration phage particles lung compartments including applying curative fodder supplement fodder, applying surface cutaneous integuments. invention provides enhancing effectiveness treatment animals poultries gastroenteric infections due reducing treatment period, expanding spectrum lytic effect biopreparation, resistance effect digestive tract enzymes convenience using. ^ effect: valuable veterinary properties biopreparation. ^ 9 cl, 5 tbl, 7 ex',\n",
              " \"biopreparation based upon bacteriophages preventing treating salmonellosis animalsfield: biotechnology, veterinary medicine. ^ substance: present innovation deals creating biological preparation treating preventing salmonellosis animals poultry. be, also, applied manufacturing curative fodders ecologically pure products human nutrition. suggested biopreparation contains strains following bacteriophages: phagum salmonella choleraesuis csl-dep and/or phagum salmonella choleraesuis cs2-dep and/or phagum salmonella enteritidis spz-1-dep and/or phagum salmonella enteritidis spz-2-dep, phagum salmonella enteritidis spz-3-dep and/or phagum salmonella enteritidis a-1-dep and/or phagum salmonella enteritidis f-6-dep and/or phagum salmonella enteritidis jun-1-dep and/or phagum salmonella enteritidis jun-2-dep and/or phagum salmonella enteritidis c-1-dep and/or phagum salmonella enteritidis g-1-dep taken efficient quantity. it, also, contains anantiseptic, example, chinosol stabilizer protein (for example, soybean protein), plant meal, organic polymer, milk, whey, albumin. organic polymers one may apply dextran, polyglycin, starch, polyvinyl pyrrolidone. biopreparation freeze dried, granulated put polymeric matrix. active salmonella enteritidis, salmonella typhimurium, salmonella heidelberg, salmonella choleraesuis, salmonella gallinarum-pullorum. biopreparation nontoxic animals, highly hygroscopic highly water-dispersed, applied liquid dry receipt forms different ways injection: due subcutaneous, intraperitoneal, intramuscular injections and, also, aerosol, due introducing phage particles pulmonary departments, perorally - including application curative fodder fodder additive and, also, due applying onto skin surface. present innovation enables increase efficiency treating intestinal infections animals poultry due shortened terms therapy, broadened range biopreparation's lytic action, resistance action gastrointestinal enzymes. ^ effect: higher convenience application. ^ 10 cl, 8 ex, 7 tbl\",\n",
              " \"bacterium strain sphingobacterium mizutae-32 producer spml restriction endonuclease, recognizing cleaving 5'-at'cgat-3' nucleotide sequencefield: biotechnology. ^ substance: invention relates bacterium strain sphingobacterium mizutae-32 producing restriction endonuclease named spml, recognizes cleaves 5'-at'cgat-3' nucleotide sequence. strain isolated melt water process searching endonuclease producing strain high activity low temperatures. strain capable growth 6°c, stable two week storage 20°c. strain-produced enzyme hydrolyzes phage-lambda dna t7 6-10°c. enzyme yield 300000 u/10 g cells. ^ effect: effective strain restriction endonuclease production. ^ 2 dwg, 1 tbl, 4 ex\",\n",
              " 'antibacterial composition prevention treatment hospital infections (versions), bacteriophage stamps used obtain compositionfield: biotechnology.substance: composition includes 7 strains bacteriophage, represented combination bacterial phagolysates filtrates lytic activity least 10according appelman concerning test strains isolated bacterial isolates, well target additives amount 0.01±99.99 wt % composition weight. that, staphylococcus aureus phagolysate filtrate obtained using staphylococcus aureus sch1 bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-105, staphylococcus aureus phagolysate filtrate obtained using staphylococcus aureus sch111 bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-95, klebsiella pneumoniae phagolysate filtrate, obtained using klebsiella pneumoniae kpv15 bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-90, klebsiella pneumoniae phagolysate filtrate, obtained using klebsiella pneumoniae kpv811 bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-91, pseudomonas aeruginosa phagolysate filtrate, obtained using pa5 pseudomonas aeruginosa bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-88, pseudomonas aeruginosa phagolysate filtrate, obtained using pseudomonas aeruginosa pa10 bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-89, acinetobacter baumannii, phagolysate filtrate, obtained using acinetobacter baumannii am24 bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-106. composition version contains acinetobacter baumannii phagolysate filtrate, obtained using acinetobacter baumannii ap22 bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-42. appropriate bacteriophage strains proposed. nucleic acid molecules corresponding genome said bacteriophages proposed.effect: expanded range products containing highly selective natural antibacterial components main active ingredient, ensured biological stability activity bacteriophages agent composition, composition low risk toxic side effects, allows expand versions methods practical application agent containing bacteriophages, provides storage stability application efficiency wide temperature range.28 cl, 1 dwg, 4 tbl, 24 ex',\n",
              " \"test system detecting coronavirus infection pathogen genome cattle means multiplex polymerase chain reaction fluorescent detection real timefield: biotechnology.substance: described test system detecting coronavirus infection pathogen genome cattle using multiplex polymerase chain reaction (pcr) real-time fluorescent detection. test system comprises pcr buffer, mixture carrying out, consisting deoxynucleoside triphosphates, primers fluorescent probes specific coronavirus internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase reverse transcriptase mmlv reverse transcriptase. mixture recombinant plasmid dna containing fragment bcov virus genome fragment bacteriophage ms2 genome contains following nucleotide sequences: bcovf 5'-gatcaaattgctagt-3' - forward primer; bcovr 5'-cagtctgcttagtta-3' - reverse primer; bcovp 5'-fam-ggatgccactaagcca-3' - bhq1 - probe; ms2f 5'-tggcactacccctctccgtattcac-3' - forward primer; ms2r, 5'-gtacgggcgaccccacgatgac-3' - reverse primer; ms2p cy5 5'-cacatcgatagatcaaggtgcctacaagc-3 bhq' probe.effect: invention extends range means detecting coronavirus infection genome cattle.1 cl, 4 tbl, 1 ex\",\n",
              " 'recombinant plasmid pet21-tf7, providing synthesis modified tissue factor, escherichia coli bl21 (de3) pet21-tf7 strain - producer recombinant human tissue factorfield: biotechnology.substance: group inventions refers recombinant plasmid providing synthesis recombinant modified human tissue factor, recombinant strain producing human recombinant tissue factor. disclosed recombinant plasmid pet21-tf7 size 6171 base pairs (bp), containing following structural elements: t7 bacteriophage promoter; recombinant gene coding modified human tissue factor; untranslated region terminating transcription bacterial operon; phage t7 rna polymerase terminator; sequence bla (ampr); cole1 (ori) sequence. recombinant gene modified human tissue factor nucleotide sequence seq id no: 1 nucleotide position 5205 bp nucleotide position 5996 bp, encodes target protein full amino acid sequence seq id no: 2, built-in faund ccini restriction sites pet21a vector polylinker region, containing t7 phage tna rna polymerase promoter terminator. said plasmid provides synthesis 29.6 kda recombinant modified human tissue factor escherichia coli bl21 (de3) cells. presented recombinant strain escherichia coli bl21 (de3)/pet21-tf7, produces recombinant human tissue factor obtained transformation said recombinant plasmid pet21-tf7.effect: group inventions provides high stable yield end product.2 cl, 5 dwg, 1 tbl, 3 ex',\n",
              " 'recombinant plasmid pet32-trex vic, provides synthesis prochymosin vicugna pacos chimeric protein, escherichia coli bl21(de3)plyse pet32-trx vic-producer prochymosin vicugna pacos chimeric proteinfield: biotechnology.substance: group inventions relates recombinant plasmid pet32-trexvic, provides synthesis chimeric protein prochymosin vicugna pacos, well recombinant strain escherichia coli, produces said protein. recombinant plasmid pet32-trexvic size 6826 base pairs (bp) provides synthesis chimeric protein prochymosin vicugna pacos size 52 kda cells escherichia coli bl21 (de3) plyse. plasmid contains structural elements essential functioning expression target protein: bacteriophage t7 promoter, recombinant proichymosin vicugna pacos gene encoding target chimeric protein, t7 rna polymerase terminator, thioredoxin sequence added nucleotide sequence prochymosin vicugna pacos gene n-terminus, bla (ampr) sequence, protein coding beta-lactamase, sequence cole1 (ori), providing replication plasmid e.coli strains. recombinant protein gene prochymosin vicugna pacos nucleotide sequence seq id no: 1 nucleotide position 5209 bp nucleotide position 6649 bp, encoding target chimeric protein prochymosin vicugna pacos full amino acid sequence seq id no: 2, built faund hindiii restriction sites polyketer region pet32a vector containing t7 phage tna rna polymerase promoter terminator. presented escherichia coli bl21 (de3) plyse/pet32-trxvic strain producing prochymosin vicugna pacos chimeric protein obtained transformation recombinant plasmid pet32-trexvic.effect: group inventions provides high rate refolding target enzyme.2 cl, 5 dwg, 2 tbl, 5 ex',\n",
              " 'method phage-mediated bioprocessing extension shelf life cooled fishfield: biotechnology.substance: group inventions relates biotechnology. composition includes combination sterile, purified toxins filtrate phagolysates bacteria lytic activity less 10pfu/ml agar-layer technique relation frequently extracted surface cooled fish strains bacteria. composition contains: phage lysate filtrate aeromonas veronii, obtained using strain bacteriophage aeromonas phage ave1, deposited all-russian state collection pathogenic vaccines strains microorganisms-agents infectious animal diseases k. i. scriabin ya. r. kovalenko all-russian research institute experimental veterinary medicine russian academy science number bf-1359; phagolysate filtrate brothothrix thermosilica obtained using strain bacteriophage brochothrix phage brother1 deposited all-russian state collection pathogenic vaccines strains microorganisms-agents infectious animal diseases k. i. scriabin ya. r. kovalenko all-russian research institute experimental veterinary medicine russian academy science number bf-1360; phagolysate filtrate buttiauxella gaviniae obtained using bacteriophage strain buttiauxella phage buga1, deposited all-russian state collection pathogenic vaccines strains microorganisms-agents infectious animal diseases k. i. scriabin ya. r. kovalenko all-russian research institute experimental veterinary medicine russian academy science number bf-1361; phlegolysate filtrate pseudomonas fluorescens obtained using strain bacteriophage pseudomonas fluorescens pf 1, deposited state collection pathogenic microorganisms cell cultures state scientific center applied microbiology biotechnology number ph-132; phagolysate filtrate aeromonas hydrophila, obtained using bacteriophage strain aeromonas hydrophila ah 1, deposited state collection pathogenic microorganisms cell cultures state scientific center applied microbiology biotechnology number ph-129; phagolysate filtrate raoultella ornithinolytica, obtained using raoultella ornithinolytica r.o. 1 bacteriophage strain, deposited state collection pathogenic microorganisms cell cultures state research center applied microbiology biotechnology number ph-128; phagolysate filtrate listeria monocytogenes obtained using strain bacteriophage listeria monocytogenes lm 1, deposited state collection pathogenic microorganisms cell cultures state research center applied microbiology biotechnology number ph-133. disclosed corresponding strains bacteriophages nucleic acid molecules corresponding genome said bacteriophages.effect: presented phage-mediated bioprocessing method prolonging shelf life cooled fish reducing risk infections antibacterial composition implementing method.9 cl, 15 tbl, 10 ex',\n",
              " 'antibacterial composition extension expiry date frozen fish risk reduction food-infection-based infections, bacteriophagic stamps used obtainingfield: biotechnology.substance: group inventions relates biotechnology. composition includes combination sterile, toxin-free filamentous phagolysates bacteria lytic activity bacteriophages less 10pfu/cmaccording grazia relation strains microorganisms often released surface chilled fish. composition includes phagolysate filtrate aeromonas hydrophila obtained using bacteriophage strain aeromonas hydrophila ah 1, deposited \"gkpm-obolensk\" (state collection pathogenic microorganisms cell cultures federal budgetary institution science \"state scientific center applied microbiology biotechnology\" federal service supervision consumer rights protection human welfare) number ph-129; filtrate phagolysate pseudomonas fluorescens obtained using strain bacteriophage pseudomonas fluorescens pf 1; deposited \"gkpm-obolensk\" number ph-132; filtrate phagolysate raoultella ornithinolytica, obtained using strain bacteriophage raoultella ornithinolytica r.o. 1, deposited \"gkpm-obolensk\" number ph-128; filtrate phagolysate pseudomonas putida, obtained using strain bacteriophage pseudomonas putida psp6, deposited \"gkpm-obolensk\" number ph-130; filtrate phagolysate citrobacter freundii, obtained using strain bacteriophage citrobacter freundii cf 1, deposited \"gkpm-obolensk\" number ph-131; filtrate phagolysate listeria monocytogenes, obtained using strain bacteriophage listeria monocytogenes lm 1, deposited \"gkpm-obolensk\" number ph-133. appropriate strains bacteriophages proposed. molecules nucleic acid corresponding genome noted bacteriophages proposed.effect: antibacterial composition proposed prolonging shelf life chilled fish reduce risk foodborn infections.13 cl, 1 dwg, 11 tbl, 11 ex',\n",
              " 'plasmid vector prh15a producing methionine-free interferon alpha-2b, bacterial strain escherichia coli bl21 de3 - producer methionine-free interferon alpha-2b method producing methionine-free interferon alpha-2bfield: biotechnology.substance: group inventions relates biotechnology. disclosed plasmid expression vector prh15a producing human methionine interferon alpha-2b, human-producing derivative human methionine interferon alpha-2b method producing human methionine-free interferon alpha-2b. plasmid expression vector prh15a contains gene methionine aminopeptidase escherichia coli, rhamnose promoter (pbadrha), rhabad operon, terminator transcription phage t7 genes, origin plasmid replication p15a, chloramphenicol acetyltransferase gene (camr) restriction sites required combining separate fragments vector. presented strain escherichia coli strain bl21star [de3] containing plasmid expression vector payc-et-(hifn-a2b)-laci vector prh15a. method producing methionine-free human interferon alpha-2b, involving culturing said strain, separating interferon-containing biomass followed chromatographic purification end product.effect: group inventions provides producing completely methionine-free interferon alpha-2b high output.3 cl, 4 dwg, 4 ex',\n",
              " 'artificial ykuj-mper gene encoding ykuj-mper recombinant protein-immunogen, pet21a-ykuj-mper recombinant plasmid dna, providing expression artificial ykuj-mper gene, ykuj-mper recombinant protein-immunogen, carrier membrane-proximal area hiv-1 intended induction broadly neutralizing antibodiesfield: biotechnology.substance: group inventions relates field biotechnology, genetic engineering medicine. proposed artificial gene ykuj-mper encodes protein-immunogen ykuj-mper hiv-1 nucleotide sequence seq id no:1 length 360 bps. recombinant plasmid dna pet21a-ykuj-mper type proposed, designed produce protein-immunogen induces hiv-specific b-cell response, size 5,700 bps molecular weight 3.8·10 kda containing ykuj-mper gene, encoding ykuj-mper anti-hiv-1 protein-immunogen, control rna polymerase promoter phage t7, ensuring expression e. coli cells. artificial ykuj-mper immunogen protein proposed, consisting b. subtilis ykuj protein site two hiv-1 mper sites, molecular weight 14.2 kda amino acid sequence seq id no:2.effect: group inventions provides effective induction broadly neutralizing anti-hiv-1 antibodies selection optimal immunization strategy.3 cl, 12 dwg, 1 tbl, 6 ex',\n",
              " \"method identification common hedgehog (erinaceus europaeus) dna tissue dry fodder semi-finished meatfield: biotechnology.substance: invention method identification common hedgehog dna (erinaceus europaeus) dry fodders semi-finished meat products, involving dna recovery animal tissue sorption method, polymerase chain reaction fluorescent detection carried 45 cycles real-time amplification using oligonucleotide primers, probes, fluorescent dyes specific dna genome region: specific signal animal – joe/yellow cy5/red – internal control sample form suspension bacteriophage t4 concentration 5×10phage particles per 1 mcl, positive control sample form mixture containing fragments animal genomes bacteriophage t4 nucleotide sequence: t4f: 5'-tacatataaatcacgcaaagc-3' – forward primer; t4r: 5'-tagtatggctaatcttattgg-3' – reverse primer; t4p: hex-5'-acattggcactgaccgagttc-3'-bhq1 – probe, taken ratio 1:1, measurement accumulation fluorescent signals channels corresponding fluorescent dyes, interpretation results based presence absence intersection fluorescence curve threshold line, fluorescence signal accumulation curves 35 cycles, reaction result considered positive, curves cross threshold line cross 35 cycles, result reaction negative, according invention, dna recovered common hedgehog tissue (erinaceus europaeus) phage antigens bacteriophage t4 used internal control sample, positive control sample – fragments genomes native bacteriophage t4 hedgehogs (erinaceus europaeus) following nucleotide sequence: hed-f: 5'-agtctattgattcgaatagagc-3' – forward primer; hed-r: 5'-catgagaggtactaaccagt-3' – reverse primer; hed-p: fam-5'-caggagctttattaggtgatgatcag-3-bhq1 – probe.effect: invention increases identification accuracy species identity, simplifies sample preparation process.1 cl, 5 tbl\",\n",
              " 'method identification species identity mutton beef food raw materials, fodder food productsfield: biotechnology.substance: invention method identification species identity mutton beef food raw materials, fodder food products, including extraction dna mutton (ovis) beef (bos) sorption method, setting single-stage polymerase chain reaction, carrying 45 amplification cycles real-time detection using mutant dna-specific mutton (ovis) beef (bos) oligonucleotide primers, probes, dyes, internal control sample form bacteriophage suspension positive control samples – containing dna genome fragments mutton (ovis) beef (bos), measuring specific signals control signal interpreting results, wherein investigating food raw materials food products containing mutton dna mutton (ovis) beef (bos), polymerase chain reaction carried fluorescent detection using thermal cycler rotor-gene q type accumulation fluorescent signals measured channels corresponding fluorescent dyes: joe / yellow specific signal mutton (ovis); rox / orange – beef (bos) cy5 / red – internal control sample, interpretation results carried based presence absence intersection fluorescence curve threshold line, curves accumulation fluorescent signal reach 35 cycles, result reaction considered positive, curves cross threshold line cross 35 cycles, result reaction negative, wherein internal reference sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample – mixture containing fragments mutton genomes (ovis), beef (bos) bacteriophage t4 taken ratio 1:1:1 following nucleotide sequences: ovis f gcctcatctccctccaacag forward primer; ovis cggaagcctgtaattacagctc reverse primer; ovis p r6g-ctcatgtctgtcctttggtgttatgaatgc-bhq1 probe; bos f aacagcatcattctacccactt forward primer; bos acctaaattcctattctaacactg reverse primer; bos p rox-acgacttacatactccactgcactcacg-bhq2 probe; t4f tacatataaatcacgcaaagc; t4r tagtatggctaatcttattgg; t4p cy5 acattggcactgaccgagttc.effect: invention makes possible increase accuracy beef mutton species identity identification.1 cl, 5 dwg, 5 tbl',\n",
              " 'method production immunogenic composition based fusion protein pesat6-dbd dextran, recombinant plasmid pesat6-dbd, strain escherichia coli, chimeric protein esat6-dbd applicationfield: biotechnology.substance: invention provides recombinant plasmid pesat6-dbd consisting artificial bacterial operon chimeric protein comprising promoter region early promoter bacteriophage t5, gene chimeric protein consisting sequence protein antigen esat6 mycobacterium tuberculosis, fused sequence dextran-binding domain (dbd) dextran-sucrase leuconostoc citreum km20 transcription terminator; bacterial operon beta-lactamase bacterial initiation site replication colel type. invention comprises strain escherichia coli - producer chimeric protein esat6-dbd, method immobilisation, concentration purification resulting protein dextran. addition, invention relates recombinant protein esat6-dbd immunogenic compositions comprising it, aiming induction immunity tuberculosis infection.effect: invention enables obtain producing strain provides high level production stable immunogenic proteins prepared, immobilised purified single step, receive effective immunogenic compositions tuberculosis.5 cl, 2 dwg, 1 tbl, 5 ex',\n",
              " 'method prenatal postnatal genetic diagnosis numerical chromosome abnormalities human embryos dna-microchip based full chromic dna probesfield: biotechnology.substance: invention refers biotechnology, particularly methods prenatal postnatal genetic diagnosis numerical chromosome abnormalities human embryos dna microarrays implementation. dna-microchip substrate made glass coated polylysine, additionally probes slots probes positive negative controls, wherein dna probes presented least two replications grouped separate rectangular zone, wherein second dna probe repeatability reversed 180 degrees copy first replication respect vertical axis, corners rectangle positive, presented human genome dna, negative, presented dna phage λ, yeast genomic dna, control, fluorescent dyes labelling used cy3, cy5, sulfo-cy3, sulfo-cy5.5.effect: technical result simplification results obtained result dna microchip analysis, use accessible equipment, reduction time financial expenses creation dna-microchip maintenance necessary sufficient accuracy information value diagnostics.4 cl, 2 tbl, 2 ex, 2 dwg',\n",
              " 'bacteriophages, phage peptides methods using themfield: biotechnology.substance: invention refers phage therapy treating preventing bacterial infections. particular, present invention refers new bacteriophages f387/08, f391/08, f394/08, f488/08, f510/08, f44/10 f125/10, recovered polypeptides, compositions containing one new bacteriophages and/or recovered polypeptides, well methods treating preventing bacterial infections using separately, combination antibacterial therapeutic agents, e.g. antibiotics and/or phages.effect: disclosed bacteriophages, phage peptides methods using them.34 cl, 21 dwg, 7 tbl',\n",
              " 'method purifying filamentous bacteriophage m13field: biotechnology.substance: invention relates method purifying filamentous bacteriophage m13. method involves removal bacterial mass producing bacteriophage first second successive centrifugation followed first purification supernatant bacteriophage isoelectric precipitation reagent ph 4.2, third centrifuging re-suspension precipitate bacteriophage, well repeated purification suspension bacteriophage isoelectric precipitation reagent ph 4.2 fourth centrifugation precipitate bacteriophage produce end product. isoelectric precipitation agent used sodium acetate buffer ph = 4.2 ratio supernatant bacteriophages less 3:1 first isoelectric precipitation, precipitate bacteriophage third centrifugation re-suspended tbs-buffer, repeated purification re-suspended bacteriophage isoelectric precipitation, sodium acetate buffer ph = 4.2 used ratio re-suspended bacteriophage less 1:1. first second centrifugation carried 5,000 rpm 12,000 rpm 10 minutes 20 °c, third fourth centrifugation carried 10,000 rpm 10 minutes 4 °c.effect: invention provides higher level sterility purity bacteriophage, especially small quantities thereof using simpler technique.1 cl, 7 tbl, 9 ex',\n",
              " 'preparation based lytic mycobacteriophage method production thereoffield: biotechnology.substance: invention relates preparation inactivation (lysis) intracellular tuberculosis mycobacteria based lytic mycobacteriophagous strain inactivates intracellular tuberculosis mycobacteria, mycobacteriophage d29 included bilayer phospholipid liposome 0.4 mcm, method production thereof, comprising separating purifying phage particles bacterial lysates m.smegmatis subsequent inclusion phospholipid liposomes, separation purification phage particles bacterial lysates m.smegmatis carried ion-exchange chromatography q-sepharose column, obtained purified mycobacteriophage concentration less 10pfu/ml shaken phospholipid film 5–10 minutes, obtained particles extruded filter 5 micron pores subsequent 20-fold extrusion using filters pore size 0.4 mcm, concentration separation fraction mycobacteriophage included liposome centrifugation 13±2 thousand rpm 30±5 minutes, using phospholipid film obtained phosphatidylcholine, cholesterol tween-80, taken weight ratio 5±1:1±0.8:1.2±0.2.effect: presented preparation intracellular mycobacterium tuberculosis inactivation (lysis).3 cl, 5 dwg',\n",
              " 'recombinant producer human omega-amidase nit2 based escherichia colifield: biotechnology.substance: invention relates recombinant strain escherichia coli bl21 (de3; pqe-nit2). strain obtained transforming escherichia coli strain bl21 (de3) plasmid construct pqe-nit2, control t5 phage promoter designed produce human ω-amidase (nit2) cultivated nutrient media based peptone, yeast extract glucose. peculiarity nit2 gene pqe-nit2 construct optimized codon composition, well presence artificially introduced 6his- affinity tag immediately initiator codon atg (met), allows one-step product purification metal-affinity chromatography ni-nta-agarose.effect: invention allows obtain human ω-amidase elevated yield.2 dwg, 1 tbl, 6 ex',\n",
              " 'strain bacteriophage pseudomonas aeruginosa n 325 (500319), intended preparation mono- polyvalent treatment-and-prophylactic preparations bacteriophagesfield: biotechnology.substance: invention relates strain bacteriophage pseudomonas aeruginosa used production medical biological antibacterial drugs – bacteriophage preparations, intended preventing treating pyoinflammatory enteral diseases caused pseudomonas aeruginosa bacteria. strain lytic activity pseudomonas aeruginosa. strain deposited state collection pathogenic microorganisms (gkpm) federal state budgetary institution \"scientific centre expert evaluation medicinal products\" ministry health russian federation (fsbi \"sceemp\" russian ministry health) registration number no. 325 (500319).effect: invention wide spectrum antibacterial activity relation epidemiologically significant hospital isolated patients various pathologies clinical strains pathogenic bacteria pseudomonas aeruginosa, 100 % resistant one antibiotics, obtained maximum expansion geography isolation regions.1 cl, 1 dwg, 5 ex',\n",
              " 'strain bacteriophage pseudomonas aeruginosa n 326 (500320), intended preparation mono- polyvalent treatment-and-prophylactic preparations bacteriophagesfield: biotechnology.substance: invention relates strain bacteriophage pseudomonas aeruginosa used production medical biological antibacterial drugs – preparations bacteriophages intended prevention treatment pyoinflammatory enteral diseases caused bacteria pseudomonas aeruginosa. strain deposited state collection pathogenic microorganisms (gkpm) federal state budgetary institution \"scientific centre expert evaluation medicinal products\" ministry health russian federation (fsbi \"sceemp\" russian ministry health) registration number 326 (500320).effect: strain lytic activity pseudomonas aeruginosa, wide spectrum antibacterial activity relation epidemiologically significant hospital isolated patients various pathologies clinical strains pathogenic bacteria pseudomonas aeruginosa, 100% resistant one antibiotics, obtained maximum expansion geography isolation regions.1 cl, 4 ex, 1 dwg',\n",
              " 'tumour-specific peptide address chemotherapy human breast cancerfield: biotechnology.substance: invention relates tumour-specific peptide. disclosed peptide selected phage peptide library one following amino acid sequences: ytydpwlifpan (seq id 1) fipfdpmsmrwe (seq id 2). peptide high specificity toward human breast cancer cells, including ones triple negative phenotype.effect: address chemotherapy human breast cancer.1 cl, 3 dwg, 1 tbl, 5 ex',\n",
              " 'strain escherichia coli bl21(de3)gold/petcypopti - producer human recombinant cyclophilin afield: biotechnology.substance: invention relates biochemistry, genetic engineering biotechnology, namely strain escherichia coli bl21(de3)goldpetcypopti. strain producer recombinant human cyclophilin a. strain produced cell transformation strain escherichia coli bl21(de3)gold petcypopti plasmid. said plasmid size 5858 base pairs contains fragment xhoi-ndei vector pet-22b(+) carrying gene ampicillin resistance ampr, promoter terminator phage t7 rna-polymerase polylinker, wherein fragment, carrying gene human recombinant cyclophilin a, cloned sites xhoi-ndei size 498 base pairs, seq id no: 1.effect: present invention enables obtain human cyclophilin high output purity.1 cl, 3 dwg, 1 ex',\n",
              " 'strain halobacterium salinarum, used preparing bacterial preparationsfield: biotechnology.substance: invention relates biotechnology used preparing bacterial preparations use medicine, veterinary medicine, cosmetology. strain halobacterium salinarum 353p-1, registration number vkpm b-12794, obtained multistage selection original strain halobacterium halobium 353 pushchinsky without using methods genetic modification treatment chemical physical mutagenic agents. strain halobacterium halobium vkpm v-12794 excels initial one yield biomass, carotenoids, important unsaturated fatty acids, increased resistance phage damage.effect: strain used production highly active bacterial preparations use various fields.1 cl, 1 tbl, 3 ex',\n",
              " \"plasmid pvax-rbd dna matrix mrna-rbd molecules, obtained using pvax - rbd dna matrix, providing synthesis secretion rbd protein sars-cov 2 mammalian cells complex form nanoparticles containing mrna-rbd molecules induce sars-cov-specific antibodies viral neutralizing activityfield: biotechnology.substance: invention relates biotechnology genetic engineering. pvax-rbd plasmid dna matrix created, nucleotide sequence seq id no: 1 size 3710 bp, molecular weight 2.6×103kda, containing target gene encoding chimeric protein 176-rbd, preceded promoter phage t7 rna polymerase, provides vitro synthesis mrna-rbd using t7 rna polymerase. mrna-rbd molecule nucleotide sequence seq id no: 2 obtained using pvax-rbd dna matrix, contains open reading frame encoding amino acid sequence seq id no: 3, provides synthesis secretion rbd sars-cov 2 immunogen protein mammalian body, contains hybrid signal sequence 176, kozak consensus sequence, 7-methylguanosine cap 5'-end mrna, polyadenosine (poly a) tail 3'-end mrna, 150-200 nucleotides long, 5'- 3'-untranslated regions (utr) open reading frame. complex form nanoparticles inducing sars-cov-specific antibodies viral neutralizing activity, consisting polyglucinepermidine conjugate molecules mrna-rbd molecules taken different charge ratios 1:1 1:30, corresponding weight ratio 1:3 1:90, size range 50-900 nanometers, nanoparticle contains core consisting mrna-rbd molecules coated layer polyglucinepermidine conjugate retained due ionic interaction negatively charged nucleus positively charged spermidine.effect: creation effective means delivering mrna-rbd cells body synthesis rbd sars-cov-2 protein increasing level secretion protein cells ensure presentation rbd protein immune system body.4 cl, 7 dwg, 1 tbl, 5 ex\",\n",
              " 'recombinant plasmid ppa-oprf-atox-opri dna, encodes synthesis hybrid recombinant protein, including amino acid sequences protein f external membrane atoxic variant pseudomonas aeruginosa exotoxin, escherichia coli pa-oprf-atox-opri strain - producer hybrid recombinant protein method obtaining specified proteinfield: biotechnology.substance: invention relates biotechnology recombinant plasmid dna ppa-oprf-atox-opri, contains fusion genes encoding proteins f outer membrane pseudomonas aeruginosa, well toxic variant exotoxin pseudomonas aeruginosa. expression control promoter phage t7, two lactose operons, lambda tof region transcription stop, transcription terminator rrnbt1. ppa-oprf-atox-opri plasmid contains kanamycin resistance gene, site replication initiation plasmid cole1. cells recipient escherichia coli bl21 (de3) strain containing highly expressed rna polymerase gene bacteriophage t7 transformed plasmid. invention relates method producing recombinant protein.effect: invention allows obtain hybrid recombinant protein, including amino acid sequence proteins f outer membrane atoxic variant exotoxin pseudomonas aeruginosa, develop vaccine prevent infections caused pseudomonas aeruginosa, well obtain donor immunoglobulins intended treatment pseudomonas infection.3 cl, 3 dwg, 1 tbl, 5 ex',\n",
              " 'method producing recombinant antimicrobial peptide ubi18-35, recombinant plasmid dna pet31b-2xubi18-35 producer-producer escherichia coli bl21 rosetta de3 pluss/pet31b-2hubi18-35 antimicrobial peptide ubi18-35field: biotechnology.substance: invention relates biotechnology represents recombinant plasmid dna pet31b-2xubi18-35 coding amino acid sequence recombinant antimicrobial peptide ubi18-35 coded nucleotide sequence: 5’-aaagtggcgaaacaggaaaagaaaaagaa aaagaccggtcgtgcgaaacgtcgt-3’, molar mass 1.8 mpa. plasmid dna consists dna fragment plasmid pet31b + hydrolysed alwni (pstni) site ligated said site fragment coding 2 ubi18-35 molecules bounded ends trinucleotides, coding methionine residues containing plasmid pbr322 replication initiation site, t7-rna polymerase phage transcription promoter terminator, starter codon, coding gene ketosteroidisomerase, coding sequence 6 histidine residues, stop codon, genetic marker ampr - β-lactamase gene determines resistance transformed plasmid pet31b-2xubi18-35 cellsto ampicillin. invention relates method producing recombinant antimicrobial peptide ubi18-35, comprising cell transformationbl21 rosetta de3 plyss said plasmid, growing cells transformed cellsin medium subsequent cultivation; separation cells centrifugation, washing inclusion bodies containing 2 molecules recombinant antimicrobial peptide ubi18-35 protein-fusion ketosteroidisomerase 6-histidine tag, dissolving buffer addition urea, followed separation peptides ketosteroidisomerase 6 histidine residues, separation thereof using bromocyan chromatographic purification recombinant peptide.effect: plasmid dna provides synthesis ubi18-35 peptide part fusion protein ketosteroidisomerase.2 cl, 9 dwg, 1 tbl',\n",
              " 'test system detection virus genome parainfluenza 3 types cattle multiplex polymerase chain reaction fluorescent detection real time modefield: biotechnology.substance: invention relates biotechnology, particular means diagnosing parainfluenza virus type 3 animals. test system detecting genome causative agent coronavirus infection animals using multiplex polymerase chain reaction fluorescence detection real time proposed. test system includes buffer carrying polymerase chain reaction, primers fluorescent probes specific coronavirus internal control sample, mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase reverse transcriptase mmlv reverse transcriptase, buffer diluting rna form deionized water, internal control sample, negative control sample, positive control sample, internal control sample – bacteriophage ms2 suspension, positive control sample, mixture recombinant plasmid dna containing fragment bpi 3 virus genome fragment bacteriophage genome used.effect: invention serves extend functionality obtain reliable diagnostics.1 cl, 5 tbl, 1 ex',\n",
              " \"recombinant gene encoding hbd-epo protein, recombinant plasmid dna pl610, method producing recombinant hbd-epo protein, recombinant hbd-epo protein, composition specifically inducing bone regeneration, method specific induction bone tissue regenerationfield: biotechnology.substance: invention relates biotechnology, genetic engineering, biochemistry, medicine, veterinary medicine. synthetic dna sequence corresponding gene encoding protein sequence heparin-binding domain (hbd) danio rerio fused human erythropoietin (epo) sequence (hbd-epo protein) nucleotide composition codons optimized heterologous expression non-pathogenic laboratory strain e. coli. synthetic hbd-epo gene flanked 5'-end ncoi site, 3'-end site kpn2i inserted plasmid pqe6 ncoi kpn2i sites. based this, recombinant plasmid pl610 obtained containing artificial bacterial operon recombinant hbd-epo protein comprising promoter region early promoter bacteriophage t5, recombinant hbd-epo protein gene, transcription terminator; bacterial operon beta-lactamase; bacterial region initiation replication cole1 type encoding recombinant hbd-epo protein providing synthesis e. coli strains. invention includes method purifying hbd-epo protein ion exchange chromatography. invention relates hbd-epo recombinant protein itself, expression vector pl610 composition (demineralized bone matrix (dcm) containing hbd-epo protein, well dcm containing protein hbd-epo bmp-2), aimed stimulating osteogenesis. invention allows obtain stable purified active protein hbd-epo, well hbd-epo, immobilized dcm, including dcm bmp-2 bone morphogenetic protein.effect: invention includes method specifically inducing bone regeneration, comprising filling defects bone tissue composition consisting hbd-epo immobilized dcm, including dcm bone morphogenetic protein bmp-2.7 cl, 4 dwg, 5 ex\",\n",
              " 'pharmaceutical composition treating eye infections caused meticillin-resistant strains staphylococcus aureus, includes active ingredient n-terminal chap-domain endolysin bacteriophage staphylococcus aureusfield: biotechnology.substance: invention relates biotechnology, particular pharmaceutical composition treating eye infections caused methicillin-resistant strains of, containing active substance n-terminal char endolysin bacteriophage k.effect: declared pharmaceutical composition non-toxic effective vancomycin antibiotic extends range products treating eye infections caused methicillin-resistantstrains.1 cl, 7 ex, 1 dwg, 5 tbl',\n",
              " 'method producing recombinant herpesviruses simultaneous transduction immortalization primary t-lymphocytes nk cellsfield: biotechnology.substance: invention relates biotechnology, namely method producing recombinant herpesviruses simultaneous transduction immortalization primary t-lymphocytes nk cells. recombinant plasmid dna puc-hvs-ofp consists following key genetic elements: puromycin resistance gene (pac); orange fluorescent protein (ofp) gene; flanking parts (600 bp) homologous vcd59 area hvs genome; ampicillin antibiotic resistance gene (ampr) bacterial promoter ampicillin resistance gene (ampr promoter); origin replication bacteriophage f1 (ori); cytomegalovirus (cmv) promoter. cell culture permissive lytic infection herpesvirus saimiri virus infected herpesvirus saimiri hvs-c488 virus strain. another interweaved cell line transfected mixture expression plasmids puc-hvs-ofp plasmid. permissive cell culture infected herpesvirus saimiri cell culture transfected expression plasmids mixed subjected co-cultivation.effect: combining productive development virus cells lines permissive lytic hvs infection high efficiency cell transfection expression plasmids encoding genetic sequences intended introduction genome “wild” virus strain makes possible obtain recombinant herpesviruses increased efficiency development.6 cl, 6 dwg',\n",
              " 'method indication identification strains plague pathogen belonging species yersinia pestis, subspecies, biovars, phylogenetic branches presence genes pathogenicity main factors dna-chip methodfield: biotechnology.substance: invention relates biotechnology, namely indication identification plague agent strains belonging species yersinia pestis, subspecies, biovars, phylogenetic branches presence genes pathogenicity main factors dna-chip method. method involves recovering dna strain, carrying multiplex pcr one step six reaction mixtures target dna: ‘pla’, ‘3a’, ‘cafl’, ‘yihn’ first; ‘irp2’, ‘lcrv’ second; ‘glpd’, ‘pro’, ‘med24’, ‘45’ third; ‘med70’, ‘phage’ fourth; ‘alt’, ‘his’, ‘u1’ fifth; ‘caucas’, ‘tal’, ‘micr’ sixth subsequent hybridisation immobilized probes, indication identification strains based presence absence fluorescence signals. fluorescence targets \"yihn\" \"3a\" observed strains y. pestis. differentiating subspecies, fluorescence signal y. pestis strains main subspecies target \"45\", strains altaic biovar central asian sub-species target \"alt\", gissar biovar central asian subspecies \"his\" target, talas biovar central asian sub-species target \"ta1\", microtias biovar central asian subspecies target \"micr\", ulegeica subspecies strains target \"u1\", strains caucasian subspecies \"caucas\" target. differentiating y. pestis strains main subspecies belonging biovars, fluorescence signal strains oriental biovar (1.ori) \"glpd\" target, strains medieval biovar except 2.med0 target \"med24\" fluorescence signals strains branch 2.med0 target \"pckp\", strains antique biovar main subspecies targets \"glpd\" \"med24\" noted. phylogenetic branch \"1\" (1.ant 1.ori) strains characterized presence fluorescent signal \"phage\" target, phylogenetic branch \"2\" (2.ant 2.med) strains characterized absence fluorescence signal \"med70\" target. detecting main pathogenicity genes, fluorescence signal y. pestis strains containing hpi high pathogenicity island chromosome pigmentation region target \"irp2\", strains carrying pla gene plasmid ppst target \"pla\", strains gene lcrv plasmid pcad target \"lcrv\", strains containing cafl gene plasmid pfra target \"caf\".effect: invention makes possible determine affiliation species, subspecies, biovars, phylogenetic branches presence main genes pathogenicity dna-chip method, provides isolation dna-strain, conducting six multiplex pcr target dna ‘yihn’, ‘3a’, ‘45’, ‘alt’, ‘his’, ‘u1’, ‘caucas’, ‘tal’, ‘micr’, ‘glpd’, ‘med24’, ‘pro’, ‘med70’, ‘phage’, ‘pla’, ‘cafl’, ‘irp2’, ‘lcrv’, subsequent hybridisation immobilized probes, indication identification strains based presence absence fluorescence signals accordance tables.1 cl, 6 tbl, 9 ex',\n",
              " \"pcdexo-gs-ssb genetic constructs containing sequences encoding chimeric ssb proteins exonucleases bacteriophage homologous recombination apparatus, combined via glycine-serine polylinkerfield: biotechnology.substance: invention relates biotechnology, namely, production recombinant ssb-gs-exo protein construct. proposed method producing recombinant ssb-gs-exo protein construct, involving transformation competent cells expression genetic constructs therein based plasmid dna, wherein 5’-3'flap exonuclease (exo) ssb protein combined genetic engineering glycine-serine spacer represented sequence seq id no: 1.effect: invention ensures cloning dna molecules increased frequency homologous recombination nucleic acids cell.1 cl, 3 dwg, 1 tbl, 2 ex\",\n",
              " 'recombinant plasmid dna p280_2gm coding polypeptide properties granulocyte-macrophage colony-stimulating factor human, strain escherichia coli sg 20050/p280_2gm - producer polypeptide properties granulocyte-macrophage colony-stimulating factor human method obtaining said polypeptidefield: biotechnology.substance: invention relates biotechnology, particularly genetic engineering, vitro constructed recombinant plasmid dna containing two copies human granulocyte-macrophage colony-stimulating factor (gm-csf) synthetic gene, escherichia coli strain sg20050/p280_2gm producer said polypeptide method producing polypeptide gm-csf properties. recombinant plasmid dna p280_2gm codes polypeptide properties granulocyte-macrophage colony-stimulating factor (gm-csf) person characterized following features: codes amino acid sequence mature human gm-csf; molecular weight 2.95 mda (4,422 base pairs); consists of: psti/bamhi(pol)-fragment plasmid dna p280gm (1,484 base pairs) containing c-terminal part beta-lactamase gene, tandem promoters tryptophan operon e. coli synthetic gene gm-csf human, well ecori(pol)/psti (2,938 base pairs) – fragment plasmid containing synthetic human gm-csf gene n-terminal portion beta-lactamase gene; contains: – tandem promoters tryptophan operon e. coli; two copies human synthetic gm-csf gene; transcription terminator t0 lambda phage; genetic marker, beta-lactamase gene determining resistance e. coli transformed plasmid p280_2gm ampicillin antibiotics; unique recognition sites restriction endonucleases located following distances right ecori site (279 base pairs) – bamhi – 912 nucleotides; psti – 3,396 nucleotides.effect: invention increases output polypeptide properties granulocyte-macrophage colony-stimulating factor.3 cl, 8 dwg, 4 tbl, 15 ex',\n",
              " 'bacteriophage lytic enzyme antibacterial composition based thereonfield: biotechnology.substance: invention relates biotechnology, specifically production antibacterial recombinant proteins, used medicine antibacterial composition exhibiting activity gram-negative bacteria pseudomonas aeruginosa. recombinant protein obtained, covalently cross-linked endolysin antipseudomonal bacteriophage krr10 modified fragment [k2,7,13]-smap-29(1-17) myeloid antimicrobial sheep peptide smap-29.effect: invention provides higher effectiveness antibacterial therapy pseudomonas aeruginosa bacteria.2 cl, 7 dwg, 1 tbl, 3 ex',\n",
              " \"recombinant plasmid dna pqe-30_p36gp12_gp57, providing synthesis recombinant protein p36gp12 cells escherichia coli, strain bacteria escherichia coli - producer recombinant protein p36gp12, recombinant protein p36gp12, capable bind lipopolysaccharides escherichia colifield: biotechnology.substance: invention relates biotechnology, specifically recombinant production hybrid protein escherichia coli cells, used purification biotechnological substances bacterial lipopolysaccharides. hybrid protein p36gp12 consisting n-terminal oligopeptide mrgshhhhhhgsan full-length protein short tail filaments t4-like bacteriophage isolate. plasmid pqe-30_p36gp12_gp57 designed, provides synthesis recombinant protein p36gp12 escherichia coli dh5αf'/pqe-30_p36gp12_gp57 strain cells, obtained transformation cells escherichia coli dh5αf' constructed plasmid.effect: invention enables obtain recombinant protein p36gp12, ability bind lipopolysaccharides escherichia coli.3 cl, 6 dwg, 6 ex\",\n",
              " 'antibacterial composition (embodiments) use protein antimicrobial agent directed bacteria pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, salmonella typhi staphylococcus haemolyticus (embodiments)field: biotechnology.substance: invention relates biotechnology, specifically therapeutic proteins used medicine antibacterial agent. disclosed use recombinant endolysin bacteriophage, including combination pharmaceutically acceptable carriers and/or substances increasing membrane permeability, antimicrobial agent directed bacteria pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, salmonella typhi staphylococcus haemolyticus. antibacterial compositions obtained based said protein, including fused 8-histidine tag.effect: invention provides effective penetration endolysin without adding various permeabilisers covalently bound penetrating peptides outer membrane said bacteria cleavage peptidoglycan, ultimately leads death bacteria.4 cl, 3 tbl, 6 ex, 5 dwg',\n",
              " 'antibacterial composition (embodiments) use protein antimicrobial agent directed acinetobacter baumannii bacteria, (embodiments)field: biotechnology.substance: invention relates biotechnology, specifically therapeutic proteins, used medicine antibacterial agent. disclosed use recombinant endolysin bacteriophage, including combination pharmaceutically acceptable carriers and/or substances, increasing permeability membranes, antimicrobial agent directed bacteria acinetobacter baumannii. antibacterial compositions obtained based said protein, including fused 8-histidine tag.effect: invention provides effective penetration endolysin without adding various permeabilisers covalently bound penetrating peptides outer membrane said bacteria cleavage peptidoglycan, ultimately leads death bacteria.4 cl, 3 tbl, 6 ex, 5 dwg',\n",
              " \"genes encoding open reading frames l-segments cchf, recombinant constructs provide expression structural glycoproteins rna-dependent rna polymerase (l) crimean-congo hemorrhagic fever virusfield: biotechnology.substance: invention relates biotechnology. described gene encoding rna-dependent rna polymerase cchf virus nucleotide sequence seq id no:1 11838 bp length. described recombinant plasmid psb3delta-rdrp, designed integration expression rna-dependent rna polymerase gene cchf virus, size 18270 bp. contains, accordance physical genetic map, target gene encoding rna-dependent rna polymerase cchf virus, amino acid sequence seq id no: 2 3945 amino acids length, consists following elements: β-lactamase gene (coordinates 17218 18078 bp) control promoter (coordinates 18079 18183 bp), genetic marker determines ampicillin resistance e. coli cells; origin replication ori plasmid vector puc (coordinates 16459 17047 bp); 5'-itr 3'-itr inverted repeats coordinates 17 288 bp. 15990 16214 p.n. accordingly, provide integration plasmid region enclosed genome mammalian cells using sleeping beauty (sb) transposase; promoter enhancer cmv - provides gene expression according claim 1 mammalian cells (coordinates 855 1438 bp); chimeric intron - chimeric intron providing efficient transcription, stability transport transcript cell nucleus (coordinates 1574 1706 bp); t7 promoter - nucleotide sequence t7 bacteriophage promoter required vitro transcription (coordinates 1751 1769 bp); l protein (rdrp) - open reading frame gene rna-dependent rna polymerase cchf virus according claim 1 (coordinates 1783 13620 bp); ires2 - internal site encephalomyelitis virus ribosome entry, providing expression puromycin resistance gene (coordinates 13854 14240 bp); puror - puromycin resistance gene, amino acids, encoding n-acetyl transferase (coordinates 14241 14843 bp); bgh poly (a) signal - polyadenelation signal (coordinates 14874 15098 bp).effect: invention expands arsenal cchf treratment.2 cl, 8 dwg, 4 tbl, 3 ex\",\n",
              " 'strain asidiomycete daedaleopsis confragosa, containing proteins, exhibiting anticancer antiviral activityfield: biotechnology.substance: invention relates biotechnology. strain basidiomycete daedaleopsis confragosa k-1326, cytostatic anticancer activity human marrow myeloma (im-9), human lymphadenoma (namalva) inhibitory activity herpes simplex virus type 2, influenza virus / h1n1 / california / 2009, deposited collection bacteria, bacteriophages fungi federal state-funded institution ssc srb wb “vektor” federal supervision agency customer protection human welfare registration number f-1368. strain basidiomycete daedaleopsis confragosa used produce anticancer antiviral drugs.effect: invention allows increase yield proteins exhibiting activity tumor cells viruses pathogenic human.1 cl, 4 dwg, 4 tbl, 6 ex',\n",
              " 'strain serratia species bacteria antiviral activityfield: biotechnology.substance: invention relates biotechnology. strain serratia species bacteria k-57 possesses rnase rna dna activity, deposited collection bacteria, bacteriophages fungi federal budgetary institution science \"state research center virology biotechnology \"vector\"of rospotrebnadzor\" registration number v-1289. strain serratia species bacteria v-1289 strain used production antiviral drugs.effect: invention makes possible expand assortment strains antiviral activity human influenza virus a/aichi/2/68 (h3n2), vaccinia virus (vov), micepox virus (mpv), herpes simplex virus type 2 (hsv-2).1 cl, 2 dwg, 8 ex, 2 tbl',\n",
              " 'method identification rat mouse tissue species dry feed semi-fenished meat productsfield: biotechnology.substance: invention relates biotechnology. invention aimed identifying rat (rattus) mouse (mus musculus) tissues spices dry feed meat semi-finished products, including isolation dna animal tissues sorption, setting polymerase chain reaction fluorescent detection 45 real-time amplification cycles using site-specific animal dna genomes, oligonucleotide primers, probes, fluorescent dyes: joe/yellow specific signal one animals cy5/red - internal control sample suspension bacteriophage t4 concentration 5×103phage particles per 1 µl positive control sample form mixture, containing fragments genomes animals bacteriophage t4 nucleotide sequence, taken ratio 1:1:1, measuring accumulation fluorescent signals channels appropriate fluorescent dyes, interpretation results basis presence absence crossing fluorescence curve threshold line, curves accumulation fluorescent signal 35 cycle, reaction considered positive, curves cross threshold line cross 35 cycles, result reaction - negative, according invention, dna isolated tissues rats (rattus) mice (mus musculus) internal control sample using phage lysate phage t4, positive control sample - fragments genomes native bacteriophage t4 tissues rats (rattus) mice (mus musculus), determination dna tissues rat (rattus) using fluorescent dye joe/yellow, fabric mouse (mus musculus) - fam/green.effect: said invention allows increasing accuracy species identification, simplifying preparation process.1 cl, 5 tbl',\n",
              " 'method introducing unmarked point substitutions chromosome microbacteriafield: biotechnology.substance: invention relates genetic engineering. described method introducing point substitutions bacterial chromosome without concomitant integration antibiotic resistance determinants. method based widely applied method phage recombination introducing mutations bacterial chromosome using short fragments. efficiency obtaining recombinant clones mycobacteria approximately 10-4to 10-3per total amount cells. accordingly, selection appropriate mutants requires checking thousands colonies. previously proposed methods improving efficiency clone selection either include use antibiotic resistance markers include creation complex genetic constructs individually introduced replacement. increase relative yield recombinant colonies achieved due transformation recombinant oligonucleotide jointly co-selective dna incapable intagreated chromosome. selection colonies based phenotypic resistance provided resistance marker coselective dna provides possibility selecting competent subpopulation cells increasing effectiveness method 10-2to 10-1recombinants. loss extra-chromosomal resistance marker provided either serial passages culture onto medium without antibiotic use counter-selective markers.effect: introduction point substitutions bacterial chromosome.9 cl, 2 dwg, 5 ex',\n",
              " 'strain bacteria bacillus thuringiensis, neutralising infectious activity human influenza virus a/h3n2 (versions)field: biotechnology.substance: invention relates novel strains bacillus thuringiensis b-1272 bacillus thuringiensis b-1273 deposited collection bacteria, bacteriophages fungi federal state-funded institution science \"state research centre virology biotechnology \"vector\". index neutralisation infectious activity virus a/h3n2 using preparations based culture fluid proposed strains 0.5-3.2 lg.effect: strains ability neutralise infectious activity human influenza virus.2 cl, 1 tbl, 8 ex',\n",
              " 'method producing bacteriophagefield: biotechnology.substance: invention relates production bacteriophage. disclosed method involves inoculation bacterial cell suspension titre 10-10cfu/ml dense nutrient medium layer thickness 3 25 mm cultivation foreign microflora, air layer thickness surface dense nutrient medium 5 50 mm optimum temperature host strain culture growth. 30-120 minutes beginning culturing every 30-60 minutes smears taken surface dense nutrient medium, coloured intercalating dye microscoped. cultivation stopped reaching least 10 % relation total amount cells host cell fraction strain heterogeneous fluorescent cytoplasm staining. obtained lawn host strain culture inoculated mother bacteriophage titre 10-10bfu/ml. cultivated 13-15 hours foreign microflora, air layer thickness surface dense nutrient medium 5 50 mm optimum temperature bacteriophage strain culture growth. obtained phage lysate suspending, sucked phage lysate sterile container cleaned. invention provides reaching stable high titre bacteriophage (10-10bfu/ml) producing phage lysates varying formulations nutrient media increasing span variation values culturing host strain bacteriophage.effect: invention used biotechnology obtaining products containing bacteriophages.9 cl',\n",
              " 'recombinant plasmid dna pest877 determining expression polypeptide activity esterase psychrobacter cryohalolentis k5on cell surface escherichia coli, bacteria strain escherichia coli bl21 (de3) plyss/pest877-producer polypeptide activity esterase psychrobacter cryohalolentis k5on cell surfacefield: biotechnology.substance: invention relates recombinant plasmid dna pest877 determining expression polypeptide activity esterase p. cryohalolentis k5t cell surface molar weight 3.64 md (5.519 kb) consisting ncoi/xhoi - dna fragment plasmid pet20b(+) length 3.654 kb, comprising promoter t7lac, bacteriophage t7 transcription terminator, gene bla ?-lactamase determines stability cells transformed plasmid pest877 ampicillin, site ori replication initiation, signal sequence pelb pectate lyase b erwinia carotovora; ncoi/xhoi-fragment dna size 1.865 kb containing fusion gene est877 encoding amino acid sequences esterase p. cryohalolentis k5t additional amino acid residue aspartic acid site cleavage signal peptide auto-transporter p. cryohalolentis k5t single reading frame. invention relates bacterial strain e. coli bl21(de3)plyss/pest877 - producer polypeptide activity esterase p. cryohalolentis k5t cell surface.effect: invention enables obtain highly active esterase wide substrate specificity.2 cl, 3 dwg, 7 ex',\n",
              " 'new methods displaying cyclic peptides bacteriophage particlesfield: biotechnology.substance: invention relates biotechnology. described method displaying cyclic peptide surface bacteriophage particle, comprising following steps: (a) providing host cell comprising nucleic acid sequence encoding precursor cyclic peptide; nucleic acid sequence encoding bacteriophage particle capsid protein; leader sequence recognized post-translational modification (ptm) system enzyme; one nucleic acid sequences encoding post-translational modification system enzyme lantypeptide synthase; (b) initiating enabling expression said cyclic peptide precursor; (c) enzymatic dehydration one amino acid residues precursor cyclic peptide; (d) forming one intramolecular bonds binding said one dehydrated residues cysteine lysine, thereby forming cyclic peptide; (e) obtaining bacteriophage particles said host cell, wherein said bacteriophage particles \"map\" said cyclic peptide surface, wherein said cyclic peptide attached c-end capsid protein said bacteriophage particles. invention relates nucleic acid molecule \"maps\" cyclic peptide surface bacteriophage particle, said nucleic acid encodes (a) capsid protein said bacteriophage particle; (b) leader sequence recognized post-translational modification (ptm) system enzyme, (c) cyclic peptide precursor, wherein nucleic acid coding cyclic peptide precursor located c-end capsid protein said bacteriophage particle, wherein said cyclic peptide precursor able form intramolecular linkage binding one dehydrated residues cysteine lysine. described bacteriophage particle \"maps\" surface cyclic peptide obtained said method, said cyclic peptide attached c-end capsid protein said bacteriophage particle. besides, genetically diverse library bacteriophage particles according para. 11, said bacteriophage particles \"maps\" cyclic peptide genetically diverse cyclic peptide library, wherein said cyclic peptides contain intramolecular linkage formed binding one dehydrated residues cysteine lysine.effect: invention extends range phage displays.13 cl, 5 dwg, 4 ex',\n",
              " \"test system genome detection rotavirus agent type agricultural animals means multiplex polymerase chain reaction fluorescent detection real timefield: biotechnology.substance: invention relates field biotechnology. described test system detecting genome rotavirus type agent agricultural animals using multiplex polymerase chain reaction fluorescent detection real time. test system comprises buffer conducting polymerase chain reaction, mixture carrying thereof, consisting deoxynucleoside triphosphates, primers fluorescent probes specific rotavirus a, mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase reverse transcriptase mmlv reverse transcriptase. mixture recombinant plasmid dna containing rva virus genome fragment bacteriophage ms2 genome fragment contains following nucleotide sequences: rvf5 5'-atttcagttgatgagacca-3'; forward primer; rvr6 5'-caattctaagcgtgagtcc-3' reverse primer; probe rvp fam – 5'-aatatgacaccagcggta-3' – bhq1,ms2f, 5'-tggcactacccctctccgtattcac-3' – forward primer; ms2r, 5'-gtacgggcgaccccacgatgac-3' – reverse primer; ms2p probe, cy5 5'-cacatcgatagatcaaggtgcctacaagc-3' bhq2.effect: invention extends range agents detecting genome rotavirus type agent agricultural animals.1 cl, 4 tbl, 1 ex\",\n",
              " 'bacteriophage bacillus anthracis f112pre strain used specific indication anthrax agentfield: biotechnology.substance: invention relates field biotechnology. invention bacillus anthracis f112pre bacteriophage strain, intended specific indication anthrax agent, deposited specialized museum collection strains branch state budgetary institution 48 central scientific research institute ministry defence russian federation.effect: invention enables create anthrax bacteriophage strain high species specificity anthrax microbe lyse closely related bacilli retains basic properties long period time.1 cl, 1 tbl, 4 ex',\n",
              " 'method detecting genotyping rna porcine reproductive-respiratory syndrome virusfield: biotechnology.substance: invention relates field biotechnology. invention method detecting genotyping rna porcine reproductive respiratory syndrome virus, involving rna extraction biological material infected pigs sorption method, synthesis cdna rna matrix staging single-step multiplex reverse transcription reaction polymerase chain reaction addition internal control sample based bacteriophage ms2 positive control sample, consisting internal control sample based bacteriophage ms2, european american genotypes porcine reproductive-respiratory syndrome virus, conducting 40 amplification cycles real-time detection using oligonucleotide primer reproductive-respiratory syndrome virus virus-specific viruses, fluorescent-labeled probes control samples, measuring accumulation fluorescent signal channels corresponding fluorescent dyes interpreting results based presence absence intersection fluorescence curve threshold line, according invention internal control sample suspension bacteriophage ms2 concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample, mixture containing nucleic acid fragments european american genotypes porcine reproductive respiratory syndrome virus native bacteriophage ms2 genome fragment taken ratio 1:1:1, wherein accumulation fluorescent signal measured channels: fam/green specific signal european genotype porcine reproductive respiratory syndrome virus; joe/yellow specific signal american genotype virus cy5/red internal control signal fluorescent signal accumulation curves 35 cycles, result reaction considered positive, curves cross threshold line cross 35 cycles, reaction result negative.effect: invention provides reliable diagnosis porcine reproductive respiratory syndrome detecting various serotypes virus.1 cl, 3 dwg, 4 tbl',\n",
              " 'method detection dna bordetlelosis (bordetella bronchiseptica) agent genome farm animalsfield: biotechnology.substance: invention relates field biotechnology. invention method detecting dna genome bordetella bronchiseptica exciter agricultural animals, involving dna recovery biological material sorption method, staged one-stage polymerase chain reaction – simultaneous carrying 40 amplification cycles real-time detection using oligonucleotide primers specific bordetella bronchiseptica genome, probes, dyes control samples form internal positive, measurement specific signal control signal channels corresponding dyes interpretation results, according invention, fluorescent detection carried out, measuring joe(hex)/yellow accumulation fluorescent signal specific dna signal bordetella bronchiseptica genome, fam/green channel signal internal control, interpretation results carried based presence/absence intersection fluorescence curve threshold line, curves accumulation fluorescent signal 35 cycles, result reaction considered positive, curves cross threshold line cross 35 cycles, result reaction negative , wherein internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample mixture recombinant plasmid dna containing fragment dna genome bordetella bronchiseptica fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables reliable diagnosis dna bordetella bronchiseptica.1 cl, 2 dwg, 4 tbl',\n",
              " 'method detecting dna leptospirosis (leptospira spp) causative agent farm animalsfield: biotechnology.substance: invention relates field biotechnology. invention method detecting dna leptospirosis agent (leptospira spp.) farm animals, involving recovering nucleic acid biological material infected animals sorption method, staged one-stage polymerase chain reaction simultaneous carrying 40 amplification cycles fluorescent detection using specific dna genome leptospirosis (leptospira spp.) causative agent oligonucleotide primers, probes, dyes control samples form internal positive, measurement joe(hex)/yellow channel, accumulation fluorescent signal specific signal testing presence dna genome leptospirarosis (leptospira spp.) causative agent, fam/green channel accumulation signal internal control sample, interpretation results based presence/absence intersection fluorescence curve threshold line, fluorescent signal accumulation curves 35 cycles, leptospirosis (leptospira spp.) dna present reaction result considered positive, curves cross threshold line cross 35 cycles, dna leptospirosis (leptospira spp.) causative agent absent result reaction negative, internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample mixture recombinant plasmid dna containing fragment genome leptospirosis (leptospira spp.lpts) fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables simplify detection leptospirosis causative agent.1 cl, 2 dwg, 4 tbl',\n",
              " 'method detecting dna avnithosis agent (chlamydophila psittaci) birdsfield: biotechnology.substance: invention relates field biotechnology. invention method detecting dna ornithosis agent (chlamydophila psittaci) birds, involving recovering dna biological material sorption method, polymerase chain reaction – addition internal positive control successively carrying 40 amplification cycles fluorescent detection real time using oligonucleotide primers, fluorescent-labeled probe, positive negative control samples dna-specific dna orbital pathogen (chlamydophila psittaci) specific dna segment , measuring accumulation fluorescent signal channels corresponding fluorescent dyes specific signal internal control signal interpreting results based presence/absence crossing fluorescence curve threshold line, according invention, biological material collected infected birds, wherein internal reference sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample – mixture recombinant plasmid dna, containing fragment genome dna exciter ornithosis (chlamydophila psittaci) fragment bacteriophage t4 genome, taken ratio 1:1, wherein accumulation fluorescent signal measured channels: joe(hex)/yellow specific dna signal ornithosis agent (chlamydophila psittaci) fam/green internal control signal, accumulation curves fluorescent signal 35 cycles, dna ornithosis agent (chlamydophila psittaci) present result reaction considered positive, curves cross threshold line cross 35 cycles, dna ornithosis agent (chlamydophilapsittaci) absent result reaction – negative.effect: invention enables authentically diagnosing ornithosis dna exciter (chlamydophila psittaci) birds.1 cl, 3 dwg, 4 tbl',\n",
              " \"method detection dna nodular dermatitis virus (lsdv) animal biological material means polymerase chain reaction real timefield: biotechnology.substance: invention relates field biotechnology. invention method detecting dna nodular dermatitis virus (lsdv) biological material animals using real-time polymerase chain reaction involving dna recovery infectious animal pathogen sorption method, staged one-stage polymerase chain reaction fluorescent detection 40 amplification cycles real time using oligonucleotide primers, probes, fluorescent dyes specific dna genome region causative agent infectious animal disease: specific animal signal fam/green internal control sample form bacteriophage t4 suspension concentration 5×10phage particles per 1 mcl, positive control sample form mixture containing volume ratio fragments animal genomes bacteriophage t4 nucleotide sequence: t4f: 5'-tacatataaatcacgcaaagc-3' – direct primer; t4r: 5'- tagtatggctaatcttattgg-3' – reverse primer; t4p: cy5-5'-acattggcactgaccgagttc-3'-bhq1 – probe, measurement accumulation fluorescent signals via channels corresponding fluorescent dyes, interpretation results based presence absence intersection fluorescence curve threshold line, fluorescence signal accumulation curves 35 cycles, reaction result considered positive, curves cross threshold line cross 35 cycles, result reaction negative, according invention, nodular dermatitis virus (lsdv) dna recovered animal's biological material, bacteriophage t4 phage lysate used internal control sample, positive control sample – fragments genomes native bacteriophage t4 fragment genome nodular dermatitis virus (lsdv) following nucleotide sequence: lsdv-f 5-tttaggagataagattgtcac-3' direct primer; lsdv-r 5'-ggagattttattatgagtggc-3' reverse primer; lsdv-p rox-5'-ggttaattttttaccacaaatagg-3'-bhq2 probe, wherein dna nodular dermatitis virus (lsdv) uses rox / orange fluorescent dye.effect: invention widens functional capabilities, increases sensitivity simplifies process preparing internal control sample.1 cl, 4 tbl\",\n",
              " 'method detecting dna rhinotracheitis virus (bovine herpes virus 1, bohv-1) cattlefield: biotechnology.substance: invention relates field biotechnology. invention method detecting dna rhinotracheitis virus (bovine herpes virus 1, bohv-1) cattle, involving dna recovery sorption method, staged one-stage polymerase chain reaction simultaneous amplification cycles real-time detection using oligonucleotide primers, probes, dyes control samples specific genome segment rhinotracheitis virus (bovine herpes virus i, bohv-1) form internal positive, measurement specific signal control signal via channels corresponding dyes interpretation results, according invention, fluorescent detection carried out, measuring joe(hex)/yellow accumulation fluorescent signal specific dna signal rhinotracheitis virus (bovine herpes virus 1, bohv-1), fam/green channel signal internal control sample interpretation results carried based presence/absence intersection fluorescence curve threshold line, accumulation curves fluorescent signal reach 35th cycle, result reaction considered positive, curves cross threshold line cross 35 cycles, reaction result negative, wherein internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample used mixture recombinant plasmid dna containing fragment genome dna rhinotracheitis virus (bovine herpes virus 1, bohv-1) fragment genome bacteriophage t4, taken ratio 1:1.effect: invention enables authentically diagnosing causative agent cattle rhinotracheitis virus dna.1 cl, 3 dwg, 4 tbl',\n",
              " 'method detecting rna arteritis virus agent horsesfield: biotechnology.substance: invention relates field biotechnology. invention method detecting rna agent arteritis virus horses, involving rna extraction biological material infected individuals sorption method, synthesis cdna rna matrix single-step staging addition internal positive controls samples multiplex reverse transcription reaction polymerase chain reaction 45 cycles amplification real-time detection using oligonucleotide primer-specific oligonucleotide primers, fluorescent-labeled probe control samples, measuring accumulation fluorescent signal channels corresponding fluorescent dyes interpreting results based presence absence intersection fluorescence curve threshold line – threshold, according invention, biological material animals used rna extraction choice: form discharge nose, eyes, faeces, blood, sperm fragments internal organs tissues taken horses infected arteritis virus (equine arteritis virus) agent, wherein internal control sample suspension bacteriophage ms2 concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample, mixture recombinant plasmid dna containing fragment genome horse arteritis virus (equine arteritis virus) fragment bacteriophage ms2 genome, taken ratio 1:1, fam/green specific signal; cy5/red internal control signal, accumulation curves fluorescent signal reach 35th cycle, result reaction considered positive, curves cross threshold line cross 35 cycles, reaction result negative.effect: invention allows expand functional capabilities conduct reliable diagnostics disease.1 cl, 3 dwg, 4 tbl',\n",
              " 'method detecting salmonella (salmonella spp) dna biological material animals, food animal vegetable foddersfield: biotechnology.substance: invention relates field biotechnology. invention method detecting salmonella dna (salmonella spp.) biological material, food fodders animal vegetable origin, involving dna recovery sorption method, staged one-stage polymerase chain reaction – simultaneous amplification cycles real-time detection using salmonella-specific (salmonella spp.) oligonucleotide primers, probes, dyes control samples form internal positive, measurement specific signal control signal channels corresponding dyes interpretation results, according invention, fluorescent detection carried out, measuring joe(hex)/yellow channel accumulating fluorescent signal specific salmonella (salmonella spp.) dna signal, fam/green channel internal control sample signal, accumulation curves fluorescent signal reach 35th cycle, result reaction considered positive, curves cross threshold line cross 35 cycles, result reaction negative, interpretation results carried based presence/absence intersection fluorescence curve threshold line, wherein internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample mixture recombinant plasmid dna containing fragment genome salmonella (salmonella spp.) dna fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables reliable diagnosis salmonella (salmonella spp) dna exciter biological material, food products fodders animal plant origin.1 cl, 3 dwg, 4 tbl',\n",
              " 'method detecting provirus dna bovine leukosis virus (blv)field: biotechnology.substance: invention relates field biotechnology. invention method detecting provirus dna bovine leukosis virus (blv), involving dna recovery biological material infected animals sorption method, staged one-stage polymerase chain reaction simultaneous amplification cycles detection oligonucleotide primers, probes, dyes control samples form internal positive, specific provirus genome bovine leukosis virus (blv), measurement specific signal control signal via channels corresponding dyes interpretation results, according invention, fluorescent detection carried out, joe(hex)/yellow accumulation fluorescent signal measured specific signal testing presence provirus genome bovine leukosis virus (blv), fam/green channel signal internal control sample interpreting results based presence/absence intersection fluorescence curve threshold line, accumulation curves fluorescent signal reach 35th cycle, result reaction considered positive, curves cross threshold line cross 35 cycles, reaction result negative, wherein internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample mixture recombinant plasmid dna containing fragment provirus genome bovine leukosis virus (blv) fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables authentically diagnosing detection provirus genome bovine leukosis virus (blv) early detection leukemia.1 cl, 2 dwg, 4 tbl',\n",
              " 'method determining dna nodular dermatitis virus (lsdv) biological material animals pcr electrophoretic detection amplification products agarose gelfield: biotechnology.substance: invention relates field biotechnology. invention method determining dna nodular dermatitis virus (lsdv) biological material animals pcr electrophoretic detection amplification products agarose gel, involving dna isolation infectious disease agent biological material infected animal sorption method, polymerase chain reaction fluorescent detection 40 cycles amplification using oligonucleotide primer dna-specific dna infectious agent causative agent dna, fluorescent dye, internal control sample form suspension bacteriophage t4 concentration 5 × 10phage particles per 1 mcl positive control sample form mixture containing volume ratio fragments genomes causative agent infectious animal disease bacteriophage t4, according invention, dna nodular dermatitis virus (lsdv) recovered biological material animals, performing electrophoretic detection amplification products agarose gel obtaining electrophoregram dna specific bands amplified product, visualizing colouring fluorescent dye, according recording interpretation pcr results carried presence absence specific strand dna fragment nodular dermatitis virus, coinciding size band fragment dna, amplified positive control sample, wherein mixture recombinant plasmid dna containing dna fragment nodular dermatitis virus fragment bacteriophage t4 genome following nucleotide sequences used.effect: invention widens functional capabilities detecting residual amount dna nodular dermatitis virus.1 cl, 6 tbl',\n",
              " 'method determining species identity tissues chickens pigs food raw materials, fodder food productsfield: biotechnology.substance: invention relates field biotechnology. invention method determining species identity tissues chickens pigs food raw materials, fodder food products, involving extraction dna chicken tissues (gallus gallus) pig (sus scrofa) sorption method, stating polymerase chain reaction detection amplification products using specific dna genome regions chicken (gallus gallus) pig (sus scrofa) oligonucleotide primers, probes, dyes, internal control sample positive control samples, measurement specific signals control signals interpretation results, according invention, single-stage polymerase chain reaction carried fluorescent detection using thermal cycler rotor-gene q type measure accumulation fluorescent signals channels corresponding fluorescent dyes: joe/yellow specific signal pig tissues (sus scrofa); fam/green – chicken tissues (gallus gallus) cy5/red – internal control sample, interpretation results carried based presence absence intersection fluorescence curve threshold line, curves accumulation fluorescent signal 35 cycles, result reaction considered positive, curves cross threshold line cross 35 cycles, result reaction negative, wherein internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample – mixture containing fragments genomes chicken tissues (gallus gallus), pig tissues (sus scrofa) bacteriophage t4, taken ratio 1:1:1.effect: invention makes possible increase accuracy identification species affiliation chicken pigs tissues.1 cl, 5 dwg, 5 tbl',\n",
              " \"method detecting rna schmallenberg disease virus farm animalsfield: biotechnology.substance: invention relates field biotechnology. invention method extracting rna biological material choice: whole blood, blood serum, tissue organ fragments sorption method, synthesis cdna rna matrix single-step staging addition internal positive control samples multiplex reverse transcription reaction polymerase chain reaction – 45 amplification cycles real-time detection using oligonucleotide primers schmallenberg virus specific region genome fluorescent-labeled probe control samples, measuring accumulation fluorescent signal channels corresponding fluorescent dyes interpreting results based presence/absence intersection fluorescence curve threshold line threshold, according invention internal control sample suspension bacteriophage ms2 concentration 5 × 10copies nucleotide sequences per 1 mcl, positive control sample, mixture recombinant plasmid dna containing fragment genome schmallenberg virus exciter fragment bacteriophage ms2 genome taken ratio 1:1, following nucleotide sequences: shm-f 5 'tcagattgtcatgccccttgc 3' – forward primer; shm-r 5' tcggccccaggtgcaaatc 3' – reverse primer; shm-z joe-accatcggcccaggtgcatccctta-bhq1 – probe; ms2f, 5'-tggcactacccctctccgtattcac-3 – forward primer; ms2r, 5'-gtacgggcgaccccacgatgac-3' – reverse primer; ms2p, 5'-cy5-cacatcgatagatcaaggtgcctacaagc-3' bhq2 – probe, wherein accumulation fluorescent signal measured channels: joe/yellow specific signal schmallenberg virus agent; cy5/red internal control signal, fluorescence signal accumulation curves 35 cycles, result reaction considered positive, curves cross threshold line cross 35 cycles, result reaction negative.effect: invention enables higher diagnostic accuracy method detecting rna schmallenberg disease virus farm animals.1 cl, 4 tbl, 3 dwg\",\n",
              " 'method identification dna domestic dog tissue (canis lupus familiaris) dry fodder meat semi-productsfield: biotechnology.substance: invention relates field biotechnology. invention method identification dna domestic dog tissue (canis lupus familiaris) dry fodder meat semi-products, involving dna recovery animal tissue sorption method, polymerase chain reaction fluorescent detection carried 45 cycles real-time amplification using oligonucleotide primers, probes, fluorescent dyes specific dna genome region: specific signal animal cy5/red internal control sample form suspension bacteriophage t4 concentration 5 × 10of phage particles per 1 mcl, positive control sample form mixture containing fragments animal genomes bacteriophage t4 nucleotide sequence: t4f tacatataaatcacgcaaagct4r tagtatggctaatcttattgg t4p cy5 acattggcactgaccgagttc, taken ratio 1:1, measurement accumulation fluorescent signals via channels corresponding fluorescent dyes, interpretation results based presence absence intersection fluorescence curve threshold line, fluorescent signal accumulation curves extend 35 cycles, result reaction considered positive, curves cross threshold line cross 35 cycles, result reaction negative, according invention, dna recovered domestic dog tissue (canis lupus familiaris) internal control sample t4 bacterial phagolysate, positive control sample - native t4 bacteriophage genome fragments domestic dog tissue (canis lupus familiaris) following nucleotide sequence: canis f attcggcctacatccgtgac forward primer canis agaagacccctgctacgact reverse primer canis p fam-cttgagtggagtagggcgg-bhq1 probe, wherein dna dog tissue fluorescent dye fam/green used.effect: invention makes possible increase accuracy species identity identification simplify sampling process.1 cl, 5 tbl',\n",
              " 'method identification domestic cat tissue dna (felis silvestris catus) dry fodders semi-finished meat productsfield: biotechnology.substance: invention relates field biotechnology. invention method identification domestic cat tissue dna (félis silvéstris cátus) dry fodder semi-finished meat products, involving extraction dna animal tissue sorption method, polymerase chain reaction fluorescent detection carried 45 cycles real-time amplification using oligonucleotide primers, probes, fluorescent dyes specific dna genome region: specific signal animal - joe/yellow cy5/red - internal control sample form suspension bacteriophage t4 concentration 5 × 10phage particles per 1 mcl, positive control sample form mixture containing fragments animal genomes bacteriophage t4 nucleotide sequence: t4f tacatataaatcacgcaaagc t4r tagtatggctaatcttattgg t4p cy5 acattggcactgaccgagttc, taken ratio 1:1 measuring accumulation fluorescent signals channels corresponding fluorescent dyes, performing interpretation results based presence absence intersection fluorescence curve threshold line, fluorescence signal accumulation curves 35 cycles, reaction result considered positive, curves cross threshold line cross 35 cycles, result reaction negative, according invention, dna recovered domestic cat tissue (félis silvéstris cátus) internal control sample phagolysate bacteriophage t4, positive control sample - fragments genomes native bacteriophage t4 domestic cat tissue (félis silvéstris cátus) following nucleotide sequence: félis f attcggcctacatccgtgac forward primer félis agaagacccctgctacgact reverse primer félis p r6g-cttgagtggagtagggcgg-bhq1 probe.effect: invention makes possible increase accuracy cat tissue species identification, simplify sample preparation process.1 cl, 5 tbl',\n",
              " 'method storing anthrax bacteriophages contact-sorption drying (dehydration) ion-exchange resin kb-4p-2 gradefield: biotechnology.substance: invention relates field biotechnology. invention method involves preparing protective medium (sucrose-gelatine containing 10 % sucrose 2 % gelatine); growing indicator strain bacillus anthracis sti-1 propagation anthrax bacteriophage; obtaining concentrated suspension anthrax bacteriophage double-layer agar method, extracting negative colonies upper, semi-liquid protective agar, sucrose-gelatinous medium; preparing ion-exchange resin penicillin bottles; sparing drying (dehydration) applying concentrated suspension anthrax bacteriophage protective medium temperature 0 °c sorbent - ion-exchange resin kb-4p-2 grade, dried weight fraction moisture 1÷3 % optimum ratio suspension bacteriophage resin -1:7; storage dried cultures anthrax bacteriophage penicillin bottles temperature 2÷6 °c.effect: declared method allows long-term storage cultures anthrax bacteriophages use resuspension resuspension temperature 0°c meat-peptone broth (mpb) obtaining diagnostic preparations used indication identification anthrax agent areas microbiology.1 cl, 2 tbl, 2 ex',\n",
              " 'recombinant plasmid dna pet21-npve containing nucleoloprotein (np) gene ebola virus recombinant protein np-ve, obtained result expression np gene ebola virus using recombinant plasmid dna pet21-npve possessing immunogenic antigenic propertiesfield: biotechnology.substance: invention relates field biotechnology. invention recombinant plasmid dna pet21-npve expression nucleoprotein gene np ebola virus (zaire strain, mayinga isolate) prokaryotic system ofe.coliand producing recombinant protein np-ve, size 7593 base pairs contains:blagene (coordinates 599 1459 base pairs) genetic marker; replication starting point ori (coordinates 1630 2218 base pairs); phage t7 promoter (coordinates 5117 5135 base pairs; lactose repressor (coordinates 3648 base pairs 4730 base pairs); dna-binding protein inhibits expression ofe.coligenes provides expression target recombinant np-ve protein addition isopropyl-β-d-1-thiogalactopyranoside (iptg); unique recognition sites restriction endonucleases, following coordinates: nhei(5209 base pair) xho i(7432 base pairs); full-length np gene ebola virus (mayinga isolate, zaire strain) 2217 base pairs (from 470 2686 nucleotide genomic rna), built expression cassette bynheirestriction sites (5209 base pair) xhoi(7432 base pairs), encodes 739 amino acid residues (ao) viral nucleoprotein; sequence (18 base pairs), encoding polyhistidine (6xhis) polithract six histidines n-end encoded protein subsequent purification affinity n-chromatography recombinant np-ve protein produced result ebola virus nucleoprotein np gene expression (zaire strain, mayinga isolate) bacterial expression systeme.coliin recombinant dna construct pet21-npve calculated molecular weight 84457.42 da, amino acid sequence seq id no: 1 length 748 amino-acid residues, including 6xhis, stop codon, immunogenic antigenic properties, intended induction body balb/c mice antibodies recognizing immunochemical reactions viral protein np-ve, well interacting mouse monoclonal antibodies, polyclonal goat human antibodies specific inactivated infectious virus, respectively.effect: invention increases output target recombinant protein np-ve.2 cl, 3 tbl, 14 dwg',\n",
              " 'test system detecting rna agent arteritis virus horsesfield: biotechnology.substance: invention relates field biotechnology. invention test system detecting rna arteritis virus agent horses, comprising buffer carrying polymerase chain reaction fluorescent detection real time, mixture carrying out, consisting deoxynucleoside triphosphates, primers fluorescent probes specific infection virus agent internal control sample; mixture enzymes dna polymerase antibodies inhibiting activity taq polymerase enzyme; rna dilution buffer, internal control sample, negative control sample, positive control sample, according invention, biological material extracted arteritis virus (equine viral arteritis – eav) infected horses used rna isolation, wherein internal control sample suspension bacteriophage ms2 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample – mixture recombinant plasmid dna containing fragment genome arteritis virus (equine viral arteritis – eav) horses fragment genome bacteriophage ms2, taken ratio 1:1.effect: invention enables authentically diagnosing rna arteritis virus agent horses.1 cl, 3 dwg, 4 tbl',\n",
              " 'test system detecting genotyping rna swine reproductive-respiratory syndrome virusfield: biotechnology.substance: invention relates field biotechnology. invention test system detecting genotyping rna virus porcine reproductive respiratory syndrome, comprising buffer polymerase chain reaction, mixture carrying out, consisting deoxynucleoside triphosphates, primers fluorescent probes, specific swine reproductive respiratory syndrome virus, taq polymerase; rna dilution buffer, internal control sample based bacteriophage ms2 positive control sample consisting internal control sample based bacteriophage ms2, european american genotypes porcine reproductive-respiratory syndrome virus control samples, according invention internal control sample suspension bacteriophage ms2 concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample, mixture containing nucleic acid fragments european american genotypes swine reproductive respiratory syndrome virus fragment native bacteriophage ms2 genome taken ratio 1:1:1 used.effect: invention provides reliable diagnosis porcine reproductive respiratory syndrome detecting various serotypes virus.1 cl, 3 dwg, 4 tbl',\n",
              " 'test system detecting dna bird flu ornithosis (chlamydophila psittaci) birdsfield: biotechnology.substance: invention relates field biotechnology. invention test system detecting dna ornithosis agent (chlamydophila psittaci) birds, comprising plastic bottles test tubes, thermostable tag-polymerase enzyme, reaction-setting buffer, mixture four deoxynucleotide triphosphates, internal control sample, positive control sample, recombinant plasmid containing gene fragment ornithosis agent (chlamydophila psittaci), synthetic oligonucleotide primers dyes labeled dyes, according invention, internal control sample, bacteriophage t4 suspension concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample – mixture recombinant plasmid dna containing fragment genome ornithosis dna (chlamydophila psittaci) fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables authentically diagnosing ornithosis dna exciter (chlamydophila psittaci) birds.1 cl, 3 dwg, 4 tbl',\n",
              " 'test system detecting dna rhinotracheitis virus (bovine herpes virus 1, bohv-1) cattlefield: biotechnology.substance: invention relates field biotechnology. invention test system detecting dna rhinotracheitis virus (bovine herpes virus 1, bohv-1) cattle, includes plastic flasks test tubes, thermostable enzyme tag-polymerase, reaction buffer, mixture four deoxynucleotide triphosphates, internal control sample, positive control sample, recombinant plasmid containing gene fragment rhinotracheitis virus, synthetic oligonucleotide primers probes marked dyes, according invention internal control sample bacteriophage t4 suspension concentration 5×10copies nucleotide sequences 1 mcl, positive control sample mixture recombinant plasmid dna containing fragment dna genome rhinotracheitis virus (bovine herpes virus 1, bohv-1) fragment genome bacteriophage t4, taken ratio 1:1.effect: invention enables authentically diagnosing causative agent cattle rhinotracheitis virus dna.1 cl, 3 dwg, 4 tbl',\n",
              " 'test system detecting provirus dna bovine leukosis virus (blv)field: biotechnology.substance: invention relates field biotechnology. invention test system detecting provirus dna bovine leukosis virus (blv), comprising plastic bottles test tubes, thermostable tag-polymerase enzyme, reaction setting buffer, mixture four deoxynucleotide triphosphates, internal control sample, positive control sample – recombinant plasmid containing fragment genome dna bovine leucosis provirus, synthetic oligonucleotide primers dyes marked dyes, according invention internal control sample bacteriophage t4 suspension concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample – mixture recombinant plasmid dna containing fragment genome dna bovine leucosis provirus fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables authentically diagnosing bovine leukosis provirus (blv) gene early detection leukemia.1 cl, 2 dwg, 4 tbl',\n",
              " 'test system detecting salmonella (salmonella spp.) dna animal biological material, food products animal vegetable foddersfield: biotechnology.substance: invention relates field biotechnology. invention test system detecting salmonella (salmonella spp.) dna biological material, food animal vegetable fodders, including plastic flasks test tubes, thermostable tag-polymerase enzyme, reaction buffer, mixture four deoxynucleotide triphosphates, internal control sample, positive control – recombinant plasmid containing gene fragment salmonella excipient (salmonella spp.), synthetic oligonucleotide primers probes, according invention internal control sample bacteriophage t4 suspension concentration 5×10copies nucleotide sequences 1 mcl, positive control sample – mixture recombinant plasmid dna containing fragment dna genome salmonella (salmonella spp.) fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables reliable diagnosis salmonella excipient (salmonella spp) dna biological material, food products animal vegetable fodders.1 cl, 3 dwg, 4 tbl',\n",
              " 'test system detecting brucella infection agent (brucella spp) genome farm animalsfield: biotechnology.substance: invention relates field biotechnology. invention test system detecting genome brucella infection agent (brucella spp.) farm animals real-time polymerase chain reaction comprising plastic bottles test tubes, thermostable tag-polymerase enzyme, reaction buffer, mixture four deoxynucleotide triphosphates, internal control sample, positive control – recombinant plasmid containing fragment brucella spp gene, synthetic oligonucleotide primers probes marked dyes, according invention internal control sample bacteriophage t4 suspension concentration 5×10copies nucleotide sequences 1 mcl, positive control sample – mixture recombinant plasmid dna containing dna fragment dna genome brucella spp dna fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables reliable diagnosis brucella spp dna exciter.1 cl, 4 tbl',\n",
              " 'test system determining species affiliation tissues chickens pigs food raw materials, fodder food productsfield: biotechnology.substance: invention relates field biotechnology. invention test system determining species identity tissues chickens pigs food raw materials, fodder food products test system determining species identity tissues chickens pigs food raw materials, fodder food products, including plastic bottles test tubes, thermostable enzyme tag-polymerase, reaction buffer, mixture four deoxynucleotide triphosphates, specific dna segments several oligonucleotide primers, probes, internal control sample form bacteriophage suspension positive control samples – containing fragments dna genomes several types meat, according invention, meat genome represented chicken tissues (gallus gallus) pig (sus scrofa), wherein internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample – mixture containing fragments genomes chicken tissues ({gallus gallus) pig (sus scrofa) bacteriophage t4, taken ratio 1:1:1.effect: invention allows expand functional capabilities increase accuracy identification species identity pigs hens tissues.1 cl, 5 dwg, 5 tbl',\n",
              " 'test system detecting genome causative agent bordetella bronchiseptica dna farm livestockfield: biotechnology.substance: invention relates field biotechnology. invention test system dna detection genome brucella spp infection agent farm livestock means polymerase chain reaction real time, including plastic bottles test tubes, thermostable enzyme tag-polymerase, reaction buffer, mixture four deoxynucleotide triphosphates, internal control sample, positive control – recombinant plasmid containing fragment brucella spp gene, synthetic oligonucleotide primers probes marked dyes, according invention internal control sample bacteriophage t4 suspension concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample – mixture recombinant plasmid dna containing fragment dna genome brucella spp fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables reliable diagnosing bordetella bronchiseptica dna exciter.1 cl, 2 dwg, 4 tbl',\n",
              " \"test system identification bear tissue (ursus) dry fodder semi-finished meat productsfield: biotechnology.substance: invention relates field biotechnology. invention test system identification dna bear tissue (ursus) dry fodder meat semi-products, comprising buffer carrying polymerase chain reaction, mixture carrying thereof, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes specific animal genome region internal control sample; mixture enzymes dna polymerase enzyme inhibiting antibodies, taq polymerase, internal control sample form bacteriophage t4 suspension concentration 5×10phagic particles per 1 mcl, negative control sample mixture recombinant plasmid dna containing fragment animal's genome fragment bacteriophage t4 genome.effect: invention used expand functional capabilities increase accuracy identification species identity, simplify sample preparation process.1 cl, 5 tbl\",\n",
              " \"test system identification dna domestic cat tissue (felis silvestris catus) dry fodder semi-finished meat productsfield: biotechnology.substance: invention relates field biotechnology. invention test system identification domestic cat tissue dna (félis silvéstris cátus) dry fodders semi-finished meat products, including polymerase chain reaction buffer, mixture carrying out, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes, specific section animal's genome internal control sample; mixture enzymes dna polymerase enzyme inhibiting enzymes, taq polymerase, internal control sample form suspension bacteriophage t4 concentration 5 × 10phage particles per 1 mcl, negative control sample, mixture recombinant plasmid dna, containing fragment animal's genome fragment bacteriophage t4 genome nucleotide sequence: t4f: 5'-tacatataaatcacgcaaagc-3' - forward primer; t4r: 5'-tagtatggctaatcttattgg-3' - reverse primer; t4p: cy-5'-acattggcactgaccgagttc-3'-bhq1 - probe, taken volume ratio 1:1, according invention internal control sample phagolysate bacteriophage t4, positive control sample fragments genomes native bacteriophage t4 domestic cat (félis silvéstris cátus) used following nucleotide sequence: félis f attcggcctacatccgtgac - forward primer; félis agaagacccctgctacgact - reverse primer; félis p r6g-cttgagtggagtagggcgg-bhq1 - probe.effect: invention allows expand functional capabilities increase accuracy species identity identification, simplify sample preparation process.1 cl, 5 tbl\",\n",
              " 'test system identification mutton beef species identity food raw material, fodder food productsfield: biotechnology.substance: invention relates field biotechnology. invention test system identification species mutton beef food raw materials, fodder food products, including plastic flasks test tubes, thermostable enzyme tag-polymerase, reaction buffer, mixture four deoxynucleotide triphosphate, mutton (ovis) dna segment beef (bos) regions specific oligonucleotide primers, probes, internal control sample form bacteriophage suspension positive control samples containing dna fragments mutton (ovis) beef (bos) genes, according invention internal control sample bacteriophage t4 suspension concentration 5×10 copies nucleotide sequences per 1 mcl, positive control sample – mixture containing fragments mutton genomes (ovis), beef (bos) bacteriophage t4, taken ratio 1:1:1.effect: invention makes possible increase accuracy beef mutton species identity identification.1 cl, 5 dwg, 5 tbl',\n",
              " \"test system determination woodpecker (picidae) dna dry fodder semi-finished meat productsfield: biotechnology.substance: invention relates field biotechnology. invention test system identifying dna woodpecker tissue (picidae) dry fodder meat semi-products, comprising buffer carrying polymerase chain reaction, mixture carrying thereof, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes specific animal genome region internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase, internal control sample form suspension bacteriophage t4 concentration 5×10phage particles per 1 mcl, negative control sample, mixture recombinant plasmid dna containing fragment animal's genome fragment bacteriophage t4 genome nucleotide sequence, taken volume ratio 1:1, according invention, phagolysate bacteriophage t4 used internal control sample, positive control sample fragments genomes native bacteriophage t4 woodpecker (picidae) following nucleotide sequence used.effect: invention widens functional capabilities accuracy identification species identity, simplifies preparation process.1 cl, 5 tbl, 1 dwg\",\n",
              " \"test system identification dna tissues rats mice dry fodder meat semi-productsfield: biotechnology.substance: invention relates field biotechnology. invention test system identifying tissue dna rats (rattus) mice (mus musculus) dry fodder meat semi-products, including buffer polymerase chain reaction, mixture carrying out, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes, specific section animal's genome internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase, internal control sample form bacteriophage t4 suspension concentration 5×10phagic particles per 1 mcl, negative control sample mixture recombinant plasmid dna, containing fragment animal's genome fragment bacteriophage t4 genome nucleotide sequence: t4f tacatataaatcacgcaaagc – forward primer, t4r tagtatggctaatcttattgg – reverse primer, t4p fam acattggcactgaccgagttc bhq1 – probe, according invention, phagolysate bacteriophage t4 used internal control sample, positive control sample fragments genomes native bacteriophage t4 rats (rattus) mice (mus musculus) taken volume ratio 1:1:1 following nucleotide sequence used: rat-f: 5'-gccttcctaccattcctgcat-3' – forward primer, rat-r: 5'-aggaggttggctactaggat-3' – reverse primer, rat-p: 5'-fam-acgcagcttaacattccgccca-3'-bhq1 – probe, mus-f: 5'-gttgctttgtctactgag-3' – forward primer, mus-r: 5'-acctgaaacattggagta-3' – reverse primer, mus-p: pam-5'-tcgcagtcatagccacagca-3-bhq1 – probe.effect: invention allows expand functional capabilities, increase accuracy identification species identity.1 cl, 5 tbl\",\n",
              " \"test system identification dna domestic dog tissue (canis lupus familiaris) dry fodder semi-finished meat productsfield: biotechnology.substance: invention relates field biotechnology. invention presents test system identification dna domestic dog tissue (canis lupus familiaris) dry fodders semi-finished meat products, including polymerase chain reaction buffer, mixture thereof, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes specific region animal genome internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase, internal control sample form suspension bacteriophage t4 concentration 5 × 10phage particles per 1 mcl, negative control sample representing mixture recombinant plasmid dna containing fragment animal's genome fragment bacteriophage t4 genome nucleotide sequence: t4f: 5' - tacatataaatcacgcaaagc-3' - forward primer; t4r: 5' - tagtatggctaatcttattgg-3' - reverse primer; t4p: su5-5' - acattggcactgaccgagttc-3'-bhq1 - probe, taken volume ratio 1:1, according invention internal control sample phagolysate bacteriophage t4, positive control sample fragments genomes native bacteriophage t4 domestic dog (canis lupus familiaris) following nucleotide sequence used: canis f attcggcctacatccgtgac forward primer; canis agaagacccctgctacgact reverse primer; canis p fam-cttgagtggagtagggcgg - bhq1 probe.effect: invention widens functional capabilities accuracy identification species identity, simplifies sampling process.1 cl, 5 tbl\",\n",
              " 'strain bacteriophage pseudomonas aeruginosa n 328 (500322), intended preparation mono- polyvalent treatment-and-prophylactic preparations bacteriophagesfield: biotechnology.substance: invention relates field biotechnology. invention relates strain bacteriophage pseudomonas aeruginosa used production medical biological antibacterial drugs – preparations bacteriophages intended prevention treatment pyoinflammatory enteral diseases caused bacteria pseudomonas aeruginosa. strain lytic activity pseudomonas aeruginosa pulp viruses. strain deposited state collection pathogenic microorganisms (gkpm) federal state budgetary institution \"scientific centre expert evaluation medicinal products” ministry health russian federation (fsbi \"sceemp\" russian ministry health) registration no. 328 (500322).effect: strain wide spectrum antibacterial activity relation epidemiologically significant hospital isolated patients various pathologies clinical strains pathogenic bacteria pseudomonas aeruginosa, 100 % resistant one antibiotics, obtained maximum extension geography isolation regions.1 cl, 4 ex, 1 dwg',\n",
              " 'test system detecting chlamydial dna livestock animals birdsfield: biotechnology.substance: invention relates field biotechnology. invention relates test system detecting genome chlamydia dna excitant livestock animals birds, comprising plastic bottles test tubes, thermally stable tag-polymerase enzyme, reaction setting buffer, mixture four deoxynucleotide triphosphates, internal control sample, positive control – recombinant plasmid containing gene fragment chlamydial agent, synthetic oligonucleotide primers dyes marked dyes, according invention internal control sample bacteriophage t4 suspension concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample – mixture recombinant plasmid dna containing dna fragment chlamydia fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables reliable diagnosing chlamydial agent dna broader functional capabilities.1 cl, 3 dwg, 4 tbl',\n",
              " 'method detecting dna chlomydia farm animals birdsfield: biotechnology.substance: invention relates field biotechnology. invention represents method detecting dna chlamydia farm animals birds, involving chlamydia dna extraction chlamydia spp. biological material infected animals sorption method, polymerase chain reaction – addition internal positive control 45 amplification cycles fluorescent detection real time using chlamydia specific chlamydia spp. oligonucleotide primers, fluorescent-labeled probe, positive negative control samples, measuring accumulation fluorescent signal channels corresponding fluorescent dyes specific signal internal control signal interpreting results based presence/absence crossing fluorescence curve threshold line, according invention, biological material additionally taken infected birds, wherein internal control sample bacteriophage t4 suspension concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample – mixture recombinant plasmid dna containing fragment dna genome chlamydia dna fragment bacteriophage t4 genome, taken ratio 1:1, wherein accumulation fluorescent signal measured channels: joe(hex)/yellow specific chlamydia dna signal chlamydia spp; fam/green internal control sample signal, fluorescence signal accumulation curves 35 cycles, result reaction considered positive, curves cross threshold line cross 35 cycles, reaction result negative.effect: invention provides accurate diagnosis presence chlamydia dna exciter broader functional capabilities.1 cl, 3 dwg, 4 tbl',\n",
              " 'method detecting genome brucella infection agent (brucella speciales) farm animalsfield: biotechnology.substance: invention represents method detecting genome brucellosis infection agent (brucella spp.) agricultural animals, involving recovering dna biological material infected animals sorption method, staged one-stage polymerase chain reaction – simultaneous amplification cycles real-time detection using oligonucleotide primers specific genome region (brucella spp.), probes, dyes control samples form internal positive, measurement specific signal control signal channels corresponding dyes interpretation results, fluorescent detection carried out, measuring joe(hex)/yellow accumulation fluorescent signal specific signal testing genome brucellosis infection agent (brucella spp.), fam/green channel – signal internal control sample, fluorescence signal accumulation curves 35 cycle, result reaction considered positive, curves cross threshold line cross 35 cycles, result reaction negative, interpretation results carried based presence/absence intersection fluorescence curve threshold line, wherein internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample mixture recombinant plasmid dna containing dna fragment brucella spp. dna used fragment bacteriophage t4 genome, taken ratio 1:1, following nucleotide sequences: b7f tgaagctgcctgcatcggtc – forward primer, b7r cataatggccgggtgttggct – reverse primer, b7p hex-caacagcatgcagcttggtcgtcaatc-bhq1 – probe, t4f tacatataaatcacgcaaagc – forward primer, t4r tagtatggctaatcttattgg – reverse primer, t4p fam acattggcactgaccgagttc – probe.effect: invention enables reliable diagnosis brucella speciales dna exciter.1 cl, 3 dwg, 4 tbl',\n",
              " \"method detection dna donkey (equus asinus) tissue dry fodder semi-finished meat productsfield: biotechnology.substance: invention represents method dna identification donkey tissue (equus asinus) dry fodder semi-finished meat products, involving dna recovery animal tissue sorption method, polymerase chain reaction fluorescent detection carried 45 cycles real-time amplification using oligonucleotide primers, probes, fluorescent dyes specific dna genome region: specific signal animal cy5 / red internal control sample form suspension bacteriophage t4 concentration 5×10phage particles per 1 mcl, positive control sample form mixture containing fragments animal genomes bacteriophage t4 nucleotide sequence: t4f tacatataaatcacgcaaagc – forward primer; t4r tagtatggctaatcttattgg – reverse primer; t4p cy5 acattggcactgaccgagttc – probe, taken ratio 1:1, measurement accumulation fluorescent signals via channels corresponding fluorescent dyes, interpretation results based presence absence intersection fluorescence curve threshold line, fluorescence signal accumulation curves 35 cycles, reaction result considered positive, curves cross threshold line cross 35 cycles, result reaction negative, according invention, dna recovered donkey tissue (equus asinus), internal control sample used phagolysate bacteriophage t4, positive control sample – fragments genomes native bacteriophage t4 donkey tissue (equus asinus) following nucleotide sequence: donk f: 5'- catatcttaatcccaataatagac-3' – forward primer; donk r: 5'- agtattcgttctgatataggc-3' – reverse primer; donk p: pam-5'- atcttatactggactattctatcgac-3 -bhq1 – probe, wherein dna detection donkey tissue (equus asinus) employs fluorescent dye fam / green.effect: invention increases accuracy identification species identity simplifies process preparing samples.1 cl, 5 tbl\",\n",
              " 'test system determining dna nodular dermatitis virus (lsdv) biological material animals pcr electrophoretic detection amplification products agarose gelfield: biotechnology.substance: invention represents test system detecting dna nodular dermatitis virus (lsdv) biological material animals pcr method electrophoretic detection amplification products agarose gel, including pcr buffer, mixture thereof, consisting deoxynucleoside triphosphates, oligonucleotide primers specific genome region causative agent infectious disease internal control sample form bacteriophage t4 suspension concentration 5×10phagene particles per 1 mcl; mixture enzymes dna polymerase enzyme inhibiting enzymes, taqpolymerase, positive control sample mixture recombinant plasmid dna containing genome fragment infectious disease agent fragment bacteriophage t4 genome, taken volume ratio 1:1, according invention, fragments bacteriophage t4 genomes nodular dermatitis virus (lsdv) genome fragment following nucleotide sequences used positive control sample. expand functional capabilities, high specificity observing residual amounts unknown dna molecules nodular dermatitis virus reduced cost method.effect: invention broadens functional capabilities, increases specificity detecting residual quantities unknown dna molecules nodular dermatitis virus.1 cl, 6 tbl',\n",
              " \"test system detecting dna lumpy skin disease virus (lsdv) biological material animals using polymerase chain reaction real timefield: biotechnology.substance: invention represents test system detecting dna lumpy skin disease virus (lsdv) animal biological material using real-time polymerase chain reaction comprising buffer polymerase chain reaction, mixture thereof, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes specific genomic region agent infectious animal disease internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase, internal control sample form suspension bacteriophage t4 concentration 5×10phage particles per 1 mcl, negative control sample positive control sample, mixture recombinant plasmid dna containing fragment genome causative agent infectious animal disease fragment bacteriophage t4 genome nucleotide sequence: t4f: 5'-tacatataaatcacgcaaagc-3' – forward primer; t4r: 5'-tagtatggctaatcttattgg-3' – reverse primer; t4p: fam-5'-acattggcactgaccgagttc-3'-bhq1 – probe, taken volumetric ratio 1:1, according invention internal control sample phagolysate bacteriophage t4 used, positive control sample – fragments genomes native bacteriophage t4 fragment genome lumpy skin disease virus (lsdv) following nucleotide sequence: lsdv-f 5-tttaggagataagattgtcac-3' forward primer; lsdv-r 5'-ggagattttattatgagtggc-3' reverse primer; lsdv-p rox-5'-ggttaattttttaccacaaatagg-3'-bhq2 probe.effect: invention widens functional capabilities, increases sensitivity simplifies process preparing internal control sample.1 cl, 4 tbl\",\n",
              " \"test system identification dna tissue common quail (coturnix coturnix) dry fodder semi-finished meat productsfield: biotechnology.substance: invention represents test system dna identification common quail (coturnix coturnix) tissue dry fodders semi-finished meat products, including polymerase chain reaction buffer, mixture carrying out, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes, specific section animal's genome internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase, internal control sample form suspension bacteriophage t4 concentration 5×10phage particles per 1 mcl, negative control sample, mixture recombinant plasmid dna, containing fragment animal's genome fragment bacteriophage t4 genome nucleotide sequence: t4f tacatataaatcacgcaaagc – forward primer, t4r tagtatggctaatcttattgg – reverse primer, t4p fam acattggcactgaccgagttc bhq – probe, taken volumetric ratio 1:1, internal control sample presented phagolysate bacteriophage t4, positive control sample – fragments genomes native bacteriophage t4 quail tissue coturnix coturnix) following nucleotide sequence: c.cot-f: 5'-ctaggaggcgtacttgc-3' – forward primer; c.cot-r: 5'-gtgggcggaatgttatg-3' – reverse primer; c.cot-z: 5'-cagtacttatcctccttctaatcc-3' – probe.effect: invention broadens functional capabilities accuracy identification species identity, simplifies sample preparation process.1 cl, 5 tbl\",\n",
              " \"test system identification common hedgehog (erinaceus europaeus) tissue dna dry fodder semi-finished meat productsfield: biotechnology.substance: invention represents test system identification common hedgehog (erinaceus europaeus) tissue dna dry fodder semi-finished meat products, including polymerase chain reaction buffer, mixture carrying out, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes region-specific animal genome internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase, internal control sample form bacteriophage t4 suspension concentration 5×10phagic particles per 1 mcl, negative control sample mixture recombinant plasmid dna, containing fragment animal's genome fragment bacteriophage t4 genome nucleotide sequence: t4f: 5`-tacatataaatcacgcaaagc-3` – forward primer; t4r: 5`- tagtatggctaatcttattgg-3` – reverse primer; t4p: hex-5`-acattggcactgaccgagttc-3`-bhq1 – probe, taken volume ratio 1:1, according invention internal control sample phagolysate bacteriophage t4 used, positive control sample fragments genomes native bacteriophage t4 hedgehog (erinaceus europaeus) following nucleotide sequence used: hed-f: 5`-agtctattgattcgaatagagc-3` – forward primer; hed-r: 5`-catgagaggtactaaccagt-3` – reverse primer; hed-p: fam-5`-caggagctttattaggtgatgatcag-3-bhq1 – probe.effect: invention allows expand functional capabilities, increase accuracy species identity identification, simplification sample preparation process.1 cl, 5 tbl\",\n",
              " \"test system detecting dna donkey (equus asinus) tissue dry fodder semi-finished meat productsfield: biotechnology.substance: invention represents test system identification dna donkey (equus asinus) tissue dry fodder meat semi-products, including buffer polymerase chain reaction, mixture carrying out, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes, specific section animal's genome internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase, internal control sample form bacteriophage t4 suspension concentration 5×10phage particles per 1 mcl, negative control sample mixture recombinant plasmid dna, containing fragment animal's genome fragment bacteriophage t4 genome nucleotide sequence: t4f tacatataaatcacgcaaagc – forward primer; t4r tagtatggctaatcttattgg – reverse primer; t4p fam acattggcactgaccgagttc bhq1 – probe, taken volume ratio 1:1, according invention internal control sample phage lysate bacteriophage t4 used, positive control sample fragments genomes native bacteriophage t4 donkey (equus asinus) following nucleotide sequence used: donk f: 5'-catatcttaatcccaataatagac-3' – forward primer; donk r: 5'-agtattcgttctgatataggc-3' – reverse primer; donk p: fam-5'-atcttatactggactattctatcgac-3 – bhq1 – probe.effect: invention used expand functional capabilities increase accuracy identification species identity, simplify sample preparation process.1 cl, 5 tbl\",\n",
              " 'antibacterial composition based strains bacteriophages preventing treating salmonellosis / escherichiosis farm animals birds humansfield: biotechnology.substance: invention represents antibacterial composition medical preventive purpose, involves combination sterile, purified toxins filtrate phage lysates titre bacteriophage less 10pfu/ml gratia non-overlapping spectrum lytic activity respect salmonella escherichiosis pathogens, capable causing mass diseases birds, farm animals humans. created composition risk toxic side effects humans animals, provides stability bacteriophage titre effectiveness application. antibacterial activity composition manifested relation 83.72 % salmonella isolates isolated birds relation 90.63 % salmonella isolates isolated pigs, lytic spectrum. case paired meat treatment bacteriophages, meat salmonella contamination rate decreased 99.95 %, 99.98 % escherichia. dissemination samples fodder escherichia treatment antibacterial composition 88.4 times lower using fodder without it.effect: percentage survival rate animals test groups pig-breeding enterprises 90.38 %, provided non-use treatment additional antibacterial agents preparations.3 cl, 12 tbl, 13 ex',\n",
              " 'bacteriophages production methodfield: biotechnology.substance: method comprises culturing bacterial cells host strain absence extraneous microflora, phage lysate preparation purification precipitation and/or filtration. 30-120 minutes culturing initiation, optimum growth temperature culture rapidly growing host strain, every 30-60 minutes, smears made host strain culture surface solid nutrient medium liquid culture medium. smears stained solution acridine orange final concentration 0.001% 0.02% acridine yellow solution final concentration 0.01% 0.2%. stained smear microscoped fluorescence microscope. time set inoculating mother bacteriophage achievement stained smear less 50% relation total host strain cells proportion orange acridine stained cells, fluorescing orange red shades, proportion yellow acridine stained cells fluorescing yellow orange shades, achevement less 10% relation total host strain cells proportion cells non-uniform fluorescence paired pole adjoining cells form rods irregular spherical cytoplasm fluorescent spherical ellipsoidal cells slightly fluorescenting central section. mother bacteriophage inoculated.effect: stability achieving high bacteriophage titer upon phage lysate production changing nutritive medium formulations, increase range variations indicator values host strain bacteriophage culturing.11 ex',\n",
              " 'method detecting microorganism species vibrio parahaemolyticusfield: biotechnology.substance: method comprises inoculation test strain lawn culture, applying drop diagnostic phage preparation centre cup, holding temperature 37°c 20-24 hours confirmation belonging microorganisms species v. parahaemolyticus presence lysis. diagnostic phage preparation prepared mixing phages fc-44 fc-46, prepared based strain vibrio parahaemolyticus km-97, ratio 1:1 titre n·108 pfu/ml.effect: present invention enables accelerate identification strains used laboratory diagnostics acute intestinal infections caused microorganism.2 cl, 1 tbl, 3 ex',\n",
              " 'method obtaining recombinant exoprotein pseudomonas aeruginosafield: biotechnology.substance: method includes obtaining expression plasmid vector pet-repa (seq no: 3), containing promotor sequence t7 bacteriophage dna dna sequences encoding n-end region protein product translation enhancer (masmt amino-acid sequence), six histidine residues, site sumo protease cleavage sequence (seq no: 1) optimized broadcasting e. coli encoding recombinant repa protein (seq no: 2). recombinant chimeric precursor protein heterological expression system electro-competent cells e. coli bl21 (de3), transformed plasmid vector pet-repa obtain e. coli bl-repa strain 37°c ensure maximum amount accumulation precursor protein soluble fraction. lysis bacterial mass carried presence 4% triton x-100 preserve precursor protein soluble form. precursor protein isolated metal chelate chromatography talon sorbent charged coions, followed hexahistidine sumo peptide cleavage sumo protease polypeptide. cleaved recombinant protein repa subject finish purification anion-exchange chromatography deae-sepharose sorbent gel-filtration chromatography superdex 200-filled column, translation target buffer ph 7.5, obtaining recombinant repa protein.effect: production protein high yield.4 dwg, 4 ex',\n",
              " 'method production bacteriophagefield: biotechnology.substance: method production bacteriophage comprises: inoculation bacterial culture host strain titre 108-109 cfu/ml vessel culturing slant layer thickness 10 mm 25 mm, culturing 3-3.5 hours optimum temperature growth host strain culture, resulting lawn culture host strain stock bacteriophage inoculated titre 10-10cfu/ml cultured 13-15 hours optimum temperature thickness air layer surface solid medium 25 mm 40 mm. phage lysate prepared sucked sterile container, chloroform added, incubated 30-45 minutes continuous shuttling. supernatant centrifuged sterilised filtration filter pore diameter 0.2-0.22 microns.effect: solution provides universal possibility production phage lysate use different bacteriophages, stability bacteriophage titre phage lysate possibility use food industry.3 cl, 3 ex',\n",
              " 'plasmid-free recombinant escherichia coli strain, constitutive aspartase activity method l-asparagin acid synthesis using strain biocatalystfield: biotechnology.substance: plasmid-free recombinant escherichia coli strain constitutive aspartic activity obtained replacing promoter aspa gene escherichia coli strain mg1655 bacteriophage t5 pg25 promoter represented. method l-aspartic acid synthesis ammonium fumarate provided, using said recombinant strain biocatalyst form either free immobilized cells.effect: efficient preparation l-aspartic acid; allows reduce time production 3-4 times due higher aspartic activity biocatalyst.2 cl, 1 tbl, 3 ex',\n",
              " 'new bacteriophage enteroinvasive escherichia coli esc-cop-4 application inhibiting proliferation enteroinvasive escherichia colifield: biotechnology.substance: present invention relates particular myovirus bacteriophage esc-cop-4 isolated nature gene represented nucleotide sequence seq id no: 1 (registration number: ksts 12663 bp). invention relates method preventing treating infections caused enteroinvasive e. coli using composition comprising said bacteriophage active ingredient.effect: inventions allow use claimed bacteriophage capable specifically destroying strains enteroinvasive escherichia coli used medical industry.5 cl, 2 dwg, 4 tbl, 8 ex',\n",
              " 'method identidying rna sars-cov2 virus using multiplex isothermal loop amplification reverse transcriptionfield: biotechnology.substance: present invention relates field biotechnology and, particular, genetic engineering. isothermal loop amplification executed using specifically selected oligonucleotide primers complementary site genomic rna sars-cov2 coronavirus genomic rna ms2 bacteriophage, wherein amplification two dna fragments complementary genomic rna sars-cov2 coronavirus genomic rna ms2 bacteriophage executed simultaneously one reaction mixture. amplification results detected real time amplification using intercalating fluorescent dye based analysis melting curves amplified fragments.effect: reduction duration method identifying rna sars-cov2 virus.2 cl, 1 dwg, 2 tbl, 2 ex',\n",
              " \"ecoli strain - producer full-dimensional protective bacillus anthracis antigen form virus-like particlesfield: biotechnology.substance: presented strain derived protective bacillus anthracis antigen inserting pgem-ttppag plasmids e. coli strain bl21 (de3). plasmid pgem-ttppag contains t7 phage promoter controls expression fusion gene full-length ttr bacteriophage dt57c gene (encodes pb6 tail tube protein) fused 3'-end b. anthracis protective antigen gene expressed form virus-like particles. obtained hpv, free soluble cell protein, used antigen immunization.effect: increasing yield target product optimal cultivation conditions, obtaining main protective antigen causative agent anthrax form virus-like particles, facilitates purification potentially increases immunogenicity.5 dwg, 3 tbl\",\n",
              " \"e. coli strain - producer isolated domain 1 protective bacillus anthracis antigen form virus-like particlesfield: biotechnology.substance: strain derived protective bacillus anthracis antigen inserting ptrppa plasmids e. coli strain bl21 (de3). plasmid ptrppa contains t7 phage promoter controls expression fusion gene product 142 t5-like phage dt57c gene, known tail-terminating protein (trp) fused 3'-end domain 1 protective b. anthracis antigen, allows proteolytic cleavage transport toxin cytoplasm target cell preserve structural stability antigen, expressed form virus-like particles.effect: increasing yield target product optimal cultivation conditions, obtaining isolated domain 1 main protective antigen anthrax form virus-like particles, facilitates purification potentially increases immunogenicity.6 dwg\",\n",
              " 'strain bacteria serratia plymuthica antiviral activity influenza virus type (versions)field: biotechnology.substance: strain bacteria serratia plymuthica b-1288, strain bacteria serratia plymuthica b-1297, strain bacteria serratia plymuthica b-1296 strain bacteria serratia plymuthica b-1285 proposed. strains deposited collection bacteria, bacteriophages fungi federal state institution science \"state research centre virology biotechnology \"vector\". using preparations basis proposed strains neutralisation index influenza virus type 2.5-6.5 lg initial concentration virus 10lg tcd/ml.effect: strains antiviral activity influenza virus type a.4 cl, 5 tbl, 13 ex',\n",
              " 'strain bacteria serratia species producer extracellular ribonuclease deoxyribonuclease antiviral activityfield: biotechnology.substance: strain bacteria serratia species producer extracellular ribonuclease deoxyribonuclease antiviral activity avian influenza virus a/chickenkurgan/05/2005 (h5n1) human influenza virus a/aichi/2/68 (h3n2). proposed strain deposited collection bacteria, bacteriophages fungi federal budget institution science \"state research centre virology biotechnology \"vector\" registration number b-1287. using culture liquid cell extract strain production antiviral preparations neutralisation influenza virus a/chickenkurgan/05/2005 a/aichi/2/68 100%.effect: increased activity strain.1 dwg, 2 tbl, 6 ex',\n",
              " \"method obtain chemeric recombinant protein flic:pagnfield: biotechnology.substance: implement method, recombinant plasmid petflicpagn constructed, escherichia coli bl21 (de3) cells said plasmid resulting bl-flicpagn strain cultured temperature 37°c. next, periplasmic fraction producer bacteria prepared cells treatment lysozyme 20% sucrose solution, followed centrifugation, chemeric flic:pagn metal chelate, anion exchange, gel filtration chromatography obtain homogeneous final preparation flic:pagn protein. recombinant petflicpagn plasmid contains t7 bacteriophage promoter carries sequences encoding flic proteins, including leader sequence protein, pagn s. typhimurium, combined short linker sequence gsvdsssggn, fused 3'-end synthetic sequence encoding six histidins.effect: method allows synthesise protein soluble form native n-terminal amino acid sequence, yielding least 0,3 g protein litre bacterial culture 98 percent purity.7 dwg, 4 ex\",\n",
              " \"test system detecting rna schmallenberg disease virus farm animalsfield: biotechnology.substance: increase diagnostic accuracy, test system detecting rna schmallenberg disease virus farm animals includes buffer carrying polymerase chain reaction, mixture carrying consisting deoxynucleoside triphosphates, primers fluorescent probes specific agent schmallenberg disease virus internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase; rna dilution buffer, internal control sample, negative control sample, positive control sample, according invention internal control sample suspension bacteriophage ms2 concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample, mixture recombinant plasmid dna containing fragment genome schmallenberg virus exciter fragment bacteriophage ms2 genome, taken ratio 1:1 following nucleotide sequences: shm-f 5' tcagattgtcatgccccttgc 3'` – forward primer; shm-r 5' tcggccccaggtgcaaatc 3' – reverse primer; shm-z joe – accatcggcccaggtgcatccctta-bhq1 – probe; ms2f, 5'-tggcactacccctctccgtattcac-3' – forward primer; ms2r, 5'-gtacgggcgaccccacgatgac-3' – reverse primer; ms2p, 5'-cy5-cacatcgatagatcaaggtgcctacaagc-3' bhq2 – probe.effect: invention provides accurate diagnosis schmallenberg disease farm animals.1 cl, 3 dwg, 4 tbl\",\n",
              " 'antibacterial composition (embodiments) use protein antimicrobial agent directed bacteria pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, salmonella typhi staphylococcus haemolyticus (embodiments)field: biotechnology; medicine.substance: invention relates biotechnology, specifically therapeutic proteins, used medicine antibacterial agent. disclosed use recombinant endolysin bacteriophage, including combination pharmaceutically acceptable carriers and/or substances increasing membrane permeability, antimicrobial agent directed bacteria pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, salmonella typhi staphylococcus haemolyticus. antibacterial compositions obtained based said protein, including fused 8-histidine tag.effect: invention provides effective penetration endolysin without adding various permeabilisers covalently bound penetrating peptides outer membrane said bacteria cleavage peptidoglycan, ultimately leads death bacteria.4 cl, 5 dwg, 3 tbl, 6 ex',\n",
              " 'antibacterial composition (embodiments) use protein antimicrobial agent directed gram-negative bacteria: pseudomonas aeruginosa, acinetobacter baumannii, klebsiella pneumoniae salmonella typhi (embodiments)field: biotechnology; medicine.substance: invention relates biotechnology, specifically therapeutic proteins, used medicine antibacterial agent. disclosed use recombinant endolysin bacteriophage, including combination pharmaceutically acceptable carriers and/or substances increasing membrane permeability, antimicrobial agent directed gram-negative bacteria: pseudomonas aeruginosa, acinetobacter baumannii, klebsiella pneumoniae salmonella typhi. antibacterial compositions obtained based said protein, including fused 8-histidine tag.effect: invention provides effective penetration endolysin without adding various permeabilisers covalently bound penetrating peptides outer membrane said bacteria cleavage peptidoglycan, ultimately leads death bacteria.4 cl, 5 dwg, 3 tbl, 6 ex',\n",
              " 'method detecting genome rotavirus infection agent farm animalsfield: biotechnology; veterinary science.substance: invention refers biotechnology veterinary virology. disclosed method detecting genome rotavirus type agent agricultural animals. rna isolated biological material infected animals sorption method. followed synthesising cdna rna matrix single-step staging addition internal positive control reverse transcription multiplex reaction polymerase chain reaction 45 amplification cycles real-time detection using specific oligonucleotide primers, fluorescently-labelled probe, control samples. then, accumulation fluorescent signal measured channels corresponding fluorescent dyes results interpreted basis presence/absence intersection fluorescence curve threshold line (threshold). internal control sample, bacteriophage ms2 suspension used, positive control sample - mixture recombinant plasmid dna containing rva virus genome fragment fragment bacteriophage ms2 genome.effect: invention enables reliable diagnosis rotavirus infection type animals.1 cl, 4 tbl',\n",
              " 'bacillus anthracis r/d bateriophage strain used produce preparation anthrax infection diagnostics, liquid preparation anthrax infection diagnostics preparation anthrax infection diagnosticsfield: chemistry, biochemistry. ^ substance: group inventions concerns medical virology microbiology. bacillus anthracis r/d bacteriophage strain, deposited collections microorganism museum state research centre applied microbiology practical molecular biology serial number ph-6, used produce preparation anthrax infection diagnostics. liquid preparation anthrax infection diagnostics contains suspended particles bacteriophage bacillus anthracis r/d-ph-6 lytic activity 1010 plaque-forming unit/cm3, 1% quinosol solution, ratio follows, wt %: suspended bacteriophage lytic activity 1010 plaque-forming unit/ml - 10.0-20.0, 1% quinosol solution - 0.5-1.0, physiologic saline - rest. dry preparation anthrax infection diagnostics contains dry solid matter bacteriophage bacillus anthracis r/d-ph-6 lytic activity 1010 plaque-forming unit/cm3, saccharose, gelatine quinosol ratio follows, wt %: saccharose - 35.0-40.0, gelatine - 6.0-10.0, quinosol - 0.03-0.06, dry solid matter bacteriophage lytic activity 1010 plaque-forming unit/cm3 - rest. ^ effect: implemented fast identification anthrax agent effective medical antiepidemic actions. ^ 3 cl, 1 tbl, 9 ex, 1 dwg',\n",
              " 'bacteria strain lactococcus lactis subsp diacetilactis --5-5, used revealing lactococci bacteriophagesfield: chemistry, organic, production fermented milk products. ^ substance: invention relates diary industry, production fermented milk products particular. bacteria strain lactococcus lactis subsp. diacetilactis \"--5-5\" (russian collection lactate bacteria production cheese bacteriophages \"\") obtained self-sour cream selected sensitivity spectrum 250 known bacteriophages. used indicator strain revealing lactococci bacteriophages, ways sources spreading enterprise. invention enables one prevent development bacteriophages production milk produce, improve quality safety human health, well increase efficiency production. ^ effect: increase production efficiency, quality safety milk produce. ^ 1 ex',\n",
              " 'lactococcus lactis subsp cremoris \"--1-1\" bacteria strain, used identifying lactococcus bacteriophagesfield: chemistry. ^ substance: present invention pertains dairy industry, particularly production fermented dairy products. lactococcus lactis subsp. cremoris \"--1-1\" bacteria strain, high specific sensitivity lactococcus lactis subsp. cremoris bacteriophages high sensitivity wide range lactococcus bacteriophages, used identifying lactococcus bacteriophages production dairy products. invention prevents development bacteriophages production dairy products, improves quality product health safety consumer, increases production efficiency well. ^ effect: prevention development bacteriophages production dairy products, improvement quality product health safety consumer, increased production efficiency. ^ 1 ex',\n",
              " 'treatment oil pipelines microbiological corrosion biocompositionfield: chemistry.substance: group inventions relates method reducing intensity preventing formation corrosive biofilm metal surface. method includes obtaining sample corresponding area, identifying culturing strain target bacterium, identifying obtaining bacteriophage microbes based said sample, immobilizing encapsulating obtained bacteriophages nanomagnetic particle, nanolignin combination thereof, preparing microbicide composition inhibiting corrosion adding least one phage release reagent stabilizer combined solution containing alcohol hydrocarbon, subsequent addition immobilized encapsulated phages, treatment corresponding area microbicide composition. cultivation strains carried presence microbial antibiotics suboptimal concentration 1/15 minimum inhibitory concentration, bacteriophages selectively released ph within range 6.5 4 microbiologic corrosion site. microbicidal composition contains least one alcohol, one liquid hydrocarbon, bacteriophage immobilized magnetic nanocomposite, least one phage release reagent one stabilizer.effect: reduced intensity biofilm formation surfaces, resulting reduction, attenuation elimination microbial corrosion inner surface oil pipelines.11 cl, 4 tbl',\n",
              " 'pet21a-prochym recombinate plasmid, providing synthesis chemeric b bos taurus proximosin protein, well escherichia coli bl21 (de3) plyse pet21a-prochym - producer chemeric b bos taurus proximosin proteinfield: chemistry.substance: group inventions relates recombinant plasmid providing synthesis chimeric protein b bos taurus prochymosin, recombinant strain e. coli, producer chimeric protein b bos taurus prochymosin e. coli cells. recombinant pet21a-prochym plasmid 6504 base pairs (bp) contains following structural elements essential functioning expression target protein: bacteriophage t7 promoter provides efficient transcription controlled mrna; recombinant gene b bos taurus prochymosin encoding target chimeric protein; t7 terminator, untranslated termination region transcription bacterial operon providing effective termination transcription; sequence t7 expression tag, added composition nucleotide sequence gene b bos taurus prochymosin n-terminus, increase yield target protein; bla sequence encoding beta-lactamase protein, selective marker transformation e. coli strains; cole1 sequence replicates plasmid e. coli strains. recombinant gene b bos taurus prochymosin nucleotide sequence seq id no: 1 nucleotide position 5205 bp. nucleotide position 6347 bp, encoding target chimeric protein b bos taurus prochymosin complete amino acid sequence seq id no: 2, embedded faund sfr274 restriction sites region pet21a polylinker containing t7 phage rna polymerase promoter terminator. proposed recombinant strain escherichia coli bl21 (de3) plyse pet21a-prochym obtained transformation recombinant plasmid pet21a-prochym deposited collection bacteria, bacteriophages fungi state research center virology biotechnology vector federal service supervision consumer rights protection human well-being registration number b-1362.effect: group inventions provides high production pro-chymosin.2 cl, 5 dwg, 6 ex, 2 tbl',\n",
              " 'peptinoglycane hydrolase, expression plasmid, containing peptidoglycane hydrolase-coding dna fragment, bacterium-producer method microbiological synthesis peptidoglycane hydrolasefield: chemistry.substance: group inventions relates biotechnology, particular peptydoglycane hydrolase biosynthesis, represents protein peptydoglycane hydrolase activity, plasmid, containing peptydoglycane hydrolase-coding fragment, bacterium-producer, method microbiological peptydoglycane hydrolase synthesis, well pharmaceutical composition, containing obtained peptydoglycane hydrolase, therapy diseases, caused gram-negative microflora.effect: elaborated method microbiological synthesis makes possible obtain bacteriophage s-394 peptydoglycane hydrolase effective way.22 cl, 2 dwg, 9 ex',\n",
              " 'recombinant plasmid dna per-arns3, encoding fusion protein capable autocatalytic splitting formation arns3, escherichia coli strain c3030/per-arns3 producer said proteins methods recombinant arns3 productionfield: chemistry.substance: invention refers biochemistry, namely recombinant plasmid dna per-arns3 providing synthesis hybrid polypeptide comprising arns3 mini-intein ssp dnab, escherichia coli cells. said plasmid dna comprises bsabi/eco0109i-dna plasmid fragment ptwin-1 gene translation amplifier 10 phage t7, ndei/bamhi-dna fragment containing mini-intein gene ssp dnab sequence arns3 recombinant gene adapted sites. plasmid contains b-lactamase gene determines resistance e. coli cells transformed plasmid per-arns3 penicillin antibiotics, genetic marker unique restriction endonuclease recognition sites. invention discloses strain escherichia coli c3030/per-arns3, producing said fusion polypeptide. invention discloses method production said arns3 recombinant protein, comprising culturing said strain escherichia coli c3030/per-arns3.effect: invention provides recombinant arns3 high yield according simplified technology.3 cl, 4 dwg, 4 ex',\n",
              " 'method producing peptides specifically identifying certain types cells intended therapeutic purposesfield: chemistry.substance: invention relates biochemistry, particularly method producing peptides specifically identify certain types cells. said method includes constructing plurality random peptide libraries based oligonucleotide fragments encoding same, via fragmentation resultant rna cells certain type cells types, may involved pathologic process affect diagnosis therapy thereof. said fragments closed correct orientation vector based bacteriophage. libraries screened using combinations cells certain type cells types obtain groups peptides specifically identify cells selected type phage particles. individual peptides phage particles separated obtained peptides tested confirm specificity thereof. peptides pure form obtained creating matrix based amino acid sequences peptides phage particles, sequences new peptides read synthesised chemically, followed confirmation specific identification cells certain type.effect: invention enables obtain highly specific highly selective peptides identify cells certain type.5 dwg, 1 tbl, 11 ex',\n",
              " 'recombinant strain escherichia coli l-threonine-producerfield: chemistry.substance: invention relates biotechnology, particular threonine-producer strain. strain escherichia coli arsim b-11820 obtained inactivation strain escherichia coli arsim b-3996 genes poxb sstt background increased expression gene gaip substitution natural promoter synthetic promoter ptac3 increased expression genes operon thrabc substitution natural promoter phage promoter p, removal sequence regulatory peptide thrl introduction densensitising mutation thra.effect: obtained strain makes possible obtain l-threonine high efficiency.1 tbl, 6 ex',\n",
              " 'recombinant plasmid dna pestpc, encoding polypeptide properties esterase psychrobacter cryohalolentis k5, escherichia coli bacteria strain - producer polypeptide properties esterase psychrobacter cryohalolentis k5field: chemistry.substance: invention relates biotechnology. described plasmid codes esterase psychrobacter cryohalolentis k5and contains ndel/xhol - dna fragment plasmid pet32a length 5.366 thousand base pairs, includes promoter bacteriophage t7, translation enhancer gene 10 bacteriophage t7, transcription terminator bacteriophage t7, bla ?-lactamase gene determines resistance cells transformed plasmid ppc023 ampicillin, replication initiation section ori; ndel/sall - dna fragment size 0.869 thousand base pairs, contains gene codes mature form esterase psychrobacter cryohalolentis k5with amino acid sequence seq id no: 2, given description, c-end hexahestidine linker. provided escherichia coli bacteria strain modified said plasmid, producer polypeptide esterase psychrobacter cryohalolentis k5activity.effect: invention increases level biosynthesis esterase 20% total cell protein.2 cl, 2 dwg, 5 ex',\n",
              " 'antibacterial composition, strain bacteriophage escherichia coli, used obtaining thereoffield: chemistry.substance: invention relates field food industry, biotechnology deals antibacterial composition strain bacteriophage escherichia coli, used obtaining said composition. characterised composition includes filtrate escherichia coli phage lysate, obtained application strain bacteriophage escherichia coli, deposited collection museum microorganisms federal budget institution science \"state research centre applied microbiology biotechnology\" federal service customers\\' rights protection human well-being surveillance (fbis src amb rospotrebnadzor) number ph 64, filtrate escherichia coli phage lysate, containing coli bacteriophage, filtrate staphylococcus phage lysate, filtrate salmonella phage lysate, filtrate listeria monocyctogenes phage lysate target additives amount 1.0÷95.0 wt % composition weight.effect: claimed composition required spectrum specific activity due inclusion polyvalent bacteriophage used production biologically active additives food additives.11 cl, 1 tbl, 13 ex',\n",
              " 'method neutralising bacillus anthracis spores vegetative cellsfield: chemistry; biochemistry. ^ substance: invention pertains biotechnology. disclosed method neutralising bacillus anthracis spores vegetative cells, involving treatment infected surface disinfectant aqueous solution containing mixture bacillus anthracis ozr-1, bacillus anthracis f-2 bacillus anthracis faut bacteriophages activity ratio (pfu/cm3) bacillus anthracis ozr-1, bacillus anthracis f-2 bacillus anthracis faut equal 1 :(0.2-1):(0.1 -1) spore germination activator l-alanine.the disinfecting solution prepared mixing separately stored l-alanine complex bacteriophages separately grown mixed specified ratios. preferably, aqueous solution containing mixture bacteriophages concentration 1010-1012 pfu/l spore germination activator concentration 0.05-0.15 mol/l used. aim receiving full effect fixing result, infected surface twice treated interval 60-180 minutes effective disinfection achieved using solution based 1011-1012 phage particles per 10 m2 infected surface. ^ effect: invention enables efficient environmentally safe neutralisation bacillus anthracis spores vegetative cells. ^ 4 cl, 2 ex',\n",
              " 'bacteriophogum salmonella ibp-1 bacteriophage strain lytic enteritidisfield: chemistry; biochemistry. ^ substance: invention refers biotechnology used production biological preparations prevention treatment salmonellosis. bacteriophogum salmonellal ibp-1 bacteriophage strain lytic s. enteritidis used production medical bacteriophage preparation. ^ effect: extended spectrum lytic action bacterium salmonella enteritidis.',\n",
              " 'method evaluating phagoimmunoassay resultsfield: chemistry; biochemistry. ^ substance: invention relates biotechnology, particular, immunoengineering, may used digital processing images lysed zones bacterial lawn, result antigen-antibody reaction, based phage label principle (phagoimmunoassay viroimmunoassay). phagoimmunoassay results evaluation method implies analysis lysed zones indicator crop plate wells experimental reference tests. plate experimental reference tests subsequently placed photo scanning unit obtain digitised image lysed zones. then, digitised image processed means adaptive filter obtain outlined individual lysed zones various size, well merged lysed zones. that, average total area lysed zones experimental reference samples determined. average total area experimental lysed zones exceeds average total area reference lysed zones 5% minimum, phagoimmunoassay considered positive. ^ effect: efficient method evaluating phagoimmunotest results. ^ 4 tbl, 5 dwg, 1 ex',\n",
              " 'exposure t-cell receptorsfield: chemistry; biochemistry. ^ substance: present invention pertains biotechnology. description given phage particle, exposing surface, t-cell receptor (tcr), human sctcr. exposed dtcr polypeptide pair exposed sctcr polypeptide contains series alpha beta chains extra-cellular constant lg native tcr domain. disulphide bond joins amino acid residues given series chains constant lg domain, given disulphide bond cysteic residues. presented library polypeptide pairs mutated tcr sctcr polypeptides, exposed described phage particle. nucleic acid, encodes described phage particle, presented. method identifying tcrs invented. invention used making various tcr libraries, identification high-affinity tcrs. ^ effect: possibility making various tcr libraries identification high-affinity tcrs. ^ 17 cl, 25 ex, 63 dwg, 2 tbl',\n",
              " 'method cosmetic rehabilitation skin tissues post-operating posttraumatic conditions (variants)field: cosmetology, esthetic surgery, applied biopharmacology. ^ substance: invention relates medicative cosmetic agents, uses biologically active substances based natural biological complexes. claimed method includes application mirralgin balm analgesic, anti-inflammation resolving action, reventon balm, vessel restorative action, edema reducing microcirculation improving. process blepharoplastic eye boundary bandage microemulsion recovery animative action eaves skin applied, process facelifting cream mask bactericide, vessel restorative recovering action, enhancing local immunity applied. mirralgin balm reventon balm treatment carried sequentially alternatively. another embodiment skin cleaning treatment damaged zone anti-septic agent bacteriophage gel, disinfects skin surface, prevents biofilm forming, accelerates cicatrizing process applied, posttraumatic zone treated cleaning milk, toned tonic lotion cream mask bactericide, vessel restorative recovering action, enhancing local immunity applied. ^ effect: method skin structure recovering without skin trauma. ^ 4 cl, 7 ex, 1 tbl',\n",
              " 'strain bacterium lactobacillus lactis subspecies lactis tk-obl-lz-3f used detection lactococcus bacteriophagefield: dairy industry, microbiology. ^ substance: invention relates, particular, production fermented dairy foodstuffs. strain lactobacillus lactis subsp. lactis tk-obl-lz-3f used detection lactococcus bacteriophages provides prevention bacteriophages development dairy production dairy foodstuffs enhance quality safety production consumer health, promotes effectiveness manufacturing. ^ effect: valuable properties strain. ^ 1 ex',\n",
              " 'recombinant plasmid dna pa3gf coding polypeptide human granulocyte colony-stimulating factor, escherichia bacteria race coli-producer human granulocyte colony-stimulating factor polypeptidefield: gene engineering. ^ substance: invention used production recombinant polypeptide human granulocyte colony-stimulating factor. recombinant plasmid dna constructed vitro. includes synthetic gene human granulocyte colony-stimulating factor, strong constitutive promoter a3 early stage bacteriophage t7 synthetic section - translation enhancer (tren) gene 10 bacteriophage t7. dna combination high copy number plasmid optimisation cultivation conditions ensures constitutive biosynthesis target protein transformed dna race escherichia coli sgk25/pa3gf high yield. ^ effect: constitutive biosynthesis target protein cells; high yield. ^ 2 cl, 4 dwg, 7 ex',\n",
              " 'recombinant plasmid dna pif tren coding human polypeptide alfa-2b interferon polypeptide escherichia bacteria race coli-producer human alfa-2b interferonfield: gene engineering. ^ substance: invention relates gene engineering may used production recombinant polypeptide human alfa-2b interferon. recombinant plasmid dna constructed vitro. includes synthetic gene human alfa-2b interferon, tandem a2 a3 promoters early stage bacteriophage t7 synthetic section - translation enhancer. elements determine constitutive biosynthesis target protein transformed dna race escherichia coli sgk25 /pif tren high yield. ^ effect: high yield. ^ 2 cl, 5 dwg, 5 ex',\n",
              " 'recombinant fragmid dna phen-tab containing human single-strand antibody gene, capable binding human tumor necrosis factor alpha; recombinant escherichia coli bacteria strain producer human single-strand antibody human tumor necrosis factor alpha; recombinant soluble human single-strand antibody human tumor necrosis factor alphafield: gene engineering. ^ substance: recombinant fragmid dna phen-tab, containing unique human single-strand antibody gene selected constructed vitro combinatorial phage library udder controlling lactose operon promoter. escherichia coli hb2151 cells transformed obtained fragmid dna produce recombinant bacterium strain escherichia coli hb2151/phen-tab producer human single-strand antibody capable binding human tumor necrosis factor alpha. said antibody gas affinity constant kaf = 3.96±0.52x108 m-1. ^ effect: new soluble human single-strand antibody sctab human tumor necrosis factor alpha high affinity. ^ 3 cl, 6 dwg, 6 ex',\n",
              " 'recombinant plasmid dna pacyclans transfer expression gene encoding erwinia carotovora (ecar-lans) l-asparaginase escherichia coli cells method preparing recombinant ecar-lans biomass escherichia coli producer strainsfield: genetic engineering, biotechnology, molecular biology. substance: invention used medico-biological industry. invention proposes constructed recombinant plasmid (pacyclans) comprising natural sequence gene encoding l-asparaginase erwinia carotovora (ecar-lans) control promoter terminator phage t7 rna-polymerase encodes full-scale enzyme precursor signal peptide export protein periplam followed processing. strain- producers content recombinant l-asparaginase 8-12% prepared transformation strains e. coli indicated plasmid able synthesize phage t7 rna-polymerase. isolation purification enzyme biomass method involves disruption cells ultrasonic disintegration, fractionation ammonium sulfate chromatography column sp-sepharose ff. invention provides preparing purified l-asparaginase preparation high yield. effect: improved preparing method. 2 cl, 3 dwg, 1 tbl',\n",
              " 'recombinant plasmid dna pes3-7 encoding peptide sequence human granulocyte colony-stimulating factor (g-csf) strain escherichia coli bl21(de3)/pes3-7 producer human recombinant g-csffield: genetic engineering, particular production human granulocyte colony-stimulating factor. ^ substance: recombinant plasmid dna pes3-7 molecular weight 3.63 mda (5907 b.p.) constructed. said dna consists dna ndel/notl-fragment containing sequence recombinant g-csf artificial gene, beta-lactamase gene; plasmid pet22b(+) dna ndel/notl-fragment containing promoter terminator t-rna-polymerase transcription, amplifier 17 phage 10 gene translation. plasmid pes3-7 contains genetic marker beta-lactamase gene determines resistance e.coli cells transformed plasmid pes3-7 ampicillin, unique restriction endonuclease recognition sites existing next distance right ndel-site: xbal - 38 b.p.; hpal - 1332 b.p.; pstl - 4065 b.p.; pvul - 4190 b.p.; xhol - 5363 b.p. obtained plasmid used transformation escherichia coli cells produce strain e.coli bl21(de3)/pes3-7 subproducer recombinant g-csf. method present invention makes possible produce recombinant g-csf high yield (20-30 % based total cell protein content). ^ effect: simplified method production recombinant g-csf high yield. ^ 2 cl, 2 dwg, 2 ex',\n",
              " 'dna pcx-302 fragment encoding synthesis penicillium canescens secreted endo-(1-4)-beta-xylanase fungus strain penicillium canescens producer secreted endo-(1-4)-beta-xylanasefield: genetic engineering, microbiology, biochemistry, enzymology. substance: invention relates preparing dna (pcx-302) fragment encoding synthesis secreted endo-(1-4)-beta-xylanase based isolation genes penicillium canescens vkpm f-178 phage library. based isolated dna fragment recombinant plasmid ppcxyla constructed used transformation strain- -recipient penicillium canescens pca 10 (nia d-). result screening transformants multicopy strain p. canescens xyl-23 (vkpm f-832) producer enzyme secreted form obtained. culturing obtained strain pectin-containing medium beet pulp possible obtain 770 u activity endo-(1-4)- beta-xylanase per 1 ml cultural medium exceeds 6-7-fold enzyme yield using strain- recipient. invention used preparing enzyme endo-xylanase industrial scale. effect: increased yield enzyme. 2 cl, 2 dwg',\n",
              " 'recombinant plasmid dna pes4-4 encoding human polypeptide interferon alpha-2b strain escherichia coli brees4 producer recombinant human interferon alpha-2bfield: genetic engineering, molecular biology, biochemistry. ^ substance: method involves construction recombinant plasmid dna pes4-4 molecular mass 3.64 mda (5917 base pairs) consisting nde i/bam hi-fragment dna comprising sequence artificial gene recombinant human interferon alpha-2b, beta-lactamase gene nde i/bam hi-fragment plasmid pet22b(+)dna comprising promoter transcription terminator t7-rna polymerase, translation enhancer phage t7 gene 10. plasmid pes4-4 comprises beta-lactamase genetic marker determining resistance e. coli cells transformed plasmid ampicillin, unique recognition sites endonuclease restriction enzymes located following distance right site nde i: xba - 38 base pairs; hpa - 1332 base pairs; pst - 4065 base pairs; pvu - 4190 base pairs, xho - 5363 base pairs. escherichia coli cells transformed prepared plasmid strain e. coli bdees4 obtained super producer recombinant human interferon alpha-2b. invention provides preparing recombinant human interferon alpha-2b high yield simplified technology. invention used preparing recombinant human interferon alpha-2b. ^ effect: improved preparing method. ^ 3 cl, 2 dwg, 2 ex',\n",
              " 'recombinant plasmid dna p30ne2, encoding 181-amino acid n-terminal fragment glycoprotein e2 classical bog cholera virus providing expression thereof cellsfield: genetic engineering. ^ substance: recombinant plasmid dna p30ne2 contains dna fragment pasmid pqe30, including promoter/operator t5 phage; ribosome-binding site; phage lambda transcription terminator, beta-lactomase gene genetic marker, well bamhi/hindiii fragment, encoding 181-amino acid n-terminal fragment glycoprotein e2 classical bog cholera virus. plasmid provides expression glycoprotein e2 classical bog cholera virus e/coli bacteria cells. invention useful diagnostic investigation vaccine production. ^ effect: genetically engineered plasmid vaccine preparations. ^ 3 dwg, 6 ex',\n",
              " 'method differentiation parahemolytic vibria iii, iv, v morphogroups filamentous bacteriophages morphogroupfield: medical microbiology, diagnosis diseases caused gastro-enteritis parahemolytic vibria. ^ substance: claimed method includes application vibro parahaemoliticus km 97 vibro parahaemoliticus km 184 test strains, separately seeded martin broth 3 % nacl placed thermostat 4 h, 0.3 ml cultivated test strain slurry mixed 4.5 ml melted cooled 45°c 0.7 % martin agar 3 % nacl poured second layer plates solidified 1.5 % martin agar 3 % nacl petri dishes. solidification agar dried drop tested probe placed center dish cultured 37°c 24-48 hours. cultivated phages differentiated. namely: lysine presence test strain km 97 km 184 correlated bacteriophages parahemolytic vibria iii, iv, v morphogroups, lysis km 184 correlated filamentous bacteriophages morphogroup. ^ effect: simplified dependable method laboratory diagnosis. ^ 2 tbl, 3 ex',\n",
              " \"method identification cholera vibrio o1 serogroups biovars classical el torfield: medical microbiology.substance: invention refers medical microbiology, particularly laboratory diagnostics, used development new diagnostic preparations allowing identify cholera strains o1 serogroup biovars classical el tor. method provides using microbial lysability diagnostic phage agar medium. bacteriophage strain rostov-6 applied, applied form path surface petri dish filled prepared solution consisting analyzed culture, introduced martin's broth left thermostat 4 hours temperature 37 °c. specified amount mixture taken added 0.7 % melted cooled 45 °c marten agar. mixture mixed test tube circular motions quickly poured onto surface petri dish 1.5 % agar. evenly distributed surface allowed dry. drying, preparation coated drop bacteriophage rostov-6 preparation, inoculation incubated thermostat temperature 37 °c 24 hours. followed identification grown culture presence phagolysis zone, confirms presence cholera vibrio o1 serogroups biovars classical el tor absence.effect: invention allows increase degree authenticity identification cholera vibrio 01 serogroup classical el tor.1 cl, 1 dwg, 3 tbl, 3 ex\",\n",
              " 'bacteriophage strain helicobacter pylori lytic activity relation bacteria helicobacter pylori method production antigastritis antiulcer drug based samefield: medical virology microbiology. ^ substance: new bacteriophage strain helicobacter pylori, lytic activity disclosed. method production antigastritis antiulcer drug based new bacteriophage strain disclosed. claimed method includes providing purified suspension bacteriophage helicobacter pylori lytic activity 109 ffu/ml addition 1 % chinozole thereto. moreover sorbitole gelatose may introduced said agent. obtained mixture frozen lyophilized. ^ effect: high effective antigastritis antiulcer drug useful medicine. ^ 3 cl, 1 tbl, 2 ex',\n",
              " 'strain legionellosis bacteriophage niim active respect legionella pneumophila, legionella micdadei, legionella dumoffii legionella bozemaniifield: medicinal microbiology. ^ substance: invention used identifying pathogens legionellosis disease excreted patient body infected objects environment. strain legionellosis bacteriophage designated identification main species pathogens legionellosis disease, i. e. legionella pneumophila, l. micdadei, l. dumoffii l. bozemanii laboratory diagnosis legionellosis isolated organs laboratory animals infected type strain philadelphia-1 l. pneumophila deposited collection phages nii microbiology mo rf designation niim. using bacteriophage allows enhancing specificity carrying identification legionellosis pathogen infections. ^ effect: valuable properties strain. ^ 3 dwg',\n",
              " \"immunobiological bactericidal preparation (versions)field: medicine biologically active additives. ^ substance: according invention, immunobiological bactericidal preparation contains species-specific virulent bacteriophages induced-virulence bacteriophages appelman's lytic activity least 10-4 respect test strains bacteria isolates recovered human body filtrate, concentrate filtrate dry biomass phage lysate filtrate nonlysogenic bacteria pharmaceutically acceptable desired additives. preparation presented ointment, suppository, powder, tablet capsule. declared immunobiological bactericidal preparation prepared sequential multiple passages phages bacteriophage preparations test strains nonlysogenic bacteria isolates fresh-recovered human body inducing agent, eg mitomycin c, added nutrient medium. according invention, immunobiological bactericidal preparation provides stable virulence bacteriophages adaptation thereof circular agents bacterial infections. ^ effect: higher clinical effectiveness. ^ 13 cl, 9 tbl, 30 ex\",\n",
              " 'method reproduction brucellous bacteriophagefield: medicine microbiology, particular technology reproduction brucellous bacteriophage. ^ substance: brucellous bacteriophage bk2 reproduced liquid synthetic nutrient medium. nutrient medium used provide suspension growth strain reproduce bacteriophage. nutrient medium contains glucose additional carbon source, amino acids salts, additionally 10-2-10-3 calcium sulfate. method present invention allows ability increase final brucellous bacteriophage bk2 concentration wherein bacteriophage reproduced 48-72 h. ^ effect: brucellous bacteriophage reproduction increased bacteriophage concentration. ^ 3 ex',\n",
              " 'method preparing bacteriophages binding specifically target-cells designated therapeutic aimsfield: medicine, genetic engineering. ^ substance: invention proposes method involves construction bacteriophage library random peptides based oligonuleotide fragments encoding their, selection bacteriophages binding target-cells binding cells types involves pathological process able show effect diagnosis therapy, confirmation specificity selected bacteriophages using combination different tests. oligonucleotide fragments encoding random peptides prepared reaction reverse transcription using random primers total rnas isolated indicated target-cells cells types. applying invention provides preparing bacteriophages binding target-cells high degree selectivity. invention used diagnosis, therapy pharmaceutical industry. ^ effect: improved preparing method. ^ 3 cl, 2 dwg, 8 ex',\n",
              " 'method therapeutic prophylactic treatment streptoococcus infection (variants) composition designated applying (variants), lysine enzyme associated phage streptococcus group c active component pharmaceutical compositionfield: medicine, infectious diseases, pharmacy. ^ substance: invention relates composition comprising lysine enzyme associated phage streptococcus group c carrier delivery lysine enzyme associated phage streptococcus group c mouth, throat nose ducts mammal. composition shows high effectiveness prophylaxis therapeutic treatment streptococcus infection including infection known usually streptococcus pharyngitis. invention allows carrying treatment prophylaxis infections caused streptococcus group c infections groups c e high effectiveness. ^ effect: improved treatment method, valuable medicinal properties composition. ^ 57 cl, 3 tbl, 5 ex',\n",
              " 'strain bacteria burkholderia cepacia - avirulent producer bacteriophage, lysing originator glandersfield: medicine, microbiology. ^ substance: invention concerns medical microbiology concerns strain burkholderia cepacia, capable produce bacteriophage lysing culture originator glanders burkholderia mallei. strain deposited collections russian science research antiplague institute microbe, number burkholderia cepacia km 203 assigned it. strain virulent white mice golden hamsters, century cepacia possesses culture-morphological properties spectrum biochemical activity characteristics. ^ effect: obtaining strain burkholderia cepacia, capable produce bacteriophage lysing culture originator glanders burkholderia mallei. ^ 4 ex',\n",
              " 'method treatment ubeitis obscure viral etiologyfield: medicine, ophthalmology. ^ substance: method involves intramuscular administration galavite dose 0.1 g, per day 5 days, 6 10 days - every day, gentamycin dose 80 mg, 3 times per day 7 days, bifidum - liquid bacteriophage 791 series production firm \"vektor\" dose one-half flask, 2 times per day, one-half hour eating, wobenzym given dose 5 tablets, 3 times per day 3 weeks dose 3 tablets, 3 times per day 3 weeks. method provides eliminating main clinical symptoms diseases based transient suppression hyperactivity lipopolysaccharides cell membrane, decreasing level tnf-alpha, il-1 anti-inflammatory cytokines increasing activity microbiocid system neutrophile granulocytes. invention used treatment uveitis obscure viral etiology. ^ effect: improved method treatment. ^ 3 ex',\n",
              " 'bacteriophage-containing pharmaceutical composition method preparingfield: medicine, pharmaceutical industry, pharmacy. ^ substance: invention relates method preparing medicinal formulations bacteriophages. pharmaceutical composition contains bacteriophages filling agent dosed medicinal formulations contains additionally water-soluble polymers sugars. derivatives cellulose, low- mean-molecular polyvinylpyrrolidones, polyethylene glycols molecular mass 4 000-6 000 da, sodium alginate used water-soluble polymers; lactose and/or mannitol used sugars; carboxymethylcellulose sodium salt hydroxypropylmethylcellulose, hydroxypropylcellulose used derivatives cellulose. pharmaceutical composition contains substances following ratio components, wt.-%: bacteriophages titer appelman, 10-4, less; calcium carbonate, 70.0-85.0; lactose and/or mannitol, 5.0-15.0; carboxymethylcellulose sodium salt, 0.1-10.0; microcrystalline cellulose, 2.0-8.0; carboxymethyl starch, 1.0-4.0; magnesium calcium stearate, 0.25-1.0. pharmaceutical composition made tablet mass 0.1 g gastric-resistance coating. invention claims method preparing indicated composition wherein synthetic water-soluble polymers added phagolysate drying additionally, sugars added filling agent phagolysate drying carried vacuum humidity value 1-2%. ^ effect: improved preparing method, enhanced stability composition. ^ 4 cl, 3 ex',\n",
              " 'biological preparation neutralising spores vegetative cells bacillus anthracisfield: medicine, pharmaceutics. ^ substance: invention refers biotechnology represents disinfectant preparation neutralising spores vegetative cells bacillus anthracis, representing aqueous solution containing mixed bacteriophages bacillus anthracis ozr-1, bacillus anthracis f-2, bacillus anthracis \"ñé\" activity relation (pfu/cm3) bacillus anthracis ozr-1: bacillus anthracis f-2: bacillus anthracis \"ñé\" = 1: (0.2-1): (0.1-1). spore germination activator l-alanine. ^ effect: invention provides prolonged disinfecting action safe. ^ 2 cl, 5 ex',\n",
              " 'recombinant plasmid dna pqe-p35d providing synthesis p35d recombinant protein cowpox virus, escherichia coli bacterial strain producer p35d recombinant protein cowpox virus, p35d recombinant protein cowpox virus used engineer test systems prepare orthopoxvirus split vaccinesfield: medicine, pharmaceutics.substance: invention refers biotechnology concerns preparing genetic construct providing synthesis p35d recombinant protein escherichia coli cells. presented: recombinant plasmid dna pqe-p35d providing synthesis p35d recombinant protein cowpox virus containing accordance physical genetic map presented fig. 2: pqe30 plasmid vector, fragment coding mrgshhhhhhg oligopeptice fragment 17 base pairs, coding fragment p35 protein cowpox virus within 1 239 amino acid residues (fig.1a); escherichia coli xl1blue/pqe-p35d b-1252 bacterial strain producer p35d recombinant protein cowpox virus, containing recombinant plasmid dna pqe-p35d deposited collection bacteria, bacteriophages fungi fbun gnts vb vector, registration no. b-1252, p35d recombinant protein cowpox virus.effect: solutions may used engineer test systems prepare orthopoxvirus split vaccines.3 cl, 7 dwg, 5 ex',\n",
              " 'recombinant plasmid ppa-oprfi dna coding hybrid recombinant f-i protein pseudomonas aeruginosa outer membrane, strain escherichia coli pa-oprfi producing hybrid recombinant f-i protein pseudomonas aeruginosa outer membrane method producing hybrid recombinant f-i protein pseudomonas aeruginosa outer membranefield: medicine, pharmaceutics.substance: invention refers biotechnology concerns recombinant plasmid ppa-oprfi dna coding hybrid recombinant f-i protein pseudomonas aeruginosa outer membrane, bacterial strain e.coli pa-oprfi producing hybrid protein, method producing recombinant protein. presented plasmid dna contains dna fragment containing sequence modified promoter bacteriophage t5 two lactose operons; dna fragment containing ribosome entry site, initiation atg-codon sequence coding six histidines; dna fragment containing full-size sequences oprf opri genes p.aeruginosa; dna fragment containing ribosome entry site, dna fragment containing lambda ttranscription stop region.effect: presented inventions enables producing hybrid recombinant f-i protein paeruginosa outer membrane carrying immunobiological assay developing pseudomonas aeruginosa vaccine, producing donor immunoglobulins therapy active forms paeruginosa infection.3 cl, 3 dwg, 1 tbl, 4 ex',\n",
              " 'pharmaceutical composition treating eye infections p. aeruginosa containing recombinant lysozymefield: medicine, pharmaceutics.substance: invention refers biotechnology medicine concerns pharmaceutical composition. presented composition contains recombinant lysozyme fmv p. aeruginosa bacteriophage, ethylene diamine tetraacetate trishcl following proportions, wt %: lysozyme 0.001; trishcl 0.68; ethylene diamine tetraacetate 0.049; water - rest.effect: characterised invention used treating infections caused pseudomonas aeruginosa possesses immediate action side effects.4 tbl, 1 ex',\n",
              " \"antibacterial agentfield: medicine, pharmaceutics.substance: invention refers biotechnology bacteriophagues. antibacterial agent contains bacteriophage concentrate, preserving agent, except related quaternary ammonium derivatives, heavy metal derivatives, oxidising agents, bromine iodine-containing, formaldehyde-releasing preserving agents, water, gelling agent form non-ionic anionic high-molecular compound, non-ionic surfactant ph adjustor following ratio, wt %: bacteriophage concentrate appelman's lytic activity min. 10for type bacteriophague - 0.001-10.0; gelling agent - 0.05-15.0; surfactant - 0.001-2.0; preserving agent - 0.05-0.6; ph adjustor 6.0-8.0; water 100.0.effect: extended range products containing bacteriophages basic active ingredient, provided biological stability activity bacteriophages composition product; composition possess low risk toxicity side effects, provides storage stability efficacy within wide range temperatures.11 cl, 15 ex\",\n",
              " 'specific high-affinity binding proteins containing modified sh3-domains fyn kinasefield: medicine, pharmaceutics.substance: present invention refers biotechnology may used medicine, particularly oncology. presented method creating library recombinant proteins presented src loop rt loop mutant forms sh3 domain, used produce library phage display containing 1 bln mutant derivatives natural sequence sh3-domain given enzyme. result screening derived library presence recombinant proteins binding ligand concern, protein produced characterised high affinity binding extra domain b fibronectin. new protein used construct fused proteins, well chemical derivatives along fused protein invention, contain pharmaceutically and/or diagnostically active ingredients.effect: presented various versions application new binding protein derivatives diagnostic therapeutic agents, particularly applied diagnosing treating malignancies.28 cl, 1 tbl, 17 dwg, 6 ex',\n",
              " 'method tuberculosis phagotherapyfield: medicine, phthisiology. substance: method involves using regionary lymphogenic delivery lipisomal form mycobacteriophage d29. invention promotes enhancement therapeutic effect phagotherapy reduction toxicity phage preparation. invention used phagotherapy tuberculosis. effect: improved method therapy. 1 dwg',\n",
              " 'method treating postoperational abscesses abdominal cavityfield: medicine, purulent surgery. ^ substance: one perform generally accepted medicinal therapy, moreover, one prescribe additional chemotrypsin first 1-2 operation locally injected twice-thrice day-time period concentration 0.5-1.0 mg/ml 10%-sodium chloride solution exposure 1.5-2 h quantity one fourth one third purulent volume removed abscess cavity, therapy course supplemented bacteriophage locally injected twice day-time period daily dosage 200 ml, exposure 1.5-2 h quantity one tenth one fifth purulent volume removed abscess cavity. bacteriophage type, matched accordance results bacteriological survey abscess cavitary content. therapy course lasts 6-9 d. ^ effect: higher efficiency therapy. ^ 2 ex',\n",
              " 'method detecting sensitivity microorganisms liquid combined bacteriophagefield: medicine, surgery. ^ substance: whole wound detritus diluted physiological solution homogenized centrifuged depositing large-scale particles wound detritus. necessary determine sensitivity obtained supernatant liquid combined bacteriophage 18-24 h due interacting liquid combined bacteriophage upon nutritive medium. innovation provides chance earlier onset purposeful bacteriophagotherapy enables shorten terms investigation. ^ effect: higher accuracy efficiency detection. ^ 2 ex',\n",
              " 'immunobiological antiallergic agent (versions) lactobacillus acidophilus 100 \"ê\" pa strain used production immunobiological antiallergic agentfield: medicine. ^ substance: according invention, versions immunobiological antiallergic agent contain lactobacillus acidophilus 100 \"ê\" pa strain, collection no. 207, stored state collection microorganisms normal microflora federal state research institution gabrichevskiy moscow research institution epidemiology microbiology federal service supervision consumer rights human welfare culture medium amount 106-1010 cfu/ml. immunobiological antiallergic agent additionally contains species-specific virulent bacteriophages bacteriophages induced virulence, biomass lactobacillus acidophilus \"ü¿4\" strain culture medium amount 106-1010 cfu/ml, biomass lactobacillus acidophilus nki strain culture medium amount 106-1010 cfu/ml biomass bifidobacterium bacteria culture medium amount 106-1010 cfu/ml. immunobiological antiallergic agent additionally contains target additives amount 0.01-95.0 wt % mass agent. additives selected number of: glycine, cysteine, copper sulphate, copper gluconate, quinosol, chitosan, licorice root extract, hips extract, origanum extract, cranberry extract flavouring agent. immunobiological antiallergic agent presented form suspension. lactobacillus acidophilus 100 \"ê\" pa strain produced means sequence multiple passages nutrient medium mpc added sources histamine, cu1+, cu2+, co2+, ni2+ ions culture ph 6.2-7.4. agent used prevention treatment allergic pseudo-allergic disease without accompanying pathology combination infectious disease, intestinal dysbacteriosis psychological adaptation disorders. ^ effect: efficient antiallergic action immunobiological agent basis lactobacilli. ^ 10 cl, 3 tbl',\n",
              " 'bacteriophage antibacterial agent selective effectfield: medicine. ^ substance: antibacterial agent selective effect contains action bacteriophage concentrate, herbal extract, stabilising additive, essence, antioxidant, preservative agent prebiotics required normal flora development - amino acid sugar, well sorbent protein-degrading enzyme desired component ratio. ^ effect: extended range ecologically safe high-effective antibacterial agents. ^ 5 cl, 2 tbl, 4 ex',\n",
              " 'bacteriophage escherichia coli v32 strain identification escherichia coli bacteria serogroup o157field: medicine. ^ substance: bacteriophage escherichia coli v32 strain deposited collections museum microorganisms federal state intuition science state science centre applied microbiology biotechnology, no. ph25 specific virulent bacteriophage, used option identification escherichia coli bacteria serogroup o157 stage bacterial colony analysis. ^ effect: simple available product requiring heavy time material consumption. ^ 1 dwg, 4 ex',\n",
              " 'device way applying active substances wound surfacefield: medicine. ^ substance: device contains wad porous material applying wound surface, encapsulating top layer overlapping surfaces wound wad fixed skin surface, least one feeding line going wad liquid active substance, one controlled locking element, controls adjustable locking element, least one taking away line going wad connected source vacuum. controls control locking elements time. liquid active substance contains bacteriophages. pump controlled pressure included feeding line. wad encapsulating top layer gauges change concentration bacteriophages, ph temperatures adjustment duration influence placed. method applying active substances containing bacteriophages discovered. ^ effect: invention provides effective treatment wounds. ^ 8 cl, 1 dwg',\n",
              " 'method producing recording marked bacteriophages cholera germ modelfield: medicine. ^ substance: donor strain producing isotope-marked bacteriophage pre-recovered lysogenic strain v.cholerae eltor 1 concentration n108 pfu/ml produced added 5 mcc/ml isotope 3h-thymidine, kept one day thermostat 37c produce marked cholera phage. latter introduced amount 1 ml test tube indicator recipient strain ratio 1:1 lysogenisation, incubated 37c within one day; 0.1 ml derived mixture seeded agar plate, grown 37c within 20-24 hours, donor strain recovered. residual portion mixture used record radioactivity bacteriophage recipient strain. positive result shown radioactivity marked bacteriophages within range 475-1269 p/min, recipient strains within range 78-103 p/min. ^ effect: invention allows higher efficiency detection recording cholera phage 3h-thymidine marked cholera germ cell. ^ 3 tbl, 4 ex',\n",
              " \"oral composition containing nonpathogenic microorganisms showing ability normalise intestinal microflora (versions)field: medicine. ^ substance: group inventions refers pharmaceutical industry medicine applicable producing using medical immunobiological preparations containing nonpathogenic microorganisms. compositions (versions) represent powder containing substances containing nonpathogenic microorganisms dried culture medium specified number: bifidobacterium bacteria and/or lactobacillus bacteria, and/or species-specific virulent bacteriophages, and/or species-specific bacteriophages induced virulence combinations composition containing target additives able form stable foam structure, characterised porous structure fragility, relative disintegration shrinkage least 10 %, equivalent pore diameter 10-110 mcm particle size 100 mcm resting angle less 50 following proportions 1.0 g composition: bifidobacterium bacteria 106-1010 cfu and/or lactobacillus bacteria 106-1010 cfu, and/or species-specific virulent bacteriophages appelman's lytic activity least 10-4 respect test strains bacterial isolates recovered human body, and/or species-specific bacteriophages induced virulence appelman's lytic activity least 10-4 respect test strains bacterial isolates recovered human body, target additives - rest. ^ effect: invention provides maximally achieved isotropic filling set volume drug containers provides accurate dosage nonpathogenic microorganisms. ^ 7 cl, 9 ex\",\n",
              " 'method screening phage display libraryfield: medicine. ^ substance: invention used obtaining diagnostic and/or therapeutic agents, particular antibodies, specifically interact proteins cell surface target cells. claimed method screening phage display library including method isolation library element, specific partner binding target cell surface protein, method isolation unknown cell surface protein, specifically interacting library element. method screening phage display library according invention includes contact said library cells interest separation cells, bound one several elements expression library, non-bound elements separation organic phase, differs introduction additional stage, consists carrying said separation least one stage material washing, ensures essential increase method efficiency. ^ effect: higher efficiency. ^ 30 cl, 7 dwg, 6 ex',\n",
              " 'yersinia enterocolitica bacteria strain used indicator culture detecting moderate bacteriophages lysogenic strains o1, o3, o12 serovarsfield: medicine. ^ substance: invention used laboratory diagnostics yersinia enterocolitica strains using moderate bacteriophages fk-99, fk-100, fk-101 intraspecific differentiation yersiniosis agent. yersinia enterocolitica 2012 strain recovered human 1966 deposited state collection pathogenic bacteria russian research antiplague institution \"microbe\", no. km-206. used mentor strain, enables particle concentration phage preparations equal n10-n10 particles/ml. ^ effect: use recovered phages yersinia enterocolitica indicator km-206 offered invention provides additional differentiation lysogenic cultures non-lysogenic ensures effectiveness laboratory diagnostics yersinia enterocolitica. ^ 1 tbl, 1 ex',\n",
              " 'method prevention bucket-handle graft plastics complicationfield: medicine. ^ substance: invention concerns medicine, namely surgery, used application fields bucket-handle graft plastics. cellulocutaneous flap cut form bucket-handle graft. suturing, tubular fenestrated drainage inserted edges formed bucket-handle graft additional vertical incision length 3-4 mm. along whole length draining part drainage, spiral holes 4ù3 mm. postoperative period, within four-six days graft irrigated either antiseptics, antibiotics, bacteriophages. drainage removed. ^ effect: application invention provides continuous outflow wound discharge allows reducing potential edema infection graft improving blood supply. ^ 1 dwg, 2 ex',\n",
              " \"bacteriophage composition (versions)field: medicine. ^ substance: invention concerns pharmaceutical industry, food industry, bioengineering used manufacturing medical immunobiological preparations, biologically active additives food additives. invention represents versions bacteriophage composition contain species-specific virulent bacteriophages induced-virulence bacteriophages appelman's lytic activity 10-4 respect test strains bacteria isolates recovered human body phage lysate filtrate nonlysogenic bacteria phage lysate concentrate filtrate nonlysogenic bacteria, desired additives. ^ effect: invention provides stable virulence bacteriophages, adaptation thereof circular agents bacterial infections. ^ 6 cl, 2 tbl\",\n",
              " 'method treating babies suffering intestinal colicsfield: medicine. ^ substance: invention refers medicine, aims treating babies suffering intestinal colics. mother breast-fed child treated simultaneously. cephalosporin antibiotic, antistaphylococcal immunoglobulin, staphylococcal bacteriophage, antifungal agent, phagocytosis activator prescribed mother 7-10 days. staphylococcal bacteriophage, hylak forte prescribed baby. second stage involves prescribing bacterial preparation, immunomodulator therapeutic staphylococcal anatoxin. baby intakes hylak forte bacterial preparation. ^ effect: method allows relieving intestinal colics preventing development complications. ^ 1 ex',\n",
              " 'method treating chronic bacterial conjunctivitisfield: medicine. ^ substance: invention refers medicine, namely ophthalmology, concerns treating chronic bacterial conjunctivitis. ensured bacteriophage instillations conjunctival cavity considering drug sensitivity bacterial flora. combined nasolacrimal duct irrigation first 3-4 days bacteriophage preparation, injected nasal passages used irrigate pharyngeal mucosa. therapy within 10 days, least 5 times day. ^ effect: method provides reduction symptoms bacterial conjunctivitis 3-4th day treatment, decreased number recurrences due simultaneous sanitation reservoirs bacterial infection. ^ 2 ex',\n",
              " 'preparation containing staphylococcal bacteriophage, preparation candidiasis treatmentfield: medicine. ^ substance: invention refers medicine, particularly antimycotic preparation. application preparation containing staphylococcal bacteriophage virulent bacteriophage induced-virulence bacteriophage specified lytic activity relation test strains staphylococcus isolates recovered human body preparation candidiasis treatment administered orally 2-3 times day within 4-7 days. ^ effect: said preparation effective candidiasis treatment. ^ 3 ex',\n",
              " 'recombinant plasmid dna per-hir coding hybrid protein capable autocatalytic breakdown form [leul, thr2]-63-desulphatohirudin, escherichia coli er2566/per-hir strain - producer said protein method producing genetically engineered [leul, thr2]-63-desulphatohirudinfield: medicine. ^ substance: invention refers recombinant plasmid dna per-hir coding hybrid protein capable autocatalytic breakdown form [leul, thr2]-63-desulphatohirudin, escherichia coli er2566/per-hir strain - producer said protein method producing genetically engineered [leu 1, thr2]-63-desulphatohirudin. presented recombinant plasmid dna consists sapi/bamhi fragment dna plasmid ptwin-1 containing promoter terminator t7-rna-polymerase transcription, amplifier phages t7 gene 10 translation, -laktamase (ap) gene, modified mini-intein ssp dnab gene, integrated sequence chitin-binding domain, sapi/bamhi-fragment dna containing sequence gene recombinant [leul, thr2]-63-desulphatohirudin-1 containing -laktamase (ap) gene genetic marker, unique recognition sites restriction endonucleases located following distance left site bamhi: nrul - 186 base pairs, ndel - 594 base pairs, xbal - 882 base pairs, ecorv - 2913 base pairs, hpal - 2966 base pairs. ^ effect: inventions allow producing said compound used drug applied prevent blood hypercoagulation. ^ 3 cl, 1 dwg, 4 ex',\n",
              " 'method obtaining remedy fly larvae wound treatment remedy obtained said methodfield: medicine. ^ substance: invention relates field medicine, namely remedy method obtaining remedy wound treatment. method obtaining remedy wound treatment lies following: fly eggs larvae gown, introduced wound treatment, larvae contaminated bacteriophages way introduced larvae bacteriophage carriers. order realising said method, particular, larvae genus lucilia used. claimed method remedy wound treatment, tampon containing bacteriophages soaked larva secret wound. ^ effect: treatment wounds fly larvae improved contamination larvae bacteriophages. ^ 14 cl',\n",
              " 'method post-operation treatment patients open trauma ankle jointfield: medicine. ^ substance: invention relates field medicine, namely traumatology applied treatment patients open fractures ankle joint area. cadaver fibrinolytically active plasma (fap), antibiotics polyvalent phages introduced ankle joint means microirrigator passed anterior joint surface unaffected skin opposite side wound. fap, activity 1500-2000 mu introduced first three days, earlier 10 hours operation, 2 times per day amount 5.0 ml following 2-3 days -1 time per day. bandaging antibiotics phages introduced ankle joint 1 time per day 5-6 days therapeutic dose. ^ effect: method allows reducing number deep purulent complications. ^ 3 cl, 2 ex, 10 dwg',\n",
              " \"left ventricle diastole malfunction severity level diagnosis patients chronic cardiac failurefield: medicine. ^ substance: invention relates medicine, namely cardiology. echocardiography used value parameters e/a, dt, ivrt (tmd) s/d spectra rest load doppler's testing - degree decline e / height valsalva test (e/a vals), diastolic left ventricle (lv) reserve altitude isometric (dr isom) cold (dr cold) loads. used determine ejection fraction value lv end diastolic volume index left right ventricles, myocardial mass meet certain rules, certain differential diagnostic phage (ddp) stage set. method allows increase accuracy identifying patients initial (stage ddp), frank diastole malfunctions, clearly distinguishing patients normal tmd spectrum patients pseudo-normalisation (stage ii ddp), determining degree lv malfunction patients chronic cardiac failure. ^ effect: diagnosis accuracy increasing patients icp. ^ 1 dwg, 5 tbl, 4 ex\",\n",
              " 'sextaphage (pyobacteriophage polyvalent) bacteriophage salmonellous pharmaceutical composition method producing thereoffield: medicine. ^ substance: invention represents pharmaceutical composition containing bacteriophage (sextaphage« (pyobacteriophage polyvalent)) bacteriophage salmonellous groups a, b, c, d, e) dried excipients (methyl cellulose, lactose, calcium carbonate, calcium magnesium stearate) form gastric-resistant uncoated tablets, differing fact relation parity bacteriophage excipients makes 1:1 1.25:1, composition contains addition - sorbite sodium alginate. one tablet weight 0.16-0.2 g contains bacteriophages appelman titre less 10-3, ingredients components certain ratio, wt %. ^ effect: higher gastric resistance tablets stabilisation bacteriophages. ^ 2 cl, 3 ex',\n",
              " 'method preparing fine-dispersed mycobacteria cell culture sensitive mycobacteriophage infectionfield: medicine. ^ substance: method preparing fine-dispersed mycobacteria cell cultures sensitive mycobacteriophage infection involves primary cultivation mycobacteria nutrient medium nonionic detergent either tween 80, tween 20, span 85 amount 0.25-0.5 wt %, and/or ionogenic detergent sodium lauroyl sarcosinate within 0.01-0.03 wt %. one reinoculation, cultivation carried without detergent. herewith throughout entire cycle, mycobacteria cell cultivation enabled nutrient medium containing, g/l: trypton - 15, yeastrel - 5, glucose - 40, sodium chloride - 2.5, potassium hydrophosphate - 5, calcium chloride - 0.111. ^ effect: higher dose accuracy fine-dispersed cell mass combined bacteriophage infection large quantity sampled cell mass reduced work content process. ^ 8 ex',\n",
              " 'virus-like particles including hybrid protein ap205 bacteriophage coat protein antigen polypeptidefield: medicine. ^ substance: modified virus-like particle (vlp) includes hybrid protein consists ap205 bacteriophage protein antigen. also, composition including vlp, derivative rna-containing ap205 bacteriophage described. besides, invention describes method producing said vlp. modified vlp present invention applicable producing compositions inducing immune response prevention treatment diseases, disorders, including infectious diseases, allergies, cancer drug addiction. ^ effect: offered group inventions used medicine, immunology, virology molecular biology. ^ 35 cl, 3 dwg, 1 tbl, 26 ex',\n",
              " 'immunomimetic peptide chemical cancerogens specific interaction effect antibodies benzo[]pyrene benzo[]anthracenefield: medicine. ^ substance: peptide obtained phage peptide library including set static peptides length 12 aminoacid residues, affine selection phage clones containing peptide capable specific linking antibodies benzo[]pyrene benzo[]anthracene. peptide displays specific interaction effect antibodies benzo[]pyrene benzo[]anthracene features molecular weight 1.3 kda registered aminoacid sequence lhlphhdgvgwg encoded nucleotide sequence seq id no:1. ^ effect: application medicine base peptide medicine development immunologic prevention malignant tumours humans. ^ 4 dwg, 3 ex',\n",
              " 'recombinant plasmid, escherichia coli strain, chimeric protein applicationfield: medicine. ^ substance: recombinant plasmid pcfp10-cbd consisting artificial bacterial operon chimeric protein containing promotor area early promotor bacteriophage t5, chimeric protein gene transcription terminator, bacterial operon beta-lactamase bacterial colel-type replication initiation site described. invention involves escherichia coli strain - producer chimeric protein cfp10-cbd, method immobilisation, concentration cellulose purification produced protein. besides, invention refers recombinant protein cfp10-cbd immunogenic composition containing used tuberculous infection immunity induction. ^ effect: invention allows producing strain - producer providing high production level resistant immunogenic proteins one-stage produced, immobilised purified, producing effective immunogenic compositions tuberculosis. ^ 5 cl, 1 dwg, 4 ex',\n",
              " 'recombinant plasmid, escherichia coli strain, chimeric protein applicationfield: medicine. ^ substance: recombinant plasmid pesat6-cbd consisting artificial bacterial operon chimeric protein containing promotor area early promotor bacteriophage t5, chimeric protein gene transcription terminator, bacterial operon beta-lactamase bacterial colel-type replication initiation site described. invention involves escherichia coli strain - producer chimeric protein esat6-cbd, method immobilisation, concentration cellulose purification produced protein. besides, invention refers recombinant protein esat6-cbd immunogenic composition containing used tuberculous infection immunity induction. ^ effect: invention allows producing producer strain providing high production level resistant immunogenic proteins one-stage produced, immobilised purified, producing effective immunogenic compositions tuberculosis. ^ 6 cl, 1 dwg, 5 ex',\n",
              " 'strain bacteriophage acinetobacter baumannii ap22i identification acinetobacter baumannii bacteria bacteriologic analysis clinical material obtaining preparation nosocomial a. baumannii-infectionsfield: medicine. ^ substance: species-specific virulent strain bacteriophage acinetobacter baumannii ap22 myoviridae family isolated clinical material deposited collection microorganisms museum fsis \"state research centre applied microbiology biotechnology\" number ph-42. bacteriophage possesses expressed lytic activity, lyses 68% a. baumannii strains, isolated clinical material, used identification microorganisms opf said species bacteriologic analysis clinical material, well elaboration complex medications a. baumannii-infections. ^ effect: invention ensures wide spectrum activity within said species. ^ 2 dwg, 1 tbl, 4 ex',\n",
              " 'strain bacteria b anthracis km104-plamid-free pxo1--à-, pxo2--cap- avirulent, çæ16- tetracycline-responsive tets, streptomycin-dependent strd used geneticsfield: medicine. ^ substance: strain deposited collections federal state health care institution \"russian research plague institution \"microbe\", assigned no. b.anthtacis km 104. plasmid pxo2 (capsule-formation) eliminated strain, avirulent white mice cavies, exhibits characteristic cultural-morphological, biological properties, sensitivity specific phages, characteristic b.anthtacis. ^ effect: genetic characteristic strain allows used genetic experiments. ^ 4 ex',\n",
              " 'strain salmonella typhimurium bacteriophage s-394, possessing lytic activityfield: medicine. ^ substance: strain bacteriophage salmonella typhimurium s-394 deposited collection microorganisms federal state institution science \"state research centre virology ad biotechnology \"vector\" rospotrebnadzor (fsis src vb \"vector\" rospotrebnadzor) number ph-1240. strain possesses polyvalent lytic activity respect bacteria genus escherichia coli, strains salmonella ta 1537 salmonella ta 100, strains shigella sonneri 32 shigella flexneri ad. high yield bacteriophage s-394 obtained opportunistic strain escherichia coli ab-259, safe case wide-scale cultivations production medications veterinary escherichia coli, salmonella shigell, well elimination prevention hospital infections. ^ effect: invention provides wider spectrum lytic activity respect gram-negative pathogenic microorganisms escherichia coli, salmonella shigella, produced action bacteriolytic enzyme, contains. ^ 4 tbl, 1 ex',\n",
              " 'recombinant plasmid pag85a-cbd, escherichia coli [prep4, pag85a-cbd] strain, chimeric protein ag85a-cbd applicationfield: medicine. ^ substance: synthetic gene ag85a mycobacterium tuberculosis optimised heterologous expression nonpathogenic laboratory strains. recombinant plasmid pag85a-cbd consisting artificial bacterial operon chimeric protein containing promotor area early promotor bacteriophage t5, chimeric protein gene transcription terminator, bacterial operon beta-lactamase bacterial colel-type replication initiation site produced. invention involves escherichia coli strain producing chimeric protein ag85a-cbd, method immobilisation, concentration cellulose purification produced protein. besides, invention refers recombinant protein ag85a-cbd immunogenic composition containing used tuberculous infection immunity induction. ^ effect: invention allows preparing producer strain providing high production level resistant immunogenic proteins one-stage produced, immobilised purified, producing effective immunogenic compositions tuberculosis. ^ 7 cl, 2 dwg, 5 ex',\n",
              " 'recombinant plasmid dna psc13d6 containing gene one-chained antibody tick-borne encephalitis virus, strain bacteria escherichia coli bl21 (de3)/psc13d6-producer one-chained antibodies tick-borne encephalitis virus, expressing virus neutralising propertiesfield: medicine. ^ substance: designed recombinant plasmid dna psc13d6 containing gene one-chained antibody tick-borne encephalitis virus sc13d6. plasmid consists 3782 basepairs contains: plasmid vector pgeml, phage t7 promotor unique restriction sites. discovered strain bacteria escherichia coli bl21 (de3)/psc13d6 - producer virus neutralising one-chained antibody sc13d6 tick-borne encephalitis virus. ^ effect: invention allows producing one-chained antibodies sc13d6 tick-borne encephalitis virus able inhibit effectively. ^ 2 cl, 5 dwg, 5 ex',\n",
              " 'method obtaining ribonucleic acidfield: medicine. ^ substance: 1 part water solution, contains 1 mg/ml plasmid dna, added 10 parts water 1 part suspension, containing 4 g/ml superparamagnetic parts magnetite. obtained solution added 1 part buffer solution ph 7.5, 2 parts 0.005 solution ribonucleotidetriphpsphates, 2 parts 0.1 dithiotreitole, 1 part solution, containing 2 mg/ml bovine serum albumin, 1 part solution, contains 10 units rnaase inhibitor 1 part solution, contains 10 units pna-polymerase t3 t7 sp6 bacteriophage. obtained mixture incubated less 1 hour temperature +37c placed magnetic field intensity less 0.2 1-3 minutes. water phase, containing target rna decanted. ^ effect: rna, obtained claimed method, high quality suitable molecular-biological studies gene structure functions, well diagnostic therapeutic purposes medical practice. ^ 2 cl, 1 dwg, 1 ex',\n",
              " 'pseudomonas aeruginosa bacteriophage strain used base preparing aseptic p aeruginosafield: medicine. ^ substance: presented virulent pseudomonas aeruginosa ph57 bacteriophage strain recovered vivarium excrement depositied collection microorganisms federal state research institution state science centre vector, registration no. v-357. ^ effect: strain shows wide spectrum pseudomonas aeruginosa lytic activity may used base preparing antiseptic agent p aeruginosa. ^ 7 tbl, 4 ex',\n",
              " 'method treating cases chronic prostatitis sexual disordersfield: medicine. substance: method involves administering ethiotropic therapy pyo bacteriophage. mud old russia resort administered alternating slips-and-socks rectal mud tampon applications. pathogenetic therapy applied inguinal lymph nodes lumbosacral area terrilitine electrophoresis. electrophoresis alternated monitor-assisted intestine cleansing mineral water old russia diluted 4-5 g/l concentration. rational psychotherapy administered first four days psychotherapy suggestion elements applied. effect: enhanced effectiveness treatment. 1 tbl',\n",
              " \"method surgical treatment large joint periprosthetic infection using polyvalent fagoderm bacteriophagefield: medicine.substance: access performed site inflammatory complications. modified necrotic tissue cut removing abnormal soft tissues, including metal endoprosthesis cavity, exposing metal endoprosthesis surface. metal endoprosthesis separated, head plastic liner removed. wound cavity surface exposed surfaces disconnected metal endoprosthesis washed, first, 3% povidone-iodine solution using pulse lavage system, wound cavity surface exposed surfaces disconnected metal endoprosthesis washed 1% lavasept solution using ultrasonic lavage. new endoprosthesis head new plastic liner suitable size placed metal endoprosthesis endoprosthesis integrity restored. wound cavity surface assembled metal endoprosthesis surface washed 1% lavasept solution using ultrasonic lavage. gel polyvalent fagoderm bacteriophages applied wound cavity surface assembled metal endoprosthesis surface, uniformly distributing across entire wound cavity surface assembled metal endoprosthesis surface, provding gel layer thickness 1 3 mm. wound closed. within 3-5 days postoperative period, wound drainage performed 1% solution fagoderm bacteriophage upwards perforated drains.effect: method allows save prosthesis, reduce risk re-intervention affected joint, restore functionality patient's limb.13 cl\",\n",
              " 'compositions methodsfield: medicine.substance: disclosed versions using purified population germination-competent bacterial spores treating preventing reducing severity least one symptom gastrointestinal dysbiosis associated clostridium difficile, including recurrent c.difficile infection, ulcerative colitis mammalian recipient, well versions therapeutic composition containing effective amount purified population germination-competent bacterial spores. germination-competent bacterial spores obtained following steps: a) providing fecal material mammalian donor, b) carrying ethanol treatment heat treatment fecal material, resulting population germination-capable bacterial spores. said purified population, pathogenic material substantially eliminated detectable level, pathogenic material substantially free pathogenic activity reduced level pathogenic activity, said pathogenic material optionally selected group consisting virus, bacterium, eukaryotic parasite, helminth, phage, mycoplasma, toxoplasma fungus. spores contain least two kinds bacteria comprising nucleic acid sequences least 97% identical nucleic acid sequences selected group consisting seq id no. 6, seq id no. 383, seq id no. 381, seq id no. 572, seq id no. 601, seq id no. 652, seq id no. 659, seq id no. 673, seq id no. 674, seq id no. 774, seq id no. 839, seq id no. 845, seq id no. 847, seq id no. 848, seq id no. 856, seq id no. 874, seq id no. 880, seq id no. 886, seq id no. 1049, seq id no. 1591, seq id no. 1655, seq id no. 1657, seq id no. 1670 seq id no. 1896.effect: group inventions provides effective prevention, control treatment diseases, disorders conditions gastrointestinal tract associated clostridium difficile, ensuring healthy functioning digestive system whole.23 cl, 21 dwg, 33 tbl, 37 ex',\n",
              " 'method device detecting bacteriafield: medicine.substance: group inventions relates accelerated highly sensitive method detecting bacterial pathogens. disclosed method detecting bacteria, comprising providing one one suspension, containing least one type labeled test bacteriophages, specifically bind type bacteria detected; adding sample checked presence least one type bacteria; filtering obtained reaction mixture; detection bacteria-bacteriophage complexes concentrate; detection unbound bacteriophages filtrate; processing obtained signals generated result detection, output detection results user. one suspensions contain labeled reference bacteriophage bind type bacteria detected, labeled micro- nanoparticles bind type bacteria detected; wherein ratio total intensity signal reference bacteriophage concentrate total intensity signal reference bacteriophage filtrate determined compared ratio total intensity signal tested bacteriophage concentrate total intensity signal tested bacteriophage filtrate. disclosed reaction vessel, cartridge measuring device detecting bacteria accordance described method.effect: group inventions provides fast reliable identification bacterial pathogens, simple implementation high sensitivity.18 cl, 19 dwg, 2 ex',\n",
              " \"strain escherichia coli bl21(de3)gold/petmin-cypa producing human recombinant cyclophilin afield: medicine.substance: invention refers biotechnology concerns strain escherichia coli bl21(de3)gold/petmin-cypa producing human recombinant cyclophilin a. characterised strain produced cell transformation strain bl21(de3)gold petmin-cypa plasmid. plasmid size 5865 base pairs contains xhoi-ndei fragment pet-22b(+) vector carrying ampr ampicillin resistance gene, promoter rna-polymerase t7 phage terminator polylinker. fragment produced pcr using oligonucleotide primers 5'-ttatacatatggtcaacccgaccgtgttcttc 5'-tttctcgagttattcgagttgtccacagtcagc pcypawt/pgex-2tk plasmid closed fragment hrcpa (human recombinant cyclophilin a) gene size 498 base pairs cloned xhoi-ndei sites.effect: presented strain high-producing; requires complicated clean-up system used cancer treatment.2 dwg\",\n",
              " 'oncolytic treatment method breast cancerfield: medicine.substance: invention refers medicine molecular biology used treating breast cancer (bc). method carried targeted delivery thallium salts using surface-modified virions phage ms2, containing cyclic ligand irgd, high affinity integrin aband covalently bonded cladding, core genomic rna thallium salts.effect: using invention enables reducing tumour size directing cytotoxic effect focal metastatic accumulations tumour cells.1 cl, 1 tbl, 2 dwg, 4 ex',\n",
              " 'method treating bacterial respiratory infectionsfield: medicine.substance: invention refers medicine, concerns method treating bacterial infections respiratory tract, involving prescribing drug therapy drug indicated nebulizer, laboratory microbiological examination microorganism sensitivity medical-diagnostic bacteriophage carried out, determining lytic activity three batches bacteriophage respect recovered microorganism, selecting bacteriophage lytic activity less \"++++\", using nebulizer inhalation therapy, inhalation, microbiological examination clinical material pathological focus performed assessment sensitivity, extracting microorganism maintaining sensitivity bacteriophage inhalation repeated.effect: invention provides higher clinical effectiveness bacterial etiology respiratory infections, including antibiotic-resistant strains etiologic agent, delivering active antimicrobial agent (bacteriophage) directly infection center.1 cl, 2 ex',\n",
              " 'method assessing bacteriophage specific activity using cell culturesfield: medicine.substance: invention refers medicine, microbiology, biology. disclosed method evaluating specific activity bacteriophages standard conditions monolayer cell culture pulmonary fibroblasts human embryo (phe-3) evaluation results degree reduction adhesion test strain microorganism cells monolayer degree lysis non-adherent bacterial cells, providing 1 hour combined cultivation test strain microorganism corresponding bacteriophage amount 0.2 ml. followed evaluating result compared bacteriophage-free control.effect: invention provides reduced reaction time.1 cl, 4 tbl, 1 ex',\n",
              " ...]"
            ]
          },
          "metadata": {},
          "execution_count": 16
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(type(txt))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "qUEXbtbaaZQL",
        "outputId": "811e3493-6213-4e0b-99fe-8eb93a19b30c"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<class 'list'>\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "import nltk\n",
        "from nltk.corpus import stopwords\n",
        "from wordcloud import WordCloud, STOPWORDS\n",
        "\n",
        "# Assume df is your original DataFrame\n",
        "# Remove rows where either 'Abstract' or 'Title' is null\n",
        "df = df.dropna(subset=['Abstract', 'Title'])\n",
        "\n",
        "# Generate the data list combining 'Title' and 'Abstract'\n",
        "data = [str(df['Title'].iloc[i]) + str(df['Abstract'].iloc[i]) for i in range(len(df))]\n",
        "\n",
        "# Download necessary NLTK resources\n",
        "nltk.download('wordnet')\n",
        "nltk.download('stopwords')\n",
        "\n",
        "# Generate a list of stopwords\n",
        "s = set(STOPWORDS)\n",
        "sw = set(stopwords.words('english'))\n",
        "sw |= s\n",
        "sw.add('amp')\n",
        "\n",
        "# Initialize a list to store cleaned texts\n",
        "cleaned_texts = []\n",
        "\n",
        "# Text preprocessing\n",
        "for text in data:\n",
        "    words = text.lower().split()\n",
        "    cleaned_words = [word for word in words if word not in sw]\n",
        "    cleaned_text = ' '.join(cleaned_words)\n",
        "    cleaned_texts.append(cleaned_text)\n",
        "\n",
        "# Add the cleaned texts back to the original DataFrame\n",
        "df['Cleaned_Text'] = cleaned_texts\n",
        "len(df)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "SZrOjwN1VKti",
        "outputId": "a66d7dd9-778a-47ec-db82-2f92110c1921"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package wordnet to /root/nltk_data...\n",
            "[nltk_data]   Package wordnet is already up-to-date!\n",
            "[nltk_data] Downloading package stopwords to /root/nltk_data...\n",
            "[nltk_data]   Package stopwords is already up-to-date!\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "5145"
            ]
          },
          "metadata": {},
          "execution_count": 18
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Drop rows where 'Cleaned_Text' is null\n",
        "df_filtered = df.dropna(subset=['Cleaned_Text'])\n",
        "\n",
        "# Keep only the rows with unique 'Cleaned_Text'\n",
        "df_filtered = df_filtered.drop_duplicates(subset=['Cleaned_Text'])\n",
        "df_filtered"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "aTZ_q8UqVMaG",
        "outputId": "d769d66f-25c8-455e-9f50-65e60eb2673a"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                         # Jurisdiction Kind  \\\n",
              "Lens ID             Publication Year                           \n",
              "088-886-194-310-021 2006              6343           FR   A1   \n",
              "147-331-231-570-922 2007              2680           WO   A1   \n",
              "148-164-161-664-368 2007               111           WO   A1   \n",
              "161-684-752-020-329 2004              3085           JP    A   \n",
              "089-102-410-621-069 2004              3892           JP    A   \n",
              "...                                    ...          ...  ...   \n",
              "179-151-089-030-564 2019              6156           CZ   U1   \n",
              "014-594-233-943-253 2020              6024           CZ   U1   \n",
              "115-179-292-453-581 2006              6234           AU   A1   \n",
              "069-774-923-021-970 2005              6214           AU   A1   \n",
              "125-476-374-578-517 2017              4736           GB   D0   \n",
              "\n",
              "                                            Display Key Publication Date  \\\n",
              "Lens ID             Publication Year                                       \n",
              "088-886-194-310-021 2006                  FR 2878165 A1       26/05/2006   \n",
              "147-331-231-570-922 2007              WO 2007/083793 A1       26/07/2007   \n",
              "148-164-161-664-368 2007              WO 2007/114139 A1       11/10/2007   \n",
              "161-684-752-020-329 2004                JP 2004097032 A       02/04/2004   \n",
              "089-102-410-621-069 2004                JP 2004099465 A       02/04/2004   \n",
              "...                                                 ...              ...   \n",
              "179-151-089-030-564 2019                    CZ 33381 U1       12/11/2019   \n",
              "014-594-233-943-253 2020                    CZ 33918 U1       14/04/2020   \n",
              "115-179-292-453-581 2006              AU 2006/201041 A1       06/04/2006   \n",
              "069-774-923-021-970 2005              AU 2005/227384 A1       24/11/2005   \n",
              "125-476-374-578-517 2017                GB 201709104 D0       19/07/2017   \n",
              "\n",
              "                                     Application Number Application Date  \\\n",
              "Lens ID             Publication Year                                       \n",
              "088-886-194-310-021 2006                   FR 0412364 A       22/11/2004   \n",
              "147-331-231-570-922 2007                JP 2007050890 W       22/01/2007   \n",
              "148-164-161-664-368 2007                JP 2007056579 W       28/03/2007   \n",
              "161-684-752-020-329 2004                JP 2002260418 A       05/09/2002   \n",
              "089-102-410-621-069 2004                JP 2002260419 A       05/09/2002   \n",
              "...                                                 ...              ...   \n",
              "179-151-089-030-564 2019                 CZ 201936608 U       09/09/2019   \n",
              "014-594-233-943-253 2020                 CZ 202037223 U       06/02/2020   \n",
              "115-179-292-453-581 2006               AU 2006/201041 A       10/03/2006   \n",
              "069-774-923-021-970 2005               AU 2005/227384 A       27/10/2005   \n",
              "125-476-374-578-517 2017                 GB 201709104 A       07/06/2017   \n",
              "\n",
              "                                                        Priority Numbers  \\\n",
              "Lens ID             Publication Year                                       \n",
              "088-886-194-310-021 2006                                    FR 0412364 A   \n",
              "147-331-231-570-922 2007                                 JP 2006014314 A   \n",
              "148-164-161-664-368 2007                                 JP 2006105143 A   \n",
              "161-684-752-020-329 2004                                 JP 2002260418 A   \n",
              "089-102-410-621-069 2004                                 JP 2002260419 A   \n",
              "...                                                                  ...   \n",
              "179-151-089-030-564 2019                                  CZ 201936608 U   \n",
              "014-594-233-943-253 2020                                  CZ 202037223 U   \n",
              "115-179-292-453-581 2006              AU 2001/027834 A;;AU 2006/201041 A   \n",
              "069-774-923-021-970 2005              AU 2000/077021 A;;AU 2005/227384 A   \n",
              "125-476-374-578-517 2017                                  GB 201709104 A   \n",
              "\n",
              "                                     Earliest Priority Date  \\\n",
              "Lens ID             Publication Year                          \n",
              "088-886-194-310-021 2006                         22/11/2004   \n",
              "147-331-231-570-922 2007                         23/01/2006   \n",
              "148-164-161-664-368 2007                         06/04/2006   \n",
              "161-684-752-020-329 2004                         05/09/2002   \n",
              "089-102-410-621-069 2004                         05/09/2002   \n",
              "...                                                     ...   \n",
              "179-151-089-030-564 2019                         09/09/2019   \n",
              "014-594-233-943-253 2020                         06/02/2020   \n",
              "115-179-292-453-581 2006                         12/01/2001   \n",
              "069-774-923-021-970 2005                         14/09/2000   \n",
              "125-476-374-578-517 2017                         07/06/2017   \n",
              "\n",
              "                                                                                  Title  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              New (mutant) netrin-4, netrin-1, netrin-3, ant...   \n",
              "147-331-231-570-922 2007              PANNING METHOD UTILIZING PHOTOREACTIVE GROUP A...   \n",
              "148-164-161-664-368 2007               PHAGE DISPLAY BY NOVEL FILAMENTOUS BACTERIOPHAGE   \n",
              "161-684-752-020-329 2004              METHOD FOR MONITORING BACTERIUM UTILIZING CHIT...   \n",
              "089-102-410-621-069 2004              METHOD FOR CONTROLLING INSECT PEST WITH ALGINA...   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019              System for preparing samples and identifying a...   \n",
              "014-594-233-943-253 2020              Test kit to determine the antimicrobial biolog...   \n",
              "115-179-292-453-581 2006              The parenteral use of bacterial phage associat...   \n",
              "069-774-923-021-970 2005              The use of bacterial phage associated lysing e...   \n",
              "125-476-374-578-517 2017              Use of Bacteriophages to control blackleg and ...   \n",
              "\n",
              "                                                                               Abstract  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              (Mutant) netrin-4 protein (I) comprising at le...   \n",
              "147-331-231-570-922 2007              [PROBLEMS] To provide a method for ensuring th...   \n",
              "148-164-161-664-368 2007              [PROBLEMS] To provide a phage display vector w...   \n",
              "161-684-752-020-329 2004              <P>PROBLEM TO BE SOLVED: To develop a method f...   \n",
              "089-102-410-621-069 2004              <P>PROBLEM TO BE SOLVED: To develop a new defo...   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                                              .   \n",
              "014-594-233-943-253 2020                                                              .   \n",
              "115-179-292-453-581 2006                                                              .   \n",
              "069-774-923-021-970 2005                                                              .   \n",
              "125-476-374-578-517 2017                                                              .   \n",
              "\n",
              "                                                                             Applicants  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              CENTRE NAT RECH SCIENT;;I V S INST DES VAISSEA...   \n",
              "147-331-231-570-922 2007              UNIV TOYAMA NAT UNIV CORP;;HATANAKA YASUMARU;;...   \n",
              "148-164-161-664-368 2007                                               UCHIYAMA FUMIAKI   \n",
              "161-684-752-020-329 2004                                                      UNIV KOBE   \n",
              "089-102-410-621-069 2004                                                      UNIV KOBE   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                                UNIV MASARYKOVA   \n",
              "014-594-233-943-253 2020                                                MB PHARMA S R O   \n",
              "115-179-292-453-581 2006              NEW HORIZONS DIAGNOSTICS CORPORATION;;UNIV ROC...   \n",
              "069-774-923-021-970 2005                                   NEW HORIZONS DIAGNOSTICS INC   \n",
              "125-476-374-578-517 2017                                 AGRI-FOOD AND BIOSCIENCES INST   \n",
              "\n",
              "                                                                              Inventors  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006                                    PLOUET JEAN;;ALEMANY MONICA   \n",
              "147-331-231-570-922 2007                             HATANAKA YASUMARU;;SADAKANE YUTAKA   \n",
              "148-164-161-664-368 2007                                               UCHIYAMA FUMIAKI   \n",
              "161-684-752-020-329 2004              MAYAMA SHIGEYUKI;;TOSA YUKIO;;OTSU YASUNARI;;T...   \n",
              "089-102-410-621-069 2004              MAYAMA SHIGEYUKI;;TOSA YUKIO;;OTSU YASUNARI;;T...   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019              PANTŮČEK ROMAN;;ŠTVERÁKOVÁ DANA;;ŠEDO ONDREJ;;...   \n",
              "014-594-233-943-253 2020                                     MOŠA MAREK;;BENEŠÍK MARTIN   \n",
              "115-179-292-453-581 2006                             FISCHETTI VINCENT;;LOOMIS LAWRENCE   \n",
              "069-774-923-021-970 2005                             LOOMIS LAWRENCE;;FISCHETTI VINCENT   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                     Owners  \\\n",
              "Lens ID             Publication Year          \n",
              "088-886-194-310-021 2006                NaN   \n",
              "147-331-231-570-922 2007                NaN   \n",
              "148-164-161-664-368 2007                NaN   \n",
              "161-684-752-020-329 2004                NaN   \n",
              "089-102-410-621-069 2004                NaN   \n",
              "...                                     ...   \n",
              "179-151-089-030-564 2019                NaN   \n",
              "014-594-233-943-253 2020                NaN   \n",
              "115-179-292-453-581 2006                NaN   \n",
              "069-774-923-021-970 2005                NaN   \n",
              "125-476-374-578-517 2017                NaN   \n",
              "\n",
              "                                                                       URL  \\\n",
              "Lens ID             Publication Year                                         \n",
              "088-886-194-310-021 2006              https://lens.org/088-886-194-310-021   \n",
              "147-331-231-570-922 2007              https://lens.org/147-331-231-570-922   \n",
              "148-164-161-664-368 2007              https://lens.org/148-164-161-664-368   \n",
              "161-684-752-020-329 2004              https://lens.org/161-684-752-020-329   \n",
              "089-102-410-621-069 2004              https://lens.org/089-102-410-621-069   \n",
              "...                                                                    ...   \n",
              "179-151-089-030-564 2019              https://lens.org/179-151-089-030-564   \n",
              "014-594-233-943-253 2020              https://lens.org/014-594-233-943-253   \n",
              "115-179-292-453-581 2006              https://lens.org/115-179-292-453-581   \n",
              "069-774-923-021-970 2005              https://lens.org/069-774-923-021-970   \n",
              "125-476-374-578-517 2017              https://lens.org/125-476-374-578-517   \n",
              "\n",
              "                                           Document Type Has Full Text  \\\n",
              "Lens ID             Publication Year                                     \n",
              "088-886-194-310-021 2006              Patent Application            no   \n",
              "147-331-231-570-922 2007              Patent Application           yes   \n",
              "148-164-161-664-368 2007              Patent Application           yes   \n",
              "161-684-752-020-329 2004              Patent Application            no   \n",
              "089-102-410-621-069 2004              Patent Application            no   \n",
              "...                                                  ...           ...   \n",
              "179-151-089-030-564 2019                  Limited Patent            no   \n",
              "014-594-233-943-253 2020                  Limited Patent            no   \n",
              "115-179-292-453-581 2006              Patent Application            no   \n",
              "069-774-923-021-970 2005              Patent Application            no   \n",
              "125-476-374-578-517 2017              Patent Application            no   \n",
              "\n",
              "                                      Cites Patent Count  \\\n",
              "Lens ID             Publication Year                       \n",
              "088-886-194-310-021 2006                               1   \n",
              "147-331-231-570-922 2007                               1   \n",
              "148-164-161-664-368 2007                               1   \n",
              "161-684-752-020-329 2004                               0   \n",
              "089-102-410-621-069 2004                               0   \n",
              "...                                                  ...   \n",
              "179-151-089-030-564 2019                               0   \n",
              "014-594-233-943-253 2020                               0   \n",
              "115-179-292-453-581 2006                               0   \n",
              "069-774-923-021-970 2005                               0   \n",
              "125-476-374-578-517 2017                               0   \n",
              "\n",
              "                                      Cited by Patent Count  \\\n",
              "Lens ID             Publication Year                          \n",
              "088-886-194-310-021 2006                                  7   \n",
              "147-331-231-570-922 2007                                  2   \n",
              "148-164-161-664-368 2007                                  0   \n",
              "161-684-752-020-329 2004                                  1   \n",
              "089-102-410-621-069 2004                                  0   \n",
              "...                                                     ...   \n",
              "179-151-089-030-564 2019                                  0   \n",
              "014-594-233-943-253 2020                                  1   \n",
              "115-179-292-453-581 2006                                  1   \n",
              "069-774-923-021-970 2005                                  0   \n",
              "125-476-374-578-517 2017                                  0   \n",
              "\n",
              "                                      Simple Family Size  \\\n",
              "Lens ID             Publication Year                       \n",
              "088-886-194-310-021 2006                               1   \n",
              "147-331-231-570-922 2007                               2   \n",
              "148-164-161-664-368 2007                               5   \n",
              "161-684-752-020-329 2004                               2   \n",
              "089-102-410-621-069 2004                               2   \n",
              "...                                                  ...   \n",
              "179-151-089-030-564 2019                               1   \n",
              "014-594-233-943-253 2020                               1   \n",
              "115-179-292-453-581 2006                               1   \n",
              "069-774-923-021-970 2005                               1   \n",
              "125-476-374-578-517 2017                               1   \n",
              "\n",
              "                                      Extended Family Size  Sequence Count  \\\n",
              "Lens ID             Publication Year                                         \n",
              "088-886-194-310-021 2006                                21               0   \n",
              "147-331-231-570-922 2007                                 2               4   \n",
              "148-164-161-664-368 2007                                 5              38   \n",
              "161-684-752-020-329 2004                                 2               0   \n",
              "089-102-410-621-069 2004                                 2               0   \n",
              "...                                                    ...             ...   \n",
              "179-151-089-030-564 2019                                 1               0   \n",
              "014-594-233-943-253 2020                                 1               0   \n",
              "115-179-292-453-581 2006                                 1               0   \n",
              "069-774-923-021-970 2005                                 1               0   \n",
              "125-476-374-578-517 2017                                 1               0   \n",
              "\n",
              "                                                                    CPC Classifications  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006                      A61K38/18;;A61P9/00;;A61P19/00;;A61P25/00   \n",
              "147-331-231-570-922 2007                             C07D229/02;;G01N33/582;;G01N33/554   \n",
              "148-164-161-664-368 2007              C07K14/005;;C12N15/1037;;C12N2795/14122;;C12N1...   \n",
              "161-684-752-020-329 2004                                                      Y02A50/30   \n",
              "089-102-410-621-069 2004                                                            NaN   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                             C12N7/02;;C12Q1/70   \n",
              "014-594-233-943-253 2020                              C12N1/205;;C12Q1/70;;C12R2001/445   \n",
              "115-179-292-453-581 2006                                                      Y02A50/30   \n",
              "069-774-923-021-970 2005                                                      Y02A50/30   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                                                   IPCR Classifications  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              A61K38/17;;A61K39/395;;A61K48/00;;A61P9/00;;A6...   \n",
              "147-331-231-570-922 2007              G01N33/53;;C07D229/02;;G01N33/15;;G01N33/543;;...   \n",
              "148-164-161-664-368 2007              C12N15/09;;C07K14/005;;C12N1/21;;C12N7/00;;C12...   \n",
              "161-684-752-020-329 2004                                  C12N15/09;;C12Q1/04;;C12Q1/34   \n",
              "089-102-410-621-069 2004              C12N15/09;;A01N25/28;;A01N63/00;;C12N1/20;;C12...   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                             C12Q1/70;;C12N7/02   \n",
              "014-594-233-943-253 2020                                             C12Q1/70;;C12R1/44   \n",
              "115-179-292-453-581 2006                                                      A61K38/00   \n",
              "069-774-923-021-970 2005                                                      A61K38/00   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                     US Classifications  NPL Citation Count  \\\n",
              "Lens ID             Publication Year                                          \n",
              "088-886-194-310-021 2006                            NaN                   1   \n",
              "147-331-231-570-922 2007                            NaN                   2   \n",
              "148-164-161-664-368 2007                            NaN                  24   \n",
              "161-684-752-020-329 2004                            NaN                   0   \n",
              "089-102-410-621-069 2004                            NaN                   0   \n",
              "...                                                 ...                 ...   \n",
              "179-151-089-030-564 2019                            NaN                   0   \n",
              "014-594-233-943-253 2020                            NaN                   0   \n",
              "115-179-292-453-581 2006                            NaN                   0   \n",
              "069-774-923-021-970 2005                            NaN                   0   \n",
              "125-476-374-578-517 2017                            NaN                   0   \n",
              "\n",
              "                                      NPL Resolved Citation Count  \\\n",
              "Lens ID             Publication Year                                \n",
              "088-886-194-310-021 2006                                        1   \n",
              "147-331-231-570-922 2007                                        1   \n",
              "148-164-161-664-368 2007                                       22   \n",
              "161-684-752-020-329 2004                                        0   \n",
              "089-102-410-621-069 2004                                        0   \n",
              "...                                                           ...   \n",
              "179-151-089-030-564 2019                                        0   \n",
              "014-594-233-943-253 2020                                        0   \n",
              "115-179-292-453-581 2006                                        0   \n",
              "069-774-923-021-970 2005                                        0   \n",
              "125-476-374-578-517 2017                                        0   \n",
              "\n",
              "                                                                NPL Resolved Lens ID(s)  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006                                            085-906-838-714-934   \n",
              "147-331-231-570-922 2007                                            016-994-266-998-256   \n",
              "148-164-161-664-368 2007              050-417-296-901-112;;051-984-368-264-261;;058-...   \n",
              "161-684-752-020-329 2004                                                            NaN   \n",
              "089-102-410-621-069 2004                                                            NaN   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                                            NaN   \n",
              "014-594-233-943-253 2020                                                            NaN   \n",
              "115-179-292-453-581 2006                                                            NaN   \n",
              "069-774-923-021-970 2005                                                            NaN   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                                            NPL Resolved External ID(s)  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006                    11038171;;pmc2192657;;10.1083/jcb.151.2.221   \n",
              "147-331-231-570-922 2007                             10.2174/1568026023394182;;11944820   \n",
              "148-164-161-664-368 2007              16277371;;10.1021/cr000261r;;10.1006/jmbi.1999...   \n",
              "161-684-752-020-329 2004                                                            NaN   \n",
              "089-102-410-621-069 2004                                                            NaN   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                                            NaN   \n",
              "014-594-233-943-253 2020                                                            NaN   \n",
              "115-179-292-453-581 2006                                                            NaN   \n",
              "069-774-923-021-970 2005                                                            NaN   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                                                          NPL Citations  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              KOCH M ET AL: \"A NOVEL MEMBER OF THE NETRIN FA...   \n",
              "147-331-231-570-922 2007              HATANAKA Y. ET AL.: \"Photoaffinity Labeling in...   \n",
              "148-164-161-664-368 2007              KEHOE J.W. ET AL.: \"Filamentous phage display ...   \n",
              "161-684-752-020-329 2004                                                            NaN   \n",
              "089-102-410-621-069 2004                                                            NaN   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                                            NaN   \n",
              "014-594-233-943-253 2020                                                            NaN   \n",
              "115-179-292-453-581 2006                                                            NaN   \n",
              "069-774-923-021-970 2005                                                            NaN   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                      Legal Status  \\\n",
              "Lens ID             Publication Year                 \n",
              "088-886-194-310-021 2006              DISCONTINUED   \n",
              "147-331-231-570-922 2007                   PENDING   \n",
              "148-164-161-664-368 2007                   PENDING   \n",
              "161-684-752-020-329 2004                   EXPIRED   \n",
              "089-102-410-621-069 2004                   EXPIRED   \n",
              "...                                            ...   \n",
              "179-151-089-030-564 2019                    ACTIVE   \n",
              "014-594-233-943-253 2020                    ACTIVE   \n",
              "115-179-292-453-581 2006              DISCONTINUED   \n",
              "069-774-923-021-970 2005              DISCONTINUED   \n",
              "125-476-374-578-517 2017              DISCONTINUED   \n",
              "\n",
              "                                                                           Cleaned_Text  \n",
              "Lens ID             Publication Year                                                     \n",
              "088-886-194-310-021 2006              new (mutant) netrin-4, netrin-1, netrin-3, ant...  \n",
              "147-331-231-570-922 2007              panning method utilizing photoreactive group k...  \n",
              "148-164-161-664-368 2007              phage display novel filamentous bacteriophage[...  \n",
              "161-684-752-020-329 2004              method monitoring bacterium utilizing chitinou...  \n",
              "089-102-410-621-069 2004              method controlling insect pest alginate microb...  \n",
              "...                                                                                 ...  \n",
              "179-151-089-030-564 2019              system preparing samples identifying least one...  \n",
              "014-594-233-943-253 2020              test kit determine antimicrobial biological ac...  \n",
              "115-179-292-453-581 2006              parenteral use bacterial phage associated lysi...  \n",
              "069-774-923-021-970 2005              use bacterial phage associated lysing enzymes ...  \n",
              "125-476-374-578-517 2017                  use bacteriophages control blackleg soft rot.  \n",
              "\n",
              "[5108 rows x 32 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-2b7eabf8-b5bc-4bc5-8436-95d159ac6b1c\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th>#</th>\n",
              "      <th>Jurisdiction</th>\n",
              "      <th>Kind</th>\n",
              "      <th>Display Key</th>\n",
              "      <th>Publication Date</th>\n",
              "      <th>Application Number</th>\n",
              "      <th>Application Date</th>\n",
              "      <th>Priority Numbers</th>\n",
              "      <th>Earliest Priority Date</th>\n",
              "      <th>Title</th>\n",
              "      <th>Abstract</th>\n",
              "      <th>Applicants</th>\n",
              "      <th>Inventors</th>\n",
              "      <th>Owners</th>\n",
              "      <th>URL</th>\n",
              "      <th>Document Type</th>\n",
              "      <th>Has Full Text</th>\n",
              "      <th>Cites Patent Count</th>\n",
              "      <th>Cited by Patent Count</th>\n",
              "      <th>Simple Family Size</th>\n",
              "      <th>Extended Family Size</th>\n",
              "      <th>Sequence Count</th>\n",
              "      <th>CPC Classifications</th>\n",
              "      <th>IPCR Classifications</th>\n",
              "      <th>US Classifications</th>\n",
              "      <th>NPL Citation Count</th>\n",
              "      <th>NPL Resolved Citation Count</th>\n",
              "      <th>NPL Resolved Lens ID(s)</th>\n",
              "      <th>NPL Resolved External ID(s)</th>\n",
              "      <th>NPL Citations</th>\n",
              "      <th>Legal Status</th>\n",
              "      <th>Cleaned_Text</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Lens ID</th>\n",
              "      <th>Publication Year</th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>088-886-194-310-021</th>\n",
              "      <th>2006</th>\n",
              "      <td>6343</td>\n",
              "      <td>FR</td>\n",
              "      <td>A1</td>\n",
              "      <td>FR 2878165 A1</td>\n",
              "      <td>26/05/2006</td>\n",
              "      <td>FR 0412364 A</td>\n",
              "      <td>22/11/2004</td>\n",
              "      <td>FR 0412364 A</td>\n",
              "      <td>22/11/2004</td>\n",
              "      <td>New (mutant) netrin-4, netrin-1, netrin-3, ant...</td>\n",
              "      <td>(Mutant) netrin-4 protein (I) comprising at le...</td>\n",
              "      <td>CENTRE NAT RECH SCIENT;;I V S INST DES VAISSEA...</td>\n",
              "      <td>PLOUET JEAN;;ALEMANY MONICA</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/088-886-194-310-021</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>1</td>\n",
              "      <td>7</td>\n",
              "      <td>1</td>\n",
              "      <td>21</td>\n",
              "      <td>0</td>\n",
              "      <td>A61K38/18;;A61P9/00;;A61P19/00;;A61P25/00</td>\n",
              "      <td>A61K38/17;;A61K39/395;;A61K48/00;;A61P9/00;;A6...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>085-906-838-714-934</td>\n",
              "      <td>11038171;;pmc2192657;;10.1083/jcb.151.2.221</td>\n",
              "      <td>KOCH M ET AL: \"A NOVEL MEMBER OF THE NETRIN FA...</td>\n",
              "      <td>DISCONTINUED</td>\n",
              "      <td>new (mutant) netrin-4, netrin-1, netrin-3, ant...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>147-331-231-570-922</th>\n",
              "      <th>2007</th>\n",
              "      <td>2680</td>\n",
              "      <td>WO</td>\n",
              "      <td>A1</td>\n",
              "      <td>WO 2007/083793 A1</td>\n",
              "      <td>26/07/2007</td>\n",
              "      <td>JP 2007050890 W</td>\n",
              "      <td>22/01/2007</td>\n",
              "      <td>JP 2006014314 A</td>\n",
              "      <td>23/01/2006</td>\n",
              "      <td>PANNING METHOD UTILIZING PHOTOREACTIVE GROUP A...</td>\n",
              "      <td>[PROBLEMS] To provide a method for ensuring th...</td>\n",
              "      <td>UNIV TOYAMA NAT UNIV CORP;;HATANAKA YASUMARU;;...</td>\n",
              "      <td>HATANAKA YASUMARU;;SADAKANE YUTAKA</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/147-331-231-570-922</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>yes</td>\n",
              "      <td>1</td>\n",
              "      <td>2</td>\n",
              "      <td>2</td>\n",
              "      <td>2</td>\n",
              "      <td>4</td>\n",
              "      <td>C07D229/02;;G01N33/582;;G01N33/554</td>\n",
              "      <td>G01N33/53;;C07D229/02;;G01N33/15;;G01N33/543;;...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>2</td>\n",
              "      <td>1</td>\n",
              "      <td>016-994-266-998-256</td>\n",
              "      <td>10.2174/1568026023394182;;11944820</td>\n",
              "      <td>HATANAKA Y. ET AL.: \"Photoaffinity Labeling in...</td>\n",
              "      <td>PENDING</td>\n",
              "      <td>panning method utilizing photoreactive group k...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>148-164-161-664-368</th>\n",
              "      <th>2007</th>\n",
              "      <td>111</td>\n",
              "      <td>WO</td>\n",
              "      <td>A1</td>\n",
              "      <td>WO 2007/114139 A1</td>\n",
              "      <td>11/10/2007</td>\n",
              "      <td>JP 2007056579 W</td>\n",
              "      <td>28/03/2007</td>\n",
              "      <td>JP 2006105143 A</td>\n",
              "      <td>06/04/2006</td>\n",
              "      <td>PHAGE DISPLAY BY NOVEL FILAMENTOUS BACTERIOPHAGE</td>\n",
              "      <td>[PROBLEMS] To provide a phage display vector w...</td>\n",
              "      <td>UCHIYAMA FUMIAKI</td>\n",
              "      <td>UCHIYAMA FUMIAKI</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/148-164-161-664-368</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>yes</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>5</td>\n",
              "      <td>5</td>\n",
              "      <td>38</td>\n",
              "      <td>C07K14/005;;C12N15/1037;;C12N2795/14122;;C12N1...</td>\n",
              "      <td>C12N15/09;;C07K14/005;;C12N1/21;;C12N7/00;;C12...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>24</td>\n",
              "      <td>22</td>\n",
              "      <td>050-417-296-901-112;;051-984-368-264-261;;058-...</td>\n",
              "      <td>16277371;;10.1021/cr000261r;;10.1006/jmbi.1999...</td>\n",
              "      <td>KEHOE J.W. ET AL.: \"Filamentous phage display ...</td>\n",
              "      <td>PENDING</td>\n",
              "      <td>phage display novel filamentous bacteriophage[...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>161-684-752-020-329</th>\n",
              "      <th>2004</th>\n",
              "      <td>3085</td>\n",
              "      <td>JP</td>\n",
              "      <td>A</td>\n",
              "      <td>JP 2004097032 A</td>\n",
              "      <td>02/04/2004</td>\n",
              "      <td>JP 2002260418 A</td>\n",
              "      <td>05/09/2002</td>\n",
              "      <td>JP 2002260418 A</td>\n",
              "      <td>05/09/2002</td>\n",
              "      <td>METHOD FOR MONITORING BACTERIUM UTILIZING CHIT...</td>\n",
              "      <td>&lt;P&gt;PROBLEM TO BE SOLVED: To develop a method f...</td>\n",
              "      <td>UNIV KOBE</td>\n",
              "      <td>MAYAMA SHIGEYUKI;;TOSA YUKIO;;OTSU YASUNARI;;T...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/161-684-752-020-329</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>2</td>\n",
              "      <td>2</td>\n",
              "      <td>0</td>\n",
              "      <td>Y02A50/30</td>\n",
              "      <td>C12N15/09;;C12Q1/04;;C12Q1/34</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>EXPIRED</td>\n",
              "      <td>method monitoring bacterium utilizing chitinou...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>089-102-410-621-069</th>\n",
              "      <th>2004</th>\n",
              "      <td>3892</td>\n",
              "      <td>JP</td>\n",
              "      <td>A</td>\n",
              "      <td>JP 2004099465 A</td>\n",
              "      <td>02/04/2004</td>\n",
              "      <td>JP 2002260419 A</td>\n",
              "      <td>05/09/2002</td>\n",
              "      <td>JP 2002260419 A</td>\n",
              "      <td>05/09/2002</td>\n",
              "      <td>METHOD FOR CONTROLLING INSECT PEST WITH ALGINA...</td>\n",
              "      <td>&lt;P&gt;PROBLEM TO BE SOLVED: To develop a new defo...</td>\n",
              "      <td>UNIV KOBE</td>\n",
              "      <td>MAYAMA SHIGEYUKI;;TOSA YUKIO;;OTSU YASUNARI;;T...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/089-102-410-621-069</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>2</td>\n",
              "      <td>2</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>C12N15/09;;A01N25/28;;A01N63/00;;C12N1/20;;C12...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>EXPIRED</td>\n",
              "      <td>method controlling insect pest alginate microb...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>179-151-089-030-564</th>\n",
              "      <th>2019</th>\n",
              "      <td>6156</td>\n",
              "      <td>CZ</td>\n",
              "      <td>U1</td>\n",
              "      <td>CZ 33381 U1</td>\n",
              "      <td>12/11/2019</td>\n",
              "      <td>CZ 201936608 U</td>\n",
              "      <td>09/09/2019</td>\n",
              "      <td>CZ 201936608 U</td>\n",
              "      <td>09/09/2019</td>\n",
              "      <td>System for preparing samples and identifying a...</td>\n",
              "      <td>.</td>\n",
              "      <td>UNIV MASARYKOVA</td>\n",
              "      <td>PANTŮČEK ROMAN;;ŠTVERÁKOVÁ DANA;;ŠEDO ONDREJ;;...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/179-151-089-030-564</td>\n",
              "      <td>Limited Patent</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>C12N7/02;;C12Q1/70</td>\n",
              "      <td>C12Q1/70;;C12N7/02</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>ACTIVE</td>\n",
              "      <td>system preparing samples identifying least one...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>014-594-233-943-253</th>\n",
              "      <th>2020</th>\n",
              "      <td>6024</td>\n",
              "      <td>CZ</td>\n",
              "      <td>U1</td>\n",
              "      <td>CZ 33918 U1</td>\n",
              "      <td>14/04/2020</td>\n",
              "      <td>CZ 202037223 U</td>\n",
              "      <td>06/02/2020</td>\n",
              "      <td>CZ 202037223 U</td>\n",
              "      <td>06/02/2020</td>\n",
              "      <td>Test kit to determine the antimicrobial biolog...</td>\n",
              "      <td>.</td>\n",
              "      <td>MB PHARMA S R O</td>\n",
              "      <td>MOŠA MAREK;;BENEŠÍK MARTIN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/014-594-233-943-253</td>\n",
              "      <td>Limited Patent</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>C12N1/205;;C12Q1/70;;C12R2001/445</td>\n",
              "      <td>C12Q1/70;;C12R1/44</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>ACTIVE</td>\n",
              "      <td>test kit determine antimicrobial biological ac...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>115-179-292-453-581</th>\n",
              "      <th>2006</th>\n",
              "      <td>6234</td>\n",
              "      <td>AU</td>\n",
              "      <td>A1</td>\n",
              "      <td>AU 2006/201041 A1</td>\n",
              "      <td>06/04/2006</td>\n",
              "      <td>AU 2006/201041 A</td>\n",
              "      <td>10/03/2006</td>\n",
              "      <td>AU 2001/027834 A;;AU 2006/201041 A</td>\n",
              "      <td>12/01/2001</td>\n",
              "      <td>The parenteral use of bacterial phage associat...</td>\n",
              "      <td>.</td>\n",
              "      <td>NEW HORIZONS DIAGNOSTICS CORPORATION;;UNIV ROC...</td>\n",
              "      <td>FISCHETTI VINCENT;;LOOMIS LAWRENCE</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/115-179-292-453-581</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>Y02A50/30</td>\n",
              "      <td>A61K38/00</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DISCONTINUED</td>\n",
              "      <td>parenteral use bacterial phage associated lysi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>069-774-923-021-970</th>\n",
              "      <th>2005</th>\n",
              "      <td>6214</td>\n",
              "      <td>AU</td>\n",
              "      <td>A1</td>\n",
              "      <td>AU 2005/227384 A1</td>\n",
              "      <td>24/11/2005</td>\n",
              "      <td>AU 2005/227384 A</td>\n",
              "      <td>27/10/2005</td>\n",
              "      <td>AU 2000/077021 A;;AU 2005/227384 A</td>\n",
              "      <td>14/09/2000</td>\n",
              "      <td>The use of bacterial phage associated lysing e...</td>\n",
              "      <td>.</td>\n",
              "      <td>NEW HORIZONS DIAGNOSTICS INC</td>\n",
              "      <td>LOOMIS LAWRENCE;;FISCHETTI VINCENT</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/069-774-923-021-970</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>Y02A50/30</td>\n",
              "      <td>A61K38/00</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DISCONTINUED</td>\n",
              "      <td>use bacterial phage associated lysing enzymes ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>125-476-374-578-517</th>\n",
              "      <th>2017</th>\n",
              "      <td>4736</td>\n",
              "      <td>GB</td>\n",
              "      <td>D0</td>\n",
              "      <td>GB 201709104 D0</td>\n",
              "      <td>19/07/2017</td>\n",
              "      <td>GB 201709104 A</td>\n",
              "      <td>07/06/2017</td>\n",
              "      <td>GB 201709104 A</td>\n",
              "      <td>07/06/2017</td>\n",
              "      <td>Use of Bacteriophages to control blackleg and ...</td>\n",
              "      <td>.</td>\n",
              "      <td>AGRI-FOOD AND BIOSCIENCES INST</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/125-476-374-578-517</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DISCONTINUED</td>\n",
              "      <td>use bacteriophages control blackleg soft rot.</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>5108 rows × 32 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-2b7eabf8-b5bc-4bc5-8436-95d159ac6b1c')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-2b7eabf8-b5bc-4bc5-8436-95d159ac6b1c button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-2b7eabf8-b5bc-4bc5-8436-95d159ac6b1c');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-096f6dbe-6949-4e05-bea9-d256d21e858a\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-096f6dbe-6949-4e05-bea9-d256d21e858a')\"\n",
              "            title=\"Suggest charts.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-096f6dbe-6949-4e05-bea9-d256d21e858a button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ]
          },
          "metadata": {},
          "execution_count": 19
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "8xYgoohpa7W8"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "text = df['Cleaned_Text'].tolist()\n",
        "text"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "MTJ6RbJHa7fM",
        "outputId": "8f68077d-1717-41c1-8725-bfe9ff216c6b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['new (mutant) netrin-4, netrin-1, netrin-3, anti-idiotypic netrin-4 antibodies, fab fragments nucleotide sequences useful preventing treating tumoral non-tumoral disorders (of angiogenesis)(mutant) netrin-4 protein (i) comprising least 230 amino acids seq id. nos 522 524, fragment, derivative homologue, new. (mutant) netrine-4 protein (i) comprising contains one following sequences; seq id no. 522 524, fragment 522/524 anti-angiogenic activity and/or perictye activation activity, fragment comprises 40 450 amino acids, preferably 40 230 amino acids represented seq id no: 2q, q variant 187 248 seq id 526 528. included sequences substitutions, suppression addition one amino acids providing sequences anti-angiogenic perictye activation activity. active homologues included least approximiately 50 % sequence identity region amino acids 261 515 seq id no: 522. sequence information fully defined specification. independent claims included for: (1) nucleotide sequence (ii) encoding proteins (i); (2) recombinant vector (iv), plasmid, cosmid, phage dna virus comprising (ii) comprising necessary elements expression suitable host cell expression (i); (3) host cell (iv), chosen bacteria, viruses, yeast, mushrooms, plants mammalian cells, transformed (iv); (4) antibody (v), specific (i); (5) anti-idiotypic antibody (vi) specific (i); activity : cytostatic; opthalmological; antiangiogenic; immunosuppressive; vasotropic; hypotensive; antiarthritic; cardiant; anorectic; cerebroprotective; dermatological; antiarteriosclerotic. biological data given. mechanism action : none given.',\n",
              " 'panning method utilizing photoreactive group kit method[problems] provide method ensuring screening protein peptide capable interacting ligand. [means solving problems] disclosed method screening protein peptide capable interacting photoreactive ligand, wherein method comprises mixing photoreactive ligand protein display phage peptide display phage liquid phase, irradiating mixed solution active ray photoreactive group photoreactive ligand, immobilizing photoreactive ligand solid phase utilizing immobilization function photoreactive ligand, washing solid phase photoreactive ligand immobilized thereon, collecting protein display phage peptide display phage bound photoreactive ligand immobilized solid phase.',\n",
              " 'phage display novel filamentous bacteriophage[problems] provide phage display vector fused inside piii phage display method using vector. [means solving problems] disclosed phage display method characterized using mutant piii protein amino acid residue inserted proline residue position 11 histidine residue position 12 m13 phage piii protein depicted seq id no:1. method enables produce random peptide high efficiency provide novel source peptide conformation.',\n",
              " 'method monitoring bacterium utilizing chitinous substance degrading enzyme gene labeling<p>problem solved: develop method monitoring labeled bacterium utilizing genes chitinase chitosanase chitinous substance degrading enzymes reporters. <p>solution: provided method detecting bacterium chitinous substance degrading gene transduced comprises following. step bringing bacterium chitinous substance degrading gene transduced contact bacteriophage specific bacterium, step reacting lysate bacterium lysed infection bacteriophage substrate chitinous degrading enzyme step detecting degradation substrate. <p>copyright: (c)2004,jpo',\n",
              " 'method controlling insect pest alginate microbead encapsulating bacterium defoliator pest-suppressing effect<p>problem solved: develop new defoliator pest control means. <p>solution: alginate microbeads characterized encapsulating bacterium defoliator pest-suppressing effect. further, alginate microbeads characterized encapsulating bacterium defoliator pest-suppressing effect bacteriophage capable infecting bacterium. method controlling insect pests alginate microbeads. <p>copyright: (c)2004,jpo',\n",
              " 'kit forming double-stranded rna lactobacillus use thereof<p>problem solved: easily stably form rnai (rna interference) human animal intestine. <p>solution: kit forming double-stranded rna lactobacillus comprises vector containing promoter derived phage. <p>copyright: (c)2009,jpo&inpit',\n",
              " 'method producing multicopy displaying phage<p>problem solved: obtain phage controls number copies objective polypeptide displayed head part phage used phage display displays desired number copies. <p>solution: expression amount fusion protein phage coat protein objective peptide controlled using suppressor trna stop codon, obtained inserting stop codon dna encoding phage coat protein dna encoding objective polypeptide temperature-sensitive suppressor activity. <p>copyright: (c)2004,jpo',\n",
              " 'staphylococcus aureus bacteriolytic bacteriophage<p>problem solved: provide bacteriophage bacteriolytic character plurality staphylococcus aureus (s. aureus) strains, method effectively removing s. aureus using bacteriophage. <p>solution: disclosed bacteriophage bacteriolytic character s. aureus strain selected accession no. nite bp-693 accession no. nite bp-694, bacteriophage composition containing bacteriophage, method preventing s. aureus proliferation characterized applying bacteriophage composition. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'autolysis-resistant cell method producing material using same<p>problem solved: provide cell resistivity lysis occurring without direct stimulation outside infection phage chemical/enzyme treatment prokaryotic cell, provide method producing material using cell. <p>solution: autolysis-resistant cell obtained transforming procaryote extraneous gene base sequence encoding active oxygen species-responsive protein. method producing material using cell provided. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'clathrin-bonding peptide derivative<p>problem solved: provide clathrin-bonding peptide derivative indwells solely cell, competitively inhibits bonding grp78 clathrin thereby exhibiting excellent anticancer action administered together anticancer agent, safe, causes little side effects even applied combination anticancer agent, low molecular weight mass-productively manufactured inexpensively good yield, drug-transporting material comprising same. <p>solution: clathrin-bonding peptide derivative contains amino acid sequence thr-pro-val-leu-glu-thr-pro-lys-leu-leu-leu-trp. drug-transporting material includes colloid particle contains clathrin-bonding peptide derivative peptide-incorporated phage clathrin-bonding peptide derivative chemically bonded extendedly end coat protein phage, clathrin-bonding peptide derivative exposed surface thereof. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'molecular antigen array<p>problem solved: provide composition comprising bacteriophage ap205 virus particle (vlp) antigen, provide process producing antigen antigenic determinant bound vlp. <p>solution: provided vlp associated coat protein bacteriophage ap205 protein, composition organic molecules bind vlp core particles. composition useful induce immune responses useful prevention treatment diseases, disorders conditions including infectious diseases, allergies, cancer, efficiently induce self-specific immune responses, particular antibody responses. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'drug treating bacterial infectious disease comprising bacteriophage<p>problem solved: provide drug treatment prophylaxis edwardsiellosis and/or streptococcus iniae infections fishes. <p>solution: drug obtained including bacteriophage specifically infected edwardsiella tarda bacteriophage specifically infected streptococcus iniae. bacteriophage obtained concentrated method double agar method using edwardsiella tarda streptococcus iniae indicating bacterium. <p>copyright: (c)2007,jpo&inpit',\n",
              " 'genotype classification method staphylococcus aureus primer set use same<p>problem solved: provide genotype classification method staphylococcus aureus, obtained improving technique described publication no.2006-141249 suitable actual industry (medical spot) primer set use same. <p>solution: genotype classification method staphylococcus aureus includes step detecting presence/absence (1) phage-derived open reading frame (orf), (2) orf derived genomic islands except staphylococcal cassette chromosome mec; sccmec, (3) transposon-derived orf, (4) sccmec-derived orf, (5) orf constituting genomic islet staphylococcus aureus genome arbitrary order performing genotype classification combination orf presence/absence. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'method producing albumin variant high ligand affinity<p>problem solved: provide high br-affinity albumin variant usable preparing albumin dialyzing fluid containing efficiently decreased amount albumin-binding toxin (abt) bilirubin (br). <p>solution: provided method screening albumin variant high ligand affinity comprising step preparing prepare phage library present human serum albumin variant phage surface; step contacting phage library ligand measure quantity ligand bound phage; step selecting phage high binding quantity ligand. human serum albumin variant amino acid sequence human serum albumin amino acid sequence first 585th sequence number 2 sequence table, wherein 195th 199th amino acids lysine arginine 240th amino acid lysine. <p>copyright: (c)2010,jpo&inpit',\n",
              " 'inspection container detection device organism-related substance<p>problem solved: provide inspection container bubbles unlikely occur liquid containing organism-related substance. <p>solution: inspection container 101 solid phase carrier 102 probe detecting organism-related substance made solid phase flow passage 103 storing sample solution liquid containing organism-related substance. solid phase carrier 102 consists porous object permits sample solution permeate. flow passage 103 large diameter part 103a extending downward opening upper face cross solid phage carrier 102 small diameter part 103b extending sidewise large diameter part 103a side face. solid carrier 102, hydrophilic processing performed. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'bacteriophage bacteriolytic action ralstonia solanacearum<p>problem solved: provide means effectively controlling ralstonia solanacearum. <p>solution: method controlling ralstonia solanacearum includes spraying bacteriophage exhibiting bacteriolytic action ralstonia solanacearum plant soil soil-improving method includes adding bacteriophage soil. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'ralstonia solanacearum infective bacteriophage<p>problem solved: provide means effectively controlling ralstonia solanacearum. <p>solution: bacteriophage isolated ralstonia solanacearum showing bacteriolytic action strains c-319, m4s, ps29, ps65, ps72, ps74, maff106603, maff106611, maff211270, maff211271, naff211272, maff301556, maff301558, maff730138 maff730139 ralstonia solanacearum. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'method labeling nucleic acid<p>problem solved: provide means efficiently obtaining labeled nucleic acid product long base pair increasing formation labeled nucleic acid. <p>solution: method efficiently obtaining labeled nucleic acid product long base pair increasing formation labeled nucleic acid comprises, labeling reaction nucleic acid, using one kinds proteins (single-stranded dna-binding protein, t4 phage gene 32, 41, 44, 45 61 protein, replication protein radiation protein) associated dna recombinational repair. labeling reaction uses either random primer method pcr method. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'means specifying cell type using virus<p>problem solved: provide means specifying cell type capable solving defects immunization methods polymerase chain reaction methods complicated, require long times, decide lives death cells. <p>solution: means specifying cell type uses specific infection ability specified virus specified cell. preliminarily, fluorescent bacteria 1 dyed fluorescent reagent infected lambda phages 2 recovered membrane filter 3. preliminary image recovered compared post image b infected fluorescent bacteria 4 lysed (5) passage time, whereby presence absence escherichia coli specifically infected lambda phages 2 rapidly detected. also, live bacteria proliferate, presence live escherichia coli detected. <p>copyright: (c)2010,jpo&inpit',\n",
              " 'medicament treating bacterial cold water disease using bacteriophage<p>problem solved: provide medicament treating preventing bacterial cold water disease fish. <p>solution: bacteriophage specifically infecting flavobacterium psychrophilum carrying bacteriolysis thereof contained medicament. bacteriophage obtained, example, concentrated culture method double agar method using flavobacterium psychrophilum indicator bacterium. <p>copyright: (c)2004,jpo&ncipi',\n",
              " 'spike g protein pentamer derived bacteriophage method producing same<p>problem solved: provide method proliferation escherichia coli c strain specifically controlled escherichia coli c strain detected among samples comprising various species escherichia coli present therein. <p>solution: chisg (pentamer g protein) obtained adding histidine tag spike g protein derived bacteriophage φx174. pentamer formed thereby bound escherichia coli c strain. result, chisg used controlling proliferation escherichia coli c strain detecting escherichia coli c strain. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'method amplifying nucleic acid reagent kit amplifying nucleic acid<p>problem solved: provide method amplifying nucleic acid desired nucleic acid amplified suppressing amplification by-product pcr reaction provide reagent kit amplification nucleic acid desired nucleic acid amplified suppressing amplification by-product pcr reaction. <p>solution: method amplifying nucleic acid comprises mixing first protein containing least one selected t. th. reca protein reca modified protein obtained modifying protein functions similar protein second protein containing least one selected phage t4 gene 32 protein phage t4 gene 32-modified protein obtained modifying 32 protein function similar protein reaction solution carrying pcr. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'method analyzing molecular interaction using phage display method<p>problem solved: provide method analyzing three-dimensional structure target molecule-polypeptide ligand complex high precision rapid simple process. <p>solution: method analyzing three-dimensional structure target molecule-polypeptide ligand complex comprises first process exhibiting polypeptide combined target molecule phage surface phage display method, second process obtaining polypeptide ligand cleaving polypeptide exhibited phage surface, third process forming target molecule-polypeptide ligand complex fourth process analyzing three-dimensional structure complex. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'phage method controlling bacterial disease damage terrestrial part plant using nonpathogenic bacterium plant<p>problem solved: provide method controlling bacterial disease damage plant, reduction environmental loading aimed using phages. <p>solution: bacterial disease damage terrestrial part plant controlled applying phages pathogenic bacterium terrestrial part plant nonpathogenic bacterium common hosts nonpathogenic bacterium terrestrial part plant keeping high number phages. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'method detecting mutation genetic polymorphism using mu phage transposase<p>problem solved: provide method detecting mismatch dna:rna double strand, detail, method detecting mutation genetic polymorphism using method detection. <p>solution: method detecting mutation genetic polymorphism comprises (11) step bringing double-stranded nucleic acid contact mu-terminal nucleic acid mu phage transposase (12) step judging mutation genetic polymorphism detecting transposition double-stranded nucleic acid specific site mu-terminal nucleic acid. method detection, double-stranded nucleic acid dna:rna double strand. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'method detecting igg using peptide bindable lgg phage presented peptide surface<p>problem solved: provide method detecting igg using detective means new peptide bindable fc fragment igg phage presented peptide surface. <p>solution: using fc fragment igg derived various animals target substance, screening carried phage display method amino acid sequence peptide bindable target substance identified. peptide thus obtained specific amino acid sequence amino acid sequence selected modified, amino acid residue-substituted, inserted and/or deleted amino acid sequence condition bindability igg fc fragment impaired, phage presented peptide surface, used detective means igg. <p>copyright: (c)2004,jpo&ncipi',\n",
              " 'method detecting material causing damage dna metabolic system utilizing phage lysogenic bacterium<p>problem solved: provide method evaluating activities causing damage dna metabolic system compound, provide method screening antimicrobial agent anticancer agent targeting metabolic system utilizing method. <p>solution: prophage induced damage dna metabolic system cleavage dna double strand phage lysogenic bacterium accompanying bacteriolysis. method evaluating presence absence activities causing damage dna metabolic system specimen comprises expressing reporter gene phage lysogenic bacterium, using activities reporter gene product released bacteriolysis accompanied induction prophage indicator. screening antimicrobial agent anticancer agent enabled utilizing evaluation method. <p>copyright: (c)2003,jpo',\n",
              " 'method identifying antibody specific sugar chain structure<p>problem solved: provide method identifying antibody specifically bonding sugar chain certain specific structure using phage presentation type antibody library sugar chain. <p>solution: method identifying antibody bonding specifically sugar chain comprises process bringing phage presentation type antibody contact sugar chain. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'antigen-specific antibody given using extracorporeally immunized peripheral hemolymphocyte<p>problem solved: provide method inducing antibody production response, extracorporeally immunizing peripheral hemolymphocyte, provide method rapidly efficiently preparing human monoclonal antibody specific arbitrary antigen, provide method acquiring antigen-specific antibody gene highly efficiently short period compared conventional phage display methods, especially, phage display method unprimed human peripheral hemolymphocyte used. <p>solution: antigen-specific human monoclonal antibody mass-produced separating human peripheral hemolymphocytes, removing cd11c-positive cells using cd11c-specific antibody magnetic beads, conducting extracorporeal immunization induce antigen-specific human antibody production response, supplying phage display method lymphocytes subjected extracorporeal immunization acquire antigen-specific human monoclonal antibody variable region gene, inserting acquired human monoclonal antibody variable region gene animal cell expression vector, introducing obtained vector highly heterologous protein-expressing host cell line express antigen-specific human monoclonal antibody. <p>copyright: (c)2004,jpo',\n",
              " 'coat protein gene phage vector<p>problem solved: provide method producing heat-resistant protein high efficiency using thermophilic phage. <p>solution: method production heat-resistant protein contains (1) step integrate gene encoding heat-resistant protein dna thermophilic phage, (2) step introduce recombinant dna obtained step 1 host cell (3) step proliferate thermophilic phage heat-resistant protein coat protein host cell. <p>copyright: (c)2004,jpo&ncipi',\n",
              " 'method producing ligand high association rate ligand production system carrying same<p>problem solved: provide method producing ligands effectively screening ligands (antibodies, like) practical level ligand library provide ligand production system realizing method. <p>solution: method sets screening conditions either one comprising association time contacting proper antigen obtained immobilizing phage library, washing time washing removing phage antibody unassociated antigen, effective concentration immobilized antigen using mathematical formula model including constants expressing recovery rate phage antibody assuming apparent association rate constant dissociation rate constant dissociation constant prescribed specific phage antibody, screening step, screening specific phase antibody associates specific antigen phage library biopanning treatment. <p>copyright: (c)2004,jpo',\n",
              " 'isolation production catalytic antibody using phage technology<p>problem solved: provide method producing isolating catalytic antibody catalytically increasing chemical reaction velocity exhibited bacteriophage. <p>solution: recombinant cloning vector containing antibody, 6his residue, part myc gene phage gene iii, method increasing rate bond cutting forming specific molecule vivo provided, method activating prodrug vivo method activating inactivating biological functions animal increasing rate bond cutting forming specific molecule vivo provided. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'analysis method sugar bonding phage presenting antibody<p>problem solved: provide method qualitatively quantitatively analyzing sugar bonding specificity phage presenting antibody. <p>solution: bonding specificity antibody sugar chain analyzed, bringing phage presenting antibody contact sugar chain immobilized carrier comprising inorganic material. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'method screening new biotin-containing protein<p>problem solved: provide method refining high purity dna removing foreign material environmental sample provide method preparing phage display library using environmental dna (dna obtained environmental sample) efficiently screening gene encoding protein display library. <p>solution: environmental dna extracted soil refined prepare phase display library bound clone group concentrated enriched solidified streptavidin avidin biopanning procedure membrane blot plaqueses carried plaqueses dyed enzyme-labeled streptavidin avidin display clone biotin-containing protein detected thereby biotin-containing protein screened. <p>copyright: (c)2007,jpo&inpit',\n",
              " 'new expression vector<p>problem solved: provide method screening replication-starting region used expression vector using genus rhodococcus microorganism host, provide expression vector expressing target protein using genus rhodococcus microorganism host. <p>solution: method making expression vector genus rhodococcus microorganism utilizing replication-starting region bacteriophage, expression vector provided. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'method screening organism mismatch target gene<p>problem solved: provide method selecting individual organism mutation transduced target gene individual organism group prepared random mutagenesis, etc., high efficiency low cost. <p>solution: method selecting organism mismatch target gene contains (a) step prepare test mu transposition product bringing nucleic acid (test nucleic acid) containing target gene target organism contact (i) mu-terminal nucleic acid (ii) phage mu transposase condition enable transposition mu-terminal nucleic acid mismatch part thereabout target gene target gene contains mismatch, (b) step detect transposition mu-terminal nucleic acid test mu transposition product target gene (c) step select test organism test nucleic acid detected remarkable transposition mu-terminal nucleic acid specific position target gene organism mismatch near specific position target gene. <p>copyright: (c)2007,jpo&inpit',\n",
              " 'method detecting bacteriophage<p>problem solved: provide method simply, rapidly specifically detecting bacteriophage infecting lactococcus lactis high sensitivity sample containing kinds lactic bacteria. <p>solution: method detecting bacteriophage infecting lactococcus lactis sample containing lactococcus lactis lactic bacteria except lactococcus lactis includes coating sample agar plate medium containing 2 mass% sodium chloride, culturing sample, observing resultant agar plate medium naked eye. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'method screening peptide o-bound sugar chain added thereto<p>problem solved: provide method totally analyzing peptides o-bound sugar chain added thereto. <p>solution: method identifying peptide o-bound sugar chain added thereto comprises steps (a) producing peptide capable substrate transglucosylation enzyme expression system protein sugar chain added, (b) adding o-bound sugar chain reacting peptide transglucosylation enzyme, (c) selecting peptide o-bound sugar chain added, (d) analyzing structure sugar chain-added peptide. preferably, production peptide step (a) carried displaying peptide surface phage. preferably, analysis peptide structure step (d) carried analyzing sequence dna inserted phage. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'method suppressing multiplication filamentous microorganism using bacteriophage<p>problem solved: provide method suppressing multiplication filamentous microorganism causing bulking. <p>solution: method suppressing multiplication filamentous microorganism performed adding bacteriophage property infected filamentous microorganism causing bulking activated sludge carrying bacteriolysis. <p>copyright: (c)2004,jpo',\n",
              " 'peptide<p>problem solved: provide new antibacterial/bactericidal compound exhibiting antibacterial and/or bactericidal properties pseudomonas aeruginosa. <p>solution: antibacterial/bactericidal compound quaternary ammonium salt-peptide compound obtained binding thiol group l-cysteine residue introduced n-terminal c-terminal peptide specific amino acid sequence quaternary ammonium salt covalent bond, determined effective phage display method using pseudomonas aeruginosa. <p>copyright: (c)2010,jpo&inpit',\n",
              " \"genotype classification method methicillin-resistant staphylococcus aureus primer set use method<p>problem solved: provide new genotype classification method methicillin-resistant staphylococcus aureus (mrsa) alternative pfge (pulse field gel electrophoresis), provide primer set use method. <p>solution: new genotype classification method comprises following procedure: presence/absence (1) phage-derived open reading frame(orf), (2) orf derived genomic islands except staphylococcal cassette chromosome mec:sccmec (3) transposon-derived orf genome mrsa detected order, objective genotype classification conducted based combination orf presence/absence. method, genotype classification mrsa conducted easily, quickly, objectively high sensitivity without need special devices operator's skill, route hospital infection determined quickly, preventing spread hospital infection. <p>copyright: (c)2006,jpo&ncipi\",\n",
              " 'new lytic enzyme, method producing use thereof<p>problem solved: provide new lytic enzyme high lytic activity wide lytic spectrum. <p>solution: protein composed gene composed dna comprising 933 nucleotide sequences obtained lactobacillus gasseri jcm1131<sp>t</sp>which one species lactic acid bacillus holding temperate phage phigay amino acid sequence encoded same. recombinant plasmid contains dna host cell transformed recombinant plasmid. method producing protein comprises culturing host cell recovering protein. composition comprising protein active ingredient, especially reagent research, food additive, preservative, industrial fungicide bactericide, agricultural fungicide bactericide medical antibiotic provided. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'bacteriophage-originated lysis gene composition gene therapy plasmid incorporated lysis gene<p>problem solved: provide new medicinal composition infection diseases improving defects using phage good use advantage conventional phage treatment, obtain plasmid same. <p>solution: medicinal composition prepared using plasmid combined lysis gene phage without using whole phage. microorganisms bacteria lysed expressing lysis gene combined plasmid, pathogenic microorganisms. gene structure containing lysis gene bacteriophage, medicinal composition containing pharmaceutically permissible support, gene structure plasmid like, microorganism lysis agent using same, method lysing pathogenic microorganisms using lysis agent treating humans provided. <p>copyright: (c)2004,jpo&ncipi',\n",
              " 'method detecting escherichia coli bacteriophage<p>problem solved: provide new method detecting escherichia coli. <p>solution: method detecting escherichia coli characterized bringing bacteriophage labeled coat protein contact sample judging whether bacteria, etc., binding label cell surface present sample. reagent detecting escherichia coli comprises bacteriophage specifically adsorbing cell surface escherichia coli labeled coat protein. label bound coat protein bacteriophage specifically adsorbing surface cell escherichia coli directly detected, escherichia coli simply accurately detected high sensitivity short time. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'peptide protein affinity il-2, il-2 absorbent, il-2 testing reagent il-2 neutralizing agent, using peptide protein<p>problem solved: provide new peptide protein affinity il-2 capable obtained easily inexpensively; provide il-2 absorbent, il-2 testing reagent il-2 neutralizing agent, using peptide protein. <p>solution: screening carried using il-2 target material phage display method, amino acid sequence peptide affinity il-2 determined. peptide specific amino acid sequence obtained thus, amino acid sequence obtained carrying decoration, substitution, insertion and/or deletion amino acid residues, amino acid sequence within range losing affinity il-2 easily chemically synthesized, utilized example il-2 absorbent, il-2 testing reagent, il-2 neutralizing agent like. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'peptide protein bondability tnf-alpha tnf-alpha adsorbent, tnf-alpha test reagent tnf-alpha neutralizing agent use peptide protein<p>problem solved: provide new peptide protein bondability tnf-α obtained ease low cost, tnf-α adsorbent, tnf-α test reagent tnf-α neutralizing agent use peptide protein. <p>solution: amino acid sequence peptide bondability tnf-α identified screening phage display method use tnf-α target substance. amino acid sequence represented one sequence nos. 1-7 thus obtained amino acid sequences, possible easily chemically synthesize peptide amino acid sequence obtained modification substitution insertion amino acid residue and/or defective amino acid sequence far bondability tnf-α adversely affected, peptide utilized, example, tnf-α adsorbent, tnf-α test reagent, tnf-α neutralizing agent. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'intracellular delivery biological effector new transporter peptide sequence<p>problem solved: provide new peptide transporter comprising least one amino acid sequences selected group consisting (a) (x<sb>m</sb>rx<sb>o</sb>rx<sb>n</sb>), (b) (x<sb>m</sb>rrrx<sb>n</sb>), (c) (x<sb>m</sb>rrxrx<sb>n</sb>), (d) (x<sb>m</sb>rxrrx<sb>n</sb>), wherein x non-basic amino acid, integer zero 14, n integer, independent m, zero 14, integer, independent n, zero 5, wherein transporter peptide capable translocating across biological membrane. <p>solution: provided method screening phage library specific peptide transporter. <p>copyright: (c)2009,jpo&inpit',\n",
              " 'expression fused polypeptide surface filamentous phage particle<p>problem solved: provide novel surface recombination technology expressing heterodimeric recombinant gene products surface filamentous phage containing recombinant gene. <p>solution: disclosed filamentous phage containing genome encoding ligand-binding heterodimeric receptor, wherein ligand-binding heterodimeric receptor contains first second polypeptide, wherein first polypeptide fused carboxy-terminal filamentous phage membrane cpiii anchor domain cpviii anchor domain, wherein first second polypeptide independently expressed separate polypeptide reconstituted surface filamentous phage ligand-binding heterodimeric receptor. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'hepatitis b virus inhibitor<p>problem solved: provide peptide composition specific diagnosis, treatment prophylaxis hepatitis b virus infection. <p>solution: present invention provides peptides molecules, inhibiting assembly hepatitis b virus, obtained selecting peptides inhibit assembly hepatitis b virus binding virus core antigen prevent binding core antigen surface antigen fused phage library presented fibrous phage, method treating pharmaceutical composition comprising them. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'peptide reactivity substrate transglutaminase utilization same<p>problem solved: provide peptide reactivity substrate transglutaminase. <p>solution: peptide provided reactivity substrate transglutaminase consisting blood coagulation xiiith factor and/or tissue type transglutaminase specific amino acid sequence transglutaminase inhibitor activity. method searching compound transglutaminase inhibitory activity utilizing peptide presented phage-displaying method compound containing primary amine provided. <p>copyright: (c)2007,jpo&inpit',\n",
              " 'cellulose-binding peptide method producing same<p>problem solved: provide peptide slight amino acid residue specifically binding cellulose provide method producing peptide. <p>solution: cellulose-binding peptide comprises amino acid 7 numbers amino acid residues least one positive hydropathy index amino acid hydroxy group amino group least one side chain. method producing cellulose-binding peptide comprises steps amplifying, separating, washing eluting phage cellulose-binding peptide phage display peptide library. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'tumor invading cyclic peptide<p>problem solved: provide peptide vector composed cyclic peptide repetitively systemically administrable advanced solid cancer hepatic cancer pancreatic cancer, useful drug delivery system, taken tumor cell transferred cytoplasm provide tumor trophic peptide vector using cyclic peptide. <p>solution: phage library peptide 9 amino acid sequences cysteine terminals displayed surface brought contact pancreatic cancer cell line tumor formed inoculating pancreatic cancer cell line. thereby, phage actually taken tumor cell amplified. dna extracted subjected sequencing cyclic peptide taken tumor cell transferred cytoplasm identified determined base sequence. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'phage acinetobacter baumannii<p>problem solved: provide phage used uses reducing amount acinetobacter baumannii, specifically infecting acinetobacter baumannii. <p>solution: phage isolated acinetobacter baumannii, four kinds isolated phages include one genome sequences selected group consisting sequences sequence similarity ≥80%. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'phage/virus inactivator water-soluble paint<p>problem solved: provide phage/virus inactivator comprising anatase-type titanium oxide containing copper effective phage/virus inactivation, water-soluble paint using same. <p>solution: phage/virus inactivator comprises anatase-type titanium oxide containing copper, wherein mass% ratio cuo/tio<sb>2</sb>ranges 1.0 3.5 relative phage titer irradiation ultraviolet intensity 10 μw/cm<sp>2</sp>for 60 min 1×10<sp>-2</sp>to 1×10<sp>-5</sp>. water-soluble paint contains paint binder phage/virus inactivator. inactivator capable inactivating phage/virus fluorescent lamp weakly emitting ultraviolet radiation. painting, water-soluble paint exerts excellent effect various applications sanitary environments required, e. g. suppresses viral growth indoor environment. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'plasmid, ralstonia solanacearum, method monitoring, method evaluation, method screening<p>problem solved: provide plasmid reinforcing expression labeling material ralstonia solanacearum, rastonia solanacearum reinforcing expression labeling material, method monitoring various pathogenic bacteria including rastonia solanacearum, method evaluating sensitivity resistance various pathogenic bacteria including rastonia solanacearum, method screening test substances effective various pathogenic bacteria including rastonia solanacearum. <p>solution: plasmid replication module genome phage ϕrss1 infective capacity rastonia solanacearum expression cassette labeling substance. expression cassette phage ϕrsb2-originated mcp (major coat protein) promotor region, gene encoding labeling material, phage ϕrsb2-originated mcp terminator region. method monitoring performed culturing plant elongate root and/or stem along agar medium surface made inclined, observing labeling substance. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'plasmid containing replicative module phage rss1 method using same<p>problem solved: provide plasmid affinity ralstonia solanacearum, simply easily taken ralstonia solanacearum, stably exists ralstonia solanacearum contains gene express ralstonia solanacearum, ralstonia solanacearum transformed plasmid, system simply monitors dynamic state ralstonia solanacearum wide strain real time using plasmid, method using system. <p>solution: plasmid contains replicative module genome phage rss1 infectious ability ralstonia solanacearum, detail, plasmid contains gene express labeled substance. method labeling ralstonia solanacearum plasmid provided. ralstonia solanacearum transformed plasmid provided. method measuring dynamic state ralstonia solanacearum plant body comprises using plant body containing ralstonia solanacearum. method screening substance effectiveness ralstonia solanacearum provided. <p>copyright: (c)2009,jpo&inpit',\n",
              " 'process recovering polypeptide unfold reversibly polypeptide repertoire<p>problem solved: provide polypeptide improved property capable producing polypeptide high yield using biological production system. <p>solution: method producing antibody variable domain library variable domain resistant thermal coagulation concentrated includes following steps of: (a) providing phage display system including plurality displayed antibody variable domains least part displayed variable domain unfolded refolded, unfolding temperature 80-100°c; (b) selecting least one phage unfolded refolded phage display system displays variable region whose connecting function recovered; (c) obtaining nucleic acid encoding cdr1 optionally cdr2 variable domain displayed selected phage; (d) preparing, nucleic acid library encoding antibody variable domain. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'cell separation method using hydrophobic solid support<p>problem solved: provide rapid ready method separating cells viruses. <p>solution: method separating cells viruses using hydrophobic solid support comprises step contacting solution containing cells viruses hydrophobic solid support water contact angle 70 90 degrees. viruses selected group consisting bacteria, bacteriophages, plant cells, animal cells, plant viruses animal viruses, hydrophobic solid support selected group consisting various kinds structures plane, pillar, bead sieve. <p>copyright: (c)2010,jpo&inpit',\n",
              " 'recognition probe sugar chain marker, nerve projection elongation inhibitor using same, neuron-dyeing agent, tumor cell dyeing agent, immunological system dyeing agent, pharmacological composition, medicine<p>problem solved: provide recognition probe sugar chain marker, capable recognizing e disaccharide unit ie disaccharide unit. <p>solution: antibody, produced phage display method, gd3g7 used recognize ie [idoua-galnac (4s, 6s)] disaccharide unit (disaccharide unit) e [glcua-galnac (4s, 6s)] disaccharide unit ie [idoua-galnac (4s, 6s)] disaccharide unit (disaccharide unit). according constitution, example, effect intensively dyeing high metastatic cells low metastatic cells obtained. recognition probe sugar chains applied widely nerve projection elongation inhibitors, neuron-dyeing agent, tumor cell dyeing agent, immunological system dyeing agent, etc. brings significant advance basic medicine, applied medicine, drug discovery field sugar-chain engineering. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'method specifying classifying target bacterium phage specific genus, species serum type<p>problem solved: provide relative-entropy algorithm genomic fingerprinting capturing host-phage similarity. <p>solution: method comprises classification target bacterium phage following steps; (a) step specify target genome sequence; (b) step form randomized background genome derived target genome; (c) step specify oligonucleotide influencing difference background genome target genome executing iterative argorithm; (d) step compare oligonucleotide sequence selected step (c) known bacterium phage sequence. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'immuno-chromatography method using single-chain variant-part antibody<p>problem solved: provide sandwich type immunoassay using recombination protein bonding property antigen, especially immuno-chromatography method, recombination protein suitable use this. <p>solution: sandwich type immunoassay using first bonding material second bonding material antigen measured, least one first bonding material second bonding material made recombination protein heavy chain variant-part light chain variant-part antibody antigen. preferably, recombination protein single-chain variant-part fragment type antibody (scfv antibody) obtained phage displaying method. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'transformant screening method using transformant<p>problem solved: provide screening method generally used enzymes without limited characteristics, sizes properties, enzymes, enables easy display products enzyme-substrates reaction surfaces phages, enables highly accurate screening. <p>solution: transformant characterized infecting protein-encoding phagemid helper phage host. phage phagemid phage characterized produced transformant. furthermore, screening method characterized using phage phagemid phage. <p>copyright: (c)2005,jpo&ncipi',\n",
              " 'sequence specific dna recombination eukaryotic cell<p>problem solved: provide simple controllable recombination system practical means carrying stable targeted integration desired dna sequence provide method affording improved protein expression system. <p>solution: method sequence specific recombination dna eukaryotic cell provided. method comprises step introducing first dna comprising nucleotide sequence containing least one recombination sequence cell, introducing second dna comprising nucleotide sequence containing least one recombination sequence cell step performing sequence specific recombination bacteriophage lambda integrase int. <p>copyright: (c)2004,jpo&ncipi',\n",
              " 'site-specific genetic recombination method<p>problem solved: provide site-specific genetic recombination method using tg1 integrase method modifying microbial genome site-specific genetic recombination method. <p>solution: provided: site-specific genetic recombination method using actinomyces proteobacteria having, genome, base sequence high homology specific site (attb<sb>tg1</sb>) host strain s. avermitilis corresponding specific site (attp<sb>tg1</sb>) tg1 phage utilizing tg1 integrase; method modifying microbial genome site-specific genetic recombination method. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'protein adsorption-inhibiting substrate use<p>problem solved: provide substrate protein adsorption-inhibiting surfaces useful wide medical material, provide use thereof. <p>solution: substrate characterized self-tissue membrane comprising peptide derivative prepared introducing polyalkylene oxide chain one end side peptide specifically affinity hydrophobic organic polymer surface support comprising hydrophobic organic polymer. peptide selected phage display method. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'system selecting delta-endotoxin variant improved effect target insect<p>problem solved: provide system selecting δ-endotoxin variant improved effect target insect. <p>solution: method selecting toxin protein variant increased insecticidal activity target insect comprises preparation toxin presentation phage express insecticidal toxin protein t7 phage form bindable receptor, selection toxin presentation phage binding affinity carrier using carrier bound receptor, selection variant increased binding affinity receptor using system. insecticidal composition contains variant active body, vermin-resisting plant contains gene encoding variant introduced plant expressible manner. <p>copyright: (c)2007,jpo&inpit',\n",
              " 'thermostable lysozyme<p>problem solved: provide thermostable lysozyme exhibiting activity high temperatures. <p>solution: thermostable lysozyme specific amino acid sequence derived bacteriophage φin93 infected thermophilic bacterium thermus aquaticus thermostable lysozyme amino acid sequence one plurality amino acids substituted, deleted added sequence exhibits thermostable activity. furthermore, gene specified base sequence encoding amino acid sequence enzyme. thermostable lysozyme exhibits good activity high temperature conditions 60-120°c reaction optimum temperature suitably used sterilization, etc., high-temperature environment. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'transformer excitation rush current supression control method, device therefor<p>problem solved: provide transformer excitation rush current suppression control method device capable suppressing excitation rush current generated connecting three-phase alternate current transformer electric power system including higher harmonic wave closing breaker. <p>solution: residual magnetic flux three-phase alternate current transformer 2 time shut-down measured, minimum phase absolute value residual magnetic flux three phases made controlling phase, two phase angles θ give residual magnetic flux controlling phase calculated, furthermore, virtual rush current respective phases time first phase angle θ virtual rush current respective phases time second phase angle θ acquired, making phase angle θ absolute value virtual rush currents becomes 1 less closing phage angle, closing transformer primary side breaker 6 controlled. <p>copyright: (c)2009,jpo&inpit',\n",
              " 'construction vector constructing expression vector host vegetable, application same<p>problem solved: provide vector constructing expression vector capable rapidly recombining vegetable transformation vector cloning target gene vector constructing expression vector good cloning efficiency sequence efficiency. <p>solution: vector constructing expression vectors constructed inserting two att sites, promotor terminator two sites cloning site put promotor terminator puc-based cloning vector, inserting gene coding functional peptide changing arbitrary transcription factor transcription control factor. vectors rapidly recombined vegetable transformation vectors using phage-derived integrase/att-system. <p>copyright: (c)2005,jpo&ncipi',\n",
              " \"vector cell-free protein synthesis system baculovirus expression system<p>problem solved: provide vector used cell-free protein synthesis system baculovirus expression system. <p>solution: baculovirus transfer vector comprises baculovirus late gene promoter sequence (a), baculovirus late gene 5' untranslated region sequence (b), sequence (c) inserting desired structural gene upstream side downstream side, comprises phage-derived rna polymerase recognition sequence (d) upstream side sequence (a) downstream side sequence (a) upstream side sequence (b). method preparing protein baculovirus expression system and/or cell-free protein synthesis system recombinant baculovirus transfer vector obtained inserting desired structural gene baculovirus transfer vector provided. <p>copyright: (c)2010,jpo&inpit\",\n",
              " 'single-stranded antibody recognizing t-antigen sugar chain derived phage library<p>problem solved: provide antibody recognizing t-antigen sugar chain function analysis sugar chain associated cancer, nucleic acid encoding antibody. <p>solution: provided antibody containing specific amino acid sequence, recognizing t-antigen sugar chain produced screening phage-presentation library present human scfv using t-antigen containing hexaethylene glycol producing t-antigen specific single-stranded antibody, method producing recombinant antibody recognizing t-antigen sugar chain using nucleic acid encoding antibody, recombinant antibody composed single-stranded antibody. <p>copyright: (c)2009,jpo&inpit',\n",
              " 'anti-suminori disease bacteriophage method preventing suminori disease cultured laver<p>problem solved: provide anti-suminori disease bacteriophage provide method preventing suminori disease cultured laver using anti-suminori disease bacteriophage. <p>solution: anti-suminori disease bacteriophage liquid b added mixed treating liquid w treating bath 1 order 1×10<sp>5</sp>to 1×10<sp>8</sp>pfu. seeded, frozen, preserved net 10 laver culture frozen preserved -20°c directly dipped thawed dipped treating liquid w treating bath 1. net 10 laver culture directly extended washed seawater extended culture farm. <p>copyright: (c)2009,jpo&inpit',\n",
              " 'encryption method decryption method<p>problem solved: provide encryption method decryption method encrypted information easily held transported. <p>solution: encrypted dna fragment dna sequence corresponding information encrypted prepared, prepared encrypted dna fragment integrated dna λ phage, λ phage 4 integrated encrypted dna fragment integrated colon bacillus 10. <p>copyright: (c)2003,jpo',\n",
              " 'variant rna polymerase<p>problem solved: provide improved t7rna polymerase increases specific activity bacteriophage t7rna polymerase improve reactivity high temperature range. <p>solution: provided variant t7rna polymerase obtained replacing tryptophan residue corresponding 344-position amino acid sequence wild t7rna polymerase derived bacteriophage t7 valine residue. <p>copyright: (c)2009,jpo&inpit',\n",
              " 'intestinal tract immunity induction type vaccine exhibiting phage head shell<p>problem solved: provide intestinal tract immunity induction type vaccine capable inexpensively efficiently inducing intestinal tract immunity. <p>solution: intestinal tract immunity induction type vaccine comprises bacteriophage infected intestinal tract contagium. vaccine, antigen protein derived intestinal tract contagium exhibited surface head shell bacteriophage. <p>copyright: (c)2007,jpo&inpit',\n",
              " 'phage treatment pseudomonas aeruginosa<p>problem solved: provide bacteriophage mpk6 progeny bacteriophage thereof. <p>solution: bacteriophage mpk6 (accession number kccm 11044p) lytic activity pseudomonas aeruginosa progeny bacteriophage thereof rflp (restriction fragment length polymorphism) dna profile bacteriophage mpk6 provided. new bacteriophage mpk6 progeny bacteriophage thereof capable treating pseudomonas aeruginosa infectious disease provided present antibacterial efficacy bacteriophage mpk6 progeny bacteriophage thereof using mammalian non-mammalian infection model. <p>copyright: (c)2010,jpo&inpit',\n",
              " 'kunitz domain library<p>problem solved: provide libraries, vectors, phage particles, host cells, methods displaying kunitz domain. <p>solution: provided library comprising plurality filamentous phage particles, phage particle includes (i) display protein comprises kunitz domain, (ii) nucleic acid comprising (a) phage genes sufficient produce infectious phage particle (b) sequence encoding display protein, wherein kunitz domain includes least varied one amino acid position two interaction loops, positions respective loops varied among plurality particles, wherein average number copies kunitz domain per phage particle less 2.0. <p>copyright: (c)2010,jpo&inpit',\n",
              " 'method constructing display library genetic package member diverse family peptides<p>problem solved: provide methods useful constructing libraries collectively display members diverse families peptides, polypeptides, proteins, libraries produced using methods. <p>solution: methods cleaving single-stranded nucleic acids selected locations, cleaved nucleic acids encodes, least part, peptides, polypeptides, proteins displayed genetic packages libraries. genetic packages filamentous phage phagemids. peptides, polypeptide, proteins identified screening provided. also, sequences may deleterious expression removed amplified dna cloning displaying. <p>copyright: (c)2011,jpo&inpit',\n",
              " 'opsonic monoclonal chimeric antibody specific lipoteichoic acid gram positive bacterium<p>problem solved: provide monoclonal antibodies binding lipoteichoic acid (lta) gram positive bacteria. <p>solution: present invention encompasses monoclonal antibodies, least part variable regions antibodies obtained phage display library containing human antibody sequences, specifically binding lipoteichoic acid (lta) gram-positive bacteria fragments. antibodies bind whole bacteria enhance phagocytosis killing bacteria vitro. invention disclose antibodies human sequences (chimeric, humanized human antibodies). invention discloses three variable regions contained antibodies. <p>copyright: (c)2008,jpo&inpit',\n",
              " 'gene cluster if1a11 expressing human fab antibody fabif1a11 effectively neutralizing influenza virus type h3n2 subtype<p>problem solved: solve problems effect oseltamivir specific therapeutic preparation influenza infectious diseases exhibited administration initial stage infection preparation administered infants specific treating method case symptom caused influenza infectious disease becomes serious established time required exhibiting effect inoculation influenza vaccine prophylaxis. <p>solution: present inventors separated gene cluster if1a11 expressing human fab using combinatorial chemistry method phage display method found fabifia11 gene product gene cluster activity effectively neutralize influenza virus type h3n2 subtype. if1a11 gene product human fab believed if1a11 molecule possibility compensate defects prophylaxis vaccine influenza infectious diseases specific therapeutic preparations present. <p>copyright: (c)2006,jpo&ncipi',\n",
              " 'human fab antibody gene cluster effectively neutralizing rabies virus<p>problem solved: solve problems equine serum neutralizing rabies comprises heterologous protein human antiserum rabies danger contraction infectious diseases mediated blood. <p>solution: gene product fabtc3g7 produced gene cluster tc3g7, wherein fabtc3g7 proven effectively neutralization activity rabies virus 3 strain, result separation gene cluster tc3g7 expresses human fab, using combinatorial science procedure phage display procedure. gene product fabtc3g7 comprises human fab seems molecule possibility covering defect caused administration equine antiserum administration human antiserum presently recommended preventive measure onset rabies exposure rabies virus. <p>copyright: (c)2006,jpo&ncipi',\n",
              " \"method down-regulating gdf-8 activity1. method vivo down-regulation growth differentiation factor 8 (gdf-8) activity animal, including human being, method comprising effecting presentation animal's immune system immunogenically effective amount least one gdf-8 analogue wherein introduced least one modification gdf-8 amino acid sequence results - immunization animal analogue induces production antibodies gdf-8 polypeptide, - substantial fraction gdf-8 b-cell epitopes preserved, - foreign helper epitope (th epitope) introduced corresponding one residues 18-41, 49-69, 79-104 seq id no: 11 12 means addition, deletion, insertion substitution, introduced corresponding equivalent sequence gdf-8 polypeptide different origin human, bovine, porcine, chicken turkey, foreign th epitope inserted substituted one loop areas flexible termini gdf-8 polypeptide, wherein number aminoacid additions, deletions, insertions substitutions 60. 2. method according claim 1, comprises - least one first moiety introduced effects targeting modified molecule antigen presenting cell (apc) b-lymphocyte, and/or - least one second moiety introduced stimulates immune system, and/or - least one third moiety introduced optimises presentation modified gdf-8 polypeptide immune system. 3. method according claim 1 2, wherein modification includes introduction side groups, covalent non-covalent binding suitable chemical groups gdf-8 subsequence thereof, foreign th epitope and/or first and/or second and/or third moiety. 4. method according one claims 1-3, wherein modification includes amino acid substitution and/or deletion and/or insertion and/or addition. 5. method according claim 4, wherein modification results provision fusion polypeptide. 6. method according claim 4 5, wherein introduction amino acid substitution and/or deletion and/or insertion and/or addition results substantial preservation overall tertiary structure gdf-8. 7. method according one claims 1-6, wherein modification includes duplication least one gdf-8 b-cell epitope and/or introduction hapten. 8. method according one claims 1-7, wherein foreign th epitope immunodominant animal. 9. method according one claims 1-8, wherein foreign th epitope promiscuous, natural promiscuous th epitope artificial mhc-ii binding peptide sequence. 10. method according claim 9, wherein natural th epitope selected tetanus toxoid epitope p2 p30, diphtheria toxoid epitope, influenza virus hemagluttinin epitope, p. falciparum cs epitope. 11. method according one claims 2-10, wherein first moiety substantially specific binding partner b-lymphocyte specific surface antigen apc specific surface antigen, hapten carbohydrate receptor b-lymphocyte apc, mannan mannose. 12. method according one claims 2-11, wherein second moiety selected cytokine, hormone, heat-shock protein. 13. method according claim 12, wherein cytokine selected from, effective part of, interferon gamma (ifngamma), flt3l, interleukin 1 (il-1), interleukin 2 (il-2), interleukin 9 (il-4), interleukin 6 (il-6), interleukin 12 (il-12), interleukin 13 (il-13), interleukin 15 (il-15), granulocyte-macrophage colony stimulating factor (gm-csf), wherein heat-shock protein selected group consisting hsp70, hsp90, hsc70, grp94, calreticulin (crt), effective part thereof. 14. method according one claims 2-13, wherein third moiety lipid nature, palmitoyl group, myristyl group, farnesyl group, geranyl-geranyl group; gpi-anchor, n-acyl diglyceride group. 15. method according one preceding claims, wherein gdf-8 subsequence gdf-8 analogue derived c-terminal, active form gdf-8, subsequence analogue derived bovine, porcine, human, chicken, sheep, turkey gdf-8 polypeptide. 16. method according claim 15, wherein gdf-8 polypeptide modified substituting least one amino acid sequence seq id no: 11 12 least one amino acid sequence equal different length contains foreign th epitope, wherein substituted amino acid sequences comprised residues 1-12, 18-91, 43-48, 49-69, 79-104 seq id no: 11 12, wherein gdf-8 polypeptide modified inserting least one amino acid sequence contains foreign th epitope, wherein insertion performed anywhere positions 1-12, 18-30, 42-51, 82-86, 105-109 seq id no: 11 12. 17. method according one preceding claims, wherein presentation immune system effected least two copies gdf-8 polypeptide, subsequence thereof modified gdf-8 polypeptide covalently non-covalently linked carrier molecule capable effecting presentation multiple copies antigenic determinants. 18. method according one preceding claims, wherein effective amount gdf-8 polypeptide gdf-8 analogue administered animal via route selected parenteral route intradermal, subdermal, intracutaneous, subcutaneous, intramuscular routes; peritoneal route; oral route; buccal route; sublinqual route; epidural route; spinal route; anal route; intracranial route. 19. method according claim 18, wherein effective amount 0.5 mug 2,000 mug gdf-8 polypeptide, subsequence thereof analogue thereof. 20. method according claim 18 19, includes least one administration gdf-8 polypeptide analogue per year, least 2, least 3, least 4, least 6, least 12 administrations per year. 21. method according one claims 18-20, wherein gdf-8 polypeptide, subsequence thereof, modified gdf-8 polypeptide optionally formulated pharmaceutically immunologically acceptable carrier and/or vehicle formulated adjuvant facilitates breaking autotolerance autoantigens, adjuvant selected group consisting immune targeting adjuvant; immune modulating adjuvant toxin, cytokine mycobacterial derivative: oil formulation; polymer; micelle forming adjuvant; saponin; immunostimulating complex matrix (an iscom matrix); particle; dda; aluminium adjuvants; dna adjuvants; gamma-inulin: encapsulating adjuvant. 22. method according one claims 19-21, wherein gdf-8 polypeptide analogue contained virtual lymph node (vln) device. 23. method according one claims 1-17, wherein presentation modified gdf-8 immune system effected introducing nucleic acid(s) encoding modified gdf-8 animal's cells thereby obtaining vivo expression cells nucleic acid(s) introduced. 24. method according claim 23, wherein nucleic acid(s) introduced is/are selected naked dna, dna formulated charged uncharged lipids, dna formulated liposomes, dna included viral vector, dna formulated transfection-facilitating protein polypeptide, dna formulated targeting protein polypeptide, dna formulated calcium precipitating agents, dna coupled inert carrier molecule, dna formulated chitin chitosan, dna formulated adjuvant. 25. method according claim 23 24, wherein nucleic acids administered intraarterially, intravenously, routes defined claim 18. 26. method according claim 24 25, wherein nucleic acid(s) is/are contained vln device and/or formulated defined claim 21. 27. method according one claims 24-26, includes least one administration nucleic acids per year, least 2, least 3, least 4, least 6, least 12 administrations per year. 28. method increasing muscle mass animal, method comprising down-regulating gdf-8 activity according method one claims 1-27 extent muscle mass increased least 5% compared animals exhibit normal gdf-8 activity, least 10, 15, 20, 25, 30, 35, 40, 45%. 29. gdf-8 analogue derived animal gdf-8 polypeptide wherein introduced modification defined one claims 1-17. 30. immunogenic composition comprising immunogenically effective amount gdf-8 analogue according claim 29, composition comprising pharmaceutically immunologically acceptable carrier and/or vehicle optionally adjuvant. 31. immunogenic composition according claim 30, wherein adjuvant selected group consisting adjuvants claim 21. 32. nucleic acid fragment encodes gdf-8 analogue according claim 29. 33. vector carrying nucleic acid fragment according claim 32, vector capable autonomous replication. 34. vector according claim 33 selected group consisting plasmid, phage, cosmid, minichromosome, virus. 35. vector according claim 33\",\n",
              " 'method device simultaneous detection multiple components mixture1. method simultaneous detection multiple components mixture, said method comprises reacting mixture components analysis specific receptors immobilized surfaces microcarriers type specific receptor bound marked microcarrier, wherein completion reacting separation microcarriers reacted non-reacted receptors judged mobility influence physical field provided, availability non-availability components analysis mixture detected identification markers separated microcarriers. 2. method claim 1, wherein physical field gravitation field, electric field, magnetic field combination thereof. 3. method claim 1, wherein microcarriers produced microscopic biological subjects, synthetic, semi-synthetic natural substances mixtures microincapsulated markers bound nucleus surface said microcarriers. 4. method claim 3, wherein microcarriers produced protysta, bacteria, viruses, phages, spores plants, bacteria fungi, flower pollen plants, erythrocytes, microscopic algae, magnetite, maghemite, iron, nickel, chrome, gold, silicagel, zeolite, carbon, polystyrene, divinyl benzene, polyacrylamide, polysulfone, polyamide, polyethylene glycol, glucans [alpha] [beta] conformations, including aminoglucans, polyuronic acids, polyacrolein, polyglutaraldehide, polymethyl(hydroxymethyl)acrylate, polychloromethylsterene, polyvinyl alcohol, polyvinyl [epsilon]-amino acids, polyvinyl isotronium, polyacrylic acid, polylactate, polyalkylcyanoacrylate mixtures combinations above. 5. method claim 3, wherein microcarriers used one analysis identical shape, dimensions differ max. 20%. 6. method claim 3, wherein shape microcarriers looks hemisphere, cone, polyhedron, rod strand. 7. method claim 3, wherein microcarriers marked symbol relief surface viewed microscope. 8. method claim 3, wherein microcarriers marked substance mixture substances included said microcarriers affixed surface. 9. method claim 8, wherein identifying features marker absorption spectra, emission spectra, reflection spectra, dispersion spectra, birefringence spectra, circular dichroism spectra energy spectra radioactive decay characteristics given substance mixture substances well intensity said spectra. 10. method claim 8, wherein markers organic complexes cations lantanum group, natural synthetic porphyrins, natural synthetic quinones, natural synthetic alkaloids with/or without paramagnetic markers, with/or without radioactivity well mixtures thereof. 11. method claim 1, wherein characteristics particles changed mobility influence physical field evaluated either visually means registering means. 12. method claim 11, wherein registering means spectrometers electromagnetic radiation radio, infra-red, visible x-ray ranges taken individually combinations thereof. 13. method claim 11, wherein evaluation provided either visually help magnifying devices. 14. method claim 13, wherein microscope, magnifying glass, projector, slide projector computer display used magnifying devices. 15. method reacting components analysis specific receptors immobilized surfaces microcarriers, said method comprising combination microcarriers mixture one chamber, wherein ordered motion microcarriers medium containing components analysis provided. 16. method claim 15, wherein counter motion medium containing components analysis provided. 17. method claims 15 16, wherein motion microcarriers provided linear path, circular path helix path. 18. method claims 15-17, wherein motion microcarriers provided influence physical field. 19. method claim 18, wherein physical field gravitation field, electric field, magnetic field combinations thereof. 20. method claim 19, wherein physical field magnetic field electric field, motion microcarriers provided counter movement medium field. 21. method claim 20, wherein microcarriers passed two times whole volume medium analysis. 22. device simultaneous detection multiple components mixture, said device comprised reacting chamber reacting mixture components analysis specific receptors immobilized surfaces microcarriers, type specific receptor bound marked microcarrier, analyzing means, wherein said device additionally supplied separating chamber inlet said chamber coupled outlet reacting chamber, said separating chamber supplied unit generating physical field separation microcarriers non-reacted reacted receptors judged mobility influence physical field, separating chamber equipped means supplying separated microcarriers and/or information latter analyzing means. 23. reacting chamber mixture components analysis specific receptors immobilized surfaces microcarriers, latter made paramagnetic, said reacting chamber comprising mixture container form channel, unit generating physical field form least one magnet generating physical field possibility movement relation said channel, wherein magnet adapted move substantially along channel constant distance therefrom. 24. reacting chamber claim 23, wherein channel made form helix. 25. reacting chamber claim 23, channel made elastic tube coiled form helix. 26. reacting chamber claim 23, wherein channel formed baffle plate made form helix cylindrical surface. 27. reacting chamber claim 23, wherein channel formed baffle plate made form helix disk plate. 28. reacting chamber claim 23, wherein least two magnets positioned sides helix channel shift relation one another. 29. reacting chamber claims 23-28, wherein said chamber additionally supplied means supplying motion mixture analysis counter direction relation motion microcarriers, supplied fittings supply collection microcarriers. 30. separating chamber comprising unit generating physical field form permanent magnet working chamber, inlet outlet fittings mixture analysis washing fluid, wherein said working chamber made two removable sterile cylindrical cases disposable ones, case presents cylindrical cover fittings, said cover groove sealed disk inserted, said disk provided possibility rotation around axis means drive. 31. separating chamber claim 30, wherein said separating chamber fixedly secured permanent magnet means projections grooves positioned magnet ring internal surface cases. 32. separating chamber claim 31, wherein magnet made form disk half two built parts form sectors truncated 90 degree half depth magnetic field orientation along central axis said disk. 33. separating chamber claim 30, wherein disk rotation drive made form friction wheel contiguous surfaces two movable disks. 34. separating chamber claim 33, wherein disks made possibility rotation counter directions equal speed. 35. separating chamber claim 30, wherein inlet outlet fittings separated fluid located median level case, fittings washing fluid supply located top part case. 36. separating chamber claim 30, wherein outlet fitting washing fluid located slightly median level case. 37. separating chamber claim 30, wherein rotating disk assembly cylindrical cover provides self-contained volume separated baffle plate falculate shape formed interior part case cover. 38. separating chamber claim 37, wherein baffle plate tight contact along full length surface rotating disk. 39. separating chamber claim 37, wherein arch-shaped central part baffle plate forms cavity, circumferential direct part located radial small angle median forms inclined channel along lower half rotating disk. 40. separating chamber claim 39, wherein bottom cavity thus formed installed fitting exhaust washing fluid microcarriers. 41. separating chamber claim 40, wherein end inclined channel installed fitting exhaust microcarriers reacted.',\n",
              " 'hbv core antigen particles multiple immunogenic components attached via peptide ligands1. hbv core antigen particle comprising least one capsid binding immunogen, said capsid binding immunogen comprising least one hbv capsid binding peptide component least one immunogenic component. 2. hbv core antigen particle according claim 1, wherein said capsid binding immunogen oriented said particle permits said immunogenic component elicit immune response said particle administered individual. 3. hbv core antigen particle according claim 1, wherein said capsid binding immunogen linked said particle amino acid residue said hbv capsid-binding peptide component. 4. hbv core antigen particle according claim 1, wherein said capsid binding immunogen linked said particle amino acid residue residue said immunogenic component. 5. hbv core antigen particle according claim 4, wherein said residue said immunogenic component carbohydrate. 6. hbv core antigen particle according claim 1, wherein said capsid binding immunogen linked said particle amino terminus said hbv capsid-binding peptide component. 7. hbv core antigen particle according claim 1, wherein said capsid binding immunogen linked said particle carboxy terminus said hbv capsid-binding peptide component. 8. hbv core antigen particle according claim 1, wherein said capsid binding immunogen crosslinked said particle crosslinker. 9. hbv core antigen particle according claim 1, wherein said immunogenic component linked said hbv capsid-binding peptide component directly linker sequence. 10. hbv core antigen particle according claim 1, wherein said immunogenic component linked amino terminus said hbv capsid-binding peptide component directly linker sequence. 11. hbv core antigen particle according claim 1, wherein said immunogenic component linked carboxy terminus said hbv capsid-binding peptide component directly linker sequence. 12. hbv core antigen particle according one claims 9-11, wherein said immunogenic component linked said hbv capsid-binding peptide component crosslinker. 13. hbv core antigen particle according claim 8, wherein said crosslinker multifunctional crosslinker. 14. hbv core antigen particle according claim 12, wherein said crosslinker multifunctional crosslinker. 15. hbv core antigen particle according claim 14, wherein said multifunctional crosslinker selected group consisting 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide hydrochloride n-hydroxy-sulphosuccinimide. 16. hbv core antigen particle according claim 1, wherein said immunogenic component comprises one epitopes selected group consisting immunologic epitopes, immunogenic epitopes antigenic epitopes. 17. hbv core antigen particle according claim 16, wherein said epitopes selected group consisting linear epitopes, conformational epitopes, single epitopes mixed epitopes. 18. hbv core antigen particle according claim 1, wherein said immunogenic component selected group consisting antigens, allergens, antigenic determinants, proteins, glycoproteins, antibodies, antibody fragments, peptides, peptide mimotopes mimic antigen antigenic determinant, polypeptides, glycopeptides, carbohydrates, oligosaccharides, polysaccharides, oligonucleotides polynucleotides. 19. hbv core antigen particle according claim 1, wherein said immunogenic component targeted derived pathogenic agent selected group consisting viruses, parasites, mycobacteria, bacteria, bacilli, fungi, protozoa, plants, phage, animal cells plant cells. 20. hbv core antigen particle according claim 19, wherein said virus selected group consisting retroviruses, herpesviruses, orthomyoxoviruses, paramyxoviruses, hepadnaviruses, flaviviruses, picornaviruses, papoviruses, adenoviruses, baculoviruses, hantaviruses, parvoviruses, enteroviruses, rhinoviruses, tumor viruses, dna viruses, rna viruses, togaviruses, rhabdoviruses poxviruses. 21. hbv core antigen particle according claim 20, wherein said virus selected group consisting human immunodeficiency type 1 virus, human immunodeficiency type 2 virus, cell-leukemia virus, herpes simplex type 1 virus, herpes simplex type 2 virus, varicella-zoster virus, cytomegalovirus, epstein-barr virus, influenza virus, influenza b virus, influenza c virus, respiratory syncytial virus, measles-like virus, mumps virus, parainfluenza virus, hepatitis b virus, hepatitis c virus, hepatitis virus, hepatitis e virus, yellow fever virus, malaria, dengue virus, tick-borne encephalitis virus, oncovirus, poliomyelitis virus, papillomavirus, rubella virus, rabies virus vaccinia virus. 22. hbv core antigen particle according claim 19, wherein said immunogenic component targeted derived bacillus, enterobacteria, clostridium, listeria, mycobacterium, pseudomonas, staphylococcus, eubacteria, mycoplasma, chlamydia, spirochetes, neisseria salmonella. 23. hbv core antigen particle according claim 19, wherein said immunogenic component targeted diptheria, tetanus, acellular pertussis, haemophilus influenza, polio, measles, mumps, rubella, varicella, hepatitis b virus, hepatitis virus, pneumococcal pneumonia, yellow fever, malaria, hepatitis b virus, hepatitis virus, typhoid fever, meningococcal encephalitis cholera. 24. hbv core antigen particle according claim 18, wherein said immunogenic component selected group consisting animal allergens, insect allergens, plant allergens, atmospheric allergens inhalant allergens. 25. hbv core antigen particle according claim 1, wherein said hbv core antigen hbv core antigen fusion protein. 26. hbv core antigen particle according claim 25, wherein said hbv core antigen fusion protein comprises immunologic epitope, immunogenic epitope antigenic epitope. 27. hbv core antigen particle according claim 26, wherein said hbv core antigen fusion protein comprises immunologic epitope, immunogenic epitope antigenic epitope fused hbv core antigen directly linker sequence. 28. hbv core antigen particle according claim 26, wherein said hbv core antigen fusion protein comprises immunologic epitope, immunogenic epitope antigenic epitope fused carboxy terminus said hbv core antigen directly linker sequence. 29. hbv core antigen particle according claim 26, wherein said hbv core antigen fusion protein comprises immunologic epitope, immunogenic epitope antigenic epitope fused amino terminus said hbv core antigen directly linker sequence. 30. hbv core antigen particle according claim 25, wherein said hbv core antigen fusion protein comprises truncated hbv core antigen. 31. hbv core antigen particle according claim 25, wherein said hbv core antigen fusion protein comprises hbv surface antigen portions thereof. 32. hbv core antigen particle according claim 31, wherein said hbv core antigen fusion protein comprises sequence selected group consisting pre-s1 region hbv surface antigen, pre-s2 region hbv surface antigen, immunodominant region hbv surface antigen portions thereof. 33. hbv core antigen particle according claim 1, wherein said hbv core antigen full length hbv core antigen polypeptide, portions, truncates, mutations derivatives thereof capable assembling particulate form. 34. hbv core antigen particle according claim 1, wherein said hbv capsid-binding peptide component selected group consisting of: sllgrmkga (seq id no: 6), gsllgrmkga (seq id no: 36), dgsllgrmkgaa (seq id no: 37), adgsllgrmkgaag (seq id no: 38), sllgrmkg(beta-a)c (seq id no: 8), rsllgrmkga (seq id no: 9), hrsllgrmkga (seq id no: 10), allgrmkg (seq id no: 12), mhrsllgrmkga (seq id no: 40), rsllgrmkga(beta-a)c (seq id no: 11) mhrsllgrmkgag(beta-a)gc (seq id no: 41). 35. vaccine comprising prophylactically effective amount hbv core antigen particle according claim 1. 36. pharmaceutical composition comprising therapeutically effective amount hbv core antigen particle according claim 1. 37. method producing immune response individual comprising step administering said individual hbv core antigen particle according claim 1 amount effective produce immune response. 38. method according claim 37, wherein said hbv core antigen particle administered said individual parenteral route. 39. method increasing immunogenicity immunogen linking said immunogen hbv core antigen particle hbv capsid-binding peptide, characterized claim 34. 40. hbv core antigen particle according claim 1, wherein said capsid binding immunogen comprises diagnostic label chemical marker. 41. method detecting presence antibodies immunogen sample comprising steps of: (a) contacting sample hbv core antigen particle according claim 40, time sufficient permit antibodies said sample form complex said capsid binding immunogen and; (b) using detection means detect complex formed capsid binding immunogen said antibodies said sample. 42. hbv capsid-binding peptide immunogen comprising least one capsid-binding peptide component least one immunogenic component. 43. hbv capsid-binding peptide immunogen according claim 42, wherein sa',\n",
              " 'method storing food agricultural products1. technical result improvement products quality, increase duration shelf life reduce net cost. 2. essence food agricultural products and/or materials packing treated homologous bacteriophage causing putrefaction. 3. field application food industry',\n",
              " 'means exposure neutralization ralstonia solanacearum bacteria water, soil, plant materials1. technical result increase efficiency exposure ralstonia solanacearum bacteria causing disease bacterial wilting (wilt) brown putrefaction, extermination development propagation disease widening assortment means biological control. 2. essence means comprises mixture specific polyvalent bacteriophages equal proportion. 3. field application agriculture, environmental protection.',\n",
              " 'bandage treatment wounds burns1. technical result increase efficiency treatment prophylaxis. 2. essence bandage comprises collagen plate impregnated bacteriophage homologous microbes infecting wounds and/or burns. 3. field application medicine, surgery.',\n",
              " 'medicinal paste filling tooth root1. technical result intensification anti-inflammatory effect, prevention side-effects widening assortment medicinal pastes filling tooth root. 2. essence medicinal paste filling tooth root comprises hydro apatite (ha), zinc oxide, combined preparation bacteriophage eugenol. 3. field application medicine, stomatology.',\n",
              " 'method water air refinement1. technical result refinement water air bacteria. 2. essence water air passed filters, pores mass bacteriophage. 3. field application ecology.',\n",
              " 'combined antimicrobial antimycotic preparation enteric infection1. technical result widening spectrum preparation effect increase efficiency treatment. 2. essence combined preparation enteric infection comprises phage lysates bacteria: shigellae, salmonellae, e.coli, proteus, pseudomo¬nas aeruginosa, staphylococcus enterococcus antimycotic preparation: nystatin, levorine, nizoral, diflukan, pimafucine, klotrimazole therapeutically effective amount. 3. field application medicine, pharmacology.',\n",
              " 'combined antimicrobial antimycotic preparation purulent infection1. technical result widening spectrum preparation effect increase efficiency treatment/ 2. essence preparation purulent infection comprises phage lysates aerobian bacteria: staphylo¬coccus, streptococcus, pathogenic esche¬richia coli, pseudomo¬nas, proteus, entero¬coc¬cus, klebseiellae и anaerobian bacteria clostri¬dium, antimycotic preparation: nystatin, levorine, nixoral, diflukan, pimafucine, klotrimazole therapeutically effective amount. 3. field application medicine, veterinary.',\n",
              " \"human nucleic acid ovarian tumor tissue123 nucleic acid (cdna) sequences (a), fully defined specification, highly expressed ovarian tumor tissue (and testis breast cancer tissue), new. independent claims included following: (a) subset (a') 56 (a) encode least part gene product, allelic variants (a') complements (a') allelic variants; (b) bacterial phage artificial chromosomes cosmid clones containing functional genes, chromosome region containing them, corresponding (a') use gene transfer vehicles; (c) nucleic acid sequences containing part (a) sufficiently long hybridize (a); (d) expression cassette (ec) comprising (a), fragments, plus control regulatory sequences; (e) dna fragments containing gene isolated using (a); (f) host cells containing (a) heterologous component; (g) recombinant production polypeptides (b), fragments, culturing cells (f); (h) antibody (ab) directed (b), fragments, encoded (a); (j) 134 partial polypeptide sequences, fully defined specification, sequences least 80% homology them; (k) pharmaceutical composition containing least one partial sequences; (l) genomic genes, promoters, enhancers, silencers, exon intron structures, splice variants obtained using (a).\",\n",
              " 'phage ?29 dna polymerase chimera597884 disclosed dna polymerase chimera comprising: a) amino acid sequence encoding ?29 type dna polymerase, bound c-terminal end b) connecting amino acid sequence bound c-terminal end c) amino acid sequence comprising least one helixhairpin-helix (hhh) domain.',\n",
              " 'method device bacterial samplinga bacterial detection sampling device comprising: sampling medium receiving bacterial sample; plurality bacteriophage. bacteriophage located sampling medium. bacteriophage comprises nucleic acid encoding protein capable emitting light output wavelength.',\n",
              " 'bacterial strain streptococcus thermophilus used production bacterial concentrates fermented milk productsa bacterial strain streptococcus thermophilus imb b-7247 used production bacterial concentrates fermented milk products. strain ability generation capsule exopolysaccharides, providing formation viscous texture fermented milk, characterized cholesterin-reducing activity, antagonistic action towards wide range pathogenic opportunistic microorganisms, moderate acid formation energy milk, resistant towards bacteriophages, providing high quality functional activity fermented milk products using thereof.',\n",
              " 'bacterium reduced sensitivity bacteriophagea bacterial strain modified reduce activity and/ expression autolysin, wherein said modified strain reduced sensitivity bacteriophage, bacterial compositions comprising bacterial strain use strain composition manufacture food feed product.',\n",
              " 'bacteriophage belonging siphoviridae bacteriocidal composition comprising samea bacteriophage belonging siphoviridae annihilating escherichia coli salmonellae infected escherichia coli salmonellae provided control antibiotic resistant bacteria cure diseases caused escherichia coli salmonellae infection. bacteriophage eps7(kctc 11121bp) belonging siphoviridae separated sewage shows host susceptibility escherichia coli salmonellae. salmonellae salmonella typhimurium salmonella enteritidis. composition bacteria extinction microbe form comprise bacteriophage eps7 (kctc 11121bp).',\n",
              " 'bacteriophage composition application inactivating antibiotic-resistant pathogenic bacteriaa bacteriophage composition application inactivating antibiotic-resistant pathogenic bacteria, comprising three bacteriophages deposited china typical culture collection aug. 1, 2018,respectively phi. yszka, accession number cctcc 2018513; phage [phi] yszkp, deposited cctcc 2018514; phage [phi] yszpa, preservation number cctcc 2018515. method apparatus treat contaminated soil adding specific bacteriophage solution plant system, directionally infecting inactivating system resistant pathogenic bacteria combined pollution remove resistance gene. restoration, diversity stability soil ecological environment function significantly restored.',\n",
              " 'bacteriophage composition, bacteriostat, use thereofa bacteriophage composition comprising clostridium perfringens phage cctcc no: 2020047, salmonella phage cctcc no: 2020710, escherichia coli phage cctcc no: 2020711, shigella flexneri phage cctcc no: 209029. bacteriophage composition present disclosure strong lytic effects clostridium perfringens, salmonella, escherichia coli, shigella flexneri, used inhibit and/or clear bacterial infections inhibiting overgrowth. bacteriophage composition effectively controls pathogenesis animal intestinal diseases; provides safe, non-toxic, side effect-free phage bacteriostat source controlling animal intestinal diseases.',\n",
              " 'bacteriophage, bacterial wilt disease control agent, bacterial wilt disease control methoda bacteriophage effective wider variety bacterial wilt diseases, bacterial wilt disease control method uses provided. bacteriophage characterized infecting bacterial wilt diseases, gene encodes lysozyme fused-type darb, gene encodes three lytic enzymes, namely endolysin, aforementioned darb, rz/rz1, gene encodes csra, gene encodes two different tail fiber proteins; bacterial wilt disease control agent characterized said bacteriophage active component; bacterial wilt disease control method plants, characterized administering said bacterial wilt disease control agent plant plant growth medium.',\n",
              " 'novel bacteriophage killing activity specific salmonella selected infectious bacteriophages salmonella enteritidisa bacteriophage selectively annihilating salmonella selected infectious bacteriophages salmonella enteritidis provided prevent cure diseases caused salmonella. bacteriophage(kctc 11173bp) killing activity specific salmonella selected infectious bacteriophages salmonella enteritidis. bacteriophage genome represented part gene sequence seq id no:1 seq id no:25. pharmaceutical composition preventing disease caused salmonella genus bacteria comprises bacteriophage killing activity specific salmonella. disease caused salmonella genus bacteria sitotoxism, lymphocytic enteritis, salmonellosis, fowl typhoid bacteremia.',\n",
              " \"bacteriophage, bacterial wilt disease control agent, method controlling bacterial wilt diseasea bacteriophage genome size 200,000 bp longer, wherein protein constituting phage particles bacteriophage contains β-subunit virion-associated rna polymerase β'-subunit virion-associated rna polymerase. bacteriophage transmitted ralstonia solanacearum.\",\n",
              " 'novel bacteriophage killing activity specific salmonella selected infectious bacteriophages salmonella gallinaruma bacteriophage killing activity specific salmonella main cause bacillus infectious disease, specifically, salmonella gallinarum provided effectively prevent cure disease caused salmonella. bacteriophage(kctc 11174bp) killing activity specific salmonella selected bacteriophage infected salmonella gallinarum. salmonella genus bacteria salmonella enteritidis, salmonella pullorum salmonella typhimuriun. bacteriophage represented part gene sequence seq id no:1 seq id no:21.',\n",
              " 'bacteriophage killing activity specific staphylococcus aureusa bacteriophage provided kill pathogenic bacteria staphylococcus aureus specifically, thereby widely used agent preventing treating infectious diseases caused staphylococcus aureus, antibiotics, antibacterial agent cosmetics preservative derived nature, various disinfectants. myoviridae family t4-like phage genus bacteriophage killing activity specific staphylococcus aureus, comprises genetic body including nucleic acid molecule described sequences consisting seq id : nos. 1 26 deposited deposition no. kacc 97001p. pharmaceutical composition preventing treating diseases induced staphylococcus aureus comprises bacteriophage effective ingredient. antibiotic disinfectant comprises bacteriophage effective ingredient.',\n",
              " 'method detecting pathogen using virusa bacteriophage linked enzyme replace antibody system detecting presence bacteria sample. specifically brucella abortus (a pathogen causes brucellosis cattle) detected using brucella bacteriophage virus, urease enzyme linked bacteriophage, m-maleimidobenzoyl-n-hydrosysuccimide ester coupling reagent, sera mice immunized brucella bacteriophage detector antibody, urease conjugated anti-mouse sheep antibody indicator, urea bromcresol purple substrate. materials used indirect (sandwich) direct enzyme-linked viral assays (elvira).',\n",
              " 'bacteriophage preparations methods usea bacteriophage preparation generally includes preparation heterogeneous bacteriophages obtained fermentative process. bacteriophage preparation may formulated pharmaceutic composition. bacteriophage preparation may used treat dysbiosis administering bacteriophage preparation subject having, risk having, dysbiosis. bacteriophage preparation may used prepare prime gut environment healthy subject prior administering source bacteria subject.',\n",
              " 'bacteriophage preparation form gel prevent treat bacterial infections dairy cattle, manufacturing method bacteriophage strainsa bacteriophage preparation form gel prevent treat bacterial infections dairy cattle, including limited infections caused e.coli and/or s. aureus, intended intramammary administration lactation dry period, particular, treat prevent mastitis dairy cattle, manufacturing method bacteriophage strains especially useful preparation manufacturing, characterised detail enclosed patent claims, revealed.',\n",
              " 'bacteriophage preparation treatment intracellular bacterial infectiona bacteriophage preparation provided comprising bacteriophage adapted enter eukaryotic cell and/or eukaryotic cellular compartment, bacteriophage lytic towards least one strain pathogenic bacteria may infect said cell compartment, bacteriophage fused to, linked to, adapted express annihilation moiety, annihilation moiety adapted presence least one specific pathogen cause stimulate death inactivation said cell; said bacteriophage preparation capable causing stimulating death inactivation cells infected said pathogen. invention comprehends pharmaceutical composition comprising bacteriophage preparation, formulated administration patient need thereof; method producing death inactivation cell infected pathogen administration bacteriophage preparation thereto; use bacteriophage preparation manufacture pharmaceutical composition, optionally use treatment and/or prophylaxis disease mediated characterised intracellular infection pathogen, including particular tuberculosis, aids, hiv infection, malaria.',\n",
              " 'thermostable variants t7 rna polymerasea bacteriophage rna polymerase variant provided. embodiments, variant may increased thermostability relative corresponding wild type bacteriophage rna polymerase and/or wildtype t7 rna polymerase. compositions, kits methods employ variant provided.',\n",
              " 'highly ordered phage structures uses thereof stem cell differentiationa bacteriophage structure, method making structure, uses structure described. structure substrate surface ordered arrangement parallel microridges thereon. microridge composed plurality nanoridges longitudinal axis. nanoridge contains bundle phage nano fibers longitudinal axes. phage nanofibers nanoridge bundle arranged substantially smectic alignment. longitudinal axis microridge perpendicular longitudinal axes phage nanofibers make nanoridges microridge. structure may used growth surface inducing differentiation stem cells neural progenitor cells.',\n",
              " 't7 phage peptide display system uses thereofa bacteriophage t7 display vector expressing displaying exogenous peptide, wherein display vector comprises polynucleotide encoding bacteriophage t7 tail fiber protein p17 hepatocyte-targeting determinant sequence inactivated, wherein cloning site contained coding sequence tail fiber protein p17 coding sequence capsid protein p10b. provided host cell containing display vector described above, bacteriophage t7 particle comprising least one copy p17 protein comprises exogenous peptide displayed thereon, least one copy p10 protein exogenous peptide displayed thereon, wherein hepatocyte-targeting determinant sequence bacteriophage t7 tail fiber protein p17 inactivated. present invention provides viral lysate containing assembled bacteriophage t7 particle described above, method determining candidate peptide liver-targeting peptide, screening liver targeting peptides.',\n",
              " 'bacteriophage methods making usinga bacteriophage defined endolysin gene provided, inhibit growth bacteria tobacco. addition, isolation bacteriophage tobacco shown. methods making using bacteriophages provided.',\n",
              " 'bacteriophage, agent preventing xanthomonas campestris disease, method preventing xanthomonas campestris diseasea bacteriophage, phage particles linear structure, infects xanthomonas campestris pv. citri. bacteriophage may genome size 7,000-8,000 b. bacteriophage may genome configuration including dna replication module, structural protein module, assembly secretion module, regulatory region.',\n",
              " 'bacteria reduced genomea bacterium genome genetically engineered least 5% smaller genome native parent strain. bacterium preferably escherichia coli strain. described methods deleting genes dna sequences bacterial genome preferably introduce scars. genes dna sequences selected group consisting flagella gene, restriction modification system gene, lipopolysaccharide surface gene, insertion sequence, rhs element, toxin gene, pathogenicity gene, fimbrae gene, invasin gene, periplasmic protein gene, membrane protein gene, prophage, pseudogene, island, bacteriophage receptor, non-transcribed region genome native parent strain gene dna sequence present two bacteria strains related species native parent strain.',\n",
              " 'antibody specificity colon cancera binding structure binds in, and/or surface of, tumour cells; target structure displayed and/or expressed in, surface of, tumour cells; binding structure recognises blocks said target structure; substance binds blocks expression said target structure; pharmaceutical compositions comprising said binding structure, target structures substance active principles; vaccine compositions comprising said target structures active principles; method phage selection; methods vitro vivo diagnosis prognosis, treatment human malignant diseases comprising use subject matters, described.',\n",
              " 'biomaterial dyeing method utilizing pipa biomaterial dyeing method utilizing pip disclosed. method includes dyeing biomaterial utilizing pip pip-containing agent complete biomaterial dyeing. chemical structure pip shown formula i. biomaterial microbes bacteriophages, viruses bacteria, animal plant cells, tissues, organs sections thereof. experiments prove pip used dyeing plurality biomaterials, pip dangerous compound, physical chemical danger, harmless health environment, easily available water-soluble, replace uranyl acetate used biomaterial dyeing.',\n",
              " 'method apparatus target detection using electrode-bound virusesa biosensor capable detecting presence and/or concentration analyte biomarker includes least one electrically conductive electrode operatively coupled impedance analyzer measuring change resistive impedance electrode response applied alternating current plurality frequencies. one embodiment, least one electrode covered self-assembled monolayer chemically bonded surface. plurality virus particles phage viruses immobilized self-assembled monolayer may exposed test sample solution. virus particles may obtained phage-displayed libraries detect wide variety targets including, example, dna, rna, small molecules, proteins polypeptides. another embodiment, virus particles electrostatically bound substrate pair elongated electrodes disposed substrate.',\n",
              " 'bacteriophage-based biosensor microbial detectiona biosensor detecting microorganism sample includes polymer matrix immobilized layer bacteriophages surface polymer matrix, wherein interaction bacteriophage microorganism causes detectable physicochemical change polymer matrix. method detecting microorganism sample using biosensor includes steps contacting sample biosensor; allowing bacteriophage bind microorganism sample; detecting physicochemical change polymer matrix, change indicative presence microorganism.',\n",
              " 'bacteriophage-based electrochemical biosensora biosensor detecting bacteria may use bacteriophages sandwich-assay system. biosensor may include capture element detection element. capture element may include substrate bacteriophage. detection element may include bacteriophage signal amplification element. biosensor may utilized target bacterium sandwiched capture element detection element, quantifiable signal may generated measure amount bacteria sample. biosensor present invention utilizes direct sensing detect bacteria sample opposed indirect sensing methods.',\n",
              " 'canine parvovirus nanobody cpv-vhh-d4 application thereofa canine parvovirus (cpv) nanobody cpv-vhh-d4 includes heavy chain variable region amino acid sequence shown seq id no: 1, nucleotide sequence gene encoding nanobody cpv-vhh-d4 shown seq id no: 2. present application constructs nanobody immune library cpv phage-display technology, obtains specific anti-cpv nanobody cpv-vhh-d4 screening, verified specifically bind cpv experiments, applicable develop nanobody preparation clinical diagnosis treatment cpv, providing certain theoretical support application nanobodies field veterinary biological products',\n",
              " 'therapeutic agent pruritusa clone bm095 potent proliferation-inhibiting activity obtained human antibody phage library il-31-dependent ba/fc cell proliferation assay system. anti-mouse nr10 neutralizing antibody administered pruritus model mouse, significant effect preventing conditions disease observed. revealed anti-nr10 neutralizing antibody useful therapeutic agent pruritus.',\n",
              " 'method generating high affinity, bivalent binding agentsa combined kunkel mutagenesis phage-display method producing bivalent binding agents provided.',\n",
              " 'method kit generating high affinity binding agentsa combined ribosome-display phage-display method kit carrying method provided. method includes screening ribosome-display library binding agents identify binding agents interact one target molecules interest, converting rna encoding binding agents phage-display format amplification primer extension, screening phage-display library enrich binding agents interact one target molecules interest.',\n",
              " 'complex bacteriophage liposomes inhibiting activity staphylococcal infectiona complex inhibiting activity staphylococcal infection contains bacteriophage base liposomes added 1:1-2:1 ratio.',\n",
              " 'composition method treating mastitisa composition method treating mastitis use effective amount least one lytic specific bacteria causing disease. lytic enzyme genetically coded bacteriophage may specific said bacteria. enzyme may least one lytic protein peptides natural modified form.',\n",
              " 'treatment bacterial infections aquaculturea composition comprises bacteriophage covalently attached edible particle use treating bacterial infection fish crustaceans. infections fish crustaceans caused vibrio, aeromonas, yersinia, moritella, rickettsia, piscirickettsia, lactococcus, pseudomonas, flavobacterium photobacterium bacteria species treated. bacteria infected lysogenic bacteriophage used treating disease fish crustaceans caused similar infections bacteria carrying lysogenic bacteriophage express toxin gene.',\n",
              " 'conjugate photosensitiser bacteriophage.a composition comprising conjugate photosensitiser bacteriophage provided. conjugate may used kill bacteria, particularly mrsa, emrsa, vrsa, hetero-vrsa ca-mrsa targeted method photodynamic therapy.',\n",
              " 'klebsiella bacteriophage uses thereofa composition comprising least two different strains isolated bacteriophages, capable infecting bacteria species klebsiella pneumoniae, wherein least one said least two different strains isolated bacteriophages genomic nucleic acid sequence least 90 % identical one nucleic acid sequence set forth seq id nos: 1-30. uses thereof disclosed.',\n",
              " 'pseudomonas bacteriophage uses thereofa composition comprising least two different strains isolated bacteriophages, capable infecting bacteria species pseudomonas aeruginosa, wherein least one said least two different strains isolated bacteriophages genomic nucleic acid sequence least 90% identical one nucleic acid sequence set forth seq id nos: 1-10. uses thereof disclosed.',\n",
              " 'staphylococcus bacteriophage uses thereofa composition comprising least two different strains isolated bacteriophages, capable infecting bacteria species staphylococcus aureus, wherein least one said least two different strains isolated bacteriophages genomic nucleic acid sequence least 90% identical one nucleic acid sequence set forth seq id nos: 1-7. uses thereof disclosed.',\n",
              " 'gastric inhibtory polypeptide (gip) antigen arrays vlps uses thereofa composition comprising: (a) virus-like particle (vlp) least one first attachment site; wherein said vlp vlp rna-phage; (b) least one antigen least one second attachment site, wherein said least one antigen gastric inhibitory peptide (glp) protein gip fragment, wherein said antigen selected ability induce immune response gip linked said vlp; wherein (a) (b) linked said least one first said least one second attachment site.',\n",
              " 'broad spectrum bacteriocin control unwanted bacteriaa composition containing newly identified bacteriocin produced lactobacillus plantarum strain, isolated natural corn mash used commercial fermentation process production ethanol. bacteriocin composition effective broad range killing vast majority lactic acid bacteria (lab) isolates ethanol fermentation mash, include multiple species lactobacillus, lactococcus, weissella, leuconostoc, pediococcus, enterococcus, streptococcus well killing activity non-lab isolates, strains staphylococcus, enterobacter, bacillus, clostridium. bacteriocin combined broad range bacteriophage provide synergistic effectiveness unwanted bacteria industrial biofuel fermentation process human animal bacterial infections.',\n",
              " 'broad spectrum bacteriocin control unwanted bacteriaa composition containing newly identified bacteriocin produced lactobacillus plantarum strain, isolated natural corn mash used commercial fermentation process production ethanol. bacteriocin composition effective broad range killing vast majority lactic acid bacteria (lab) isolates ethanol fermentation mash, include multiple species lactobacillus, lactococcus, weissella, leuconostoc, pediococcus, enterococcus, streptococcus well killing activity non-lab isolates, strains staphylococcus, enterobacter, bacillus, clostridium. bacteriocin combined broad range bacteriophage provide synergistic effectiveness unwanted bacteria industrial biofuel fermentation process human animal bacterial infections.',\n",
              " 'bacteriophage particle agglutinationa composition detecting one species, classes, and/or types bacteriophage present sample. embodiments, disclosed composition includes plurality detection particles, wherein plurality detection particles includes one binding molecules complexed therewith, specifically binds one species bacteriophage. provided methods employing disclosed compositions testing and/or direct indirect identification indicators presence bacteria, viruses, microbes sample testing and/or identification desired.',\n",
              " 'agent use bacteriophagea composition lysing least one type staphylococcus bacteria selected group consisting staphylococcus hyicus, staphylococcus chromogenes, staphylococcus simulans, staphylococcus schleiferi, staphylococcus felis, prevention treatment diseases caused said bacteria, said composition containing, active ingredients: least one bacteriophage selected group consisting bacteriophages identified accession number nite bp-693 bacteriophages identified accession number nite bp-694; endolysin, protein specified amino acid sequence seq id no: 1.',\n",
              " 'bacteriophage compositiona composition lysing staphylococcus aureus composition preventing treating disease caused staphylococcus aureus, said composition comprising, active ingredients, least one bacteriophage selected group consisting bacteriophage identified accession number nite bp-693 bacteriophage identified accession number nite bp-694, endolysin least one protein selected group consisting (a) protein amino acid sequence represented seq id no: 1, (b) protein amino acid sequence least 80% identity amino acid sequence represented seq id no: 1, (c) protein amino acid sequence substitution, deletion, addition and/or insertion one amino acids amino acid sequence represented seq id no: 1.',\n",
              " 'composition making milk products prophylactic propertiesa composition making milk products prophylactic properties comprises milk base biologically active additive. comprises intesti-bacteriophage inducing virulence lytic activity 10by apelman biologically active additive.',\n",
              " 'compositions methods inhibiting proliferation pathogenic escherichia colia composition preventing treating infection disease caused pathogenic escherichia coli includes myoviridae bacteriophage (esc-cop-23) ability lyse pathogenic escherichia coli pharmaceutically acceptable carrier. method preventing treating infection disease caused pathogenic escherichia coli includes administering subject myoviridae bacteriophage lysing pathogenic escherichia coli myoviridae bacteriophage.',\n",
              " 'compositions methods inhibiting proliferation pathogenic escherichia colia composition preventing treating infection disease caused pathogenic escherichia coli includes myoviridae bacteriophage esc-cop-18 ability lyse pathogenic escherichia coli pharmaceutically acceptable carrier. method preventing treating infection disease caused pathogenic escherichia coli includes administering subject myoviridae bacteriophage lysing pathogenic escherichia coli myoviridae bacteriophage.',\n",
              " 'compositions methods inhibiting proliferation pathogenic escherichia colia composition preventing treating infection disease caused pathogenic escherichia coli includes podoviridae bacteriophage (esc-cop-30) ability lyse pathogenic escherichia coli pharmaceutically acceptable carrier. method preventing treating infection disease caused pathogenic escherichia coli includes administering subject podoviridae bacteriophage lysing pathogenic escherichia coli podoviridae bacteriophage.',\n",
              " 'compositions methods inhibiting proliferation enterotoxigenic bacteroides fragilisa composition preventing treating infection disease caused enterotoxigenic bacteroides fragilis includes siphoviridae bacteriophage (bac-frp-3) ability lyse enterotoxigenic bacteroides fragilis cells pharmaceutically acceptable carrier. method preventing treating infection disease caused enterotoxigenic bacteroides fragilis includes administering subject siphoviridae bacteriophage lysing enterotoxigenic bacteroides fragilis cells siphoviridae bacteriophage.',\n",
              " 'compositions methods inhibiting proliferation enterotoxigenic bacteroides fragilisa composition preventing treating infection disease caused enterotoxigenic bacteroides fragilis includes siphoviridae bacteriophage (bac-frp-4) ability lyse enterotoxigenic bacteroides fragilis cells pharmaceutically acceptable carrier. method preventing treating infection disease caused enterotoxigenic bacteroides fragilis includes administering subject siphoviridae bacteriophage lysing enterotoxigenic bacteroides fragilis cells siphoviridae bacteriophage.',\n",
              " 'compositions methods inhibiting proliferation enterotoxigenic bacteroides fragilisa composition preventing treating infection disease caused enterotoxigenic bacteroides fragilis includes siphoviridae bacteriophage (bac-frp-5) ability lyse enterotoxigenic bacteroides fragilis cells pharmaceutically acceptable carrier. method preventing treating infection disease caused enterotoxigenic bacteroides fragilis includes administering subject siphoviridae bacteriophage lysing enterotoxigenic bacteroides fragilis cells siphoviridae bacteriophage.',\n",
              " 'compositions methods inhibiting proliferation pathogenic escherichia colia composition preventing treating infections diseases caused pathogenic escherichia coli, comprising bacteriophage muscular tail bacteriophage family ability lyse pathogenic escherichia coli pharmaceutically acceptable carrier. method preventing treating infection disease caused pathogenic escherichia coli comprises administering subject bacteriophage family muscapulobacteriophage family lysing pathogenic escherichia coli bacteriophage family muscapulobacteriophage family.',\n",
              " 'bacteriophage lytic protein derived bacteriophage effective treatment staphylococcus aureus biofilma composition removing pellicle formed owing staphylococcus aureus provided improve antibiotic treatment effect disease caused staphylococcus aureus forming pellicle. composition removing pellicle formed owing staphylococcus aureus staphylococcus aureus extinction ability includes bacteriophage ability removing pellicle formed staphylococcus aureus active ingredient. bacteriophage myoviridae sp. t4-similarity phage sp. bacteriophage( accession number kctc 11153bp, sap-1) podoviridae sp. phi29-similarity phage sp. bacteriophage( accession number kctc11154bp, sap-2).',\n",
              " 'composition method preventing infections vegetable tissues caused erwinia amylovoraa composition treating preventing infections vegetable tissues caused erwinia amylovora comprises phage m9, deposited number dsm 27111; method treating preventing infections vegetable tissues caused erwinia amylovora comprises administering said phage m9 said vegetable tissues.',\n",
              " 'topical treatment streptococcal infections using lysin enzyme coded c1 bacteriophagea composition treating dermatological streptococcal infections comprises effective amount therapeutic agent. therapeutic agent produced obtaining lysin enzyme genetically coded fro c1 bacteriophage mixing lysin enzyme pharmaceutically acceptable carrier topical application lysin enzyme. described time-release patch liquid absorbed wipe comprising therapeutic agent.',\n",
              " 'composition comprising group c streptococcal phage associated lysin enzyme, use composition preventing treating streptoccocal infectionsa composition use therapeutic prophylactic treatment streptococcal infection, comprising effective amount group c streptococcal phage associated lysine enzyme carrier delivering enzyme mouth, throat, nasal passage, wherein lysine enzyme kills bacteria responsible infection. above-described composition useful therapeutic prophylactic treatment streptococcal infections alleviation symptoms thereof.',\n",
              " 'method prevention treatment streptococcus parauberis infectionsa composition includes isolated bacteriophage str-pap-1 ability kill streptococcus parauberis cells specifically infecting same, may used prevent treat streptococcus parauberis infections. bacteriophage str-pap-1 active ingredient composition ability kill streptococcus parauberis cells characteristically genome represented nucleotide sequence seq. id. no: 1.',\n",
              " 'plant vascular disease treatment compositiona composition including lyophilized bacteriophage expression thereof present amount effective elimination xylella fastiodisa xanthomonas plant. lyophilized bacteriophage expression thereof combined bacteriophage nutrient water soluble polymer.',\n",
              " 'compositions comprising rankl peptide attached core virus-like particle treatment bone disease immunizationa composition described comprises virus-like particle (vlp) least one antigen antigenic determinant wherein antigen antigenic determinant rankl protein, rankl fragment rankl peptide, antigen bound vlp. preferably vlp selected recombinant proteins of: hepatitis b virus, measles virus, sindbis virus, rotavirus, foot-and-mouth-disease virus, retrovirus, norwalk virus, alphavirus, human papilloma virus, polyoma virus, bacteriophages, rna-phages ty. composition useful treating preventing bone diseases. described method immunizing non-human animals using composition.',\n",
              " 'computer implemented method analysing host phage response dataa computer implemented method analyzing host phage response data comprises fitting sequence sigmoidal functions time point start time end time selecting best fit point. best fit time points selected, search performed time point similar coefficient determination, closer time minimum time point indicative end lag phase. lag time best fit time point obtained fitted model. best fit fails threshold test dataset considered flat lag time set end time.',\n",
              " 'computer implemented method system optimizing phage selectiona computer implemented method optimizing selection bacteriophage (phage) grow advance order target large range bacteria comprising performing multiple phage susceptibility assays susceptibility n bacteria assessed phage. efficacy measures obtained assay efficacy summary measure obtained phage assessed n bacteria. possible phage combination, coverage value overall efficacy value determined coverage percent n bacterial combination phage efficacious. filtered ranked enable selection best phage combinations manufacture use treating patient.',\n",
              " 'machine learning system interpreting host phage responsea computer implemented method generating machine learning model interpreting host phage response data comprising receiving datasets labels host phage response, training machine learning model using model estimate efficacy test phage inhibiting growth test bacteria.',\n",
              " 'methods compositions controlled release bioactive compoundsa controlled release pharmaceutical dosage form bacteriophage presented. dosage form prepared drying active ingredient together dispersion solution polymethacrylate copolymer lyprotectant using mild, entirely aqueous conditions.',\n",
              " 'cross-species cleavable xanthomonas phage composition, kit use thereofa cross-species cleavable xanthomonas phage composition, kit use thereof. xanthomonas axonopodis phage xanthomonas phage gj19p1 accession number cctcc no: 2020805; composition least contains one strain xanthomonas phage gj19p1; kit contains xanthomonas phage gj19p1 composition containing xanthomonas phage gj19p1; composition containing xanthomonas phage gj19p1 used for, limited to, killing xanthomonas.',\n",
              " 'phage culturing device, method preparing phages, filtration device samea device method clinically providing preparation autologous phages, namely, verifiably traced back originating specific person preferably intended use one specific person includes phage culturing device fluid line system sealed respect outside environment phages fluid line system obtained least one-time culturing separated bacteria way filtration, preferably way tangential flow filtration. phages separated way filtration transferred collection vessel connected fluid line system preferably removed fluid line system, using collection vessel, usable, preferably autologous preparation.',\n",
              " 'detecting bacteria using fluorescently-labeled phage immobilized optically transparent surfacea device method detecting bacteria sample include optically transparent substrate phage known react bacteria detected. phage tagged fluorescent tag dapi sbyr® gold cyanine dye. fluorescently tagged, phage-substrate combination illuminated light source, wavelength corresponds excitation wavelength fluorescent tag establish baseline intensity device. device exposed sample illuminated establish test intensity. bacteria detected deemed present test intensity less baseline intensity.',\n",
              " 'optical method detecting bacteriaa device method determining total bacteria count sample include step removing eukaryotes sample filtering sample 0.45 μm pore size syringe filter made low protein binding material. next, sample tagged fluorescent tag illuminated light source excitation wavelength fluorescent tag. resulting fluorescent intensity compared calibration curve determine total bacteria count. cases total bacteria count specific bacteria desired, phage known react bacteria interest fluorescently tagged mixed sample, combination illuminated establish test intensity said sample, used obtain total bacteria count bacteria species interest.',\n",
              " 'diagnostic reagent, containing bioparticles, method production thereof use thereof internal standard nucleic acid preparation nucleic acid detection methodsa diagnostic reagent form composition dimensionally stable standard conditions, comprising bioparticles customary pharmaceutical excipients, wherein bioparticles selected group consisting bacteria, viruses, fungi, protozoa, bacteriophages, yeasts, spores, parasites, plant cells, animal human cells, gametes, plasmids, viroids.',\n",
              " 'method preparing immunobiological composition form foam aerosol treating dermatological diseases infectious etiologya diseases infectious etiology comprises mixing basic components preserving agent aqueous solution bacteriophages. mixtures emulsifier first class preserving agent emulsifier second class vegetable oil produced followed mixing together adding aqueous solution bacteriophages. composition obtained packed aerosol balloons propellant added.',\n",
              " 'dna polymerase possessing continuous catalytic capacity salt tolerancea dna polymerase, amino acid sequence represented seq id no. 2, derivative amino acid sequence substitution, deletion, addition least one amino acid residue. dna polymerase hybrid dna polymerase prepared inserting thioredoxin binding domain (tbd) bacteriophage t7 dna polymerase dna polymerase (sau) staphylococcus aureus. method preparing dna polymerase includes: 1) determining corresponding position target substitution sequence sau protein tbd bacteriophage t7 dna polymerase; 2) devising synthesizing primer according gene sequence sau sequence tbd published genbank; 3) cloning sau-tbd segment acquired (2) expression vector ptrc99a construct recombinant vector ptrc99a-sau-tbd; 4) transforming escherichia coli recombinant vector ptrc99a-sau-tbd inducing protein expression.',\n",
              " \"vaccine diabetes type i, constructing methoda dna vaccine able express antisense peptide diabetes preventing diabetes disclosed prepared. configuration method features coding genes diabetes a's early-phase antigen (insulin, preinsulin, ia-2 beta, igrg gad 65) specific epitopes t, b ctl inserted eukaryon expression plasmid terminal 3' t7 phage dna capsid protein b10 coding gene.\",\n",
              " 'open-reading-frame (orf) phage displaya dual display phage system identification protein interaction networks therapeutic targets.',\n",
              " 'fimh vaccine urinary tract infections (uti)a engineered bacteriophage herein described, displaying surface multiple copies polypeptide, comprises domain bacterial adhesion protein fimh fused coat protein pviii. domain preferably region 45-159aa mature protein fimh. polypeptide beingantigenic, raises desired immunological response, particular urinary tract infections (uti) human animal. engineered bacteriophage suitable preparation vaccinesfor therapy, diagnosis and/or prevention urinary tract infections (uti) human animal.',\n",
              " 'combinatorial libraries proteins scaffold structure c-type lectin-like domainsa family protein libraries comprising ctlds (c-type lectin-like domains) internal polypeptide loop-regions lining ligand binding sites ctlds replaced ensembles completely partially randomised polypeptide segments. tetranectin ctlds chosen framework preferred embodiment; versatile phagemid vectors useful generation manipulation human murine tetranectin ctld libraries disclosed. tetranectin ctlds monomeric well trimeric form efficiently displayed gene iii fusions fully functional form recombinant fd phage display vector. ctld derivatives affinity new ligands may readily isolated libraries vectors displaying ctlds, loop-regions randomised, using one rounds enrichment screening selection followed amplification enriched subpopulation round. efficiency protein products containing ctlds new binding properties produced, e.g. bacterial expression vitro refolding, mono-, tri-, multimeric formats provides important advantages terms simplicity, cost efficiency generation, production diagnostic therapeutic applications comparison recombinant antibody derivatives.',\n",
              " 'utilization bacteriophage control bacterial contamination fermentation processesa fermentation process production ethanol natural sources, corn, comprising introducing fermentable sugar inoculant, bacteriophage cocktail fermentation system introducing cocktail comprising one lytic bacteriophage added one fermentable sugar, inoculant, fermentation system. bacteriophages infect lyse bacteria contaminate fermentable sugars selected. bacteriophage cocktail added amount effective substantially prevent growth bacteria.',\n",
              " 'abiz phage resistance genea first aspect present invention isolated nucleic acid encoding phage abortive defense protein, isolated nucleic acid selected group consisting of: (a) isolated nucleic acid sequence coding sequence given seq id no: 1 (by \"coding sequence\" meant nucleotides 373 1668 therein); (b) isolated nucleic acid encoding phage abortive defense protein hybridizes nucleic acid sequence coding sequence given seq id no: 1, and/or sequence least 60, 70, 80, 90, 92 95 percent identical sequence coding sequence given seq id no: 1; (c) isolated nucleic acid encoding phage abortive defense protein encoded isolated nucleic acid (a) (b) above, differing sequence therefrom due degeneracy genetic code (e.g., nucleic acid encoding protein given seq id no: 2).',\n",
              " 'food save couragea food storage container provided prevent foods going bad allow maintaining freshness foods good long time inhaling purifying gases surrounding environment. food storage container comprises: storage container(100); sealing cover(200) close upper part storage container, includes assembly groove part(20) leaning phage grooves(21) established sides top part cover; medium pack(30) containing medium inhaling purifying gases, received combined assembly groove part removably. medium contained medium pack comprises one activated charcoal, activated charcoal mixture, zeolite, porous ceramic material.',\n",
              " 'preparation containing bacteriophage kctc 11120bp inhibit kill bacteriaa formulation provided inhibit bacteria genesistasis induce apoptosis due bacteriophage kctc 11120bp effects reducing pathogenicity host inhibiting growth host. formulation comprises bacteriophage kctc 11120bp separated cheonggyecheon(one korean streams) active ingredient. bacteriophage kctc 11120bp dissolve salmonella escherichia coli. bacteriophage kctc 11120bp susceptibility salmonella enteritidis separated human organs salmonella typhimurium separated animals. formulation containing bacteriophage kctc 11120bp inhibits bacteria genesistasis induce apoptosis. bacteria represent salmonella escherichia coli.',\n",
              " 'fusion protein method detecting bacteria pseudaminic acida fusion protein including phage tail-spike protein φab6tsp signal indicator provided. also, method detecting bacteria pseudaminic acid (pse) provided, including steps contacting sample phage tail-spike protein φdab6tsp; detecting signal sample. fusion protein method detecting bacteria applied set practical diagnosis therapeutic alternative pse-coated antibiotic resistant pathogenic bacteria.',\n",
              " 'antibody proteina genera! method recombinant nucleic acid sequences, means method selects recombinant protein containing fha domain binding target molecule library proteins high-throughput method creating protein variations within fha domain non-conserved non-structural sequences fha scaffold, library may form phagemid phage library wherein alp nucleic acid sequence inserted vector capable allowing vector expressed alp protein virally packaged, recombinant nucleic acid sequences randomly mutated varying non-conserved non- structural fha domain sequences.',\n",
              " 'general strategy antibody library screening.a generally applicable method selective covalent attachment reporter molecule replicating entity allows one obtain specific binders single round library screening disclosed. example, selective biotinylation phage particles yeast cells displaying binder given target achieved via application coupled enzyme reaction includes peroxidase, oxidase catalase.',\n",
              " 'm13 bacteriophage high cysteine content genetically engineerable hydrogelsa genetically engineered bacteriophage crosslinked form solid material, example, hydrogel.',\n",
              " 'genetically engineered bacterium producing tetrahydropyrimidine induction using xylosea genetically engineered bacterium producing tetrahydropyrimidine induction using xylose, construction method therefor, application thereof. strain obtained heterologously expressing ectabc gene cluster halomonas elongatus chromosome e. coli, reconstructing tetrahydropyrimidine synthesis pathway, constructing plasmid-free system, using promoter xylose transporter encoding gene control rna polymerase t7 phage, utilizing t7 strong promoter system initiate efficient expression target gene, yield tetrahydropyrimidine reaches 12-16 g/l shake-flask fermentation 20-28 h, yield tetrahydropyrimidine reaches 35-50 g/l fermentation 5 l fermentation tank 24-40 h.',\n",
              " 'bacteriophages reducing toxicity bacteriaa genetically modified bacteriophage disclosed comprises: (i) exogenous polynucleotide encodes agent reduces toxicity bacterium; (ii) exogenous polynucleotide encodes selectable marker. uses thereof kits comprising disclosed.',\n",
              " \"genotoxic substance detection vector detection method thereofa genotoxic substance detection vector detection method thereof provided. vector escherichia coli expression vector sequentially having, 5' end 3' end, genotoxic response promoter, bacteriophage lysis gene, escherichia coli terminator. detection method includes introducing genotoxic substance response vector escherichia coli obtain recombinant bacteria, incubating recombinant bacteria genotoxic substances, lysing escherichia coli. recombinant escherichia coli genotoxic response vector, self-cell lysis initiated recombinant bacteria contacts genotoxic substances. detection method quantitates genotoxic substances means lysis efficiency. method consumes little time, high detection sensitivity, easy implement, low cost, easy promote.\",\n",
              " 'method screen selecting polypeptides excitomotor glucagon-like peptide-1 receptor vitroa glucagon peptide-1 receptor (glp-1 receptor) one nowadays recognized, important anti-diabetic drug targets. invention relates multi- peptide agonist vitro screening method glucagon peptide-1 receptor screened multi- peptide. invention discloses multi-peptide agonist method vitro screening glucagon peptide-1 receptor, screening method regards restructure glp-1 receptor membrane protein n-terminal fragment (n-glp-1r) target, method established utilizing vitro combining capacity combining phage display technology phage-elisa technology. invention discloses multi- peptide sequences acquired screening method. screening method disclosed invention simple convenient, appropriate vitro high flux screening glp-1 receptor multi-peptide agonist, invention provides novel method idea development treatment diabetes multi- peptide drugs, saves screening time reduces development cost.',\n",
              " 'healing promotion coated bandagea healing promotion coated bandage belongs medical appliance, comprises surface layer, medical adhesive, wound protecting layer piece adhesion-proof isolation paper, wherein, wound protecting layer contains enough sugar. ideal compatibility sugar solution osmotic pressure human tissue important biochemical action grapesugar wound tissue, utility model outstanding effect wound hemostasia, acesodyne, inflammation diminish healing promotion. utility model advantages anaphylaxis drug-resistance, low cost less use bacteriophage wound, thereby important product trauma care.',\n",
              " 'helical antennaa helical antenna comprises dielectric frame, matching board, quadri-filar radiating element assembly excite coaxial cables balancing loops, phasing bridge strong rings provided high-frequency connectors. phase bridge performed one high-frequency connector. strong rings made metal discs holes fixing protection cylindrical antenna body, inside diameter less than, made internal ring flange upper external flange. internal flange fixed strong rings phage bridge. external upper flange protection body protective dielectric cover fixed through-holes antenna fixing made.',\n",
              " 'human bladder cancer specific antigen binding peptidea human bladder cancer specific antigen binding peptide belongs field bio-medicines, characterized human bladder cancer specific antigen binding peptide composed 12 amino acids sequence mpmfkhrmfhth, wherein methionine residue, p proline residue, f phenylalanine residue, lysine residue, h histidine residue, arginine residue, threonine residue. human bladder cancer specific antigen binding peptide molecular weight 2024.0, specifically bound bladder cancer antigen human urine. human bladder cancer specific antigen binding peptide beneficial effects follows: polypeptide fragment derivatives thereof important application value early diagnosis, screening targeted therapy bladder cancer tumors. compared traditional screening method, phage display technology simple application, convenient operation easy large-scale production. human bladder cancer specific antigen binding peptide lays foundation targeted development targeted drug selection due advantages small relative molecular weight, weak immunogenicity, high activity, etc.',\n",
              " 'human monoclonal antibody targeting tnfer2 cancer immunotherapya human monoclonal antibody specifically binds tumor necrosis factor receptor 2 (tnfr2), defucosylated form antibody, described. tnfr2-specific antibody isolated human scfv phage display antibody library. disclosed antibodies promote antibody-dependent cell-mediated cytotoxicity (adcc) human tnfr2',\n",
              " \"heteroprotein melanoma epi (mage-1, hla-al) bacteriophage coat protein applicationa hybrid protein melanoma epitope (mage-1, hla-al) bacteriophage's coat protein application disclosed. melanoma epitope (mage-1, hla-al) gene fragment inserted carrier integrated main coat protein gene filamentous bacteriophage dna recombination technique configure new recombinant carrier. host, epitope gene product secreted outside cell assembled coat protein bacteriophage form said hybrid protein. used antigen generate immunore sponse antibody serum tumor patient, used prepare medicines diagnosing, preventing treating tumor.\",\n",
              " 'tumour vascular-targeting novel recombinant human tumour necrosis factor fusion protein preparationa kind amalgamation albumen combined peptide hrn tnf specificity knub neconatal vein preparation method disclosed invention. knub necro-gene kind multi-functional cell gene, participates immunity metabolizating modulation economy, restriant cell poison action growth cancer cells. invention wipes 1-7 bit amino acid amido end knub necro-gene, changes 8-10 bit amino acid arg-lys-arg 157 bit amino acid carboxyl end phe, composes new type high effect low poison knub necro-gene nrhtnf. basis, prepared amalgamation albumen combined peptide nrhtnf specificity ofthe knub neonatal vein enrich place knub neonated vein use cyclopeptide crgdc containing five amino acids elected phage revelation library.',\n",
              " 'method rapid detection enumeration viruses, bacteriophage and/or bacteriaa kit method rapid cost-effective culturing and/or detecting viruses, bacteriophage and/or bacteria provided. viruses, bacteriophage and/or bacteria cultured and/or detected within, on, absorptive fibrous matrix, cellulose fibre absorbent pad, allows growth detection viruses, bacteriophage and/or bacteria. detection may qualitative, semi-quantitative quantitative.',\n",
              " 'methods kits determine sensitivity strains lactococcus lactis bacteria phage infectiona kit useful determining phage susceptibility one strains lactococcus lactis means multiplex polymerase chain reaction (pcr) described. kit comprises: (a) first primer pair adapted generate first amplicon correlating region cwps operon unique l. lactis strains mg1363 sk11; (b) second primer pair adapted generate second amplicon correlating region cwps operon unique l. lactis strains il1403 kf147; (c) third primer pair adapted generate third amplicon correlating region cwps operon uniqueto l. lactis strains uc509.9 cv56; (d) optionally, control primer pair adapted amplify sequence conserved l.lactis. methods kits invention may employed type strains l. lactis phage-sensitivity groups, sub-type phage-sensitivity groups according phage sensitivity. invention described methods formulation mixed defined starter cultures using strains different phage sensitivity groups.',\n",
              " 'method apparatus enhanced bacteriophage-based diagnostic assaya labeled first bacteriophage (112) capable selectively attaching target microorganism (110) combined sample sample incubated sufficiently allow bacteriophage attach target microorganism. labeled first bacteriophage/target microorganism complex (136, 436) bound substrate (125) using second bacteriophage (104) selective target microorganism, substrate assayed detect presence absence label determine presence absence target microorganism. antibiotic may added least portion sample determine antibiotic susceptibility target microorganism.',\n",
              " 'bacteriophage resistant lactic acid bacteriaa lactic acid bacterium (lab) wherein yjae protein essentially inactive lab thereby improved resistance bacteriophages, starter culture composition comprising lactic acid bacterium use starter culture manufacturing food feed product.',\n",
              " 'phage display librarya library replicating entities, entity comprises recombinant vector comprising randomized nucleic acid sequence, reading frame structure [nxx]n [coraa] [nxx]m [nzz]o, [nzz]o [nxx]m [coraa] [nxx]n. nxx independently codon encoding amino acid except cysteine, coraa codon encoding cysteine least one amino acid, nzz independently codon encoding amino acid, n integer 0 40, integer 1 20, integer 1 40, least 20 percent coraa encode cysteine. invention relates set recombinant vectors set randomized oligonucleotides, oligonucleotide said structure, well method generating library replicating entities method identifying amino acid polymer.',\n",
              " 'light green balloon bacteriophage avp use thereofa light green balloon bacteriophage avp brought forward, deposited china typical culture preservation center deposit number cctcc no:m 2018155, deposited 25 march 2018. new light green balloon bacteriophage avp lyse bacteriophage avp lysate aeromonas aeruginosa, bacteriophage wide lysis spectrum, lyse pale green balloon bacteria, lyse staphylococcus aureus staphylococcus epidermidis. lyse standard strains clinical strains isolated environment diseased animal feces. used alone combination substances provide safe non-toxic bacteriophage sterilization product disinfection purification environment.',\n",
              " 'targetted polypeptide specificity liver cancer blood vessela liver cancer blood vessel specific target polypeptide lci-x7 able specific binding liver cancer blood vessel extracted naked mouse model human liver cancer showing technique phage random peptide library body microscopic laser cutting technique. provides important theory practical basis diagnosis liver cancer transfer recurrence target therapy.',\n",
              " 'methods isolating phage controlling microorganism populations phagea lytic virus specific target strain microorganism substantially free undesirable genes may utilized processes including control populations microorganisms. virus may include host-range mutant, \"h-mutant.\" method generating virus includes growing virus-resistant variants target strain microorganism presence viruses specific target strain. h-mutant viruses proliferate. wild-type virus-resistant virus-resistant variants microorganism disclosed, methods generating variants. methods controlling target strain microorganisms include introducing virus treatment site control population target strain microorganism desired introducing virus-resistant variants microorganism treatment sites presence microorganism desired.',\n",
              " 'medical devices coating promoting endothelial cell adhesiona medical device coating cell adhesion polypeptides enhance endothelial cell adhesion onto medical device. cell adhesion polypeptides may proteins extracellular matrix known play role cell adhesion derivative peptides rgd yigsr. polypeptides may incorporated backbone polymer polyurethane, grafted onto polymer polybisphosphonate. polypeptides may carried antibodies displayed bacteriophages. polypeptides may modified adhesive amino acid sequences. certain embodiments, medical device comprises temporary barrier protects polypeptides biofouling. temporary barrier may formed biodegradable polymer constructed coating polypeptides plurality micelles encapsulating polypeptides. certain embodiments, polypeptides may coated onto medical device manner form monolayer polypeptides.',\n",
              " 'plasma immobilization bacteriophages applications thereofa medical device, medical device including substrate defining surface; plasma polymer layer bound coating surface; bactericide layer bound plasma polymer layer, plasma polymer layer substrate bactericide layer. also, method coating surface substrate medical device bactericide layer, method including: exposing surface plasma form plasma polymer layer bound surface; binding bactericide layer plasma polymer layer.',\n",
              " 'means treatment colibacillosis birdsa medical means contains phage lysate e.coli o111 e.coli o26 therapeutically effective amount. tables: 1',\n",
              " 'means treatment salmonellosis birdsa medical means contains phage lysate s. typhimurium, s. gallinarum s. enteritidis therapeutically effective amount. tables: 1',\n",
              " 'means treatment salmonellosis pigsa medical means contains phage lysate s. typhimurium, s.cholerae suis s. enteritidis therapeutically effective amount. tables: 1',\n",
              " 'bacteriophage medical meansa medical means contains therapeutically effective amount phage lysates salmonella enteritidus.',\n",
              " 'bacteriophage medical meansa medical means contains therapeutically effective amount phage lysates xanthomonas campestris pv. malvaceum strains.',\n",
              " 'bacteriophage medical meansa medical means contains therapeutically effective amount phage lysates xanthomonas campestris pv. orizae strains.',\n",
              " 'method site-directed immunisationa method phage used producing antibodies selective (specific) certain antigen. antigen expressed surface phage presented immune system produce antibodies said antigen, phage used screening specific antibodies sample form immunised individual. further, specific antibodies may isolated.',\n",
              " 'methods composition production sequence specific antimicrobialsa method composition production sequence specific antimicrobials capable overcoming inefficient delivery, narrow host range, potential transfer virulence genes generalized transduction phage-based delivery systems integrating crispr/cas9 system phage genome, removing major virulence genes host chromosome, expanding host specificity phage complementing tail fiber protein significantly improves efficacy safety crispr/cas9 antimicrobials alternative therapeutics. method composition provide efficacious safe crispr/cas9 antimicrobial, broadly applicable mrsa.',\n",
              " 'bacteriophage-encoded antibacterial enzyme treatment prevention gingivitis root surface cariesa method composition treatment prevention gingivitis root surface caries using actinomyces naeslundii bacteriophage av-1 encoded anti-bacterial enzyme (av-1 lysin) remove inhibit establishment cariogenic pathogenic bacteria oral cavity disclosed, along amino acid sequence enzyme used therein isolated dna molecule encoding same.',\n",
              " 'bacteriophage-encoded antibacterial enzyme treatment prevention gingivitis root surface cariesa method composition treatment prevention gingivitis root surface caries using actinomyces naeslundii bacteriophage av-1 encoded anti-bacterial enzyme (av-1 lysin) remove inhibit establishment cariogenic pathogenic bacteria oral cavity disclosed, along amino acid sequence enzyme used therein isolated dna molecule encoding same.',\n",
              " 'identification phage associated lytic enzyme rapidly specifically detect kill bacillus anthracisa method composition treating bacillus anthracis infection disclosed comprises steps of: administering site infection colonization effective amount least one lytic enzyme genetically coded bacteriophage specific bacillus anthracis, wherein said least one said lytic enzyme specific ability digest cell wall said bacillus anthracis. lytic enzyme may chimeric shuffled, holin protein may used. sequence lytic enzyme gamma bacteriophage disclosed.',\n",
              " 'method kit identifying antimicrobial agents effective concentrations thereofa method kit determining effective concentration antimicrobial agent inhibiting bacterial growth provided. method kit involve use first second multiwell receptacle. fluid sample containing suspected contain one microbial organisms dispensed wells first multiwell receptacle containing range dilutions antimicrobial agent, growth medium bacteriophage form assay mixtures wells. assay mixtures transferred corresponding wells second multiwell receptacle detection.',\n",
              " 'method system high throughput screening antibacterial phagea method system high throughput screening antibacterial phage. method comprises: 1) spotting, plate containing host bacteria, multiple phages detected performing cultivation; 2) capturing image cultivation plate obtain plaque image; 3) performing binarization plaque image convert phage image binary image; 4) filtering binary image basis appearance transmittance plaque binary image obtain phage antibacterial phenotype data; 5) screening, basis phage antibacterial phenotype data, phages detected, obtain antibacterial phage. method system used identifying phage infection capacity, selecting phage monoclones, preparing phage cocktail preparation phage therapy, performing phage function verification, reversely screening anti-phage host bacteria, performing phage lysin function verification.',\n",
              " 'method manipulating phages within body attack infectious target cellsa method system disclosed regulating, manipulating inducing change activity, lysogenic lytic activities native naturally occurring phages within subject treat bacterial, viral, fungal, parasitic infection, pathological biologically-physiologically advantageous target subject, method including steps identifying target within subject exposing subject treatment electromagnetic signature suitable induce native phages subject attack target, advantageously modify target pathology substance. method include implanting treatment electromagnetic signature within ingestible carrier medium providing ingestible carrier medium subject.',\n",
              " 'method production mono combined dry bacteriophage preparationa method comprises concentrating separate united phage lysates centrifuging following adding fillers lyophilization.',\n",
              " 'method capable auto rejecting marking gene trans gene planta method autonomously rejecting marker gene transgenic plant includes using lambda bacteriophage attp-specific recombinant site recombinant enzyme gene int configure plant transfer carrier pamf containing int, target gene marker gene, preparing transgenic plants, selfing cutting marker gene, screening plants without marker gene, determining pcr southern molecule test.',\n",
              " 'method detecting bacteria bacteriophagea method detecting bacterium measurement, including steps of: allowing bacteriophage bind bacterium, bacteriophage capable specifically binding bacterium growing bacterium, whereby gene within bacteriophage expresses light-emission protein introduced bacterium protein produced within bacterium product gene; providing external factor non-invasive manner outside bacterium, thereby causing actually-present bacterium emit light specific manner.',\n",
              " \"method detection mitigation compound producing microbiota aquaculture systema method detecting mitigating compound producing microbiota aquaculture system. method detecting mitigating off-flavor producing microbiota includes, taking least one sample water portion aquaculture system contains aquaculture, extracting genetic material microbiota sample taken, quantifying extracted genetic material creating least one bacteriophage relation microbiota's genetic material, introducing bacteriophage(s) aquaculture system.\",\n",
              " 'method apparatus detecting bacteriaa method detecting bacteria enables detection judgement specific bacterias simple operation, shortened measurement time, improved efficiency, excellent detection accuracy labelling bacteria per se simple specific manner without resort color tone changes caused metabolism fermentation substrate. bacteriophage nucleic add labelled fluorescent substance subjected bacterial contact host cell judge whether specific bacterias present absent utilizing fact significant difference fluorescence intensity fluorescence-labelled nucleic acid present phage fluorescence intensity state fluorescence-labelled nucleic add introduced bacteria.',\n",
              " 'apparatus method detecting microscopic living organisms using bacteriophagea method detecting one target bacteria (14) raw sample where: bacteriophage(s) (18, 102) specific target bacterium added raw sample, test sample incubated, test sample applied substrate (64, 220) changes color either bacteriophage biological substance associated bacteriophage present. substrate contains antibodies (44, 228) bind specifically phage. bacteria test sample may lysed adding microbial lysozyme (22) bacteriophage exposed sample. parent phages (102) tagged (105) way separated progeny phage (106) prior detection process. phage dissociated (94, 124) incubation process sample tested (99, 116) presence individual capsid proteins (97, 72) phage nucleic acids (74). invention used (140) test target bacteria antibiotic resistance.',\n",
              " \"method detection coagulant's anti-virus activity water conditioninga method detection coagulants antivirus activity consists determination intestinal bacteriophages number eluent treatment ofprecipitate therewith. determination antivirus activity made according decrease bacteriophages number eluent treatment explored coagulant precipitate statically valid value (p<0,05) compared eluent treatment control coagulant precipitate.\",\n",
              " 'method detection low-molecular inhibitors biosynthesis nucleic acidsa method detection low-molecular inhibitors biosynthesis nucleic acids using combination model dna-containing enzymatic complexes comprises using reaction transcription using dna-dependent rna-polymerase phage t7, polymerase chain reaction using tag-polymerase reaction relaxation superhelicited dna topoisomerase test systems.',\n",
              " 'method detection pathogens pileate fungi (basidiomicetes)a method detection pathogenes pileate fungi (basidiomicetes) preparing preparation mycelium layer thereof 2- mixed phosphotungstic acid (pta) ph 5.5-6.5 prepared mixture contracts prepared mixture exposure 150-180 seconds, coated onto grid-substrate, dried, photograph taken electronic microscope; assessing external characters carried basis images (photographs) contrasted mycelium preparation; preparing fungal fruiting body preparation sample taken pileus fruiting body shaped triangle side 2.5- contrasting treatment pta ph 5.5-6.5 exposure 90-180 seconds, applying mixture onto grid-substrate drying. final assessment contrasted preparation fungal fruiting body external characters carried basis images (photographs). structure-morphological objects bacteria, microscopic fungi viruses detected whole preparation short period time. addition bacteria, phages thereof (viruses), microscopic fungi fragments thereof (organelles) preparations mycelium (fruiting body) pileate fungi (basidiomicetes) detected fixed images magnification 10000-25000 times, viruses rod, bacillary isometric form detected photographs thereof taken magnification 25000-45000 times.',\n",
              " 'method determination antiviarl action preparations based fluorenesa method determination antiviarl action preparations based fluorenes, described themes, characterized test tube investigated preparation based fluorenes entered equal quantities certain concentration well staphylococcal bacteriophage intestiphage. incubated thermostate temperature 37 ° c 30 minutes, drop put agar surface sowing staphylococcal culture incubated thermostate 24 hours, registration - absence lysis zones site drop application evidence antiviral action preparation.',\n",
              " 'method determination electromagnetic radiation influence biological objectsa method determination electromagnetic radiation influence biological objects comprises selection radiation parameters. bacteriophage used biological object, irradiations carried polarized electromagnetic field power 2 mw 15 minutes, influence radiation determined quantitative indices infectious titres prior irradiation.',\n",
              " 'autonomous inducible directed evolution complex pathwaysa method directed evolution microbe, method comprising: introducing first host cell propagation deficient phage genome vector comprising target gene sequence mutated phage propagation component responsive induce lysis first host cell provide propagation phage genome; exposing first host cell mutagenesis agent; inducing lysis first host cell phage propagation produce lysate comprising phage particles comprising target gene sequence; infecting second host cell lysate. systems kits practicing method disclosed.',\n",
              " 'method vivo directed evolution target proteina method directed evolution target protein cell provided perform treatment, culture screening repetitive mutant-inducing agent. hybrid helper phage fusion genome comprises: genome dna first phage origin replication removed; genome dna second phage origin replication different first phage. directed evolution method target protein cell comprises: step preparing carrier plasmid contains origin replication polynucleotide encoding target protein; step selection plasmid containing antibiotics-resistance gene promoter; step preparing first transformant second transformant; step infecting hybrid helper phage second transformant; step producing mutant carrier phage; step collecting mutant carrier phage; step preparing third transformant; step infecting mutant carrier phage third transformant; step culturing third transformant; step screening single colony.',\n",
              " 'peroral pharge display process, enterocyte-transcytotic peptide identified thereby peroral drug delivery system using samea method displaying peroral phage provided identify peptide showing optimum absorption efficiency passing small intestine mucosa highest frequency. peroral administration system identified peptide introduced provided increase absorption efficiency protein drug bio-membrane significantly, thereby enlarging usability protein drug. method displaying peroral phage comprises steps of: (a) forming phage-peptide library; (b) perorally injecting library rat; (c) blood-irrigating rat; (d) taking organs rat taking tissue sample therefrom, washing homogenizing sample, neutralizing titrating it; (e) quantifying phage sample; (f) titrating separated phage separate phage dna therefrom, analyzing sequence dna identify peptide functional group characterized steps (b) (e) repeated 3 times perform biopanning, phage passing small intestine mucosa biopanning identified various tissues organs liver, lung, heat, spleen blood, acid elution step homogenization step(d) added identify organ targeting peptide specifically bound specific tissue passing small intestine mucosa. peptide identified method inducing absorption promotion small intestinal epithelium includes amino acid sequence cskssdyqc. peroral administration system characterized peptide inducing absorption promotion small intestinal epithelium introduced protein-based drug.',\n",
              " 'selection system phagemids using proteolytically sensitive helper phagea method effecting helper phage rescue phagemid comprising fusion polypeptide form progeny bacteriophage wherein <sl> <li>(a) helper phage encodes viral coat protein comprising protease sensitive cleavage site <li>(b) phagemid comprises fusion polypeptide <li>(c) progeny phage exposed protease capable cleaving proteolytically cleavable site cleavage protein derived helper phage impairs ability mediate infection <li>(d) progeny propagated infection. </sl> helper phage protease sensitive site within p3 coat protein filamentous bacteriophage m13, fd related species.',\n",
              " 'methods testing integrity membranes optically electrochemically detectable nanoprobes thereofa method evaluating integrity microf iltration, ultrafiltration nanof iltration membranes, method comprises passing liquid contains substantially mono-dispersed population nano-probes selected gold nanoparticles, viruses bacteriophages labled fluorescent marker reaction catalyzing group said membrane form permeate testing said permeate presence said nano-probes, wherein non-detection said nano-probes said permeate indicates said membrane substantially intact.',\n",
              " 'sensitive preparation amplification eukaryotic derived nucleic acid fortranscriptional profilinga method global amplification c dna rna template described. c dna produced retains relative abundance across sample rna transcripts produced. embodiments method sensitive enough produce c dna samples equivalent single cell amounts rna. method comprises steps of: a) reverse transcription template rna population, produce global c dna population; b) homopolymer tailing c dna population, produce c dna molecules homopolymer tail; c)amplifying tailed global c dna; wherein least one steps (a) (b), preferably both, is/are effected presence acetate buffer. preferred embodiments, step (a) carried presence non specific rna template (nsrt) comprise sequences found target; example, target may mammalian rna nsrt may lambda phage rna. preferred embodiments, step (b) carried presence co cl2..',\n",
              " 'method pegylating human monoclonal antibody antibody methoda method glycolating human monoclonal antibody provided stabilize scfv(single chain fv fragment) antibody glycolated polyethylene trypsin, extend half life scfv antibody maintaining biological function resistance. human monoclonal antibody specifically bound duffy-binding protein plasmodium bovis stabilized glycolation polyethylene, wherein antibody sfdbii-12 clone, sfdbii-58 clone sfdbii-92 clone derived scfv phage expression library human body.',\n",
              " 'phage antibodies radiation-inducible neoantigensa method identifying molecule binds irradiated tumor subject molecules identified thereby. method includes steps of: (a) exposing tumor ionizing radiation; (b) administering subject library diverse molecules; (c) isolating tumor one molecules library diverse molecules, whereby molecule binds irradiated tumor identified. provided therapeutic diagnostic methods using targeting ligands bind irradiated tumor.',\n",
              " 'method sorting vesicle-entrapped, coupled nucleic acid-protein displaysa method identifying sorting variants chosen enzyme disclosed. enzyme variants chosen enzyme obtained linked corresponding genetic code family suitable surface display methods. enzyme variants, displayed surface biological particle phage, virus, yeast, bacterium encapsulated vesicle containing enzyme activity-sensitive assay reagent. enzyme variant thus exposed assay reagent, displays signal using enzyme activity-sensitive assay reagent manner proportionate levels activity enzyme, thus rendering vesicles suitable mechanical sorting based levels. vesicles sorted using methods known art isolate variants exhibiting possibly beneficial variations enzyme function.',\n",
              " 'method identifying interaction partners using phage displaya method identifying/selecting interaction partners interact target molecule, aid support anchor molecules applied form polymer-free surface affinity ligands covalently bonded, said ligands brought contact viruses plurality peptides proteins interaction partners surface described. method described guarantees accumulation viruses present specific interaction partners optionally cyclic repetition selection. optionally, selected specific interaction partners expressed recombinantly coding nucleotide identified. furthermore, surface use phage display method described.',\n",
              " 'magnetic nanoparticlesa method making composition magnetic nanoparticles, includes step forming magnetic nanoparticles, within protein template, wherein liquid composition said protein template subunits thereof subjected microporous membrane filtration step prior formation magnetic nanoparticles. protein template may comprise flagellar l-p rings, microtubules, bacteriophages, chaperonins, virus capsids preferably members ferritin family, preferably apoferritin. magnetic nanoparticles preferably comprise ferri- ferro-magnetic materials, metal alloys, m-type spinel ferrite. claimed method treating liquid composition magnetic nanoparticles, formed within macromolecular template, method including subjecting composition microporous membrane filtration step. claimed composition encapsulated magnetic nanoparticles, wherein least 70% weight nanoparticles agglomerated form wherein composition comprises 30% free encapsulating material, based total weight encapsulating material composition.',\n",
              " 'detection infectious agents using antigen mimics.a method making diagnosis antigen, comprising identifying binding specificity anti-antigen antibody molecules serum antibody detection antigen mimics (adam) methodology, comprising screening phage libraries using sera antigen-infected patients non-infected individuals, identifying peptides binding antibodies (ligands) specifically associated said antigen. improvements method given vitro maturation strategies; linking ligands common core, map. particular method applies hcv.',\n",
              " 'modifying bacteriophagea method modifying genome lytic target phage, uses method products thereof described. compositions comprising phage described. compositions may formulated medicament, useful human treatment may treat various conditions, including bacterial infections.',\n",
              " 'modifying bacteriophage using beta-galactosidase selectable markera method modifying genome target phage described. compositions comprising modified phage described. compositions may formulated medicament, useful human treatment may treat various conditions, including bacterial infections.',\n",
              " 'bacteriophage activity pathogenic strains salmonellaa method obtaining strain bacteriophage specific selected strain bacteria found well bacteriophage strains obtained way. moreover, application bacteriophages manufacturing preparation preventing fighting infections farm animals, especially poultry, pathogenic strains bacteria sensitive phages described.',\n",
              " 'method liberating bacteriophages uses thereofa method obtaining bacteriophages stressing bacteria. method involves isolating bacteria, propagating bacteria, exposing bacteria least one environmental stressing agent induce excision bacteriophage present bacterial genome. multiple individual environmental stressing agents may applied. liberated bacteriophages may collected purposes treating pathogenic infections, protecting plants agricultural products general sterilization sanitation.',\n",
              " 'site-specific serine recombinases mycobacterium tuberculosis phage phirv1 m. smegmatis phage bxb1and methods usea method obtaining site-specific recombination isolated eukaryotic cell comprising: - providing isolated eukaryotic cell comprises first recombination site second recombination site; - contacting first second recombination site prokaryotic recombinase polypeptide resulting recombination two sites; -the first recombination site either phage genomic recombination attachment site (attp) bacterial genomic recombination attachment site (attb) second recombination either attp attb, provided first recombination site attp second recombination site attb vice versa; - recombinase mycobacterium tuberculosis phage recombinase m. smegmatis phage recombinase particular recombinases phirv1 bxb1 recombinase. method encompasses use pseudo attp attb recombination sites well third fourth, fifth sixth recombination site.',\n",
              " 'method potentiating effects antibiotics fluoroquinolone groupa method potentiating effects antibiotics fluoroquinolone group comprises combination antibiotic coli-proteus phage.',\n",
              " 'method predicting relationship bacteriophage bacterial infectiona method predicting relationship bacteriophage bacterial infection, comprising learning model bacteriophage-host infection relationship construction method therefor. method constructing learning model bacteriophage-host infection relationship comprises: training learning model using data training set bacteriophages bacterial strains, data training set bacteriophages bacterial strains comprising genome data phenotypic assay data. method using learning model bacteriophage-host infection relationship predict bacteriophage infect bacteria method predicting bacteria infected bacteriophage, computer-executable medium comprising computer program performing methods.',\n",
              " 'method preparing bacteriophage preparation, pharmaceutical composition, applicationa method preparing bacteriophage preparation, pharmaceutical composition, application. method comprises: percolating bacteriophage mixed culture solution using tangential flow system obtain bacteriophage original solution; concentrating bacteriophage original solution using tangential flow system concentration 7-10 times concentration bacteriophage original solution obtain bacteriophage concentrate; performing cesium chloride density gradient centrifugation bacteriophage concentrate using cesium chloride solution obtain bacteriophage density gradient solution; dialyzing bacteriophage density gradient solution using 20 kd membrane obtain bacteriophage preparation. way, endotoxin bacteriophage preparation removed quickly, low cost high efficiency.',\n",
              " 'bioactive peptide-based probesa method preparing site-specific peptide probe, wherein peptide specific receptor, includes modifying marker include tether molecule covalently binding tether molecule peptide. present invention provides labeled probe, comprising peptide specific receptor marker. marker modified include tether molecule capable covalently binding peptide. peptide typically derived bacteriophage synthetic analog derivative peptide. receptor typically found surface bacterial cell. method probe invention suitable rapid assay bacteria complex mixture.',\n",
              " 'frame-shifting pcr germline immunoglobulin genes retrieval antibody engineeringa method preparing antigen-specific antibody constructing library phage-displayed single chain variable fragment antibody novel frame-shifting pcr disclosed. disclosed method preparing clone producing antigen-specific antibody.',\n",
              " 'bacteriophage composition useful treating food products prevent bacterial contaminationa method preventing growth e. coli microorganisms food product comprising contacting food product microbial growth inhibiting effective amount bacteriophage composition comprising bacteriophage isolate 119u, wherein application time said bacteriophage composition least fraction second prevent growth microorganisms food product',\n",
              " 'method producing antigen-binding molecule using modified helper phagea method producing bacteriophage presenting antigen-binding molecule, method characterized including step brings helper phage capable expressing first polypeptide contact bacterium capable expressing second polypeptide, first polypeptide second polypeptide associating forming antigen-binding molecule.',\n",
              " 'process production bacteriophage compositions methods phage therapy fielda method producing bacteriophage stock compositions including (a) incubating culture medium including least one bacterial strain, least one bacteriophage strain infect bacterial strain, least one antibiotic, wherein concentration antibiotic medium range causes 0.1% 99.9% inhibition growth bacterial strain absence bacteriophage strain; (b) continuing incubation culture medium bacterial lysis occurs, thereby obtaining bacteriophage lysate; preparing crude bacteriophage extract culture medium.',\n",
              " 'method producing new medicinesa method producing new medicines wherein organisms cells 1 known producer medicines exposed offending medicine resistant organisms cells 3 almost destroyed 4 offending organisms cells killed organism cell killing substance radiation 5 kill offending organisms cells organisms cells enable surviving organisms cells reproduce 6 enabling inherited resistance harvested steps repeated sufficient number times organisms cells kill offending organisms cells without help. organisms cells may fungi mould offending organisms cells may bacteria organism cell killing substance may bleach phages. method may used develop new antibiotics, antifungals, antivirals, antiparasitics anticancer drugs.',\n",
              " 'modifying bacteriophagea method producing one hybrid bacteriophage host range determinant (hrd) sequences, comprises: (1) identifying least two dna sequences, encoding hrd series regions dna sequence, wherein hrds different one another, (2) incorporating region vector region flanked recognition site restriction enzyme capable cutting dna specific cleavage site outside recognition sequence, cleavage site restriction enzyme situated boundary region, wherein cleavage site sequences regions individual series different one another wherein cleavage site sequences boundaries corresponding regions different series same; (3) treating vectors restriction enzyme capable cutting dna specific cleavage site outside recognition sequence generate mixture regions; (4) treating mixture regions ligase ligate form array dna sequences encoding array hybrid hrds.',\n",
              " 'methods profiling extracellular vesicles combinatorial phage display librariesa method profiling extracellular vesicles (ev) provided. method includes: (a) incubating isolated ev one sources phage display library conditions suitable forming ev-bound phage, wherein phage display library comprises one types phage, type phage displayed proteinaceous display binding moieties capable recognizing one epitopes surface ev, wherein type phage comprises nucleic acids encoding displayed proteinaceous display binding moieties, wherein displayed proteinaceous display binding moieties type phage different; (b) isolating ev-bound phage; (c) extracting nucleic acids ev-bound phage; (d) amplifying extracted nucleic acids; (e) sequencing amplified nucleic acids identify specific nucleic acid sequences associated type phage library enriched isolated ev; (f) comparing specific nucleic acid sequences (output) nucleic acid sequences phage display library (input) nucleic acid sequences control identify sequences distinguish ev one sources.',\n",
              " 'high density growth t7 expression strains auto-induction optiona method promoting suppressing auto-induction transcription cloned gene 1 bacteriophage t7 cultures bacterial cells grown batchwise disclosed. transcription control promoter whose activity induced exogenous inducer whose ability induce said promoter dependent metabolic state said bacterial cells.',\n",
              " 'method protecting plants black stem disease using lactobacilli erwinia autolysatea method protecting plants black stem disease using lactobacilli erwinia autolysate lies fact treating roots vegetable seedlings lactic acid bacteria lactobacillus plantarum, grown 48 hours liquid medium mrs concentrationcfu/ml, used. roots treated complex mixture, composition supplemented autolysate bacterium erwinia carotovora subsp. carotovora, comprises bacteriophages macromolecular bacteriocines allows controlling pathogens plant black stem disease.',\n",
              " 'method protecting roots tubers soft rot using lactobacilli erwinia autolysatea method protecting roots tubers soft rot lies fact treating roots bulbs lactic acid bacteria lactobacillus plantarum, grown 48 hours liquid mrs medium concentration ofcfu/ml, used. composition bacterial suspension supplemented autolysate bacteria erwinia carotovora subsp. carotovora, comprises bacteriophages macromolecular bacteriocines specifically killing phytopathogenic bacteria.',\n",
              " 'method protection short-circuit currents power supply network asynchronous motora method protection short-circuit currents asynchronous motor power supply circuit comprises measuring time slot passing currens preset low upper levels, comparison said time slot pulse length, corresponds short-circuit failure, shaping command network voltage protection turn off, said time slot exceed maximum allowable time slot. time slot measuring, control pulse length 90 electrical degrees shaped case presence time phase current semi-wave pulse preset maximum permissible length, leading edge coincides beginning voltage wave phase corresponding polarity. shaped command protection supply voltage turn used, control pulse present. momentary values phage current used current parameter measured.',\n",
              " 'method quantitative detecting fusion protein affiliation object fusion protein using display technique bacteriophagea method quantitative-detecting quantity external source protein applies bacteriophage demonstration technique expression qualitative detection external source protein applies bacteriophage demonstration technique carry quantitative detection external source protein.',\n",
              " 'method rapidly preparing antigen-specific antibodya method rapidly preparing antigen-specific antibody provided. method includes establishing antibody-polypeptide corresponding relationship antibody-motif corresponding relationship; finding polypeptide amino acid sequence target protein searching antibody-polypeptide corresponding relationship, antibody corresponding polypeptide antigen-specific antibody; calculating similarity degree motifs antibody modules target protein antibody-motif corresponding relationship, antibody corresponding motif similarity degree greater 0.4 antigen-specific antibody. phage display technology high throughput sequencing technology combined method, information polypeptide motif recognized given antibody efficiently acquired overall manner, antibody-polypeptide corresponding relationship antibody-motif corresponding relationship established, relationship, specific antibody corresponding target protein rapidly determined. method wide application prospect.',\n",
              " 'method treating food surfaces bacteriophagesa method reducing bacterial contamination food surface. method comprises applying food surface bacteriophage methylcellulose. methylcellulose anhydroglucose units joined 1-4 linkages wherein hydroxy groups anhydroglucose units substituted methyl groups s23/s26 0.36 less, wherein s23 molar fraction anhydroglucose units wherein two hydroxy groups 2- 3-positions anhydroglucose unit substituted methyl groups wherein s26 molar fraction anhydroglucose units wherein two hydroxy groups 2- 6-positions anhydroglucose unit substituted methyl groups.',\n",
              " 'location-specific bacterial managementa method reducing population pathogenic bacteria animal reared animal rearing facility provided. method involves using one one naturally-occurring location-specific bacteriophages selected highly specific strains one one pathogen present facility, phage component derived one one naturally-occurring location-specific bacteriophages, combination thereof, produce location-specific bacteriophage preparation. preparation administered animal, reduce one one pathogenic bacteria. method may involve step identifying location-specific isolates one one pathogenic bacteria near animal rearing facility.',\n",
              " 'method rejecting marking gene trans gene planta method rejecting marker gene transgenic plant order increase safety includes using lambda bacteriophage attp-specific recombinant site recombinant enzyme gene int configure plant transfer carriers pmfc containing int pmfb containing target gene marker gene, preparing transferred plants respectively, crossing specifically cutting marker gene, screening transgenic plants without said marker gene, determinating.',\n",
              " 'methods compositions remediating microbial induced corrosion environmental damage improving wastewater treatment processesa method remediating bacterially-induced corrosion, environmental damage, and/or process inefficiencies industrial process includes identifying industrial process target bacteria adversely affect corrosion, environmental impact, and/or process efficiencies. process includes identifying strains target bacteria, obtaining bacteriophage virulent one strains target bacteria, exposing target bacteria bacteriophage. method utilize aqueous composition comprising bacteriophage encapsulated least one selected group consisting of: liposomes, foam, gel.',\n",
              " 'methods nucleic acid manipulationa method replicating amplifying target nucleic acid sequence described. method invention involves formation recombination intermediate without prior denaturing nucleic acid duplex use recombination factor. recombination intermediate treated high fidelity polymerase permit replication amplification target nucleic acid sequence. preferred embodiments, polymerase comprises polymerase holoenzyme. preferred embodiments, recombination factor bacteriophage t4 uvsx protein homologs species, polymerase holoenzyme comprises polymerase enzyme, clamp protein clamp loader protein, derived viral, bacteriophage, prokaryotic, archaebacterial, eukaryotic systems.',\n",
              " 'method revealing pathogens pileate mushrooms (basidiomicetes)a method revealing pathogens pileate mushrooms (basidiomicetes), which, preparing preparation mycelium, layer latter 2-4 mm mixed phosphoric-tungstic acid (phta) ph 5,5-6,5, prepared mixture contrasted exposure 150-180 seconds, coated onto liner net, dried photographed electron microscope. assessment outward signs carried basis images contrasted mycelium preparation; and, compounding preparation fruit body mushroom, sample taken pileus fruit body mushroom contrasting thereof phta ph 5,5-6,5 exposure 90-180 seconds, coating mixture onto liner net dried, final assessment preparation outward signs carried basis images thereof. structural-morphological objects bacteria, microscopic fungi viruses revealed integrated manner one preparation short time; addition bacteria, phages thereof (viruses), microscopic fungi fragments thereof (organelles) preparations mycelium (fruit body) pileate mushrooms (basidiomicetes) revealed fixed images magnification 10000-25000 times, viruses rod-like, bacillus isometric shape revealed photographed magnification 25000-45000 times.',\n",
              " 'inhibitors viral infection targeting integrase n-terminal regiona method screening novel integrase inhibitor completely different conventional integrase inhibitors drug function point hiv-infection inhibited reverse transcription step; novel integrase inhibitors obtained using screening method; medicinal compositions containing integrase inhibitors dna encoding highly expected novel remedies aids. peptide inhibiting infection proliferation retrovirus (hiv-1, etc.) reverse transcription obtained screening phage display method peptide binding specifically n-terminal region retrovirus integrase.',\n",
              " 'method screening catalytic peptides using phage display technologya method screening catalytic peptides using phage display technology disclosed. compound exposed phage library. peptide library catalyzes reaction, gel formed phage displays peptide. gel, including first phage, separated un-reacted phages released gel. phage replicated analyzed determine composition peptide functioned catalyst.',\n",
              " \"method screening αβ-tcr heterodimer mutantsa method screening αβ-tcr mutants, method comprising construction phagemid. construction, gene encoding a1 polypeptide gene encoding b1 polypeptide inserted 3' ends genes encoding constant regions α chain β chain tcr respectively, ribosome binding site molecular chaperone gene integrated phage vector, wherein amino acid sequence a1 polypeptide shown seq id no: 1 represented variant a1 polypeptide; amino acid sequence b1 polypeptide shown seq id no: 2 represented variant b1 polypeptide; variants least retain function polypeptides mutation. a1 peptide b1 peptide used promoting correct pairing folding αβ heterodimer tcr, efficiency displaying correctly folded tcr surface phage improved. method efficiently complete screening αβ heterodimer tcr mutants.\",\n",
              " 'vector method screening functional antigen-binding proteina method selecting functional antigen-binding protein. method comprises step constructing expression vector, means phage display technique and/or cell display technique, using light chain fragment thereof reference antigen-binding protein known sequence function, heavy chain fragment thereof reference antigen-binding protein, thereby selecting functional antigen-binding protein binds epitope reference antigen-binding protein. provided functional antigen-binding protein obtained means method.',\n",
              " 'use native epitope selecting evolved binding members library mutants protein capable binding said epitopea method selecting mutant molecule (such antibody) capable binding epitope (such ep-cam), comprising: (a) generating phage display library mutants molecule, said molecule capable binding epitope; (b) incubating phage display library cell crude cellular extract thereof, said cell crude cellular extract thereof displaying epitope; (c) selecting least phages binding cell crude cellular extract thereof displaying epitope, and; (d) separating recovering phages binding cell crude cellular extract thereof displaying epitope.',\n",
              " 'method selecting peptide polypeptide binds targeta method selecting peptide polypeptide binds target provided. method based protein splicing phage display.',\n",
              " 'method selecting method sanitization abdominal cavity generalized peritonitisa method selecting method sanitization abdominal cavity generalized peritonitis comprises washing abdominal cavity antiseptic solutions followed studying morphometric parameters parietal peritoneum. specific volume 0.1314 ± 0.0546 neutrophilic polymorphonuclear leukocytes (npml), 0.0145 ± 0.0038 lymphocytes, 0.0046 ± 0.0013 macrophages, abdominal cavity washed antiseptic solutions irrigated bacteriophage. specific volume 0.2614 ± 0.0431 npml, 0.0126 ± 0.0023 lymphocytes, 0.0039 ± 0.0010 macrophages, washing antiseptic solutions irrigation bacteriophage supplemented infiltration mesenteric root small intestine, purulent foci omentum parietal peritoneum bacteriophage.',\n",
              " \"optical mapping genomic dnaa method single-molecule optical dna profiling using exceptionally dense, yet sequence-specific coverage dna fluorescent probe, using dna methyltransferase enzyme direct dna labeling, followed molecular combing dna onto polymer-coated surface subsequent sub-diffraction limit localization fluorophores. result 'dna fluorocode'; simple description dna sequence, maximum achievable resolution less 20 bases, read analyzed barcode. method generates fluorocode genomic dna lambda bacteriophage using dna methyltransferase direct fluorescent labels four-base sequences reading 5'-gcgc-3'. consensus fluorocode constructed allows study dna sequence level individual labeling site generated handful molecules entirely independently reference sequence.\",\n",
              " 'method synthesis gold nanostructures using dodecamer peptides midas-1 midas-12a method synthesizing nanosturecture gold using dodecamer peptides midas-1 midas-12 provided synthesize nanosturecture gold environment-friendly easily without using high temperature, pressure high toxic chemicals. method synthesizing nanosturecture gold using dodecamer peptides midas-1 midas-12 comprises following steps of: eluting phage combined metallic gold powder adding glycine-hcl cultivating metallic gold powder solution phage; amplifying eluted phage infection e.coli neutralizing supernatant including phage tris hydrochloride; separating phage combined surface metallic gold powder polyethylene glycol/nacl; repeating first third step 2 times; acquiring dodeca peptide midas-2 synthesizing gold; substituting amino acid glycine midas-2.',\n",
              " 'mycobacteria detection using bacteriophagesa method testing target mycobacteria reaction mixture comprising steps of: providing reaction mixture; admixing bacteriophage reaction mixture conditions suitable allow bacteriophage infect target mycobacteria present reaction mixture; allowing time bacteriophage lyse infected live target mycobacteria; analysing said reaction mixture dna lysed mycobacteria identify signature dna sequence occurs target mycobacteriumspedes.',\n",
              " 'modifying bacteriophagea method genetic modification, mutation, homologous recombination recombineering naturally obligate lytic phage bacteriophage disclosed wherein variant usually lytic phage lacking endolysin gene introduced first host cell together vector comprising target nucleic acid modified trans endolysin gene. target nucleic acid incorporates genome endolysin deficient phage, endolysin gene comes it. thus phage subsequently propagated usual host cell (also endolysin deficient), presence endolysin gene within phage genome facilitates lytic cycle enabling ready selection phages comprising recombinant nucleic acid.',\n",
              " 'method isolation unicellar algae algoviruses, e.g., platymonas viridis rouch (chlorophita)a method isolation algoviruses unicellar algae, e.g, platymonas viridis rouch (chlorophita), consists revealing interaction bacterial sensitive (indicative bacteriophage) culture predictable bacteriophage. revealing culture microalga p.viridis cultural medium logarithmic stage used, culture contaminated equal volumes material tested. availability pathogenic microorganisms material tested determined according changes test compared control. that, effect inhibition fixed subsequent subinoculations revealed suppressing material culture microalgae. .',\n",
              " 'phage display librariesa method preparation phage display library selection high affinity binding phage (shaved phage) comprising: providing library phage expressing proteinaceous ligand plurality phage surfaces wherein ligand attached phage coat protein wherein cleavable site located within expressed ligand-coat protein; treating library cleaving agent proportion phage monovalent proteinaceous ligand. claimed method selection phage library, phage particle comprising ligand attached phage gene iii coat protein wherein particle cleavable site within said surface-expressed ligand-coat protein shaved phage library.',\n",
              " 'antibody anthraxa method production antibody specific b. anthracis comprising steps i) generating immune scfv phage-display library ii) panning library immobilised b. anthracis spore presence spore one bacillus species.',\n",
              " 'affinity separation means, uses thereof separate, purify concentrate target moleculea method purification target molecule sample containing, suspected containing, target molecule, employs filamentous phage functionalised magnetic particle filamentous phage genetically engineered express least one coat protein form fusion protein comprising foreign peptide specific binding affinity binding partner selected target molecule surface magnetic particle. method comprising steps incubating affinity separation means sample period time sufficient allow filamentous phage bind target molecule present sample, separating affinity separation means sample, eluting bound target molecule affinity separation means.',\n",
              " 'method sanitization abdominal cavity generalized peritonitisa method sanitization abdominal cavity generalized peritonitis comprises washing abdominal cavity decaxan solution followed infiltration mesenteric root small intestine, purulent foci omentum parietal peritoneum bacteriophage.',\n",
              " 'semiconductor nanoparticlesa method synthesis semiconductor nanoparticles within protein template, wherein semiconductor selected cdse, cdte, znse, zns znte, method comprising forming reaction mixture combining liquid medium cation source selected cadmium zinc ions anion source selected sulfur, selenium tellurium ions presence source protein capable acting template formation nanoparticles maintaining liquid medium temperature least 24{c time sufficient permit nanoparticle formation within protein template, proviso cation source cadmium, anion source sulfur. protein template may comprise flagellar l-p rings, microtubules, bacteriophages, chaperonins, virus capsids preferably members ferritin family, preferably apoferritin. encapsulated nanoparticle may subjected membrane filtration. independently claimed composition protein-encapsulated semiconductor nanoparticles wherein semiconductor selected cdse, cdte, znse, zns znte.',\n",
              " 'method preventing spoilage food bacteriophagea method treatment prevention dental caries periodontal diseases using bacteriophages phage-encoded anti-bacterial enzymes inhibit establishment bacteria oral cavity provided. provided methods studying cell wall oral bacterium, method preventing spoilage perishable items method removing dextrans surfaces utilized sugar manufacture. purified enzymes isolated dna fragments encoding provided.',\n",
              " 'microbiome byproducts uses thereofa method treating microorganism-related condition patient may include detecting microorganisms set samples collected population comparing relative abundance co-occurrence different microbial taxa set samples. method includes associating change relative abundance co-occurrence microbial taxa samples people, among population, microorganism-related condition samples people, among population, without microorganism-related condition determine target taxa. blend bacteriophages identified, blend configured remove target taxa community microorganisms. therapeutic composition comprising blend administered patient microorganism-related condition.',\n",
              " 'method treating acute cholecystitis complicated peritonitis elderly patients heart failure ischemic origina method treating acute cholecystitis complicated peritonitis elderly patients heart failure ischemic origin includes laparoscopy, aspiration peritoneal fluid, laparoscopic cholecystectomy, sanitization inflammatory focus, drainage abdominal cavity. following sanitization inflammatory foci physiological saline, irrigation therapeutic bacteriophage volume 50-100 ml provided. abdominal cavity drained. postoperatively, bacteriophage administered fractionally volume 20 ml every 8 hours drainages pinching drainages one hour followed passive aspiration.',\n",
              " 'method treating individual suffering bladder cancera method treating individual suffering bladder cancer employs crispr system selectively kill reduce numbers pathogenic bacteria within individual individual administered immune checkpoint inhibitor. particular embodiments, pathogenic bacteria one e. coli, pseudomonas aeruginosa klebsiella bacteria, checkpoint inhibitor selected group consisting nivolumab, pembrolizumab, dostarlimab, pidilizumab, amp-224, amp-514, sti-a1110, tsr-042, rg-7446, bms-936559, medi-4736, msb-0020718c, aur-012 sti-a1010. embodiments include enhancing growth second bacteria individual, bacteria including akkermansia, bacteroides, bifidobacterium, clostridium, enterococcus, fusobacterium, coprococcus, lactobacillus, propionibacterium, ruminococcus, veillonella, prevotella, escherichia streptococcus. crispr system may include cas9, cpf1 cas3, may delivered using bacteriophage.',\n",
              " 'method treatment atopic dermatitis children first year lifea method treatment atopic dermatitis children first year life comprises use antihistamine drugs, topical compositions, hypoallergenic mixtures prebiotic additives, bacteriophages. bacteriophage strain selected depending conditionally pathogenic bacteria isolated patient. bacteriophage prescribed age-related dosage. bifidumbacterin lactobacteria used normalization laboratory parameters.',\n",
              " 'systems methods specimen processing storagea method including receiving specimen comprising carrier, first target species, first component storing least portion carrier first target species storage media self-driven filtering specimen storage media, wherein storage media comprises porous superabsorbent polymer (psap) beads. psap beads provide fast self-driven microfiltration biofluid samples. treatment effectively separates small analytical targets (e.g., glucose, catalase, bacteriophage) large undesired components (e.g., bacteria blood cells) biofluids capturing former inside excluding latter outside psap beads. treatment reduce sample volume, self-aliquot liquid sample, avoid microbial contamination, separate plasma blood cells, stabilize target species inside beads, enable long-term storage room temperature.',\n",
              " 'identification specific tumour antigens means selection cdna libraries sera use said antigens diagnostic imaging techniques.a method described identification specific tumour antigens means selection cdna display libraries using sera characterised said selection accomplished phage display technique, particular said selection accomplished means serex technique (serological analysis autologous tumour antigens expression recombinant cdna). method according invention described herein advantageously combines serex approach potency phage display technique defined above, time avoiding drawbacks characteristic serex technique.',\n",
              " 'identification specific tumor antigens means selection cdna libraries sera use said antigena treatment tumorsa method described identification specific tumour antigens means selection cnd display libraries using sera, characterised said selection accomplished phage display technique, particular said selection accomplished means serex technique (serological analysis autologous tumor antigens expression recombinant cdna). method according invention described herein advantageously combines serex approach potency phage display technique defined above, time avoiding drawbacks characteristic serex technique. identified antigens useful preparation medicaments treatment tumors.',\n",
              " 'bacteriophage immobilization biosensorsa method disclosed anchoring bacteriophage substrate, bacteriophage phage amine moiety, method comprising: producing free amine terminal moiety substrate chemical modification substrate; activating free amine terminal moiety cross-linking agent produce active functional group couple phage amine moiety; anchoring bacteriophage substrate using active functional group. sensor disclosed comprising: substrate; anchor group attached chemical modification substrate active functional group produced activation free amine terminal moiety; bacteriophage phage amine moiety coupled active functional group anchor bacteriophage substrate.',\n",
              " 'bacteriophage immobilization biosensorsa method disclosed anchoring bacteriophage substrate, bacteriophage phage amine moiety, method comprising: producing free amine terminal moiety substrate chemical modification substrate; activating free amine terminal moiety cross-linking agent produce active functional group couple phage amine moiety; anchoring bacteriophage substrate using active functional group. sensor disclosed comprising: substrate; anchor group attached chemical modification substrate active functional group produced activation free amine terminal moiety; bacteriophage phage amine moiety coupled active functional group anchor bacteriophage substrate.',\n",
              " 'method prevention and/or biological control bacterial wilt caused ralstonia solanacearum, via use bacteriophages suitable purpose compositions thereofa method prevention and/or biological control wilt caused ralstonia solanacearum, use suitable bacteriophages. addition method uses structural characterisation, genome sequence activity three specific lytic bacteriophages r. solanacearum. podovirus presents elevated stability 4° c. 30° c. aqueous medium absence host. result high level stability, lytic activity, elevated specificity towards r. solanacearum absence activity microbiota associated plants protected, bacteriophages used biological control r. solanacearum river courses irrigation water, well method preventing and/or controlling wilt produced bacteria, least one bacteriophages, combinations thereof, delivered plants and/or soil irrigation water.',\n",
              " 'method isolating binding peptides combinatorial phage display library peptides produced therebya method provided identifying isolating peptides capable binding inorganic materials silica, cobalt, iron, oxides thereof using combinatorial phage display peptide library. method invention, combinatorial phage display library used isolate select desired binding peptides series steps target binding phage inorganic material interest, elution purification bound phages, amplification determine sequences phages producing desired binding peptides. binding peptides invention particularly advantageous may used templates guide development useful structures nanometric scale.',\n",
              " 'peptide templates nanoparticle synthesis obtained pcr-driven phage display methoda method provided identifying isolating peptides capable binding inorganic materials silica, silver, germanium, cobalt, iron, oxides thereof, materials nanometric scale carbon nanotubes, using combinatorial phage display peptide library polymerase-chain reaction (pcr) step obtain specific amino acids sequences. method invention, combinatorial phage display library used isolate select desired binding peptides series steps target binding phage nanometric material interest, elution purification bound phages, amplification using pcr determine sequences phages producing desired binding peptides. binding peptides invention particularly advantageous may used templates guide development useful structures nanometric scale.',\n",
              " 'method screening peptides diagnostic probe anthrax infection resulting novel peptides specifically recognizing anthrax protective antigena method provided screen peptide recognizes anthrax toxin protein specifically bonded thereto diagnose anthrax infection. screened peptide provided used low molecular weight probe diagnosing anthrax infection. method screening peptide diagnostic probe anthrax infection comprises steps of: (a) mass-producing protective antigen anthrax toxin proteins genetic recombination; (b) bonding mass-produced protective antigen 96-well plate certain directivity; (c) screening specific peptide bonded protective antigen using library phage display. peptide probe characterized specifically bonded protective antigen anthrax toxin proteins screened method act low-molecular weight picomole probe diagnosing anthrax infection, wherein amino acid sequence peptide consists amino acid described seq id : no. 1, 2, 3, 4, 5, 6, 7, 8.',\n",
              " 'nucleic acid sequencing-based methods analyzing affinities libraries binding compoundsa method analysing affinities library binding compounds one ligands disclosed comprising steps reacting one ligands library binding compounds (e.g. antibodies), binding compound consisting encoded nucleotide sequence, determining nucleotide sequences binding compounds forming complexes ligands binding compounds free ligand determining affinities respective binding compounds comparing number times nucleotide sequence identified among binding compounds forming complexes ligands number times nucleotide sequence identified among binding compounds free ligand. library may phage display system expressing antibody. methods identifying binding compounds increased stability utilising aforementioned steps claimed.',\n",
              " 'multiple virus reaction assaya method assay outcome reaction comprises conducting reaction first reactant second reactant produce first reactant product least one new structural feature present first reactant second reactant, e.g. cleaving first reactant adding it, producing multiple-phage tagged complex comprising least two different viruses said product said first reactant, complex least one said viruses connected said product using said new structural feature lost said first reactant upon formation said new structural feature, determining presence amount said complex dual-phage assay.',\n",
              " 'particle bindinga method binding bacteriophage particles. method comprising steps exposing particles electrical discharge mixing activated particles bacteriophage. bacteriophage bound particles.',\n",
              " 'method cleaning implement handling plurality samplesa method cleaning pin head implements handling plurality samples nucleic acid subject amplification process using biochemical amplification product. method comprises exposing pin head implement ultraviolet (uv) preferably infrared (ir) illumination handling different samples order suppress cross-contamination non-specific amplification. biochemical amplification product may obtained rolling circle amplification (rca) procedure, catalyzed bacteriophage phi29, polymerase chain reaction (pcr) amplification product. <image>',\n",
              " 'method use nitrate reducing bacteria phages mitigating biogenic sulfide productiona method controlling deleterious bacteria fluid including injecting nitrite nitrate fluid, identifying phage capable infecting deleterious bacteria, injecting phage fluid.',\n",
              " 'method control deleterious microbes oil gas industrial fluids.a method controlling deleterious bacteria oil gas production, oil gas completion fluids industrial fluids described includes identifying phage capable infecting deleterious bacteria, identifying biocide compatible phage effective deleterious bacteria injecting biocide phage oil gas production, oil gas completion industrial fluid.',\n",
              " 'methods compositions controlling body odora method controlling body odor disclosed. method comprises topically administering subject effective amount least one species lytic bacteriophage capable killing odor-generating bacteria. deodorant compositions comprising bacteriophages disclosed.',\n",
              " 'control filamentous bacteria induced foaming wastewater systemsa method controlling filamentous bacteria responsible foaming bulking wastewater systems virulent bacteriophage. method includes, optionally, identification problematic filamentous bacteria matching virulent bacteriophage, use bacteriophage phage libraries concentration filamentous bacteria bacteriophage wastewater treated.',\n",
              " 'control unwanted bacteria fermentation systems bacteriocina method controlling unwanted bacteria fermentation processes comprising contacting reactants process effective amount bacteriocin. bacteriocin, indigenous produced independent sources, optionally bacteriocin plus bacteriophages virulent unwanted bacteria used reduce control unwanted bacteria.',\n",
              " 'artificial cellulosome bacteriophage scaffold, method decomposing cellulose manufacturing alcohol using samea method decomposing cellulose provided, including building recombinant bacteriophage, wherein genome bacteriophage modified express linking peptide affinity decomposing enzyme anchoring peptide affinity anchoring site surface cell, applying decomposing enzyme contact recombinant bacteriophage, applying cellulose contact decomposing enzyme.',\n",
              " 'delivery active proteins central nervous system using phage vectors.a method delivering protein central nervous system active form comprises: (1) preparing single-stranded filamentous bacteriophage vector comprising nucleic acid construct protein delivered central nervous system encoded fusion protein coat protein filamentous phage; (2) preparing phage particles incorporating nucleic acid construct phage genome fusion protein expressed coat protein; (3) delivering phage particles mammal route phage particles reach central nervous system protein delivered central nervous system active form. protein delivered antibody, enzyme, reporter protein, receptor, another type protein. method wide diagnostic therapeutic application. invention encompasses nucleic acid constructs, bacteriophage particles including protein delivered, pharmaceutical compositions.',\n",
              " 'detection bacteria using bacteriophagea method detecting species, strain type bacteria includes mixing labeled bacteriophage including label detectible via detection system bacterial culture including species, strain type bacteria labeled bacteriophage selectively binds using detection system detect labeled bacteriophage bound species, strain type bacteria.',\n",
              " 'method detecting escherichia coli phage detecting escherichia colia method detecting escherichia coli contained test sample bringing sample contact specific phage infected e. coli comprises using phage expressing fluorescent protein form fused protein together phage coat protein coat phage defect lytic enzyme. particular, method comprises detecting fluorescence strong level emitted fluorescent protein phage adsorbed e. coli and/or detecting fluorescence strong level emitted fluorescent protein expressed e. coli caused adsorption phage.',\n",
              " 'bacteriophage-based microorganism diagnostic assay using speed acceleration bacteriophage reproductiona method determining presence absence target microorganism sample tested, method comprising: combining sample amount bacteriophage capable infecting target microorganism create bacteriophage-exposed sample; measuring time rate change amount said bacteriophage change rate change amount said bacteriophage indication presence absence target microorganism function time.',\n",
              " 'brain tumor targeting peptides methodsa method diagnosing treating human glioblastoma multiforme (gbm) brain tumor subject disclosed. method includes administering subject, effective amount composition peptide 12-20 amino acid residues length selected ability bind preferentially subtype human gbm cells identified brain tumor initiating cells (btics) highly invasive glioma cells (higcs). disclosed phage-display screening method identifying therapeutic peptides, peptides hind specifically btics higcs.',\n",
              " 'disinfection foodstuffsa method disinfection livestock provided. method comprises administering least one bacteriophage effective amount said livestock reduce number campylobacter spp present gastro-intestinal tract said livestock. bacteriophage selected cp8 (ncimb accession no. 41184) cp34 (ncimb accession no. 41185).',\n",
              " 'bacterial control dispersion bacteriophage powdersa method eliminating, reducing preventing bacterial contamination surface, method comprising dispersing bacteriophage containing composition air proximity surface. embodiments, bacteriophage containing composition powder dispersed pressurizing load chamber containing powder powder expelled outlet. also, devices performing method powder used method.',\n",
              " 'genetically engineered bacteriophagea method engineering bacteriophages comprising isolating bacteriophage; removing attachment genes genome said bacteriophage; inserting first unique open reading frame encoding one attachment genes inserting second unique open reading frame encoding one genes useful overcoming bacterial defenses; inserting non-natural attachment gene said first open reading frame, wherein said non-natural attachment gene specific attaching selected bacteria.',\n",
              " 'anti-sialic acid antibody moleculesa method generating isolating recombinant high affinity anti-sialic acid antibody molecules comprises steps immunising avian host immunogen comprising conjugate sialic acid carrier protein generate anti-sialic acid polyclonal serum, isolating sample rna immunised avian host, using phage display generation screening library recombinant avian antibody molecules rna sample, isolating recombinant high affinity anti-sialic acid antibody molecules. antibody molecule selected group consisting of: whole antibodies; scfv fragments; fab fragments, avian host gallus domesticus. recombinant avian antibody fragment high binding affinity sialic acid obtainable method invention, anti-sialic acid polyclonal serum obtainable immunising avian host conjugate sialic acid carrier protein, described.',\n",
              " 'identification gene editing gene excising (cas9-like argonaute-like) proteins organismsa method identifying gene editor gene excisor nuclease (cas9-like argonaute-like) protein assay, stressing microbial strain bacteriophage infection, separating nuclease proteins non-nuclease proteins, identifying nuclease proteins. method identifying cas9 nuclease activity nuclease protein, verifying sgrna (and/or sgdna) nuclease activity nuclease protein, determining pam sequence nuclease protein. method identifying argonaute nuclease activity nuclease protein, verifying sgrna (and/or sgdna) nuclease activity nuclease protein. molecule gene editing and/or gene excising capabilities obtained isolated methods described above. gene excisor obtained isolated methods described above.',\n",
              " 'method high throughput screening inhibitors inhibit interaction attachment protein cell receptors using recombinant phage displaya method identifying potential reagent inhibit reaction target polypeptides recombinant protein comprises steps providing plurality target polypeptides attached solid platform; bringing plurality potential reagent contact bind onto recombinant protein expressed displayed phage; bringing plurality recombinant protein potential reagent contact target polypeptides; removing unbound recombinant protein phage; adding plurality bacterial cells capable infected phage solid platform; determining presence number infected bacterial cells; whereby binding potential reagent onto recombinant protein inhibits binding interaction target polypeptides recombinant protein well subsequent infection bacterial cells, incapability potential reagent bind onto recombinant protein allows subsequent infection bacterial cells recombinant phage.',\n",
              " 'method high throughput screening inhibitors inhibit interaction attachment protein cell receptors using recombinant phage displaya method identifying potential reagent inhibit reaction target polypeptides recombinant protein comprises steps providing plurality target polypeptides attached solid platform; bringing plurality potential reagent contact bind onto recombinant protein expressed displayed phage; bringing plurality recombinant protein potential reagent contact target polypeptides; removing unbound recombinant protein phage; adding plurality bacterial cells capable infected phage solid platform; determining presence number infected bacterial cells; whereby binding potential reagent onto recombinant protein inhibits binding interaction target polypeptides recombinant protein well subsequent infection bacterial cells, incapability potential reagent bind onto recombinant protein allows subsequent infection bacterial cells recombinant phage.',\n",
              " 'identification useful bacteriophagea method identifying particular bacteriophage provided.',\n",
              " 'bacteriophage displaying abeta epitopes method usea method immunizing plaque forming diseases using display technology provided. method utilize novel agents, pharmaceutical compositions vaccination plaque forming diseases rely upon presentation antigen epitope display vehicle. method includes agents, pharmaceutical compositions vaccination plaque forming diseases, rely upon presentation antibody, active portion thereof, display vehicle. whether antigens antibodies employed, disaggregation plaques results immunization.',\n",
              " 'method treating drug resistant eskape pathogens using therapeutic bacteriophagesa method improving immunological response human subject suffering pseudomonas aeruginosa wound comprising step of: (i) administering one isolated purified strains pseudomonas aeruginosa one pharmaceutically acceptable carriers adjuvants wounded area human subject, said genomic phages interacting innate adaptive immune system human subject, providing biological protection and/or wound recovery stimulation; (ii) co-administering one additional genomic phages selected genomic phages selected myoviridae, podoviridae siphoviridae interacts one pharmaceutically acceptable carriers adjuvants wounded area human subject.',\n",
              " 'tagging microorganismsa method labelling microorganism comprises introducing label first microorganism, wherein phenotype labelled first microorganism second microorganism strain first labelled and, separately, mutating first microorganism. one method, label introduced phage integration site genome microorganism. another label istron. gene identification assays gene function carried using microorganisms labelled way, invention provides vectors carrying labelling.',\n",
              " 'modification nucleic acid-containing biological entitiesa method modifying surface nucleic acid-containing biological entity comprising growing polymer chains one initiation points said surface, presence one catalysts, wherein nucleic acid-containing biological entity optionally virus, bacteriophage, prokaryotic cell, bacterium, archaeum, eukaryotic cell, fungus, spore, nucleic acid-containing viral core outer membrane(s) and/or capsids removed, membrane-stripped virus, viral core, eukaryotic cell nucleus, mitochondrion, mammalian cell nucleus, complex comprising nucleic acid condensing agent complex comprising sirna condensing agent; preferably virus bacterium; preferably adenovirus, adenovirus core, pox virus, pox virus core, herpes virus.',\n",
              " 'methods analyzing microbiome, immunoglobulin profile physiological statea method predicting microbiome profile subject provided. method comprising: (a) providing phage display library comprising phages displaying surface peptides microbiome mammalian host, wherein phage display library comprises peptides frequency predetermined threshold; (b) contacting library biological sample subject, biological sample comprising immunoglobulins, wherein contacting performed conditions allow specific immunocomplexation immunoglobulins peptides; (c) isolating immunecomplexes resultant immunocomplexation; (d) identifying peptides immunocomplexes, peptides indicative microbiome subject.',\n",
              " 'purified bacteriophage, preparation applicationa method preparation purified bacteriophage increased antibacterial activity, bacterial lysate phages obtained, advantageously presence lysozyme, chelating factor detergent, continuous manner ultrafiltration membranes, phage containing high molecular mass preparation, devoid bacterial cell wall contaminants, free toxins endotoxins, active tests bacterial lysis, characterized chromatography hplc, sds-page electrophoresis, immunoblotting, biological tests bacterial lysis, dedicated phage therapy bacterial infections tumors production phage deriving pharmaceutical preparations.',\n",
              " 'use recombinant antibacterial enzyme lyssap26 effectively killing pathogenic bacteriaa method preventing treating pathogenic bacterial infectious diseases, includes: providing pharmaceutical composition comprising lyssap26 protein, wherein lyssap26 protein recombinant protein composed amino acid sequence derived bacteriophage genome includes amino acid sequence represented seq id no: 1 active ingredient; administering pharmaceutical composition subject.',\n",
              " 'method preventing wound pyoinflammatory complications laparoscopic cholecystectomy acute destructive cholecystitis complicated formsa method preventing wound pyoinflammatory complications laparoscopic cholecystectomy acute destructive cholecystitis, including laparoscopic cholecystectomy, gallbladder removal sub-xyphoid wound container, introduction medication wound closure skin. removal container gallbladder closure skin sub-xyphoid wound irrigated polyvalent bacteriophage (sekstafage) volume 3-5 ml; container damaged extraction, deferred sutures applied sub-xyphoid wound, wound swabbed tampon, dipped sekstafage every 8 hours bandage tampon irrigated, alternating one following bacteriophages: coliproteous, sekstafage, intest-bacteriophage.',\n",
              " 'bacterial ghost (bg) production process using betapropiolactone (blp) final inactivationa method producing bacterial ghost preparation using betapropiolactone inactivate bacteria. method performed 0.01-1% (v/v) betapropiolactone 26-50 degrees celsius bacteria inactivated 10-60 min. bacterial ghosts obtained expressing lytic protein encoded bacteriophage phix174 gene e. bacterial ghosts used human veterinary medicine vaccination adjuvant.',\n",
              " 'bacteriophage production methoda method producing bacterial replication host bacteriophage provided, including selecting bacterial species, strain, serotype isolate different pathogenic bacterium host replication bacteriophage. bacterial replication host provides safe, efficient non-toxic vehicle propagating bacteriophage capable infecting pathogenic bacterium different bacterial species, strain, serotype isolate replication host. pathogenic bacterium may genus vibrio, aeromonas pseudomonas. particular vibrio bacteria pathogens shrimps prawns, vibrio parahaemolyticus. invention may particular applicability aquaculture.',\n",
              " 'methods expanding bacteriophage host-range bacteriophage produced methodsa method producing novel bacteriophages expanded host-range bacteriophages expanded host ranges disclosed. method produces mutant phage strains infectious second host infectious natural host natural state. method includes repeatedly passaging selected phage strain bacterial cultures contain varied ratios natural host bacterial strain bacterial strain phage interest unable infect; target-host. passage resulting phage purified screened activity target-host via double-overlay assays. mutant phages shown infect target-host discovered, propagated culture contains target-host produce stock resulting mutant phage.',\n",
              " 'phage display assaya method producing specific binding members cell surface antigen, wherein cells antigen surface control cells without antigen surface immobilised solid surface, without fixation, contacted phage display library blocking non-specific binding, population phage displaying specific binding members cell surface antigen identified, method comprising obtaining nucleic acid nucleotide sequence encoding specific binding members displayed phage population producing one specific binding members cell surface antigen recombinant expression nucleic acid nucleotide sequence derivative nucleotide sequence produce product specific binding member.',\n",
              " 'method purification bacteriophage particlesa method recovering viable phage from, example, crude phage preparation lysate resulting amplification phage bacterial cell culture disclosed. method may \"universal\"; is, applicable purification broad range phage species strains. phage product resulting method may acceptably low endotoxin titer (e.g. less 500 eu/ml) sufficiently high phage titer (e.g. > 1 x 10',\n",
              " 'application bacteriophages control unwanted bacteria biofuel production mediated non-bacterial reactive agentsa method reducing process interruptions biofuel production systems reducing amount unwanted bacteria biofuel production system reduction effected use effective amount one types bacteriophages virulent least strains unwanted bacteria.',\n",
              " 'application bacteriophages control unwanted bacteria biofuel production mediated bacterial reactive agentsa method reducing process interruptions biofuel production systems mediated bacterial reactive agents reducing amount unwanted bacteria without reduction wanted useful bacteria. method comprises applying phage panel(s) containing phage virulent unwanted bacteria contain phage phages virulent wanted bacteria. method includes, optionally, selective production solutions phage unwanted bacteria phages wanted bacteria screened out.',\n",
              " 'system method select phage therapy based time locationa method selecting phage formulation described wherein method comprises storing bacterial infection/contamination data one treatment locations spatio-temporal infection database, database comprising least one following data fields: (1) clinical indication, (2) bacteria identification, (3) clinical outcome, (4) phage resistance status, (5) phage susceptibility profile, (6) antibiotic susceptibility profile, and/or (7) lab test result relating one (1)-(6); identifying one phage suitable inclusion phage formulation analyzing data fields (1)-(7) database identify one infections associated treatment location historical time period based least one frequency infections/contamination, geographic clustering infections/contamination, and/or phage usage data; generating selected list phage included phage formulation. uses formulations described.',\n",
              " 'bacteriophage selection breedinga method selectively breeding bacteriophages comprises incubating phage obtained natural sources bacterial host, removing host cells plating phages bacterial lawn, assessing plaques isolating phage plaques showing greatest activity, culturing isolated phage host bacteria adding viricidal medium remove free phage, plating viricidally-treated culture onto host bacterial lawn, identifying selecting plaques showing virulent phage activity. methods described use genetic manipulation techniques. viricidal medium preferably comprises pomegranate rind extract, iron salt (preferably ferrous sulphate), polysorbate surfactant (preferably tween (rtm) 20). method modifying phage host sensitivity disclosed, phages incubated one chelating agent (such edta), detergent (preferably tween (rtm) 20), lantibiotic nisin a, enzyme lysozyme and/or cell wall-destroying agent.',\n",
              " 'sequence specific dna recombination eukaryotic cellsa method sequence-specific recombination dna eukaryotic cells, comprising introducing first dna comprising attb, attp, attl attr, comprising introducing second dna comprising attb, attp, attl attr performing sequence specific recombination bacteriophage lambda integrase int.',\n",
              " 'method sterilizing object comprising gold nanorod home electronic products employing methoda method sterilizing object comprising gold nano-rod home electronic products employing method provided perform sterilization efficiently using light harmful human. method sterilizing object comprising gold nano-rod includes irradiating light wavelength absorbed gold nano-rod gold nano-rod, includes steps of: applying gold nano-rod material solid phase sterilized; irradiating light wavelength absorbed gold nano-rod material solid phage coated gold nano-rod. gold nano-rod contained material solid phase permeated light. material solid phase consists silicone, metal, glass polymer.',\n",
              " 'fusobacterium bacteriophage uses thereofa method treating disease associated fusobacterium nucleatum infection subject need thereof disclosed. method comprises administering subject therapeutically effective amount least one isolated bacteriophage capable infecting fusobacterium nucleatum bacterial species, wherein said least one bacteriophage genomic nucleic acid sequence least 85 % identical nucleic acid sequence set forth seq id nos: 1-7 15-20. compositions treating disease disclosed.',\n",
              " 'composition comprising amino acid polymers bioactive agent method preparing thereofa method treating, reducing preventing bacterial infection wound, method comprising: applying film wound, film including biodegradable polymer bacteriophages dispersed therein, wherein polymer poly (ester amide urea).',\n",
              " 'composition comprising amino acid polymers bioactive agent method preparing thereofa method treating, reducing preventing bacterial infection wound, method comprising: applying film wound, film including biodegradable polymer bacteriophages dispersed therein, wherein polymer poly (ester amide urea).',\n",
              " 'methodology detection, enumeration, propagation manipulation bacteriophagesa method propagate, enumerate quantify bacteriophage(s) water sample aqueous sample designed contains ingredients stimulate growth select bacterial species susceptible infection specific bacteriophage(s), interfering background organisms either inhibited inconsequential. important features medium include oxidation-reduction compounds producing colored and/or fluorescent products, chromogenic and/or fluorogenic enzyme substrates, temperature-independent gelling agent(s). preferred combination growth medium containing 2,3,5-triphenyl tetrazolium chloride, 5-bromo-4-chloro-3-indolyl-b-d-galactoside, appropriate gelling agents, (when properly used) produces dark red bacterial lawn containing teal blue-green, irregularly circular spots representing individual phage plaque, discernible eye visible light. procedure readily applied towards automatic counting systems artificial illumination. procedure employed water samples elution buffers retain bacteriophages suspension following contact buffer foods, soils, hard surfaces solids may contaminated bacteriophages.',\n",
              " 'method determining order food product cultureda method, process, computer program determining order food product successively cultured set bacterial cultures process producing fermented food product, bacterial culture set bacterial cultures including least one bacterial strain, wherein set bacterial cultures comprises first subset one bacterial cultures comprising one unknown bacterial strain, second subset one bacterial cultures comprising one known bacterial strains, wherein bacterial strains second subset known; wherein process carried initial order set bacterial cultures; wherein culturing bacterial culture first subset process sample collected, wherein culture sample bacterial culture second subset exposed collected process samples order determine bacteriophage sensitivities one bacterial cultures second subset bacteriophages present collected process sample, wherein adapted order set bacterial cultures determined based determined bacteriophage sensitivities reduce common bacteriophage sensitivities successive bacterial cultures.',\n",
              " 'rotation scheme bacterial cultures food product fermentationa method, system computer program selecting consecutive bacterial cultures culturing food product process producing fermented food product, method comprising steps of: culturing food product first bacterial culture comprising least one bacterial strain; isolating sample culturing first bacterial culture; determining least one value indicative number bacteriophages sample, e.g. using pcr, plaque assay, ph; selecting second bacterial culture culturing food product value larger predetermined threshold, wherein second bacterial culture comprises least one bacterial strain, wherein second bacterial culture differs first bacterial culture, wherein sensitivities first second bacterial culture bacteriophages sample known wherein second bacterial culture selected reduce common bacteriophage sensitivities first second bacterial culture, culturing food product second bacterial culture.',\n",
              " 'particulate labelsa methodology bioassays diagnostics particulate label (ranging size nm-scale molecular assemblages organisms scale tens hundreds microns), as, limited to, nanoparticles, bacteria, bacteriophage, daphnia, magnetic particles, serve carriers analytes bound molecular recognition elements antibodies, aptamers, etc. described methodology generally applicable pathogen assays molecular diagnostics leads enhanced sensitivity convenience use.',\n",
              " 'microarray kit diagnosing cmt1aa microarray kit diagnosis cmt1a(charcot-marie-tooth neuropathy 1a) syndrome provided detect chromosome disorder resulting cmt1a syndrome, especially chromosome 17 dna duplication total human genomic dna rapidly accurately. microarray diagnosis cmt1a syndrome comprises least one probe selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-235, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, wherein content ratio repeated sequence nucleotide sequence probe 85%; nucleotide sequence probe single locus chromosome; probe produced inserting genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid, immobilized microarray concentration 2-100 pg per spot; least two kinds probes immobilized per one spot. kit diagnosis cmt1a syndrome comprises microarray marker material-detecting tool, determines chromosome disorder testing sample reacting total genomic dna testing sample labeled first probe detectable marker material standard dna labeled second probe detectable marker material, measuring hybridization ratio testing sample dna standard dna, wherein first second marker materials independently radioactive isotope, fluorescent material, chemiluminescent enzyme.',\n",
              " \"microarray kit diagnosing down's syndromea microarray kit diagnosis syndrome provided analyze chromosome disorder total human genomic dna, improve rapidness accuracy diagnosis, diagnose health status subject examined. microarray diagnosis syndrome comprises least one probe selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-34 bac8_g15, bac11_l10, bac29_l21, bac36_d16, bac37_m17, bac42_o16, bac56_c18, bac65_n02, bac82_f19, bac88_n11, bac88_n19, bac96_c04, bac109_e20, bac117_h13, bac141_f01, bac145_k01, bac147_a13, bac182_i05, bac190_j11, bac203_b21, bac203_m13, bac207_b17, bac213_c09, bac1_c02, bac84_o06, bac88_n19, bac100_h22, bac155_l05, bac165_i10, bac166_i08, bac183_c22, bac46_a15, bac65_c07, bac136_d13, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, wherein content ratio repeated sequence nucleotide sequence probe 85%; nucleotide sequence probe single locus chromosome; probe produced inserting genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid, immobilized microarray concentration 2-100 pg per spot; least two kinds probes immobilized per one spot.\",\n",
              " 'microarray kit diagnosing hnpp diseasea microarray kit diagnosis hnpp(hereditary neuropathy liability pressure palsies) syndrome provided detect chromosome disorder, especially deletion chromosome 17p11.2 total human genomic dna resulting hnpp syndrome, rapidly accurately using immobilized probe specific hnpp syndrome. microarray diagnosis hnpp syndrome comprises least one probe selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-165 listed, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, wherein probe produced inserting genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid, immobilized microarray concentration 2-100 pg per spot, 85% content ratio repeated sequence nucleotide sequence; least two kinds probes immobilized per one spot; nucleotide sequence probe single locus chromosome. kit diagnosis hnpp syndrome comprises microarray marker material-detecting tool, determines chromosome disorder testing sample reacting total genomic dna testing sample labeled first probe detectable marker material standard dna labeled second probe detectable marker material, measuring hybridization ratio testing sample dna standard dna, wherein first second marker materials independently radioactive isotope, fluorescent material, chemiluminescent enzyme; kit determines (i) none chromosome disorder, (ii) increase chromosome (iii) deletion chromosome hybridization ratio testing dna (i) identical to, (ii) higher (iii) lower standard dna, respectively.',\n",
              " \"microarray kit diagnosing klinefelter's syndromea microarray kit diagnosis klinefelter syndrome provided detect chromosome disorder, especially sex chromosome disorder containing addition one x chromosome results klinefelter syndrome total human genomic dna rapidly accurately. microarray diagnosis klinefelter syndrome comprises least one probe selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-10 bac10-i08, bac52_l18, bac126_d02, bac147_n13, bac170_j12, bac194_k10, bac37_g04, bac41_i24, bac202_c09 bac220_p01, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, wherein content ratio repeated sequence nucleotide sequence probe 85%; nucleotide sequence probe single locus chromosome; probe produced inserting genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid, immobilized microarray concentration 2-100 pg per spot; least two kinds probes immobilized per one spot. kit diagnosis klinefelter syndrome comprises microarray marker material-detecting tool, determines chromosome disorder testing sample reacting total genomic dna testing sample labeled first probe detectable marker material standard dna labeled second probe detectable marker material, measuring hybridization ratio testing sample dna standard dna, wherein first second marker materials independently radioactive isotope, fluorescent material, chemiluminescent enzyme.\",\n",
              " 'microarray kit diagnosing miller-dieker syndromea microarray kit diagnosis miller-dieker syndrome provided detect chromosome disorder resulting miller-dieker syndrome, especially deletion chromosome 17p13.3 total human genomic dna, rapidly accurately using immobilized probe specific miller-dieker syndrome. microarray diagnosis miller-dieker syndrome comprises least one probe selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-137, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, wherein nucleotide sequence probe single locus chromosome; probe produced introducing genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid, 85% content ratio repeated sequence nucleotide sequence, immobilized microarray concentration 2-100 pg per spot; least one two kinds probes immobilized per one spot. kit diagnosis miller-dieker syndrome comprises microarray marker material-detecting tool, determines chromosome disorder testing sample reacting total genomic dna testing sample labeled first probe detectable marker material standard dna labeled second probe detectable marker material, measuring hybridization ratio testing sample dna standard dna, wherein kit determines (i) none chromosome disorder, (ii) increase chromosome (iii) deletion chromosome hybridization ratio testing dna (i) identical to, (ii) higher (iii) lower standard dna, respectively.',\n",
              " \"microarray kit diagnosing patau's syndromea microarray kit diagnosis patau syndrome provided easily diagnose health status subject examined identify disease specific chromosome disorder detecting chromosome disorder total human genomic dna resulting patau syndrome rapidly accurately. microarray diagnosis patau syndrome comprises least one probe selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-34 bac27_o11, bac123_j22, bac145_o09, bac155_b10, bac157_j18, bac199_l02, bac232_g07, bac235_d20, bac29_d09, bac29_k13, bac60_f12, bac63_i22, bac73_o17, bac77_m02, bac80_f19, bac84_e11, bac88_k22, bac91_o18, bac92_j05, bac96_a02, bac96_n17, bac97_a19, bac143_b05, bac147_i15, bac154_e21, bac166_a03, bac168_m20, bac171_b19, bac175_n19, bac193_h21, bac233_l22, bac29_c16, bac66_b10 bac122_p16, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, wherein content ratio repeated sequence nucleotide sequence probe 85%. nucleotide sequence probe single locus chromosome. probe produced inserting genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid, immobilized microarray concentration 2-100 pg per spot, least two kinds probes immobilized per one spot.\",\n",
              " 'microarray kit diagnosing rubinstein-taybi syndromea microarray kit diagnosis rubinstein-taybi syndrome provided detect chromosome disorder resulting rubinstein-taybi syndrome caused deletion chromosome 16p13.3 total human genomic dna rapidly accurately. microarray diagnosis rubinstein-taybi syndrome comprises least one probe immobilized therein selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-141, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, wherein probe 85% content ratio repeated sequence nucleotide sequence produced inserting genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid; concentration immobilized prove 2-100 pg per spot; least two kinds probes immobilized per one spot; nucleotide sequence probe single locus chromosome. kit diagnosis rubinstein-taybi syndrome comprises microarray marker material-detecting tool determines (i) none chromosome disorder, (ii) increase chromosome (iii) deletion chromosome hybridization ratio testing dna (i) identical to, (ii) higher (iii) lower standard dna, respectively.',\n",
              " 'microarray kit diagnosing rubinstein-taybi syndromea microarray kit diagnosis smith-magenis syndrome provided detect chromosome disorder caused interstitial deletion p11.2 region chromosome 17 total human genomic dna rapidly accurately. microarray diagnosis smith-magenis syndrome comprises least one probe (i) immobilized microarray concentration 2-100 pg per spot, (ii) selected (a) least one genomic dna fragment selected bac(bacterial artificial chromosome) dna nos. 1-165, (b) 20-100 bp oligonucleotide continuously positioned genomic dna fragment, (c) 100bp-10kbp cdna(complementary dna) derived genomic dna fragment, (d) complementary gene genomic dna fragment, oligonucleotide cdna, (iii) produced inserting genomic dna fragment vector selected bac, hac(human artificial chromosome), tac(transformation competent artificial chromosome), yac(yeast artificial chromosome), pac(p1-derived artificial chromosome), p1(phage) cosmid, (iv) 85% content ratio repeated sequence nucleotide sequence, wherein least two kinds probes immobilized per one spot; nucleotide sequence probe single locus chromosome.',\n",
              " \"microbe pesticidea microbe pesticide disclosed. microbe pesticide comprises bdellovibrio bacteriovorus powder, phage powder, oceanospirillales powder, hirsutella thompsonii fisher powder, chinaberry seeds, macleaya cordata, tobacco stems, sanqi flower, sichuan chinaberry bark, herba houttuyniae, herb named chinese characters 'layecao' inventor, synergist, nux vomica, camphor, anemone vitifolia, dalbergia hupeana, dandelion, lightyellow sophora root, common andrographis herb water. microbe pesticide adopts natural microbes microbe pesticide free side toxic effects crops microbe pesticide used killing pests, agricultural products eaten safely persons without safe toxic effects human body health, quality agricultural products significantly improved, microbe pesticide suitable large-scale popularization application.\",\n",
              " 'microfluidic platform concentration detection bacterial populations liquida microfluidic device concentrating detecting bacteria liquids, related methods described. device includes first filter chamber capturing bacteria performing incubations bacteria one reagents, second filter chamber capturing concentrating detectable material, little binding detectable material first filter. aspect, bacteria incubated growth media engineered phage cause bacteria produce enzyme. aspect, enzyme capture second filter chamber exposed substrate produce detectable signal.',\n",
              " 'regulated antigen delivery system (rads) comprising two origin replicationsa microorganism comprising regulated antigen delivery system (rads) described. rads comprises (a) vector comprising (1) site insertion gene encoding desired gene product (2) first origin replication (ori) conferring vector replication using dna polymerase iii (3) second ori conferring vector replication using dna polymerase i, wherein second ori operably linked first control sequence repressible first repressor wherein runaway vector comprise phage lysis gene; (b) gene encoding first repressor operably lined first activatible control sequence. preferably microorganism salmonella sp., vector plasmid, repressor laci c2 repressor desired gene product antigen. described vaccine immunization comprising attenuated derivative pathogenic bacterium microorganism use microorganism manufacture medicament delivering desired gene product vertebrate.',\n",
              " 'mimic antigen epitope her-2 composition comprise epitopea mimic antigen epitope (formula i) isolated screening phage display library. derivatives antigenic epitope immunogenic activity identified mutative modification research. peptides comprising epitope derivatives related compositions including proteins used vaccines inducing immune response her-2 prevent treat malignancies. prevent invention synthesized oligonucleotides encode peptides constructed expression vectors comprising oligonucleotides fusion nucleotides gene transferred cells. present invention provided methods pharmaceutical compositions oligonucleotides, vectors, cells treating malignancies.',\n",
              " 'polypeptide activity targeting intestine inflammation, use thereofa model animal inflammation small intestine prepared ischemic reperfusion. search peptide specifically adsorbing onto inflammation site intestine made conducting ex vivo panning using small intestine tissue collected model animal respect phage library displays peptide comprising randomly arranged seven amino acid residues surface particle. result, peptide capable causing phage particle specifically bind intestine inflammation found, sequence peptide found.',\n",
              " 'modified antibody comprising substitution mutation confers increased stabilitya modified antibody selectively binds specific target, antibody modified least one amino acid residue determines antigen binding selectivity/affinity characterised antibody molecule exhibits great stability unmodified parent antibody. mutation may variable heavy domain position vh71 comprises substitution smaller amino acid native residue. antibody molecule, eg scfv, diabody, may derived humanised hmfg-1 antibody raised cancer specific glycoprotein antigen, muc-1. conjugation antibody drugs, toxins, radionucleides, nucleases use fusion molecules pharmaceutical compositions treatment cancer, particularly adenocarcinoma, described. use antibody phage display system identify target molecules described. host cells vectors comprising nucleic acid figure 8, encoding mutated antibody, described.',\n",
              " 'modified bacteriophagea modified bacteriophage capable infecting target bacterium, bacteriophage comprises bacteriophage phi33 includes toxin gene encoding toxin protein toxic target bacteria; wherein bacteriophage lytic.',\n",
              " 'porea modified portal protein bacteriophage dna packaging motor, wherein modified portal protein capable direct insertion membrane wherein portal protein modified compared wild type portal protein one amino acid residues outer surface portal protein substituted one amino acid residue, and/or wherein one amino acid residue inserted outer surface portal protein alter outer surface hydrophobicity modified portal protein compared wild type portal protein.',\n",
              " 'nasally-administered vaccinesa molecular complex comprising bacteriophage displaying peptide targets nasal-associated lymphoid tissue (nalt) antigen use vaccine intranasal administration. gene encoding antigen inserted coat protein phage. claimed method selecting phage comprising peptide targets nalt.',\n",
              " 'chimeric phage tail proteins uses thereofa multi-protein pyocin-like structure derived bacteriophage bacteriocin includes chimeric tail fiber protein receptor binding domain capable recognizing lipid a. multiprotein pyocin-like structure, derived bacteriophage bacteriocin includes chimeric tail fiber capable recognizing binding murnac-l-ala-d-glu. phage including chimeric tail fiber binds lipid a. plasmid encoding chimeric ail fiber binds murnac-l-ala-d-glu. plasmid encoding chimeric tail fiber binds lipid a. chimeric bacteriocin bacteriophage derived tail fiber includes amino terminal human bactericidal/permeability-increasing protein (bpintd)- chimeric bacteriophage bacteriocin derived tail fiber includes binding domain encoding mammalian nod2ctd- antibacterial agent includes bacteriocidal/permeability-increasing protein receptor domain binds lipid a. antibacterial agent includes nod2 carboxyl-terminus receptor domain binds murnac-l-ala-d-glu.',\n",
              " 'application bacteriophages transplantationa new application bacteriophages preparation pharmaceuticals administration patients undergoing transplantation and/or invoke immunosuppression revealed.',\n",
              " 'new lytic phage specific klebsiella pneumoniaea new lytic phage specific klebsiella pneumoniae, deposited number: bcrc 970052, strong infectious lytic effects vivo vitro klebsiella pneumoniae selected taiwan area.',\n",
              " 'methods apparatus whole cell panninga new method apparatus whole cell panning employs homegenous populations cells separated membrane(s) permeable phage/phagemid particles.',\n",
              " 'rna ligase bacteriophage rm 378a novel bacteriophage rm 378 rhodothermus marinus, nucleic acids genome, nucleic acids comprising nucleotide sequences open reading frames (orfs) genome, polypeptides encoded nucleic acids, described.',\n",
              " 'circular dna molecule conditional origin replication, method preparing use thereof gene therapya novel circular dna molecule (i), useful gene therapy, comprises >= 1 sequence interest, replication controlled origin replication (ori) plasmid bacteriophage, active host cell presence one specific proteins foreign cell.',\n",
              " 'conformation type peptide library based insect alexins, constitute method applicationa novel conformational peptide library random phage display uses fragment terminal c insect phylacin basic protein skeleton. random region introduced configure random peptide library simple two-class structure. used protein engineering research developing novel medicines vaccines.',\n",
              " 'scattering interference correlation spectroscopy (sics)a novel fluctuation spectroscopy technique based interferometry described. technique, termed scattering interference correlation spectroscopy (sics), autocorrelates signal forward scattered transmitted laser light nanoparticles (nps) solution. sics two important features: firstly, unlabeled nps known refractive index, analyses diffusion coefficient, effective cross-section concentration, single measurement. secondly, combined fluorescence correlation spectroscopy (fcs) simultaneous analysis labeled unlabeled nps. sics demonstrated unlabeled m13 phages unlabeled nps 210 nm 26 nm diameter. shown combination sics fcs determine fraction fluorescent nps mixture, estimate kd single binding measurement.',\n",
              " 'new inducible vector system coryneform bacteriaa novel induced expression system provided usefully used effectively expressing green fluorescence protein(gfp) coryne-form bacteria corynebacterium glutamicum corynebacterium ammoniagenes. promoter induced expression obtained linking bacteriophage lambda(ol1) promoter nucleotide sequence described seq id : no. 27(cj1) derived corynebacterium ammoniagenes nucleotide sequence described seq id : no. 1(cj10g), wherein induced expression protein achieved increasing temperature. shuttle vector able reproduced escherichia coli corynebacterium genus bacteria includes promoter induced expression. transformant microorganism selected group consisting escherichia, brevibacterium, corynebacterium, serattia providentia genera, includes shuttle vector.',\n",
              " 'novel cell target peptidea novel cell target peptide provided induce absorption macromolecular materials mucosal immune response passing cell mucous membrane small intestine without passage epithelia cell layer small intestine, peptide useful improvement absorption efficiency oral vaccines biomembrane. vitro phage display method comprises steps of: forming phage display peptide library; establishing vitro cell model; screening cell target peptides; analyzing vitro phage transcytosis; identifying peptide sequence screened cell target peptides; retesting cell target candidate peptides; selecting cell target peptide amino acid sequence cksthplsc. oral vaccine transfer system contains cell target peptide capable passing cell mucous membrane small intestine.',\n",
              " 'method detecting endotoxina novel method detecting endotoxin described. sample containing endotoxins contacted surface coated endotoxin binding substance. p12 bacteriophage tail proteins incubated endotoxin immobilised surface. p12 bacteriophage tail proteins detected means spectroscopic methods, enzyme-linked immunosorbent assay (elisa), chemical enzymatic detection reaction endotoxins cleaved-of endotoxin components, means capacitance measurements.',\n",
              " 'peptide protein capable binding lipid lps, dna coding peptide protein, utilizing peptide protein, lps adsorbent lps poison neutralizera novel peptide protein capable binding lipid lps, highly safe obtained low cost; dna coding peptide protein; utilizing peptide protein, lps adsorbent lps poison neutralizer. screening carried accordance phage display method use lipid lps target substance thereby identify amino acid sequence peptide capable binding lipid lps dna coding amino acid sequence. peptides amino acid sequence thus obtained seq id nos. 1 6 amino acid sequences resulting modification, amino acid residue substitution, insertion and/or deletion amino acid sequences performed without detriment capability binding lipid easily produced chemical synthesis. example, lps adsorbent obtained immobilizing peptides support. lps poison neutralizer obtained containing peptides active ingredient.',\n",
              " \"pseudo-rabies virus proteina novel recombinant dna molecule comprises dna sequence coding polypeptide displaying pseudorabies virus (prv) glycoprotein gp50, gp63 gi immunogenicity, dna sequence operatively linked expression control sequence. prv genomic dna derived prv rice strain isolated cytoplasm prv-infected vero cells (atcc ccl 81). genomic dna fragmented sonication cloned lambda gt11 produce lambda/prv recombinant (lambda prv) dna library. antisera screening lambda prv library produced inoculating mice proteins isolated cells infected prv (infected cell proteins icp's) segregated according size sds gels isolating antibodies. lambda prv phages screened plated lawn e.coli foreign dna's inserted unique cloning site 3' end lacz gene proper orientation reading frame produce, expression, polypeptides fused beta-galactosidase.\",\n",
              " 'phage-derived vectors methods protein expressiona novel system, including vectors, phage particles, host cells methods use, expressing one polypeptides interest prokaryotes described.',\n",
              " 'novel virus-like particle expression vector, construction method application thereofa novel virus-like particle expression vector ptmsca2c provided. firstly, apply gene mutation technique plasmid ptrchis-ms2, mutate fifth base 19mer pack site genetic sequence ms2 bacteriophage c obtain plasmid ptmsc; mutate amino acid corresponding start codon maturation protein coding ms2 bacteriophage plasmid ptmsc valine methionine, order obtain plasmid ptmsca; finally, apply gene cloning technique remove stop codon genetic coding sequence capsid protein wildtype ms2 bacteriophage, use form tandem array genetic coding sequence capsid protein his-tagged ms2 bacteriophage pseudo viral vector ptrcms, insert genetic sequences tandem plasmid ptmsca construct obtain expression vector ptmsca2c.',\n",
              " 'bacteriophage lysina nucleic acid comprising nucleotide sequence encoding lysin, nucleotide sequence comprises sequence shown seq idno. 1 variant, homologue derivative thereof. novel lysin obtainable bacteriophage capable colonising clostridium perfringens, use thereof medicament treatment disorder associated pathogenic clostridium bacteria, example.',\n",
              " 'baculovirus-based gene librariesa nucleotide molecule comprising selectable gene flanked anl1 anl2 attachment sites bacteriophage additionally comprising origin replication. used create baculovirus-based gene library.',\n",
              " 'bacteriophages useful therapy prophylaxis bacterial infectionsa panel bacteriophages comprising first vir mutant bacteriophage capable infecting lysing first strain bacteria, second vir mutant capable infecting lysing second strain bacteria. pharmaceutical composition including panel bacteriophages disclosed above. method identifying bacteriophage suitable killing bacterium obtaining sample bacterium patient site infected bacterium, identifying one phage sensitivity characteristics bacterium, comparing characteristics identification step known host range library bacteriophages, library bacteriophages including first vir mutant bacteriophage capable infecting lysing first strain bacteria, second vir mutant capable infecting lysing second strain bacteria, identifying one bacteriophages panel suitable killing bacterium.',\n",
              " 'peptides enhance transport across tissuesa peptide permits facilitates transport active agent human animal tissue. predetermined amount phage random phage library preselected phage library administered vivo s6itu site animal, gastro-intestinal tract. predetermined time, phage transported across tissue barrier harvested harvesting site separated site administration tissue barrier select transported phage. transported phage amplified host. cycle events repeated (using transported phage produced recent cycle) predetermined number times obtain selected phage library containing phage transported site administration harvesting site. identity least one peptide coded phage selected phage library determined identify peptide permits facilitates transport active agent human animal tissue.',\n",
              " 'permanent magnet synchronous excitation generatora permanent magnet synchronous excitation generator, magnetic steel distributed fixed according polarity 16 polars surface rotor core permanent magnet synchronous excitation generator, rotor core welded rotating shaft via front back stuffy board; 1,2,3 tooth disposed among grooves rotor core permanent magnet synchronous excitation generator winded centralization coil windings belong a,b,c three phages separately, 16 polars 8 pair polars, 8 pair coil windings, three-phase coil windings formed connectng them; winding rotor core containing centralization coil windings, front end embedded installation mouth generator front end cover, front back rotor core rotating shaft covered bearings, fromt bearing disposed bearing chamber front end cover, back bearing disposed bearing chamber back end cover, front back end covers fixed tightly pin screws. invention features high efficieny, high turning frequency width accuracy, great improvement every frequencies pressure drop generator.',\n",
              " 'evaluation different delivery strategies therapeutic applications klebsiella pneumoniae phages burn wound modela phage cocktail composition comprises five different strains bacteriophages alongwith phosphotidylcholine (pc), tween 80 stearylamaine.',\n",
              " 'phage dispensing systema phage dispensing method, phage dispensing apparatus phage dispensing system configured dispense phage prescription. dose calculation performed using patient weight, target phage dose, titer phage vial contaminant level phage vial determine dispensing set associated dispensing volumes phage vials stored phage storage apparatus. storage locations dose preparation instructions including respective dispensing volumes provided pharmacist verification vials performed check correct vials removed phage storage apparatus.',\n",
              " 'phage dispensing systema phage dispensing system comprises user interface, phage treatment computing system, phage laboratory, phage dispensing apparatus, including dispensing kiosk. user interface allowsa treating physician request testing patient sample phage laboratory identify phage mixture treatment. phage computing system arranges shipping sample provision identified phage mixture treatment dispensing apparatus located near patient. dispensing apparatus stock phage vials used prepare dispense doses identified phage mixture treatment.',\n",
              " 'randomized humanized antibody libraries engineered sequence insert diversitya phage display library formed plurality recombinant phages; plurality recombinant phages comprising m13-derived expression vector; m13-derived expression vector comprising polynucleotide sequence encoding randomized peptide, wherein randomized peptide variable region human igg1 heavy chain; randomized peptide expressed absence immunoglobulin light chain protein outer surface recombinant phage phage display antibody library; protein product expressed recombinant phage phage display antibody library fuses human immunoglobulin constant region form full human igg1 heavy chain molecule. phage display library utilized identify candidate antibodies bind receptor axl receptors.',\n",
              " 'single-domain antigen-binding antibody fragments derived llama antibodiesa phage display library variable heavy domain (vhh vh) fragments (sdab fragments) derived antibody repertoire non-immunized llama disclosed. sdab fragments library characterized absence cysteine residues complementarity determining regions (cdrs) low presence residues glutamic acid, arginine glycine positions 44, 45 47, respectively, vl interface variable heavy domain vhh. large size library (in order 109) makes source antigen-binding fragments high affinity almost antigen interest. library preferably generated using modified fd-tet phage growing plaques absence tetracycline.',\n",
              " 'phage display method detecting low molecule target materiala phage display method according present invention fixed substrate high binding force even low molecular weight target material poor binding force substrate, excellent binding force target phage phage-peptide library, excellent selectivity precision.',\n",
              " 'phage display systema phage display system provided comprising mutant phage-infected host cell adapted express peptide interest fused phage capsid protein, wherein mutant phage includes nonsense mutation prevents expression capsid protein functional protein, wherein expression peptide interest controlled inducible repressor suppressor suppresses nonsense mutation.',\n",
              " 'phage display vector application thereofa phage display vector comprises ampicillin resistance gene open reading frame containing phage capsid protein p6 gene, wherein exogenous gene inserted downstream phage capsid protein p6 gene open reading frame, upstream phage capsid protein p6 gene connected protein secretion signal peptide gene, upstream open reading framecontains promoter sequence ribosome binding site, e-tag arranged phage capsid protein p6 gene exogenous gene, downstream exogenous gene histidinetag, c-myc tag gene amber codon. exogenous gene antibody gene, protein gene polypeptide gene, anti-hiv virus antibody gene, anti-influenza virus antibody gene like. protein gene gene various enzymes, polypeptide gene gene antimicrobial polypeptide gene physiologically functional polypeptide.',\n",
              " 'phage staphylococcus aureus application thereofa phage staphylococcus aureus, preservation number cctcc m2011409, effective splitting effect staphylococcus aureus; storage condition phage filtered degermed, phage culture solution stored two months 4 deg c, stored two years glycerin tube 70 deg c zero; concentration stored phage culture solution 1011pfu/ml; application phage staphylococcus aureus, phage culture solution directly sprayed surface solid food mixed bacteria-containing food inhibit staphylococcus aureus food. dosage phage bacteria-containing material 0.0001pfu/cfu 100pfu/cfu. phage effectively control contamination staphylococcus aureus food system, relative antibiotics chemical preservatives, phage characteristics high specificity, residues safety.',\n",
              " 'novel 88 phage vectorsa phage genome engineered include novel restriction site one two different positions. first embodiment, restriction site inserted phage genome end gene iv mos hairpin serves phage packaging signal newly synthesized single strands phage dna. second embodiment, restriction site inserted phage genome mos hairpin prior minus strand origin. phage genome modified contain new restriction site, vector engineered \"88\" vector inserting new restriction site nucleotide sequence encoding least functional domain pviii least first cloning site receiving gene encoding polypeptide displayed and, optionally second cloning site receiving displayed. particularly useful embodiments, novel vectors engineered produce phage particles display antibodies.',\n",
              " 'novel 33 phage vectorsa phage genome engineered include novel restriction site one two different positions. first embodiment, restriction site inserted phage genome end gene iv mos hairpin serves phage packaging signal newly synthesized single strands phage dna. second embodiment, restriction site inserted phage genome mos hairpin prior minus strand origin. phage genome modified contain new restriction site, vector engineered \"33\" vector inserting new restriction site nucleotide sequence encoding least functional domain piii least first cloning site receiving gene encoding polypeptide displayed and, optionally second cloning site receiving second gene encoding polypeptide capable dimerizing polypeptide displayed. particularly useful embodiments, novel vectors engineered produce phage particles display antibodies.',\n",
              " 'novel 33 phage vectorsa phage genome engineered include novel restriction site one two different positions. first embodiment, restriction site inserted phage genome end gene iv mos hairpin serves phage packaging signal newly synthesized single strands phage dna. second embodiment, restriction site inserted phage genome mos hairpin prior minus strand origin. phage genome modified contain new restriction site, vector engineered \"33\" vector inserting new restriction site nucleotide sequence encoding least functional domain piii least first cloning site receiving gene encoding polypeptide displayed and, optionally second cloning site receiving second gene encoding polypeptide capable dimerizing polypeptide displayed. particularly useful embodiments, novel vectors engineered produce phage particles display antibodies.',\n",
              " 'novel 33 phage vectorsa phage genome engineered include novel restriction site one two different positions. first embodiment, restriction site inserted phage genome end gene iv mos hairpin serves phage packaging signal newly synthesized single strands phage dna. second embodiment, restriction site inserted phage genome mos hairpin prior minus strand origin. phage genome modified contain new restriction site, vector engineered \"33\" vector inserting new restriction site nucleotide sequence encoding least functional domain piii least first cloning site receiving gene encoding polypeptide displayed and, optionally second cloning site receiving second gene encoding polypeptide capable dimerizing polypeptide displayed. particularly useful embodiments, novel vectors engineered produce phage particles display antibodies.',\n",
              " 'phage application thereofa phage phage-hy19 separated farm environment, characteristic wide host range main pathogen etec-k88ac causing animal diarrhea phage product nontoxic, sothe phage safely used preventing treating animal diarrhea, used specifically crack etec-k88acin order avoid etec-k88ac evolution drug-resistant strains caused use antibiotics avoided, used killing breeding environment keeping foods fresh.',\n",
              " 'pathogenic escherichia coli phage oral preparation preparation method thereofa phage phage-hy19 strong cracking effect pathogenic escherichia coli etec-k88ac separated farm environment, processed oral preparation, oral preparation thecharacteristic wide host range main pathogen etec-k88ac causing animal diarrhea, phage product nontoxic, phase product safely applied prevention treatment animal diarrhea; etec-k88ac specifically cracked phage, etec-k88ac evolution drug-resistant strains caused use process antibiotics avoided.',\n",
              " 'detection phage amplification sers nanoparticlesa phage specific antibody presenting particle, devices methods related detection phage amplification provided.',\n",
              " 'pathogen detection sers nanoparticlesa phage specific antibody presenting particle, devices methods related detection phage amplification provided. specifically, described herein compositions methods detecting listeria bacteria using antibody recognized a511 anti-listeria phage, wherein antibody conjugated nanoparticle detected surface-enhanced raman scattering (sers).',\n",
              " 'phage-based limulus amoebocyte lysate assay rapid detection bacteriaa phage-based limulus amoebocyte lysate (lal) assay able detect low levels viable bacteria water vegetable samples described.',\n",
              " 'pharmaceutical composition based bacteriophages f. nucleatum; use treatment diseases associated pathogena pharmaceutical composition comprising: a) effective amount one lytic bacteriophages specific fusobacterium nucleatum selected fnpφ02-14, fnpφ11 fnnφ107 mixtures them; b) one pharmaceutically acceptable carrier and/or excipients. method preventing and/or treating diseases associated fusobacterium nucleatum use pharmaceutical composition treating disease associated fusobacterium nucleatum oral cavity periodontal disease, among others.',\n",
              " 'polyclonal antibody composition treating allergya pharmaceutical composition treating allergy described. composition comprises active ingredient recombinant polyclonal antibody mixture different monoclonal antibodies capable reacting binding allergen together one pharmaceutically acceptable excipients. composition may used topically solution, dispersion, powder, form microspheres. polyclonal antibody preferably recombinant polyclonal antibody produced phage display technology. pairing specific immunoglobulin variable region light chain heavy chain maintained original polyclonal immune response selected panning using allergen question preferably maintained bulk transfer pairs expression vector.',\n",
              " \"virus-like particle compositions methods using samea pharmaceutical composition includes preparation virus-like particles (vlps) obtained gastrointestinal tract subject pharmaceutically-acceptable carrier. vlps include bacteriophages, eukaryotic viruses, gene transfer agents. vlp composition may administered subject having, risk dysbiosis, amount effective ameliorate least one symptom clinical sign dysbiosis. vlp composition may administered subject preparation administering source bacteria, improve receptivity subject's gut source bacteria.\",\n",
              " 'podoviridae bacteriophage killing activity specific staphylococcus aureusa podoviridae bacteriophage provided specifically kill staphylococcus aureus, useful therapeutic agent preventing treating infectious disease caused staphylococcus aureus, antibiotic, cosmetic antibiotics, antiseptic disinfectant. podoviridae bacteriophage(kctc 11154bp) killing activity specific staphylococcus aureus, gene nucleotide sequence seq id no:1. pharmaceutical composition preventing treating infectious disease caused staphylococcus aureus comprises podoviridae bacteriophage(kctc 11154bp).',\n",
              " 'nano-antibody capable binding sftsv application thereofa polypeptide capable binding sftsv, comprising 3 complementarity determining regions (cdrs) 1-3, cdr1 sequence comprising one sequences shown seq id nos: 1-74, cdr2 sequence comprising one sequences shown seq id nos: 75-151, cdr3 sequence comprising one sequences shown seq id nos: 152-232. means preparation gn protein, immunization two-humped camel, use phage library display platform technology nano-monoclonal antibodies, etc., nano-antibody vhh specifically binds gn screened, cdr sequence thereof identified, humanized antibody snb constructed; addition, humanized mouse model used evaluate efficacy snb treatment sftsv infection. present solution provides potential novel nano-antibody drugs clinical treatment sfts, provides corresponding detection kits diagnosis sfts.',\n",
              " \"novel allergen diagnostic method ectoparasite infestationa polypeptide derived louse parasitic, preferably bovicola ovis, provokes humoral and/or cellular immunological response, allergen designated bo1 amino acid sequence seq id no:2. nucleic acid comprises nucleotide sequence seq id no:1. antibodies phage display molecules bind polypeptide uses ligands antigen present ectoparasite's faeces diagnosing ectoparasite infestation animal described. described vaccines prevent reduce bo1 hypersensitivity, methods treating preventing non-human animals exhibiting allergic hypersensitivity bo1 polypeptide test kits methods assaying samples presence ligands bind bo1. (62) divided 504096\",\n",
              " 'preparation method polypeptide inhibiting gelatin enzyme activity applicationa polypeptide m204c4 suppressing activity gelatinase (mmp-2) composed amino acid sequence shown hnwtrwllhpdrgggs disclosed. suppress invasion transfer external pancreas cancer cells panc01 cfpac-1. preparing process includes steps affinity screening reproduction bacteriophage several times obtain bacteriophage specific binding mmp-2, coating, cloning monoclonal screening fluorescent screening reagent kit.',\n",
              " 'polypeptide inhibiting gelatin enzyme activity preparation method applicationa polypeptide m205c4 suppressing activity gelatinase (mmp-2) composed amino acid sequence shown hnwtrwllhpdrgggs disclosed. suppress invasion transfer external pancreas cancer cells panc01 cfpac-1. preparing process includes steps affinity screening reproduction bacteriophage several times obtain bacteriophage specific binding mmp-2, coating, cloning monoclonal screening fluorescent screening reagent kit.',\n",
              " 'method apparatus determining level microorganisms using bacteriophagea predetermined amount parent bacteriophage capable infecting target microorganism added sample create bacteriophage-exposed sample; sample incubated defined incubation time assayed determine level bacteriophage bacterial marker sample; measured marker level increased, initial concentration microorganism exceeds specific threshold value. antibiotic different concentrations added different separate portions sample tested determine bacteriophage marker present thereby determine minimum inhibitory concentration (mic) given antibiotic. antibiotic preferably antibiotic inhibits dna replication protein synthesis.',\n",
              " 'probe combination detection cancera probe combination detecting cancer includes one sets partial hepatitis b virus (hbv) targeting probes. sequences sets partial hbv targeting probes aligned,an overall sequence aligned set probes matches reference sequence genome hbv genotype direct repeat (dr) region genome. aligned set probes, probes overlap one two adjacent probes portion length probe. probe combination may includes one sets hotspot gene targeting probes targeting cancer hotspotgenes ctnnb1, tert, tp53 genes, one sets exogenous gene targeting probes targeting portions lambda phage genome, endogenous gene targeting probes targeting endogenous genes gapdh gdx genes.',\n",
              " 'preparation peptide mixtures protease catalysis designed provide useful biological physical propertiesa process preparing unique peptide mixtures broad range uses using combinations natural non-natural amino acid alkyl ester monomers specific combinations monomers dimers, trimers higher oligomers selected large group structural motifs lead useful physical and/or biological properties may identified solid state peptide synthesis, isolation peptides natural sources, production peptides recombinant dna methods, identification peptides recombinant methods phage display, method peptide synthesis comprising a) admixing one natural non-natural amino acid alkyl ester monomer, dimer, trimer higher oligomers one proteases reaction medium; b) heating mixture 5° c. 90° c. 5 minutes 24 hours; c) recovering formed oligopeptide.',\n",
              " 'staged bacteriophage remediation target bacteriaa process remediation target bacteria, particularly sulfur reducing bacteria (srb), waters (“target water”) multiplicity diverse host target bacteria employing serial staged bacteria culturing lysing dominant bacteria. remediation sulfur reducing bacteria (srb) effected application series bacteriophage isolated staged culturing bacteriophage lysing successive aliquots waters containing multiplicity srb.',\n",
              " 'process separation prokaryotic dna eukaryotic dna whole blood samplea process separating prokaryotic dna eukaryotic dna whole blood sample infected pathogen provided. process includes extracting prokaryotic eukaryotic dna whole blood sample, contacting prokaryotic dna whole blood sample motif specifically binds prokaryotic dna, generating bound pair. process includes separating bound pair. whole blood sample transfected bacteriophages genetically modified contain defined dna sequence selectable marker dna. dna sequence integrates prokaryotic dna, motif oligonucleotide specific defined dna sequence engineered bacteriophages.',\n",
              " 'processes preparation highly pure plasmid compositions enzymatic digestion colanic acida process purification plasmid dna, process comprising treating aqueous composition containing plasmid dna polypeptide obtained nst1 phage digest colanic acid separating plasmid dna treated aqueous composition.',\n",
              " 'viral-based antimicrobial agent use ethanol productiona process controlling unwanted microorganism contamination fermentation mash form ethanol, particularly control lactobacilli contamination, achieved adding viral agents adapted destroy deactivate lactobacilli and/or selected microorganisms. amount viral agents added sufficient amount keep presence undesired microorganisms, particularly lactic acid bacteria family particularly lactobacilli, level 5 times 106 viable cells per milliliter mash, example level 1 times 106 viable cells per milliliter mash, fermentation. treatment may include bacteriophages one stabilizers trehalose, sucrose, maltose, glycerol, divalent alkaline earth metal salt, salts gluconic acid.',\n",
              " 'medicinal preparation form antistaphylococcal phage lysate, process preparation usea process production medicinal product form antistaphylococcal phage lysate, including following successive steps: revival bacterial strain, passaging bacterial strain, preparation cell sub-cultures, preparation phage starter via double-layer agar method, preparation phage starter liquid medium, preparation bacterial suspension, preparation phage lysate, filtration phage lysate lysate mixture, filling filtered lysate lysate mixture vials, lyophilisation lysate lysate mixture vials; whereas final medicinal product lyophilized powder preparation solution (lyophilisate) produced via sterile filtration lyophilisation mixture antistaphylococcal phage lysate containing active phage particles polyvalent staphylococcal bacteriophage. medicinal product local use contains high-potent virulent phage particles polyvalent effect.',\n",
              " 'peptide antagonists inhibiting heat shock protein (hsp 16.3) mycobacterium tuberculosisa process identify peptide antagonists hsp16.3, chaperon protein necessary survival mycobacterium tuberculosis dormant phase described. affinity selection 7-mer 12-mer random peptide libraries displayed bacteriophage m13 performed using recombinant hsp16.3 template two peptide phage clones, bind hsp16.3 protein identified. synthetic peptides corresponding peptide sequences displayed phage clones able specifically bind inhibit chaperone function hsp16.3 vitro dose dependent manner. corresponding inhibitory effect peptides chaperon activity alphab-crystallin, constituent human eye lens homologue hsp16.3, found substantially less. peptide inhibitors, similar inhibitors generated process described, specifically target hsp16.3, used lead compounds obtain better therapeutics latent tuberculosis.',\n",
              " 'treating & preventing microbial infectionsa programmable nuclease use method durable treating microbial infection subject. infection caused microbes first species strain. nuclease programmed cut target site within genome microbes, thereby durably killing reducing growth proliferation microbes. method comprises reducing infection 100 fold least 60 minutes exposing subject nuclease. subject immunosuppressant medication. method comprise use rna complexes nuclease target nuclease target site. infection vaginosis, meningitis, pneumonia, urinary tract infection, cystitis, nephritis, gastroenteritis, skin infection, impetigo, erysipelas, cellulitis, septicaemia sepsis. subject cancer patient. nuclease cas nuclease, meganuclease, talen, zinc finger nuclease. aspects invention viruses, phages, phagemids, compositions, vectors, viriophages, plasmids transposons comprising copy nucleic acid encoding nuclease. aspect crispr/cas system comprising nuclease guide rna. microbes e. coli (e.g., ehec), c. difficile, klebsiella, pseudomonas bacteria.',\n",
              " 'expression systema protein expression system use prokaryotic host provided, expression system comprising: a) expression cassette comprising nucleic acid sequence encoding protein interest operably linked t7 rna polymerase-dependent promoter; b) expression cassette comprising nucleic acid sequence encoding t7 rna polymerase operably linked host polymerase-dependent λ phage promoter single perfect palindrome operator sequence; wherein expression cassette t7 rna polymerase located chromosome host cell.',\n",
              " 'phi 15 dna polymerasea purified recombinant dna polymerase high processivity strand-displacement activity. isolated nucleic acid encodes bacteriophage dna polymerase. kit method amplifying dna disclosed.',\n",
              " 'methods evaluation bacteriophage preparationa quality assurance/quality control paradigm bacteriophage provided.',\n",
              " 'rapid simplified developing antibodies fabs molecules consisting amino acids recognizing natural antigens non-natural molecular targets using special blocking agenta rapid simplified method developing antibodies monoclonal antigen-recognizing polypeptides comprised amino acids (polypeptides capable forming complexes targeted antigens, comprised natural non-natural molecular targets), using bioparticle display library approach, bioparticle bioparticle display library containing gene coding polypeptide capable multiplying presence particular multiplication limiting factor. polypeptide-carrying bioparticle insulated complex mixture similar bioparticles bioparticle display library using first blocking agent, said blocking agent consisting bioparticle strain lacks resistant multiplication limiting factor (for example phage display library multiplication limiting factor antibiotic, blocking agent phage strain lacks resistance particular antibiotic).',\n",
              " 'production recombinant protein pap 31 diagnosis prevention bartonella bacilliformis infectiona recombinant dna polypeptide sequence immuno-dominant phage particle associated protein bartonella bacilliformis. recombinant protein easily produced permitting conduct accurate rapid diagnositic assays detection b. bacilliformis infection reduced reagent equipment requirements required currently available methods diagnosis. dna polypeptide sequence useful vaccine preparations b. bacilliformis.',\n",
              " 'recombinant double-stranded rna phage, use samea recombinant double stranded rna (dsrna) phage expresses dsrna-encoded genes eukaryote cells. recombinant dsrna phage useful expression dsrna expression cassettes encoding passenger genes, as, restricted to, vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense rnas, catalytic rnas eukaryotic cells tissues. methods provided deliver recombinant dsrna phage eukaryotic cells tissues, either direct administration, formulated lipid polylactide-coglycolide, utilizing bacterial vaccine vector.',\n",
              " 'bioreporter detection microbesa recombinant phage system developed rapid detection bacteria, particularly fecal coliform indicator bacteria. systems invention link phage infection events quorum sensing signal molecule biosynthesis bioluminescent bioreporter induction, facilitating detection pathogens may present low numbers. phage-based systems invention maintain specificity pathogen still producing significant signal amplification sensitive quantitative detection. systems require combination sample phage bioreporter organisms; extraneous addition substrates user intervention kind necessary, making approach significantly less technical standard molecular immunological methods.',\n",
              " 'recombinant plasmid dna pspaa(tr) coding surface spaa antigen erysipelothrix rhusiopathiaea recombinant plasmid dna pspaa(tr) coding surface spaa antigen erysipelothrix rhusiopathiae contains fragment spaa gene gram-positive erysipelothrix rhusiopathiae, regulatory elements expression target protein (t7/lac promoter t7 terminator), ori – site origin replication coiei plasmids, selective marker – kan gene kanamycin resistance, ori fl – site origin replication fl phage providing synthesis recombinant protein spaa erysipelothrix rhusiopathie upon transformation cells escherichia coli strain b121 (de3).',\n",
              " 'human mini-antibody cytotoxic tumor cells express erbb2 receptora recombinant single chain anti-erbb2 antibody human origin able inhibit growth cells expressing erbb2 receptor; nucleotide sequences encoding recombinant antibody; vector bacteriophage comprising nucleotide sequences; pharmaceutical composition comprising antibody; use composition preparation anti-proliferative anti-tumor drugs; process preparation bacteriophage.',\n",
              " 'reporter mycobacteriophage, assays methods comprising reporter mycobacteriophagea reporter mycobacteriophage comprising heterologous nucleic acid comprising promoter-reporter construct encoding promotor operably linked nucleotide sequence encoding fusion protein, wherein fusion protein comprises luciferase protein linked fluorescent protein. methods utilizing reporter mycobacteriophage detection viable target microbe sample, screening test substance treatment tuberculosis, detecting drug-resistant mycobacterium subject provided.',\n",
              " 'bacteriophage compositions treatment bacterial infectionsa respirable composition treatment bacterial infection includes one active bacteriophages combination pharmaceutically acceptable respirable carrier. composition includes carbohydrate carrier, prepared fine powder. another aspect, bacteriophages provided liquid carrier administration nebulization. one aspect, bacteriophages anti-bacterial activity one species strains burkholderia cepacia complex (bcc) bacteria. invention relates use bcc bacteriophage treat bcc infection, particular individual suffering cystic fibrosis.',\n",
              " 'sequence natural synthetic retroelements enabling nucleotide sequence insertion eukaryotic cella retroviral vector eliminates cis-acting retroviral elements, useful may cause problems for, integrated provirus utilizes recombination system, bacteriophage p1 cre-lox recombination system. gene interest loxp site inserted long terminal repeat, duplicated. enzyme cre inserted long terminal repeats combines them. structure resulting provirus host genome single, long terminal repeat carrying single copy gene interest. following infection, retrovirus produces proviral structures single long terminal repeat.',\n",
              " 'method apparatus identification microorganisms using bacteriophagea sample tested presence bacteria, automatic blood culturing apparatus. bacteria determined present, bacteriophage-based bacteria identification process performed identify bacteria present. plurality bacteria detection processes, blood culture test gram stain test may carried prior bacteria identification process. bacteriophage-based antibiotic resistance test antibiotic susceptibility test conducted sample.',\n",
              " 'preservation phage concentration clinical samplesa simple method kit preserving clinical specimens biological samples, particularly purpose preserving concentration bacteriophage and/or bacteria present sample, described. method involves rapidly lowering temperature sample (e.g. freezing) temperature -50°c lower (especially -78°c) presence suitable cryoprotectant (e.g. 20% glycerol). one application, method used clinical samples (e.g. urine) taken patient undergoing phage therapy bacterial infection, wherein method permits samples transported and/or stored following collection viability phage and/or bacteria present maintained inhibiting potential interactions phage bacteria. thawing samples, samples may analyzed phage and/or bacterial concentration provide information effectiveness phage therapy.',\n",
              " 'scfv antibody fragments grp78 used cancer treatmenta single chain variable fragment (scfv) antibody glucose-regulated protein 78 (grp78, bip) provided. antibody fragment may used diagnosis cancer tumour cells, upregulated response increased nitric oxide synthase activity higher concentrations. anti-grp78 fragment may used treatment cancer, possibly combination another radiotherapeutic chemotherapeutic etoposide. particular antibody defined amino acid seqid no:i dna seqid no: 2 provided. antibody fragments isolated phage libraries recombinant grp78 protein. treatment cells antibody abolished no-mediated cytoprotection increased apoptosis prostate cancer colon cancer cell lines, enhanced combination etoposide.',\n",
              " 'human monoclonal antibodies block invasion duffy binding protein plasmodium vivax human erythrocyte using antibody phage displaya single chain variable fragment(scfv) recombinant antibody provided able inhibit binding duffy receptor erythrocyte duffy binding protein(dbp), thereby utilized developing therapeutic agent vaccine plasmodium vivax. scfv recombinant antibody includes nucleotide sequence light-chain variable portion one kind selected seq id : nos. 9, 10 11 heavy-chain variable portion one kind selected seq id : nos. 12, 13 14, specifically bound dbp antigen plasmodium vivax merozoite. recombinant antibody characterized encoded nucleotide sequence described seq id : no. 21, 22 23.',\n",
              " \"apparatus method targeted biodetection using phage carrying single electron transistora single electron transistor conjugated bacteriophage form detectable probe rf signal identify location probe site specific biological matrix provide unique electronic signal coulomb staircase signal act diagnostic beacon probe detector form mesoscopic detector. detector uses: bioprobe containing phage conjugated set properties phage specificity; phage mobility within biological environment phage ability act carrier set; set's ultimate use beacon detection.\",\n",
              " 'parathyroid hormone related protein antagonistsa single-chain triple-stranded alpha-helical coiled coil polypeptide binds parathyroid hormone related protein (pthrp) act antagonist it. pthrp-binding \"alpha-body\" may used treatment cancer, hypercalcemia associated cancer cancer metastasis. nucleic acids encoding said alpha-bodies, host cells comprising said nucleic acids, well pharmaceutical compositions comprising said alpha-bodies provided. alpha-bodies preferably selected phage display coiled-coil scaffold.',\n",
              " 'strain bacteria streptococcus thermophilus, used production bacterial preparations fermented milk products functional actiona strain bacteria streptococcus thermophilus imb b-7179 used production bacterial preparations fermented milk products functional action, characterized number probiotic properties: resistance products human alimentary system metabolism, adhesiveness, expressed antagonistic action wide range pathogenic opportunistic microorganisms, high cholesterase activity. strain streptococcus thermophilus imb b-7179 phage-resistant, moderate energy acid formation milk, forms clots high viscosity. strain enables prepare fermented milk products functional action.',\n",
              " 'modified streptococcus bacteriuma streptococcus bacterium auxotrophic least one amino acid normally present milk, normally present low concentrations. bacterium preferably dependent upon one glutamine, tryptophan proline, capable growing production medium containing one amino acids upon dependent. bacterium may reduced susceptibility bacteriophage multiplication, preferably streptococcus thermophilus. starter cultures comprising bacterium disclosed, methods preparing starter cultures comprising admixing bacterium dairy medium milk provided. bacterium invention may used decontamination equipment contaminated bacteriphage.',\n",
              " 'surface acoustic wave biosensor employing analog front end dna encoded libraries improved limit detection (lod) exemplary apparatus samea surface acoustic wave (saw) performs rapid, label-free detection biological species. biosensing detection multiple analytes multiplexed array sensing lanes configured enable bio-amplification using engineered dna encoded libraries probe phage display procedure enhance specificity, capture statistics detection, screening analyzing analyte vitro. biochemical formulation minimizes limit detection (lod) threshold magnitude order femtomolar concentration. additional enhancement apparatus achieved use analog front end amplify biochemical events.',\n",
              " 'process preparation synergistic herbal preparation extracts picrorhiza kurroa glycyrrhiza glabra medicinal valuea synergistic herbal preparation extracts picrorhiza kurroa royle close species family picrorhiza scrophulariflora pennel neopicrorhiza scrophulariiflora, glycyrrhiza glabra medicinal values antiviral immune boosting activity dna virus -bacteriophage pi 300 mug/ml plaque reduction assay',\n",
              " 'cancer stem cell targeting peptide use thereofa synthetic peptide targets cancer stem cells provided. peptide consists amino acid sequence anyone seq id no: 1 seq id no: 15. provided composition comprising said synthetic peptide therapeutic agent fused thereto, pharmaceutically acceptable carrier diluent. provided method screening peptide specifically targeting cancer stem cell. method comprises steps establishing oligopeptide library using phage expression system, contacting library culture bulk tumor cells cancer cell line, contacting phages bind bulk tumor cells culture cancer stem cells said cancer cell line, screening peptide specifically targeting cancer stem cell phages bind cancer stem cells.',\n",
              " 'cancer stem cell targeting peptide use thereofa synthetic peptide targets cancer stem cells provided. peptide consists amino acid sequence anyone seq id no: 1 seq id no: 15. provided composition comprising said synthetic peptide therapeutic agent fused thereto, pharmaceutically acceptable carrier diluent. provided method screening peptide specifically targeting cancer stem cell. method comprises steps establishing oligopeptide library using phage expression system, contacting library culture bulk tumor cells cancer cell line, contacting phages bind bulk tumor cells culture cancer stem cells said cancer cell line, screening peptide specifically targeting cancer stem cell phages bind cancer stem cells.',\n",
              " 'bacteriophage treatment reducing preventing bacterial contaminationa system method reducing preventing bacterial contamination food includes application bacteriophage treatment type food product stage processing food product. bacteriophage treatment may applied non-food surfaces water systems, may susceptible bacterial contamination subsequent spread bacteria. bacteriophage treatment comprises least one bacteriophage concentration sufficient reduce prevent bacterial contamination pathogenic bacteria and/or spoilage bacteria. embodiments, bacteriophage able reduce eliminate bacteria introduced food product bacteriophage treatment applied food product. embodiments, bacteriophage treatment includes buffering agent maintain bacteriophage ph level sustains bacteriophage. embodiments, bacteriophage treatment includes surfactant and/or thickener aid applying bacteriophage. additional adjuvants enhancers may used embodiments stabilize bacteriophage enhance performance antibacterial agent.',\n",
              " 'systems method electrophoretic fractionation microbiomea system methods characterizing population virus, bacteriophage, microbes microbiome includes steps separating sample microbiota one fraction continuous capillary zone electrophoresis based physiochemical properties microbes microbiota using constant voltage applied sample continuous zone electrophoresis. least one separated fraction includes intact virus, bacteriophage, microbe may visualized and/or directly sequenced characterize population virus, bacteriophage, microbe microbiome.',\n",
              " 'automatic phagograma system measuring sensitivity bacterium plurality phages, system comprising: microwell plate comprising plurality wells, said plurality wells configured contain one plurality phages, wherein said microwell plate configured sample comprising said bacterium dispensed said plurality wells; least one reagent and/or additive, configured added mixtures said sample comprising said bacterium phage said plurality phages; control unit configured interpret present results measurements form phagogram, said measurements provided least one analytical device, said least one analytical device configured measure interaction said plurality phages said bacterium. invention relates corresponding method use same.',\n",
              " 'methods compositions identifying peptide intermolecular interaction target interesta system recombinant bacteriophage library target interest complex, wherein recombinant bacteriophage peptide library includes plurality peptides expressed surface recombinant bacteriophages wherein recombinant bacteriophage includes (a) pill protein; wherein pill protein includes (b) peptide polypeptide involved intermolecular interaction, differs least one amino acid peptides polypeptides library; (c) modified protease cleavage site proximal peptide, wherein modified protease cleavage site bacteriophage, modified cleavage site reduced binding affinity protease, compared non-modified cleavage site, wherein target interest complex includes protease, flexible linker attached protease, target interest attached flexible linker, wherein target interest participates intermolecular interaction.',\n",
              " 'carrier construction methoda carrier higher ta cloning efficiency includes gene sequence pblue script ii sk(-), colei ori sequence pblue script ii sk (-), flori sequence pblue script ii sk(-), lacz gene sequence pblue script iisk (-), t3 bacteriophage promoter sequence pblue script ii sk (-), t7 bacteriophage promoter sequence pblue script ii sk(-), two polycloning site sequences ends. process preparing carrier disclosed.',\n",
              " 't4 bacteriophage teaching demonstration modela t4 bacteriophage teaching demonstration model comprises head portion, support pedestal, iron wires, iron nails spring. t4 bacteriophage teaching demonstration model solves abstractness hard understanding problem previous teaching process, vividly demonstrate structure t4 bacteriophage, help students better understand t4 bacteriophage, simple structure convenient carry.',\n",
              " 'bacteriophage t4 nanoparticles eukaryotic deliverya t4 nanoparticle non-infectious, tail-less variant t4 bacteriophage. one embodiment, eukaryotic cells labeled dyed t4 nanoparticles, wherein dyed t4 nanoparticle comprises least 350 dye molecules covalently bound thereto. another embodiment, t4 nanoparticles used deliver exogenous dna eukaryotic cells protein expression therein. contemplated t4 nanoparticles may used deliver exogenous material eukaryotic cells.',\n",
              " 't7 bacteriophage display fabsa t7 bacteriophage vector displays fab fragments disclosed. host cells methods making bacteriophage described.',\n",
              " 'high-affinity target peptidyl ligands tumor biomarker, grp-78, screening method thereofa target peptidyl ligands revealed. peptidyl ligands high-affinity. peptidyl ligands tumor biomarker, grp-78. phage display libraries coordinated panning used screening peptidyl ligands. peptidyl ligands labeled fluorescent substance laser used probes tumors.',\n",
              " 'drug delivery nanocarriers targeted landscape phagea targeted drug delivery nanocarrier method forming disclosed herein. targeted drug delivery nanocarrier includes plurality amphipathic molecules forming carrier particle plurality drug molecules contained therein. targeted landscape phage protein assembly complexed carrier particle preferably using unique method disclosed herein. targeted landscape phage protein assembly displays binding peptide selected specifically selectively bind target site. method forming targeted drug delivery nanocarriers includes steps obtaining plurality bacteriophage displaying binding peptide desired target site, treating bacteriophage denaturing agent, mixing treated bacteriophage plurality carrier particles purifying mixture obtain plurality targeted drug delivery nanocarriers.',\n",
              " 'technique orienting binding phage bacteria detectiona technique orienting binding head end phage substrate disclosed. tail end phage thereby made readily available bacteria sensing.',\n",
              " 'use phage displaying peptide adhesion protein treating disease associated intracellular formation protein fibrillar inclusions aggregatesa therapeutic agent carries peptide sequence containing mammalian cell adhesion sequence used inhibit treat diseases associated intracellular formation protein fibrillar inclusions aggregates, inhibit intracellular formation protein fibrillar inclusions aggregates, disaggregate pre-formed intracellular protein fibrillar inclusions aggregates. filamentous bacteriophage displays non-filamentous bacteriophage rgd cell adhesion sequence surface, antibody non-filamentous bacteriophage antigen said rgd cell adhesion sequence, preferred embodiment therapeutic agent.',\n",
              " 'therapy prophylaxis klebsiella pneumoniae infections lytic bacteriophage specifically k. pneumoniaea therapy prophylaxis k. pneumoniae infections lytic bacteriophage specifically k. pneumoniae, provides lytic bacteriophage (dsm 24329) k. pneumoniae infected organism sake relieving serious complications liver abscesses bacteremia, high mortality rate k. pneumoniae infections taiwan.',\n",
              " 'methods vaccination using icosahedral phagea transdermal membrane comprising non-infectious icosahedral phage vaccine displaying antigen described wherein membrane stable room temperature greater 3 months uses thereof vaccinate subject antigen.',\n",
              " 'transformation method actinoplanes teichomyceticus conjugal transfera transformation method actinoplanes teichomyceticus using vector containing bacteriophage c31 att/int system provided improve transformation rate. method transforming conjugal transfer actinoplanes teichomyceticus comprises: step inducing vector e.coli et12567/puz8002 culturing strain produce 1.2î 10^8 donor; step culturing actinoplanes teichomyceticus atcc31121 medium collecting 1î 10^5 receptor; step mixing donor receptor.',\n",
              " 'novel tricistronic vectors uses therefora tricistronic vector (i.e., vector capable expressing three exogenous genet, fused together, control one promoter) effectively encode immunoglobulin-presenting polypeptide two immunoglobulin (ig) polypeptides. encoded ig-presenting polypeptide able associate least one ig polypeptides via co-expressed associating agents. vector according present invention particularly suited phage display technology, e.g., ig-presenting polypeptide phage coat protein ig polypeptides associate form fab.',\n",
              " 'triple vector expressing antibody molecules full therapeutic formata triple expression vector disclosed expressing antibody molecule comprising fc domain prokaryotic cells eukaryotic cells. triple expression vector comprises polynucleotide encoding fc domain; polynucleotide encoding phage coat protein; cloning site cloning genes encoding antibody molecule part thereof wherein antibody molecule part thereof comprise fc domain; prokaryotic secretion signal sequence eukaryotic secretion signal sequence, secretion signal sequence drives efficient secretion prokaryotic eukaryotic cells; promoter mediating expression eukaryotic cells; stop codon preventing expression phage coat protein eukaryotic cells. triple expression vector used expressing antibody molecule phage display format; producing antibody molecule prokaryotic cell, example periplasm prokaryotic cell; producing antibody molecule eukaryotic cell, example mammalian cell, particularly human cell. antibody molecule contains fc domain, may example vhh-fc molecule scfv-fc molecule vh-fc vl-fc. phage display libraries produced vector present antibody molecule therapeutic format. use vector avoids need repeated cloning moving one expression medium another.',\n",
              " 'phage displayed cell binding peptidesa tryptophan cage binding domain polypeptide containing part amino acid sequence aaadx<sub>1</sub>yx<sub>2</sub>qwlx<sub>3</sub>x<sub>4</sub>x<sub>5</sub>gpx<sub>6</sub>sgrpppx<sub>7 </sub>(seq id no: 4), wherein x<sub>n </sub>represents amino acid found position n, polypeptide comprising tryptophan cage (trp cage). cell binding domain polypeptide amino acid sequence produced phage display.',\n",
              " 'temporal traumatic brain injury biomarkers methods use thereofa unique pipeline employed biomarker discovery entailed domain antibody phage display, next generation sequencing analysis, nanotechnology strategies generate antibody mimetics disclosed. disclosed temporal biomarkers traumatic brain injury methods use. embodiments, temporal biomarkers synthetic peptides comprising hcdr3 sequences identified using disclosed pipeline. aspects, synthetic peptides less 30 amino acid residues comprise biotin scaffold linked hcdr3 sequences.',\n",
              " 'use tail fiber protein prevention acinetobacter baumannii infectionsa use tail fiber protein prevention acinetobacter baumannii infections disclosed. tail fiber protein bacteriophages coated sprayed carriers (such pipelines medical devices hospitals) inhibit biofilm formation acinetobacter baumannii prevent acinetobacter baumannii infections.',\n",
              " 'functional proteomics using double phage display screeninga use identifying protein double phage screening.',\n",
              " 'schistosoma recombinant fusion protein vaccinea vaccine eliciting immunity schistosoma parasites, comprises recombinant fusion protein capable comprising 27/28 kda cercarial elastase sequence ofs. mansoni active fragment, homologue variant thereof, fused suitable bacterial, phage viral protein, together pharmaceutically acceptable excipient carrier. vaccine used combat s. mansoni, s. japonicum and/or s. haematobium mammals, especially humans.',\n",
              " 'vibrio parahaemolyticus phage separation methoda vibrio parahaemolyticus phage separation method provided invention comprises steps culture medium reagent treatment, water sample treatment, phage enrichment phage separation.through observation, large transparent spots appear double-layer flat plate, thereby proving vibrio parahaemolyticus phage successfully separated out. method beneficial effects phage separation quicker accurate, experiment period short, experiment operation requirement high, phage separation success rate greatly improved, themethod quite high practical applicability application prospect.',\n",
              " 'waterless toilet system fece-urine separation, odor vermin seal, thermal biological disinfection, gas ozonationa waterless toilet system fece urine separation, odor vermin seal, thermal biological disinfection, gas ozonation includes system components. feces urine kept separate ridge separating urine bowl fece chute. seat forms temporary seal platform, lid forms temporary seal seat closed. rest components sealed keep vermin outside odors inside, exception gas vent hose screened opening. biological disinfection achieved phage focused human pathogens. thermal disinfection human pathogens achieved insulating fece receptacle containing metabolic heat. air toilet ozonated electrical discharges hand operated device.',\n",
              " 'skin care wipes comprising added natural antibacterial agentsa wet wipe product including fibrous porous substrate material combined aqueous personal care lotion, lotion including preservative added bacteriophage composition, methods making same, disclosed. bacteriophage composition may include one bacteriophages selected effective one respective bacteria strains.',\n",
              " 'differential phage capture proteomicsabstract disclosure disclosed herein methods identifying, isolating comparing proteins biomolecules differing two complex biological samples using affinity chromatography phage display techniques. 3224244_1 (ghmatter) p49917.au.2',\n",
              " 'method isolation soluble polypeptidesabstract polypeptides desirable biophysical properties solubility, stability, high expression, monomericity, binding specificity non-aggregation, including monomeric human vhs vls, identified using high throughput method screening polypeptides, comprising steps obtaining phage display library, allowing infection bacterial lawn library phage, identifying phage form larger average plaques bacterial lawn. sequences monomeric human vhs vls identified, may useful immunotherapy diagnostic agents. multimer complexes human vhs vls identified. vhs vls identified may used create libraries identifying additional polypeptides. further, vhs vls may subjected dna shuffling select improved biophysical properties.',\n",
              " 'anti-bacteria compositionsabstract invention relates anti-bacterial compositions comprising bacteriophage (phage) sufficiently high concentrations induce lysis without bacteria. uses compositions disclosed. phage and/or p68 especially preferred.',\n",
              " 'anti-bacteria compositionsabstract invention relates anti-bacterial compositions comprising bacteriophage (phage) sufficiently high concentrations induce lysis without bacteria. uses compositions disclosed. phage and/or p68 especially preferred.',\n",
              " 'phage display fmd particle preparation method vaccineabstract present invention belongs field veterinary biological products discloses fmd (foot-and-mouth disease) particle phage display technique preparation method vaccine. phage display fmd particles either type phage display fmd particles type 0 phage display fmd particles. type phage display fmd particles consist structural protein vp1 type fmd virus combined phage capsid, type 0 phage display fmd particles consist structural protein vp1 type 0 fmd virus combined phage capsid. stable structure, phage foot-and-mouth disease particle invention composed structural protein vp1 foot-and-mouth disease virus phage. temperature stability acid-base environment stability increased, prepared foot-and-mouth disease phage particle quickly induce production specific antibody, prolong duration immunity, reduce production cost usage adjuvant.',\n",
              " 'method producing polypeptide displayed phage display system conjugated molecular scaffoldabstract present invention relates method producing polypeptide displayed phage display system conjugated molecular scaffold. method comprises following steps: (a) combining polypeptides displayed phage display system purification resin phage display system bound resin treating bound phage display system reducing agent; (b) exposing bound phage display system molecular scaffold; (c) removing unreacted molecular scaffold bound phage display system; (d) eluting phage display system purification resin thereby producing polypeptide displayed phage display system conjugated molecular scaffold. date recue/date received 2020-06-01',\n",
              " \"composition comprising amyloid beta 1-6 peptide coupled virus-like particle adjuvantabstract present invention relates compositions comprising construct comprising ap1-6 peptide pharmaceutically acceptable adjuvant, treatment patients suffering dementia, particular dementia alzheimer's type. one embodiment, construct containing ap1-6 peptide consists virus-like particle (vlp) rna bacteriophage qp chemically coupled said ap1-6 peptide.\",\n",
              " \"native phage enrichment combat bacterial proliferation critical non-food-contact surface areas food industriesabstract: phage therapy applied means selective phage introduction desired spot. unfortunately, successful phage treatment wastewater bacterial pathogens dependent prevalence diversity pathogen species within wastewater microbial community structure vary substantially processing sites. therefore, attempt enrich native phages selective bacteria present respective industry combat pathogenic bacterial proliferation. effluent treated using mf contain none bacteria, fungi protozoan's contains phages. therefore, treated water circulated infect bacteria proliferating drainage system used hosing down/dripping floor prewashing utensils. approach actually increases effectiveness increase time exponential manner high degree safety associated phage treatment suggests low risk-to-benefit ratio uv treatment kill bacteria facilitates conversion lysogenic lytic phages. thus, phage left lysogenic normal operation.\",\n",
              " 'phage-based method detecting biomarkersaccording example aspect present invention, provided method determining presence biomarker disease pretreated biological sample comprising steps diluting sample, contacting sample europium label, terbium label samarium label, dye, contacting sample phage, incubating sample, measuring luminescence emission intensity absorption emission intensity, determining presence biomarker based measurement luminescence emission intensity absorption emission intensity.',\n",
              " 'specific single-chain antibody resisting canine pancreatic lipase, plasmid vector methodaccording anti-canine pancreatic lipase specific single-chain antibody, plasmid vector method, recombinant protein provided, amino acid sequence recombinant protein formed repeatedly connecting two dominant epitopes canine pancreatic lipase series, amino acid sequence recombinant protein converted corresponding nucleotide sequence adopting escherichia coli preferred codons; nucleotide sequence chemically synthesized, recombinant expression vector constructed, expression quantity recombinant protein escherichia coli improved. invention relates phage library established immunizing mice recombinant protein, corresponding cpl single-chain antibody scfv sequence obtained panning screening, complete mouse igg antibody sequence expression vector constructed obtained scfv sequence, monoclonal antibody expression monoclonal antibody purification transient hek293f cells, optimal monoclonal antibody pairing combination determined immunofluorescence orthogonal experiment.',\n",
              " 'semi-synthetic antibody fragment combinatorial libraryaccording invention provided semi-synthetic antibody fragment combinatorial library based avian immunoglobulin genes. avian immunoglobulin genes poultry chicken immunoglobulin genes. antibodies single chain antibody fragments library displayed large phages. least third complementarity determining region (cdr 3) variable (v) domain heavy (h) chains antibody fragments replaced synthetically randomised peptides. synthetically randomised variable heavy (vh) regions paired natural repertoire avian vh regions defined light chains, arrangement combinatorial diversity contributed variable light (vl) vh regions natural vh repertoire avian vh regions adds diversity.',\n",
              " 'fully-humanized anti-human interleukin 17a single-chain antibodyaccording present invention, constructing great-capacity natural phage antibody library, single-chain antibody specific affinity il-17a obtained biological elutriation. antibody inhibit reaction il-17a il-6 released human fibrosarcoma cell ht1080 used detecting treating rheumatoid arthritis.',\n",
              " 'enterocyte-transcytotic, tissue target cell target peptide identified phage display process drug delivery systems using sameaccording present invention, peptide specific amino acid sequence identified using phage display technique vitro phage display technique, grouped basis similarity sequence meaningful sequence selected statistical analysis grouped peptide sequence group, binding motif extracted means selected meaning sequence thereafter generalized amino acid sequence extracted means extracted binding motif. also, according present invention, peptide introduced protein group ligand vaccine efficiently, efficient drug delivery system designed absorption efficiency biological membrane significantly increased. also, optimized delivery system designed behavior drug body controlled means tissue target type peptide. accordingly, present invention increases use possibility protein drug vaccine great ripple effect medicine, pharmacy, livestock farming veterinary fields.',\n",
              " 'cancer treatment novel technology cellular molecule nuclear fission mode-regulation technologyactive carbon fiber (acf) controlling pin novel biotechnology urgently demanded current cancer treating. acf controlling pin technology irrefutable confirms special function anti-cancer medicine capturing virus biological neutrons thus treating cancers. medicine positive active effect protecting normal cells. therefore, medicine effective special anti-cancer treatment medicine. bio-energetic era, acf controlling pin technology provide significant contributions virus cancer treatments. according characteristic active carbon fiber (acf) absorb neutrons, controlling rods inserted cancer cells. adjustment depth controlling rods, cancer cell fission reaction speeds controlled. controlling pin designed cubic lattice. without actions controlling rods, cancer cells subjected self-sustaining chain reaction. therefore, human-controllable cell nuclear fission started controllable phage chain reaction. scheme utilizing active carbon fiber (acf) controlling pin cubic lattice capturing virus biological neutrons, human canceration conquered.',\n",
              " 'methods preventing adhesions following laminectomies surgical proceduresadhesions scar formation following surgical procedure controlled providing human recombinant phage antibody, introducing antibody onto area body following procedure inhibit adhesions, scar formation. according one embodiment, antibody used prevent formation scar tissue following spinal surgery. may carried placing antibody dura lining spinal nerves spinal cord. alternatively, antibody may used inhibit adhesions following abdominal surgery, placed around great vessels following anterior approach spine regions. importantly, antibody may used inhibit adhesion formation adjacent areas growth factors used stimulate healing. invention may include step protecting growth factors and/or area body stimulated healing desired antibodies growth factors. option, medications therapeutic substances may added antibody(ies) enhance healing effectiveness.',\n",
              " 'aggregation induced emission-bacteriophage bioconjugatesaggregation-induced emission-bacteriophage bioconjugate including bacteriophage covalently bonded least one aggregation-induced emission luminogen via optional linker, pharmaceutical compositions including same, methods preparation use thereof.',\n",
              " 'bacteriophages control bacterial speck diseaseagricultural compositions disclosed comprise least one isolated bacteriophage capable infecting plant pathogen pseudomonas syringae pv. tomato, least one bacteriophage genomic nucleic acid sequence least 85 % identical one nucleic acid sequence set forth seq id nos: 1-23. composition comprises 10 different strains bacteriophage. uses thereof treating bacterial speck disease disclosed.',\n",
              " 'method positioning main allergen epitopes cow milkaiming cow milk alpha-lactalbumin, specific ige igg antibodies cow milk allergy patient subjected affinity purification serve target molecules, phage random peptide library subjected affinity panning, finally cow milk alpha-lactalbumin epitope positioned network server. according invention, bacteriophage display technology adopted, positive clone simulating epitope screened bacteriophage peptide library specific target molecule, allergen epitope positioned using bioinformatics method. compared traditional analysis method, novel analysis method many advantages, simple operate relatively low cost, easily screen mimic epitope retaining antigen reactivity, wide prospect application analyzing antigen epitope food protein.',\n",
              " 'composition comprising polymer bioactive agent method preparing thereofamino acid based polymers polymer blends. compositions comprising least one amino acid based polymer polymer blend, least one bioactive agent, optionally least one filler. additionally, compositions comprising least one bacteriophage least one salt buffer, which, example, form dry powder, methods preparing thereof disclosed.',\n",
              " 'compositions methods binding agglomeration proteinsamplibody compositions methods used interact agglomeration proteins disclosed herein. compositions herein comprise one dna rna molecules affinity least one agglomeration protein. nucleic acid component naturally non-naturally occuring molecule twenty ribonucleotide bases. rna, least one nucleotide sequence portion rna molecule affinity least one consensus sequence present agglomeration rna-binding protein. portion nucleotide sequence rna affinity agglomeration proteins sequence derived either rna virus, rna agglomeration proteins sequence derived either rna virus, rna phage, messenger rna (\"mrna\"), ribosomal rna (\"rrna), transfer rna (\"trna\"), sequence received template one rna dependent rna polymerases, combination thereof. methods disclosed herein directed towards detecting presence one agglomeration proteins sample matrix using amplibody compositions described herein.',\n",
              " 'active phage-based inks, methods printing materials phage-based bioactivean active phage bio-ink composition phage-based bioactive paper, wherein phage oriented immobilized paper surface heads, phage tail fibers free capture target bacterial pathogens.',\n",
              " 'rapid detection microorganisms using acyltransferase-labeled engineered bacteriophagean acyltransferase-labeled engineered bacteriophage kit developed invention directly analyze microorganisms environmental biological sample. acyltransferase-labeled engineered bacteriophage specifically recognize pathogenic microorganisms. engineered bacteriophage recognizes combined microorganisms, genetically engineered dna injected microorganisms recombine, express amplify large amount new bacteriophage acyltransferase protein microorganisms. recognition mechanism reaction kinetics engineered bacteriophage microbiological response material designed, action rule functional modules recognition responses rapid detection microbes instant analysis microorganisms investigated. references provided solving problems \"online\", \"portable\" \"automatic\" mechanical electrical engineering biology compounding microbial detection method.',\n",
              " 'modified adenovirus containing fiber replacement proteinan adenovirus modified replacing adenovirus fibre protein fibre replacement protein. fibre replacement protein comprises amino-terminal portion comprising adenoviral fibre tail domain associates penton base protein, chimeric fibre replacement protein provides trimerization function carboxy-terminal portion comprising targeting ligand. fibre replacement protein t4 bacteriophage fibritin protein. adenovirus may comprise therapeutic gene preferably herpes simplex virus thymidine kinase gene.',\n",
              " 'affinity carrier selective uptake / separation bacteriophages method selective uptake / separation bacteriophages capillary electrophoresisan affinity carrier designated selective uptake bacteriophages / separating them. carrier consisting substrate, surface substrate adhered cells least one bacterial strain. cells infected specific bacteriophages incubated, bacteriophages released cells. isolated separated, preferably capillary electrophoresis.',\n",
              " 'rapid detection microorganisms using aminopeptidase-labeled engineered bacteriophagean aminopeptidase-labeled engineered bacteriophage kit developed invention directly analyze microorganisms environmental biological sample. aminopeptidase-labeled engineered bacteriophage specifically recognize pathogenic microorganisms. engineered bacteriophage recognizes combined microorganisms, genetically engineered dna injected microorganisms recombine, express amplify large amount new bacteriophage aminopeptidase protein microorganisms. recognition mechanism reaction kinetics engineered bacteriophage microbiological response material designed, action rule functional modules recognition responses rapid detection microorganisms instant analysis microorganisms investigated. interaction relation functionalized bacteriophage microorganisms disclosed base researches order solve problems \"online\", \"portable\" \"automatic\" mechanical electrical engineering biology compounding microbial detection method.',\n",
              " 'agonist antibody heteroreceptoran animal immunized chain b chain receptor mrna extracted spleen cells animal. next, l-chain h-chain variable regions collected rt-pcr use primers corresponding variable regions including cdr. single-strand fv synthesized assembly pcr thus phage library constructed. next, antigen-binding antibody clones concentrated cloned panning. single-strand variable region inserted signal sequence animal cells ch1-hinge-ch2-ch3 prepare scfv-ch1-fc expression vector. transferring various combinations vector cells, antibodies expressed antibody clone showing ligand-like activity selected.',\n",
              " 'bacteriophage cocktail-containing hydrogel compositions methods production use thereofan anti-bacterial coating composition use medical implant disclosed. anti-bacterial coating composition includes bacteriophage cocktail encapsulated beads embedded within hydrogel. disclosed kits containing anti-bacterial coating composition well methods producing using coating composition.',\n",
              " 'anti-cd22 fully human antibody antigen binding fragment thereof, preparation method therefor, use thereofan anti-cd22 fully human antibody antigen binding fragment thereof, preparation method therefor use thereof. anti-cd22 antibody antigen binding fragment thereof screened fully human phage display library, formed means flexible linker peptide linking heavy chain variable region light chain variable region. framework region sequences complementarity determining region (cdr) sequences heavy chain variable region light chain variable region derived humans.',\n",
              " 'anti-hgf/sf humanized antibody method preparation thereofan anti-hgf/sf humanized antibody provided show low immunity side reaction binding affinity higher mother monoclonal antibody. method preparing using phage surface expression provided. anti-hgf/sf humanized antibody comprises heavy chain variable region amino acid sequence complementarity determining region(cdr), respectively, tyyms seq id : no. 1, yigtssgttyyansvkg seq id : no. 2, glgrinl seq id : no. 3; light chain variable region light chain variable region human antibody; heavy chain invariable region heavy chain invariable region human antibody; light chain invariable region light chain invariable region human antibody. dna encodes heavy variable region humanized antibody sequence seq id : no. 7, 11, 15 19. method preparing anti-hgf/sf humanized antibody comprises steps of: (a) preparing fab library including combination heavy chain variable region light chain variable region; (b) surface-expressing library phage. composition preventing treating cancer comprises humanized antibody.',\n",
              " 'antimicrobial protein derived podoviridae bacteriophage specific staphylococcus aureusan antimicrobial protein derived podoviridae bacteriophage specific staphylococcus aureus provided selectively kill staphylococcus aureus, thereby preventing treating infectious disease caused staphylococcus aureus. antimicrobial protein derived podoviridae bacteriophage(kctc 11154bp) specific staphylococcus aureus amino acid sequence seq id no:3. gene encoding antimicrobial protein nucleotide sequence seq id no:2. transformed escherichia coli(kctc 11152bp) over-expresses gene encoding antimicrobial protein.',\n",
              " 'packaged antimicrobial medical device method preparing samean antimicrobial suture assembly comprising containment compartment comprising one surfaces antimicrobial agent disposed thereon, said antimicrobial agent selected group consisting halogenated hydroxyl ethers, acyloxydiphenyl ethers, combinations thereof, amount sufficient substantially inhibit bacterial colonization said containment compartment; suture positioned within containment compartment, suture comprising one surfaces antimicrobial agent disposed thereon, said antimicrobial agent selected group consisting halogenated hydroxyl ethers, acyloxydiphenyl ethers, combinations thereof, least one active agent selected group consisting biocide, disinfectant, antiseptic, antibiotic, antimicrobial peptide, lytic bacteriophage, surfactant; adhesion blocker; oligonucleotide, efflux pump inhibitors; photosensitive dye, immune modulator chelator.',\n",
              " 'anti-pd-1 antibody, preparation method therefor use thereofan anti-pd-1 antibody molecule comprising variable region combination, nucleic acid molecule encoding antibody molecule, corresponding expression vector, host cell, method screening antibody using phage library, immunoconjugate, bis- poly-specific antibody molecule pharmaceutical composition comprising antibody molecule. antibody molecule coupled compound, conjugate, derivative composition thereof used treating cancer diseases infectious diseases. antibody molecule used detect pd-1.',\n",
              " 'surface-effect sensor formulationan area sensor chip (700) coating contains fiber bundles (622) including phage bioengineered interact target analyte. quartz crystal microbalance (qcm) surface acoustic wave (saw) sensing circuit, may connected integrated sensor chip (700), measures effects result interaction coating target analyte. spin coating spray coating may produce coating suitable qcm sam sensing techniques.',\n",
              " 'article storage bacteriophages method thereofan article, kit method. article includes composition comprising phage, gelling agent thickening agent, disaccharide, trisaccharide polysaccharide; nonwoven; wherein composition adsorbed onto nonwoven. kit includes article present disclosure; solid support; wherein article embedded solid support. method includes immobilizing composition comprising phage, gelling agent, disaccharide, trisaccharide polysaccharide onto nonwoven; wherein phage immobilized onto nonwoven stored room temperature 180 days, least 60% phages remain viable.',\n",
              " 'bacterial identification assay using bacteriophages colony growth measurementsan assay typing bacterial strains comprising: (a) providing isolated colony bacteria; (b) combining said isolated colony selected bacteriophage container, incubating medium containing nutrients required bacterial growth, enables phage/bacteria interaction; (c) determining extent bacterial growth compared control sample, comparing value obtained predetermined growth data known bacteria said bacteriophage, thereby identifying bacteria. method using said assay select bacteriophages work specific bacterial species covered.',\n",
              " 'preparation method gfp (green fluorescent protein) antibody gfp antibodyan embodiment invention provides preparation method gfp (green fluorescent protein) antibody gfp antibody. preparation method comprises steps follows: gerbu-lq mixed emulsified antigen serve immunogen, immunogen injected alpaca, wherein antigen gfp label; peripheral blood lymphocytes immunized alpaca extracted; phage library constructed peripheral blood lymphocytes; target phage screened phage library, wherein phage plasmid target phage contains gene segments gfp antibody; phage plasmid target phage expressed. method standardized batched whole antibody preparation process, prepared antibodies smalldifference batches high stability.',\n",
              " 'microencapsulation bacteriophages related productsan encapsulated bacteriophage formulation method encapsulating bacteriophages bacteriophage-related products polymeric microcapsules provided. embodiments method producing encapsulated bacteriophages involves water-in-oil-in-water double emulsion.',\n",
              " 'genetically encoded system constructing detecting biologically active agentsan engineered bacterial cell, comprising: bacterial two-hybrid system linking expression reporter protein production inhibitor protein phosphatase engineered bacterial cell; isoprenoid pathway producing inhibitor protein phosphatase. bacterial two-hybrid system may comprise one components encode: substrate recognition domain sh2 domain coupled dna-binding protein 434 phage ci repressor; substrate domain coupled subunit rna polymerase (rna polymerase omega); protein kinase (src); protein phosphatase; operon comprising: operator dna-binding protein; binding site rna polymerase; reporter gene encoding reporter protein. methods producing two-hybrid system claimed.',\n",
              " 'm13 phage based gene therapy platforman engineered phage-derived particle (pdp) expressing transgene target cell transduced bacteriophage, pdp includes (i) less 500 bp dna bacteriophage genome, (ii) itr-flanked therapeutic gene 20 kb, (iii) endosomal escape sequence, (iv) nuclear localization sequence, (v) cell-specific targeting moiety. pdp may escape lysosomal degradation, traffic across nuclear envelope expressed therapeutic gene mammalian cell.',\n",
              " 'igy purification methodan igy purification method comprises following steps: obtaining anti-igy nano antibody subjecting igy immunized two-humped camel phage display biocompatibility screening; fetching 2 to4 grams 4ff gel filler, washing 4ff gel filler dmso solutions volume ratios 20%, 50%, 70% sequence, washing 4ff gel filler water, drying; adding dmso, nabh4, naoh, epoxy chloropropane sequence obtain mixed filler; coupling nano antibody na2co3 solution mixed filler; coupling, adding glycine, using nacl solution wash column obtain affinity column coupled nano antibody, wherein volume ratio nacl solution column 10-20:1; adding igy sample, needs purified, intothe nano antibody affinity column carry coupling, coupling, washing column pbs; finally washing igy column using glycinate, neutralizing separated igy glycinate (ph=8) avoid situation igy inactivated acidic condition. provided method obtain high purity igy.',\n",
              " 'il-18-like peptide, fused peptide thereof, method producing use samean il-18-like peptide capable regulating/controlling interaction il-18, participates inflammation immune abnormality diseases atopic dermatitis, receptor; medicinal composition containing peptide active ingredient; physiological activity inhibitor. intended disclose method producing above-described il-18-like peptide comprises screening phage random peptide library use human anti-il-18 antibody. il-18-like peptide regulate/control interaction il-18, seemingly participates immune abnormality diseases atopic dermatitis, receptor useful il-18 activity inhibitor. thus, expected applicable various inflammatory diseases.',\n",
              " 'immunobiological agent form gel treating staphylococcus pyodermiaan immunobiological agent form gel treating staphylococcus pyodermia contains antistaphylococcus bacteriophage lytic activity least 10according appelman, carbomer constifuens, preserving agent, alkaline neutralizer, macrogol.',\n",
              " 'immunobiological composition form foam aerosol treating dermatological diseases infectious etiologyan immunobiological composition form foam aerosol treating dermatological diseases infectious etiology comprises aqueous solution bacteriophages preserving agent. mixture contains emulsifiers first second classes, vegetable oil propellant.',\n",
              " 'egfrviii immunogen methods using samean immunogen includes antigenic egfrviii peptide linked qβ bacteriophage virus-like particle (vlp) carrier. antigenic egfrviii peptide least 53%, least 61%, least 69%, least 76%, least 84%, least 92% sequence similarity amino acid similarity leekkgnyvvtdh (seq id no:1).',\n",
              " 'improved bacteriophage expression carrrieran improved expression carrier phen2 used screen phagemid single-chain antibody phage display method features enzyme severing site apal1 multiple enzyme severing sites removed replaced bssh ii, products coded light-chain gene human immunoglobulin effectively inserted single-chain antibody library ensure diversity high volume.',\n",
              " \"method simultaneous identification differentially expressed mrnas measurement relative concentrationsan improved method simultaneous sequence-specific identification mrnas mrna population allows visualization nearly every mrna expressed tissue distinct band gel whose intensity corresponds roughly concentration mrna. general, method comprises formation cdna using anchor primers fix 3'-endpoint, producing cloned inserts cdna vector containing bacteriophage-specific promoter subsequent rna synthesis, generating linearized fragments cloned inserts, preparing crna, transcribing cdna crna using set 5'-rt primers, performing pcr using 3'-pcr primer whose sequence derived vector set 5'-pcr primers derived 5'-rt primers used transcription cdna crna. method identify changes expression mrna associated administration drugs physiological pathological conditions.</ptext>\",\n",
              " 'method vitro synthesis short double stranded rnasan vitro transcription method using bacteriophage polymerases target sequence-specific single-stranded dna oligonucleotides templates disclosed. present invention finds particularly advantageous use synthesis short interfering rnas (sirnas) shown function key intermediates triggering sequence-specific rna degradation posttranscriptional gene silencing plants rna interference invertebrates vertebrate systems.',\n",
              " 'inorganic nanowiresan inorganic nanowire organic scaffold substantially removed inorganic nanowire, inorganic nanowire consisting essentially fused inorganic nanoparticles substantially free organic scaffold, methods making same. example, virus-based scaffold synthesis single crystal zns, cds free-standing l10 copt fept nanowires used, means modifying substrate specificity standard biological methods. peptides selected evolutionary screening process exhibit control composition, size, phase nanoparticle nucleation expressed highly ordered filamentous capsid m13 bacteriophage. incorporation specific, nucleating peptides generic scaffold m13 coat structure provide viable template directed synthesis variety materials including semiconducting magnetic materials. removal viral template via annealing promote oriented aggregation-based crystal growth, forming individual crystalline nanowires. unique ability interchange substrate specific peptides linear self\\xadassembled filamentous construct 13 virus introduces material tunability seen previous synthetic routes. therefore, system provides genetic tool kit growing organizing nanowires various materials including semiconducting magnetic materials.',\n",
              " 'treatment intracellular bacterial infectionan intracellular bacterial infection plant animal treated administration plant cell animal cell particle infectious bacteriophage covalently attached, wherein particle internalised cell. particles phage attached compositions comprising particles provided. formulation, treatment bacterial infection, comprises bacteriophage, liquid carrier adhesive, dries adhesive adheres bacteriophage surface, one formulation comprising liquid carrier: 85%-99.98% weight; bacteriophage: 0.01%-5% weight; adhesive: 0.01%-10% weight.',\n",
              " 'coupling borrelial protein bb0689 virus-like particles generation lyme disease vaccinean invention discloses lyme disease vaccine obtaining high immune response surface protein bb069 borrelia burgdorferi, causative agent lyme disease. present invention includes protein comprising amino acids identical least 80% modified borrelia burgdorferi bb0689 protein (as set forth seq id 5), chemically coupled bacteriophage q² virus-like particles. said invention relates method production purification protein, comprising amino acids identical least 80% modified borrelia burgdorferi bb0689 protein set forth seq id 5.',\n",
              " 'pseudomonas aeruginosa bacteriophage uses thereofan isolated bacteriophage mr299-2 nh-4 deposited ncimb deposit accession nos. 41729 41730, respectively, described. phages lytic activity p. aeruginosa strains, including mucoid cf clinical isolate strains. variant hages described, wherein said variants retain phenotypic characteristics said phage wherein said phage variants thereof lytic activity p. aeruginosa strains.',\n",
              " 'compositions methods producing single stranded dnaan isolated nucleic acid includes first sequence filamentous bacteriophage, first sequence initiator terminator functions; second sequence identical first sequence; single-strand dna sequence interest located first sequence second sequence. host cell including isolated nucleic acid method producing single-stranded dna disclosed.',\n",
              " 'brucella phage polynucleotides uses thereofan isolated polynucleotide disclosed comprises nucleic acid sequence brucella phage, nucleic acid sequence specific brucella phage comprising sequence selected group consisting seq id nos: 387-393. exemplary polynucleotide sequence one comprises least 100 consecutive nucleotides nucleic acid sequence set forth seq id no: 396. uses sequences disclosed.',\n",
              " 'bacterial anti-phage defense systemsan isolated polypeptide disclosed comprising amino acid sequence selected group consisting seq id nos: 2773-5544 11089-11094, wherein polypeptide antimicrobial activity. uses thereof treating microbial infections disclosed.',\n",
              " 'bacteriophages useful prophylaxis therapy vibrio anguillaruman isolated strain bacteriophage, specific bacteria belonging vibrio genre, particularly anguillarum species, deposited 3 oct. 2012 polish collection microorganisms (pcm) ludwik hirszfeld institute immunology experimental therapy polish academy sciences, access number f/00072, characterized said strain efficient prophylaxis, control and/or treatment infection caused vibrio anguillarum types species fish, mollusks crustaceans important aquaculture susceptible bacteria, genome size 48.6 kb, sensitive chloroform storage temperature −80° c.',\n",
              " 'isolation viruses using anionic resin beadsan isolation detection method viruses large quantities water aqueous media. technology employs charged resins isolate viral particles liquid sources water, milk, juices, homogenized food. anionic resin beads added sample liquid suspended within liquid. suspension anionic beads complex negatively charged virus particles pathogens. complexed beads removed liquid, effecting isolation virus. detection techniques performed directly complexed beads without resorting additional steps elute virus pathogen bead. methodology employed detection bacteriophage aqueous medium bacteriophage serves surrogate presence pathogen contaminant, enteric virus.',\n",
              " 'modified cre recombinase gene mammalsan object present invention provide modified gene mammals expression level, mammalian cells, tissues, organs bodies, several times high phage-derived cre recombinase. attain aforementioned object, present invention provides modified cre recombinase gene mammals consisting codons frequently used mammalian cells.',\n",
              " 'host bacterium specific nanoparticlean object present invention provide recombinant phage high safety excellent practicality usefulness. provided recombinant bacteriophage deprived proliferative capacity infect due fact bacteriophage genome part virion constituent gene deleted stored head, method preparing same. addition, provided recombinant bacteriophage deprived proliferative capacity infect due fact plasmid packaging site encoding target gene stored head, method preparing same.',\n",
              " 'fiber light emitting device using functionally characterized bacteriophagean objective present invention provide fibrous light-emitting device using bacteriophage. according present invention, silver nanowire produced mixing bacteriophage solution silver acetate, irradiating bacteriophage solution light, adsorbing silver (ag) onto bacteriophage electrophoresis photoreaction, fibrous light-emitting device produced using silver nanowire electrode, providing electron transport layer, light-emitting layer, hole transport layer, upper electrode silver nanowire, light-emitting layer coated using bacteriophage. words, electrode electron transport layer immersed bacteriophage solution pulled allow bacteriophage enclose electron transport layer self-assembling property, electrode immersed phosphorescent material (+) charge efficiently produce light-emitting layer, using fact bacteriophage (-) charge.',\n",
              " 'ointment containing bacteriophagean ointment contains bacteriophage base – vaseline, lanolin vaseline oil.',\n",
              " 'systems methods using bacteriophage-mediated lysis detection identification microorganisms fluid samplean optical measurement instrument includes optical cavity light source, plurality fluid containers, optical sensor. fluid container holds test portion fluid sample containing unknown microorganism, either distinct microorganism- attracting substance distinct growth-inhibiting substance. distinct microorganism- attracting growth-inhibiting substance configured react single type microorganism. instrument incubates test portions fluid sample within fluid containers. using microorganism-attracting substances, presence microorganism growth within one fluid containers simultaneously indicates presence identity unknown microorganism. using growth-inhibiting substances, absence microorganism growth within one fluid containers simultaneously indicates presence identity unknown microorganism. incubated test portions fluid sample compared incubated control portion fluid sample.',\n",
              " 'optical sensor methodan optical sensor waveguide core, cladding outer surface long period fiber grating. core, cladding long period fiber grating collectively provide least two resonant wavelengths. optical sensor binding sites outer surface cladding binding elements detected outer surface cladding. cladding may thinned thickness sufficiently low produce resonant wavelengths. binding sites include agents binding elements detected agents covalently bonded surface cladding. example binding sites include bacteriophages detecting e. coli bacteria, palladium detecting hydrogen, synthetic dna detecting viruses certain molecules example.',\n",
              " 'ozone disinfection filtering system swimming pool water bodyan ozone disinfection filtration system used water system swimming pool comprising water pump filtration unit, water pump connected filtration unit comprising filtering sand cylinder, connected pressure water pump, mixing pot communicated tube ozone generator, reactive pot communicated outflow tube one one pipe. water swimming pool pumped filtering sand cylinder filtrate quickly, afterwards pressurized pressure water pump sent mixing pot. ozone ozone generator sent mixing pot mix water sent reactive pot oxidative decompose bacteria, removal effectiveness distinctly especially brood-cell strong chlorine resistance f bacteriophage. water disinfection discharged cycle swimming pool. invention disinfects quickly side effect.',\n",
              " 'thermostable rna ligase thermus phagean rna ligase derived bacteriophage ts2126 infects thermus scotoductus, nucleic acids comprising nucleotide sequences open reading frame (orf) polypeptides encoded nucleic acids, described.',\n",
              " 'agonist antibody heteroreceptoranimals immunized either b chain receptor, mrna extracted spleen cells animals, variable regions l h chains isolated rt-pcr using primers variable regions comprising cdrs. single-chain fv synthesized assembly pcr construct phage library. clones antigen-bound antibodies concentrated cloned panning. expression vector scfv-ch1-fc prepared inserting single-chain variable region ch1-hinge-ch2-ch3 signal sequence animal cells. various combinations expression vectors introduced cells express antibodies, antibody clones exhibiting ligand-like activity selected.',\n",
              " \"single chain antibodies beta-amyloid peptideanti-a~p scfvs single domain antibodies generated, antibodies displayed filamentous phage soluble protein molecules, stabilized maltose binding protein, prevent fibrilization abp 1-40 disaggregate abp 1-40 fibrils generated vitro. anti-a~p scfv antibodies stained amyloid neuritic plaques slices transgenic mice. anti-a~p scfv single domain antibodies used inhibiting treating alzheimer's disease.\",\n",
              " 'antimicrobial proteins spo1 bacteriophageanti-bacterial peptides provided derived bacteriophage spo1.',\n",
              " 'antibacterial phage peptides methods use thereofantibacterial phage peptides methods use thereofthe present invention directed isolated chimeric polypeptides bacteriophage origin antibiotic activity use thereof treatment control bacterial infections. specifically, present invention directed 0 use novel antibacterial polypeptide derived bacteriophage f87s/06 chimeric constructs thereof, use ibr treatment control infections caused gram-positive bacteria, including staphylococcus ameus.figure no.',\n",
              " \"identifying affinity-matured human antibodies.antigen-specific immunoglobulin v-regions identified library nucleic acids amplified using polymerase chain reaction using leader sequence-specific forward primers. use leader sequence primers allows v-region sequences amplified (including extensive 5' end mutations) without loss original 5' v gene segment sequence. libraries screened antigen-specific v-regions using eukaryotic cells engineered express amplified v-region-encoding nucleic acids using bacterial phage display techniques. latter, second v-region library made using larger conventional set 5' v-region primers. sequence errors introduced amplification products method corrected using sequence information obtained products amplified v-region primers screen library created using leader sequence primers. amino acid sequence information fragments donor immunoglobulins used assist identification nucleic acids encoding heavy light chains donor antibodies well design primers amplify nucleic acids.\",\n",
              " 'antimicrobial composition use thereofantimicrobial composition contains bacterio¬phage strains sensitive staphylococcus aureus: dsm 32631, dsm 32629, dsm 32630, bacterio¬pha¬ge strains sensitive streptococcus pyogenes: dsm 32634, dsm 32635, bacteriophage strains sensitive escherichia coli: dsm 32612, dsm 32611, dsm 32610, bacteriophage strains sensitive proteus vulgaris: dsm 32613, dsm 32614, dsm 32615, bacteriophage strains sensitive pseudomonas aeruginosa: dsm 32616, dsm 32618, dsm 32617 optionally pharmaceuti¬cally acceptable excipient. that, said bacteriophages deposited german collection microorganisms cell cultures (dsmz). composition used treatment and/or prevention purulent-inflammatory people, animals birds, well.',\n",
              " 'colonic delivery antimicrobial agentsantimicrobial compositions oral delivery, administration colon, distal ileum, portion gastrointestinal tract stomach, bacteriophage, phage proteins, antimicrobial peptides, antimicrobial aptamers, disclosed. one embodiment, active agent capable lysing bacterial cell wall. another embodiment, active agent capable interacting receptor enzyme bacteria. embodiments, active agents selectively act one harmful bacteria, clostridium dificile, either act, act lesser extent, helpful bacteria, bifidobacteria. agents delivered directly colon, active agents ultimately enter colon affect bacteria present colon. compositions include beads pectin form cationic salt enclosing active agent, types drug delivery systems designed targeted delivery desired portion gastrointestinal tract.',\n",
              " 'anti-vegf antibodiesanti-vegf antibodies variants thereof, including high affinity 5 binding vegf, disclosed. provided methods using phage display technology naive libraries generate select anti-vegf antibodies desired binding biological activities. contemplated uses antibodies research, diagnostic therapeutic applications.',\n",
              " 'anti-vegf antibodiesanti-vegf antibodies variants thereof, including high affinity 5 binding vegf, disclosed. provided methods using phage display technology naive libraries generate select anti-vegf antibodies desired binding biological activities. contemplated uses antibodies research, diagnostic therapeutic applications. 5919798_1 (ghmatters) p59588.au.2 leownr',\n",
              " 'anti-vegf antibodies methods useanti-vegf antibodies variants thereof, including high affinity binding vegf, disclosed. provided methods using phage display technology naive libraries generate select anti-vegf antibodies desired binding biological activities, used diagnostics therapy corresponding diseases.',\n",
              " 'synthetic non-covalently self-assembling bipartite prna chimerasartificial packaging rna (prna) polynucleotides share secondary structure dsdna bacteriophage prna (e.g., phi29 prna) formed non-covalent self-assembly two rna pieces form prna monomers may include heterologous sequences form chimeric prna monomers. two rna pieces (p1 p2) made non-enzymatic chemical synthesis resulting monomer includes break single- stranded head loop corresponding positions 53-58 wild-type phi29 prna. synthetic prna monomers assembled multimeric polyvalent nanoparticles may include heterologous components payloads sirna, ribozymes, aptamers, antisense rna, detectable labels, therapeutic drugs like, well targeting moieties, endosome- disrupting agents moieties.',\n",
              " 'process continuous production bacteriophageas bacteriophage use industrial application grows need commercial quantities identified bacteriophage. invention discloses continuous flow bacteriophage proliferation process provide commercial quantities desired bacteriophage concentrations suitable industrial use. host bacteria virulent bacteriophage fed reactor vessel phage attach to, infect lyse host bacteria providing multiple replications coincidentally concentrating phage.',\n",
              " 'methods periplasmic phage-assisted continuous evolutionaspects disclosure relate compositions, systems, methods evolving nucleic acids proteins utilizing continuous directed evolution periplasm host cell. embodiments, methods comprise passing nucleic acid cell-to-cell desired, function dependent manner. linkage desired function passage nucleic acid cell-to-cell allows continuous selection mutation nucleic acid.',\n",
              " 'method vitro screening in-vivo antibacterial activity phagesaustracy present invention discloses method vitro screening in-vivo antibacterial activity phages. method includes following steps: si, selecting appropriate culture dish, sterilizing culture dish; s2, adding culture medium culture dish, wherein culture medium includes 10-15 g beef soup, 5-10 g peptone, 30-50 g sodium chloride, 10-20 g glucose 5-18 g blood, mixing substances prepare fluid, semisolid solid culture media; s3, obtaining serum experiment subjects, dividing serum four parts, without performing treatment serum b, inactivating serum c, adding sterilizing agent serum d; s4, collecting secretions infected persons discharged vitro body, wherein secretions specifically include blood, urine, feces, pus secretions; s5, selecting colonies secretions, selecting host bacteria phages; s6, respectively performing following treatments four parts serum: still performing treatment serum a, adding host bacteria phages serum b, serum c serum d. present invention high screening accuracy.',\n",
              " 'method preserving freeze-dried powder capsules phagesaustracy present invention discloses method preserving freeze-dried powder capsules phages. method includes following steps: s, performing primary treatment phages, selecting host bacteria phages, inoculating phages fluid medium, performing shake culture 10 hours, collecting phage-containing supernatant; s2, preparing phage protectant, mixing phages protectant together, fully mixng phages protectant together stirring stirring rod; s3, preparing freeze-dried powder, placing mixed solution prepared s2 freezing chamber freezing, performing primary drying vacuum condition, adding 10-20 parts glycerin phage fluid subjected primary drying, heating, performing secondary drying obtain phage freeze-dried powder; s4, preparing capsules, filling freeze-dried powder capsules sterile environment using encapsulating machine, sealing capsules, preserving sealed capsules shade. preservation effect present invention excellent.',\n",
              " 'fluorescent virus probes identification bacteriabacteria fluid systems identified using fluorescently labeled virus molecular recognition element bacteria. virus, bacteriophage, optically encoded fluorescent reporter molecules allow detection quantitation phage host/phage complex. biosensors provided molecular recognition element immobilized substrate.',\n",
              " 'bacteria sensitive endodontic pointsbacteria sensitive endodontic points modern endodontic treatment directed elimination microorganisms infected root canal tooth obturation. follow-up studies examined outcome endodontic therapy revealed high success rate negative bacterial culture prerequisite root filling (sjogren et al.). insome conditions bacteria survive biomechanical preparation ofroot canal long-term success endodontic therapy doubtful bacteria present root canal prior obturation. biomechanical preparation root canal followed complete obturation. prior that, root canal thoroughly dried using paper points (a cone variable width taper, usually made paper paper product). obturation done using gutta percha. invention endodontic point fabricated bacteria specific antibody/bacteriophage vertical strips impregnated (as shown figure). strips vertical detect result apical, middle coronal third ofthe rootcanal. points used prior obturation procedure check sterility ofthe root canal long term success endodontic therapy. detection gram-positive bacteria, endodontic points impregnated gram positive bacteria specific antibody indicator used detection gram-negative bacteria, endodontic points impregnated gram negative bacteria specific antibody indicator used. 1|pa ge bacteria sensitive endodontic points drawings endodontic point detection bacteria bacte ria pe cific antibody/bacteriophage strips endodontic 2a ge',\n",
              " 'process remediating biofouling water systems virulent bacteriophagebacterial contamination industrial water systems lead biofouling biofilms corrosion bacterial induced corrosion. invention provides method control fouling contamination industrial water systems caused bacteria. prevention reduction process interruptions general contamination, fouling corrosion achieved destruction targeted problematic bacteria naturally occurring, non-engineered bacteriophage virulent targeted bacteria. invention provides in-situ confirmation proper identification target bacteria mobile laboratory adapted implement method.',\n",
              " 'bacteriophage adhesion proteinsbacteriophage adhesion proteins binding o-antigen gram negative bacteria, lacking ability binding bacteriophage hydrolysing lipopolysaccharides, described, well nucleic acid molecules encoding proteins. addition, methods generating bacteriophage adhesion proteins use detection, purification enrichment bacteria described.',\n",
              " 'endolysin bacteriophage geobacillus methods usingbacteriophage geobacillus provided, methods making using bacteriophage provided.',\n",
              " 'culture bacteriophagebacteriophage produced continuous process comprising maintaining culture bacteriophage first vessel (16); feeding culture bacteria maintained second vessel (12a, 12b) stationary phase harvesting bacteriophage first vessel (16), wherein first vessel operated dilution rate excess 1 / (bacteriophage lysis time).',\n",
              " 'bacteriophage methods usingbacteriophage provided, methods making using bacteriophage provided.',\n",
              " 'bacteriophage treatment acne biofilmsbacteriophage compositions therapeutic uses thereof. particular, compositions lytic bacteriophages capable lysing',\n",
              " 'bacteriophage compositions.bacteriophage compositions, methods preparing bacteriophage compositions provided. method producing antibacterial composition involves adsorbing aqueous solution one bacteriophages, one phage components, onto matrix produce composition, drying composition produce antibacterial composition. antibacterial composition comprising one strain bacteriophage, one phage component, adsorbed onto matrix provided. antibacterial composition may encapsulated. antibacterial composition, encapsulated antibacterial composition, may used within cream, lotion gel, admixed pharmaceutical carrier administered topically, orally, nasally, used powdered inhalant, antibacterial composition encapsulated antibacterial composition, may added feed animal, aquatic avian uses.',\n",
              " 'treatment topical systemic bacterial infectionsbacteriophage covalently attached carrier particle average diameter 0.1 microns 15 microns, used topical treatment bacterial infection. bacteriophage covalently attached carrier particle average diameter 7 microns less used systemic treatment bacterial infection. plurality bacteriophages lytic different bacterial strains gives wide antibacterial activity. combination therapy comprises administration antibiotic bacteriophage covalently attached carrier particle.',\n",
              " 'lambdasa2 endolysin truncationbacteriophage endolysins demonstrating bactericidal peptidoglycan hydrolase activity comprise one group new candidate antimicrobials reportedly refractory antibiotic resistance development. isolated recombinant nucleic acid encoding antimicrobial truncated lambdasa2 endolysin enzyme molecule specificity exolytic endopeptidase activity peptidoglycan cell wall untreated host species streptococcus agalactiae addition, least one streptococcal species: streptococcus dysgalactiae, s. dysgalactiae subs, equisimilis, s. equi subs, zooepidemicus, group e streptococcus, group g streptococcus, streptococcus pyogenes, streptococcus uberis. lambdasa2 prophage endolysin gene isolated group b streptococcal genome, expressed e. coli plasmid, shown harbor amidase-5 (endopeptidase), amidase-4 (glycosidase) domain two cp1-7 cell wall-binding domains. isolated antimicrobial lambdasa2 truncated endolysin protein encoded nucleic acid used treatment diseases caused streptococcal staphylococcal microorganisms.',\n",
              " 'bacteriophage lambda-vaccine systembacteriophage λ disclosed herein include head, tail, lambda genome comprising nucleic acid sequence encoding fusion protein comprising protein linked heterologous antigen, wherein nucleic acid sequence inserted native gene locus adjacent gene e, lambda genome, wherein expression fusion protein results head bacteriophage λ comprising fusion protein. host bacterial cells disclosed herein infected bacteriophage λ. addition, immunogenic compositions disclosed include effective amount bacteriophage λ. methods disclosed inducing immune response heterologous antigen subject. furthermore, methods disclosed preparing bacteriophage λ.',\n",
              " 'phage insensitive streptococcus thermophilusbacteriophage insensitive mutants (bims) three streptococcus thermophilus parent strains generated characterized phage sensitivity, sedimentation rate, cell chain length, phage adsorption crispr loci alterations. several bims showed altered sedimentation phenotype well increase cell chain length, reduced phage sensitivity, reduced phage adsorption 100% identity three crispr loci. results show derived bims become phage-resistant mechanism crispr.',\n",
              " 'production immobilised bacteriophagebacteriophage covalently attached substrate (a) combining (i) substrate (ii) bacteriophage, wherein prior combining (i) (ii) (i) (ii) activated, wherein (b) combining bacteriophage contained within liquid droplet average diameter 150 microns less.',\n",
              " 'novel strains bacteriophages treatment bacterial infections, particularly strains drug-resistant bacteria genus stenotrophomonasbacteriophage strains use production preparations use treatment bacterial infections, particularly strains drug-resistant bacteria genus stenotrophomonas, particularly belonging species stenotrophomonas maltophilia',\n",
              " 'bacteriophage-based contrast agents, use thereof method production thereofbacteriophage-based contrast agents method production thereof disclosed. bacteriophages, least one embodiment, contain first fusion protein comprising phage-surface protein ligand specific identifiable target structure second fusion protein comprising phage-surface protein peptide binding signal generating molecule.',\n",
              " 'enterococcus faecalis bacteriophage uses thereofbacteriophages provided infect strains enterococcus faecalis, opportunistic bacterial pathogen causes human disease. provided methods treating enterococcus faecalis therapeutic administration bacteriophages.',\n",
              " 'bacteriophage dna vaccine vectorbacteriophages used dna delivery system vaccine pathogens glycosylation critical immunity.',\n",
              " 'phage lambda display constructsbacteriophages general lambda phage particular powerful, flexible reagents yet exploited full potential. discussed herein, lambda phage head and/or genome comprises easy use highly efficient delivery vehicle delivering expression products gene interest systemically particular tissue.',\n",
              " 'lysin bacteriophage clostridia sppbacteriophages food-contaminating pathogenic bacteria lysine thereof used kill bacteria. examples include lysins bacteriophages listeria monocytogenes clostridium tyrobutyrlcum. tests bacterial contamination made specific specific bacteria using appropriate bacteriophage lysin thereof determining whether cells lysed thereby.',\n",
              " 'method obtaining bacteriophage strain increased affinity eukaryotic cells, preparations containing it, applications bacteriophagesbacteriophages showing affinity eukaryotic cells serve diagnosis and/or treatment and/or prevention and/or developmental arrest diseases connected appearance eukaryotic cells, particular neoplastic cells.',\n",
              " 'preparation method bacteriophage lyase capable lysing escherichia coli salmonellabelonging field animal biomedical engineering, invention specifically discloses preparation method bacteriophage lyase capable lysing escherichia coli salmonella. primer design, lyase gene bacteriophage ecgd1 successfully amplified pcr, transferred expression system obtain recombinant strain. iptg induction carried recombinant strain obtain expression, strain lysed obtain soluble recombinant lyase bacteriophage ecgd1, recombinant lyase lyse plurality escherichia coli salmonella, i.e. wide lysis spectrum. addition, synergistic effect result recombinant lyase polymyxin b shows existence recombinant lyase lowers minimum inhibitory concentration polymyxin b, i.e. two synergistic bacteriostatic effect. identification lysis activity recombinant lyase identification wide lysis spectrum thereof reveal recombinant lyase bacteriophage ecgd1 potential application value prevention control escherichia coli salmonella infection.',\n",
              " 'anti-idiotypic nano antibody based zearalenone green immunoassay methodbelonging field molecular biology, invention particular relates anti-idiotypic nano antibody based zearalenone green immunoassay method. according invention, zearalenone monoclonal antibody 2d3 employed immunize alpaca, leukocyte total rna extracted construct phage displayed nano antibody library; 2d3 antibody adopted target, four rounds affinity enrichment panning conducted lower coating concentration competitive elution concentration round round, positive phage zearalenone anti-idiotypic nano antibody good specificity obtained. invention employs zearalenone anti-idiotypic nano antibody substitute zearalenone standard elisa method determine naturally polluted corn feed samples, performs comparison hplc detection result, two methods good correlation, r2 0.997, thus proving zearalenone anti-idiotypic nano antibody substitute standard method accurate reliable result effective feasible green immunoassay method.',\n",
              " 'anti-tnfalpha fully human monoclonal antibodies application thereofbelonging technical field antibody drugs, invention provides anti-tnfalpha fully human monoclonal antibodies application thereof. antibodies derived human hybrid tumors obtained cytotoxin functional test screening affinity screening phage display technology, excellent affinity specificity tnfalpha. pharmacodynamic experiments cell models, antibodies effectively neutralize nfalpha cytological effect generated thereby. animal experiments, antibodies effectively neutralize tnfalpha inhibit phenotype brought tnfalpha animal models. effect lower better humira.',\n",
              " 'cn 102268072 abelonging technical field biomedicine, invention relates sequence structure polypeptide able specifically bind influenza virus hemagglutinin protein, application polypeptide anti-influenza viruses. expressing purified influenza virus hemagglutinin protein screening random peptide library phage display technology, polypeptide specifically bound influenza virus hemagglutinin equipped sequences numbered 1-18 obtained. hemagglutinin-binding peptide hinder combination hemagglutinin host cell receptor, influenza virus inhibited infecting host cell. thus, invention conducts anti-influenza virus activity study hemagglutinin-binding peptide selected phase peptide library, finds polypeptide h17, sequence nh2-shgritfayfan-cooh, effectively inhibit influenza virus infecting host cell small toxicity. therefore, hemagglutinin-binding peptide invention h17 polypeptide therein anti-influenza virus activity expected become novel treatment medicaments treating diseases caused influenza virus infection reducing hazards diseases caused influenza viruses.',\n",
              " 'bursin bpp-ii specific binding peptide application thereofbelonging technical field protein polypeptide, invention discloses bursin bpp-ii specific binding peptide application thereof. amino acid sequence bursin bpp-ii specific binding peptide following: short peptide 1: qslpsplwiqqs, short peptide 2: drmpdsawttrk, short peptide 3: alwppnlhawvp. according invention, bpp-ii-bsa fusion protein taken target molecule, bacteriophage random 12 peptide library screening carried out, elisa identification competitive inhibition test combined obtain bpp-ii specific binding bacteriophage, sequencing performed artificial synthesis bpp-ii specific binding peptide. binding peptide obtained screening specifically bound bursin bpp-ii, inhibit activity bpp-ii mouse wehi-231b lymphoma cell proliferation certain concentration, good application prospects preparation drugs inhibiting resistance bursin bpp-ii tumor cell proliferation, thus laying foundation research, development application bpp-ii inhibitors.',\n",
              " 'cadmium ion targeted metal-binding peptide z1 application thereofbelonging technical field wastewater treatment, invention particular relates cadmium ion targeted metal-binding peptide z1 application thereof. polypeptide sequence metal-binding peptide z1 shown seq id no.1, specifically mhpnaghgslmr. invention utilizes random phage dodecapeptide library screening technology obtain specifically bound dodecapeptide high affinity cadmium ions, bound peptide coded gene integrated saccharomyces cerevisiae, saccharomyces cerevisiae lectin surface display system eby100 utilized display metal-binding peptide specific cadmium ion adsorption ability outer surface cell wall, cadmium ion targeted metal-binding peptide z1 applied asan adsorbent. preliminary test shows that: gram wet bacteria adsorb 257mg cadmium ions, gram dry bacteria adsorb 2500-3000mg cadmium ions, cadmium ion targeted metal-binding peptide z1 shows good application effect, certain industrial application prospect.',\n",
              " 'methods producing biofuels compositions use biofuel production methodsbeneficial virus, phage, used fermentation methods techniques producing biofuels. beneficial virus (e.g., phage) may targeted toward microorganisms (e.g., bacteria, etc.) undesirably affect fermentation biofuel production process. beneficial virus targeted toward microorganisms undesirably affect product by-product process, processing, results processing may incorporated fermentation biofuel production process. compositions include beneficial viruses, phage, useful processes disclosed.',\n",
              " 'dual anthrax-plague vaccines protect two tier-1 bioterror pathogens, bacillus anthracis yersinia pestisbivalent immunogenic compositions anthrax plague disclosed herein. one bivalent immunogenic composition comprises triple fusion protein containing three antigens, f1 v yersinia pestis pa antigen bacillus anthracia fused in-frame retaining structural functional integrity three antigens. another bivalent immunogenic composition comprises bacteriophage nanoparticles arrayed three antigens capsid surface bacteriophage nanoparticles. bivalent immunogenic compositions able elicit robust immune response subject administered said bivalent immunogenic compositions provide protection subject sequential simultaneous challenge anthrax plague pathogens.',\n",
              " 'breathing filter bacteriophage filtration efficiency testerbreathing filter bacteriophage filtration efficiency tester, power distribution box comprises box body, set aerosol room box respectively, test tube, first anderson sample thief inclosed detection cover, set clamp box lateral wall, clamp fixes aerosol room box middle part, one end first outlet duct connected aerosol room bottom,the end first outlet duct upper end intercommunication detects cover, one end intake pipe connected air inlet first anderson sample thief, endof intake pipe lower extreme intercommunication detects cover. beneficial effects utility model aspirate detecting cover intake pipe suckfirst anderson sample thief gaseous gauze mask awaits measuring later stage cultivation fungus fungus clear, thereby convenient directly perceived accurate measuring goes blocking bacteria performance gauze mask.',\n",
              " 'anti-idiotype antibody antifungal activity fungus carrying ß-glucan synthase utilization sameby using neutralizing antibody nmab-kt hm-1 killer toxin idiotype antigen, single-chain fv antibody successfully obtained phage display method. confirmed antibody actually hm-1 killer toxin activity exhibits antifungal activity fungus carrying ß-glucan synthase. antibody used antifungal agent highly useful.',\n",
              " 'peptides methods treating cancerby using phage display derived peptide initial template, compounds developed highly specific mdm2/mdm4. compounds exhibit greater potency p53 activation protein-protein interaction assays compound derived p53 wild-type sequence. unlike nutlin, small molecule inhibitor mdm2/mdm4, phage derived compounds arrest cells resistant p53 induced apoptosis wide concentration range without cellular toxicity, suggesting highly suitable cyclotherapy.',\n",
              " 'anti-campylobacter jejuni antibodies uses thereforcampylobacter jejuni leading cause bacterial food-borne diseases humans, ranging acute diarrheal disease neurological disorders. isolated purified antibody fragment thereof specific c. jejuni described. antibody fragment thereof binds flagellar protein reduces motility c. jejuni. antibody fragment thereof derived heavy chain igg variable domain fragment (vhh) camelid animal immunized c. jejuni flagellar protein. multivalent form, well phage format, antibody fragment thereof described. methods reducing presence c. jejuni animal animal environment, methods formulations treating c. jejuni infection, method detecting c. jejuni described.',\n",
              " 'anti-angiogenin peptides, compositions, methods usecarrier compositions, including human-safe phages, equipped one angiogenin-binding peptides, optionally tumor-homing peptides use anti-tumor therapies, described. angiogenin-binding peptides bind inactivate angiogenin molecules thereby blocking angiogenic activity thus inhibiting angiogenesis tissue compositions localized.',\n",
              " 'anti-bacterial cosmetic pharmaceutical compositions suitable deodorising body, fighting body odourcertain bacteriophages suitable incorporating certain antiperspirant deodorant compositions, effective specific fighting bacteria causing odour without irritating skin damaging germs flora skin positive effect. according invention, cosmetic pharmaceutical compositions suitable deodorising body contain, cosmetic dermatologically acceptable carrier, least one deodorant antiperspirant active substance least one representative group bacteriophages effective least one following: staphylococcus aureus and/or staphylococcus hominis and/or corynebacteriumtuberculostearicum and/or anaerococcus octavius and/or staphylococcus lugdunensis and/or finegoldia magna and/or corynebacterium amycolatum and/or corynebacterium afermentans and/or staphylococcus epidermidis and/or staphylococcus capitis and/or staphylococcus haemolyticus and/or propionibacterium avidum and/or corynebacterium kroppenstedtii and/or peptinophilus spec.',\n",
              " 'methods isolating bacterial strainscertain embodiments directed methods developing bacterial strains selected metabolism producing target molecule(s) bacterial strains bacteriophage strains comprising modified gene encoding selected agent.',\n",
              " 'system molecular imagingcharged neutral particles, photons, photonic optics, detectors sensor arrays used application molecular imaging, communication biological organisms monitoring learning biological activity inside living organisms. living organisms include among others living tissue, biological organs, cells, eukaryotes, prokaryotes, viruses phages. molecular imaging effective new tool understand mechanisms life communicate, modify control it. techniques, methods devices described achieve aims. probes used molecular imaging described include full spectrum photons; charged uncharged particles; chemicals; biological probes.',\n",
              " \"immunization and/or treatment parasites infectious agents live bacteriachimeric proteins expressed, secreted released bacterium immunize treat parasite, infectious disease malignancy. delivery vector may attenuated, non-pathogenic, low pathogenic, probiotic bacterium. chimeric proteins include chimeras of, e.g., phage coat and/or colicin proteins, bacterial toxins and/or enzymes, autotransporter peptides, lytic peptides, multimerization domains, and/or membrane transducing (ferry) peptides. active portion immunogenic chimeric proteins include antigens wide range parasites infectious agents, cancers, alzheimer's huntington's diseases, enhanced activity secreted released bacteria, and/or direct anti-parasite infectious agent activity. activity secreted proteins increased co-expression protease inhibitor prevents degradation effector peptides. addition antibody binding antibody-degrading protein prevents premature elimination vector enhances immune response.\",\n",
              " 'peptide ligands erythropoietin receptorclones isolated phage display libraries bound erythropoietin (epo) receptor probe disclosed. peptides encoded sequences clones bound epo receptor disclosed. 12-mer amino acid consensus sequence, cxxgwvgxcxxw (where x represents one many amino acids), common peptides bound epo receptor, unrelated primary structure epo, disclosed.',\n",
              " 'characterization four prophage endolysins specific clostridium perfringensclostridium perfringens cause food poisoning major agent necrotic enteritis. laws banning use antibiotics animal feed become common, need alternatives antibiotics becomes greater. peptidoglycan hydrolases target cell wall specific bacteria one alternative. genes four endolysins, plycp10, plycp18, plycp33, plycp41, found within clusters phage associated genes, likely prophages strains cp10, cp18, cp33, cp41. plycp18 plycp33 harbor l-alanine amidase catalytic domains, plycp10 plycp41 glycosyl hydrolase catalytic domains predicted blastp pfam searches. four genes synthesized e. coli codon optimization, expressed e. coli expression vectors 6×his tag nickel column purification, recombinant proteins purified. four endolysins capable lysing 66 c. perfringens strains tested bacteria tested.',\n",
              " 'protein nucleic acid delivery vehicles, components mechanisms thereofcomplex viruses assembled simple protein subunits sequential irreversible assembly. genome packaging bacteriophages, powerful molecular motor assembles special portal vertex empty prohead initiate packaging. aspect invention relates phage t4 packaging machine highly promiscuous, translocating dna finished phage heads well proheads. single motors force exogenous dna phage heads rate proheads phage heads undergo repeated initiations, packaging multiple dna molecules head. shows phage dna packaging machine unusual conformational plasticity, powering dna apparently passive capsid receptacle, including highly stable virus shell, full. features allow design novel class nanocapsid delivery vehicles.',\n",
              " 'recombinant phage methods detecting listeriacomposition methods detection one target microbe(s) provided. compositions disclosure include least one recombinant phage capable infecting target microbe, said phage comprising least capsid protein sequence, ribosome binding site, codon-optimized marker. compositions disclosure may include aqueous solution enhances ability detect marker expression upon phage infection target microbe. embodiments target microbe listeria.',\n",
              " 'methods compositions preventing infection vibrio speciescompositions methods provided preventing, ameliorating, treating disease caused species bacterial genus vibrio, example, cholera caused v. cholerae, compositions containing two strains lytic bacteriophage infect kill vibrio cells. bacteriophage virulent, replicate intracellularly lyse kill bacteria. use two strains single treatment, result rate mutation bacteria simultaneous resistance bacteriophage low negligible, reduces appearance phage-resistant bacteria statistical negligibility. normal human microbial flora species affected. alternative embodiments method composition, antibiotic agents treatment agents administered cocktail plurality bacteriophage strains.',\n",
              " 'methods compositions comprising bacteriophage nanoparticlescompositions methods comprising bacteriophages provided. particular, present invention includes novel customized t4 bacteriophages uniquely designed effective antigen foreign particle presentation. present invention provides vitro methods making customized t4 bacteriophages. compositions methods present invention may used effective vaccine delivery systems.',\n",
              " 'rna replication using transcription polymerasescompositions methods amplifying rna replication using transcription polymerases disclosed. replicated rnas used various applications rnai therapeutics, diagnostic probes, rna sequencing, directed evolution rna aptamers without intermediate conversion dna, rna vaccines. transcription polymerases comprise t7 bacteriophage rna polymerase.',\n",
              " 'bacteriophage derived methods control lactic acid bacterial growthcompositions methods protection bacterial contamination disclosed antibacterial proteins methods use thereof disclosed',\n",
              " 'compositions methods molecular memory storage retrievalcompositions methods storage, organization, access, retrieval information encoded sequence controlled polymers data storage nucleic acids provided. embodiments, organization, storage, and/or selective retrieval data facilitated hybridization barcode sequence sequence controlled polymer reverse complementary sequence oligonucleotide. plurality oligonucleotides arrayed using known organization scheme, selectively capture localize corresponding sequence controlled polymer. embodiments, compositions methods utilize recombinant bacteriophage, typically featuring minigenome bacteriophage origin replication packaging signal separated data storage sequence barcodes.',\n",
              " 'phage-based pesticide varroa destructorcompositions methods use preserving beehive bees associated beehive varroa destructor infestation-induced collapse death, supporting health, vitality, longevity beehive bees associated beehive controlling, reducing, eliminating population varroa destructor associated beehive bees associated beehive targeted, phage-based, bactericidal bacteriostatic activity bacillus sp., hafnia sp., and/or escherichia sp. present varroa destructor associated beehive bees associated beehive, specifically applying administering beehive, bees associated beehive, composition comprising one bacteriophage cellular tropism for, infectivity specific for, bacillus sp., hafnia sp., and/or escherichia sp. varroa destructor associated beehive bees associated beehive.',\n",
              " 'bacteriophages selective agentscompositions containing bacteriophages methods using bacteriophages microorganism detection assays microbial growth plating media disclosed. lytic ability phages control growth non-target populations provides superior sensitivity specificity detection assays reduces false negative false positive results. removal contaminating bacteria reduces microbial competition nutrients growth media thereby increasing efficiency productivity culture. phage treatment sample increases proportion target microorganisms sample contaminating bacteria thereby requiring less time enrichment obtain significant signal improving overall signal noise ratio assays providing higher yield end product microbiological production systems.',\n",
              " 'bacteriophages selective agentscompositions containing bacteriophages methods using bacteriophages microorganism detection assays microbial growth plating media disclosed. lytic ability phages control growth non-target populations provides superior sensitivity specificity detection assays reduces false negative false positive results. removal contaminating bacteria reduces microbial competition nutrients growth media thereby increasing efficiency productivity culture. phage treatment sample increases proportion target microorganisms sample contaminating bacteria thereby requiring less time enrichment obtain significant signal improving overall signal noise ratio assays providing higher yield end product microbiological production systems.',\n",
              " 'compositions vivo expression therapeutic sequences microbiomecompositions phage particle disclosed. phage particle non-replicating includes least one heterologous nucleic acid sequence capable expressed target bacteria. expressed heterologous nucleic acid sequence non-lethal target bacteria.',\n",
              " 'bacteriophage compositions kits related methodscompositions affecting intestinal microbiome mammalian subject include pharmaceutically-acceptable carrier greater equal 1×104 pfu/ml pfu/mg bacteriophage tropism includes obesogenic and/or inflammatory bacterium associated intestinal microbiome mammal. processes preparing disclosed compositions include isolating bacteriophage environmental source, characterizing bacteriophage, combining bacteriophage pharmaceutically acceptable carrier greater equal 1×104 pfu/ml pfu/mg. methods include administering disclosed compositions mammalian subject without co-administration disclosed probiotics. administering disclosed compositions reduce concentration obesogenic and/or inflammatory bacteria intestinal microbiome mammalian subject, promote induce weight loss, reduce inflammation, support metabolic health, and/or support healthy balance/diversity within intestinal microbiome mammalian subject.',\n",
              " 'methods creating consumable strains compositions thereofconsumable biotech strain improvement products presented, well methods preparation using them. technology based reversible, single-crossover insertion vectors, plasmids phage. single crossover event reversible absence drug selection, products maintained useful form without knowledge drug selection agent. consumable strain improvement products constructed 1st generation reverse engineering protections, least 25%-75% effectiveness equivalent traditional (permanent) strain improvement product laboratory condition.',\n",
              " 'monoclonal antibody vaccine targeting filamentous bacteriophagedescribed method reducing preventing pseudomonas aeruginosa biofilm formation human subject need thereof, comprising administering human subject first composition comprising (a) antigen-binding polypeptide binds pf-family bacteriophage, (b) vaccine pf-family bacteriophage. described antigen-binding polypeptide binds specifically coab protein pf-family bacteriophage fragment thereof.',\n",
              " 'bacteriophage therapy adherent-invasive escherichia colidescribed herein bacteriophages infect lyse adherent-invasive escherichia coli (aiec). bacteriophages useful, example, prophylactic therapeutic treatment subjects infected aiec risk infection aiec, prophylactic therapeutic treatment diseases conditions associated aiec, including inflammatory bowel disease (ibd), urinary tract infection (uti), neonatal meningitis, asthma, chronic obstructive pulmonary disease (copd), bronchitis, pneumonia, lung cancer, subject uses described herein.',\n",
              " 'bacteriophages vancomycin-resistant enterococcidescribed herein bacteriophages infect lyse vancomycin-resistant enterococci (vre). bacteriophages useful, example, prophylactic therapeutic treatment subjects infected enterococci, including vre, risk infection enterococci, including vre, uses described herein.',\n",
              " 'methods treating preventing viral infection using bacteriophagesdescribed herein compositions treating preventing viral infection comprising bacteriophages bind virus block inhibit viral entry host cell. bacteriophage libraries may screened identify bacteriophages bind virus interest, identified bacteriophages may used treat prevent infection caused virus interest. described herein methods treating preventing viral infection administering bacteriophage composition subject vivo surface vitro. bacteriophages composition may bind virus inhibit viral entry host cell, thereby reducing infectivity virus. reducing infectivity virus may treat prevent viral infection.',\n",
              " 'bacteriophage hydrogel compositions uses thereofdescribed herein hydrogel compositions comprising cross-linked bacteriophages. hydrogels typically bioactive, degradable, example biodegradable, self-healing, fluorescent, example autofluorescent, and/or birefringent. hydrogels described herein may used therapeutics diagnostics, scaffolds material synthesis, catalysts, membranes filters, biosensor substrates, example.',\n",
              " 'recombinant renewable polyclonal antibodiesdescribed herein methods combine phage yeast display create polyclonal antibodies renewable, amplified 100 million fold, maintain diversity without loss representation antibodies present. antibody representation remains essentially constant, confirmed deep sequencing. provided methods allow generation, use propagation polyclonal antibodies, without concern representation lost. furthermore, derivation polyclonal pool carried vitro using phage yeast display, possible various embodiments eliminate reactivities considered undesirable. additionally, polyclonal pool enriched higher affinity antibodies.',\n",
              " 'integrases, landing pad architectures, engineered cells comprising samedescribed herein modified bacteriophage serine integrases function mammalian cells. described herein landing pad architectures. engineered cells comprising integrases landing pads described, facilitate site-specific genomic integration pay load molecules.',\n",
              " 'synthetic bacteriophage compositions methods selection usedescribed herein novel engineered bacteriophages bacteriophage compositions, methods production thereof, therapeutic uses thereof. engineered bacteriophages may properties conferring enhanced stability subjected conditions elevated heat, extreme ph, medically relevant conditions. properties may provide advantages alternatives current reliance upon antimicrobials.',\n",
              " 'peptides antibody fusions bind sars-cov-2 methods using samedescribed herein peptides peptide-antibody fusions bind sars-cov-2 protein receptor binding domain (rbd), methods using compositions containing antibodies treatment covid-19. specifically, developed novel cov-2 protein binding peptides making use naïve phage-displayed 16mer peptide library- wherein cov-2 protein binding peptides bind epitopes rbd protein outside rbd. addition, show fusion peptides n-terminus nabs improves apparent affinity, potency breadth neutralization, without compromising developability profile. thus, peptides represent novel class sars-cov-2 protein binders, formatted various ways improve functional properties nabs used treatment many different diseases.',\n",
              " 'peptide displaying bacteriophage nanoparticles related compositions methodsdescribed herein fusion protein comprising bacteriophage protein fused cancer antigen. vaccines described, well methods treatment and/or prevention cancer methods immunizing individual.',\n",
              " 'organization polymers inovirus bacteriophagedescribed herein method organizing polymers, comprising mixing first composition comprising purified inovirus bacteriophage (e.g., pf-family bacteriophage) second composition comprising one polymers. described liquid crystal comprising inovirus bacteriophage (e.g., pf-family bacteriophage) one polymers, wherein liquid crystal substantially free bacterial strain (e.g., pseudomonas aeruginosa strain) capable producing inovirus bacteriophage.',\n",
              " 'identification antibodies specific lyssaviruses methods usedescribed herein method identifying monoclonal antibody (or antigen-binding fragment thereof) specifically binds plurality lyssaviruses use post-exposure rabies prophylaxis treatment clinical rabies. method includes using naïve antibody phage display library screen phage clones bind whole recombinant rabies virus cells expressing glycoprotein multiple lyssaviruses (such rabv, mokv wcbv) and/or specifically bind recombinant glycoprotein different lyssaviruses.',\n",
              " 'methods making unbiased phage librariesdescribed herein method preparing unbiased library phage variants, comprising (a) preparing population “acceptor phage”; (b) removing endogenous target gene inserting gene variants acceptor phage genomes; (c) enriching recombined phages; (d) expressing library selection. acceptor phage lytic phage comprising synthetic genome wherein target gene interest flanked recombinase sites. acceptor phage infects first host bacteria expressing recombination plasmid facilitating recombination. phages infect second host bacteria expressing counterselection system accumulates recombined phage variants selecting non-recombined phages. accumulated phage variants infect third host bacteria. phage library may sequenced characterized.',\n",
              " 'use spycatcher protein scaffold peptide display; spycatcher/spytag cyclised peptides displayed bacteriophagedescribed herein modified spycatcher protein (comprising amino acid sequence least 80% identity seq id no: 1) wherein modification comprises peptide inserted region protein corresponding amino acid residues 12- 22, 27-31, 38-43, 48-50 59-68 seq id no: 1. described bacteriophage particles displaying chimeric protein comprising spycatcher, peptide interest, spytag, spycatcher spytag linked via isopeptide bond.',\n",
              " 'display systems proteins interestdescribed herein protein display selection method uncouples protein interest (poi) library display selection system. display poi achieved forming covalent bond poi anchor protein post expression either enzymatic protein ligation (e.g. spyligase, snoopligase, sortase, butelase, peptiligase etc.) spontaneous covalent bond formation (e.g. spy tag/spy catcher, snooptag/snoopcatcher, etc.). poi library fused tethering sequence, example spytag, c-terminus poi forms covalent bond capture sequence found anchor protein, example, spycatcher-fused anchor protein, e.g., spycatcher-genelll protein (spycatcher-piii) fusion, common form phage display. nucleic acid constructs, host cell systems methods producing protein display systems provided.',\n",
              " 'designing soluble full-length hiv-1 gp41 trimerdescribed herein soluble hiv-1 retrovirus transmembrane glycoprotein gp41 trimer (soc-gp41m-fd) containing partial ectodomain cytoplasmic domain, fused small outer capsid (soc) protein bacteriophage t4 foldon domain bacteriophage t4 fibritin (fd). gp41 trimer prehairpin structure utilized understand mechanism viral entry candidate development hiv-1 vaccines, diagnostics therapeutics. secondary embodiments gp41 proteins containing different modifications disclosed. according one embodiment, gp41 trimer attached cell penetration peptide (cpp). methods producing gp41 trimers disclosed.',\n",
              " 'generation use fab, scfv, related binding molecules specific hiv-1 revdescribed herein identification, though phage display, chimeric rabbit/human anti-rev fab (sjs-r1) readily solubilized polymeric hiv-1 rev. fab binds high affinity conformational epitope n-terminal half hiv-1 rev. corresponding single chain antibody (scfv) prepared characterized. methods making using sjs-r1 fab sjs-r1 scfv, antibodies antibody fragments share least one cdr sjs-r1 fab, provided. specific described methods include methods preventing reversing polymerization hiv rev, methods preventing inhibiting replication lentivirus cell, methods reducing infectivity replication lentivirus, inhibiting rev function cell infected lentivirus, methods treating disease symptom associated rev expression animal.',\n",
              " 'mesothelin antibodies methods eliciting potent antitumor activitydescribed herein use phage display antibody engineering technology synthetic peptide screening identify sdl sd2, human single-domain antibodies mesothelin. sdl recognizes conformational epitope c-terminal end (residues 539-588) human mesothelin close cell surface. sd2 binds full-length mesothelin. investigate sdl potential therapeutic agent, recombinant human fc (sdl-hfc) fusion protein generated. sdl-hfc protein exhibits strong complement-dependent cytotoxicity (cdc), addition antibody- dependent cellular cytotoxicity (adcc), mesothelin-expressing tumor cells. furthermore, sdl-hfc protein causes significant tumor growth inhibition tumor xenografts nude mice. sdl sd2 first human single-domain antibodies targeting mesothelin-expressing tumors.',\n",
              " 'engineered multi-omic display constructs display systemsdescribed several embodiments herein engineered phagemids bacteriophages containing same. described several embodiments herein methods using engineered phagemids bacteriophages containing same. embodiments, engineered phagemids bacteriophages containing capable providing multi-omic information single-cell level.',\n",
              " 'bioadhesive biodegradable formulations provide sustained release antimicrobials, bacteriophages anti-inflammatory medications inactivation biofilms treatment rhinosinusitis infectionsdescribed composition comprising one active ingredients coated, dispersed, dissolved mucoadhesive polymer. although subject multiple uses, composition, embodiments, usable treating rhinosinusitis.',\n",
              " \"novel family dna polymerases accepting 2-aminoadenine rejecting adenine substratesdescribed novel family dna polymerases identified bacteriophages (mainly family siphiroviridae) able accept 2-amino-2'-deoxyadenosine 5'-triphosphate (dztp) substrate accept deoxyadenosine 5'-triphosphate (datp) substrate. described recombinant nucleic acid molecules, encoding polymerases, vectors comprising nucleic acid molecules, host cells transformed nucleic acid molecules vectors well methods producing dna molecules containing 2-amino-2'-deoxyadenosine (dz) instead 2'-deoxyadenosine (da) making use novel polymerase.\",\n",
              " 'bacteriophage-based artificial viruses human genome remodelingdescribed “artificial virus” (av) programmed biomolecules enter human cells carry precise human genome modification. avs comprise: least one viral vector, bacteriophage t4; least one therapeutic molecule, dna, rna, protein complex; lipid coating. described method human genome modification, using av, method program av.',\n",
              " 'engineered bacteriophage t4 nanoparticles potential targeted activator hiv-1 latency cd4+ human t-cellsdescribed engineered viral particle programmed cell targeting specificity. viral particles comprise: least one viral vector, bacteriophage t4; least one cd4-binding protein displayed surface viral vector. described method reactivate latent hiv-1 cure patient hiv-1 infection, using engineered viral particle.',\n",
              " 'improved method selecting desired protein librarydescribed improved method selecting member specific binding pair (sbp) desired specify, preferably antibody, library expressing said member sbp, preferably phage-display antibody library.',\n",
              " 'fabrication phage nanobioparticles burn wound methicillin-resistant staphylococcus aureus (mrsa) infectionsdespite advances field control treatment burn wounds infection main cause mortality burn patients. control treatment infected wound one main problems due increased strains mdr (multi drug resistance) methicillin-resistant staphylococcal aureus (mrsa). according increased multidrug resistance (mdr) return infections need new product treatment infection. lytic bacteriophages products endolysin suggested. order optimal using bacteriophages field nanomedicine phage display technique used. results showed phage nanobioparticles lytic activity mrsa vitro, phage nanobioparticle gel lytic activity mrsa vivo. 30 days observed reepithelization, scar formation, fibroblast maturation, collagen deposition, granulation tissue, neovascularization infected group treated phage nanobioparticle gel.',\n",
              " 'detection bacteriofagos infecting lactobacillus delbrueckii real-time quantitative polymerase chain reaction (qrt-pcr) use. (machine-translation google translate, legally binding)detection bacteriophages infect lactobacillus delbrueckii real-time quantitative polymerase chain reaction (qrt-pcr) use. present invention describes method detection, especially milk, traces destructive bacteriophages species lactobacillus delbrueckii used industrial lactic fermentations, means qrt-pcr. amplification carried using single pair oligonucleotide primers which, suitable conditions, amplify double-stranded fragment flanked said oligonucleotides. viruses one main causes failure industrial dairy fermentations, causing significant economic losses. procedure allows make decisions allocating contaminated milk processes lb intervene. delbrueckii sensitive detected phages inactivation treatments, well disinfection production plant. main advantage procedure speed, together specificity, simplicity sensitivity. (machine-translation google translate, legally binding)',\n",
              " 'method distinguishing origin crop means virus-based discoloration sensor device discriminating origin crop comprising virus-based discoloration sensordisclosed method distinguishing origin crop means virus-based discoloration sensor, device distinguishing origin crop means virus-based discoloration sensor. method distinguishing origin crop means virus-based discoloration sensor comprises steps of: preparing sample color change values original color virus-based discoloration sensor altered colors changed exposing virus-based discoloration sensor components included sample crops classified origin, wherein nanofiber bundle formed m13 bacteriophages arranged base substrate virus-based discoloration sensor; obtaining color change values analysis altered colors crop analyzed respect discoloration sensor original color discoloration sensor; distinguishing origin crop analyzed according degree similarity color change values analysis sample color change values.',\n",
              " 'cd19-targeted human antibody preparation use thereofdisclosed method screening cd19-targeted human antibody means phage display technology cd19-targeted human antibody, wherein combined single chain antibody seq1-seq5, seq1-seq6, seq2-seq7, seq3-seq8 seq4-seq9 specifically bind cd19 protein. cd19-targeted human antibody used chimeric antigen receptor technology, construction monoclonal antibody kill tumor cells adcc cdc action mechanism, combining antibodies construct bispecific antibody.',\n",
              " 'method screening identifying live attenuated influenza vaccine strainsdisclosed method screening identifying live attenuated influenza vaccine strains, method obtaining candidate viral strains live attenuated vaccines means constructing screening high density random insertion mutant library viral genes mediated mu phage transposons. present invention develops set technical systems use systematically evaluating obtained live attenuated vaccine strains.',\n",
              " 'bacteriophage pbes04 cronobacter sakazakii uses thereofdisclosed novel bacteriophage infecting cronobacter sakazakii, mutant thereof, progeny thereof, uses thereof. bacteriophage accordance present invention effectively eliminates cronobacter sakazakii strains, pathogen resistant various antibiotics becomes big problem medical world, specifically infecting opportunistic cronobacter sakazakii, thereby able used antibiotic.',\n",
              " 'bacteriophage pbes01 cronobacter sakazakii uses thereofdisclosed novel bacteriophage infecting cronobacter sakazakii, mutant thereof, progeny thereof, uses thereof. bacteriophage accordance present invention effectively eliminates cronobacter sakazakii, pathogen resistant various antibiotics becomes big problem medical world, specifically infecting opportunistic cronobacter sakazakii, thereby able used antibiotic.',\n",
              " 'bacteriophage escherichia coli uses thereofdisclosed novel bacteriophage infectious escherichia coli o157:h7, mutant thereof, progeny thereof, use thereof. according present invention, bacteriophage specifically infects pathogenic escherichia coli o157:h7, effectively eliminates pathogenic escherichia strain, thus used antibiotic. moreover, bacteriophage inhibits biofilm generated thus provide effect preventing food hygienic equipment medical equipment polluted.',\n",
              " 'bacteriophage pbes02 cronobacter sakazakii uses thereofdisclosed novel bacteriophage possessing infectious property cronobacter sakazakii, mutant thereof, progeny thereof, use thereof. bacteriophage according present invention used antibiotics specifically infecting cronobacter sakazakii infectious strain eliminating cronobacter sakazakii strains effectively.',\n",
              " 'vector expressing antibody fragments method producing recombinant phage displays antibody fragments using vectordisclosed plasmid vector (pla- 1 plt-2) producing water-soluble light chain antibody fragments (vl+cl), phagemid vector (phflg3t-l phflg3a-2) heavy chain antibody fragments (vh+chl)-?piii fusion protein expression genotype-phenotype linkage function, host transformed using vectors, method producing selecting water-soluble antibody recombinant phage displaying antibody host. also, provided method producing combinatorial phage display combinatorial fab fragment libraries dvfab-il dvfab- 13 il using dual vector system (dvs-ii) method selecting antigen- specific human fab fragment combinatorial fab fragment libraries.',\n",
              " 'endothelial-targeted adenoviral vectors, methods uses therefordisclosed adenovirus vectors comprising robo4 enhancer/promoter operatively linked transgene. disclosed adenovirus vectors comprising chimeric ad5-t4 phage fibritin shaft, trimerization domain displaying myeloid cell-binding peptide (mbp), robo4 enhancer/promoter operatively linked transgene. disclosed methods expressing transgene endothelial cell vivo, comprising administering mammal adenovirus comprising robo4 enhancer/promoter operatively linked transgene. disclosed uses adenoviral vectors, including mobilization granulocytes, monocytes lymphocytes bone marrow, mobilization cancer cells vivo, selective targeting endothelial cells, cancer treatment methods.',\n",
              " 'dendritic cell targeted adenovirus vaccinationdisclosed camelid single domain antibody (sdab) dendritic cell surface antigens clec9a cd40. disclosed chimeric adenoviruses used vaccines pathogen cancer. chimeric adenovirus targeted dendritic cells incorporates sequence encoding sdab dendritic cell surface antigen. chimeric adenovirus includes phage t4 fibritin trimerization foldon replace ad5 fiber knob. furthermore, e1a/b genetic region chimeric adenovirus replaced heterologous sequence structural gene heterologous virus sequence encoding tumor antigen. examples heterologous viruses include flaviviruses zika, chikungunya, dengue, yellow fever, west nile virus. exemplary zika sequences introduced chimeric adenovirus include full length prm, e ectodomain.',\n",
              " 'p100 bacteriophage control listeria monocytogenesdisclosed compositions methods treating preventing listeriosis using recombinant bacteriophage (p100) bacteriophage-derived endolysin (ply100).',\n",
              " 'bacteriophage compositions methods treatment bacterial infectionsdisclosed compositions, devices, kits, methods treatment enterobacteriaceae infection. aspects present disclosure directed bacteriophage compositions comprising one es17, es19, hp3, hp3.1, hp3.2. certain aspects disclosure directed compositions comprising (a) bacteriophage es17 bacteriophage es19, (b) bacteriophage hp3, (c) bacteriophage hp3.1. disclosed compositions comprising bacteriophage hp 3.2. disclosed devices kits comprising compositions methods use compositions treatment prevention pathogenic e. coli infection.',\n",
              " 'compositions, methods, systems detecting methicillin-resistant staphylococcus aureusdisclosed compositions, methods systems detecting mrsa, example mrsa nasal colonization. certain embodiments, methods use bacteriophage-based amplification signal detection bacteria microorganisms detect mrsa. methods detecting mrsa may include preparing assay comprising selective agent cocktail comprising least two different types recombinant bacteriophages, incubating sample assay, capturing indicator protein product, detecting indicator protein product produced recombinant bacteriophage, wherein positive detection indicator protein product indicates mrsa present sample.',\n",
              " 'enterococcus faecalis strains production bacteriophage preparationsdisclosed enterococcus faecalis strains obtaining monoclonal preparations lytic bacteriophages high titer, particularly devoid contamination undesired bacteriophages, strains guaranteeing production safe use bacteriophage preparations, source dissemination genes associated bacterial virulence.',\n",
              " 'phages biomarker capture methods usedisclosed genetically-modified phages, comprising first nucleic acid sequence encoding least first peptide able bind magnetic nanoparticle, second nucleic acid sequence encoding least second peptide able bind high specificity predetermined biomarker, method using genetically-modified phage displaying first peptide second peptide method analyzing fluid sample predetermined biomarker.',\n",
              " 'edwardsiella ictaluri bacteriophage uses thereofdisclosed isolated bacteriophage lytic activity species edwardsiella bacteria including edwardsiella ictaluri. disclosed bacteriophage designated “φeiau” “φeidwf.” disclosed variant bacteriophage φeiau φeidwf bacteriophage, variant bacteriophage lytic activity edw. ictaluri. disclosed isolated edwardsiella ictaluri bacteriophage polynucleotides polypeptides.',\n",
              " 'compositions methods treating nervous system injuriesdisclosed methods compositions treating traumatic brain injury (tbi). brain injury-specific 4-amino acid peptide (sequence caqk), identified vivo phage display screening mice acute brain injury, shows selective binding mouse human brain injury lesions, systemically injected, specifically homes sites injury penetrating non-penetrating (controlled cortical impact) brain injury models. significantly, peptide alone produces therapeutic effect used absence therapeutic compound.',\n",
              " 'methods compositions controlling valency phage displaydisclosed methods compositions useful, e.g., controlling valency display proteins display library screenings selections. one embodiment, applicable phage phage libraries based bacteriophage, e.g., filamentous bacteriophage.',\n",
              " 'bioluminescent biosensor devicedisclosed methods devices detection bacteria based recognition infection one selected strains bacteria bacteriophage genetically modified cause production inducer molecule bacterium following phage infection. inducer molecule released infected bacterium detected genetically modified bacterial bioreporter cells designed emit bioluminescence upon stimulation inducer. autoamplification bioluminescent signal permits detection low levels bacteria without sample enrichment. disclosed methods detection select bacteria, kits detection select bacteria based described technology.',\n",
              " 'compositions methods identification isolation cell-membrane protein specific binding moietiesdisclosed methods identifying binding moieties recognize antigens displayed cells, membrane proteins recombinant proteins display eptiopes surface cells. binding moieties capable binding membrane proteins difficult obtain proteins depend native environments structural integrity. methods scfv phage display libraries panned whole cells expressing membrane protein emulsion. certain methods permit discrimination binding moieties according affinity avidity target. approach allows rapid identification cell surface epitope specific antibodies research, diagnostics, immunotherapeutics.',\n",
              " 'methods identifying peptides compositions bind oocytes species-specific mannerdisclosed methods identifying peptides compositions bind oocytes animals species-specific manner. methods utilize phage libraries oocytes isolated target species non-target species.',\n",
              " 'methods compositions involving bacteriophage isolatesdisclosed methods increasing virulence bacteriophage, comprising contacting bacteriophage composition comprising bacterium bacterial extract; polymer. disclosed methods propagating isolating therapeutic bacteriophages involve use dilute polymer compositions. disclosed pharmaceutical compositions bacteriophage virulence increased methods set forth herein isolated methods set forth herein.',\n",
              " 'display library processdisclosed methods selecting phage encoding target binding protein. methods include forming mixture comprising plurality diverse display phage, target, support, forming phage immobilized support, comprises phage binds target target immobilized support. phage bind target separated. host cells contacted phage immobilized support via binding target host cells infected phage immobilized support. replicate phage produced infected cells presence target immobilized support, thereby forming replicate phage immobilized support via binding support. replicate phage bind target separated. host cells contacted replicate phage immobilized support.',\n",
              " 'method bacteriophage delivery amplificationdisclosed methods selecting wide host range bacteriophage capable growing plurality bacteria including pathogenic non-pathogenic bacteria bacteriophage selected methods. disclosed methods treating subject infected pathogenic bacterium using bacteriophage methods decontaminating objects using bacteriophage. disclosed methods producing vaccines. another aspect, methods determining bacterial viability methods improving sensitivity biosensor using wide host range bacteriophages disclosed.',\n",
              " 'coliphage biosensordisclosed methods, apparatuses, genetically modified bacteria may used detect bacteriophages sample. embodiments, rapid detection test disclosed test presence coliphages may indicate presence human animal waste contamination water samples.',\n",
              " 'phage constructs, sequences antigenic compositions immunocontraception animalsdisclosed methods, compositions, zona pellucida binding peptides polypeptides, expression vectors use species-specific immunocontraception animals, include landscape bacteriophage. disclosed compositions may include immunogenic compositions vaccines.',\n",
              " 'biologic machines detection biomoleculesdisclosed methods, devices systems isolation detection biomolecules sample. embodiments, detection biomolecules provides detection microorganisms. example, disclosed methods, devices systems use bacteriophage-based amplification signal detection bacteria microorganisms. devices, systems methods invention may allow detection certain biomolecules peptides ions real time using minute amounts sample.',\n",
              " 'dual-image based bioimaging devices techniquesdisclosed methods, systems, devices detecting biological analytes sample. disclosed technology used obtain readings analyte concentration sample imaging scattered light angled narrow beam illuminator. fluid sample containing one biological, organic, inorganic analytes including proteins, viruses, bacteria, phages, toxins, peptides, dna, rna, hormones, chemicals, drugs, isotopes transferred microfluidic device one channels dimensions generate capillary action sample transport. geometry microfluidic device may include reservoir sensing area, wherein immunometric reaction take place narrow beam scanning. test particle may coated specific binding member used bind binding pair member analyte sample. test particles form binding particle/analyte conjugate may scanned.',\n",
              " 'highly productive one-pot system incorporation non-standard amino acids cell-free synthesized proteinsdisclosed methods, systems, components, compositions related genomically recoded engineered organisms. disclosed genomically recoded engineered organisms may used prepare extracts use platforms methods preparing sequence defined biopolymers vitro. particular, methods, systems, components, compositions relate genomically recoded engineered organisms comprising strain deficient release factor 1 (rf-1) genetic homolog thereof, wherein genomically recoded organisms engineered express heterologous rna polymerase may utilized express target protein transcription template comprising promoter heterologous rna polymerase, bacteriophage t7 rna polymerase.',\n",
              " 'bacteriophage pseudomonas aeruginosa uses thereofdisclosed new bacteriophage contagiosity pseudomonas aeruginosa, mutant thereof, progeny thereof, use thereof. bacteriophage present invention specifically infects pseudomonas aeruginosa opportunistic strain, resistance various kinds antibiotics effectively removing pseudomonas strains pathogenic bacteria causing serious problems medical world used antibiotic. bacteriophage interferes generation biofilm provides anti-fouling effect food hygiene devices medical devices.',\n",
              " \"bacteria high efficiency cloningdisclosed novel bacterial hosts capable high efficiency transformation methylated and/or unmethylated nucleic acids, bacteriophage resistant. bacteria contain: (1) f' episome confers high efficiency transformability; (2) one mutations allow transformation methylated nucleic acids; (3) one mutations allow transformation unmethylated nucleic acids; and/or (4) one mutations confer resistance bacteriophage infection. disclosed methods transforming bacteria, kits contain bacteria (e.g., made competent transformation).\",\n",
              " 'phage displaying system expressing single chain antibodydisclosed nucleic acid libraries identifying signal peptide facilitates production disulfide-stabilized single chain antibody, facilitating production disulfide-stabilized single chain antibody. disclosed host cell libraries phage libraries including nucleic acid libraries. disclosed methods identifying signal peptide facilitates production disulfide-stabilized single chain antibody, methods producing disulfide-stabilized single chain antibody non-fusion form thereof.',\n",
              " 'peptides, especially polypeptides, phage display screening method associated means, uses research biomedical applicationsdisclosed peptides, hosts expressing peptides process producing screening peptides hosts. disclosed use peptide host expressing peptide detection disease, method constructing library hosts, particular phages expressing peptides. disclosed library hosts expressing peptides use example detecting molecules and/or cells sample, treatment disease. find application therapeutic diagnostic medical technical fields.',\n",
              " 'bacteriophages treatment tuberculosisdisclosed pharmaceutical compositions comprising combination five phages pharmaceutically acceptable carrier, well methods treating, reducing, preventing disease caused mycobacterium tuberculosis mammal, methods treating antibiotic resistant infection mammal, methods treating, reducing, preventing activation latent disease caused m. tuberculosis.',\n",
              " 'phage-peptide constructs stimulating immune response cd47disclosed recombinant bacteriophage constructs related exogenous peptide sequences generating immune responses cd47. disclosed recombinant phage constructs bind antibodies cd47 administered animal generate immune response cd47, including generating anti-cd47 antibodies. disclosed recombinant phage may comprise amino acid sequence cd47, epitopic fragments, variants, functional mimics thereof. disclosed methods making selecting recombinant phage constructs compositions comprise constructs (e.g., compositions inducing immune response cd47 including pharmaceutical veterinary compositions used vaccines). disclosed recombinant polynucleotides comprising genomic nucleic acid recombinant phage constructs disclosed herein.',\n",
              " 'phage-gnrh constructs, mimics, antigenic compositions, sequences immunocontraception animals applicationsdisclosed recombinant bacteriophage constructs related heterologous peptide sequences contraception animals. disclosed recombinant phage constructs bind antibodies gonadotropin releasing hormone (gnrh) administered animal generate immune response gnrh, including generating anti-gnrh antibodies. disclosed recombinant phage may comprise amino acid sequence gonadotropin releasing hormone (gnrh), epitopic fragments, variants, functional mimics thereof. disclosed methods making selecting recombinant phage constructs compositions comprise constructs (e.g., compositions inducing immune response gnrh including pharmaceutical veterinary compositions used vaccines). disclosed recombinant polynucleotides comprising genomic nucleic acid recombinant phage constructs disclosed herein.',\n",
              " 'phage-gnrh constructs, mimics, antigenic compositions, sequences induce anti-gnrh antibodies animalsdisclosed recombinant bacteriophage constructs related heterologous peptide sequences generating anti-gnrh immune responses animals. disclosed recombinant phage constructs heterologous peptides, bind antibodies gonadotropin releasing hormone (gnrh) administered mammal generate immune response gnrh, including generating anti-gnrh antibodies, particular anti-gnrh antibodies neutralize gnrh reduce hormone levels mammal immunocontraception treating gnrh -dependent cancers. disclosed recombinant phage may comprise amino acid sequence gonadotropin releasing hormone (gnrh), epitopic fragments, variants, functional mimics thereof. disclosed methods making selecting recombinant phage constructs compositions comprise constructs (e.g., compositions inducing immune response gnrh including pharmaceutical veterinary compositions used vaccines). disclosed recombinant polynucleotides including genomic nucleic acid recombinant phage constructs disclosed herein.',\n",
              " 'system protein inactivation recombinant phages targeted bacterial killing, infection, biodetection, means protein extractiondisclosed recombinant phages infect kill bacterial hosts response user-defined inputs. components encode user-defined inputs combined, multiple inputs maintained single recombinant phage, enabling precise control targeting strategy. phages engineered kill specific bacterial species multiple species simultaneously. recombinant phages engineered harbor fluorescent bioluminescent reporter genes enable used tracking, detection, biosensing applications. recombinant phages used lyse bacterial cells produce recombinant proteins, rapid method enable extraction high-level purification potentially valuable and/or industrially important proteins. disclosed system used control activity protein interest, taking advantage interaction qtip phage repressor protein; phage repressor protein fused protein-of-interest, controlling expression qtip, phage repressor protein fused protein-of-interest inactivated qtip expressed interacts phage repressor protein.',\n",
              " 'staphylococcus aureus strains production monoclonal phage preparations deprived contamination plasmid dnadisclosed staphylococcus aureus strains obtaining monoclonal preparations lytic bacteriophages high titer, devoid contamination undesired bacteriophages plasmid dna, guarantee production safe use bacteriophage preparations, source dissemination genes associated bacterial virulence.',\n",
              " 'targeted particles comprising landscape phage fusion proteins heterologous nucleic aciddisclosed targeted particles comprising consisting plurality landscape phage fusion proteins complexed heterologous nucleic acid, landscape phage fusion proteins displaying heterologous peptide targeted particle binding specifically target site. particles may utilized methods modulating expression genes target cells.',\n",
              " \"phage compositions comprising crispr-cas systems methods use thereofdisclosed phage compositions comprising crispr-cas systems methods use thereof. certain embodiments, disclosed herein bacteriophage comprising nucleic acid sequence encoding type crispr-cas system comprising: (a) crispr array; (b) cascade polypeptide; (c) cas3 polypeptide. embodiments, crispr array comprises spacer sequence least one repeat sequence. embodiments, least one repeat sequence operably linked spacer sequence either 5' end 3' end.\",\n",
              " 'phage compositions comprising crispr-cas systems methods use thereofdisclosed phage compositions comprising type crispr-cas systems methods use thereof. embodiments, disclosed herein nucleic acid sequence comprising (a) first crispr array designed operable first type crispr-cas system, (b) second crispr array designed operable second type crispr-cas system, wherein first type crispr-cas system second type crispr-cas system different type crispr-cas systems.',\n",
              " 'phage compositions escherichia comprising crispr-cas systems methods use thereofdisclosed phage compositions escherichia comprising crispr-cas systems methods use thereof.',\n",
              " 'phage compositions staphylococcus comprising crispr-cas systems methods use thereofdisclosed phage compositions staphylococcus comprising crispr-cas systems methods use thereof.',\n",
              " 'phage compositions pseudomonas comprising crispr-cas systems methods use thereofdisclosed phage compositions targeting pseudomonas species comprising crispr-cas systems methods use thereof.',\n",
              " 'phage display biologically active bacillus thuringiensis toxindisclosed herein activated bt toxins expressed e. coli translational fusion phage coat protein filamentous phage. phage displaying fusion protein viable, infectious, lethal pure toxin molar basis fed insects susceptible native bt toxins.',\n",
              " 'bacteriophage modulating inflammatory bowel diseasedisclosed herein bacteriophage compositions therapeutic uses thereof. disclosure relates bacteriophage capable lysing klebsiella bacterial strains, e.g., strains associated inflammatory bowel disease, thereby capable modulating disease.',\n",
              " 'bacteriophage modulating inflammatory bowel diseasedisclosed herein bacteriophage compositions therapeutic uses thereof. disclosure relates bacteriophage capable lysing klebsiella bacterial strains, e.g., strains associated inflammatory bowel disease, thereby capable modulating disease.',\n",
              " 'crispr cas systems lysogeny modulesdisclosed herein compositions methods modifying bacterial population. embodiments, described herein bacteriophage comprising first nucleic acid sequence encoding first spacer sequence crrna transcribed therefrom, wherein first spacer sequence complementary target nucleotide sequence target gene target bacterium, provided bacteriophage rendered lytic.',\n",
              " 'bacteriophage-derived nanopore sensorsdisclosed herein compositions methods involve inserting connector protein channels bacteriophage dna packaging motors copolymeric membranes via liposome-polymer fusion, canbe used nanopore sensors biomedical applications high throughput protein sequencing cancer diagnosis. example, disclosed compositions comprising copolymeric membrane connector protein channel bacteriophage packaging motor inserted.',\n",
              " 'use specific phages treatment nontuberculosis mycobacteria (ntm) infectionsdisclosed herein compositions comprising bacteriophages methods using compositions treating ntm infections. present disclosure provides compositions screening bacteriophages effective treating ntm infections methods using same.',\n",
              " 'prebiotic compositions comprising one types bacteriophagedisclosed herein compositions comprise one types bacteriophage methods using bacteriophages prebiotic promote growth beneficial bacteria decreasing harmful bacterial populations releasing nutrients environment good bacteria digestive system individual.',\n",
              " 'devices methods detecting microorganisms using recombinant reproduction-deficient indicator bacteriophagedisclosed herein compositions, methods, kits systems rapid detection microorganisms using reproduction-deficient indicator bacteriophage. specificity reproduction-deficient indicator bacteriophage binding infecting particular microorganisms interest allows targeted sensitive detection microorganism interest.',\n",
              " 'self-contained apparatus system detecting microorganismsdisclosed herein devices, methods, systems rapid detection microorganisms using recombinant bacteriophage. specificity recombinant bacteriophages binding microorganisms allows targeted highly specific detection microorganism interest.',\n",
              " 'humanized antibodiesdisclosed herein humanized antibodies human germline residues introduces complementarity determining regions (cdrs) non-human donor antibody. described herein libraries antibody variable domains (e.g., phage-display libraries) methods screening humanized antibodies.',\n",
              " 'improved methods performing differential capture proteomicsdisclosed herein improved methods identifying, isolating, comparing proteins biomolecules differing two biological samples using affinity chromatography phage display techniques.',\n",
              " 'inhibition biofilm formation using bacteriophagedisclosed herein indwelling medical devices suitable introduction body subject, wherein indwelling medical devices comprise one surfaces bacterial biofilm form, effective amount bacteriophage composition carried one surfaces, wherein bacteriophage composition inhibits formation bacterial biofilm indwelling medical device. disclosed herein methods inhibiting formation bacterial biofilms indwelling medical devices.',\n",
              " 'novel bacteriophage antibacterial composition comprising samedisclosed herein novel bacteriophage specific bactericidal activity one salmonella bacteria selected group consisting salmonella enteritidis, salmonella typhimurium, salmonella gallinarum, salmonella pullorum without affecting beneficial bacteria. disclosed compositions, animal feeds drinking water, cleaners sanitizers preventing treating infectious diseases caused salmonella enteritidis, salmonella typhimurium, salmonella gallinarum salmonella pullorum including salmonellosis, salmonella food poisoning, fowl typhoid, pullorum disease controlling salmonella bacteria.',\n",
              " 'novel bacteriophage antibacterial composition comprising samedisclosed herein novel bacteriophage specific bactericidal activity one salmonella bacteria selected group consisting salmonella enteritidis, salmonella typhimurium, salmonella gallinarum, salmonella pullorum without affecting beneficial bacteria. disclosed compositions, animal feeds drinking water, cleaners sanitizers preventing treating infectious diseases caused salmonella enteritidis, salmonella typhimurium, salmonella gallinarum salmonella pullorum including salmonellosis, salmonella food poisoning, fowl typhoid, pullorum disease controlling salmonella bacteria.',\n",
              " 'novel bacteriophage antibacterial composition comprising samedisclosed herein novel bacteriophage specific bactericidal activity one salmonella bacteria selected group consisting salmonella enteritidis, salmonella typhimurium, salmonella gallinarum, salmonella pullorum without affecting beneficial bacteria. disclosed compositions, animal feeds drinking water, cleaners sanitizers preventing treating infectious diseases caused salmonella enteritidis, salmonella typhimurium, salmonella gallinarum salmonella pullorum including salmonellosis, salmonella food poisoning, fowl typhoid, pullorum disease controlling salmonella bacteria.',\n",
              " 'compositions methods manufacturing bacteriophage cancer vaccines uses thereofdisclosed herein methods compositions manufacturing nanoparticle bacteriophage-based vaccines useful anti-cancer treatments. disclosed herein methods using bacteriophage-based vaccines expressing aspartyl (asparaginyl) β-hydroxylase treating cancer.',\n",
              " 'recombinant bacteriophage detection nosocomial infectiondisclosed herein methods devices detection bacterial hai. disclosed methods may utilized continuous vivo monitoring potential bacterial infection site may utilized alert patients and/or health care providers presence pathogenic bacteria early stage infection. disclosed methods include utilization recombinant bacteriophage deliver pathogenic bacteria translatable genetic sequence encoding optically detectable marker enzyme capable producing optically detectable marker. upon detection optical signal produced marker, medical personnel may alerted presence pathogenic bacteria site inquiry. bacterial causative agent hai may detected according disclosed methods.',\n",
              " 'indicator bacteriophage selecting monitoring efficacy therapeutics methods using samedisclosed herein methods systems detection microorganisms sample utilization methods selecting monitoring therapies. specificity indicator bacteriophage, staphylococcus-specific bacteriophage, allows detection specific microorganism, staphylococcus indicator signal may amplified optimize assay sensitivity.',\n",
              " 'methods systems detection antibiotic resistancedisclosed herein methods systems rapid detection antibiotic resistance microorganism sample. modified recombinant phage disclosed comprises indicator gene late gene region. specificity infectious agents allows specific microorganism targeted, indicator signal may amplified optimize assay sensitivity.',\n",
              " 'methods systems rapid detection microorganisms using recombinant bacteriophagedisclosed herein methods systems rapid detection microorganisms sample, without culturing enrichment microorganism. modified bacteriophage disclosed comprises non-native indicator gene late gene region. indicator product fusion protein. specificity infectious agents allows specific microorganism targeted, indicator signal may amplified optimize assay sensitivity.',\n",
              " 'methods systems rapid detection bacteria using recombinant bacteriophage express indicator subunitdisclosed herein methods systems rapid detection microorganisms bacteria sample. genetically modified bacteriophage disclosed comprises indicator gene encoding one subunit indicator protein. specificity bacteriophage allows detection particular bacteria interest indicator signal may amplified optimize assay sensitivity.',\n",
              " 'methods systems rapid detection listeria using infectious agentsdisclosed herein methods systems rapid detection microorganisms listeria spp. sample. genetically modified bacteriophage disclosed comprises indicator gene late gene region. specificity bacteriophage, listeria-specific bacteriophage, allows detection specific microorganism, listeria spp. indicator signal may amplified optimize assay sensitivity.',\n",
              " 'methods systems rapid detection listeria using infectious agentsdisclosed herein methods systems rapid detection microorganisms listeria spp. sample. genetically modified bacteriophage disclosed comprises indicator gene late gene region. specificity bacteriophage, listeria-specific bacteriophage, allows detection specific microorganism, listeria spp. indicator signal may amplified optimize assay sensitivity.',\n",
              " 'high-throughput screening functional antibody fragments, immunoconjugate comprising same, adaptor-drug conjugate screeningdisclosed herein methods high-throughput screening functional antibody fragment immunoconjugate targets protein antigen. method combines phage-displayed synthetic antibody library high-throughput cytotoxicity screening non-covalently assembled immunotoxins cytotoxic drug identify highly functional synthetic antibody fragments delivering toxin payloads.',\n",
              " 'differential phage capture proteomicsdisclosed herein methods identifying, isolating comparing proteins biomolecules differing two complex biological samples using affinity chromatography phage display techniques.',\n",
              " 'methods producing mutant bacteriophages detection listeriadisclosed herein methods production mutant bacteriophages altered host range. additionally, disclosed herein methods systems rapid detection microorganisms listeria spp. sample. genetically modified bacteriophage disclosed comprises indicator gene late gene region. specificity bacteriophage, listeria-specific bacteriophage, allows detection specific microorganism, listeria spp. indicator signal may amplified optimize assay sensitivity.',\n",
              " 'combination therapies cancerdisclosed herein methods treating cancer administering subject composition comprising bacteriophage expressing fragment human aspartate β-hydroxylase (asph) immune checkpoint protein inhibitor.',\n",
              " 'universal method extracting nucleic acid molecules diverse population one types microbes sampledisclosed herein methods extracting genetic material diverse population one types microbes sample. microbes prokaryotes eukaryotes may include bacteria, archaea, fungi, protozoa, helminths, parasites, viruses, phages, others. extraction may single sample subsequent identification may molecular method qpcr, pcr, rflp, sscp, allele specific pcr, targeted sequencing, pull sequencing, whole shotgun sequencing, methods.',\n",
              " 'antiviral, bacteriophage-derived polypeptides use virusesdisclosed herein methods using chp peptides treating viral infection coronavirus, including, example, covid-19, subject. disclosed methods using chp peptides inhibiting growth, reducing population, neutralizing infectivity of, and/or killing virus, coronavirus, including, example, covid-19. disclosed pharmaceutical compositions comprising effective amount chp peptide; pharmaceutically acceptable carrier treating viral infection, infection caused coronavirus, covid-19.',\n",
              " 'methods systems detection microorganisms using infectious agentsdisclosed herein methods, compositions, kits, systems rapid detection microorganism interest surface, including medical devices. cocktail compositions recombinant bacteriophages used detect potentially harmful bacteria. specificity recombinant bacteriophages binding microorganisms allows targeted highly specific detection microorganism interest.',\n",
              " 'compositions methods multiplex detection microorganisms using peptide-tagged recombinant infectious agentsdisclosed herein methods, compositions, kits, systems rapid multiplex detection microorganism interest. recombinant bacteriophages encoding capture moiety-indicator protein fusion products allow capture indicator proteins surface. cocktail compositions recombinant bacteriophages used detect potentially harmful bacteria. specificity recombinant bacteriophages binding microorganisms allows targeted highly specific detection microorganism interest.',\n",
              " 'genetic systems defend foreign dna uses thereofdisclosed herein microbial defense systems, provide cells protection phage infection plasmid transformation. methods use defense systems protecting cells phage infection plasmid transformation disclosed, wherein defense systems may used individually combination. addition, disclosed herein methods making cells express defense systems.',\n",
              " 'modified phage displaying post-translationally modified proteins uses thereofdisclosed herein modified phage comprising fusion protein located surface phage wherein fusion protein comprises surface protein post-translationally modified protein. disclosed methods making using modified phage comprising post-translationally modified proteins located surface phage.',\n",
              " 'phi29 dna polymerase mutants improved primer recognitiondisclosed herein mutants bacteriophage phi29 dna polymerase improved primer recognition, compared wild-type enzyme. certain mutants comprise one mutations k64r m97k. provided mutants capable using efficiently shorter longer random synthetic dna primers wild-type phi29 dna polymerase, generating amplification product multiple displacement amplification (mda) reactions. inventive mutants amplify human genomic dna less bias better coverage comparison reactions carried wild-type phi29 dna polymerase.',\n",
              " 'methods cloning prophages producing lytic phage particlesdisclosed herein novel methodologies cloning prophage genome sequences identified target organisms dna sequencing data contain mutations decrease function prophage repressor proteins producing lytic phage particles decreased prophage repressor protein function.',\n",
              " 'synthetic bacteriophages bacteriophage compositionsdisclosed herein novel synthetic bacteriophages bacteriophage compositions, methods production thereof, therapeutic uses thereof.',\n",
              " 'phage-displayed antibody libraries usesthereofdisclosed herein phage-displayed single-chain variable fragment (scfv) libraries, comprised plurality scfvs specific sequence cdr. present scfv libraries used efficiently produce different antibodies high binding affinity h1 hemagglutinin influenza virus. accordingly, present disclosure provides potential means generate different antigen-specific antibodies promptly accordance need experimental researches and/or clinical applications.',\n",
              " 'antimicrobial, bacteriophage-derived polypeptides use gram-negative bacteria.disclosed herein pharmaceutical compositions comprising effective amount isolated chp peptide amino acid sequence selected group consisting seq id nos. 1-4, 6-26 54-66, modified chp peptide 80% sequence identity therewith, wherein modified chp peptide inhibits growth, reduces population, kills least one species gram-negative bacteria; pharmaceutically acceptable carrier. disclosed herein isolated chp peptides, well vectors comprising nucleic acid molecule encode chp peptides host cells comprising vector. disclosed herein methods inhibiting growth, reducing population, killing least one species gram-negative bacteria methods treating bacterial infection subject.',\n",
              " 'antimicrobial, bacteriophage-derived polypeptides use gram-negative acid-fast bacteriadisclosed herein pharmaceutical compositions comprising effective amount isolated chp peptide amino acid sequence selected group consisting seq id nos. 81-91 94-102, modified chp peptide 80% sequence identity therewith, wherein modified chp peptide inhibits growth, reduces population, kills least one species gram-negative acid-fast bacteria; pharmaceutically acceptable carrier. disclosed herein isolated chp peptides, well vectors comprising nucleic acid molecule encode chp peptides host cells comprising vector. disclosed herein methods inhibiting growth, reducing population, killing least one species gram-negative acid-fast bacteria, methods treating bacterial infection subject, methods prevention, disruption, treatment biofilm comprising gram-negative bacteria.',\n",
              " 'bacteriophage preparations methods use thereofdisclosed herein purified bacteriophage preparations effectively lyse plurality c. perfringens strains. one embodiment, purified bacteriophage preparation includes four c. perfringens-specific bacteriophage, wherein bacteriophage lytic activity least five clostridium species strains. another embodiment, purified bacteriophage preparation includes five c. perfringens-specific bacteriophage.',\n",
              " 'situ readout dna barcodesdisclosed herein include systems, methods, compositions, kits situ readout barcodes, dna barcodes. barcode constructs containing promoter (e.g., phage promoter) inactive live cells integrated genomes cells. cells fixed, phage rna polymerase used transcription barcode rna transcripts. rna transcripts detected using, example, fluorescent imaging used determine barcode sequences.',\n",
              " 'phi29 nanochannel early detection breast cancer biomarkersdisclosed herein biosensor detecting breast cancer biomarkers biological sample subject. biosensor based double-stranded dna bacteriophage dna-packaging motor connector protein modified 1) contain affinity domain least one breast cancer biomarker, 2) incorporated membrane layer phospholipid bilayer membrane, form aperture conductance occur electrical potential applied across membrane. embodiments, binding breast cancer biomarker affinity domain alters conductance aperture, measured disclosed herein.',\n",
              " 'phage characterization method devicesdisclosed herein method characterizing phage solution microfluidic device comprising steps mixing phage solution dilution thereof bacterial solution, thereby generating phage/bacteria solution; set microfluidic channels said microfluidics device pumping phage/bacteria solution droplet generator unit, thereby generating phage/bacteria droplets; incubating generated phage/bacteria droplets transparent incubation chamber; and; monitoring, function time, characteristics phage/bacteria droplets said incubation chamber.',\n",
              " 'bacteriophage antibacterial composition comprising samedisclosed herein novel bacteriophage specific bactericidal activity one salmonella bacteria selected group consisting salmonella enteritidis, salmonella typhimurium, salmonella gallinarum, salmonella pullorum without affecting beneficial bacteria, addition showing excellent tolerance acid, heat desiccation. novel bacteriophage present invention widely used active ingredient therapeutic agents, animal feeds drinking water, cleaners sanitizers preventing treating infectious diseases caused salmonella enteritidis, salmonella typhimurium, salmonella gallinarum salmonella pullorum including salmonellosis, salmonella food poisoning, fowl typhoid, pullorum disease controlling salmonella bacteria. present invention provides important insights prevention control strategies salmonella infection suggests use bacteriophage novel, safe, effectively plausible alternative antibiotics prevention salmonella infection poultry.',\n",
              " 'particle delivery via small-scale morphology materials antibacterial applicationsdisclosed herein particle delivery system comprising electrospun nanofiber comprised coaxial fiber microfluidic core. iron-doped apatite nanoparticles (idanps) demonstrated unique influence phage killing bacteria, whereby, idanp-exposed bacterial cultures experience 2× bacterial death controls. idanps consist hydroxyapatite (ha) doped iron. ha mineral known biocompatible analogous inorganic constituent mammalian bone teeth approved food drug administration (fda) many applications medicine dentistry. previous work shown idanps enhance antibacterial activity phage greatest extent, bacterial cultures exposed idanps 1 hr prior phage introduction. biocompatible polymer materials encase idanps and/or phage used disseminate idanps and/or phage controlled manner physiological system treatment bacterial infection. components said materials contain micro- nano-scale components, high surface-to-volume ratio treatment delivery garnered.',\n",
              " 'phage-displayed single-chain variable fragment librarydisclosed herein phage-displayed single-chain variable fragment (scfv) library, comprised plurality phage-displayed scfvs characterized (1 ) specific cs combination; (2) specific distribution aromatic residues cdr; (3) specific sequence cdr. present scfv library used efficiently produce different antibodies binding affinity different antigens. accordingly, present disclosure provides potential means generate different antigen-specific antibodies promptly accordance need experimental researches and/or clinical applications.',\n",
              " 'phage-displayed single-chain variable fragment libraries uses thereofdisclosed herein phage-displayed single-chain variable fragment (scfv) library, comprises plurality phage-displayed scfvs characterized specific cs combination specific sequence cdr. present scfv library useful efficiently producing different antibodies binding affinity different antigens. accordingly, present disclosure provides potential means generate different antigen-specific antibodies promptly accordance need experimental researches and/or clinical applications.',\n",
              " 'phage-displayed single-chain variable fragment library selecting antibody fragments specific mesothelindisclosed herein phage-displayed single-chain variable fragment (scfv) library, comprises plurality phage-displayed scfvs characterized specific sequence cdr. present phage-displayed scfv library useful selecting antibody fragment exhibiting binding affinity specificity mesothelin (msln). disclosed herein recombinant antibody specific msln, immunoconjugate comprising recombinant antibody, uses thereof treating cancers.',\n",
              " 'egfr binding moiety-presenting bacteriophages tumour treatmentdisclosed herein targeted tumour-infiltrating bacteriophage. bacteriophage engineered present epidermal growth factor receptor (egfr)-binding moiety bacteriophage cell surface. egfr-binding moiety capable binding extracellular domain egfr. disclosed compositions, kits, methods uses thereof. disclosed method treating tumour subject need thereof, method comprising: administering subject composition comprising plurality bacteriophage engineered present epidermal growth factor receptor (egfr)-binding moiety bacteriophage cell surface dose effective treat tumour, wherein tumour egfr-positive tumour egfr-binding moiety capable binding egfr extracellular domain.',\n",
              " 'methods devices related controlled delivery phages theranostic tooldisclosed herein engineered bacteriophage comprising indicator gene, wherein said indicator gene rna aptamer green fluorescent protein (gfp) gfp-like protein, wherein said indicator gene indicate presence microorganism, bacterial infection. engineered bacteriophage capable infecting killing microorganism. engineered microorganism composition delivery subject, hyaluronic acid, example. disclosed methods using engineered bacteriophage diagnose and/or treat subject bacterial infection.',\n",
              " 'phage wrappingdisclosed herein, inter alia, compositions methods useful improving detection analytes. compositions methods provided include polymer-wrapped viral particles useful, inter alia, detection psma.',\n",
              " 'bacteriophage pa7 pseudomonas aeruginosadisclosed present invention novel bacteriophage infecting pseudomonas aeruginosa, mutant same, progeny same, use same. bacteriophage according present invention specifically infects pseudomonas aeruginosa oppotunistic strain, thereby effectively removing pseudomonas aeruginsa pathogen tolerance various antibiotics major problem medical circle, used antibiotic, moreover, prevents biofilm formation, thus, provide anti-fouling effect hygienic device food medical device.',\n",
              " 'carrier conjugates gnrh-peptidesdisclosed composition comprising: (a) virus particle (vlp), wherein said vlp vlp rna-phage, (b) least one gonadotrophin releasing hormone (gnrh) peptide; wherein a) b) linked one another, wherein said vlp (a) linked least one gnrh-peptide (b) least one non-peptide covalent bond; wherein said composition comprising linker (c) said vlp said least one gnrh-peptide wherein said linker consists less 4 amino acids.',\n",
              " 'vlp-antigen conjugates uses vaccinesdisclosed composition comprising: (a) virus-like particle (vlp) comprising coat proteins, mutants fragments thereof, rna-bacteriophage least one first attachment site, wherein said vlp recombinantly produced host, said vlp essentially free host rna, wherein said mutant said fragment said coat protein said rna-bacteriophage capable assembling vlp, wherein said mutant said coat protein said rna-bacteriophage amino acid sequence identity least 80% amino acid sequence said coat protein, wherein said fragment said coat protein said rna-bacteriophage polypeptide least 70% length said coat protein (b) least one antigen least one second attachment site; wherein said least one antigen (b) linked said vlp (a) said least one first attachment site said least one second attachment site, wherein said composition comprises least one polyanionic macromolecule packaged inside said vlp, wherein said polyanionic macromolecule selected group consisting of: (a) polyanionic polypeptides; (b) polyanionic saccharides; (c) polyanionic organic polymers; (d) nucleic acids, wherein said nucleic acid toll-like receptor ligand.',\n",
              " 'compositions reducing virus infection rate aquatic crustaceans applications thereofdisclosed composition reducing virus infection rates crustaceans, applied prevention and/or treatment viral infection crustaceans, improves survival rate. composition comprises least one antibodies bind specifically virus, antibodies selected group consisting monoclonal antibody, phage display antibody antibody produced recombinant organism. monoclonal antibodies produced large scale hybridoma cells bioreactor injecting abdominal cavities mice. alternatively, two highly specific antibodies produced phage clones recombinant organisms. composition used forms therapeutic medicines, nutritious feeding supplements addition feeds. also, composition used aqueous solution expose crustaceans fulfill needs treatment and/or prevention viral infection crustaceans.',\n",
              " 'detecting plate bacterial medicine sensitivity experiment detecting minimum bacterium-inhibiting concentration antibioticsdisclosed detection plate detecting minimum antibacterial concentration bacteriophages. filtration-membrane strip quantitative concentration gradient bacteriophages fixed substrate, thus leading detection plate bacterial drug sensitivity test. concentration adjacent bacteriophages increases doubly filtration-membrane strip 8-13 grades concentration units arranged. utility model carries two-in-one detection measure including drug sensitivity minimum antibacterial concentration (mic) bacteriophages surface solid semisolid culture medium; device applied easily, function detecting minimum antibacterial concentration (mic) bacteriophages replace current expensive apparatus produced overseas, utility model applied various-level hospitals, veterinary stations food industries. utility model advantages reliability, simple easy application low cost.',\n",
              " 'methods detecting separating culturing separating/identifying target bacteriophagedisclosed method detecting target bacteriophage. method detecting target bacteriophage comprises step of: immobilizing host bacterium selectively reacts target bacteriophage outer membrane host bacterium surface substrate conductive nano-islands formed; treating surface substrate host bacterium outer membrane host bacterium immobilized detection sample; detecting whether target bacteriophage present detection sample surface plasmon resonance (spr) method.',\n",
              " 'method efficiently screening fibrinogen using phage antibody librarydisclosed method efficiently screening fibrinogen using phage antibody library, comprising steps of: coating protein, sealing flat plate, removing background phage library, combining phage like. compared phage, phage screened present invention may specifically combined human fibrinogen, strong binding force easy process. phage may added various coagulation materials, enrichment fibrinogen promoted means targeted combination human fibrinogen, blood coagulation effect enhanced. method characteristics simple easy use reagents, high success rate like.',\n",
              " 'improved bacterial two-hybrid assaydisclosed method rapidly efficiently screening substance (e.g., antibody, peptide) capable interacting target substance. specifically disclosed are: novel bacterial two-hybrid assay utilizing gene transfer phage; screening method comprising combination bacterial two-hybrid assay phage display system. bacterial two-hybrid assay screening method enable rapidly efficiently screen substance (e.g., antibody, peptide) capable interacting target substance.',\n",
              " 'real time binding analysis antigens biosensor surfacedisclosed method detecting binding binding partner phage comprising: (a) immobilizing crude phage preparation, unconcentrated phage preparation, non-homogenous phage preparation, concentrated phage preparation combination thereof biosensor, wherein crude phage preparation, unconcentrated phage preparation, non-homogenous phage preparation, concentrated phage preparation combination thereof immobilized biosensor by: (i) antibody specific phage coat protein antibody fragment specific phage coat protein; (ii) passive immobilization; (b) contacting biosensor binding partner; (c) detecting binding binding partner phage immobilized biosensor.',\n",
              " 'cocaine-and amphetamine-regulated transcript peptides single-chain antibody application thereofdisclosed new antibody used relieve addiction caused nerve active substances, including opium, cocaine, benzedrine, ketamine, etc. cocain amphetamine-regulated transcript peptide antibody gene selected phage display technology; single-chain antibody sequence cocain amphetamine-regulated transcript peptide(cart) procaryon expression vector connected induced express purified obtain single-chain antibody response cart, named cartscfv(ah1,ah4b,ah6,ah19,ah33b,ah36). injecteion cartscfv abdominal cavity mouse, together cart peripheral circulation system, leads reduction cart central nervous system mouse. animal model behavioral sensitization induced cocain proves cart single-chain antibody restrain expression behavioral sensitization mouse induced cacain, shows cart single-chain antibody great potential curing addiction particularly relapse caused nerve active.',\n",
              " 'site-specific recombination method kitdisclosed novel integrase catalyse site-specific recombination rapidly low substrate concentrations. site-specific recombination method comprises use integrase recombine first dna flanked two attb second dna flanked two attp, first dna flanked two attp second dna flanked two attb, integrase tg1 phage integrase.',\n",
              " 'novel variable lymphocyte receptor, method screening phage capable binding target antigen, method producing variable lymphocyte receptor target antigendisclosed novel variable lymphocyte receptor (vlr) recognize antigen recognized known molecules vlra vlrb. disclosed method screening phage capable binding target antigen, utilizes vlr. vlr comprises one lrrnt, one lrrct, least one lrr arranged lrrnt lrrct, wherein lrrct motif comprising either amino acid sequence (a) and/or amino acid sequence (b) shown below. (a) val-lys-x1-val-asn-(x8)-cys (b) val-lys-x1-val-x1-thr-(x7)-cys (in formulae (a) (b), x represents amino acid residue; xn represents amino acid sequence composed n amino acid residues xs different other, wherein n represents natural number.)',\n",
              " 'cosmid vector transforming plant use thereofdisclosed novel vector plant transformation. vector cosmid vector entire length 15 kb shorter following properties: 1) vector contains replication initiation point incp plasmid contain replication initiation point plasmid; 2) vector contains trfa1 gene incp plasmid; 3) vector contains orit incp plasmid; 4) vector contains incc1 gene incp plasmid; 5) vector contains cos site lambda phage cos site located outside t-dna; 6) vector contains drug-resistant gene expressed escherichia coli bacterium belonging genus',\n",
              " 'phage display intact domains high copy numberdisclosed phage display system molecules displayed (i.e., molecules interest) bound dispensable capsid polypeptides soc (small outer capsid) hoc (highly antigenic outer capsid) polypeptides are, turn, bound surface lattice protein, surface virion polyhead. disclosed methods displaying molecule interest, methods immunizing patient administering displayed antigen, methods treating patient disorder associated aberrent expression activity biological molecule. latter instance, method includes administering displayed polypeptide, immunoglobulin molecule enzyme, capable specifically interacting aberrent biological molecule.',\n",
              " 'process inhibiting formation nitrosaminesdisclosed process inhibiting formation nitrosamines bacteria tobacco, comprising contacting tobacco substance comprising plurality bacteriophages capable lysing bacteria form nitrosamines. disclosed tobacco product possessing diminished concentration nitrosamines.',\n",
              " 'process production chicken recombinant divalent antibody chicken single-chain variable fragment (scfv) antibody produced processdisclosed process simple production chicken recombinant divalent antibody dimerizing single-chain variable fragment (scfv) produced phage display method produce chicken antibody. disclosed antibody produced process. discloses representative application antibody. process producing chicken recombinant divalent antibody comprising steps amplifying light-chain variable region gene heavy-chain variable region gene using, template, polynucleotide encoding chicken single-chain variable fragment, preparing gene fragment expression light chain ligating light-chain leader sequence operable host cell, light-chain variable region gene gene light-chain constant region chicken antibody, preparing gene fragment expression heavy chain ligating heavy-chain leader sequence operable host cell, heavy-chain variable region gene gene heavy-chain constant region chicken antibody.',\n",
              " 'bacteriolysis-resistant cell method production thereofdisclosed prokaryotic cell resistance bacteriolysis induced regardless presence absence external direct stimulus infection phage treatment chemical substance/an enzyme. disclosed method producing cell. specifically disclosed cell srna gene (a bacteriolytic gene) whose expression controlled se factor disrupted acquire bacteriolysis-resistance trait. specifically disclosed method producing bacteriolysis-resistant cell, comprises steps of: inserting gene encoding protein nucleotide sequence bacteriolytic gene; causing protein expressed separate bacteriolysis-resistant cell non-bacteriolysis-resistant cell.',\n",
              " 'multivalent, drying resistant, evolution-based vaccinesdisclosed recombinant nonpermutated bacteriophage includes nucleic acid sequence least 150 kb length wherein bacteriophage made display one surface antigens heterologous polypeptides, compositions kits include recominant nonpermutated bacteriophages present invention. disclosed methods inducing immune response subject involve administration pharmaceutically effective amount composition comprising recombinant nonpermutated bacteriophages present invention.',\n",
              " 'phage-displaying single-chain antibody capable recognizing non-reduced mannose residuedisclosed antibody capable recognizing non-reduced mannose residue. antibody produced screening phage-displaying library displays human scfv, using man3-dppe (which artificial glycolipid synthesized reductive amination mannotriose dipalmitoylphosphatidylethanolamine) antigen.',\n",
              " 'anti-tnf-alpha antibodydisclosed anti-tnf-alpha antibody. according antibody, natural rabbit-derived phage antibody library subjected antigen immunostimulation constructed, tnf-alpha recombinant protein target, three rounds screening enrichment, single-chain antibody specifically combined tnf-alpha obtained. antibody applied specificity capture tnf-alpha antibody, tnf-alpha signal antibody like. meanwhile, successful natural antibody library constructed directly applied screening targets.',\n",
              " 'effect sle antigen epitope polypeptide identification sle autoimmune diseasesdisclosed effect sle antigen epitope polypeptide identification sle autoimmune diseases. according effect, sle related polypeptides screened phage display peptide technology, antigen epitope polypeptide diagnostic value obtained polypeptide chip verification elisa method verification. addition, screening carried sle patient group healthy population group, screening carried disease control group autoimmune diseases, effect antigen epitope polypeptide distinguishing sle autoimmune diseases verified comparing antigen epitope polypeptide control group autoimmune diseases multiple verification processes; results show antigen epitope polypeptide effectively distinguish sle autoimmune diseases, antigen epitope polypeptide beneficial distinguishing sle autoimmune diseases diagnosis process providing accurate diagnosis result timely formulate corresponding treatment strategy realize effective treatment.',\n",
              " 'imine-resistant bacillus pyocyaneus bacteriophage use treating infection therefromdisclosed imine-resistant bacillus pyocyaneus bacteriophage use treating infection, wherein stain broad-spectrum drug-resistant bacillus pyocyaneus bacteriophage phia392, effectively kill drug-resistant bacillus pyocyaneus vivo vitro, bacteriophage decompose multiple strains clinically segregated imipenem-resistant bacillus pyocyaneus vivo. invention proves superiority feasibility bacteriophage therapeutic substance clinical application treatment bacillus pyocyaneus resistant affection, provides novel therapeutic means clinical imipenem-resistant bacillus pyocyaneus affection.',\n",
              " 'rescue influenza virusdisclosed vitro method producing replicative influenza virus particle without use helper virus, comprising culturing cell transfected least one nucleic acid, characterized nucleic acid comprises influenza gene segment bacteriophage polymerase promoter nucleic acid comprises complement influenza gene segment bacteriophage polymerase promoter.',\n",
              " 'method determining escherichia colidisclosed information related determining escherichia coli sample urine. according method, part sample admixed reagent including lanthanide(iii) ion, transition metal ion, transition metal ion/e. coli-specific m13 phage, another part sample admixed reagent including lanthanide(iii) ion, transition metal ion wild-type m13 phage. signals derived lanthanide(iii) ions admixtures detected time-gated luminescence measurement. presence e. coli sample determined comparing lanthanide(iii) ion signal presence transition metal ion/e. coli-specific m13 phage wild type m13 phage.',\n",
              " 'sars-cov-specific b-cell epitope applications thereofdisclosed sars-cov-specific b-cell epitope applications thereof. epitopes peptides either expressed phages synthesized diagnose sars patients accurately. high sensitivity specificity serologic detection achievable using plurality sars-cov-specific b-cell epitope-based peptides. therefore, peptides applied sars diagnosis potentials immunogens producing antibodies sars.',\n",
              " 'modified peptides therapeutic agentsdisclosed fusion fc domains independently randomised il antagonist peptide sequences. linkage vehicle increases half-life peptide, quickly degraded vivo. preferred vehicle fc domain. peptide preferably selected phage display, e. coli display, ribosome display, rna-peptide screening, chemical-peptide screening. peptides useful pharmacologically active agents.',\n",
              " 'bacteriophage prophage proteins cancer gene therapydisclosed use isolated bacteriophage-derived protein manufacture medicament treatment proliferative disease disorder, wherein bacteriophage- derived protein induces cell growth inhibitory activity cell killing effect eukaryotic cells.',\n",
              " 'methods generate bacteriophage resistant bacterial strains produce bacteriophage crispr loci phage mutantsdiscloses method generating crispr (clustered regularly interspaced short palindromic repeat) escape phage mutants comprising: (i) obtaining: least one parent phage phage-resistant bacterial strain comprising least one crispr locus, crispr locus comprises bacteriophage nucleic acid sequence least 95% identical least one proto-spacer sequence genome said least one parent phage; (ii) exposing least one parent phage said phage-resistant bacterial strain, conditions least one phage variant produced; (iii) selecting least one phage variant, least one phage variant exhibits ability infect said phage-resistant bacterial strain crispr-escape phage mutant discloses method generating phage-resistant bacterial strain (i) modified crispr locus comprising least portion crispr locus least one nucleic acid sequence. methods screening said phage-resistant bacterial strain variant phages capable infecting phage-resistant bacterial strain disclosed. bacteriophage selected group virus families consisting of: corticoviridae, cystoviridae, inoviridae, leviviridae, microviridae, myoviridae, podoviridae, siphoviridae, tectiviridae. suitable phage-resistant bacterial strains may used methods disclosed. invention finds application provision methods generate screen useful phage-resistant bacterial strains use e.g. dairy manufacturing processes. invention finds application provision methods generate useful phage-resistant bacterial strains use biocontrol agents e.g. dairy manufacturing processes.',\n",
              " 'phage phimru polynucleotides polypeptides uses thereofdiscloses isolated polypeptide comprising seq id no: 63 polynucleotide comprising seq id no: 136, wherein sequence comprised residues 74-228 seq id no: 63. discloses sequences within methanobrevibacter ruminantium cell, method inhibiting methanogen cell contacting cell polypeptide.',\n",
              " 'inhibition dispersion biofilms plants imidazole-triazole derivativesdisclosure provided methods preventing, removing inhibiting microbial biofilm formation microbial infection plant plant part thereof, including applying thereto treatment effective amount active compound described herein, agriculturally acceptable salt thereof. methods enhancing microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator provided, including applying active compound described herein. compositions comprising active compound described herein agriculturally acceptable carrier provided, embodiments compositions include microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator.',\n",
              " 'inhibition biofilms plants imidazole derivativesdisclosure provided methods preventing, removing inhibiting microbial biofilm formation microbial infection plant plant part thereof, including applying thereto treatment effective amount active compound described herein, agriculturally acceptable salt thereof. methods enhancing microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator provided, including applying active compound described herein. compositions comprising active compound described herein agriculturally acceptable carrier provided, embodiments compositions include microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator.',\n",
              " 'use aryl carbamates agriculture plant-related areasdisclosure provided methods preventing, removing inhibiting microbial biofilm formation microbial infection plant plant part thereof, including applying thereto treatment effective amount aryl carbamate described herein, agriculturally acceptable salt thereof. methods enhancing microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator provided, including applying active compound described herein. compositions comprising aryl carbamate compound described herein agriculturally acceptable carrier provided, embodiments compositions include microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator.',\n",
              " 'bacteriophage based microfluidic assay bacterial detectiondisclosures herein directed detection bacteria using bacteriophage recognition element animplementation framework characteristic microfluidic devices wherein magnetic nanoparticles deployed immobilization target entities detected using fluorescent nanocrystals. figure accompany published abstract: fig. 3',\n",
              " 'method disinfection box tall internal part premises contaminated bacterium means bacteriophagesdisinfection effected means containing bacteriophages sprinkling, spraying applying another method certain distances local sites box stall premises observing conditions ventilation, relative humidity temperature.',\n",
              " 'polypeptides brain -localizing activity uses thereofdnas encoding polypeptides comprising random amino acid sequences synthesized, incorporated phage library. phage library produced used screen polypeptides brain-localizing activity. result, several polypeptides brain-localizing activity obtained. polypeptides comprise common sequences, amino acid motif sequences involved brain-localizing activity successfully identified.',\n",
              " 'pharmaceutical composition antibiotics comprising bacteriophage endolysin plant extract본 발명에 따른 여드름 치료용 조성물은 엔도라이신 및 토복령 추출물을 포함하고, 천연성분을 주성분으로 하여 피부에 자극을 주지 않으면서도 항생제 내성여드름 원인균을 살균하고 염증을 완화할 수 있는 효과가 있으며, 피부를 보호 할 수 있는 효과가 있다.',\n",
              " 'crispr-cas9 method genome editing clostridium perfringens bacteriophage crispr-cas9 system본 발명은 crispr-cas9 시스템을 활용하여 클로스트리디움 퍼프린젠스 균주 및 박테리오파지의 유전자를 제거 또는 치환할 수 있는 방법에 관한 것으로, 본 발명에서 새롭게 구축한 플라스미드 및 유전자 조작 방법은 클로스트리디움 퍼프린젠스와 이를 감염시키는 박테리오파지의 유전자를 쉽게 조작할 수 있는데, 식품, 의약 및 동물 의약 산업 등에 활용될 수 있다.',\n",
              " 'bac-anp-1 bacillus anthracis bacteriophage bac-anp-1 use preventing proliferation bacillus anthracis본 발명은 바실러스 안트라시스 균을 특이적으로 사멸시킬 수 있는 능력을 갖고 서열번호 1로 표시되는 유전체를 갖는 것을 특징으로 하는 자연으로부터 분리한 시포비리대 박테리오파지 bac-anp-1(수탁번호 kctc 12942bp), 및 이를 유효성분으로 포함하는 조성물을 이용한 바실러스 안트라시스 균의 감염을 방지 및 치료하는 방법에 관한 것이다.',\n",
              " 'lytic bacteriophage specific pseudomonas genus resistant antibiotics본 발명은 강력한 항균제인 카바페넴(carbapenem)에 대한 내성을 보이는 슈도모나스 균속을 용균시키는 박테리오파지 ymc11/06/c171 ppu bp [kctc18380p]에 관한 것이다. 본 발명에서 제공하는 신규한 박테리오파지는 강력한 항균제인 카바페넴 내성 슈도모나스 균속에 대하여 특이적 사멸능을 가지므로, 상기한 카바페넴 내성 슈도모나스 균속에 의해 유발되는 질환의 예방 및 치료 목적으로 활용할 수 있다.',\n",
              " 'lytic bacteriophage specific pseudomonas genus resistant antibiotics본 발명은 강력한 항균제인 카바페넴(carbapenem)에 대한 내성을 보이는 슈도모나스 균속을 용균시키는 박테리오파지 ymc11/07/p54 pae bp [kctc18381p]에 관한 것이다. 본 발명에서 제공하는 신규한 박테리오파지는 강력한 항균제인 카바페넴 내성 슈도모나스 균속에 대하여 특이적 사멸능을 가지므로, 상기한 카바페넴 내성 슈도모나스 균속에 의해 유발되는 질환의 예방 및 치료 목적으로 활용할 수 있다.',\n",
              " 'coating composition comprising bacteriophage antibacterial film formed using same본 발명은 박테리오파지를 포함하는 코팅 조성물 및 이를 이용하여 제조된 항균 필름에 관한 것이다. 본 발명의 코팅 조성물은 살모넬라균에 대해 사멸능을 갖는 박테리오파지를 포함하므로 이를 이용하면 항균 활성을 갖는 코팅을 제조할 수 있으며, 코팅 형성 후에도 박테리오파지가 안정적으로 생존하여 우수한 항균 활성을 지속적으로 유지할 수 있다. 본 발명을 식품 포장용 코팅 또는 필름에 적용하는 경우, 살모넬라균에 의해 식품이 오염되는 것을 효과적으로 방지하여 식품의 안전성 및 저장성을 향상시킬 수 있다.',\n",
              " 'pathogenic escherichia coli salmonella shigella-specific bacteriophage antibacterial composition comprising same본 발명은 병원성 대장균, 살모넬라균, 시겔라균에 대해 특이적인 사멸능을 갖는 신규 박테리오파지 kfs-ec3 및 이의 조성물에 관한 것이다. 본 발명의 박테리오파지 kfs-ec3는 병원성 대장균, 살모넬라균 또는 시겔라균에 특이적 사멸능을 가지는 넓은 숙주 범위를 가지는 반면, 유익균은 사멸시키지 않고 내산성 및 내열성이 우수하므로, 병원성 대장균, 살모넬라균 및 시겔라균 중 어느 하나 이상의 균에 의한 감염성 질병의 예방 또는 치료에 활용할 수 있을 뿐만 아니라, 항생용 조성물, 사료 첨가용 조성물, 소독제, 또는 세척제 등에도 광범위하게 이용될 수 있다.',\n",
              " 'novel bacteriophage effective fire blight bacteria black shoot blight disease bacteria use thereof본 발명은 과수 화상병 및 가지검은마름병 원인균에 사멸능을 갖는 신규 박 테리오파지 및 이의 용도에 관한 것이다.',\n",
              " 'bacteriophage killing activity specific escherichia coli shigella본 발명은 대장균 또는 시겔라속 균에 특이적 사멸능을 갖는 박테리오파지 및 이의 용도에 관한 것으로, 본 발명의 박테리오파지인 sme50 (기탁번호: kctc 14641bp)은 신규한 파지로서 병원성 대장균 o157과 시겔라 플렉시너리를 동시에 제어할 수 있는 우수한 숙주 세균 사멸 범위를 가지고, 고온에서의 안정성과 큰 burst size가 다른 파지들과 대비하여 가지는 것을 특징으로 하여 항균제 등으로 유용하게 활용될 수 있다.',\n",
              " 'bacteriophage e. coli specificity composition treating swine e. coli infection using same본 발명은 대장균인 e.coli sw1 및 e.coli o157:h7l에 대해 특이적 사멸능을 갖는 박테리오파아지 ecsw 및 이를 이용한 돼지 대장균 감염증 치료용 조성물에 관한 것이다.',\n",
              " 'sa11 lyssa11 endolysin novel host binding domain staphylococcus aureus bacteriophage sa11 antibiotic composition thereof본 발명은 포도상구균 바인딩 도메인을 갖는 sa11 유래 엔도라이신 lyssa11 및 이를 포함하는 세균 사멸용 조성물에 관한 것이다. 본 발명에서 새롭게 확인한 포도상구균 박테리오파지 sa11 유래의 엔도라이신인 lyssa11은 포도상구균에 특이적으로 결합하여 넓은 범위의 포도상구균 뿐만 아니라, 메티실린에 감수성 및 저항성을 갖는 포도상구균에 대해서도 용균작용을 나타내고, 적은 양으로도 강한 항균 활성을 보이기 때문에, 식품, 의약, 동물의약, 사료 산업 등에 활용될 수 있는 효과가 있다. 또한, 박테리오파지와 달리 lyssa11은 포도상구균에 특이적으로 부착하는 호스트 바인딩 도메인을 가지므로 이는 식품 내에서의 포도상구균 검출에 활용될 수 있다.',\n",
              " 'method regrowth pool culture-based bacteriophage screening본 발명은 재증식 풀 컬쳐(regrowth pool culture)를 기반으로 하는 신규한 박테리오파지 스크리닝 방법에 관한 것으로, 이는 박테리오파지를 이용한 유해균을 제어할 때 발생하는 유해균의 재증식 문제를 효과적으로 해결할 수 있는 유용한 방법으로서 다양한 세균들에 적용될 수 있다.',\n",
              " 'escalator hand rail phage easy본 고안은 파지가 용이한 에스컬레이터용 핸드레일에 관한 것으로, 더욱 상세하게는 통상 백화점, 지하철 등과 같은 대형 건축물에서 층간의 이동을 위하여 설치되는 에스컬레이터의 손잡이부분인 핸드레일을 노약자나 어린이들이 쉽고 강력하게 파지할 수 있어 급정지에 따른 넘어짐, 추락과 같은 안전재해를 방지할 수 있는 파지가 용이한 에스컬레이터용 핸드레일에 관한 것이다.',\n",
              " 'bacteriophage capable killing infectious bacteria fish plankton ingested thereof uses thereof본 출원은 어류의 감염성 박테리아에 대하여 사멸능을 가지는 박테리오파지와 이를 섭취한 플랑크톤의 용도에 관한 것으로서, 어류용 항생 조성물 및 어류의 박테리아 감염성 질병을 예방 또는 치료하는 방법 등을 제공한다.',\n",
              " 'inhibition biofilm formation genetically engineered bacteriophagesembodiments directed engineered bacteriophages produce polypeptides interfere quench quorum sensing. certain aspects quorum quenching enzyme aiia broad specificity degrading substrates, small signal molecule acyl homoserine factories (ahl) initiates quorum sensing pathway global impact diverse bacteria biofilm. certain embodiments directed engineered t7aiia phage effectively degraded ahl diverse bacteria inhibited formation mixed species biofilms containing pseudomonas aeruginosa e. coli. engineered phages used antifouling antibacterial agents industrial clinical settings lysing host bacteria stably expressing quorum quenching enzyme broad substrate specificity impacting diverse bacteria community.',\n",
              " 'malaria vaccineembodiments directed malaria vaccines comprising bacteriophage vlp displaying heterologous peptide identified affinity selection anti-malaria mimotope.',\n",
              " 'methods compositions bacteriophage therapyembodiments directed methods composition preparing using therapeutic phage.',\n",
              " 'stable mixtures related methodsembodiments include colloidal mixture comprising liquid component solid component dispersed liquid component. solid component comprises plurality fine-solid (fs) particles, plurality phage particles binding domains, binding portions thereof, selected bind plurality fs particles. embodiments include methods making colloids, method improving colloidal stability mixture, methods inhibiting growth unwanted organisms, storage shipping systems, bio-additives.',\n",
              " 'identification characterization peptide affinity reagent detection noroviruses samplesembodiments disclosure include methods and/or compositions detection viral infection, including least norovirus infection. particular embodiments, methods and/or compositions employing particular peptides and/or phage useful detecting norovirus sample. sample may environment individual. individual may mammal, including human, cow, horse, dog, cat, pig, forth. certain exemplary peptides phage express peptides identified useful binding norovirus. peptides phage provided one samples order identify whether norovirus present sample.',\n",
              " 'methods compositions related phage-nanoparticle assembliesembodiments invention include additional compositions related methods devices use phage-nanoparticle assemblies. embodiments invention include compositions, methods devices related phage-nanoparticle assemblies use variety methods including detection methods, vitro vivo diagnostic methods, direct and/or indirect therapeutic methods, combinations thereof. phage-nanoparticle assemblies invention comprise plurality nanoparticles complexed one phage particles form phage-nanoparticle assembly. certain aspects, phage-nanoparticle assembly may include agents, including limited organizing agents and/or therapeutic agents.',\n",
              " 'compositions methods related synchronous selection homing peptides multiple tissues vivo phage displayembodiments invention include methods selecting parallel (i.e., synchronously simultaneously) peptides target number organs, peptide targets distinct tissues organs. typically, methods invention provide peptide selection minimal number subjects still provides selectively binding peptide. certain aspects, methods identifying peptides bind multiple selected tissues organs organism may comprise steps administering phage display library first subject; obtaining sample two selected tissues; obtaining phage displaying peptides bind samples first subject; enriching peptides administering phage isolated samples first subject second subject; obtaining sample two selected tissues second subject; identifying peptides displayed.',\n",
              " 'engineering bacteriophages genome editing using crispr-cas9 systemembodiments invention provide systems, methods, kits crispr-based editing dna targets crispr-associated (cas) enzyme. systems include bacterial host cell adapted produce engineered bacteriophage comprising cas protein guide rna naturally occur together, i.e. engineered occur together, well dna repair template comprising donor dna desired mutation. guide rna comprises trans-activating crrna guide sequence complementary target protospacer bacteriophage genome. wild-type bacteriophage glucosylhydroxymethyl cytosine (ghmc)-unmodified mutant bacteriophage may delivered disclosed bacterial host cell create recombinants bacteriophage desired mutation provided donor dna.',\n",
              " 'methods making utilizing amber-obligated phage display librariesembodiments present disclosure pertain methods constructing phage display library least 90% combinatorial regions phage display library include least one in-frame amber codon. embodiments present disclosure pertain formed phage display libraries. additional embodiments present disclosure pertain methods selecting peptides proteins bind desired target (e.g., ligand binding site desired target) utilizing phage display libraries present disclosure. embodiments present disclosure pertain peptides screened phage display libraries methods present disclosure, inhibitors sirtuin 2, inhibitors enl.',\n",
              " 'genetically encoded, phage-displayed cyclic peptide library methods making sameembodiments present disclosure pertain methods selecting cyclic peptides bind target transforming phage display library plurality nucleic acids bacterial host cells, nucleic acids include phage coat protein genes combinatorial region encodes least one cysteine least one non-canonical amino acid. transformation results production phage particles phage coat proteins cysteine non-canonical amino acid couple one another form cyclic peptide library. phage particles screened desired target select bound cyclic peptides. amino acid sequences selected cyclic peptides identified. additional embodiments pertain methods constructing phage display library encodes cyclic peptides. embodiments present disclosure pertain produced cyclic peptides, phage display libraries phage particles.',\n",
              " 'microorganism detection method apparatusembodiments present invention relate selective organism detection, and, particularly recombinant bacteriophages use recombinant bacteriophages detect target bacteria detect specific nucleic acid sequences within said target bacteria thus allowing detection phenotypic characteristics said bacteria determining drug(s) target bacteria resistant. present invention relates sample preparation apparatuses preparing samples detection analysis using bacteriophage-based techniques, lowin cost, easy use, require technical expertise additional laboratory infrastructure perform.',\n",
              " 'systems methods amplification phage displayembodiments various aspects described herein directed amplification biological entities, example, phage display. one aspect, members library biological entities encapsulated separate compartments (e.g., separate microfluidic droplets) amplified. example, putting members phage display library microfluidic droplets droplet contains one member library, library amplified without substantial changes population distributions, artifacts created due differences growth rates amplification different members library. cases, volume compartments used control copy number biological entity amplification. advantageous, example, preserving diversity within library preventing rapidly amplifying biological entities outcompeting slowly amplifying biological entities.',\n",
              " 'sp35 antibodies uses thereofendogenous sp35 negative regulator neuronal survival, axon regeneration, oligodendrocyte differentiation myelination (negative regulator). molecules block endogenous sp35 function, anti-sp35 antibodies used therapeutics treatment neuron oligodendrocyte dysfunction. present invention provides antibodies specific sp35, methods using antibodies antagonists endogenous sp35 function. invention provides specific hybridoma phage library-derived monoclonal antibodies, nucleic acids encoding antibodies, vectors host cells comprising antibodies. invention provides methods promoting oligodendrocyte survival myelination vertebrate, comprising administering vertebrate need treatment effective amount anti-sp35 antibody.',\n",
              " 'sp35 antibodies uses thereofendogenous sp35 negative regulator neuronal survival, axon regeneration, oligodendrocyte differentiation myelination (negative regulator). molecules block endogenous sp35 function, anti-sp35 antibodies used therapeutics treatment neuron oligodendrocyte dysfunction. present invention provides antibodies specific sp35, methods using antibodies antagonists endogenous sp35 function. invention provides specific hybridoma phage library-derived monoclonal antibodies, nucleic acids encoding antibodies, vectors host cells comprising antibodies. invention provides methods promoting oligodendrocyte survival myelination vertebrate, comprising administering vertebrate need treatment effective amount anti-sp35 antibody.',\n",
              " 'sp35 antibodies uses thereofendogenous sp35 negative regulator neuronal survival, axon regeneration, oligodendrocyte differentiation myelination. molecules block endogenous sp35 function, anti-sp35 antibodies used therapeutics treatment neuron oligodendrocyte dysfunction. present invention provides antibodies specific sp35, methods using antibodies antagonists endogenous sp35 function. invention provides specific hybridoma phage library-derived monoclonal antibodies, nucleic acids encoding antibodies, vectors host cells comprising antibodies. invention provides methods promoting oligodendrocyte survival myelination vertebrate, comprising administering vertebrate need treatment effective amount anti-sp35 antibody.',\n",
              " 'sp35 antibodies uses thereofendogenous sp35 negative regulator neuronal survival, axon regeneration, oligodendrocyte differentiation myelination. molecules block endogenous sp35 function, anti-sp35 antibodies used therapeutics treatment neuron oligodendrocyte dysfunction. present invention provides antibodies specific sp35, methods using antibodies antagonists endogenous sp35 function. invention provides specific hybridoma phage library-derived monoclonal antibodies, nucleic acids encoding antibodies, vectors host cells comprising antibodies. invention provides methods promoting oligodendrocyte survival myelination vertebrate, comprising administering vertebrate need treatment effective amount anti-sp35 antibody.',\n",
              " 'bacteriophage-based vaccines engineered bacteriophageengineered bacteriophage methods forming bacteriophage described. multivalent bacteriophage described include multiple different exogenous polypeptides surface capsid head. vaccines methods forming using vaccines described. vaccine include engineered bacteriophage exhibits immunogenic exogenous polypeptide surface bacteriophage. multivalent bacteriophage immunogenic bacteriophage free nucleic acids encoding exogenous polypeptide(s).',\n",
              " 'bacteriophage-based antibodies bindersengineered bacteriophage methods forming bacteriophage described. multivalent bacteriophage described include multiple different exogenous polypeptides include specific binding agents proteinaceous targets surface capsid head. therapeutic compositions, e.g., antiviral compositions, methods forming described. therapeutic composition include engineered bacteriophage includes polypeptide binds pathogen binds cellular receptor pathogen surface bacteriophage. engineered bacteriophage free nucleic acids encoding exogenous polypeptide(s).',\n",
              " 'enterocyte-transcytotic peptide identified peroral pharge display process peroral drug delivery systems using sameenterocyte-transcytotic peptides identified peroral phage display process provided increase absorption efficiency macromolecular materials improve mucoadhesive properties efficiently binding small intestine epithelial cell layer oral administration, absorption efficiency peroral drug delivery systems biomembrane enhanced. enterocyte-transcytotic peptide identified peroral phage display process amino acid sequence cqpapgkqc. small intestine mucoadhesive peptide identified peroral pharge display process amino acid sequence ctadqqrqc. peroral drug delivery system contains enterocyte-transcytotic peptide protein drug.',\n",
              " \"metal-reducing enzymatic tag optical electron microscopyenzymes reduce specific metal metalloid ions insoluble form important science. peptides isolated yeast- phage-display libraries affect size morphology inorganic materials synthesis. herein, se binding peptide fused enzyme capable reducing selenite (seo32-) se0 nanoparticle (senp). fusion se binding peptide metalloid reductase provided size control resulting senp. senp product remains associated enzyme fusion. se binding peptide fusion enzyme increases enzyme's seo32- reductase activity. modification enzyme activity absent, size control particles diminished se binding peptide added exogenously reaction mixture. binding peptide attributed based ligation results conformational change peptide.\",\n",
              " 'peptidoglycan hydrolase antimicrobials eradicating lactobacilli contaminate reduce ethanol yields biofuel fermentationethanol losses due bacterial contamination fermentation cultures weakens economics biofuel production. lactobacillus species predominant contaminant. bacteriophage lytic enzymes peptidoglycan hydrolases degrade gram positive cell walls exposed externally novel source antimicrobials. streptococcal phage λsa2 endolysin construct demonstrated strong lytic activity towards 17 22 strains lactobacilli, staphylococci streptococci maintaining optimal specific activity fermentation conditions toward l. fermentum substrates. lactobacillus bacteriophage endolysin constructs lysa, lysa2 lysgay showed exolytic activity towards ˜60% lactobacilli tested including four l. fermentum isolates fuel ethanol fermentations. presence ethanol (≰5%) affect lytic activity. lysins able reduce l. fermentum l. reuteri contaminants mock fermentations corn fiber hydrolysates. recombinant lysa λsa2 expressed yeast saccharomyces cerevisiae functional; lysa shown reduce lactobacilli experimentally infected fermentations.',\n",
              " 'expression vectors encoding bacteriophage signal peptidesexpression vectors encoding bacteriophage signal peptides described. vectors may used heterologous expression secretion polypeptides antibodies bacterial host cells.',\n",
              " 'display dimeric proteins phageexpression vectors expressing multimeric polypeptides anchored surfaces genetically replicable packages disclosed. expression vectors include vector segment encoding polypeptide sequence three polypeptide segments. one segments contains cleavable peptide sequence cleavable proteolytic agent, another segment anchoring peptide sequence anchoring multimeric polypeptide surface genetically replicable package. cleavable peptide sequence cleaved proteolytic agent first segment associates third segment form multimeric polypeptide. disclosed methods, host cells, kits employing expression vectors.',\n",
              " 'winter aconite fatty acid elongase uses thereof production fatty acidsfatty acids, methods production thereof, provided. transgenic organisms, microbes, plants, seeds, cells useful production fatty acids, along related expression vectors, phages, plasmids, nucleic acids, enzymes, provided. methods production fatty acids docosadienoic acid docosatrienoic acid, involving use winter aconite (eranthis hyemalis) ehelo1 elongase, described detail.',\n",
              " 'fibrous structures comprising surface care composition bacteriophagefibrous structures containing surface care composition, particularly dry fibrous structures containing surface care composition comprising one bacteriophage, methods making same, methods treating surfaces using provided.',\n",
              " 'method preparing cultures conserving plant substratesfield: agriculture. ^ substance: invention relates fodder production farm livestock. method preparing cultures conserving plant substrates, provides selection strains mesophilic lactobacillus resistance virulent bacteriophage, circulating conserved plant substrates, strains propionate bacteria species p.freudenreichii capability ferment plant carbohydrates, actively grow plant substrates display biocompatibility chosen strains mesophilic lactobacilli, separate cultivation, mixing drying. ^ effect: invention makes possible increase output quality silage. ^ 2 cl, 2 tbl',\n",
              " 'method breeding common greenbug (schizaphis graminum rond)field: agriculture.substance: method breeding common greenbug comprises sowing seeds, growing fodder plants, greenbug infestation plants, collection accounting greenbugs. seeds sowing processed plant growth stimulant.effect: method enables improve performance mass breeding greenbug conditions large-scale production aphido-phages.1 tbl, 4 ex',\n",
              " 'method evaluating specific activity bacteriophagesfield: analytical methods microbiology. ^ substance: substance method resides performing, human embryo cell culture monolayer conditions, common 2-h culturing test strains microorganisms suitable therapeutical bacteriophage multifunctional (polyvalent) bacteriophage, includes phage corresponding test culture. specific activity bacteriophage evaluated degree adhesion test strain microorganism monolayer cells compared control (cell monolayer test strain without bacteriophage). ^ effect: speeded determination enabled evaluation therapeutical bacteriophage due approaching evaluation conditions microorganism conditions. ^ 2 tbl',\n",
              " 'non-replicative transduction particles transduction particle based reporter systemsfield: biochemistry.substance: invention relates biochemistry virology relates methods systems packaging reporter nucleic acid molecules non-replicative transduction particles use reporter molecules. bacterial cell packaging system packaging reporter nucleic acid molecule non-replicative contains lysogenised bacteriophage genome contain first bacteriophage gene encoding first sequence packaging initiation site, wherein removal said first bacteriophage gene prevents packaging bacteriophage nucleic acid molecule said non-replicative transduction particle; plasmid reporter nucleic acid molecule containing reporter gene containing second bacteriophage gene, wherein said second bacteriophage gene encodes second sequence packaging initiation site facilitates packaging copy said plasmid reporter nucleic acid molecule said non-replicative transduction particle, wherein said second bacteriophage gene capable expressing protein encoded said second gene, wherein said copy said plasmid reporter nucleic acid molecule forms replicon packaged said non-replicative transduction particle, said bacteriophage selected bacteriophage p1 enterobacteriaceae, bacteriophage ϕ80α bacteriophage ϕ11 s. aureus.effect: invention makes possible obtain non-replicative transduction particles suffer harmful effects lytic functions virus.136 cl, 35 dwg, 13 tbl, 10 ex',\n",
              " 'antiviral agent based serratia-family bacteria nucleasefield: bioengineering.substance: invention relates asubstance antiviral activity respect influenza virus, variolovaccine, mousepox virus herpes virus 2type. discloses serratia-family nucleases-based bacteria. source latter includes purified culture fluid serratia plymuthica bacteria strain pna-like activity 190.0-926 unit/ml protein content 3.6-13.5 mg/ml. said serratia plymuthica bacteria strain represent serratia plymuthica bacteria strain dg-91 dg-98, bp-868 az-372 deposited collection bacteria, bacteriophages fungi federal budget scientific centre \"state r&d centre virology biotechnology \"vector\" enumerated b-1288, b-1297, b-1296, b-1285, respectively. invention may used medicine microbiological industry.effect: higher efficiency.6 cl, 4 tbl, 22 ex',\n",
              " 'strain bacteriophage citrobacter freundii cf17 able lyse pathogenic strains citrobacter freundiifield: bioengineering.substance: invention relates strain bacteriophage citrobacter freundii able lyse pathogenic strains citrobacter freundii, containing gene coding ribonucleotide reductase iii. suggested strain bacteriophage extracted clinic sample septic wound bacterium culture test-strain citrobacter freundii atcc 8090, deposited collection bacteria, bacteriophages fungus fbis ssc vb vector no. ph-1311.effect: bacteriophage strain lytic activity relation citrobacter freundii bacteria, suitable create specimen treat diseases result said bacteria.4 dwg, 5 ex',\n",
              " 'strain bacteriophage staphylococcus aureus sa20 ensuring destruction biofilms created bacteria staphylococcus familyfield: bioengineering.substance: strain ensures destruction biofilms created bacteria staphylococcus family, contains gene coding alpha-subunit ribonucleotide reductase 1b. strain deposited collection bacteria, bacteriophages fungi fbis ssc vb vector no. ph-1312.effect: bacteriophage strain wide spectrum lytic activity relation test-strains clinic isolates bacteria staphylococcus family, used creation germicides resulting death bacteria staphylococcus family.7 dwg, 1 tbl, 8 ex',\n",
              " 'method identification bacteriophage, method isolation mammal cells, method selection bacteriophage (variants), method identification bacteriophage subgroup internalizing ligand (variants)field: biology, genetic engineering. ^ substance: invention relates technology phage display used selection bacteriophages expressing peptides proteins bound cell surface receptors internalized. bacteriophage subgroup bacteriophages identified contacting bacteriophages library expressing multiple peptides cell cells mammal wherein bacteriophage genome carries least one gene encoding product determined. invention relates method isolation mammal cells internalized bacteriophage presenting bacteriophages library involves contacting bacteriophages library expressing multiple peptides mammal cell wherein bacteriophage carried gene encoding product determined, assay product isolation mammal cells express product. invention relates method selection bacteriophage expressing heterologous peptide bound receptor mammal cell surface internalized. method carried contacting library bacteriophages expressing multiple peptides mammal cell wherein bacteriophage carried gene encoding product determined. method involves assay product isolation bacteriophage gene encoding peptide mammal cells expressing product. invention provides carrying identification peptide protein ligands vitro vivo able internalization. ^ effect: improved methods selection, identification internalization. ^ 64 cl, 8 dwg, 12 ex',\n",
              " 'method producing functionally active recombinant protein lethal factor anthrax (lf), recombinant plasmid dna petgst-lfmin, encoding active lf protein strain escherichia coli bl-gstlfmin, producing active protein lethal factor anthraxfield: biology. ^ substance: designed new recombinant plasmid petgst-lfmin (7704 nucleotide pairs), containing catalytically active fragment gene lethal factor anthrax (lf) controlled bacteriophage t7 promoter, determinant resistance ampicillin glutathione-s-transferase sequence efficient purification recombinant protein sorbent immobilised glutathione. plasmid provided efficient sythensis protein lf anthrax, chimerised sequence glutathione-s-transferase purification immobilised glutathione. escherichia coli bl-lfmingst strain obtained transformation said plasmid dna e.coli bl21 (de3) strain, provides output synthesised lf protein less 90 mg/l g raw biomass. active lf protein obtained using method involves culturing said recombinant strain, destruction bacterial cells buffer solution ph 7.4 presence triton x-100 protease inhibitor, purification sorbent immobilised glutathione. ^ effect: output proteolytic active recombinant chimeric purified protein lf anthrax amount less 70 mg/l g raw biomass. ^ 3 cl, 3 dwg, 3 ex',\n",
              " \"method synthesysing nucleoside-5'-triphosphates, labelled radioactive isotopes phosphorous alpha-positionfield: biology. ^ substance: present invention relates biotechnology, specifically obtaining nucleoside-5'-triphosphates, labelled phosphorous-32 (phosphorous-33) alpha-position, used analysis molecular biology, genetics medical biochemistry. method realised treatment labelled nucleosidephosphate buffer solution mixture deoxyribonucleoside monophosphate kinase bacteriophage t5 pyruvate kinase subsequent chromatographic purification target product. ^ effect: simple method obtaining nucleoside-5'-triphosphates stable output target product. ^ 4 ex\",\n",
              " 'method dna molecules separationfield: biology.substance: invention relates molecular biology. method separating dna molecules, providing negative selection target dna molecules solution non-target dna molecules, involves interaction non-target dna molecules, containing recombinase cre recognition site bacteriophage p1 loxp, cre recombinase bacteriophage p1, defective ability covalently modify dna, provides transfer non-target dna molecules solution solid phase. addition, proposed method require presence minimal differences lengths target non-target dna molecules effective separation.effect: application principle negative selection makes possible exclude necessity presence additional nucleotide sequences target dna molecules.15 cl, 8 dwg, 5 ex',\n",
              " \"method extraction differentiation phage vibrio mimicusfield: biotechnologies. ^ substance: indicator strain use vibrio cholerae eltor km 199. three-hour broth culture amount 0.2 ml introduced mixture incubated, filtered lysogenic microorganism: 1 ml latter joined 5 ml 0.7% martin's agar. suspension seeded onto agar plate 1.5% martin's agar cultivated 37c 20-24 hours. lytic response conclusion made availability phage vibrio mimicus f-19. time differentiation cholera phage fb 0139 serogroup carried help strain vibrio cholerae 1322-69-037 serovar. prepare 0.2 ml four-hour broth culture latter, 5 ml 0.7% agar added poured onto agar plate petri dish. congelation, one path apply phage f-19, second one - cholera phage fb. placed thermostat grown 24-48 hours temperature 37c. registration lysis one paths decide availability phage vibrio mimicus it. ^ effect: method suggested extraction differentiation phage vibrio mimicus. ^ 2 tbl\",\n",
              " 'recombinant dna, codes functionally active hybrid protein gl7aca-acylase chitin-binding domain (brdgl7aca-cbd) recombinant plasmid psvh0108, providing synthesis cells escherichia coli, recombinant strain escherichia coli bl21(de3)/psvh0108-producer brdgl7aca-cbdfield: biotechnologies. ^ substance: recombinant dna produced, codes functionally active hybrid protein (brdgl7aca-cbd), consisting amino-acid sequence acylase glutaryl-7- aminocephalosporanic acid strain brevundimonas diminuta all-russian collection industrial microorganisms b-1297 chitin-binding domain chitinase al bacillus circulans. recombinant plasmid psvh0108 constructed expression brdgl7aca-cbd cells e.coli, containing sequence recombinant dna codes hybrid protein control promotor terminator rna-polymerase phage t7. result e.coli strain tranformation recombinant plasmid selection transformed clones, new strain e.coli bl21(de3)/psvh0108 cbd produced - producer hybrid protein brdgl7aca-cbd. ^ effect: high yield recombinant ferment. ^ 4 dwg, 2 tbl, 7 ex',\n",
              " 'vibrio metschnikovii bacteria strain indicator culture specific phage detectionfield: biotechnologies. ^ substance: vibrio metschnikovii bacteria strain km-185 recovered water vibrioflora analysis. strain sensitive specific pk-85 phage recovered vibrio metschnikovii bacteria strain 15818. phage titre 108- 109 particles per ml. ^ effect: maintaining phage reproduction mentor culture. ^ 2 tbl, 1 ex',\n",
              " 'aeromonas bestiarum bacteria strain - producer alkaline ribonuclease antiviral activityfield: biotechnologies.substance: invention proposes aeromonas bestiarum bacteria strain - producer alkaline ribonuclease antiviral activity deposited collection bacteria, bacteriophages fungi federal budgetary scientific institution \"the state scientific centre virology biotechnology \"vector\" registration no. b-1270. strain high production rate alkaline ribonuclease - 921.8 u/ml activity a/h5n1 bird a/aichi/2/68 (h3n2) human flu viruses.effect: improving strain properties.2 dwg, 7 tbl, 8 ex',\n",
              " 'strain bacteriophage escherichia coli ecd4, lytic activity respect bacteria escherichia coli serotype o104:h4field: biotechnologies.substance: invention relates strain bacteriophage escherichia coli ecd4. strain bacteriophage escherichia coli ecd4 isolated faeces broiler chickens culture bacteria strain escherichia coli o104.h4 rk1no.112027 deposited state collection pathogenic microorganisms cell cultures \"gkpm-obolensk\" number ph63. proposed strain bacteriophage lytic activity respect bacteria strain escherichia coli o104:h4 rkino.112027, lyses escherichia serotype 0157:h7, suppress growth cells escherichia coli m-17, lytic activity respect several clinically significant serotypes escherichia, several types shigella. strain bacteriophage escherichia coli ecd4 propagates laboratory non-pathogenic strain escherichia coli k-12 c600f.effect: invention may used creation new preparations treatment disease caused bacteria escherichia coli elimination pathogen food products.4 ex',\n",
              " 'strain basidiomycete inonotus obliquus - producer melanin pigment possessing antiviral antitumoral activityfield: biotechnologies.substance: invention relates biotechnology. strain basidium fungus inonotus obliquus tv-18, antiviral antitumoral activity, deposited collection bacteria, bacteriophages fungi fbun state research center virology biotechnology vector registration number f-1375.effect: strain basidium fungus inonotus obliquus used production medical preparations, creams, lotions, tonic biologically active additives; invention allows increase output melanin.1 cl, 4 dwg, 3 tbl, 6 ex',\n",
              " \"plasmid expression cells bacterium belonging escherichia class, non-active predecessor dnase human muteins; bacterium belonging escherichia class, - producer non-active predecessor recombinant dnase human mutein; predecessor recombinant dnase human mutein; method obtaining recombinant dnase human mutein; method obtaining conjugates polyethylene glycol recombinant mutein human dnase i, fermentative active conjugate mutein recombinant dnase humanfield: biotechnologies.substance: invention represents method obtaining recombinant dnase human mutein, well conjugates polyethylene glycol, using bacterium belonging escherichia class, transformed expression plasmid, containing promoter functioning bacterial cell, dna fragment coding hexahistidine cluster, fragment coding enterokinase recognition sequence amalgamated frame human dnase functionally active mutein containing replacements asparagine cysteine, transcription termination section, vector pet28a(+) fragment containing initiation section replication bacteriophage fl, sequence coding aminoglycoside-3'-phosphotransferase, area beginning plasmid pbr322 replication, gene rna-organising protein rop, sequence coding lactose operon repressor.effect: invention allows obtaining recombinant human dnase mutein high yield.18 cl, 7 dwg, 1 tbl, 12 ex\",\n",
              " 'method obtaining immunogenic composition based cfp10-dbd hybrid protein dextrane; pcfp10-dbd recombinant plasmide; escherichia coli [prep4, pcfp10-dbd] strain; cfp10-dbd chimeric protein applicationfield: biotechnologies.substance: invention represents pcfp10-dbd recombinant plasmide consisting artificial bacterial operon chimeric protein including promoter region early promoter t5 bacteriophage, chimeric protein gene consisting sequence protein antigene cfp10 mycobacterium tuberculosis, merged sequence dextrane-binding domain (dbd) dextrane sucrase leuconostoc citreum km20, transcription terminator, bacterial operon beta-lactamase bacterial initiation section replication cole1 type. besides, strain escherichia coli - producer cfp10-dbd chimeric protein presented. invention describes method immobilisation, concentration cleaning obtained protein cellulose. invention describes immunogenic composition containing cfp10-dbd recombinant protein, aimed induction immunity tuberculous infection.effect: invention enlarges range devices used treatment tuberculosis.4 cl, 6 dwg, 1 tbl, 4 ex',\n",
              " 'method quantitative assessment lytic activity bacteriophagesfield: biotechnologies.substance: method quantitative assessment lytic activity bacteriophages envisions preparation bacterial suspension ephemeral microorganism culture grown pre-set conditions joined beef-extract broth specific bacteriophage. assessment lytic activity bacteriophage performed average value multiple measurements optical density deduction optical density background reaction interaction components. obtained value parameter 0.045±0.025 tested microorganism assessed sensitive bacteriophage. obtained value parameter lytic activity higher named microorganism deemed steady studied bacteriophage.effect: invention allows improving reliability result.4 tbl, 2 ex',\n",
              " 'method extracting bacteriophage bordetella bronchisepticafield: biotechnologies.substance: method relates microbiology biotechnology. method extracting bacteriophage bordetella bronchiseptica includes ultraviolet radiation inducing mutagenic action wavelength 250-260 nm cell lysogenic bacterial cultures bordetella bronchiseptica, grown solid agar medium. uv radiation exposure time equal 1 day 5-7 minutes, 2 day - 7-10 minutes, 3 day - 7-10 minutes. distance irradiated cells lysogenic bacterial cultures bordetella bronchiseptica uv emitter 1 day 1 metre, 2 day-1 3 days - 0.5 m.effect: disclosed method enables relatively short time isolating bacteriophages lysogenic bacterial cells bordetella bronchiseptica without using antibacterial preparations.1 cl, 1 tbl',\n",
              " 'pharmaceutical composition treatment prophylaxis bacterial infectionfield: biotechnologies.substance: pharmaceutical composition includes bacteriophages obtained cultivation nutritional medium containing glucose, sodium chloride, twice-substituted sodium phosphate, liquid autolysed yeast clean water specified ratio, dried filler without lyophilisation, form pills gastral-resistant coating.effect: invention allows increasing safety pharmaceutical composition.7 ex',\n",
              " 'species-specific bacteriophage strain lytic activity relation staphylococcus aureus, including multi-drug resistant strainsfield: biotechnologies.substance: strain deposited number ph 62 gkpm-obolensk collection. strain used development complex medical disinfective preparations infections caused staphylococcus aureus, well preparations sanitation food products staphylococcus aureus.effect: strain lytic activity relation staphylococcus aureus.3 dwg, 6 ex',\n",
              " 'recombinant plasmid dna encoding tul4spcbd recombinant protein synthesis, m15[prep4, ptul4spcbd] escherichia coli strain producer tul4spcbd recombinant protein, tul4spcbd recombinant protein, method production thereof, method production specific antibody tul4spcbd proteinfield: biotechnology, gene engineering, microbiology. ^ substance: invention relates tul4spcbd recombinant protein comprising tul4 francisella tulergenis protein, gly-ser spacer cellulose-binding domain celd endoglucanase gen anaerocellum thermophilus. said protein tul protein antigen properties capable spontaneous binding cellulose-containing sorbents. described recombinant plasmid ptul4spcbd dna 4388 n.p. length, encoding tul4spcbd recombinant protein. abovementioned plasmid contains: artificial bacterial operon tul4spcbd recombinant protein, including promoter region n5 bacteriophage earlier promoter (7-87 n.p.); tul4spcbd recombinant protein gene (115-1113 n.p.); transcription terminator (1134-1230 n.p.); beta-lactamase bacterial operon (4183-3323 n.p. complementary chain)), providing ampicillin resistance; cole1-type bacterial site replication initiation, providing plasmid replication e.coli strain (4388 n.p.). discoised m15[prep4, ptul4spcbd] escherichia coli strain producer tul4spcbd recombinant protein method production purified, concentrated immobilized tul4spcbd recombinant protein said strain treatment cell hydrolyzate supernatant m15[prep4, ptul4spcbd] escherichia coli cellulose-containing sorbent. method production specific antibodies tul4spcbd protein described. said method includes animal immunization tul4spcbd recombinant protein immobilized onto cellulose. ^ effect: method high yield production tul4spcbd recombinant protein; simplified method purification, concentration immobilization said protein. ^ 5 cl, 1 dwg, 4 ex',\n",
              " 'recombinant plasmid dna ptrcte-oph producer enzyme organophosphate hydrolasefield: biotechnology, genetic engineering, biochemistry. ^ substance: invention represents constructed vitro recombinant plasmid dna comprising processed form enzyme organophosphate hydrolase (oph), escherichia coli trc-promoter synthetic site enhancer translation providing biosynthesis enzyme oph, strain escherichia coli producer protein also. recombinant enzyme used producing oph-base preparations designated decomposition organophosphorus compounds analytical determination also. invention solves problem development genetic-engineering construction strain cells provide preparing significant amounts active soluble form organophosphate hydrolase cell cytoplasm inducible synthesis enzyme. problem solved construction recombinant dna ptrcte-oph encoding inducible synthesis oph strain escherichia coli dh5alpha/ptrcte-oph providing synthesis protein expression level allowing prepare 12 mg purified protein 1 g wetted biomass. high inducible level synthesis end polypeptide provided fact proposed plasmid ptrcte-oph differs known one presence e. coli trc-promoter synthetic enhancer translation bacteriophage t7 gene 10. ^ effect: valuable biological properties dna. ^ 3 cl, 2 tbl, 4 dwg, 3 ex',\n",
              " 'recombinant plasmid dna pes1-6 encoding polypeptide somatotropin strain escherichia coli bl21(de3)/pes1-6 producer recombinant somatotropinfield: biotechnology, genetic engineering, molecular biology. ^ substance: invention used preparing recombinant human growth hormone. recombinant plasmid dna pes1-6 encoding polypeptide somatotropin amino acid sequence molecular mass 3.66 mda (5949 pair bases) consists of: nde i/xho dna fragment plasmid pet22b(+) comprising transcription promoter terminator t7 rna-polymerase, translation enhancer phage t7 gene 10, beta-lactamase gene nde i/xho dna fragment comprising sequence artificial gene recombinant somatotropin comprising: genetic marker beta-lactamase gene determining resistance e. coli cells transformed plasmid pse1-6 ampicillin; unique recognition sites site-specific endonuclease restriction enzymes located following distance right site nde : xba - 38 pair bases, hpa - 1332 pair bases, pst - 4065 pair bases, pvu - 4190 pair bases, xho - 5363 pair bases. invention provides preparing strain escherichia coli bl21(de3)/pes1-6 comprising recombinant plasmid dna pes1-6 producer recombinant somatotropin. invention provides preparing recombinant somatotropin high yield simplified technology. ^ effect: improved preparing method, valuable biological properties plasmid dna. ^ 3 cl, 2 dwg, 2 ex',\n",
              " 'recombinant plasmid dna pcl1 encoding polypeptide property human light chain antibody ebola virus, recombinant plasmid dna pch1 encoding polypeptide property indicated antibody heavy chain usingfield: biotechnology, genetic engineering, virology, medicine. ^ substance: invention reports construction recombinant plasmid dnas pcl1 pch1 vitro comprising artificial genes encoding light heavy chains human full-scale antigen ebola virus prepared genetic engineering methods created basis variable fragments recombinant antibody 4d1 light heavy chains phage library human single-chain antibody, human constant genes igg1, cytomegalovirus promoter polyadenylation bgh site. combining use plasmid dna pcl1 pch1 provides biosynthesis human recombinant full-size antibodies class igg1 interacting ebola virus. using recombinant full-size antibodies raised ebola virus used basis development preparations used diagnosis treatment dangerous diseases caused infectious agent. ^ effect: valuable medicinal properties plasmid. ^ 4 cl, 7 dwg, 6 ex',\n",
              " 'nutrient medium production bacteriophages method preparingfield: biotechnology, medicinal microbiology. ^ substance: invention relates, particular, method preparing nutrient medium used production bacteriophages. nutrient medium production bacteriophages contains acidic casein hydrolyzate base hydrolysis degree 0.6-0.7 vitamins: nicotinic acid, folic acid, calcium pantothenate, riboflavin, thiamine bromide biotin, distilled water. also, invention relates method preparing nutrient medium used production bacteriophages involving hydrolysis natural casein mixed water using hydrochloric acid pressure 0.2 0.05 mpa attainment hydrolysis degree 0.6-0.7 isoprecipitation treatment carbon carried simultaneously. invention provide enhancing growth properties medium quality bacteriophages produced reducing cost. ^ effect: improved preparing method. ^ 3 cl, 1 ex',\n",
              " 'recombitant plasmid dna pet21-vp40ve containing gene matrix protein vp40 ebola virus recombitant protein vp40-ve obtained result gene expression protein vp40 ebola virus using recombitant plasmid dna pet21-vp40ve exhibiting immunogenic antigenic propertiesfield: biotechnology, medicine molecular biology.substance: invention relates particular vitro construction dna construct pet21-vp40ve containing gene matrix protein vp40 ebola virus (strain zaire, isolate mayinga) recombinant protein vp40-ve, immunogenic antigenic properties. recombinant plasmid dna pet21-vp40ve intended expression ebola virus matrix protein vp40 gene (strain zaire, mayinga isolate) thee.coliprokaryotic system production recombinant vp40-ve protein, size 6366 bp. contains: theblagene (coordinates 599 1459 bp) genetic marker determines ampicillin resistance ofe.coli(bl21/de3(+) cells transformed recombinant plasmid pet21-vp40ve; site origin replication ori (coordinates 1630 2218 bp); phage t7 promoter (coordinates 5117 5135 bp); lactose repressor (coordinates 3648 bp 4730 bp); dna-binding protein inhibits expression ofe.coligenes ensures expression target recombinant protein vp40-ve; unique recognition sites restriction endonucleases following coordinates: nhei(5204 bp) xhoi(6205 bp); vp40 gene (strain zaire, mayinga isolate) (981 bp), inserted expression cassette restriction sites nhei(5204 bp) xhoi(6205 bp) (from 4479 5459 nucleotides genomic rna), encodes 327 amino acid residues (a.a.) viral matrix protein vp40; sequence (18 bp) encoding polyhistidine (6xhis) polytract six histidines n-end encoded protein subsequent purification using method ni affinity chromatography. recombinant vp40-ve protein obtained result expression ebola virus matrix protein vp40 gene (strain zaire, mayinga isolate) bacterial expression system ofe.colias part recombinant dna construct pet21-vp40ve, molecular weight 36114.68 da amino acid sequence seq id no: 1 333 a.a. length, including 6 histidines stop codon, immunogenic antigenic properties intended induction antibodies body balb/c mice recognize viral protein vp40-be immunochemical reactions, well interacts mouse monoclonal antibodies, polyclonal goat human antibodies specific inactivated infectious ebola virus.effect: increased yield target recombinant matrix protein vp40 ve.2 cl, 14 dwg, 3 tbl, 8 ex',\n",
              " 'tumor-targeted peptidefield: biotechnology, medicine, oncology, peptides. ^ substance: invention relates method based phage display preparing peptides interacting specifically mammary ehrlich tumor used therapy diagnosis malignant neoplasm. peptides prepared affinity selection phage peptide libraries comprising ten millions different peptides size 15 amino acid residues, group nine peptides wherein peptide shows ability accumulation ehrlich tumor. practice using mimetic-peptides selected manner prepared chemical synthesis use preparing conjugates basis known cytotoxic preparations, radioactive isotopes incorporated composition liposomal preparations visualization tumor neoplasm also. ^ effect: valuable medicinal properties peptides. ^ 2 dwg, 2 ex',\n",
              " 'tumor-targeted peptidefield: biotechnology, medicine, oncology. ^ substance: invention relates peptides found selection phage peptide library feature selective binding target-cells. peptides able accumulate lung adenocarcinoma cells show following amino acid sequences: rnvppifndvywiaf, svailprsfspfxvg, pfarapvehhdvvgl. new tumor-targeted peptides allow carrying purposeful delivery preparation different designation lung adenocarcinoma cells. invention used medicine treatment diagnosis lung adenocarcinoma metastasis. ^ effect: valuable medicinal properties peptides. ^ 2 dwg, 2 ex',\n",
              " \"method preparing polybacteriophagefield: biotechnology, medicine. ^ substance: method preparing polybacteriophage involves combination single volume bacteriophages obtained culturing microorganisms phages casein-acidic medium content total nitrogen 1.96 0.10 mg/ml. bacteriophages appelman's titer 10-5, less, combined obtain single volume following sterilizing filtration membranes pores size 0.2 mcm carried out. invention provides simplifying method, reducing time technological cycle enhancing preparation quality. invention used manufacturing medicinal biological bacteriophage-base preparations. ^ effect: improved preparing method. ^ 4 cl, 2 tbl, 2 ex\",\n",
              " 'high levels constructive producing anthrax protective antigenfield: biotechnology, microbiology, genetic engineering, molecular biology. ^ substance: invention relates method preparing anthrax protective antigenic protein (pa). protective antigenic protein prepared using modified e. coli culture culturing feeding. e. coli cells transformed recombinant constitutive expression plasmid dh5alpha comprising pa gene obtain e. coli dh5alpha cells expressing protein pa. culturing high density cells selected, solubilized 6-8 urea separated centrifugation. urea-denaturated pa isolated supernatant, purified eluted. also, method describes anthrax pa 6x-histidine-fused protein prepared method. culturing method involves using primary additive chosen group consisting polythiol, carbohydrate organic acid, lb medium (luria broth) used feeding beginning middle log-phase. plasmid transformation e. coli cells method involves vector series pqe comprising phage promoter recognized e. coli cells. using invention provides enhancing level producing anthrax protective antigen wherein antigen obtained form protein fused 6x-histidine. ^ effect: improved preparing method, high level antigen. ^ 13 cl, 3 dwg, 1 tbl',\n",
              " 'recombinant plasmid expressing module polypeptide delivery photosensitizer strain escherichia coli vkpm b-8356 - producer module polypeptidefield: biotechnology, microbiology, genetic engineering. ^ substance: invention proposes new recombinant plasmid pr752 (5269 pair bases) comprising genetic construction control bacteriophage t5 promoter encoding module polypeptide consisting 6 histidine residues, hemoglobin-like protein e. coli, modified fragment large t-antigen sv-40, translocation domain diphtheria toxin, spacer sequence (gly-ser)5 human epidermal growth factor (6 his-hmp-nls-dtox-(gly-ser)5-egf) designated directed transfer photosensitizers target-cell nuclei. transformation strain e. coli m15 (rep 4) plasmid pr752 recombinant strain e. coli vkpm b-8356 producer new polypeptide vector prepared. usage new strain able enhance effectiveness effect photosensitizers orders. invention used medicinal-biological industry preparing agents providing directed transport photosensitizing agents tumor cell nuclei. ^ effect: valuable biological medicinal properties polypeptide. ^ 3 dwg, 4 ex',\n",
              " 'method indication microorganismsfield: biotechnology, microbiology. ^ substance: method involves sampling specimen environment addition bacteriophage sample able multiplicate analyzed microorganism. inoculate kept definite time bacteriophage titer determined. presence microorganism proved increase bacteriophage titer value measuring degree light diffusion sample. except for, increase light diffusion sample contacted either immunosorbent radioactivity immunosorbent determined piezoelectric resonator electrodes covered antiphage ig presence piezoeffect assayed. invention used carrying analysis presence microorganisms air liquid medium, monitoring environment periodic regime closed compartments mainly places human mass. ^ effect: improved method indication. ^ 3 cl',\n",
              " 'bacteriophage n15 replicon-base vector recombinant vector regulated expression target gene escherichia coli cells, strain escherichia coli providing possibility regulation vector copy number expression systemfield: biotechnology, molecular biology, genetic engineering. ^ substance: invention relates creature expression system target proteins escherichia coli cells combines high level biosynthesis end product large range regulation. invention proposes constructed expression systems representing strain e. coli comprising phage n15 anti-repressor gene integrated chromosome cells wherein gene control functionally active promoter induced e. coli, sop-operon phage n15 transformed recombinant vector based phage n15 replicon comprising dna fragment encoding end protein control promoter chromosome another induced promoter. proposed vectors inherited stably growing microorganisms antibiotic-free medium based correct distribution replicated plasmid copies daughter cells. using invention provides broad range regulation yield end product possibility using single expression system preparing large assortment protein products independently functional activity. ^ effect: valuable biological properties vector. ^ 20 cl, 7 dwg, 2 tbl, 8 ex',\n",
              " 'combinatorial fragmid library human single-stranded antibodies enriched antibodies variolovaccine virus, recombinant fragmid phen-2a8 dna containing unique gene human single-stranded antibody, capable neutralizing variolovaccine virus cowpox virus, artificial human single-stranded 2a8 antibody capable neutralizing variolovaccine virus cowpox virusfield: biotechnology, protein engineering. ^ substance: claimed library represents e.coli tgi cells wherein cell contains fragmid dna providing biosynthesis filamentous bacteriophages exposing unique human single-stranded antibody surface thereof. disclosed recombinant fragmid phen-2a8 dna containing artificial gene human single-stranded antibody control lactose operon promoter providing synthesis human single-stranded antibody composition chimerical protein membrane piii protein m13 bacteriophage e.coli cells. disclosed method production artificial human single-stranded 2a8 antibody using fragmid dna. ^ effect: fragmid library useful medicine. ^ 3 cl, 7 dwg, 10 ex',\n",
              " 'bacteriophage-base biopreparation prophylaxis treatment colibacillosis (eshcerichiosis)in animalsfield: biotechnology, veterinary medicine. ^ substance: invention relates development biological preparation prophylaxis treatment colibacillosis (escherichiosis) control carriage escherichious infections pathogens animals poultries also. also, invention used producing curative fodders ecologically pure human foodstuffs. biopreparation prophylaxis treatment escherichiosis animals poultries comprises strains bacteriophages phagum escherichia coli ec022-dep and/or phagum escherichia coli ec021-dep, and/or phagum escherichia coli ex0782-dep, and/or phagum escherichia coli ec0781-dep, and/or phagum escherichia coli epz-1-dep, and/or phagum escherichia coli epz-2-dep, and/or phagum escherichia coli eg-5-dep, and/or phagum escherichia coli bc-1-dep, and/or phagum escherichia coli m78-dep, and/or phagum escherichia coli sheksna 2k-dep taken effective amount. biopreparation comprises antiseptic, example, quinosol stabilizing agent. protein (for example, soybean protein), vegetable meal, organic polymer, milk, serum, albumin used stabilizing agent. among organic polymers used: dextran, polyglucin, starch, polyvinylpyrrolidone. biopreparation dried lyophilization, granulated placed polymeric matrix. biopreparation toxic properties animals, shows good hygroscopicity good dispersed water. biopreparation used liquid dry prescription formulations different methods administrations: subcutaneous, intraperitoneal, intramuscular injections aerosol, administration phage particles lung compartments including applying curative fodder supplement fodder, applying surface cutaneous integuments. invention provides enhancing effectiveness treatment animals poultries gastroenteric infections due reducing treatment period, expanding spectrum lytic effect biopreparation, resistance effect digestive tract enzymes convenience using. ^ effect: valuable veterinary properties biopreparation. ^ 9 cl, 5 tbl, 7 ex',\n",
              " \"biopreparation based upon bacteriophages preventing treating salmonellosis animalsfield: biotechnology, veterinary medicine. ^ substance: present innovation deals creating biological preparation treating preventing salmonellosis animals poultry. be, also, applied manufacturing curative fodders ecologically pure products human nutrition. suggested biopreparation contains strains following bacteriophages: phagum salmonella choleraesuis csl-dep and/or phagum salmonella choleraesuis cs2-dep and/or phagum salmonella enteritidis spz-1-dep and/or phagum salmonella enteritidis spz-2-dep, phagum salmonella enteritidis spz-3-dep and/or phagum salmonella enteritidis a-1-dep and/or phagum salmonella enteritidis f-6-dep and/or phagum salmonella enteritidis jun-1-dep and/or phagum salmonella enteritidis jun-2-dep and/or phagum salmonella enteritidis c-1-dep and/or phagum salmonella enteritidis g-1-dep taken efficient quantity. it, also, contains anantiseptic, example, chinosol stabilizer protein (for example, soybean protein), plant meal, organic polymer, milk, whey, albumin. organic polymers one may apply dextran, polyglycin, starch, polyvinyl pyrrolidone. biopreparation freeze dried, granulated put polymeric matrix. active salmonella enteritidis, salmonella typhimurium, salmonella heidelberg, salmonella choleraesuis, salmonella gallinarum-pullorum. biopreparation nontoxic animals, highly hygroscopic highly water-dispersed, applied liquid dry receipt forms different ways injection: due subcutaneous, intraperitoneal, intramuscular injections and, also, aerosol, due introducing phage particles pulmonary departments, perorally - including application curative fodder fodder additive and, also, due applying onto skin surface. present innovation enables increase efficiency treating intestinal infections animals poultry due shortened terms therapy, broadened range biopreparation's lytic action, resistance action gastrointestinal enzymes. ^ effect: higher convenience application. ^ 10 cl, 8 ex, 7 tbl\",\n",
              " \"bacterium strain sphingobacterium mizutae-32 producer spml restriction endonuclease, recognizing cleaving 5'-at'cgat-3' nucleotide sequencefield: biotechnology. ^ substance: invention relates bacterium strain sphingobacterium mizutae-32 producing restriction endonuclease named spml, recognizes cleaves 5'-at'cgat-3' nucleotide sequence. strain isolated melt water process searching endonuclease producing strain high activity low temperatures. strain capable growth 6°c, stable two week storage 20°c. strain-produced enzyme hydrolyzes phage-lambda dna t7 6-10°c. enzyme yield 300000 u/10 g cells. ^ effect: effective strain restriction endonuclease production. ^ 2 dwg, 1 tbl, 4 ex\",\n",
              " 'antibacterial composition prevention treatment hospital infections (versions), bacteriophage stamps used obtain compositionfield: biotechnology.substance: composition includes 7 strains bacteriophage, represented combination bacterial phagolysates filtrates lytic activity least 10according appelman concerning test strains isolated bacterial isolates, well target additives amount 0.01±99.99 wt % composition weight. that, staphylococcus aureus phagolysate filtrate obtained using staphylococcus aureus sch1 bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-105, staphylococcus aureus phagolysate filtrate obtained using staphylococcus aureus sch111 bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-95, klebsiella pneumoniae phagolysate filtrate, obtained using klebsiella pneumoniae kpv15 bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-90, klebsiella pneumoniae phagolysate filtrate, obtained using klebsiella pneumoniae kpv811 bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-91, pseudomonas aeruginosa phagolysate filtrate, obtained using pa5 pseudomonas aeruginosa bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-88, pseudomonas aeruginosa phagolysate filtrate, obtained using pseudomonas aeruginosa pa10 bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-89, acinetobacter baumannii, phagolysate filtrate, obtained using acinetobacter baumannii am24 bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-106. composition version contains acinetobacter baumannii phagolysate filtrate, obtained using acinetobacter baumannii ap22 bacteriophage strain, deposited collection fbis ssc pvb rospotrebnadzor number ph-42. appropriate bacteriophage strains proposed. nucleic acid molecules corresponding genome said bacteriophages proposed.effect: expanded range products containing highly selective natural antibacterial components main active ingredient, ensured biological stability activity bacteriophages agent composition, composition low risk toxic side effects, allows expand versions methods practical application agent containing bacteriophages, provides storage stability application efficiency wide temperature range.28 cl, 1 dwg, 4 tbl, 24 ex',\n",
              " \"test system detecting coronavirus infection pathogen genome cattle means multiplex polymerase chain reaction fluorescent detection real timefield: biotechnology.substance: described test system detecting coronavirus infection pathogen genome cattle using multiplex polymerase chain reaction (pcr) real-time fluorescent detection. test system comprises pcr buffer, mixture carrying out, consisting deoxynucleoside triphosphates, primers fluorescent probes specific coronavirus internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase reverse transcriptase mmlv reverse transcriptase. mixture recombinant plasmid dna containing fragment bcov virus genome fragment bacteriophage ms2 genome contains following nucleotide sequences: bcovf 5'-gatcaaattgctagt-3' - forward primer; bcovr 5'-cagtctgcttagtta-3' - reverse primer; bcovp 5'-fam-ggatgccactaagcca-3' - bhq1 - probe; ms2f 5'-tggcactacccctctccgtattcac-3' - forward primer; ms2r, 5'-gtacgggcgaccccacgatgac-3' - reverse primer; ms2p cy5 5'-cacatcgatagatcaaggtgcctacaagc-3 bhq' probe.effect: invention extends range means detecting coronavirus infection genome cattle.1 cl, 4 tbl, 1 ex\",\n",
              " 'recombinant plasmid pet21-tf7, providing synthesis modified tissue factor, escherichia coli bl21 (de3) pet21-tf7 strain - producer recombinant human tissue factorfield: biotechnology.substance: group inventions refers recombinant plasmid providing synthesis recombinant modified human tissue factor, recombinant strain producing human recombinant tissue factor. disclosed recombinant plasmid pet21-tf7 size 6171 base pairs (bp), containing following structural elements: t7 bacteriophage promoter; recombinant gene coding modified human tissue factor; untranslated region terminating transcription bacterial operon; phage t7 rna polymerase terminator; sequence bla (ampr); cole1 (ori) sequence. recombinant gene modified human tissue factor nucleotide sequence seq id no: 1 nucleotide position 5205 bp nucleotide position 5996 bp, encodes target protein full amino acid sequence seq id no: 2, built-in faund ccini restriction sites pet21a vector polylinker region, containing t7 phage tna rna polymerase promoter terminator. said plasmid provides synthesis 29.6 kda recombinant modified human tissue factor escherichia coli bl21 (de3) cells. presented recombinant strain escherichia coli bl21 (de3)/pet21-tf7, produces recombinant human tissue factor obtained transformation said recombinant plasmid pet21-tf7.effect: group inventions provides high stable yield end product.2 cl, 5 dwg, 1 tbl, 3 ex',\n",
              " 'recombinant plasmid pet32-trex vic, provides synthesis prochymosin vicugna pacos chimeric protein, escherichia coli bl21(de3)plyse pet32-trx vic-producer prochymosin vicugna pacos chimeric proteinfield: biotechnology.substance: group inventions relates recombinant plasmid pet32-trexvic, provides synthesis chimeric protein prochymosin vicugna pacos, well recombinant strain escherichia coli, produces said protein. recombinant plasmid pet32-trexvic size 6826 base pairs (bp) provides synthesis chimeric protein prochymosin vicugna pacos size 52 kda cells escherichia coli bl21 (de3) plyse. plasmid contains structural elements essential functioning expression target protein: bacteriophage t7 promoter, recombinant proichymosin vicugna pacos gene encoding target chimeric protein, t7 rna polymerase terminator, thioredoxin sequence added nucleotide sequence prochymosin vicugna pacos gene n-terminus, bla (ampr) sequence, protein coding beta-lactamase, sequence cole1 (ori), providing replication plasmid e.coli strains. recombinant protein gene prochymosin vicugna pacos nucleotide sequence seq id no: 1 nucleotide position 5209 bp nucleotide position 6649 bp, encoding target chimeric protein prochymosin vicugna pacos full amino acid sequence seq id no: 2, built faund hindiii restriction sites polyketer region pet32a vector containing t7 phage tna rna polymerase promoter terminator. presented escherichia coli bl21 (de3) plyse/pet32-trxvic strain producing prochymosin vicugna pacos chimeric protein obtained transformation recombinant plasmid pet32-trexvic.effect: group inventions provides high rate refolding target enzyme.2 cl, 5 dwg, 2 tbl, 5 ex',\n",
              " 'method phage-mediated bioprocessing extension shelf life cooled fishfield: biotechnology.substance: group inventions relates biotechnology. composition includes combination sterile, purified toxins filtrate phagolysates bacteria lytic activity less 10pfu/ml agar-layer technique relation frequently extracted surface cooled fish strains bacteria. composition contains: phage lysate filtrate aeromonas veronii, obtained using strain bacteriophage aeromonas phage ave1, deposited all-russian state collection pathogenic vaccines strains microorganisms-agents infectious animal diseases k. i. scriabin ya. r. kovalenko all-russian research institute experimental veterinary medicine russian academy science number bf-1359; phagolysate filtrate brothothrix thermosilica obtained using strain bacteriophage brochothrix phage brother1 deposited all-russian state collection pathogenic vaccines strains microorganisms-agents infectious animal diseases k. i. scriabin ya. r. kovalenko all-russian research institute experimental veterinary medicine russian academy science number bf-1360; phagolysate filtrate buttiauxella gaviniae obtained using bacteriophage strain buttiauxella phage buga1, deposited all-russian state collection pathogenic vaccines strains microorganisms-agents infectious animal diseases k. i. scriabin ya. r. kovalenko all-russian research institute experimental veterinary medicine russian academy science number bf-1361; phlegolysate filtrate pseudomonas fluorescens obtained using strain bacteriophage pseudomonas fluorescens pf 1, deposited state collection pathogenic microorganisms cell cultures state scientific center applied microbiology biotechnology number ph-132; phagolysate filtrate aeromonas hydrophila, obtained using bacteriophage strain aeromonas hydrophila ah 1, deposited state collection pathogenic microorganisms cell cultures state scientific center applied microbiology biotechnology number ph-129; phagolysate filtrate raoultella ornithinolytica, obtained using raoultella ornithinolytica r.o. 1 bacteriophage strain, deposited state collection pathogenic microorganisms cell cultures state research center applied microbiology biotechnology number ph-128; phagolysate filtrate listeria monocytogenes obtained using strain bacteriophage listeria monocytogenes lm 1, deposited state collection pathogenic microorganisms cell cultures state research center applied microbiology biotechnology number ph-133. disclosed corresponding strains bacteriophages nucleic acid molecules corresponding genome said bacteriophages.effect: presented phage-mediated bioprocessing method prolonging shelf life cooled fish reducing risk infections antibacterial composition implementing method.9 cl, 15 tbl, 10 ex',\n",
              " 'antibacterial composition extension expiry date frozen fish risk reduction food-infection-based infections, bacteriophagic stamps used obtainingfield: biotechnology.substance: group inventions relates biotechnology. composition includes combination sterile, toxin-free filamentous phagolysates bacteria lytic activity bacteriophages less 10pfu/cmaccording grazia relation strains microorganisms often released surface chilled fish. composition includes phagolysate filtrate aeromonas hydrophila obtained using bacteriophage strain aeromonas hydrophila ah 1, deposited \"gkpm-obolensk\" (state collection pathogenic microorganisms cell cultures federal budgetary institution science \"state scientific center applied microbiology biotechnology\" federal service supervision consumer rights protection human welfare) number ph-129; filtrate phagolysate pseudomonas fluorescens obtained using strain bacteriophage pseudomonas fluorescens pf 1; deposited \"gkpm-obolensk\" number ph-132; filtrate phagolysate raoultella ornithinolytica, obtained using strain bacteriophage raoultella ornithinolytica r.o. 1, deposited \"gkpm-obolensk\" number ph-128; filtrate phagolysate pseudomonas putida, obtained using strain bacteriophage pseudomonas putida psp6, deposited \"gkpm-obolensk\" number ph-130; filtrate phagolysate citrobacter freundii, obtained using strain bacteriophage citrobacter freundii cf 1, deposited \"gkpm-obolensk\" number ph-131; filtrate phagolysate listeria monocytogenes, obtained using strain bacteriophage listeria monocytogenes lm 1, deposited \"gkpm-obolensk\" number ph-133. appropriate strains bacteriophages proposed. molecules nucleic acid corresponding genome noted bacteriophages proposed.effect: antibacterial composition proposed prolonging shelf life chilled fish reduce risk foodborn infections.13 cl, 1 dwg, 11 tbl, 11 ex',\n",
              " 'plasmid vector prh15a producing methionine-free interferon alpha-2b, bacterial strain escherichia coli bl21 de3 - producer methionine-free interferon alpha-2b method producing methionine-free interferon alpha-2bfield: biotechnology.substance: group inventions relates biotechnology. disclosed plasmid expression vector prh15a producing human methionine interferon alpha-2b, human-producing derivative human methionine interferon alpha-2b method producing human methionine-free interferon alpha-2b. plasmid expression vector prh15a contains gene methionine aminopeptidase escherichia coli, rhamnose promoter (pbadrha), rhabad operon, terminator transcription phage t7 genes, origin plasmid replication p15a, chloramphenicol acetyltransferase gene (camr) restriction sites required combining separate fragments vector. presented strain escherichia coli strain bl21star [de3] containing plasmid expression vector payc-et-(hifn-a2b)-laci vector prh15a. method producing methionine-free human interferon alpha-2b, involving culturing said strain, separating interferon-containing biomass followed chromatographic purification end product.effect: group inventions provides producing completely methionine-free interferon alpha-2b high output.3 cl, 4 dwg, 4 ex',\n",
              " 'artificial ykuj-mper gene encoding ykuj-mper recombinant protein-immunogen, pet21a-ykuj-mper recombinant plasmid dna, providing expression artificial ykuj-mper gene, ykuj-mper recombinant protein-immunogen, carrier membrane-proximal area hiv-1 intended induction broadly neutralizing antibodiesfield: biotechnology.substance: group inventions relates field biotechnology, genetic engineering medicine. proposed artificial gene ykuj-mper encodes protein-immunogen ykuj-mper hiv-1 nucleotide sequence seq id no:1 length 360 bps. recombinant plasmid dna pet21a-ykuj-mper type proposed, designed produce protein-immunogen induces hiv-specific b-cell response, size 5,700 bps molecular weight 3.8·10 kda containing ykuj-mper gene, encoding ykuj-mper anti-hiv-1 protein-immunogen, control rna polymerase promoter phage t7, ensuring expression e. coli cells. artificial ykuj-mper immunogen protein proposed, consisting b. subtilis ykuj protein site two hiv-1 mper sites, molecular weight 14.2 kda amino acid sequence seq id no:2.effect: group inventions provides effective induction broadly neutralizing anti-hiv-1 antibodies selection optimal immunization strategy.3 cl, 12 dwg, 1 tbl, 6 ex',\n",
              " \"method identification common hedgehog (erinaceus europaeus) dna tissue dry fodder semi-finished meatfield: biotechnology.substance: invention method identification common hedgehog dna (erinaceus europaeus) dry fodders semi-finished meat products, involving dna recovery animal tissue sorption method, polymerase chain reaction fluorescent detection carried 45 cycles real-time amplification using oligonucleotide primers, probes, fluorescent dyes specific dna genome region: specific signal animal – joe/yellow cy5/red – internal control sample form suspension bacteriophage t4 concentration 5×10phage particles per 1 mcl, positive control sample form mixture containing fragments animal genomes bacteriophage t4 nucleotide sequence: t4f: 5'-tacatataaatcacgcaaagc-3' – forward primer; t4r: 5'-tagtatggctaatcttattgg-3' – reverse primer; t4p: hex-5'-acattggcactgaccgagttc-3'-bhq1 – probe, taken ratio 1:1, measurement accumulation fluorescent signals channels corresponding fluorescent dyes, interpretation results based presence absence intersection fluorescence curve threshold line, fluorescence signal accumulation curves 35 cycles, reaction result considered positive, curves cross threshold line cross 35 cycles, result reaction negative, according invention, dna recovered common hedgehog tissue (erinaceus europaeus) phage antigens bacteriophage t4 used internal control sample, positive control sample – fragments genomes native bacteriophage t4 hedgehogs (erinaceus europaeus) following nucleotide sequence: hed-f: 5'-agtctattgattcgaatagagc-3' – forward primer; hed-r: 5'-catgagaggtactaaccagt-3' – reverse primer; hed-p: fam-5'-caggagctttattaggtgatgatcag-3-bhq1 – probe.effect: invention increases identification accuracy species identity, simplifies sample preparation process.1 cl, 5 tbl\",\n",
              " 'method identification species identity mutton beef food raw materials, fodder food productsfield: biotechnology.substance: invention method identification species identity mutton beef food raw materials, fodder food products, including extraction dna mutton (ovis) beef (bos) sorption method, setting single-stage polymerase chain reaction, carrying 45 amplification cycles real-time detection using mutant dna-specific mutton (ovis) beef (bos) oligonucleotide primers, probes, dyes, internal control sample form bacteriophage suspension positive control samples – containing dna genome fragments mutton (ovis) beef (bos), measuring specific signals control signal interpreting results, wherein investigating food raw materials food products containing mutton dna mutton (ovis) beef (bos), polymerase chain reaction carried fluorescent detection using thermal cycler rotor-gene q type accumulation fluorescent signals measured channels corresponding fluorescent dyes: joe / yellow specific signal mutton (ovis); rox / orange – beef (bos) cy5 / red – internal control sample, interpretation results carried based presence absence intersection fluorescence curve threshold line, curves accumulation fluorescent signal reach 35 cycles, result reaction considered positive, curves cross threshold line cross 35 cycles, result reaction negative, wherein internal reference sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample – mixture containing fragments mutton genomes (ovis), beef (bos) bacteriophage t4 taken ratio 1:1:1 following nucleotide sequences: ovis f gcctcatctccctccaacag forward primer; ovis cggaagcctgtaattacagctc reverse primer; ovis p r6g-ctcatgtctgtcctttggtgttatgaatgc-bhq1 probe; bos f aacagcatcattctacccactt forward primer; bos acctaaattcctattctaacactg reverse primer; bos p rox-acgacttacatactccactgcactcacg-bhq2 probe; t4f tacatataaatcacgcaaagc; t4r tagtatggctaatcttattgg; t4p cy5 acattggcactgaccgagttc.effect: invention makes possible increase accuracy beef mutton species identity identification.1 cl, 5 dwg, 5 tbl',\n",
              " 'method production immunogenic composition based fusion protein pesat6-dbd dextran, recombinant plasmid pesat6-dbd, strain escherichia coli, chimeric protein esat6-dbd applicationfield: biotechnology.substance: invention provides recombinant plasmid pesat6-dbd consisting artificial bacterial operon chimeric protein comprising promoter region early promoter bacteriophage t5, gene chimeric protein consisting sequence protein antigen esat6 mycobacterium tuberculosis, fused sequence dextran-binding domain (dbd) dextran-sucrase leuconostoc citreum km20 transcription terminator; bacterial operon beta-lactamase bacterial initiation site replication colel type. invention comprises strain escherichia coli - producer chimeric protein esat6-dbd, method immobilisation, concentration purification resulting protein dextran. addition, invention relates recombinant protein esat6-dbd immunogenic compositions comprising it, aiming induction immunity tuberculosis infection.effect: invention enables obtain producing strain provides high level production stable immunogenic proteins prepared, immobilised purified single step, receive effective immunogenic compositions tuberculosis.5 cl, 2 dwg, 1 tbl, 5 ex',\n",
              " 'method prenatal postnatal genetic diagnosis numerical chromosome abnormalities human embryos dna-microchip based full chromic dna probesfield: biotechnology.substance: invention refers biotechnology, particularly methods prenatal postnatal genetic diagnosis numerical chromosome abnormalities human embryos dna microarrays implementation. dna-microchip substrate made glass coated polylysine, additionally probes slots probes positive negative controls, wherein dna probes presented least two replications grouped separate rectangular zone, wherein second dna probe repeatability reversed 180 degrees copy first replication respect vertical axis, corners rectangle positive, presented human genome dna, negative, presented dna phage λ, yeast genomic dna, control, fluorescent dyes labelling used cy3, cy5, sulfo-cy3, sulfo-cy5.5.effect: technical result simplification results obtained result dna microchip analysis, use accessible equipment, reduction time financial expenses creation dna-microchip maintenance necessary sufficient accuracy information value diagnostics.4 cl, 2 tbl, 2 ex, 2 dwg',\n",
              " 'bacteriophages, phage peptides methods using themfield: biotechnology.substance: invention refers phage therapy treating preventing bacterial infections. particular, present invention refers new bacteriophages f387/08, f391/08, f394/08, f488/08, f510/08, f44/10 f125/10, recovered polypeptides, compositions containing one new bacteriophages and/or recovered polypeptides, well methods treating preventing bacterial infections using separately, combination antibacterial therapeutic agents, e.g. antibiotics and/or phages.effect: disclosed bacteriophages, phage peptides methods using them.34 cl, 21 dwg, 7 tbl',\n",
              " 'method purifying filamentous bacteriophage m13field: biotechnology.substance: invention relates method purifying filamentous bacteriophage m13. method involves removal bacterial mass producing bacteriophage first second successive centrifugation followed first purification supernatant bacteriophage isoelectric precipitation reagent ph 4.2, third centrifuging re-suspension precipitate bacteriophage, well repeated purification suspension bacteriophage isoelectric precipitation reagent ph 4.2 fourth centrifugation precipitate bacteriophage produce end product. isoelectric precipitation agent used sodium acetate buffer ph = 4.2 ratio supernatant bacteriophages less 3:1 first isoelectric precipitation, precipitate bacteriophage third centrifugation re-suspended tbs-buffer, repeated purification re-suspended bacteriophage isoelectric precipitation, sodium acetate buffer ph = 4.2 used ratio re-suspended bacteriophage less 1:1. first second centrifugation carried 5,000 rpm 12,000 rpm 10 minutes 20 °c, third fourth centrifugation carried 10,000 rpm 10 minutes 4 °c.effect: invention provides higher level sterility purity bacteriophage, especially small quantities thereof using simpler technique.1 cl, 7 tbl, 9 ex',\n",
              " 'preparation based lytic mycobacteriophage method production thereoffield: biotechnology.substance: invention relates preparation inactivation (lysis) intracellular tuberculosis mycobacteria based lytic mycobacteriophagous strain inactivates intracellular tuberculosis mycobacteria, mycobacteriophage d29 included bilayer phospholipid liposome 0.4 mcm, method production thereof, comprising separating purifying phage particles bacterial lysates m.smegmatis subsequent inclusion phospholipid liposomes, separation purification phage particles bacterial lysates m.smegmatis carried ion-exchange chromatography q-sepharose column, obtained purified mycobacteriophage concentration less 10pfu/ml shaken phospholipid film 5–10 minutes, obtained particles extruded filter 5 micron pores subsequent 20-fold extrusion using filters pore size 0.4 mcm, concentration separation fraction mycobacteriophage included liposome centrifugation 13±2 thousand rpm 30±5 minutes, using phospholipid film obtained phosphatidylcholine, cholesterol tween-80, taken weight ratio 5±1:1±0.8:1.2±0.2.effect: presented preparation intracellular mycobacterium tuberculosis inactivation (lysis).3 cl, 5 dwg',\n",
              " 'recombinant producer human omega-amidase nit2 based escherichia colifield: biotechnology.substance: invention relates recombinant strain escherichia coli bl21 (de3; pqe-nit2). strain obtained transforming escherichia coli strain bl21 (de3) plasmid construct pqe-nit2, control t5 phage promoter designed produce human ω-amidase (nit2) cultivated nutrient media based peptone, yeast extract glucose. peculiarity nit2 gene pqe-nit2 construct optimized codon composition, well presence artificially introduced 6his- affinity tag immediately initiator codon atg (met), allows one-step product purification metal-affinity chromatography ni-nta-agarose.effect: invention allows obtain human ω-amidase elevated yield.2 dwg, 1 tbl, 6 ex',\n",
              " 'strain bacteriophage pseudomonas aeruginosa n 325 (500319), intended preparation mono- polyvalent treatment-and-prophylactic preparations bacteriophagesfield: biotechnology.substance: invention relates strain bacteriophage pseudomonas aeruginosa used production medical biological antibacterial drugs – bacteriophage preparations, intended preventing treating pyoinflammatory enteral diseases caused pseudomonas aeruginosa bacteria. strain lytic activity pseudomonas aeruginosa. strain deposited state collection pathogenic microorganisms (gkpm) federal state budgetary institution \"scientific centre expert evaluation medicinal products\" ministry health russian federation (fsbi \"sceemp\" russian ministry health) registration number no. 325 (500319).effect: invention wide spectrum antibacterial activity relation epidemiologically significant hospital isolated patients various pathologies clinical strains pathogenic bacteria pseudomonas aeruginosa, 100 % resistant one antibiotics, obtained maximum expansion geography isolation regions.1 cl, 1 dwg, 5 ex',\n",
              " 'strain bacteriophage pseudomonas aeruginosa n 326 (500320), intended preparation mono- polyvalent treatment-and-prophylactic preparations bacteriophagesfield: biotechnology.substance: invention relates strain bacteriophage pseudomonas aeruginosa used production medical biological antibacterial drugs – preparations bacteriophages intended prevention treatment pyoinflammatory enteral diseases caused bacteria pseudomonas aeruginosa. strain deposited state collection pathogenic microorganisms (gkpm) federal state budgetary institution \"scientific centre expert evaluation medicinal products\" ministry health russian federation (fsbi \"sceemp\" russian ministry health) registration number 326 (500320).effect: strain lytic activity pseudomonas aeruginosa, wide spectrum antibacterial activity relation epidemiologically significant hospital isolated patients various pathologies clinical strains pathogenic bacteria pseudomonas aeruginosa, 100% resistant one antibiotics, obtained maximum expansion geography isolation regions.1 cl, 4 ex, 1 dwg',\n",
              " 'tumour-specific peptide address chemotherapy human breast cancerfield: biotechnology.substance: invention relates tumour-specific peptide. disclosed peptide selected phage peptide library one following amino acid sequences: ytydpwlifpan (seq id 1) fipfdpmsmrwe (seq id 2). peptide high specificity toward human breast cancer cells, including ones triple negative phenotype.effect: address chemotherapy human breast cancer.1 cl, 3 dwg, 1 tbl, 5 ex',\n",
              " 'strain escherichia coli bl21(de3)gold/petcypopti - producer human recombinant cyclophilin afield: biotechnology.substance: invention relates biochemistry, genetic engineering biotechnology, namely strain escherichia coli bl21(de3)goldpetcypopti. strain producer recombinant human cyclophilin a. strain produced cell transformation strain escherichia coli bl21(de3)gold petcypopti plasmid. said plasmid size 5858 base pairs contains fragment xhoi-ndei vector pet-22b(+) carrying gene ampicillin resistance ampr, promoter terminator phage t7 rna-polymerase polylinker, wherein fragment, carrying gene human recombinant cyclophilin a, cloned sites xhoi-ndei size 498 base pairs, seq id no: 1.effect: present invention enables obtain human cyclophilin high output purity.1 cl, 3 dwg, 1 ex',\n",
              " 'strain halobacterium salinarum, used preparing bacterial preparationsfield: biotechnology.substance: invention relates biotechnology used preparing bacterial preparations use medicine, veterinary medicine, cosmetology. strain halobacterium salinarum 353p-1, registration number vkpm b-12794, obtained multistage selection original strain halobacterium halobium 353 pushchinsky without using methods genetic modification treatment chemical physical mutagenic agents. strain halobacterium halobium vkpm v-12794 excels initial one yield biomass, carotenoids, important unsaturated fatty acids, increased resistance phage damage.effect: strain used production highly active bacterial preparations use various fields.1 cl, 1 tbl, 3 ex',\n",
              " \"plasmid pvax-rbd dna matrix mrna-rbd molecules, obtained using pvax - rbd dna matrix, providing synthesis secretion rbd protein sars-cov 2 mammalian cells complex form nanoparticles containing mrna-rbd molecules induce sars-cov-specific antibodies viral neutralizing activityfield: biotechnology.substance: invention relates biotechnology genetic engineering. pvax-rbd plasmid dna matrix created, nucleotide sequence seq id no: 1 size 3710 bp, molecular weight 2.6×103kda, containing target gene encoding chimeric protein 176-rbd, preceded promoter phage t7 rna polymerase, provides vitro synthesis mrna-rbd using t7 rna polymerase. mrna-rbd molecule nucleotide sequence seq id no: 2 obtained using pvax-rbd dna matrix, contains open reading frame encoding amino acid sequence seq id no: 3, provides synthesis secretion rbd sars-cov 2 immunogen protein mammalian body, contains hybrid signal sequence 176, kozak consensus sequence, 7-methylguanosine cap 5'-end mrna, polyadenosine (poly a) tail 3'-end mrna, 150-200 nucleotides long, 5'- 3'-untranslated regions (utr) open reading frame. complex form nanoparticles inducing sars-cov-specific antibodies viral neutralizing activity, consisting polyglucinepermidine conjugate molecules mrna-rbd molecules taken different charge ratios 1:1 1:30, corresponding weight ratio 1:3 1:90, size range 50-900 nanometers, nanoparticle contains core consisting mrna-rbd molecules coated layer polyglucinepermidine conjugate retained due ionic interaction negatively charged nucleus positively charged spermidine.effect: creation effective means delivering mrna-rbd cells body synthesis rbd sars-cov-2 protein increasing level secretion protein cells ensure presentation rbd protein immune system body.4 cl, 7 dwg, 1 tbl, 5 ex\",\n",
              " 'recombinant plasmid ppa-oprf-atox-opri dna, encodes synthesis hybrid recombinant protein, including amino acid sequences protein f external membrane atoxic variant pseudomonas aeruginosa exotoxin, escherichia coli pa-oprf-atox-opri strain - producer hybrid recombinant protein method obtaining specified proteinfield: biotechnology.substance: invention relates biotechnology recombinant plasmid dna ppa-oprf-atox-opri, contains fusion genes encoding proteins f outer membrane pseudomonas aeruginosa, well toxic variant exotoxin pseudomonas aeruginosa. expression control promoter phage t7, two lactose operons, lambda tof region transcription stop, transcription terminator rrnbt1. ppa-oprf-atox-opri plasmid contains kanamycin resistance gene, site replication initiation plasmid cole1. cells recipient escherichia coli bl21 (de3) strain containing highly expressed rna polymerase gene bacteriophage t7 transformed plasmid. invention relates method producing recombinant protein.effect: invention allows obtain hybrid recombinant protein, including amino acid sequence proteins f outer membrane atoxic variant exotoxin pseudomonas aeruginosa, develop vaccine prevent infections caused pseudomonas aeruginosa, well obtain donor immunoglobulins intended treatment pseudomonas infection.3 cl, 3 dwg, 1 tbl, 5 ex',\n",
              " 'method producing recombinant antimicrobial peptide ubi18-35, recombinant plasmid dna pet31b-2xubi18-35 producer-producer escherichia coli bl21 rosetta de3 pluss/pet31b-2hubi18-35 antimicrobial peptide ubi18-35field: biotechnology.substance: invention relates biotechnology represents recombinant plasmid dna pet31b-2xubi18-35 coding amino acid sequence recombinant antimicrobial peptide ubi18-35 coded nucleotide sequence: 5’-aaagtggcgaaacaggaaaagaaaaagaa aaagaccggtcgtgcgaaacgtcgt-3’, molar mass 1.8 mpa. plasmid dna consists dna fragment plasmid pet31b + hydrolysed alwni (pstni) site ligated said site fragment coding 2 ubi18-35 molecules bounded ends trinucleotides, coding methionine residues containing plasmid pbr322 replication initiation site, t7-rna polymerase phage transcription promoter terminator, starter codon, coding gene ketosteroidisomerase, coding sequence 6 histidine residues, stop codon, genetic marker ampr - β-lactamase gene determines resistance transformed plasmid pet31b-2xubi18-35 cellsto ampicillin. invention relates method producing recombinant antimicrobial peptide ubi18-35, comprising cell transformationbl21 rosetta de3 plyss said plasmid, growing cells transformed cellsin medium subsequent cultivation; separation cells centrifugation, washing inclusion bodies containing 2 molecules recombinant antimicrobial peptide ubi18-35 protein-fusion ketosteroidisomerase 6-histidine tag, dissolving buffer addition urea, followed separation peptides ketosteroidisomerase 6 histidine residues, separation thereof using bromocyan chromatographic purification recombinant peptide.effect: plasmid dna provides synthesis ubi18-35 peptide part fusion protein ketosteroidisomerase.2 cl, 9 dwg, 1 tbl',\n",
              " 'test system detection virus genome parainfluenza 3 types cattle multiplex polymerase chain reaction fluorescent detection real time modefield: biotechnology.substance: invention relates biotechnology, particular means diagnosing parainfluenza virus type 3 animals. test system detecting genome causative agent coronavirus infection animals using multiplex polymerase chain reaction fluorescence detection real time proposed. test system includes buffer carrying polymerase chain reaction, primers fluorescent probes specific coronavirus internal control sample, mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase reverse transcriptase mmlv reverse transcriptase, buffer diluting rna form deionized water, internal control sample, negative control sample, positive control sample, internal control sample – bacteriophage ms2 suspension, positive control sample, mixture recombinant plasmid dna containing fragment bpi 3 virus genome fragment bacteriophage genome used.effect: invention serves extend functionality obtain reliable diagnostics.1 cl, 5 tbl, 1 ex',\n",
              " \"recombinant gene encoding hbd-epo protein, recombinant plasmid dna pl610, method producing recombinant hbd-epo protein, recombinant hbd-epo protein, composition specifically inducing bone regeneration, method specific induction bone tissue regenerationfield: biotechnology.substance: invention relates biotechnology, genetic engineering, biochemistry, medicine, veterinary medicine. synthetic dna sequence corresponding gene encoding protein sequence heparin-binding domain (hbd) danio rerio fused human erythropoietin (epo) sequence (hbd-epo protein) nucleotide composition codons optimized heterologous expression non-pathogenic laboratory strain e. coli. synthetic hbd-epo gene flanked 5'-end ncoi site, 3'-end site kpn2i inserted plasmid pqe6 ncoi kpn2i sites. based this, recombinant plasmid pl610 obtained containing artificial bacterial operon recombinant hbd-epo protein comprising promoter region early promoter bacteriophage t5, recombinant hbd-epo protein gene, transcription terminator; bacterial operon beta-lactamase; bacterial region initiation replication cole1 type encoding recombinant hbd-epo protein providing synthesis e. coli strains. invention includes method purifying hbd-epo protein ion exchange chromatography. invention relates hbd-epo recombinant protein itself, expression vector pl610 composition (demineralized bone matrix (dcm) containing hbd-epo protein, well dcm containing protein hbd-epo bmp-2), aimed stimulating osteogenesis. invention allows obtain stable purified active protein hbd-epo, well hbd-epo, immobilized dcm, including dcm bmp-2 bone morphogenetic protein.effect: invention includes method specifically inducing bone regeneration, comprising filling defects bone tissue composition consisting hbd-epo immobilized dcm, including dcm bone morphogenetic protein bmp-2.7 cl, 4 dwg, 5 ex\",\n",
              " 'pharmaceutical composition treating eye infections caused meticillin-resistant strains staphylococcus aureus, includes active ingredient n-terminal chap-domain endolysin bacteriophage staphylococcus aureusfield: biotechnology.substance: invention relates biotechnology, particular pharmaceutical composition treating eye infections caused methicillin-resistant strains of, containing active substance n-terminal char endolysin bacteriophage k.effect: declared pharmaceutical composition non-toxic effective vancomycin antibiotic extends range products treating eye infections caused methicillin-resistantstrains.1 cl, 7 ex, 1 dwg, 5 tbl',\n",
              " 'method producing recombinant herpesviruses simultaneous transduction immortalization primary t-lymphocytes nk cellsfield: biotechnology.substance: invention relates biotechnology, namely method producing recombinant herpesviruses simultaneous transduction immortalization primary t-lymphocytes nk cells. recombinant plasmid dna puc-hvs-ofp consists following key genetic elements: puromycin resistance gene (pac); orange fluorescent protein (ofp) gene; flanking parts (600 bp) homologous vcd59 area hvs genome; ampicillin antibiotic resistance gene (ampr) bacterial promoter ampicillin resistance gene (ampr promoter); origin replication bacteriophage f1 (ori); cytomegalovirus (cmv) promoter. cell culture permissive lytic infection herpesvirus saimiri virus infected herpesvirus saimiri hvs-c488 virus strain. another interweaved cell line transfected mixture expression plasmids puc-hvs-ofp plasmid. permissive cell culture infected herpesvirus saimiri cell culture transfected expression plasmids mixed subjected co-cultivation.effect: combining productive development virus cells lines permissive lytic hvs infection high efficiency cell transfection expression plasmids encoding genetic sequences intended introduction genome “wild” virus strain makes possible obtain recombinant herpesviruses increased efficiency development.6 cl, 6 dwg',\n",
              " 'method indication identification strains plague pathogen belonging species yersinia pestis, subspecies, biovars, phylogenetic branches presence genes pathogenicity main factors dna-chip methodfield: biotechnology.substance: invention relates biotechnology, namely indication identification plague agent strains belonging species yersinia pestis, subspecies, biovars, phylogenetic branches presence genes pathogenicity main factors dna-chip method. method involves recovering dna strain, carrying multiplex pcr one step six reaction mixtures target dna: ‘pla’, ‘3a’, ‘cafl’, ‘yihn’ first; ‘irp2’, ‘lcrv’ second; ‘glpd’, ‘pro’, ‘med24’, ‘45’ third; ‘med70’, ‘phage’ fourth; ‘alt’, ‘his’, ‘u1’ fifth; ‘caucas’, ‘tal’, ‘micr’ sixth subsequent hybridisation immobilized probes, indication identification strains based presence absence fluorescence signals. fluorescence targets \"yihn\" \"3a\" observed strains y. pestis. differentiating subspecies, fluorescence signal y. pestis strains main subspecies target \"45\", strains altaic biovar central asian sub-species target \"alt\", gissar biovar central asian subspecies \"his\" target, talas biovar central asian sub-species target \"ta1\", microtias biovar central asian subspecies target \"micr\", ulegeica subspecies strains target \"u1\", strains caucasian subspecies \"caucas\" target. differentiating y. pestis strains main subspecies belonging biovars, fluorescence signal strains oriental biovar (1.ori) \"glpd\" target, strains medieval biovar except 2.med0 target \"med24\" fluorescence signals strains branch 2.med0 target \"pckp\", strains antique biovar main subspecies targets \"glpd\" \"med24\" noted. phylogenetic branch \"1\" (1.ant 1.ori) strains characterized presence fluorescent signal \"phage\" target, phylogenetic branch \"2\" (2.ant 2.med) strains characterized absence fluorescence signal \"med70\" target. detecting main pathogenicity genes, fluorescence signal y. pestis strains containing hpi high pathogenicity island chromosome pigmentation region target \"irp2\", strains carrying pla gene plasmid ppst target \"pla\", strains gene lcrv plasmid pcad target \"lcrv\", strains containing cafl gene plasmid pfra target \"caf\".effect: invention makes possible determine affiliation species, subspecies, biovars, phylogenetic branches presence main genes pathogenicity dna-chip method, provides isolation dna-strain, conducting six multiplex pcr target dna ‘yihn’, ‘3a’, ‘45’, ‘alt’, ‘his’, ‘u1’, ‘caucas’, ‘tal’, ‘micr’, ‘glpd’, ‘med24’, ‘pro’, ‘med70’, ‘phage’, ‘pla’, ‘cafl’, ‘irp2’, ‘lcrv’, subsequent hybridisation immobilized probes, indication identification strains based presence absence fluorescence signals accordance tables.1 cl, 6 tbl, 9 ex',\n",
              " \"pcdexo-gs-ssb genetic constructs containing sequences encoding chimeric ssb proteins exonucleases bacteriophage homologous recombination apparatus, combined via glycine-serine polylinkerfield: biotechnology.substance: invention relates biotechnology, namely, production recombinant ssb-gs-exo protein construct. proposed method producing recombinant ssb-gs-exo protein construct, involving transformation competent cells expression genetic constructs therein based plasmid dna, wherein 5’-3'flap exonuclease (exo) ssb protein combined genetic engineering glycine-serine spacer represented sequence seq id no: 1.effect: invention ensures cloning dna molecules increased frequency homologous recombination nucleic acids cell.1 cl, 3 dwg, 1 tbl, 2 ex\",\n",
              " 'recombinant plasmid dna p280_2gm coding polypeptide properties granulocyte-macrophage colony-stimulating factor human, strain escherichia coli sg 20050/p280_2gm - producer polypeptide properties granulocyte-macrophage colony-stimulating factor human method obtaining said polypeptidefield: biotechnology.substance: invention relates biotechnology, particularly genetic engineering, vitro constructed recombinant plasmid dna containing two copies human granulocyte-macrophage colony-stimulating factor (gm-csf) synthetic gene, escherichia coli strain sg20050/p280_2gm producer said polypeptide method producing polypeptide gm-csf properties. recombinant plasmid dna p280_2gm codes polypeptide properties granulocyte-macrophage colony-stimulating factor (gm-csf) person characterized following features: codes amino acid sequence mature human gm-csf; molecular weight 2.95 mda (4,422 base pairs); consists of: psti/bamhi(pol)-fragment plasmid dna p280gm (1,484 base pairs) containing c-terminal part beta-lactamase gene, tandem promoters tryptophan operon e. coli synthetic gene gm-csf human, well ecori(pol)/psti (2,938 base pairs) – fragment plasmid containing synthetic human gm-csf gene n-terminal portion beta-lactamase gene; contains: – tandem promoters tryptophan operon e. coli; two copies human synthetic gm-csf gene; transcription terminator t0 lambda phage; genetic marker, beta-lactamase gene determining resistance e. coli transformed plasmid p280_2gm ampicillin antibiotics; unique recognition sites restriction endonucleases located following distances right ecori site (279 base pairs) – bamhi – 912 nucleotides; psti – 3,396 nucleotides.effect: invention increases output polypeptide properties granulocyte-macrophage colony-stimulating factor.3 cl, 8 dwg, 4 tbl, 15 ex',\n",
              " 'bacteriophage lytic enzyme antibacterial composition based thereonfield: biotechnology.substance: invention relates biotechnology, specifically production antibacterial recombinant proteins, used medicine antibacterial composition exhibiting activity gram-negative bacteria pseudomonas aeruginosa. recombinant protein obtained, covalently cross-linked endolysin antipseudomonal bacteriophage krr10 modified fragment [k2,7,13]-smap-29(1-17) myeloid antimicrobial sheep peptide smap-29.effect: invention provides higher effectiveness antibacterial therapy pseudomonas aeruginosa bacteria.2 cl, 7 dwg, 1 tbl, 3 ex',\n",
              " \"recombinant plasmid dna pqe-30_p36gp12_gp57, providing synthesis recombinant protein p36gp12 cells escherichia coli, strain bacteria escherichia coli - producer recombinant protein p36gp12, recombinant protein p36gp12, capable bind lipopolysaccharides escherichia colifield: biotechnology.substance: invention relates biotechnology, specifically recombinant production hybrid protein escherichia coli cells, used purification biotechnological substances bacterial lipopolysaccharides. hybrid protein p36gp12 consisting n-terminal oligopeptide mrgshhhhhhgsan full-length protein short tail filaments t4-like bacteriophage isolate. plasmid pqe-30_p36gp12_gp57 designed, provides synthesis recombinant protein p36gp12 escherichia coli dh5αf'/pqe-30_p36gp12_gp57 strain cells, obtained transformation cells escherichia coli dh5αf' constructed plasmid.effect: invention enables obtain recombinant protein p36gp12, ability bind lipopolysaccharides escherichia coli.3 cl, 6 dwg, 6 ex\",\n",
              " 'antibacterial composition (embodiments) use protein antimicrobial agent directed bacteria pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, salmonella typhi staphylococcus haemolyticus (embodiments)field: biotechnology.substance: invention relates biotechnology, specifically therapeutic proteins used medicine antibacterial agent. disclosed use recombinant endolysin bacteriophage, including combination pharmaceutically acceptable carriers and/or substances increasing membrane permeability, antimicrobial agent directed bacteria pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, salmonella typhi staphylococcus haemolyticus. antibacterial compositions obtained based said protein, including fused 8-histidine tag.effect: invention provides effective penetration endolysin without adding various permeabilisers covalently bound penetrating peptides outer membrane said bacteria cleavage peptidoglycan, ultimately leads death bacteria.4 cl, 3 tbl, 6 ex, 5 dwg',\n",
              " 'antibacterial composition (embodiments) use protein antimicrobial agent directed acinetobacter baumannii bacteria, (embodiments)field: biotechnology.substance: invention relates biotechnology, specifically therapeutic proteins, used medicine antibacterial agent. disclosed use recombinant endolysin bacteriophage, including combination pharmaceutically acceptable carriers and/or substances, increasing permeability membranes, antimicrobial agent directed bacteria acinetobacter baumannii. antibacterial compositions obtained based said protein, including fused 8-histidine tag.effect: invention provides effective penetration endolysin without adding various permeabilisers covalently bound penetrating peptides outer membrane said bacteria cleavage peptidoglycan, ultimately leads death bacteria.4 cl, 3 tbl, 6 ex, 5 dwg',\n",
              " \"genes encoding open reading frames l-segments cchf, recombinant constructs provide expression structural glycoproteins rna-dependent rna polymerase (l) crimean-congo hemorrhagic fever virusfield: biotechnology.substance: invention relates biotechnology. described gene encoding rna-dependent rna polymerase cchf virus nucleotide sequence seq id no:1 11838 bp length. described recombinant plasmid psb3delta-rdrp, designed integration expression rna-dependent rna polymerase gene cchf virus, size 18270 bp. contains, accordance physical genetic map, target gene encoding rna-dependent rna polymerase cchf virus, amino acid sequence seq id no: 2 3945 amino acids length, consists following elements: β-lactamase gene (coordinates 17218 18078 bp) control promoter (coordinates 18079 18183 bp), genetic marker determines ampicillin resistance e. coli cells; origin replication ori plasmid vector puc (coordinates 16459 17047 bp); 5'-itr 3'-itr inverted repeats coordinates 17 288 bp. 15990 16214 p.n. accordingly, provide integration plasmid region enclosed genome mammalian cells using sleeping beauty (sb) transposase; promoter enhancer cmv - provides gene expression according claim 1 mammalian cells (coordinates 855 1438 bp); chimeric intron - chimeric intron providing efficient transcription, stability transport transcript cell nucleus (coordinates 1574 1706 bp); t7 promoter - nucleotide sequence t7 bacteriophage promoter required vitro transcription (coordinates 1751 1769 bp); l protein (rdrp) - open reading frame gene rna-dependent rna polymerase cchf virus according claim 1 (coordinates 1783 13620 bp); ires2 - internal site encephalomyelitis virus ribosome entry, providing expression puromycin resistance gene (coordinates 13854 14240 bp); puror - puromycin resistance gene, amino acids, encoding n-acetyl transferase (coordinates 14241 14843 bp); bgh poly (a) signal - polyadenelation signal (coordinates 14874 15098 bp).effect: invention expands arsenal cchf treratment.2 cl, 8 dwg, 4 tbl, 3 ex\",\n",
              " 'strain asidiomycete daedaleopsis confragosa, containing proteins, exhibiting anticancer antiviral activityfield: biotechnology.substance: invention relates biotechnology. strain basidiomycete daedaleopsis confragosa k-1326, cytostatic anticancer activity human marrow myeloma (im-9), human lymphadenoma (namalva) inhibitory activity herpes simplex virus type 2, influenza virus / h1n1 / california / 2009, deposited collection bacteria, bacteriophages fungi federal state-funded institution ssc srb wb “vektor” federal supervision agency customer protection human welfare registration number f-1368. strain basidiomycete daedaleopsis confragosa used produce anticancer antiviral drugs.effect: invention allows increase yield proteins exhibiting activity tumor cells viruses pathogenic human.1 cl, 4 dwg, 4 tbl, 6 ex',\n",
              " 'strain serratia species bacteria antiviral activityfield: biotechnology.substance: invention relates biotechnology. strain serratia species bacteria k-57 possesses rnase rna dna activity, deposited collection bacteria, bacteriophages fungi federal budgetary institution science \"state research center virology biotechnology \"vector\"of rospotrebnadzor\" registration number v-1289. strain serratia species bacteria v-1289 strain used production antiviral drugs.effect: invention makes possible expand assortment strains antiviral activity human influenza virus a/aichi/2/68 (h3n2), vaccinia virus (vov), micepox virus (mpv), herpes simplex virus type 2 (hsv-2).1 cl, 2 dwg, 8 ex, 2 tbl',\n",
              " 'method identification rat mouse tissue species dry feed semi-fenished meat productsfield: biotechnology.substance: invention relates biotechnology. invention aimed identifying rat (rattus) mouse (mus musculus) tissues spices dry feed meat semi-finished products, including isolation dna animal tissues sorption, setting polymerase chain reaction fluorescent detection 45 real-time amplification cycles using site-specific animal dna genomes, oligonucleotide primers, probes, fluorescent dyes: joe/yellow specific signal one animals cy5/red - internal control sample suspension bacteriophage t4 concentration 5×103phage particles per 1 µl positive control sample form mixture, containing fragments genomes animals bacteriophage t4 nucleotide sequence, taken ratio 1:1:1, measuring accumulation fluorescent signals channels appropriate fluorescent dyes, interpretation results basis presence absence crossing fluorescence curve threshold line, curves accumulation fluorescent signal 35 cycle, reaction considered positive, curves cross threshold line cross 35 cycles, result reaction - negative, according invention, dna isolated tissues rats (rattus) mice (mus musculus) internal control sample using phage lysate phage t4, positive control sample - fragments genomes native bacteriophage t4 tissues rats (rattus) mice (mus musculus), determination dna tissues rat (rattus) using fluorescent dye joe/yellow, fabric mouse (mus musculus) - fam/green.effect: said invention allows increasing accuracy species identification, simplifying preparation process.1 cl, 5 tbl',\n",
              " 'method introducing unmarked point substitutions chromosome microbacteriafield: biotechnology.substance: invention relates genetic engineering. described method introducing point substitutions bacterial chromosome without concomitant integration antibiotic resistance determinants. method based widely applied method phage recombination introducing mutations bacterial chromosome using short fragments. efficiency obtaining recombinant clones mycobacteria approximately 10-4to 10-3per total amount cells. accordingly, selection appropriate mutants requires checking thousands colonies. previously proposed methods improving efficiency clone selection either include use antibiotic resistance markers include creation complex genetic constructs individually introduced replacement. increase relative yield recombinant colonies achieved due transformation recombinant oligonucleotide jointly co-selective dna incapable intagreated chromosome. selection colonies based phenotypic resistance provided resistance marker coselective dna provides possibility selecting competent subpopulation cells increasing effectiveness method 10-2to 10-1recombinants. loss extra-chromosomal resistance marker provided either serial passages culture onto medium without antibiotic use counter-selective markers.effect: introduction point substitutions bacterial chromosome.9 cl, 2 dwg, 5 ex',\n",
              " 'strain bacteria bacillus thuringiensis, neutralising infectious activity human influenza virus a/h3n2 (versions)field: biotechnology.substance: invention relates novel strains bacillus thuringiensis b-1272 bacillus thuringiensis b-1273 deposited collection bacteria, bacteriophages fungi federal state-funded institution science \"state research centre virology biotechnology \"vector\". index neutralisation infectious activity virus a/h3n2 using preparations based culture fluid proposed strains 0.5-3.2 lg.effect: strains ability neutralise infectious activity human influenza virus.2 cl, 1 tbl, 8 ex',\n",
              " 'method producing bacteriophagefield: biotechnology.substance: invention relates production bacteriophage. disclosed method involves inoculation bacterial cell suspension titre 10-10cfu/ml dense nutrient medium layer thickness 3 25 mm cultivation foreign microflora, air layer thickness surface dense nutrient medium 5 50 mm optimum temperature host strain culture growth. 30-120 minutes beginning culturing every 30-60 minutes smears taken surface dense nutrient medium, coloured intercalating dye microscoped. cultivation stopped reaching least 10 % relation total amount cells host cell fraction strain heterogeneous fluorescent cytoplasm staining. obtained lawn host strain culture inoculated mother bacteriophage titre 10-10bfu/ml. cultivated 13-15 hours foreign microflora, air layer thickness surface dense nutrient medium 5 50 mm optimum temperature bacteriophage strain culture growth. obtained phage lysate suspending, sucked phage lysate sterile container cleaned. invention provides reaching stable high titre bacteriophage (10-10bfu/ml) producing phage lysates varying formulations nutrient media increasing span variation values culturing host strain bacteriophage.effect: invention used biotechnology obtaining products containing bacteriophages.9 cl',\n",
              " 'recombinant plasmid dna pest877 determining expression polypeptide activity esterase psychrobacter cryohalolentis k5on cell surface escherichia coli, bacteria strain escherichia coli bl21 (de3) plyss/pest877-producer polypeptide activity esterase psychrobacter cryohalolentis k5on cell surfacefield: biotechnology.substance: invention relates recombinant plasmid dna pest877 determining expression polypeptide activity esterase p. cryohalolentis k5t cell surface molar weight 3.64 md (5.519 kb) consisting ncoi/xhoi - dna fragment plasmid pet20b(+) length 3.654 kb, comprising promoter t7lac, bacteriophage t7 transcription terminator, gene bla ?-lactamase determines stability cells transformed plasmid pest877 ampicillin, site ori replication initiation, signal sequence pelb pectate lyase b erwinia carotovora; ncoi/xhoi-fragment dna size 1.865 kb containing fusion gene est877 encoding amino acid sequences esterase p. cryohalolentis k5t additional amino acid residue aspartic acid site cleavage signal peptide auto-transporter p. cryohalolentis k5t single reading frame. invention relates bacterial strain e. coli bl21(de3)plyss/pest877 - producer polypeptide activity esterase p. cryohalolentis k5t cell surface.effect: invention enables obtain highly active esterase wide substrate specificity.2 cl, 3 dwg, 7 ex',\n",
              " 'new methods displaying cyclic peptides bacteriophage particlesfield: biotechnology.substance: invention relates biotechnology. described method displaying cyclic peptide surface bacteriophage particle, comprising following steps: (a) providing host cell comprising nucleic acid sequence encoding precursor cyclic peptide; nucleic acid sequence encoding bacteriophage particle capsid protein; leader sequence recognized post-translational modification (ptm) system enzyme; one nucleic acid sequences encoding post-translational modification system enzyme lantypeptide synthase; (b) initiating enabling expression said cyclic peptide precursor; (c) enzymatic dehydration one amino acid residues precursor cyclic peptide; (d) forming one intramolecular bonds binding said one dehydrated residues cysteine lysine, thereby forming cyclic peptide; (e) obtaining bacteriophage particles said host cell, wherein said bacteriophage particles \"map\" said cyclic peptide surface, wherein said cyclic peptide attached c-end capsid protein said bacteriophage particles. invention relates nucleic acid molecule \"maps\" cyclic peptide surface bacteriophage particle, said nucleic acid encodes (a) capsid protein said bacteriophage particle; (b) leader sequence recognized post-translational modification (ptm) system enzyme, (c) cyclic peptide precursor, wherein nucleic acid coding cyclic peptide precursor located c-end capsid protein said bacteriophage particle, wherein said cyclic peptide precursor able form intramolecular linkage binding one dehydrated residues cysteine lysine. described bacteriophage particle \"maps\" surface cyclic peptide obtained said method, said cyclic peptide attached c-end capsid protein said bacteriophage particle. besides, genetically diverse library bacteriophage particles according para. 11, said bacteriophage particles \"maps\" cyclic peptide genetically diverse cyclic peptide library, wherein said cyclic peptides contain intramolecular linkage formed binding one dehydrated residues cysteine lysine.effect: invention extends range phage displays.13 cl, 5 dwg, 4 ex',\n",
              " \"test system genome detection rotavirus agent type agricultural animals means multiplex polymerase chain reaction fluorescent detection real timefield: biotechnology.substance: invention relates field biotechnology. described test system detecting genome rotavirus type agent agricultural animals using multiplex polymerase chain reaction fluorescent detection real time. test system comprises buffer conducting polymerase chain reaction, mixture carrying thereof, consisting deoxynucleoside triphosphates, primers fluorescent probes specific rotavirus a, mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase reverse transcriptase mmlv reverse transcriptase. mixture recombinant plasmid dna containing rva virus genome fragment bacteriophage ms2 genome fragment contains following nucleotide sequences: rvf5 5'-atttcagttgatgagacca-3'; forward primer; rvr6 5'-caattctaagcgtgagtcc-3' reverse primer; probe rvp fam – 5'-aatatgacaccagcggta-3' – bhq1,ms2f, 5'-tggcactacccctctccgtattcac-3' – forward primer; ms2r, 5'-gtacgggcgaccccacgatgac-3' – reverse primer; ms2p probe, cy5 5'-cacatcgatagatcaaggtgcctacaagc-3' bhq2.effect: invention extends range agents detecting genome rotavirus type agent agricultural animals.1 cl, 4 tbl, 1 ex\",\n",
              " 'bacteriophage bacillus anthracis f112pre strain used specific indication anthrax agentfield: biotechnology.substance: invention relates field biotechnology. invention bacillus anthracis f112pre bacteriophage strain, intended specific indication anthrax agent, deposited specialized museum collection strains branch state budgetary institution 48 central scientific research institute ministry defence russian federation.effect: invention enables create anthrax bacteriophage strain high species specificity anthrax microbe lyse closely related bacilli retains basic properties long period time.1 cl, 1 tbl, 4 ex',\n",
              " 'method detecting genotyping rna porcine reproductive-respiratory syndrome virusfield: biotechnology.substance: invention relates field biotechnology. invention method detecting genotyping rna porcine reproductive respiratory syndrome virus, involving rna extraction biological material infected pigs sorption method, synthesis cdna rna matrix staging single-step multiplex reverse transcription reaction polymerase chain reaction addition internal control sample based bacteriophage ms2 positive control sample, consisting internal control sample based bacteriophage ms2, european american genotypes porcine reproductive-respiratory syndrome virus, conducting 40 amplification cycles real-time detection using oligonucleotide primer reproductive-respiratory syndrome virus virus-specific viruses, fluorescent-labeled probes control samples, measuring accumulation fluorescent signal channels corresponding fluorescent dyes interpreting results based presence absence intersection fluorescence curve threshold line, according invention internal control sample suspension bacteriophage ms2 concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample, mixture containing nucleic acid fragments european american genotypes porcine reproductive respiratory syndrome virus native bacteriophage ms2 genome fragment taken ratio 1:1:1, wherein accumulation fluorescent signal measured channels: fam/green specific signal european genotype porcine reproductive respiratory syndrome virus; joe/yellow specific signal american genotype virus cy5/red internal control signal fluorescent signal accumulation curves 35 cycles, result reaction considered positive, curves cross threshold line cross 35 cycles, reaction result negative.effect: invention provides reliable diagnosis porcine reproductive respiratory syndrome detecting various serotypes virus.1 cl, 3 dwg, 4 tbl',\n",
              " 'method detection dna bordetlelosis (bordetella bronchiseptica) agent genome farm animalsfield: biotechnology.substance: invention relates field biotechnology. invention method detecting dna genome bordetella bronchiseptica exciter agricultural animals, involving dna recovery biological material sorption method, staged one-stage polymerase chain reaction – simultaneous carrying 40 amplification cycles real-time detection using oligonucleotide primers specific bordetella bronchiseptica genome, probes, dyes control samples form internal positive, measurement specific signal control signal channels corresponding dyes interpretation results, according invention, fluorescent detection carried out, measuring joe(hex)/yellow accumulation fluorescent signal specific dna signal bordetella bronchiseptica genome, fam/green channel signal internal control, interpretation results carried based presence/absence intersection fluorescence curve threshold line, curves accumulation fluorescent signal 35 cycles, result reaction considered positive, curves cross threshold line cross 35 cycles, result reaction negative , wherein internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample mixture recombinant plasmid dna containing fragment dna genome bordetella bronchiseptica fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables reliable diagnosis dna bordetella bronchiseptica.1 cl, 2 dwg, 4 tbl',\n",
              " 'method detecting dna leptospirosis (leptospira spp) causative agent farm animalsfield: biotechnology.substance: invention relates field biotechnology. invention method detecting dna leptospirosis agent (leptospira spp.) farm animals, involving recovering nucleic acid biological material infected animals sorption method, staged one-stage polymerase chain reaction simultaneous carrying 40 amplification cycles fluorescent detection using specific dna genome leptospirosis (leptospira spp.) causative agent oligonucleotide primers, probes, dyes control samples form internal positive, measurement joe(hex)/yellow channel, accumulation fluorescent signal specific signal testing presence dna genome leptospirarosis (leptospira spp.) causative agent, fam/green channel accumulation signal internal control sample, interpretation results based presence/absence intersection fluorescence curve threshold line, fluorescent signal accumulation curves 35 cycles, leptospirosis (leptospira spp.) dna present reaction result considered positive, curves cross threshold line cross 35 cycles, dna leptospirosis (leptospira spp.) causative agent absent result reaction negative, internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample mixture recombinant plasmid dna containing fragment genome leptospirosis (leptospira spp.lpts) fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables simplify detection leptospirosis causative agent.1 cl, 2 dwg, 4 tbl',\n",
              " 'method detecting dna avnithosis agent (chlamydophila psittaci) birdsfield: biotechnology.substance: invention relates field biotechnology. invention method detecting dna ornithosis agent (chlamydophila psittaci) birds, involving recovering dna biological material sorption method, polymerase chain reaction – addition internal positive control successively carrying 40 amplification cycles fluorescent detection real time using oligonucleotide primers, fluorescent-labeled probe, positive negative control samples dna-specific dna orbital pathogen (chlamydophila psittaci) specific dna segment , measuring accumulation fluorescent signal channels corresponding fluorescent dyes specific signal internal control signal interpreting results based presence/absence crossing fluorescence curve threshold line, according invention, biological material collected infected birds, wherein internal reference sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample – mixture recombinant plasmid dna, containing fragment genome dna exciter ornithosis (chlamydophila psittaci) fragment bacteriophage t4 genome, taken ratio 1:1, wherein accumulation fluorescent signal measured channels: joe(hex)/yellow specific dna signal ornithosis agent (chlamydophila psittaci) fam/green internal control signal, accumulation curves fluorescent signal 35 cycles, dna ornithosis agent (chlamydophila psittaci) present result reaction considered positive, curves cross threshold line cross 35 cycles, dna ornithosis agent (chlamydophilapsittaci) absent result reaction – negative.effect: invention enables authentically diagnosing ornithosis dna exciter (chlamydophila psittaci) birds.1 cl, 3 dwg, 4 tbl',\n",
              " \"method detection dna nodular dermatitis virus (lsdv) animal biological material means polymerase chain reaction real timefield: biotechnology.substance: invention relates field biotechnology. invention method detecting dna nodular dermatitis virus (lsdv) biological material animals using real-time polymerase chain reaction involving dna recovery infectious animal pathogen sorption method, staged one-stage polymerase chain reaction fluorescent detection 40 amplification cycles real time using oligonucleotide primers, probes, fluorescent dyes specific dna genome region causative agent infectious animal disease: specific animal signal fam/green internal control sample form bacteriophage t4 suspension concentration 5×10phage particles per 1 mcl, positive control sample form mixture containing volume ratio fragments animal genomes bacteriophage t4 nucleotide sequence: t4f: 5'-tacatataaatcacgcaaagc-3' – direct primer; t4r: 5'- tagtatggctaatcttattgg-3' – reverse primer; t4p: cy5-5'-acattggcactgaccgagttc-3'-bhq1 – probe, measurement accumulation fluorescent signals via channels corresponding fluorescent dyes, interpretation results based presence absence intersection fluorescence curve threshold line, fluorescence signal accumulation curves 35 cycles, reaction result considered positive, curves cross threshold line cross 35 cycles, result reaction negative, according invention, nodular dermatitis virus (lsdv) dna recovered animal's biological material, bacteriophage t4 phage lysate used internal control sample, positive control sample – fragments genomes native bacteriophage t4 fragment genome nodular dermatitis virus (lsdv) following nucleotide sequence: lsdv-f 5-tttaggagataagattgtcac-3' direct primer; lsdv-r 5'-ggagattttattatgagtggc-3' reverse primer; lsdv-p rox-5'-ggttaattttttaccacaaatagg-3'-bhq2 probe, wherein dna nodular dermatitis virus (lsdv) uses rox / orange fluorescent dye.effect: invention widens functional capabilities, increases sensitivity simplifies process preparing internal control sample.1 cl, 4 tbl\",\n",
              " 'method detecting dna rhinotracheitis virus (bovine herpes virus 1, bohv-1) cattlefield: biotechnology.substance: invention relates field biotechnology. invention method detecting dna rhinotracheitis virus (bovine herpes virus 1, bohv-1) cattle, involving dna recovery sorption method, staged one-stage polymerase chain reaction simultaneous amplification cycles real-time detection using oligonucleotide primers, probes, dyes control samples specific genome segment rhinotracheitis virus (bovine herpes virus i, bohv-1) form internal positive, measurement specific signal control signal via channels corresponding dyes interpretation results, according invention, fluorescent detection carried out, measuring joe(hex)/yellow accumulation fluorescent signal specific dna signal rhinotracheitis virus (bovine herpes virus 1, bohv-1), fam/green channel signal internal control sample interpretation results carried based presence/absence intersection fluorescence curve threshold line, accumulation curves fluorescent signal reach 35th cycle, result reaction considered positive, curves cross threshold line cross 35 cycles, reaction result negative, wherein internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample used mixture recombinant plasmid dna containing fragment genome dna rhinotracheitis virus (bovine herpes virus 1, bohv-1) fragment genome bacteriophage t4, taken ratio 1:1.effect: invention enables authentically diagnosing causative agent cattle rhinotracheitis virus dna.1 cl, 3 dwg, 4 tbl',\n",
              " 'method detecting rna arteritis virus agent horsesfield: biotechnology.substance: invention relates field biotechnology. invention method detecting rna agent arteritis virus horses, involving rna extraction biological material infected individuals sorption method, synthesis cdna rna matrix single-step staging addition internal positive controls samples multiplex reverse transcription reaction polymerase chain reaction 45 cycles amplification real-time detection using oligonucleotide primer-specific oligonucleotide primers, fluorescent-labeled probe control samples, measuring accumulation fluorescent signal channels corresponding fluorescent dyes interpreting results based presence absence intersection fluorescence curve threshold line – threshold, according invention, biological material animals used rna extraction choice: form discharge nose, eyes, faeces, blood, sperm fragments internal organs tissues taken horses infected arteritis virus (equine arteritis virus) agent, wherein internal control sample suspension bacteriophage ms2 concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample, mixture recombinant plasmid dna containing fragment genome horse arteritis virus (equine arteritis virus) fragment bacteriophage ms2 genome, taken ratio 1:1, fam/green specific signal; cy5/red internal control signal, accumulation curves fluorescent signal reach 35th cycle, result reaction considered positive, curves cross threshold line cross 35 cycles, reaction result negative.effect: invention allows expand functional capabilities conduct reliable diagnostics disease.1 cl, 3 dwg, 4 tbl',\n",
              " 'method detecting salmonella (salmonella spp) dna biological material animals, food animal vegetable foddersfield: biotechnology.substance: invention relates field biotechnology. invention method detecting salmonella dna (salmonella spp.) biological material, food fodders animal vegetable origin, involving dna recovery sorption method, staged one-stage polymerase chain reaction – simultaneous amplification cycles real-time detection using salmonella-specific (salmonella spp.) oligonucleotide primers, probes, dyes control samples form internal positive, measurement specific signal control signal channels corresponding dyes interpretation results, according invention, fluorescent detection carried out, measuring joe(hex)/yellow channel accumulating fluorescent signal specific salmonella (salmonella spp.) dna signal, fam/green channel internal control sample signal, accumulation curves fluorescent signal reach 35th cycle, result reaction considered positive, curves cross threshold line cross 35 cycles, result reaction negative, interpretation results carried based presence/absence intersection fluorescence curve threshold line, wherein internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample mixture recombinant plasmid dna containing fragment genome salmonella (salmonella spp.) dna fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables reliable diagnosis salmonella (salmonella spp) dna exciter biological material, food products fodders animal plant origin.1 cl, 3 dwg, 4 tbl',\n",
              " 'method detecting provirus dna bovine leukosis virus (blv)field: biotechnology.substance: invention relates field biotechnology. invention method detecting provirus dna bovine leukosis virus (blv), involving dna recovery biological material infected animals sorption method, staged one-stage polymerase chain reaction simultaneous amplification cycles detection oligonucleotide primers, probes, dyes control samples form internal positive, specific provirus genome bovine leukosis virus (blv), measurement specific signal control signal via channels corresponding dyes interpretation results, according invention, fluorescent detection carried out, joe(hex)/yellow accumulation fluorescent signal measured specific signal testing presence provirus genome bovine leukosis virus (blv), fam/green channel signal internal control sample interpreting results based presence/absence intersection fluorescence curve threshold line, accumulation curves fluorescent signal reach 35th cycle, result reaction considered positive, curves cross threshold line cross 35 cycles, reaction result negative, wherein internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample mixture recombinant plasmid dna containing fragment provirus genome bovine leukosis virus (blv) fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables authentically diagnosing detection provirus genome bovine leukosis virus (blv) early detection leukemia.1 cl, 2 dwg, 4 tbl',\n",
              " 'method determining dna nodular dermatitis virus (lsdv) biological material animals pcr electrophoretic detection amplification products agarose gelfield: biotechnology.substance: invention relates field biotechnology. invention method determining dna nodular dermatitis virus (lsdv) biological material animals pcr electrophoretic detection amplification products agarose gel, involving dna isolation infectious disease agent biological material infected animal sorption method, polymerase chain reaction fluorescent detection 40 cycles amplification using oligonucleotide primer dna-specific dna infectious agent causative agent dna, fluorescent dye, internal control sample form suspension bacteriophage t4 concentration 5 × 10phage particles per 1 mcl positive control sample form mixture containing volume ratio fragments genomes causative agent infectious animal disease bacteriophage t4, according invention, dna nodular dermatitis virus (lsdv) recovered biological material animals, performing electrophoretic detection amplification products agarose gel obtaining electrophoregram dna specific bands amplified product, visualizing colouring fluorescent dye, according recording interpretation pcr results carried presence absence specific strand dna fragment nodular dermatitis virus, coinciding size band fragment dna, amplified positive control sample, wherein mixture recombinant plasmid dna containing dna fragment nodular dermatitis virus fragment bacteriophage t4 genome following nucleotide sequences used.effect: invention widens functional capabilities detecting residual amount dna nodular dermatitis virus.1 cl, 6 tbl',\n",
              " 'method determining species identity tissues chickens pigs food raw materials, fodder food productsfield: biotechnology.substance: invention relates field biotechnology. invention method determining species identity tissues chickens pigs food raw materials, fodder food products, involving extraction dna chicken tissues (gallus gallus) pig (sus scrofa) sorption method, stating polymerase chain reaction detection amplification products using specific dna genome regions chicken (gallus gallus) pig (sus scrofa) oligonucleotide primers, probes, dyes, internal control sample positive control samples, measurement specific signals control signals interpretation results, according invention, single-stage polymerase chain reaction carried fluorescent detection using thermal cycler rotor-gene q type measure accumulation fluorescent signals channels corresponding fluorescent dyes: joe/yellow specific signal pig tissues (sus scrofa); fam/green – chicken tissues (gallus gallus) cy5/red – internal control sample, interpretation results carried based presence absence intersection fluorescence curve threshold line, curves accumulation fluorescent signal 35 cycles, result reaction considered positive, curves cross threshold line cross 35 cycles, result reaction negative, wherein internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample – mixture containing fragments genomes chicken tissues (gallus gallus), pig tissues (sus scrofa) bacteriophage t4, taken ratio 1:1:1.effect: invention makes possible increase accuracy identification species affiliation chicken pigs tissues.1 cl, 5 dwg, 5 tbl',\n",
              " \"method detecting rna schmallenberg disease virus farm animalsfield: biotechnology.substance: invention relates field biotechnology. invention method extracting rna biological material choice: whole blood, blood serum, tissue organ fragments sorption method, synthesis cdna rna matrix single-step staging addition internal positive control samples multiplex reverse transcription reaction polymerase chain reaction – 45 amplification cycles real-time detection using oligonucleotide primers schmallenberg virus specific region genome fluorescent-labeled probe control samples, measuring accumulation fluorescent signal channels corresponding fluorescent dyes interpreting results based presence/absence intersection fluorescence curve threshold line threshold, according invention internal control sample suspension bacteriophage ms2 concentration 5 × 10copies nucleotide sequences per 1 mcl, positive control sample, mixture recombinant plasmid dna containing fragment genome schmallenberg virus exciter fragment bacteriophage ms2 genome taken ratio 1:1, following nucleotide sequences: shm-f 5 'tcagattgtcatgccccttgc 3' – forward primer; shm-r 5' tcggccccaggtgcaaatc 3' – reverse primer; shm-z joe-accatcggcccaggtgcatccctta-bhq1 – probe; ms2f, 5'-tggcactacccctctccgtattcac-3 – forward primer; ms2r, 5'-gtacgggcgaccccacgatgac-3' – reverse primer; ms2p, 5'-cy5-cacatcgatagatcaaggtgcctacaagc-3' bhq2 – probe, wherein accumulation fluorescent signal measured channels: joe/yellow specific signal schmallenberg virus agent; cy5/red internal control signal, fluorescence signal accumulation curves 35 cycles, result reaction considered positive, curves cross threshold line cross 35 cycles, result reaction negative.effect: invention enables higher diagnostic accuracy method detecting rna schmallenberg disease virus farm animals.1 cl, 4 tbl, 3 dwg\",\n",
              " 'method identification dna domestic dog tissue (canis lupus familiaris) dry fodder meat semi-productsfield: biotechnology.substance: invention relates field biotechnology. invention method identification dna domestic dog tissue (canis lupus familiaris) dry fodder meat semi-products, involving dna recovery animal tissue sorption method, polymerase chain reaction fluorescent detection carried 45 cycles real-time amplification using oligonucleotide primers, probes, fluorescent dyes specific dna genome region: specific signal animal cy5/red internal control sample form suspension bacteriophage t4 concentration 5 × 10of phage particles per 1 mcl, positive control sample form mixture containing fragments animal genomes bacteriophage t4 nucleotide sequence: t4f tacatataaatcacgcaaagct4r tagtatggctaatcttattgg t4p cy5 acattggcactgaccgagttc, taken ratio 1:1, measurement accumulation fluorescent signals via channels corresponding fluorescent dyes, interpretation results based presence absence intersection fluorescence curve threshold line, fluorescent signal accumulation curves extend 35 cycles, result reaction considered positive, curves cross threshold line cross 35 cycles, result reaction negative, according invention, dna recovered domestic dog tissue (canis lupus familiaris) internal control sample t4 bacterial phagolysate, positive control sample - native t4 bacteriophage genome fragments domestic dog tissue (canis lupus familiaris) following nucleotide sequence: canis f attcggcctacatccgtgac forward primer canis agaagacccctgctacgact reverse primer canis p fam-cttgagtggagtagggcgg-bhq1 probe, wherein dna dog tissue fluorescent dye fam/green used.effect: invention makes possible increase accuracy species identity identification simplify sampling process.1 cl, 5 tbl',\n",
              " 'method identification domestic cat tissue dna (felis silvestris catus) dry fodders semi-finished meat productsfield: biotechnology.substance: invention relates field biotechnology. invention method identification domestic cat tissue dna (félis silvéstris cátus) dry fodder semi-finished meat products, involving extraction dna animal tissue sorption method, polymerase chain reaction fluorescent detection carried 45 cycles real-time amplification using oligonucleotide primers, probes, fluorescent dyes specific dna genome region: specific signal animal - joe/yellow cy5/red - internal control sample form suspension bacteriophage t4 concentration 5 × 10phage particles per 1 mcl, positive control sample form mixture containing fragments animal genomes bacteriophage t4 nucleotide sequence: t4f tacatataaatcacgcaaagc t4r tagtatggctaatcttattgg t4p cy5 acattggcactgaccgagttc, taken ratio 1:1 measuring accumulation fluorescent signals channels corresponding fluorescent dyes, performing interpretation results based presence absence intersection fluorescence curve threshold line, fluorescence signal accumulation curves 35 cycles, reaction result considered positive, curves cross threshold line cross 35 cycles, result reaction negative, according invention, dna recovered domestic cat tissue (félis silvéstris cátus) internal control sample phagolysate bacteriophage t4, positive control sample - fragments genomes native bacteriophage t4 domestic cat tissue (félis silvéstris cátus) following nucleotide sequence: félis f attcggcctacatccgtgac forward primer félis agaagacccctgctacgact reverse primer félis p r6g-cttgagtggagtagggcgg-bhq1 probe.effect: invention makes possible increase accuracy cat tissue species identification, simplify sample preparation process.1 cl, 5 tbl',\n",
              " 'method storing anthrax bacteriophages contact-sorption drying (dehydration) ion-exchange resin kb-4p-2 gradefield: biotechnology.substance: invention relates field biotechnology. invention method involves preparing protective medium (sucrose-gelatine containing 10 % sucrose 2 % gelatine); growing indicator strain bacillus anthracis sti-1 propagation anthrax bacteriophage; obtaining concentrated suspension anthrax bacteriophage double-layer agar method, extracting negative colonies upper, semi-liquid protective agar, sucrose-gelatinous medium; preparing ion-exchange resin penicillin bottles; sparing drying (dehydration) applying concentrated suspension anthrax bacteriophage protective medium temperature 0 °c sorbent - ion-exchange resin kb-4p-2 grade, dried weight fraction moisture 1÷3 % optimum ratio suspension bacteriophage resin -1:7; storage dried cultures anthrax bacteriophage penicillin bottles temperature 2÷6 °c.effect: declared method allows long-term storage cultures anthrax bacteriophages use resuspension resuspension temperature 0°c meat-peptone broth (mpb) obtaining diagnostic preparations used indication identification anthrax agent areas microbiology.1 cl, 2 tbl, 2 ex',\n",
              " 'recombinant plasmid dna pet21-npve containing nucleoloprotein (np) gene ebola virus recombinant protein np-ve, obtained result expression np gene ebola virus using recombinant plasmid dna pet21-npve possessing immunogenic antigenic propertiesfield: biotechnology.substance: invention relates field biotechnology. invention recombinant plasmid dna pet21-npve expression nucleoprotein gene np ebola virus (zaire strain, mayinga isolate) prokaryotic system ofe.coliand producing recombinant protein np-ve, size 7593 base pairs contains:blagene (coordinates 599 1459 base pairs) genetic marker; replication starting point ori (coordinates 1630 2218 base pairs); phage t7 promoter (coordinates 5117 5135 base pairs; lactose repressor (coordinates 3648 base pairs 4730 base pairs); dna-binding protein inhibits expression ofe.coligenes provides expression target recombinant np-ve protein addition isopropyl-β-d-1-thiogalactopyranoside (iptg); unique recognition sites restriction endonucleases, following coordinates: nhei(5209 base pair) xho i(7432 base pairs); full-length np gene ebola virus (mayinga isolate, zaire strain) 2217 base pairs (from 470 2686 nucleotide genomic rna), built expression cassette bynheirestriction sites (5209 base pair) xhoi(7432 base pairs), encodes 739 amino acid residues (ao) viral nucleoprotein; sequence (18 base pairs), encoding polyhistidine (6xhis) polithract six histidines n-end encoded protein subsequent purification affinity n-chromatography recombinant np-ve protein produced result ebola virus nucleoprotein np gene expression (zaire strain, mayinga isolate) bacterial expression systeme.coliin recombinant dna construct pet21-npve calculated molecular weight 84457.42 da, amino acid sequence seq id no: 1 length 748 amino-acid residues, including 6xhis, stop codon, immunogenic antigenic properties, intended induction body balb/c mice antibodies recognizing immunochemical reactions viral protein np-ve, well interacting mouse monoclonal antibodies, polyclonal goat human antibodies specific inactivated infectious virus, respectively.effect: invention increases output target recombinant protein np-ve.2 cl, 3 tbl, 14 dwg',\n",
              " 'test system detecting rna agent arteritis virus horsesfield: biotechnology.substance: invention relates field biotechnology. invention test system detecting rna arteritis virus agent horses, comprising buffer carrying polymerase chain reaction fluorescent detection real time, mixture carrying out, consisting deoxynucleoside triphosphates, primers fluorescent probes specific infection virus agent internal control sample; mixture enzymes dna polymerase antibodies inhibiting activity taq polymerase enzyme; rna dilution buffer, internal control sample, negative control sample, positive control sample, according invention, biological material extracted arteritis virus (equine viral arteritis – eav) infected horses used rna isolation, wherein internal control sample suspension bacteriophage ms2 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample – mixture recombinant plasmid dna containing fragment genome arteritis virus (equine viral arteritis – eav) horses fragment genome bacteriophage ms2, taken ratio 1:1.effect: invention enables authentically diagnosing rna arteritis virus agent horses.1 cl, 3 dwg, 4 tbl',\n",
              " 'test system detecting genotyping rna swine reproductive-respiratory syndrome virusfield: biotechnology.substance: invention relates field biotechnology. invention test system detecting genotyping rna virus porcine reproductive respiratory syndrome, comprising buffer polymerase chain reaction, mixture carrying out, consisting deoxynucleoside triphosphates, primers fluorescent probes, specific swine reproductive respiratory syndrome virus, taq polymerase; rna dilution buffer, internal control sample based bacteriophage ms2 positive control sample consisting internal control sample based bacteriophage ms2, european american genotypes porcine reproductive-respiratory syndrome virus control samples, according invention internal control sample suspension bacteriophage ms2 concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample, mixture containing nucleic acid fragments european american genotypes swine reproductive respiratory syndrome virus fragment native bacteriophage ms2 genome taken ratio 1:1:1 used.effect: invention provides reliable diagnosis porcine reproductive respiratory syndrome detecting various serotypes virus.1 cl, 3 dwg, 4 tbl',\n",
              " 'test system detecting dna bird flu ornithosis (chlamydophila psittaci) birdsfield: biotechnology.substance: invention relates field biotechnology. invention test system detecting dna ornithosis agent (chlamydophila psittaci) birds, comprising plastic bottles test tubes, thermostable tag-polymerase enzyme, reaction-setting buffer, mixture four deoxynucleotide triphosphates, internal control sample, positive control sample, recombinant plasmid containing gene fragment ornithosis agent (chlamydophila psittaci), synthetic oligonucleotide primers dyes labeled dyes, according invention, internal control sample, bacteriophage t4 suspension concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample – mixture recombinant plasmid dna containing fragment genome ornithosis dna (chlamydophila psittaci) fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables authentically diagnosing ornithosis dna exciter (chlamydophila psittaci) birds.1 cl, 3 dwg, 4 tbl',\n",
              " 'test system detecting dna rhinotracheitis virus (bovine herpes virus 1, bohv-1) cattlefield: biotechnology.substance: invention relates field biotechnology. invention test system detecting dna rhinotracheitis virus (bovine herpes virus 1, bohv-1) cattle, includes plastic flasks test tubes, thermostable enzyme tag-polymerase, reaction buffer, mixture four deoxynucleotide triphosphates, internal control sample, positive control sample, recombinant plasmid containing gene fragment rhinotracheitis virus, synthetic oligonucleotide primers probes marked dyes, according invention internal control sample bacteriophage t4 suspension concentration 5×10copies nucleotide sequences 1 mcl, positive control sample mixture recombinant plasmid dna containing fragment dna genome rhinotracheitis virus (bovine herpes virus 1, bohv-1) fragment genome bacteriophage t4, taken ratio 1:1.effect: invention enables authentically diagnosing causative agent cattle rhinotracheitis virus dna.1 cl, 3 dwg, 4 tbl',\n",
              " 'test system detecting provirus dna bovine leukosis virus (blv)field: biotechnology.substance: invention relates field biotechnology. invention test system detecting provirus dna bovine leukosis virus (blv), comprising plastic bottles test tubes, thermostable tag-polymerase enzyme, reaction setting buffer, mixture four deoxynucleotide triphosphates, internal control sample, positive control sample – recombinant plasmid containing fragment genome dna bovine leucosis provirus, synthetic oligonucleotide primers dyes marked dyes, according invention internal control sample bacteriophage t4 suspension concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample – mixture recombinant plasmid dna containing fragment genome dna bovine leucosis provirus fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables authentically diagnosing bovine leukosis provirus (blv) gene early detection leukemia.1 cl, 2 dwg, 4 tbl',\n",
              " 'test system detecting salmonella (salmonella spp.) dna animal biological material, food products animal vegetable foddersfield: biotechnology.substance: invention relates field biotechnology. invention test system detecting salmonella (salmonella spp.) dna biological material, food animal vegetable fodders, including plastic flasks test tubes, thermostable tag-polymerase enzyme, reaction buffer, mixture four deoxynucleotide triphosphates, internal control sample, positive control – recombinant plasmid containing gene fragment salmonella excipient (salmonella spp.), synthetic oligonucleotide primers probes, according invention internal control sample bacteriophage t4 suspension concentration 5×10copies nucleotide sequences 1 mcl, positive control sample – mixture recombinant plasmid dna containing fragment dna genome salmonella (salmonella spp.) fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables reliable diagnosis salmonella excipient (salmonella spp) dna biological material, food products animal vegetable fodders.1 cl, 3 dwg, 4 tbl',\n",
              " 'test system detecting brucella infection agent (brucella spp) genome farm animalsfield: biotechnology.substance: invention relates field biotechnology. invention test system detecting genome brucella infection agent (brucella spp.) farm animals real-time polymerase chain reaction comprising plastic bottles test tubes, thermostable tag-polymerase enzyme, reaction buffer, mixture four deoxynucleotide triphosphates, internal control sample, positive control – recombinant plasmid containing fragment brucella spp gene, synthetic oligonucleotide primers probes marked dyes, according invention internal control sample bacteriophage t4 suspension concentration 5×10copies nucleotide sequences 1 mcl, positive control sample – mixture recombinant plasmid dna containing dna fragment dna genome brucella spp dna fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables reliable diagnosis brucella spp dna exciter.1 cl, 4 tbl',\n",
              " 'test system determining species affiliation tissues chickens pigs food raw materials, fodder food productsfield: biotechnology.substance: invention relates field biotechnology. invention test system determining species identity tissues chickens pigs food raw materials, fodder food products test system determining species identity tissues chickens pigs food raw materials, fodder food products, including plastic bottles test tubes, thermostable enzyme tag-polymerase, reaction buffer, mixture four deoxynucleotide triphosphates, specific dna segments several oligonucleotide primers, probes, internal control sample form bacteriophage suspension positive control samples – containing fragments dna genomes several types meat, according invention, meat genome represented chicken tissues (gallus gallus) pig (sus scrofa), wherein internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample – mixture containing fragments genomes chicken tissues ({gallus gallus) pig (sus scrofa) bacteriophage t4, taken ratio 1:1:1.effect: invention allows expand functional capabilities increase accuracy identification species identity pigs hens tissues.1 cl, 5 dwg, 5 tbl',\n",
              " 'test system detecting genome causative agent bordetella bronchiseptica dna farm livestockfield: biotechnology.substance: invention relates field biotechnology. invention test system dna detection genome brucella spp infection agent farm livestock means polymerase chain reaction real time, including plastic bottles test tubes, thermostable enzyme tag-polymerase, reaction buffer, mixture four deoxynucleotide triphosphates, internal control sample, positive control – recombinant plasmid containing fragment brucella spp gene, synthetic oligonucleotide primers probes marked dyes, according invention internal control sample bacteriophage t4 suspension concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample – mixture recombinant plasmid dna containing fragment dna genome brucella spp fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables reliable diagnosing bordetella bronchiseptica dna exciter.1 cl, 2 dwg, 4 tbl',\n",
              " \"test system identification bear tissue (ursus) dry fodder semi-finished meat productsfield: biotechnology.substance: invention relates field biotechnology. invention test system identification dna bear tissue (ursus) dry fodder meat semi-products, comprising buffer carrying polymerase chain reaction, mixture carrying thereof, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes specific animal genome region internal control sample; mixture enzymes dna polymerase enzyme inhibiting antibodies, taq polymerase, internal control sample form bacteriophage t4 suspension concentration 5×10phagic particles per 1 mcl, negative control sample mixture recombinant plasmid dna containing fragment animal's genome fragment bacteriophage t4 genome.effect: invention used expand functional capabilities increase accuracy identification species identity, simplify sample preparation process.1 cl, 5 tbl\",\n",
              " \"test system identification dna domestic cat tissue (felis silvestris catus) dry fodder semi-finished meat productsfield: biotechnology.substance: invention relates field biotechnology. invention test system identification domestic cat tissue dna (félis silvéstris cátus) dry fodders semi-finished meat products, including polymerase chain reaction buffer, mixture carrying out, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes, specific section animal's genome internal control sample; mixture enzymes dna polymerase enzyme inhibiting enzymes, taq polymerase, internal control sample form suspension bacteriophage t4 concentration 5 × 10phage particles per 1 mcl, negative control sample, mixture recombinant plasmid dna, containing fragment animal's genome fragment bacteriophage t4 genome nucleotide sequence: t4f: 5'-tacatataaatcacgcaaagc-3' - forward primer; t4r: 5'-tagtatggctaatcttattgg-3' - reverse primer; t4p: cy-5'-acattggcactgaccgagttc-3'-bhq1 - probe, taken volume ratio 1:1, according invention internal control sample phagolysate bacteriophage t4, positive control sample fragments genomes native bacteriophage t4 domestic cat (félis silvéstris cátus) used following nucleotide sequence: félis f attcggcctacatccgtgac - forward primer; félis agaagacccctgctacgact - reverse primer; félis p r6g-cttgagtggagtagggcgg-bhq1 - probe.effect: invention allows expand functional capabilities increase accuracy species identity identification, simplify sample preparation process.1 cl, 5 tbl\",\n",
              " 'test system identification mutton beef species identity food raw material, fodder food productsfield: biotechnology.substance: invention relates field biotechnology. invention test system identification species mutton beef food raw materials, fodder food products, including plastic flasks test tubes, thermostable enzyme tag-polymerase, reaction buffer, mixture four deoxynucleotide triphosphate, mutton (ovis) dna segment beef (bos) regions specific oligonucleotide primers, probes, internal control sample form bacteriophage suspension positive control samples containing dna fragments mutton (ovis) beef (bos) genes, according invention internal control sample bacteriophage t4 suspension concentration 5×10 copies nucleotide sequences per 1 mcl, positive control sample – mixture containing fragments mutton genomes (ovis), beef (bos) bacteriophage t4, taken ratio 1:1:1.effect: invention makes possible increase accuracy beef mutton species identity identification.1 cl, 5 dwg, 5 tbl',\n",
              " \"test system determination woodpecker (picidae) dna dry fodder semi-finished meat productsfield: biotechnology.substance: invention relates field biotechnology. invention test system identifying dna woodpecker tissue (picidae) dry fodder meat semi-products, comprising buffer carrying polymerase chain reaction, mixture carrying thereof, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes specific animal genome region internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase, internal control sample form suspension bacteriophage t4 concentration 5×10phage particles per 1 mcl, negative control sample, mixture recombinant plasmid dna containing fragment animal's genome fragment bacteriophage t4 genome nucleotide sequence, taken volume ratio 1:1, according invention, phagolysate bacteriophage t4 used internal control sample, positive control sample fragments genomes native bacteriophage t4 woodpecker (picidae) following nucleotide sequence used.effect: invention widens functional capabilities accuracy identification species identity, simplifies preparation process.1 cl, 5 tbl, 1 dwg\",\n",
              " \"test system identification dna tissues rats mice dry fodder meat semi-productsfield: biotechnology.substance: invention relates field biotechnology. invention test system identifying tissue dna rats (rattus) mice (mus musculus) dry fodder meat semi-products, including buffer polymerase chain reaction, mixture carrying out, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes, specific section animal's genome internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase, internal control sample form bacteriophage t4 suspension concentration 5×10phagic particles per 1 mcl, negative control sample mixture recombinant plasmid dna, containing fragment animal's genome fragment bacteriophage t4 genome nucleotide sequence: t4f tacatataaatcacgcaaagc – forward primer, t4r tagtatggctaatcttattgg – reverse primer, t4p fam acattggcactgaccgagttc bhq1 – probe, according invention, phagolysate bacteriophage t4 used internal control sample, positive control sample fragments genomes native bacteriophage t4 rats (rattus) mice (mus musculus) taken volume ratio 1:1:1 following nucleotide sequence used: rat-f: 5'-gccttcctaccattcctgcat-3' – forward primer, rat-r: 5'-aggaggttggctactaggat-3' – reverse primer, rat-p: 5'-fam-acgcagcttaacattccgccca-3'-bhq1 – probe, mus-f: 5'-gttgctttgtctactgag-3' – forward primer, mus-r: 5'-acctgaaacattggagta-3' – reverse primer, mus-p: pam-5'-tcgcagtcatagccacagca-3-bhq1 – probe.effect: invention allows expand functional capabilities, increase accuracy identification species identity.1 cl, 5 tbl\",\n",
              " \"test system identification dna domestic dog tissue (canis lupus familiaris) dry fodder semi-finished meat productsfield: biotechnology.substance: invention relates field biotechnology. invention presents test system identification dna domestic dog tissue (canis lupus familiaris) dry fodders semi-finished meat products, including polymerase chain reaction buffer, mixture thereof, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes specific region animal genome internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase, internal control sample form suspension bacteriophage t4 concentration 5 × 10phage particles per 1 mcl, negative control sample representing mixture recombinant plasmid dna containing fragment animal's genome fragment bacteriophage t4 genome nucleotide sequence: t4f: 5' - tacatataaatcacgcaaagc-3' - forward primer; t4r: 5' - tagtatggctaatcttattgg-3' - reverse primer; t4p: su5-5' - acattggcactgaccgagttc-3'-bhq1 - probe, taken volume ratio 1:1, according invention internal control sample phagolysate bacteriophage t4, positive control sample fragments genomes native bacteriophage t4 domestic dog (canis lupus familiaris) following nucleotide sequence used: canis f attcggcctacatccgtgac forward primer; canis agaagacccctgctacgact reverse primer; canis p fam-cttgagtggagtagggcgg - bhq1 probe.effect: invention widens functional capabilities accuracy identification species identity, simplifies sampling process.1 cl, 5 tbl\",\n",
              " 'strain bacteriophage pseudomonas aeruginosa n 328 (500322), intended preparation mono- polyvalent treatment-and-prophylactic preparations bacteriophagesfield: biotechnology.substance: invention relates field biotechnology. invention relates strain bacteriophage pseudomonas aeruginosa used production medical biological antibacterial drugs – preparations bacteriophages intended prevention treatment pyoinflammatory enteral diseases caused bacteria pseudomonas aeruginosa. strain lytic activity pseudomonas aeruginosa pulp viruses. strain deposited state collection pathogenic microorganisms (gkpm) federal state budgetary institution \"scientific centre expert evaluation medicinal products” ministry health russian federation (fsbi \"sceemp\" russian ministry health) registration no. 328 (500322).effect: strain wide spectrum antibacterial activity relation epidemiologically significant hospital isolated patients various pathologies clinical strains pathogenic bacteria pseudomonas aeruginosa, 100 % resistant one antibiotics, obtained maximum extension geography isolation regions.1 cl, 4 ex, 1 dwg',\n",
              " 'test system detecting chlamydial dna livestock animals birdsfield: biotechnology.substance: invention relates field biotechnology. invention relates test system detecting genome chlamydia dna excitant livestock animals birds, comprising plastic bottles test tubes, thermally stable tag-polymerase enzyme, reaction setting buffer, mixture four deoxynucleotide triphosphates, internal control sample, positive control – recombinant plasmid containing gene fragment chlamydial agent, synthetic oligonucleotide primers dyes marked dyes, according invention internal control sample bacteriophage t4 suspension concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample – mixture recombinant plasmid dna containing dna fragment chlamydia fragment bacteriophage t4 genome, taken ratio 1:1.effect: invention enables reliable diagnosing chlamydial agent dna broader functional capabilities.1 cl, 3 dwg, 4 tbl',\n",
              " 'method detecting dna chlomydia farm animals birdsfield: biotechnology.substance: invention relates field biotechnology. invention represents method detecting dna chlamydia farm animals birds, involving chlamydia dna extraction chlamydia spp. biological material infected animals sorption method, polymerase chain reaction – addition internal positive control 45 amplification cycles fluorescent detection real time using chlamydia specific chlamydia spp. oligonucleotide primers, fluorescent-labeled probe, positive negative control samples, measuring accumulation fluorescent signal channels corresponding fluorescent dyes specific signal internal control signal interpreting results based presence/absence crossing fluorescence curve threshold line, according invention, biological material additionally taken infected birds, wherein internal control sample bacteriophage t4 suspension concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample – mixture recombinant plasmid dna containing fragment dna genome chlamydia dna fragment bacteriophage t4 genome, taken ratio 1:1, wherein accumulation fluorescent signal measured channels: joe(hex)/yellow specific chlamydia dna signal chlamydia spp; fam/green internal control sample signal, fluorescence signal accumulation curves 35 cycles, result reaction considered positive, curves cross threshold line cross 35 cycles, reaction result negative.effect: invention provides accurate diagnosis presence chlamydia dna exciter broader functional capabilities.1 cl, 3 dwg, 4 tbl',\n",
              " 'method detecting genome brucella infection agent (brucella speciales) farm animalsfield: biotechnology.substance: invention represents method detecting genome brucellosis infection agent (brucella spp.) agricultural animals, involving recovering dna biological material infected animals sorption method, staged one-stage polymerase chain reaction – simultaneous amplification cycles real-time detection using oligonucleotide primers specific genome region (brucella spp.), probes, dyes control samples form internal positive, measurement specific signal control signal channels corresponding dyes interpretation results, fluorescent detection carried out, measuring joe(hex)/yellow accumulation fluorescent signal specific signal testing genome brucellosis infection agent (brucella spp.), fam/green channel – signal internal control sample, fluorescence signal accumulation curves 35 cycle, result reaction considered positive, curves cross threshold line cross 35 cycles, result reaction negative, interpretation results carried based presence/absence intersection fluorescence curve threshold line, wherein internal control sample suspension bacteriophage t4 concentration 5×10copies nucleotide sequences 1 mcl, positive control sample mixture recombinant plasmid dna containing dna fragment brucella spp. dna used fragment bacteriophage t4 genome, taken ratio 1:1, following nucleotide sequences: b7f tgaagctgcctgcatcggtc – forward primer, b7r cataatggccgggtgttggct – reverse primer, b7p hex-caacagcatgcagcttggtcgtcaatc-bhq1 – probe, t4f tacatataaatcacgcaaagc – forward primer, t4r tagtatggctaatcttattgg – reverse primer, t4p fam acattggcactgaccgagttc – probe.effect: invention enables reliable diagnosis brucella speciales dna exciter.1 cl, 3 dwg, 4 tbl',\n",
              " \"method detection dna donkey (equus asinus) tissue dry fodder semi-finished meat productsfield: biotechnology.substance: invention represents method dna identification donkey tissue (equus asinus) dry fodder semi-finished meat products, involving dna recovery animal tissue sorption method, polymerase chain reaction fluorescent detection carried 45 cycles real-time amplification using oligonucleotide primers, probes, fluorescent dyes specific dna genome region: specific signal animal cy5 / red internal control sample form suspension bacteriophage t4 concentration 5×10phage particles per 1 mcl, positive control sample form mixture containing fragments animal genomes bacteriophage t4 nucleotide sequence: t4f tacatataaatcacgcaaagc – forward primer; t4r tagtatggctaatcttattgg – reverse primer; t4p cy5 acattggcactgaccgagttc – probe, taken ratio 1:1, measurement accumulation fluorescent signals via channels corresponding fluorescent dyes, interpretation results based presence absence intersection fluorescence curve threshold line, fluorescence signal accumulation curves 35 cycles, reaction result considered positive, curves cross threshold line cross 35 cycles, result reaction negative, according invention, dna recovered donkey tissue (equus asinus), internal control sample used phagolysate bacteriophage t4, positive control sample – fragments genomes native bacteriophage t4 donkey tissue (equus asinus) following nucleotide sequence: donk f: 5'- catatcttaatcccaataatagac-3' – forward primer; donk r: 5'- agtattcgttctgatataggc-3' – reverse primer; donk p: pam-5'- atcttatactggactattctatcgac-3 -bhq1 – probe, wherein dna detection donkey tissue (equus asinus) employs fluorescent dye fam / green.effect: invention increases accuracy identification species identity simplifies process preparing samples.1 cl, 5 tbl\",\n",
              " 'test system determining dna nodular dermatitis virus (lsdv) biological material animals pcr electrophoretic detection amplification products agarose gelfield: biotechnology.substance: invention represents test system detecting dna nodular dermatitis virus (lsdv) biological material animals pcr method electrophoretic detection amplification products agarose gel, including pcr buffer, mixture thereof, consisting deoxynucleoside triphosphates, oligonucleotide primers specific genome region causative agent infectious disease internal control sample form bacteriophage t4 suspension concentration 5×10phagene particles per 1 mcl; mixture enzymes dna polymerase enzyme inhibiting enzymes, taqpolymerase, positive control sample mixture recombinant plasmid dna containing genome fragment infectious disease agent fragment bacteriophage t4 genome, taken volume ratio 1:1, according invention, fragments bacteriophage t4 genomes nodular dermatitis virus (lsdv) genome fragment following nucleotide sequences used positive control sample. expand functional capabilities, high specificity observing residual amounts unknown dna molecules nodular dermatitis virus reduced cost method.effect: invention broadens functional capabilities, increases specificity detecting residual quantities unknown dna molecules nodular dermatitis virus.1 cl, 6 tbl',\n",
              " \"test system detecting dna lumpy skin disease virus (lsdv) biological material animals using polymerase chain reaction real timefield: biotechnology.substance: invention represents test system detecting dna lumpy skin disease virus (lsdv) animal biological material using real-time polymerase chain reaction comprising buffer polymerase chain reaction, mixture thereof, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes specific genomic region agent infectious animal disease internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase, internal control sample form suspension bacteriophage t4 concentration 5×10phage particles per 1 mcl, negative control sample positive control sample, mixture recombinant plasmid dna containing fragment genome causative agent infectious animal disease fragment bacteriophage t4 genome nucleotide sequence: t4f: 5'-tacatataaatcacgcaaagc-3' – forward primer; t4r: 5'-tagtatggctaatcttattgg-3' – reverse primer; t4p: fam-5'-acattggcactgaccgagttc-3'-bhq1 – probe, taken volumetric ratio 1:1, according invention internal control sample phagolysate bacteriophage t4 used, positive control sample – fragments genomes native bacteriophage t4 fragment genome lumpy skin disease virus (lsdv) following nucleotide sequence: lsdv-f 5-tttaggagataagattgtcac-3' forward primer; lsdv-r 5'-ggagattttattatgagtggc-3' reverse primer; lsdv-p rox-5'-ggttaattttttaccacaaatagg-3'-bhq2 probe.effect: invention widens functional capabilities, increases sensitivity simplifies process preparing internal control sample.1 cl, 4 tbl\",\n",
              " \"test system identification dna tissue common quail (coturnix coturnix) dry fodder semi-finished meat productsfield: biotechnology.substance: invention represents test system dna identification common quail (coturnix coturnix) tissue dry fodders semi-finished meat products, including polymerase chain reaction buffer, mixture carrying out, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes, specific section animal's genome internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase, internal control sample form suspension bacteriophage t4 concentration 5×10phage particles per 1 mcl, negative control sample, mixture recombinant plasmid dna, containing fragment animal's genome fragment bacteriophage t4 genome nucleotide sequence: t4f tacatataaatcacgcaaagc – forward primer, t4r tagtatggctaatcttattgg – reverse primer, t4p fam acattggcactgaccgagttc bhq – probe, taken volumetric ratio 1:1, internal control sample presented phagolysate bacteriophage t4, positive control sample – fragments genomes native bacteriophage t4 quail tissue coturnix coturnix) following nucleotide sequence: c.cot-f: 5'-ctaggaggcgtacttgc-3' – forward primer; c.cot-r: 5'-gtgggcggaatgttatg-3' – reverse primer; c.cot-z: 5'-cagtacttatcctccttctaatcc-3' – probe.effect: invention broadens functional capabilities accuracy identification species identity, simplifies sample preparation process.1 cl, 5 tbl\",\n",
              " \"test system identification common hedgehog (erinaceus europaeus) tissue dna dry fodder semi-finished meat productsfield: biotechnology.substance: invention represents test system identification common hedgehog (erinaceus europaeus) tissue dna dry fodder semi-finished meat products, including polymerase chain reaction buffer, mixture carrying out, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes region-specific animal genome internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase, internal control sample form bacteriophage t4 suspension concentration 5×10phagic particles per 1 mcl, negative control sample mixture recombinant plasmid dna, containing fragment animal's genome fragment bacteriophage t4 genome nucleotide sequence: t4f: 5`-tacatataaatcacgcaaagc-3` – forward primer; t4r: 5`- tagtatggctaatcttattgg-3` – reverse primer; t4p: hex-5`-acattggcactgaccgagttc-3`-bhq1 – probe, taken volume ratio 1:1, according invention internal control sample phagolysate bacteriophage t4 used, positive control sample fragments genomes native bacteriophage t4 hedgehog (erinaceus europaeus) following nucleotide sequence used: hed-f: 5`-agtctattgattcgaatagagc-3` – forward primer; hed-r: 5`-catgagaggtactaaccagt-3` – reverse primer; hed-p: fam-5`-caggagctttattaggtgatgatcag-3-bhq1 – probe.effect: invention allows expand functional capabilities, increase accuracy species identity identification, simplification sample preparation process.1 cl, 5 tbl\",\n",
              " \"test system detecting dna donkey (equus asinus) tissue dry fodder semi-finished meat productsfield: biotechnology.substance: invention represents test system identification dna donkey (equus asinus) tissue dry fodder meat semi-products, including buffer polymerase chain reaction, mixture carrying out, consisting deoxynucleoside triphosphates, oligonucleotide primers fluorescent probes, specific section animal's genome internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase, internal control sample form bacteriophage t4 suspension concentration 5×10phage particles per 1 mcl, negative control sample mixture recombinant plasmid dna, containing fragment animal's genome fragment bacteriophage t4 genome nucleotide sequence: t4f tacatataaatcacgcaaagc – forward primer; t4r tagtatggctaatcttattgg – reverse primer; t4p fam acattggcactgaccgagttc bhq1 – probe, taken volume ratio 1:1, according invention internal control sample phage lysate bacteriophage t4 used, positive control sample fragments genomes native bacteriophage t4 donkey (equus asinus) following nucleotide sequence used: donk f: 5'-catatcttaatcccaataatagac-3' – forward primer; donk r: 5'-agtattcgttctgatataggc-3' – reverse primer; donk p: fam-5'-atcttatactggactattctatcgac-3 – bhq1 – probe.effect: invention used expand functional capabilities increase accuracy identification species identity, simplify sample preparation process.1 cl, 5 tbl\",\n",
              " 'antibacterial composition based strains bacteriophages preventing treating salmonellosis / escherichiosis farm animals birds humansfield: biotechnology.substance: invention represents antibacterial composition medical preventive purpose, involves combination sterile, purified toxins filtrate phage lysates titre bacteriophage less 10pfu/ml gratia non-overlapping spectrum lytic activity respect salmonella escherichiosis pathogens, capable causing mass diseases birds, farm animals humans. created composition risk toxic side effects humans animals, provides stability bacteriophage titre effectiveness application. antibacterial activity composition manifested relation 83.72 % salmonella isolates isolated birds relation 90.63 % salmonella isolates isolated pigs, lytic spectrum. case paired meat treatment bacteriophages, meat salmonella contamination rate decreased 99.95 %, 99.98 % escherichia. dissemination samples fodder escherichia treatment antibacterial composition 88.4 times lower using fodder without it.effect: percentage survival rate animals test groups pig-breeding enterprises 90.38 %, provided non-use treatment additional antibacterial agents preparations.3 cl, 12 tbl, 13 ex',\n",
              " 'bacteriophages production methodfield: biotechnology.substance: method comprises culturing bacterial cells host strain absence extraneous microflora, phage lysate preparation purification precipitation and/or filtration. 30-120 minutes culturing initiation, optimum growth temperature culture rapidly growing host strain, every 30-60 minutes, smears made host strain culture surface solid nutrient medium liquid culture medium. smears stained solution acridine orange final concentration 0.001% 0.02% acridine yellow solution final concentration 0.01% 0.2%. stained smear microscoped fluorescence microscope. time set inoculating mother bacteriophage achievement stained smear less 50% relation total host strain cells proportion orange acridine stained cells, fluorescing orange red shades, proportion yellow acridine stained cells fluorescing yellow orange shades, achevement less 10% relation total host strain cells proportion cells non-uniform fluorescence paired pole adjoining cells form rods irregular spherical cytoplasm fluorescent spherical ellipsoidal cells slightly fluorescenting central section. mother bacteriophage inoculated.effect: stability achieving high bacteriophage titer upon phage lysate production changing nutritive medium formulations, increase range variations indicator values host strain bacteriophage culturing.11 ex',\n",
              " 'method detecting microorganism species vibrio parahaemolyticusfield: biotechnology.substance: method comprises inoculation test strain lawn culture, applying drop diagnostic phage preparation centre cup, holding temperature 37°c 20-24 hours confirmation belonging microorganisms species v. parahaemolyticus presence lysis. diagnostic phage preparation prepared mixing phages fc-44 fc-46, prepared based strain vibrio parahaemolyticus km-97, ratio 1:1 titre n·108 pfu/ml.effect: present invention enables accelerate identification strains used laboratory diagnostics acute intestinal infections caused microorganism.2 cl, 1 tbl, 3 ex',\n",
              " 'method obtaining recombinant exoprotein pseudomonas aeruginosafield: biotechnology.substance: method includes obtaining expression plasmid vector pet-repa (seq no: 3), containing promotor sequence t7 bacteriophage dna dna sequences encoding n-end region protein product translation enhancer (masmt amino-acid sequence), six histidine residues, site sumo protease cleavage sequence (seq no: 1) optimized broadcasting e. coli encoding recombinant repa protein (seq no: 2). recombinant chimeric precursor protein heterological expression system electro-competent cells e. coli bl21 (de3), transformed plasmid vector pet-repa obtain e. coli bl-repa strain 37°c ensure maximum amount accumulation precursor protein soluble fraction. lysis bacterial mass carried presence 4% triton x-100 preserve precursor protein soluble form. precursor protein isolated metal chelate chromatography talon sorbent charged coions, followed hexahistidine sumo peptide cleavage sumo protease polypeptide. cleaved recombinant protein repa subject finish purification anion-exchange chromatography deae-sepharose sorbent gel-filtration chromatography superdex 200-filled column, translation target buffer ph 7.5, obtaining recombinant repa protein.effect: production protein high yield.4 dwg, 4 ex',\n",
              " 'method production bacteriophagefield: biotechnology.substance: method production bacteriophage comprises: inoculation bacterial culture host strain titre 108-109 cfu/ml vessel culturing slant layer thickness 10 mm 25 mm, culturing 3-3.5 hours optimum temperature growth host strain culture, resulting lawn culture host strain stock bacteriophage inoculated titre 10-10cfu/ml cultured 13-15 hours optimum temperature thickness air layer surface solid medium 25 mm 40 mm. phage lysate prepared sucked sterile container, chloroform added, incubated 30-45 minutes continuous shuttling. supernatant centrifuged sterilised filtration filter pore diameter 0.2-0.22 microns.effect: solution provides universal possibility production phage lysate use different bacteriophages, stability bacteriophage titre phage lysate possibility use food industry.3 cl, 3 ex',\n",
              " 'plasmid-free recombinant escherichia coli strain, constitutive aspartase activity method l-asparagin acid synthesis using strain biocatalystfield: biotechnology.substance: plasmid-free recombinant escherichia coli strain constitutive aspartic activity obtained replacing promoter aspa gene escherichia coli strain mg1655 bacteriophage t5 pg25 promoter represented. method l-aspartic acid synthesis ammonium fumarate provided, using said recombinant strain biocatalyst form either free immobilized cells.effect: efficient preparation l-aspartic acid; allows reduce time production 3-4 times due higher aspartic activity biocatalyst.2 cl, 1 tbl, 3 ex',\n",
              " 'new bacteriophage enteroinvasive escherichia coli esc-cop-4 application inhibiting proliferation enteroinvasive escherichia colifield: biotechnology.substance: present invention relates particular myovirus bacteriophage esc-cop-4 isolated nature gene represented nucleotide sequence seq id no: 1 (registration number: ksts 12663 bp). invention relates method preventing treating infections caused enteroinvasive e. coli using composition comprising said bacteriophage active ingredient.effect: inventions allow use claimed bacteriophage capable specifically destroying strains enteroinvasive escherichia coli used medical industry.5 cl, 2 dwg, 4 tbl, 8 ex',\n",
              " 'method identidying rna sars-cov2 virus using multiplex isothermal loop amplification reverse transcriptionfield: biotechnology.substance: present invention relates field biotechnology and, particular, genetic engineering. isothermal loop amplification executed using specifically selected oligonucleotide primers complementary site genomic rna sars-cov2 coronavirus genomic rna ms2 bacteriophage, wherein amplification two dna fragments complementary genomic rna sars-cov2 coronavirus genomic rna ms2 bacteriophage executed simultaneously one reaction mixture. amplification results detected real time amplification using intercalating fluorescent dye based analysis melting curves amplified fragments.effect: reduction duration method identifying rna sars-cov2 virus.2 cl, 1 dwg, 2 tbl, 2 ex',\n",
              " \"ecoli strain - producer full-dimensional protective bacillus anthracis antigen form virus-like particlesfield: biotechnology.substance: presented strain derived protective bacillus anthracis antigen inserting pgem-ttppag plasmids e. coli strain bl21 (de3). plasmid pgem-ttppag contains t7 phage promoter controls expression fusion gene full-length ttr bacteriophage dt57c gene (encodes pb6 tail tube protein) fused 3'-end b. anthracis protective antigen gene expressed form virus-like particles. obtained hpv, free soluble cell protein, used antigen immunization.effect: increasing yield target product optimal cultivation conditions, obtaining main protective antigen causative agent anthrax form virus-like particles, facilitates purification potentially increases immunogenicity.5 dwg, 3 tbl\",\n",
              " \"e. coli strain - producer isolated domain 1 protective bacillus anthracis antigen form virus-like particlesfield: biotechnology.substance: strain derived protective bacillus anthracis antigen inserting ptrppa plasmids e. coli strain bl21 (de3). plasmid ptrppa contains t7 phage promoter controls expression fusion gene product 142 t5-like phage dt57c gene, known tail-terminating protein (trp) fused 3'-end domain 1 protective b. anthracis antigen, allows proteolytic cleavage transport toxin cytoplasm target cell preserve structural stability antigen, expressed form virus-like particles.effect: increasing yield target product optimal cultivation conditions, obtaining isolated domain 1 main protective antigen anthrax form virus-like particles, facilitates purification potentially increases immunogenicity.6 dwg\",\n",
              " 'strain bacteria serratia plymuthica antiviral activity influenza virus type (versions)field: biotechnology.substance: strain bacteria serratia plymuthica b-1288, strain bacteria serratia plymuthica b-1297, strain bacteria serratia plymuthica b-1296 strain bacteria serratia plymuthica b-1285 proposed. strains deposited collection bacteria, bacteriophages fungi federal state institution science \"state research centre virology biotechnology \"vector\". using preparations basis proposed strains neutralisation index influenza virus type 2.5-6.5 lg initial concentration virus 10lg tcd/ml.effect: strains antiviral activity influenza virus type a.4 cl, 5 tbl, 13 ex',\n",
              " 'strain bacteria serratia species producer extracellular ribonuclease deoxyribonuclease antiviral activityfield: biotechnology.substance: strain bacteria serratia species producer extracellular ribonuclease deoxyribonuclease antiviral activity avian influenza virus a/chickenkurgan/05/2005 (h5n1) human influenza virus a/aichi/2/68 (h3n2). proposed strain deposited collection bacteria, bacteriophages fungi federal budget institution science \"state research centre virology biotechnology \"vector\" registration number b-1287. using culture liquid cell extract strain production antiviral preparations neutralisation influenza virus a/chickenkurgan/05/2005 a/aichi/2/68 100%.effect: increased activity strain.1 dwg, 2 tbl, 6 ex',\n",
              " \"method obtain chemeric recombinant protein flic:pagnfield: biotechnology.substance: implement method, recombinant plasmid petflicpagn constructed, escherichia coli bl21 (de3) cells said plasmid resulting bl-flicpagn strain cultured temperature 37°c. next, periplasmic fraction producer bacteria prepared cells treatment lysozyme 20% sucrose solution, followed centrifugation, chemeric flic:pagn metal chelate, anion exchange, gel filtration chromatography obtain homogeneous final preparation flic:pagn protein. recombinant petflicpagn plasmid contains t7 bacteriophage promoter carries sequences encoding flic proteins, including leader sequence protein, pagn s. typhimurium, combined short linker sequence gsvdsssggn, fused 3'-end synthetic sequence encoding six histidins.effect: method allows synthesise protein soluble form native n-terminal amino acid sequence, yielding least 0,3 g protein litre bacterial culture 98 percent purity.7 dwg, 4 ex\",\n",
              " \"test system detecting rna schmallenberg disease virus farm animalsfield: biotechnology.substance: increase diagnostic accuracy, test system detecting rna schmallenberg disease virus farm animals includes buffer carrying polymerase chain reaction, mixture carrying consisting deoxynucleoside triphosphates, primers fluorescent probes specific agent schmallenberg disease virus internal control sample; mixture enzymes dna polymerase antibodies inhibiting enzyme activity, taq polymerase; rna dilution buffer, internal control sample, negative control sample, positive control sample, according invention internal control sample suspension bacteriophage ms2 concentration 5×10copies nucleotide sequences per 1 mcl, positive control sample, mixture recombinant plasmid dna containing fragment genome schmallenberg virus exciter fragment bacteriophage ms2 genome, taken ratio 1:1 following nucleotide sequences: shm-f 5' tcagattgtcatgccccttgc 3'` – forward primer; shm-r 5' tcggccccaggtgcaaatc 3' – reverse primer; shm-z joe – accatcggcccaggtgcatccctta-bhq1 – probe; ms2f, 5'-tggcactacccctctccgtattcac-3' – forward primer; ms2r, 5'-gtacgggcgaccccacgatgac-3' – reverse primer; ms2p, 5'-cy5-cacatcgatagatcaaggtgcctacaagc-3' bhq2 – probe.effect: invention provides accurate diagnosis schmallenberg disease farm animals.1 cl, 3 dwg, 4 tbl\",\n",
              " 'antibacterial composition (embodiments) use protein antimicrobial agent directed bacteria pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, salmonella typhi staphylococcus haemolyticus (embodiments)field: biotechnology; medicine.substance: invention relates biotechnology, specifically therapeutic proteins, used medicine antibacterial agent. disclosed use recombinant endolysin bacteriophage, including combination pharmaceutically acceptable carriers and/or substances increasing membrane permeability, antimicrobial agent directed bacteria pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, salmonella typhi staphylococcus haemolyticus. antibacterial compositions obtained based said protein, including fused 8-histidine tag.effect: invention provides effective penetration endolysin without adding various permeabilisers covalently bound penetrating peptides outer membrane said bacteria cleavage peptidoglycan, ultimately leads death bacteria.4 cl, 5 dwg, 3 tbl, 6 ex',\n",
              " 'antibacterial composition (embodiments) use protein antimicrobial agent directed gram-negative bacteria: pseudomonas aeruginosa, acinetobacter baumannii, klebsiella pneumoniae salmonella typhi (embodiments)field: biotechnology; medicine.substance: invention relates biotechnology, specifically therapeutic proteins, used medicine antibacterial agent. disclosed use recombinant endolysin bacteriophage, including combination pharmaceutically acceptable carriers and/or substances increasing membrane permeability, antimicrobial agent directed gram-negative bacteria: pseudomonas aeruginosa, acinetobacter baumannii, klebsiella pneumoniae salmonella typhi. antibacterial compositions obtained based said protein, including fused 8-histidine tag.effect: invention provides effective penetration endolysin without adding various permeabilisers covalently bound penetrating peptides outer membrane said bacteria cleavage peptidoglycan, ultimately leads death bacteria.4 cl, 5 dwg, 3 tbl, 6 ex',\n",
              " 'method detecting genome rotavirus infection agent farm animalsfield: biotechnology; veterinary science.substance: invention refers biotechnology veterinary virology. disclosed method detecting genome rotavirus type agent agricultural animals. rna isolated biological material infected animals sorption method. followed synthesising cdna rna matrix single-step staging addition internal positive control reverse transcription multiplex reaction polymerase chain reaction 45 amplification cycles real-time detection using specific oligonucleotide primers, fluorescently-labelled probe, control samples. then, accumulation fluorescent signal measured channels corresponding fluorescent dyes results interpreted basis presence/absence intersection fluorescence curve threshold line (threshold). internal control sample, bacteriophage ms2 suspension used, positive control sample - mixture recombinant plasmid dna containing rva virus genome fragment fragment bacteriophage ms2 genome.effect: invention enables reliable diagnosis rotavirus infection type animals.1 cl, 4 tbl',\n",
              " 'bacillus anthracis r/d bateriophage strain used produce preparation anthrax infection diagnostics, liquid preparation anthrax infection diagnostics preparation anthrax infection diagnosticsfield: chemistry, biochemistry. ^ substance: group inventions concerns medical virology microbiology. bacillus anthracis r/d bacteriophage strain, deposited collections microorganism museum state research centre applied microbiology practical molecular biology serial number ph-6, used produce preparation anthrax infection diagnostics. liquid preparation anthrax infection diagnostics contains suspended particles bacteriophage bacillus anthracis r/d-ph-6 lytic activity 1010 plaque-forming unit/cm3, 1% quinosol solution, ratio follows, wt %: suspended bacteriophage lytic activity 1010 plaque-forming unit/ml - 10.0-20.0, 1% quinosol solution - 0.5-1.0, physiologic saline - rest. dry preparation anthrax infection diagnostics contains dry solid matter bacteriophage bacillus anthracis r/d-ph-6 lytic activity 1010 plaque-forming unit/cm3, saccharose, gelatine quinosol ratio follows, wt %: saccharose - 35.0-40.0, gelatine - 6.0-10.0, quinosol - 0.03-0.06, dry solid matter bacteriophage lytic activity 1010 plaque-forming unit/cm3 - rest. ^ effect: implemented fast identification anthrax agent effective medical antiepidemic actions. ^ 3 cl, 1 tbl, 9 ex, 1 dwg',\n",
              " 'bacteria strain lactococcus lactis subsp diacetilactis --5-5, used revealing lactococci bacteriophagesfield: chemistry, organic, production fermented milk products. ^ substance: invention relates diary industry, production fermented milk products particular. bacteria strain lactococcus lactis subsp. diacetilactis \"--5-5\" (russian collection lactate bacteria production cheese bacteriophages \"\") obtained self-sour cream selected sensitivity spectrum 250 known bacteriophages. used indicator strain revealing lactococci bacteriophages, ways sources spreading enterprise. invention enables one prevent development bacteriophages production milk produce, improve quality safety human health, well increase efficiency production. ^ effect: increase production efficiency, quality safety milk produce. ^ 1 ex',\n",
              " 'lactococcus lactis subsp cremoris \"--1-1\" bacteria strain, used identifying lactococcus bacteriophagesfield: chemistry. ^ substance: present invention pertains dairy industry, particularly production fermented dairy products. lactococcus lactis subsp. cremoris \"--1-1\" bacteria strain, high specific sensitivity lactococcus lactis subsp. cremoris bacteriophages high sensitivity wide range lactococcus bacteriophages, used identifying lactococcus bacteriophages production dairy products. invention prevents development bacteriophages production dairy products, improves quality product health safety consumer, increases production efficiency well. ^ effect: prevention development bacteriophages production dairy products, improvement quality product health safety consumer, increased production efficiency. ^ 1 ex',\n",
              " 'treatment oil pipelines microbiological corrosion biocompositionfield: chemistry.substance: group inventions relates method reducing intensity preventing formation corrosive biofilm metal surface. method includes obtaining sample corresponding area, identifying culturing strain target bacterium, identifying obtaining bacteriophage microbes based said sample, immobilizing encapsulating obtained bacteriophages nanomagnetic particle, nanolignin combination thereof, preparing microbicide composition inhibiting corrosion adding least one phage release reagent stabilizer combined solution containing alcohol hydrocarbon, subsequent addition immobilized encapsulated phages, treatment corresponding area microbicide composition. cultivation strains carried presence microbial antibiotics suboptimal concentration 1/15 minimum inhibitory concentration, bacteriophages selectively released ph within range 6.5 4 microbiologic corrosion site. microbicidal composition contains least one alcohol, one liquid hydrocarbon, bacteriophage immobilized magnetic nanocomposite, least one phage release reagent one stabilizer.effect: reduced intensity biofilm formation surfaces, resulting reduction, attenuation elimination microbial corrosion inner surface oil pipelines.11 cl, 4 tbl',\n",
              " 'pet21a-prochym recombinate plasmid, providing synthesis chemeric b bos taurus proximosin protein, well escherichia coli bl21 (de3) plyse pet21a-prochym - producer chemeric b bos taurus proximosin proteinfield: chemistry.substance: group inventions relates recombinant plasmid providing synthesis chimeric protein b bos taurus prochymosin, recombinant strain e. coli, producer chimeric protein b bos taurus prochymosin e. coli cells. recombinant pet21a-prochym plasmid 6504 base pairs (bp) contains following structural elements essential functioning expression target protein: bacteriophage t7 promoter provides efficient transcription controlled mrna; recombinant gene b bos taurus prochymosin encoding target chimeric protein; t7 terminator, untranslated termination region transcription bacterial operon providing effective termination transcription; sequence t7 expression tag, added composition nucleotide sequence gene b bos taurus prochymosin n-terminus, increase yield target protein; bla sequence encoding beta-lactamase protein, selective marker transformation e. coli strains; cole1 sequence replicates plasmid e. coli strains. recombinant gene b bos taurus prochymosin nucleotide sequence seq id no: 1 nucleotide position 5205 bp. nucleotide position 6347 bp, encoding target chimeric protein b bos taurus prochymosin complete amino acid sequence seq id no: 2, embedded faund sfr274 restriction sites region pet21a polylinker containing t7 phage rna polymerase promoter terminator. proposed recombinant strain escherichia coli bl21 (de3) plyse pet21a-prochym obtained transformation recombinant plasmid pet21a-prochym deposited collection bacteria, bacteriophages fungi state research center virology biotechnology vector federal service supervision consumer rights protection human well-being registration number b-1362.effect: group inventions provides high production pro-chymosin.2 cl, 5 dwg, 6 ex, 2 tbl',\n",
              " 'peptinoglycane hydrolase, expression plasmid, containing peptidoglycane hydrolase-coding dna fragment, bacterium-producer method microbiological synthesis peptidoglycane hydrolasefield: chemistry.substance: group inventions relates biotechnology, particular peptydoglycane hydrolase biosynthesis, represents protein peptydoglycane hydrolase activity, plasmid, containing peptydoglycane hydrolase-coding fragment, bacterium-producer, method microbiological peptydoglycane hydrolase synthesis, well pharmaceutical composition, containing obtained peptydoglycane hydrolase, therapy diseases, caused gram-negative microflora.effect: elaborated method microbiological synthesis makes possible obtain bacteriophage s-394 peptydoglycane hydrolase effective way.22 cl, 2 dwg, 9 ex',\n",
              " 'recombinant plasmid dna per-arns3, encoding fusion protein capable autocatalytic splitting formation arns3, escherichia coli strain c3030/per-arns3 producer said proteins methods recombinant arns3 productionfield: chemistry.substance: invention refers biochemistry, namely recombinant plasmid dna per-arns3 providing synthesis hybrid polypeptide comprising arns3 mini-intein ssp dnab, escherichia coli cells. said plasmid dna comprises bsabi/eco0109i-dna plasmid fragment ptwin-1 gene translation amplifier 10 phage t7, ndei/bamhi-dna fragment containing mini-intein gene ssp dnab sequence arns3 recombinant gene adapted sites. plasmid contains b-lactamase gene determines resistance e. coli cells transformed plasmid per-arns3 penicillin antibiotics, genetic marker unique restriction endonuclease recognition sites. invention discloses strain escherichia coli c3030/per-arns3, producing said fusion polypeptide. invention discloses method production said arns3 recombinant protein, comprising culturing said strain escherichia coli c3030/per-arns3.effect: invention provides recombinant arns3 high yield according simplified technology.3 cl, 4 dwg, 4 ex',\n",
              " 'method producing peptides specifically identifying certain types cells intended therapeutic purposesfield: chemistry.substance: invention relates biochemistry, particularly method producing peptides specifically identify certain types cells. said method includes constructing plurality random peptide libraries based oligonucleotide fragments encoding same, via fragmentation resultant rna cells certain type cells types, may involved pathologic process affect diagnosis therapy thereof. said fragments closed correct orientation vector based bacteriophage. libraries screened using combinations cells certain type cells types obtain groups peptides specifically identify cells selected type phage particles. individual peptides phage particles separated obtained peptides tested confirm specificity thereof. peptides pure form obtained creating matrix based amino acid sequences peptides phage particles, sequences new peptides read synthesised chemically, followed confirmation specific identification cells certain type.effect: invention enables obtain highly specific highly selective peptides identify cells certain type.5 dwg, 1 tbl, 11 ex',\n",
              " 'recombinant strain escherichia coli l-threonine-producerfield: chemistry.substance: invention relates biotechnology, particular threonine-producer strain. strain escherichia coli arsim b-11820 obtained inactivation strain escherichia coli arsim b-3996 genes poxb sstt background increased expression gene gaip substitution natural promoter synthetic promoter ptac3 increased expression genes operon thrabc substitution natural promoter phage promoter p, removal sequence regulatory peptide thrl introduction densensitising mutation thra.effect: obtained strain makes possible obtain l-threonine high efficiency.1 tbl, 6 ex',\n",
              " 'recombinant plasmid dna pestpc, encoding polypeptide properties esterase psychrobacter cryohalolentis k5, escherichia coli bacteria strain - producer polypeptide properties esterase psychrobacter cryohalolentis k5field: chemistry.substance: invention relates biotechnology. described plasmid codes esterase psychrobacter cryohalolentis k5and contains ndel/xhol - dna fragment plasmid pet32a length 5.366 thousand base pairs, includes promoter bacteriophage t7, translation enhancer gene 10 bacteriophage t7, transcription terminator bacteriophage t7, bla ?-lactamase gene determines resistance cells transformed plasmid ppc023 ampicillin, replication initiation section ori; ndel/sall - dna fragment size 0.869 thousand base pairs, contains gene codes mature form esterase psychrobacter cryohalolentis k5with amino acid sequence seq id no: 2, given description, c-end hexahestidine linker. provided escherichia coli bacteria strain modified said plasmid, producer polypeptide esterase psychrobacter cryohalolentis k5activity.effect: invention increases level biosynthesis esterase 20% total cell protein.2 cl, 2 dwg, 5 ex',\n",
              " 'antibacterial composition, strain bacteriophage escherichia coli, used obtaining thereoffield: chemistry.substance: invention relates field food industry, biotechnology deals antibacterial composition strain bacteriophage escherichia coli, used obtaining said composition. characterised composition includes filtrate escherichia coli phage lysate, obtained application strain bacteriophage escherichia coli, deposited collection museum microorganisms federal budget institution science \"state research centre applied microbiology biotechnology\" federal service customers\\' rights protection human well-being surveillance (fbis src amb rospotrebnadzor) number ph 64, filtrate escherichia coli phage lysate, containing coli bacteriophage, filtrate staphylococcus phage lysate, filtrate salmonella phage lysate, filtrate listeria monocyctogenes phage lysate target additives amount 1.0÷95.0 wt % composition weight.effect: claimed composition required spectrum specific activity due inclusion polyvalent bacteriophage used production biologically active additives food additives.11 cl, 1 tbl, 13 ex',\n",
              " 'method neutralising bacillus anthracis spores vegetative cellsfield: chemistry; biochemistry. ^ substance: invention pertains biotechnology. disclosed method neutralising bacillus anthracis spores vegetative cells, involving treatment infected surface disinfectant aqueous solution containing mixture bacillus anthracis ozr-1, bacillus anthracis f-2 bacillus anthracis faut bacteriophages activity ratio (pfu/cm3) bacillus anthracis ozr-1, bacillus anthracis f-2 bacillus anthracis faut equal 1 :(0.2-1):(0.1 -1) spore germination activator l-alanine.the disinfecting solution prepared mixing separately stored l-alanine complex bacteriophages separately grown mixed specified ratios. preferably, aqueous solution containing mixture bacteriophages concentration 1010-1012 pfu/l spore germination activator concentration 0.05-0.15 mol/l used. aim receiving full effect fixing result, infected surface twice treated interval 60-180 minutes effective disinfection achieved using solution based 1011-1012 phage particles per 10 m2 infected surface. ^ effect: invention enables efficient environmentally safe neutralisation bacillus anthracis spores vegetative cells. ^ 4 cl, 2 ex',\n",
              " 'bacteriophogum salmonella ibp-1 bacteriophage strain lytic enteritidisfield: chemistry; biochemistry. ^ substance: invention refers biotechnology used production biological preparations prevention treatment salmonellosis. bacteriophogum salmonellal ibp-1 bacteriophage strain lytic s. enteritidis used production medical bacteriophage preparation. ^ effect: extended spectrum lytic action bacterium salmonella enteritidis.',\n",
              " 'method evaluating phagoimmunoassay resultsfield: chemistry; biochemistry. ^ substance: invention relates biotechnology, particular, immunoengineering, may used digital processing images lysed zones bacterial lawn, result antigen-antibody reaction, based phage label principle (phagoimmunoassay viroimmunoassay). phagoimmunoassay results evaluation method implies analysis lysed zones indicator crop plate wells experimental reference tests. plate experimental reference tests subsequently placed photo scanning unit obtain digitised image lysed zones. then, digitised image processed means adaptive filter obtain outlined individual lysed zones various size, well merged lysed zones. that, average total area lysed zones experimental reference samples determined. average total area experimental lysed zones exceeds average total area reference lysed zones 5% minimum, phagoimmunoassay considered positive. ^ effect: efficient method evaluating phagoimmunotest results. ^ 4 tbl, 5 dwg, 1 ex',\n",
              " 'exposure t-cell receptorsfield: chemistry; biochemistry. ^ substance: present invention pertains biotechnology. description given phage particle, exposing surface, t-cell receptor (tcr), human sctcr. exposed dtcr polypeptide pair exposed sctcr polypeptide contains series alpha beta chains extra-cellular constant lg native tcr domain. disulphide bond joins amino acid residues given series chains constant lg domain, given disulphide bond cysteic residues. presented library polypeptide pairs mutated tcr sctcr polypeptides, exposed described phage particle. nucleic acid, encodes described phage particle, presented. method identifying tcrs invented. invention used making various tcr libraries, identification high-affinity tcrs. ^ effect: possibility making various tcr libraries identification high-affinity tcrs. ^ 17 cl, 25 ex, 63 dwg, 2 tbl',\n",
              " 'method cosmetic rehabilitation skin tissues post-operating posttraumatic conditions (variants)field: cosmetology, esthetic surgery, applied biopharmacology. ^ substance: invention relates medicative cosmetic agents, uses biologically active substances based natural biological complexes. claimed method includes application mirralgin balm analgesic, anti-inflammation resolving action, reventon balm, vessel restorative action, edema reducing microcirculation improving. process blepharoplastic eye boundary bandage microemulsion recovery animative action eaves skin applied, process facelifting cream mask bactericide, vessel restorative recovering action, enhancing local immunity applied. mirralgin balm reventon balm treatment carried sequentially alternatively. another embodiment skin cleaning treatment damaged zone anti-septic agent bacteriophage gel, disinfects skin surface, prevents biofilm forming, accelerates cicatrizing process applied, posttraumatic zone treated cleaning milk, toned tonic lotion cream mask bactericide, vessel restorative recovering action, enhancing local immunity applied. ^ effect: method skin structure recovering without skin trauma. ^ 4 cl, 7 ex, 1 tbl',\n",
              " 'strain bacterium lactobacillus lactis subspecies lactis tk-obl-lz-3f used detection lactococcus bacteriophagefield: dairy industry, microbiology. ^ substance: invention relates, particular, production fermented dairy foodstuffs. strain lactobacillus lactis subsp. lactis tk-obl-lz-3f used detection lactococcus bacteriophages provides prevention bacteriophages development dairy production dairy foodstuffs enhance quality safety production consumer health, promotes effectiveness manufacturing. ^ effect: valuable properties strain. ^ 1 ex',\n",
              " 'recombinant plasmid dna pa3gf coding polypeptide human granulocyte colony-stimulating factor, escherichia bacteria race coli-producer human granulocyte colony-stimulating factor polypeptidefield: gene engineering. ^ substance: invention used production recombinant polypeptide human granulocyte colony-stimulating factor. recombinant plasmid dna constructed vitro. includes synthetic gene human granulocyte colony-stimulating factor, strong constitutive promoter a3 early stage bacteriophage t7 synthetic section - translation enhancer (tren) gene 10 bacteriophage t7. dna combination high copy number plasmid optimisation cultivation conditions ensures constitutive biosynthesis target protein transformed dna race escherichia coli sgk25/pa3gf high yield. ^ effect: constitutive biosynthesis target protein cells; high yield. ^ 2 cl, 4 dwg, 7 ex',\n",
              " 'recombinant plasmid dna pif tren coding human polypeptide alfa-2b interferon polypeptide escherichia bacteria race coli-producer human alfa-2b interferonfield: gene engineering. ^ substance: invention relates gene engineering may used production recombinant polypeptide human alfa-2b interferon. recombinant plasmid dna constructed vitro. includes synthetic gene human alfa-2b interferon, tandem a2 a3 promoters early stage bacteriophage t7 synthetic section - translation enhancer. elements determine constitutive biosynthesis target protein transformed dna race escherichia coli sgk25 /pif tren high yield. ^ effect: high yield. ^ 2 cl, 5 dwg, 5 ex',\n",
              " 'recombinant fragmid dna phen-tab containing human single-strand antibody gene, capable binding human tumor necrosis factor alpha; recombinant escherichia coli bacteria strain producer human single-strand antibody human tumor necrosis factor alpha; recombinant soluble human single-strand antibody human tumor necrosis factor alphafield: gene engineering. ^ substance: recombinant fragmid dna phen-tab, containing unique human single-strand antibody gene selected constructed vitro combinatorial phage library udder controlling lactose operon promoter. escherichia coli hb2151 cells transformed obtained fragmid dna produce recombinant bacterium strain escherichia coli hb2151/phen-tab producer human single-strand antibody capable binding human tumor necrosis factor alpha. said antibody gas affinity constant kaf = 3.96±0.52x108 m-1. ^ effect: new soluble human single-strand antibody sctab human tumor necrosis factor alpha high affinity. ^ 3 cl, 6 dwg, 6 ex',\n",
              " 'recombinant plasmid dna pacyclans transfer expression gene encoding erwinia carotovora (ecar-lans) l-asparaginase escherichia coli cells method preparing recombinant ecar-lans biomass escherichia coli producer strainsfield: genetic engineering, biotechnology, molecular biology. substance: invention used medico-biological industry. invention proposes constructed recombinant plasmid (pacyclans) comprising natural sequence gene encoding l-asparaginase erwinia carotovora (ecar-lans) control promoter terminator phage t7 rna-polymerase encodes full-scale enzyme precursor signal peptide export protein periplam followed processing. strain- producers content recombinant l-asparaginase 8-12% prepared transformation strains e. coli indicated plasmid able synthesize phage t7 rna-polymerase. isolation purification enzyme biomass method involves disruption cells ultrasonic disintegration, fractionation ammonium sulfate chromatography column sp-sepharose ff. invention provides preparing purified l-asparaginase preparation high yield. effect: improved preparing method. 2 cl, 3 dwg, 1 tbl',\n",
              " 'recombinant plasmid dna pes3-7 encoding peptide sequence human granulocyte colony-stimulating factor (g-csf) strain escherichia coli bl21(de3)/pes3-7 producer human recombinant g-csffield: genetic engineering, particular production human granulocyte colony-stimulating factor. ^ substance: recombinant plasmid dna pes3-7 molecular weight 3.63 mda (5907 b.p.) constructed. said dna consists dna ndel/notl-fragment containing sequence recombinant g-csf artificial gene, beta-lactamase gene; plasmid pet22b(+) dna ndel/notl-fragment containing promoter terminator t-rna-polymerase transcription, amplifier 17 phage 10 gene translation. plasmid pes3-7 contains genetic marker beta-lactamase gene determines resistance e.coli cells transformed plasmid pes3-7 ampicillin, unique restriction endonuclease recognition sites existing next distance right ndel-site: xbal - 38 b.p.; hpal - 1332 b.p.; pstl - 4065 b.p.; pvul - 4190 b.p.; xhol - 5363 b.p. obtained plasmid used transformation escherichia coli cells produce strain e.coli bl21(de3)/pes3-7 subproducer recombinant g-csf. method present invention makes possible produce recombinant g-csf high yield (20-30 % based total cell protein content). ^ effect: simplified method production recombinant g-csf high yield. ^ 2 cl, 2 dwg, 2 ex',\n",
              " 'dna pcx-302 fragment encoding synthesis penicillium canescens secreted endo-(1-4)-beta-xylanase fungus strain penicillium canescens producer secreted endo-(1-4)-beta-xylanasefield: genetic engineering, microbiology, biochemistry, enzymology. substance: invention relates preparing dna (pcx-302) fragment encoding synthesis secreted endo-(1-4)-beta-xylanase based isolation genes penicillium canescens vkpm f-178 phage library. based isolated dna fragment recombinant plasmid ppcxyla constructed used transformation strain- -recipient penicillium canescens pca 10 (nia d-). result screening transformants multicopy strain p. canescens xyl-23 (vkpm f-832) producer enzyme secreted form obtained. culturing obtained strain pectin-containing medium beet pulp possible obtain 770 u activity endo-(1-4)- beta-xylanase per 1 ml cultural medium exceeds 6-7-fold enzyme yield using strain- recipient. invention used preparing enzyme endo-xylanase industrial scale. effect: increased yield enzyme. 2 cl, 2 dwg',\n",
              " 'recombinant plasmid dna pes4-4 encoding human polypeptide interferon alpha-2b strain escherichia coli brees4 producer recombinant human interferon alpha-2bfield: genetic engineering, molecular biology, biochemistry. ^ substance: method involves construction recombinant plasmid dna pes4-4 molecular mass 3.64 mda (5917 base pairs) consisting nde i/bam hi-fragment dna comprising sequence artificial gene recombinant human interferon alpha-2b, beta-lactamase gene nde i/bam hi-fragment plasmid pet22b(+)dna comprising promoter transcription terminator t7-rna polymerase, translation enhancer phage t7 gene 10. plasmid pes4-4 comprises beta-lactamase genetic marker determining resistance e. coli cells transformed plasmid ampicillin, unique recognition sites endonuclease restriction enzymes located following distance right site nde i: xba - 38 base pairs; hpa - 1332 base pairs; pst - 4065 base pairs; pvu - 4190 base pairs, xho - 5363 base pairs. escherichia coli cells transformed prepared plasmid strain e. coli bdees4 obtained super producer recombinant human interferon alpha-2b. invention provides preparing recombinant human interferon alpha-2b high yield simplified technology. invention used preparing recombinant human interferon alpha-2b. ^ effect: improved preparing method. ^ 3 cl, 2 dwg, 2 ex',\n",
              " 'recombinant plasmid dna p30ne2, encoding 181-amino acid n-terminal fragment glycoprotein e2 classical bog cholera virus providing expression thereof cellsfield: genetic engineering. ^ substance: recombinant plasmid dna p30ne2 contains dna fragment pasmid pqe30, including promoter/operator t5 phage; ribosome-binding site; phage lambda transcription terminator, beta-lactomase gene genetic marker, well bamhi/hindiii fragment, encoding 181-amino acid n-terminal fragment glycoprotein e2 classical bog cholera virus. plasmid provides expression glycoprotein e2 classical bog cholera virus e/coli bacteria cells. invention useful diagnostic investigation vaccine production. ^ effect: genetically engineered plasmid vaccine preparations. ^ 3 dwg, 6 ex',\n",
              " 'method differentiation parahemolytic vibria iii, iv, v morphogroups filamentous bacteriophages morphogroupfield: medical microbiology, diagnosis diseases caused gastro-enteritis parahemolytic vibria. ^ substance: claimed method includes application vibro parahaemoliticus km 97 vibro parahaemoliticus km 184 test strains, separately seeded martin broth 3 % nacl placed thermostat 4 h, 0.3 ml cultivated test strain slurry mixed 4.5 ml melted cooled 45°c 0.7 % martin agar 3 % nacl poured second layer plates solidified 1.5 % martin agar 3 % nacl petri dishes. solidification agar dried drop tested probe placed center dish cultured 37°c 24-48 hours. cultivated phages differentiated. namely: lysine presence test strain km 97 km 184 correlated bacteriophages parahemolytic vibria iii, iv, v morphogroups, lysis km 184 correlated filamentous bacteriophages morphogroup. ^ effect: simplified dependable method laboratory diagnosis. ^ 2 tbl, 3 ex',\n",
              " \"method identification cholera vibrio o1 serogroups biovars classical el torfield: medical microbiology.substance: invention refers medical microbiology, particularly laboratory diagnostics, used development new diagnostic preparations allowing identify cholera strains o1 serogroup biovars classical el tor. method provides using microbial lysability diagnostic phage agar medium. bacteriophage strain rostov-6 applied, applied form path surface petri dish filled prepared solution consisting analyzed culture, introduced martin's broth left thermostat 4 hours temperature 37 °c. specified amount mixture taken added 0.7 % melted cooled 45 °c marten agar. mixture mixed test tube circular motions quickly poured onto surface petri dish 1.5 % agar. evenly distributed surface allowed dry. drying, preparation coated drop bacteriophage rostov-6 preparation, inoculation incubated thermostat temperature 37 °c 24 hours. followed identification grown culture presence phagolysis zone, confirms presence cholera vibrio o1 serogroups biovars classical el tor absence.effect: invention allows increase degree authenticity identification cholera vibrio 01 serogroup classical el tor.1 cl, 1 dwg, 3 tbl, 3 ex\",\n",
              " 'bacteriophage strain helicobacter pylori lytic activity relation bacteria helicobacter pylori method production antigastritis antiulcer drug based samefield: medical virology microbiology. ^ substance: new bacteriophage strain helicobacter pylori, lytic activity disclosed. method production antigastritis antiulcer drug based new bacteriophage strain disclosed. claimed method includes providing purified suspension bacteriophage helicobacter pylori lytic activity 109 ffu/ml addition 1 % chinozole thereto. moreover sorbitole gelatose may introduced said agent. obtained mixture frozen lyophilized. ^ effect: high effective antigastritis antiulcer drug useful medicine. ^ 3 cl, 1 tbl, 2 ex',\n",
              " 'strain legionellosis bacteriophage niim active respect legionella pneumophila, legionella micdadei, legionella dumoffii legionella bozemaniifield: medicinal microbiology. ^ substance: invention used identifying pathogens legionellosis disease excreted patient body infected objects environment. strain legionellosis bacteriophage designated identification main species pathogens legionellosis disease, i. e. legionella pneumophila, l. micdadei, l. dumoffii l. bozemanii laboratory diagnosis legionellosis isolated organs laboratory animals infected type strain philadelphia-1 l. pneumophila deposited collection phages nii microbiology mo rf designation niim. using bacteriophage allows enhancing specificity carrying identification legionellosis pathogen infections. ^ effect: valuable properties strain. ^ 3 dwg',\n",
              " \"immunobiological bactericidal preparation (versions)field: medicine biologically active additives. ^ substance: according invention, immunobiological bactericidal preparation contains species-specific virulent bacteriophages induced-virulence bacteriophages appelman's lytic activity least 10-4 respect test strains bacteria isolates recovered human body filtrate, concentrate filtrate dry biomass phage lysate filtrate nonlysogenic bacteria pharmaceutically acceptable desired additives. preparation presented ointment, suppository, powder, tablet capsule. declared immunobiological bactericidal preparation prepared sequential multiple passages phages bacteriophage preparations test strains nonlysogenic bacteria isolates fresh-recovered human body inducing agent, eg mitomycin c, added nutrient medium. according invention, immunobiological bactericidal preparation provides stable virulence bacteriophages adaptation thereof circular agents bacterial infections. ^ effect: higher clinical effectiveness. ^ 13 cl, 9 tbl, 30 ex\",\n",
              " 'method reproduction brucellous bacteriophagefield: medicine microbiology, particular technology reproduction brucellous bacteriophage. ^ substance: brucellous bacteriophage bk2 reproduced liquid synthetic nutrient medium. nutrient medium used provide suspension growth strain reproduce bacteriophage. nutrient medium contains glucose additional carbon source, amino acids salts, additionally 10-2-10-3 calcium sulfate. method present invention allows ability increase final brucellous bacteriophage bk2 concentration wherein bacteriophage reproduced 48-72 h. ^ effect: brucellous bacteriophage reproduction increased bacteriophage concentration. ^ 3 ex',\n",
              " 'method preparing bacteriophages binding specifically target-cells designated therapeutic aimsfield: medicine, genetic engineering. ^ substance: invention proposes method involves construction bacteriophage library random peptides based oligonuleotide fragments encoding their, selection bacteriophages binding target-cells binding cells types involves pathological process able show effect diagnosis therapy, confirmation specificity selected bacteriophages using combination different tests. oligonucleotide fragments encoding random peptides prepared reaction reverse transcription using random primers total rnas isolated indicated target-cells cells types. applying invention provides preparing bacteriophages binding target-cells high degree selectivity. invention used diagnosis, therapy pharmaceutical industry. ^ effect: improved preparing method. ^ 3 cl, 2 dwg, 8 ex',\n",
              " 'method therapeutic prophylactic treatment streptoococcus infection (variants) composition designated applying (variants), lysine enzyme associated phage streptococcus group c active component pharmaceutical compositionfield: medicine, infectious diseases, pharmacy. ^ substance: invention relates composition comprising lysine enzyme associated phage streptococcus group c carrier delivery lysine enzyme associated phage streptococcus group c mouth, throat nose ducts mammal. composition shows high effectiveness prophylaxis therapeutic treatment streptococcus infection including infection known usually streptococcus pharyngitis. invention allows carrying treatment prophylaxis infections caused streptococcus group c infections groups c e high effectiveness. ^ effect: improved treatment method, valuable medicinal properties composition. ^ 57 cl, 3 tbl, 5 ex',\n",
              " 'strain bacteria burkholderia cepacia - avirulent producer bacteriophage, lysing originator glandersfield: medicine, microbiology. ^ substance: invention concerns medical microbiology concerns strain burkholderia cepacia, capable produce bacteriophage lysing culture originator glanders burkholderia mallei. strain deposited collections russian science research antiplague institute microbe, number burkholderia cepacia km 203 assigned it. strain virulent white mice golden hamsters, century cepacia possesses culture-morphological properties spectrum biochemical activity characteristics. ^ effect: obtaining strain burkholderia cepacia, capable produce bacteriophage lysing culture originator glanders burkholderia mallei. ^ 4 ex',\n",
              " 'method treatment ubeitis obscure viral etiologyfield: medicine, ophthalmology. ^ substance: method involves intramuscular administration galavite dose 0.1 g, per day 5 days, 6 10 days - every day, gentamycin dose 80 mg, 3 times per day 7 days, bifidum - liquid bacteriophage 791 series production firm \"vektor\" dose one-half flask, 2 times per day, one-half hour eating, wobenzym given dose 5 tablets, 3 times per day 3 weeks dose 3 tablets, 3 times per day 3 weeks. method provides eliminating main clinical symptoms diseases based transient suppression hyperactivity lipopolysaccharides cell membrane, decreasing level tnf-alpha, il-1 anti-inflammatory cytokines increasing activity microbiocid system neutrophile granulocytes. invention used treatment uveitis obscure viral etiology. ^ effect: improved method treatment. ^ 3 ex',\n",
              " 'bacteriophage-containing pharmaceutical composition method preparingfield: medicine, pharmaceutical industry, pharmacy. ^ substance: invention relates method preparing medicinal formulations bacteriophages. pharmaceutical composition contains bacteriophages filling agent dosed medicinal formulations contains additionally water-soluble polymers sugars. derivatives cellulose, low- mean-molecular polyvinylpyrrolidones, polyethylene glycols molecular mass 4 000-6 000 da, sodium alginate used water-soluble polymers; lactose and/or mannitol used sugars; carboxymethylcellulose sodium salt hydroxypropylmethylcellulose, hydroxypropylcellulose used derivatives cellulose. pharmaceutical composition contains substances following ratio components, wt.-%: bacteriophages titer appelman, 10-4, less; calcium carbonate, 70.0-85.0; lactose and/or mannitol, 5.0-15.0; carboxymethylcellulose sodium salt, 0.1-10.0; microcrystalline cellulose, 2.0-8.0; carboxymethyl starch, 1.0-4.0; magnesium calcium stearate, 0.25-1.0. pharmaceutical composition made tablet mass 0.1 g gastric-resistance coating. invention claims method preparing indicated composition wherein synthetic water-soluble polymers added phagolysate drying additionally, sugars added filling agent phagolysate drying carried vacuum humidity value 1-2%. ^ effect: improved preparing method, enhanced stability composition. ^ 4 cl, 3 ex',\n",
              " 'biological preparation neutralising spores vegetative cells bacillus anthracisfield: medicine, pharmaceutics. ^ substance: invention refers biotechnology represents disinfectant preparation neutralising spores vegetative cells bacillus anthracis, representing aqueous solution containing mixed bacteriophages bacillus anthracis ozr-1, bacillus anthracis f-2, bacillus anthracis \"ñé\" activity relation (pfu/cm3) bacillus anthracis ozr-1: bacillus anthracis f-2: bacillus anthracis \"ñé\" = 1: (0.2-1): (0.1-1). spore germination activator l-alanine. ^ effect: invention provides prolonged disinfecting action safe. ^ 2 cl, 5 ex',\n",
              " 'recombinant plasmid dna pqe-p35d providing synthesis p35d recombinant protein cowpox virus, escherichia coli bacterial strain producer p35d recombinant protein cowpox virus, p35d recombinant protein cowpox virus used engineer test systems prepare orthopoxvirus split vaccinesfield: medicine, pharmaceutics.substance: invention refers biotechnology concerns preparing genetic construct providing synthesis p35d recombinant protein escherichia coli cells. presented: recombinant plasmid dna pqe-p35d providing synthesis p35d recombinant protein cowpox virus containing accordance physical genetic map presented fig. 2: pqe30 plasmid vector, fragment coding mrgshhhhhhg oligopeptice fragment 17 base pairs, coding fragment p35 protein cowpox virus within 1 239 amino acid residues (fig.1a); escherichia coli xl1blue/pqe-p35d b-1252 bacterial strain producer p35d recombinant protein cowpox virus, containing recombinant plasmid dna pqe-p35d deposited collection bacteria, bacteriophages fungi fbun gnts vb vector, registration no. b-1252, p35d recombinant protein cowpox virus.effect: solutions may used engineer test systems prepare orthopoxvirus split vaccines.3 cl, 7 dwg, 5 ex',\n",
              " 'recombinant plasmid ppa-oprfi dna coding hybrid recombinant f-i protein pseudomonas aeruginosa outer membrane, strain escherichia coli pa-oprfi producing hybrid recombinant f-i protein pseudomonas aeruginosa outer membrane method producing hybrid recombinant f-i protein pseudomonas aeruginosa outer membranefield: medicine, pharmaceutics.substance: invention refers biotechnology concerns recombinant plasmid ppa-oprfi dna coding hybrid recombinant f-i protein pseudomonas aeruginosa outer membrane, bacterial strain e.coli pa-oprfi producing hybrid protein, method producing recombinant protein. presented plasmid dna contains dna fragment containing sequence modified promoter bacteriophage t5 two lactose operons; dna fragment containing ribosome entry site, initiation atg-codon sequence coding six histidines; dna fragment containing full-size sequences oprf opri genes p.aeruginosa; dna fragment containing ribosome entry site, dna fragment containing lambda ttranscription stop region.effect: presented inventions enables producing hybrid recombinant f-i protein paeruginosa outer membrane carrying immunobiological assay developing pseudomonas aeruginosa vaccine, producing donor immunoglobulins therapy active forms paeruginosa infection.3 cl, 3 dwg, 1 tbl, 4 ex',\n",
              " 'pharmaceutical composition treating eye infections p. aeruginosa containing recombinant lysozymefield: medicine, pharmaceutics.substance: invention refers biotechnology medicine concerns pharmaceutical composition. presented composition contains recombinant lysozyme fmv p. aeruginosa bacteriophage, ethylene diamine tetraacetate trishcl following proportions, wt %: lysozyme 0.001; trishcl 0.68; ethylene diamine tetraacetate 0.049; water - rest.effect: characterised invention used treating infections caused pseudomonas aeruginosa possesses immediate action side effects.4 tbl, 1 ex',\n",
              " \"antibacterial agentfield: medicine, pharmaceutics.substance: invention refers biotechnology bacteriophagues. antibacterial agent contains bacteriophage concentrate, preserving agent, except related quaternary ammonium derivatives, heavy metal derivatives, oxidising agents, bromine iodine-containing, formaldehyde-releasing preserving agents, water, gelling agent form non-ionic anionic high-molecular compound, non-ionic surfactant ph adjustor following ratio, wt %: bacteriophage concentrate appelman's lytic activity min. 10for type bacteriophague - 0.001-10.0; gelling agent - 0.05-15.0; surfactant - 0.001-2.0; preserving agent - 0.05-0.6; ph adjustor 6.0-8.0; water 100.0.effect: extended range products containing bacteriophages basic active ingredient, provided biological stability activity bacteriophages composition product; composition possess low risk toxicity side effects, provides storage stability efficacy within wide range temperatures.11 cl, 15 ex\",\n",
              " 'specific high-affinity binding proteins containing modified sh3-domains fyn kinasefield: medicine, pharmaceutics.substance: present invention refers biotechnology may used medicine, particularly oncology. presented method creating library recombinant proteins presented src loop rt loop mutant forms sh3 domain, used produce library phage display containing 1 bln mutant derivatives natural sequence sh3-domain given enzyme. result screening derived library presence recombinant proteins binding ligand concern, protein produced characterised high affinity binding extra domain b fibronectin. new protein used construct fused proteins, well chemical derivatives along fused protein invention, contain pharmaceutically and/or diagnostically active ingredients.effect: presented various versions application new binding protein derivatives diagnostic therapeutic agents, particularly applied diagnosing treating malignancies.28 cl, 1 tbl, 17 dwg, 6 ex',\n",
              " 'method tuberculosis phagotherapyfield: medicine, phthisiology. substance: method involves using regionary lymphogenic delivery lipisomal form mycobacteriophage d29. invention promotes enhancement therapeutic effect phagotherapy reduction toxicity phage preparation. invention used phagotherapy tuberculosis. effect: improved method therapy. 1 dwg',\n",
              " 'method treating postoperational abscesses abdominal cavityfield: medicine, purulent surgery. ^ substance: one perform generally accepted medicinal therapy, moreover, one prescribe additional chemotrypsin first 1-2 operation locally injected twice-thrice day-time period concentration 0.5-1.0 mg/ml 10%-sodium chloride solution exposure 1.5-2 h quantity one fourth one third purulent volume removed abscess cavity, therapy course supplemented bacteriophage locally injected twice day-time period daily dosage 200 ml, exposure 1.5-2 h quantity one tenth one fifth purulent volume removed abscess cavity. bacteriophage type, matched accordance results bacteriological survey abscess cavitary content. therapy course lasts 6-9 d. ^ effect: higher efficiency therapy. ^ 2 ex',\n",
              " 'method detecting sensitivity microorganisms liquid combined bacteriophagefield: medicine, surgery. ^ substance: whole wound detritus diluted physiological solution homogenized centrifuged depositing large-scale particles wound detritus. necessary determine sensitivity obtained supernatant liquid combined bacteriophage 18-24 h due interacting liquid combined bacteriophage upon nutritive medium. innovation provides chance earlier onset purposeful bacteriophagotherapy enables shorten terms investigation. ^ effect: higher accuracy efficiency detection. ^ 2 ex',\n",
              " 'immunobiological antiallergic agent (versions) lactobacillus acidophilus 100 \"ê\" pa strain used production immunobiological antiallergic agentfield: medicine. ^ substance: according invention, versions immunobiological antiallergic agent contain lactobacillus acidophilus 100 \"ê\" pa strain, collection no. 207, stored state collection microorganisms normal microflora federal state research institution gabrichevskiy moscow research institution epidemiology microbiology federal service supervision consumer rights human welfare culture medium amount 106-1010 cfu/ml. immunobiological antiallergic agent additionally contains species-specific virulent bacteriophages bacteriophages induced virulence, biomass lactobacillus acidophilus \"ü¿4\" strain culture medium amount 106-1010 cfu/ml, biomass lactobacillus acidophilus nki strain culture medium amount 106-1010 cfu/ml biomass bifidobacterium bacteria culture medium amount 106-1010 cfu/ml. immunobiological antiallergic agent additionally contains target additives amount 0.01-95.0 wt % mass agent. additives selected number of: glycine, cysteine, copper sulphate, copper gluconate, quinosol, chitosan, licorice root extract, hips extract, origanum extract, cranberry extract flavouring agent. immunobiological antiallergic agent presented form suspension. lactobacillus acidophilus 100 \"ê\" pa strain produced means sequence multiple passages nutrient medium mpc added sources histamine, cu1+, cu2+, co2+, ni2+ ions culture ph 6.2-7.4. agent used prevention treatment allergic pseudo-allergic disease without accompanying pathology combination infectious disease, intestinal dysbacteriosis psychological adaptation disorders. ^ effect: efficient antiallergic action immunobiological agent basis lactobacilli. ^ 10 cl, 3 tbl',\n",
              " 'bacteriophage antibacterial agent selective effectfield: medicine. ^ substance: antibacterial agent selective effect contains action bacteriophage concentrate, herbal extract, stabilising additive, essence, antioxidant, preservative agent prebiotics required normal flora development - amino acid sugar, well sorbent protein-degrading enzyme desired component ratio. ^ effect: extended range ecologically safe high-effective antibacterial agents. ^ 5 cl, 2 tbl, 4 ex',\n",
              " 'bacteriophage escherichia coli v32 strain identification escherichia coli bacteria serogroup o157field: medicine. ^ substance: bacteriophage escherichia coli v32 strain deposited collections museum microorganisms federal state intuition science state science centre applied microbiology biotechnology, no. ph25 specific virulent bacteriophage, used option identification escherichia coli bacteria serogroup o157 stage bacterial colony analysis. ^ effect: simple available product requiring heavy time material consumption. ^ 1 dwg, 4 ex',\n",
              " 'device way applying active substances wound surfacefield: medicine. ^ substance: device contains wad porous material applying wound surface, encapsulating top layer overlapping surfaces wound wad fixed skin surface, least one feeding line going wad liquid active substance, one controlled locking element, controls adjustable locking element, least one taking away line going wad connected source vacuum. controls control locking elements time. liquid active substance contains bacteriophages. pump controlled pressure included feeding line. wad encapsulating top layer gauges change concentration bacteriophages, ph temperatures adjustment duration influence placed. method applying active substances containing bacteriophages discovered. ^ effect: invention provides effective treatment wounds. ^ 8 cl, 1 dwg',\n",
              " 'method producing recording marked bacteriophages cholera germ modelfield: medicine. ^ substance: donor strain producing isotope-marked bacteriophage pre-recovered lysogenic strain v.cholerae eltor 1 concentration n108 pfu/ml produced added 5 mcc/ml isotope 3h-thymidine, kept one day thermostat 37c produce marked cholera phage. latter introduced amount 1 ml test tube indicator recipient strain ratio 1:1 lysogenisation, incubated 37c within one day; 0.1 ml derived mixture seeded agar plate, grown 37c within 20-24 hours, donor strain recovered. residual portion mixture used record radioactivity bacteriophage recipient strain. positive result shown radioactivity marked bacteriophages within range 475-1269 p/min, recipient strains within range 78-103 p/min. ^ effect: invention allows higher efficiency detection recording cholera phage 3h-thymidine marked cholera germ cell. ^ 3 tbl, 4 ex',\n",
              " \"oral composition containing nonpathogenic microorganisms showing ability normalise intestinal microflora (versions)field: medicine. ^ substance: group inventions refers pharmaceutical industry medicine applicable producing using medical immunobiological preparations containing nonpathogenic microorganisms. compositions (versions) represent powder containing substances containing nonpathogenic microorganisms dried culture medium specified number: bifidobacterium bacteria and/or lactobacillus bacteria, and/or species-specific virulent bacteriophages, and/or species-specific bacteriophages induced virulence combinations composition containing target additives able form stable foam structure, characterised porous structure fragility, relative disintegration shrinkage least 10 %, equivalent pore diameter 10-110 mcm particle size 100 mcm resting angle less 50 following proportions 1.0 g composition: bifidobacterium bacteria 106-1010 cfu and/or lactobacillus bacteria 106-1010 cfu, and/or species-specific virulent bacteriophages appelman's lytic activity least 10-4 respect test strains bacterial isolates recovered human body, and/or species-specific bacteriophages induced virulence appelman's lytic activity least 10-4 respect test strains bacterial isolates recovered human body, target additives - rest. ^ effect: invention provides maximally achieved isotropic filling set volume drug containers provides accurate dosage nonpathogenic microorganisms. ^ 7 cl, 9 ex\",\n",
              " 'method screening phage display libraryfield: medicine. ^ substance: invention used obtaining diagnostic and/or therapeutic agents, particular antibodies, specifically interact proteins cell surface target cells. claimed method screening phage display library including method isolation library element, specific partner binding target cell surface protein, method isolation unknown cell surface protein, specifically interacting library element. method screening phage display library according invention includes contact said library cells interest separation cells, bound one several elements expression library, non-bound elements separation organic phase, differs introduction additional stage, consists carrying said separation least one stage material washing, ensures essential increase method efficiency. ^ effect: higher efficiency. ^ 30 cl, 7 dwg, 6 ex',\n",
              " 'yersinia enterocolitica bacteria strain used indicator culture detecting moderate bacteriophages lysogenic strains o1, o3, o12 serovarsfield: medicine. ^ substance: invention used laboratory diagnostics yersinia enterocolitica strains using moderate bacteriophages fk-99, fk-100, fk-101 intraspecific differentiation yersiniosis agent. yersinia enterocolitica 2012 strain recovered human 1966 deposited state collection pathogenic bacteria russian research antiplague institution \"microbe\", no. km-206. used mentor strain, enables particle concentration phage preparations equal n10-n10 particles/ml. ^ effect: use recovered phages yersinia enterocolitica indicator km-206 offered invention provides additional differentiation lysogenic cultures non-lysogenic ensures effectiveness laboratory diagnostics yersinia enterocolitica. ^ 1 tbl, 1 ex',\n",
              " 'method prevention bucket-handle graft plastics complicationfield: medicine. ^ substance: invention concerns medicine, namely surgery, used application fields bucket-handle graft plastics. cellulocutaneous flap cut form bucket-handle graft. suturing, tubular fenestrated drainage inserted edges formed bucket-handle graft additional vertical incision length 3-4 mm. along whole length draining part drainage, spiral holes 4ù3 mm. postoperative period, within four-six days graft irrigated either antiseptics, antibiotics, bacteriophages. drainage removed. ^ effect: application invention provides continuous outflow wound discharge allows reducing potential edema infection graft improving blood supply. ^ 1 dwg, 2 ex',\n",
              " \"bacteriophage composition (versions)field: medicine. ^ substance: invention concerns pharmaceutical industry, food industry, bioengineering used manufacturing medical immunobiological preparations, biologically active additives food additives. invention represents versions bacteriophage composition contain species-specific virulent bacteriophages induced-virulence bacteriophages appelman's lytic activity 10-4 respect test strains bacteria isolates recovered human body phage lysate filtrate nonlysogenic bacteria phage lysate concentrate filtrate nonlysogenic bacteria, desired additives. ^ effect: invention provides stable virulence bacteriophages, adaptation thereof circular agents bacterial infections. ^ 6 cl, 2 tbl\",\n",
              " 'method treating babies suffering intestinal colicsfield: medicine. ^ substance: invention refers medicine, aims treating babies suffering intestinal colics. mother breast-fed child treated simultaneously. cephalosporin antibiotic, antistaphylococcal immunoglobulin, staphylococcal bacteriophage, antifungal agent, phagocytosis activator prescribed mother 7-10 days. staphylococcal bacteriophage, hylak forte prescribed baby. second stage involves prescribing bacterial preparation, immunomodulator therapeutic staphylococcal anatoxin. baby intakes hylak forte bacterial preparation. ^ effect: method allows relieving intestinal colics preventing development complications. ^ 1 ex',\n",
              " 'method treating chronic bacterial conjunctivitisfield: medicine. ^ substance: invention refers medicine, namely ophthalmology, concerns treating chronic bacterial conjunctivitis. ensured bacteriophage instillations conjunctival cavity considering drug sensitivity bacterial flora. combined nasolacrimal duct irrigation first 3-4 days bacteriophage preparation, injected nasal passages used irrigate pharyngeal mucosa. therapy within 10 days, least 5 times day. ^ effect: method provides reduction symptoms bacterial conjunctivitis 3-4th day treatment, decreased number recurrences due simultaneous sanitation reservoirs bacterial infection. ^ 2 ex',\n",
              " 'preparation containing staphylococcal bacteriophage, preparation candidiasis treatmentfield: medicine. ^ substance: invention refers medicine, particularly antimycotic preparation. application preparation containing staphylococcal bacteriophage virulent bacteriophage induced-virulence bacteriophage specified lytic activity relation test strains staphylococcus isolates recovered human body preparation candidiasis treatment administered orally 2-3 times day within 4-7 days. ^ effect: said preparation effective candidiasis treatment. ^ 3 ex',\n",
              " 'recombinant plasmid dna per-hir coding hybrid protein capable autocatalytic breakdown form [leul, thr2]-63-desulphatohirudin, escherichia coli er2566/per-hir strain - producer said protein method producing genetically engineered [leul, thr2]-63-desulphatohirudinfield: medicine. ^ substance: invention refers recombinant plasmid dna per-hir coding hybrid protein capable autocatalytic breakdown form [leul, thr2]-63-desulphatohirudin, escherichia coli er2566/per-hir strain - producer said protein method producing genetically engineered [leu 1, thr2]-63-desulphatohirudin. presented recombinant plasmid dna consists sapi/bamhi fragment dna plasmid ptwin-1 containing promoter terminator t7-rna-polymerase transcription, amplifier phages t7 gene 10 translation, -laktamase (ap) gene, modified mini-intein ssp dnab gene, integrated sequence chitin-binding domain, sapi/bamhi-fragment dna containing sequence gene recombinant [leul, thr2]-63-desulphatohirudin-1 containing -laktamase (ap) gene genetic marker, unique recognition sites restriction endonucleases located following distance left site bamhi: nrul - 186 base pairs, ndel - 594 base pairs, xbal - 882 base pairs, ecorv - 2913 base pairs, hpal - 2966 base pairs. ^ effect: inventions allow producing said compound used drug applied prevent blood hypercoagulation. ^ 3 cl, 1 dwg, 4 ex',\n",
              " 'method obtaining remedy fly larvae wound treatment remedy obtained said methodfield: medicine. ^ substance: invention relates field medicine, namely remedy method obtaining remedy wound treatment. method obtaining remedy wound treatment lies following: fly eggs larvae gown, introduced wound treatment, larvae contaminated bacteriophages way introduced larvae bacteriophage carriers. order realising said method, particular, larvae genus lucilia used. claimed method remedy wound treatment, tampon containing bacteriophages soaked larva secret wound. ^ effect: treatment wounds fly larvae improved contamination larvae bacteriophages. ^ 14 cl',\n",
              " 'method post-operation treatment patients open trauma ankle jointfield: medicine. ^ substance: invention relates field medicine, namely traumatology applied treatment patients open fractures ankle joint area. cadaver fibrinolytically active plasma (fap), antibiotics polyvalent phages introduced ankle joint means microirrigator passed anterior joint surface unaffected skin opposite side wound. fap, activity 1500-2000 mu introduced first three days, earlier 10 hours operation, 2 times per day amount 5.0 ml following 2-3 days -1 time per day. bandaging antibiotics phages introduced ankle joint 1 time per day 5-6 days therapeutic dose. ^ effect: method allows reducing number deep purulent complications. ^ 3 cl, 2 ex, 10 dwg',\n",
              " \"left ventricle diastole malfunction severity level diagnosis patients chronic cardiac failurefield: medicine. ^ substance: invention relates medicine, namely cardiology. echocardiography used value parameters e/a, dt, ivrt (tmd) s/d spectra rest load doppler's testing - degree decline e / height valsalva test (e/a vals), diastolic left ventricle (lv) reserve altitude isometric (dr isom) cold (dr cold) loads. used determine ejection fraction value lv end diastolic volume index left right ventricles, myocardial mass meet certain rules, certain differential diagnostic phage (ddp) stage set. method allows increase accuracy identifying patients initial (stage ddp), frank diastole malfunctions, clearly distinguishing patients normal tmd spectrum patients pseudo-normalisation (stage ii ddp), determining degree lv malfunction patients chronic cardiac failure. ^ effect: diagnosis accuracy increasing patients icp. ^ 1 dwg, 5 tbl, 4 ex\",\n",
              " 'sextaphage (pyobacteriophage polyvalent) bacteriophage salmonellous pharmaceutical composition method producing thereoffield: medicine. ^ substance: invention represents pharmaceutical composition containing bacteriophage (sextaphage« (pyobacteriophage polyvalent)) bacteriophage salmonellous groups a, b, c, d, e) dried excipients (methyl cellulose, lactose, calcium carbonate, calcium magnesium stearate) form gastric-resistant uncoated tablets, differing fact relation parity bacteriophage excipients makes 1:1 1.25:1, composition contains addition - sorbite sodium alginate. one tablet weight 0.16-0.2 g contains bacteriophages appelman titre less 10-3, ingredients components certain ratio, wt %. ^ effect: higher gastric resistance tablets stabilisation bacteriophages. ^ 2 cl, 3 ex',\n",
              " 'method preparing fine-dispersed mycobacteria cell culture sensitive mycobacteriophage infectionfield: medicine. ^ substance: method preparing fine-dispersed mycobacteria cell cultures sensitive mycobacteriophage infection involves primary cultivation mycobacteria nutrient medium nonionic detergent either tween 80, tween 20, span 85 amount 0.25-0.5 wt %, and/or ionogenic detergent sodium lauroyl sarcosinate within 0.01-0.03 wt %. one reinoculation, cultivation carried without detergent. herewith throughout entire cycle, mycobacteria cell cultivation enabled nutrient medium containing, g/l: trypton - 15, yeastrel - 5, glucose - 40, sodium chloride - 2.5, potassium hydrophosphate - 5, calcium chloride - 0.111. ^ effect: higher dose accuracy fine-dispersed cell mass combined bacteriophage infection large quantity sampled cell mass reduced work content process. ^ 8 ex',\n",
              " 'virus-like particles including hybrid protein ap205 bacteriophage coat protein antigen polypeptidefield: medicine. ^ substance: modified virus-like particle (vlp) includes hybrid protein consists ap205 bacteriophage protein antigen. also, composition including vlp, derivative rna-containing ap205 bacteriophage described. besides, invention describes method producing said vlp. modified vlp present invention applicable producing compositions inducing immune response prevention treatment diseases, disorders, including infectious diseases, allergies, cancer drug addiction. ^ effect: offered group inventions used medicine, immunology, virology molecular biology. ^ 35 cl, 3 dwg, 1 tbl, 26 ex',\n",
              " 'immunomimetic peptide chemical cancerogens specific interaction effect antibodies benzo[]pyrene benzo[]anthracenefield: medicine. ^ substance: peptide obtained phage peptide library including set static peptides length 12 aminoacid residues, affine selection phage clones containing peptide capable specific linking antibodies benzo[]pyrene benzo[]anthracene. peptide displays specific interaction effect antibodies benzo[]pyrene benzo[]anthracene features molecular weight 1.3 kda registered aminoacid sequence lhlphhdgvgwg encoded nucleotide sequence seq id no:1. ^ effect: application medicine base peptide medicine development immunologic prevention malignant tumours humans. ^ 4 dwg, 3 ex',\n",
              " 'recombinant plasmid, escherichia coli strain, chimeric protein applicationfield: medicine. ^ substance: recombinant plasmid pcfp10-cbd consisting artificial bacterial operon chimeric protein containing promotor area early promotor bacteriophage t5, chimeric protein gene transcription terminator, bacterial operon beta-lactamase bacterial colel-type replication initiation site described. invention involves escherichia coli strain - producer chimeric protein cfp10-cbd, method immobilisation, concentration cellulose purification produced protein. besides, invention refers recombinant protein cfp10-cbd immunogenic composition containing used tuberculous infection immunity induction. ^ effect: invention allows producing strain - producer providing high production level resistant immunogenic proteins one-stage produced, immobilised purified, producing effective immunogenic compositions tuberculosis. ^ 5 cl, 1 dwg, 4 ex',\n",
              " ...]"
            ]
          },
          "metadata": {},
          "execution_count": 20
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "UK9v8v9iSZKh"
      },
      "outputs": [],
      "source": [
        "def lemmatization (texts, allowed_postags=['NOUN','ADJ','VERB']):\n",
        "    texts_out = []\n",
        "    for text in texts:\n",
        "        doc = nlp(text)\n",
        "        new_text = []\n",
        "        for token in doc:\n",
        "            if token.pos_ in allowed_postags:\n",
        "                new_text.append (token.lemma_)\n",
        "        final = \" \".join(new_text)\n",
        "        texts_out.append (final)\n",
        "    return (texts_out)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "UiT1-qgKSZNY"
      },
      "outputs": [],
      "source": [
        "txt = lemmatization (txt)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "PDzd9JvsiwXt"
      },
      "outputs": [],
      "source": [
        "# Tokenization\n",
        "def tokenize (texts):\n",
        "    tokens = [word for word in nltk.word_tokenize(texts) if len(word) > 2]\n",
        "    return tokens"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "k8L0qBHdiwYz"
      },
      "outputs": [],
      "source": [
        "tok = []\n",
        "for item in txt:\n",
        "  tok.append (tokenize (item))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "j8C04E9eiwck"
      },
      "outputs": [],
      "source": [
        "vectorizer_tf = TfidfVectorizer (tokenizer=tokenize, stop_words='english', max_df=0.75, min_df=50,  use_idf=False, norm=None) #max_features=10000,"
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "yV59G7XQGGng"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#df"
      ],
      "metadata": {
        "id": "pVXNaQzIMZ6k"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "QEVoazI2iwjV",
        "outputId": "91b2011d-8709-4432-b0b8-c7c256e23663"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/sklearn/feature_extraction/text.py:528: UserWarning: The parameter 'token_pattern' will not be used since 'tokenizer' is not None'\n",
            "  warnings.warn(\n"
          ]
        }
      ],
      "source": [
        "df1 = pd.DataFrame(data={'Text':txt})\n",
        "tf_vectors = vectorizer_tf.fit_transform (df1['Text'])"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#data.to_frame()"
      ],
      "metadata": {
        "id": "hDGmlg_ZPHi2"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df1"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 423
        },
        "id": "ssM423WKO_ud",
        "outputId": "0c3f86d7-8169-474b-bc6a-079903e7a059"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                                   Text\n",
              "0     new mutant anti - idiotypic antibody fragment ...\n",
              "1     pan method utilize photoreactive group kit pro...\n",
              "2     phage display novel filamentous bacteriophage[...\n",
              "3     method monitor bacterium utilize chitinous sub...\n",
              "4     method control insect pest alginate microbead ...\n",
              "...                                                 ...\n",
              "5103  system prepare sample identify least bacteriop...\n",
              "5104  test determine antimicrobial biological activi...\n",
              "5105  parenteral use bacterial phage associate lyse ...\n",
              "5106  use bacterial phage associate lyse enzyme prop...\n",
              "5107                 use bacteriophage control soft rot\n",
              "\n",
              "[5108 rows x 1 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-707e4931-efda-4c9b-930b-636c5237b4ef\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>new mutant anti - idiotypic antibody fragment ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>pan method utilize photoreactive group kit pro...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>phage display novel filamentous bacteriophage[...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>method monitor bacterium utilize chitinous sub...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>method control insect pest alginate microbead ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5103</th>\n",
              "      <td>system prepare sample identify least bacteriop...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5104</th>\n",
              "      <td>test determine antimicrobial biological activi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5105</th>\n",
              "      <td>parenteral use bacterial phage associate lyse ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5106</th>\n",
              "      <td>use bacterial phage associate lyse enzyme prop...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5107</th>\n",
              "      <td>use bacteriophage control soft rot</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>5108 rows × 1 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-707e4931-efda-4c9b-930b-636c5237b4ef')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-707e4931-efda-4c9b-930b-636c5237b4ef button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-707e4931-efda-4c9b-930b-636c5237b4ef');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-232b3054-5a90-4fa8-b683-d5fbff262bbf\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-232b3054-5a90-4fa8-b683-d5fbff262bbf')\"\n",
              "            title=\"Suggest charts.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-232b3054-5a90-4fa8-b683-d5fbff262bbf button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ]
          },
          "metadata": {},
          "execution_count": 29
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "R9lXQcfWiwlA"
      },
      "outputs": [],
      "source": [
        "import pickle\n",
        "with open('/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/vectorizer_tf_patent.pk', 'wb') as f:\n",
        "     pickle.dump(vectorizer_tf, f)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "twrDwj6Ciwph"
      },
      "outputs": [],
      "source": [
        "import scipy.sparse\n",
        "scipy.sparse.save_npz('/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/tf_vectors_patent.npz', tf_vectors)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "C3lUbC4Gj5ju"
      },
      "outputs": [],
      "source": [
        "# Save this model with 20 topics:\n",
        "import pickle\n",
        "with open(\"/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/vectorizer_tf_patent.pk\",\"rb\") as f:\n",
        "    vectorizer_tf = pickle.load (f)\n",
        "\n",
        "import scipy.sparse\n",
        "tf_vectors = scipy.sparse.load_npz('/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/tf_vectors_patent.npz')"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "fIjl8SpElpzg"
      },
      "source": [
        "# Finding the Best Number of Topics"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "yu-J05OOj5k-",
        "outputId": "a3e6be01-58a1-4497-b065-eb332317d31b"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: tmtoolkit in /usr/local/lib/python3.10/dist-packages (0.12.0)\n",
            "Requirement already satisfied: numpy<2.0,>=1.23.0 in /usr/local/lib/python3.10/dist-packages (from tmtoolkit) (1.23.5)\n",
            "Requirement already satisfied: scipy<2.0,>=1.7.0 in /usr/local/lib/python3.10/dist-packages (from tmtoolkit) (1.11.2)\n",
            "Requirement already satisfied: globre<0.2,>=0.1.5 in /usr/local/lib/python3.10/dist-packages (from tmtoolkit) (0.1.5)\n",
            "Requirement already satisfied: pandas<3.0,>=1.4.0 in /usr/local/lib/python3.10/dist-packages (from tmtoolkit) (1.5.3)\n",
            "Requirement already satisfied: xlrd>=2.0.0 in /usr/local/lib/python3.10/dist-packages (from tmtoolkit) (2.0.1)\n",
            "Requirement already satisfied: openpyxl<4.0,>=3.0.0 in /usr/local/lib/python3.10/dist-packages (from tmtoolkit) (3.1.2)\n",
            "Requirement already satisfied: matplotlib<4.0,>=3.5.0 in /usr/local/lib/python3.10/dist-packages (from tmtoolkit) (3.7.1)\n",
            "Requirement already satisfied: bidict<1.0,>=0.21.0 in /usr/local/lib/python3.10/dist-packages (from tmtoolkit) (0.22.1)\n",
            "Requirement already satisfied: wheel<1.0,>=0.40 in /usr/local/lib/python3.10/dist-packages (from tmtoolkit) (0.41.2)\n",
            "Requirement already satisfied: contourpy>=1.0.1 in /usr/local/lib/python3.10/dist-packages (from matplotlib<4.0,>=3.5.0->tmtoolkit) (1.1.0)\n",
            "Requirement already satisfied: cycler>=0.10 in /usr/local/lib/python3.10/dist-packages (from matplotlib<4.0,>=3.5.0->tmtoolkit) (0.11.0)\n",
            "Requirement already satisfied: fonttools>=4.22.0 in /usr/local/lib/python3.10/dist-packages (from matplotlib<4.0,>=3.5.0->tmtoolkit) (4.42.1)\n",
            "Requirement already satisfied: kiwisolver>=1.0.1 in /usr/local/lib/python3.10/dist-packages (from matplotlib<4.0,>=3.5.0->tmtoolkit) (1.4.5)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.10/dist-packages (from matplotlib<4.0,>=3.5.0->tmtoolkit) (23.1)\n",
            "Requirement already satisfied: pillow>=6.2.0 in /usr/local/lib/python3.10/dist-packages (from matplotlib<4.0,>=3.5.0->tmtoolkit) (9.4.0)\n",
            "Requirement already satisfied: pyparsing>=2.3.1 in /usr/local/lib/python3.10/dist-packages (from matplotlib<4.0,>=3.5.0->tmtoolkit) (3.1.1)\n",
            "Requirement already satisfied: python-dateutil>=2.7 in /usr/local/lib/python3.10/dist-packages (from matplotlib<4.0,>=3.5.0->tmtoolkit) (2.8.2)\n",
            "Requirement already satisfied: et-xmlfile in /usr/local/lib/python3.10/dist-packages (from openpyxl<4.0,>=3.0.0->tmtoolkit) (1.1.0)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.10/dist-packages (from pandas<3.0,>=1.4.0->tmtoolkit) (2023.3.post1)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.7->matplotlib<4.0,>=3.5.0->tmtoolkit) (1.16.0)\n"
          ]
        }
      ],
      "source": [
        "!pip install tmtoolkit"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "pJO2fZUIluMQ"
      },
      "outputs": [],
      "source": [
        "import tmtoolkit\n",
        "from tmtoolkit.topicmod.evaluate import metric_coherence_gensim\n",
        "from statistics import mean\n",
        "from sklearn.metrics import jaccard_score"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "tAk1XHTrluNz",
        "outputId": "47b7a364-92c1-4a1d-811f-4253d9476730"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "num_topic:  5 Coherence:  0.3108665230505656 Jaccard:  0.5289914192228857 Perplexity:  17984.236646838803\n",
            "num_topic:  6 Coherence:  0.32087704024081715 Jaccard:  0.4615886832606044 Perplexity:  22207.375932724557\n",
            "num_topic:  7 Coherence:  0.3267058421249324 Jaccard:  0.42447409081641496 Perplexity:  37037.84018243344\n",
            "num_topic:  8 Coherence:  0.34431825526688253 Jaccard:  0.3680336473888281 Perplexity:  38428.386485963485\n",
            "num_topic:  9 Coherence:  0.31936696036819323 Jaccard:  0.34307143064908413 Perplexity:  46015.56442912667\n",
            "num_topic:  10 Coherence:  0.32213571083033077 Jaccard:  0.3265723540064453 Perplexity:  110684.65574950636\n",
            "num_topic:  11 Coherence:  0.33291721604131225 Jaccard:  0.3213762686191022 Perplexity:  114314.54251754786\n",
            "num_topic:  12 Coherence:  0.33425632014067774 Jaccard:  0.2876168389259063 Perplexity:  113724.47483893906\n",
            "num_topic:  13 Coherence:  0.32836353706931226 Jaccard:  0.2772779361251824 Perplexity:  153945.61024117155\n",
            "num_topic:  14 Coherence:  0.32857450786168535 Jaccard:  0.27330008734656425 Perplexity:  195535.29187071216\n",
            "num_topic:  15 Coherence:  0.3317453537667456 Jaccard:  0.2555428465597776 Perplexity:  168648.63852648815\n",
            "num_topic:  16 Coherence:  0.3247200558486879 Jaccard:  0.24804440533550856 Perplexity:  325487.0303077249\n",
            "num_topic:  17 Coherence:  0.3251909637501935 Jaccard:  0.23900191821880945 Perplexity:  549499.8303970208\n",
            "num_topic:  18 Coherence:  0.3380497214657677 Jaccard:  0.23327910734143123 Perplexity:  525975.910271359\n",
            "num_topic:  19 Coherence:  0.33435852388681975 Jaccard:  0.20800077603686587 Perplexity:  594360.715496438\n",
            "num_topic:  20 Coherence:  0.3297812076605383 Jaccard:  0.209261115824096 Perplexity:  874581.0015994832\n",
            "num_topic:  21 Coherence:  0.33213600204555876 Jaccard:  0.18875789080869598 Perplexity:  807777.6774913891\n",
            "num_topic:  22 Coherence:  0.3197321890482641 Jaccard:  0.19449533160325364 Perplexity:  1362369.914471188\n",
            "num_topic:  23 Coherence:  0.3136080149288492 Jaccard:  0.1657443568002022 Perplexity:  1653667.4528694076\n",
            "num_topic:  24 Coherence:  0.34045228136438727 Jaccard:  0.16414315223217765 Perplexity:  2000839.059363133\n",
            "num_topic:  25 Coherence:  0.3262928267247756 Jaccard:  0.16045108825711948 Perplexity:  2359190.0422909907\n",
            "num_topic:  26 Coherence:  0.33296312120137106 Jaccard:  0.14955979224526086 Perplexity:  3149831.8634917545\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/sklearn/metrics/_classification.py:1344: UndefinedMetricWarning: Jaccard is ill-defined and being set to 0.0 due to no true or predicted samples. Use `zero_division` parameter to control this behavior.\n",
            "  _warn_prf(average, modifier, msg_start, len(result))\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "num_topic:  27 Coherence:  0.33421700061807935 Jaccard:  0.13978840195453063 Perplexity:  2624011.7266943404\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/sklearn/metrics/_classification.py:1344: UndefinedMetricWarning: Jaccard is ill-defined and being set to 0.0 due to no true or predicted samples. Use `zero_division` parameter to control this behavior.\n",
            "  _warn_prf(average, modifier, msg_start, len(result))\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "num_topic:  28 Coherence:  0.33069126540438337 Jaccard:  0.131587157472573 Perplexity:  2669800.951453526\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/sklearn/metrics/_classification.py:1344: UndefinedMetricWarning: Jaccard is ill-defined and being set to 0.0 due to no true or predicted samples. Use `zero_division` parameter to control this behavior.\n",
            "  _warn_prf(average, modifier, msg_start, len(result))\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "num_topic:  29 Coherence:  0.3250647919147073 Jaccard:  0.1425050239126077 Perplexity:  5149477.36941325\n"
          ]
        }
      ],
      "source": [
        "coh0 = 0\n",
        "js0 = 100\n",
        "ppx0 = 100\n",
        "num = 1\n",
        "for topic_num in range (5, 30):\n",
        "  lda = decomposition.LatentDirichletAllocation (n_components=topic_num, learning_method='online', learning_offset=50, n_jobs=-1, random_state=111)\n",
        "  # n_components is the number of topics\n",
        "\n",
        "  w1 = lda.fit_transform (tf_vectors)\n",
        "  #h1 = lda.components_\n",
        "\n",
        "  ppx = lda.perplexity(w1,  sub_sampling=False)\n",
        "\n",
        "  coh = mean (metric_coherence_gensim(measure='c_v', top_n=30, topic_word_distrib=lda.components_, vocab=np.array([x for x in vectorizer_tf.vocabulary_.keys()]), texts=tok))\n",
        "\n",
        "  l = len (lda.components_)\n",
        "  n = 0\n",
        "  js = 0\n",
        "  for i in range(0, l-1):\n",
        "    topic1 = [1 if x>1 else 0 for x in lda.components_[i]]\n",
        "    for j in range(i+1, l):\n",
        "      topic2 = [1 if x>1 else 0 for x in lda.components_[j]]\n",
        "      js += jaccard_score (topic1, topic2)\n",
        "      n += 1\n",
        "  js /= n\n",
        "\n",
        "  if js > js0 and coh < coh0 and ppx > ppx0:\n",
        "    pass\n",
        "  else:\n",
        "    num = topic_num\n",
        "    js0 = js\n",
        "    coh0 = coh\n",
        "    ppx0 = ppx\n",
        "\n",
        "  print ('num_topic: ', topic_num, 'Coherence: ', coh, 'Jaccard: ', js, 'Perplexity: ', ppx)\n",
        "#print ('BEST: ', 'num_topic: ', num, 'Coherence: ', coh0, 'Jaccard: ', js0, 'Perplexity: ', ppx0)"
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "ZpP7rnDqcKff"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "vTL6wrYHmLoX"
      },
      "source": [
        "# Topic Modeling"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "kYgcPNdUluRk",
        "outputId": "2a0cc25b-aa88-4474-ea0e-2348149a49b2"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: pyLDAvis==3.4.0 in /usr/local/lib/python3.10/dist-packages (3.4.0)\n",
            "Requirement already satisfied: numpy>=1.22.0 in /usr/local/lib/python3.10/dist-packages (from pyLDAvis==3.4.0) (1.23.5)\n",
            "Requirement already satisfied: scipy in /usr/local/lib/python3.10/dist-packages (from pyLDAvis==3.4.0) (1.11.2)\n",
            "Requirement already satisfied: pandas>=1.3.4 in /usr/local/lib/python3.10/dist-packages (from pyLDAvis==3.4.0) (1.5.3)\n",
            "Requirement already satisfied: joblib>=1.2.0 in /usr/local/lib/python3.10/dist-packages (from pyLDAvis==3.4.0) (1.3.2)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from pyLDAvis==3.4.0) (3.1.2)\n",
            "Requirement already satisfied: numexpr in /usr/local/lib/python3.10/dist-packages (from pyLDAvis==3.4.0) (2.8.5)\n",
            "Requirement already satisfied: funcy in /usr/local/lib/python3.10/dist-packages (from pyLDAvis==3.4.0) (2.0)\n",
            "Requirement already satisfied: scikit-learn>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from pyLDAvis==3.4.0) (1.2.2)\n",
            "Requirement already satisfied: gensim in /usr/local/lib/python3.10/dist-packages (from pyLDAvis==3.4.0) (4.3.2)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.10/dist-packages (from pyLDAvis==3.4.0) (67.7.2)\n",
            "Requirement already satisfied: python-dateutil>=2.8.1 in /usr/local/lib/python3.10/dist-packages (from pandas>=1.3.4->pyLDAvis==3.4.0) (2.8.2)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.10/dist-packages (from pandas>=1.3.4->pyLDAvis==3.4.0) (2023.3.post1)\n",
            "Requirement already satisfied: threadpoolctl>=2.0.0 in /usr/local/lib/python3.10/dist-packages (from scikit-learn>=1.0.0->pyLDAvis==3.4.0) (3.2.0)\n",
            "Requirement already satisfied: smart-open>=1.8.1 in /usr/local/lib/python3.10/dist-packages (from gensim->pyLDAvis==3.4.0) (6.4.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->pyLDAvis==3.4.0) (2.1.3)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.8.1->pandas>=1.3.4->pyLDAvis==3.4.0) (1.16.0)\n"
          ]
        }
      ],
      "source": [
        "!pip install pyLDAvis==3.4.0"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "zn6zDCOzluTB"
      },
      "outputs": [],
      "source": [
        "import pyLDAvis\n",
        "import pyLDAvis.sklearn"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "jmnWjExZluXG",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "b80a3fab-7d36-4637-9297-2f99c8e20e37"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ],
      "source": [
        "lda = decomposition.LatentDirichletAllocation (n_components=8, learning_method='online', learning_offset=50, n_jobs=-1, random_state=111)\n",
        "# n_components is the number of topics\n",
        "\n",
        "w1 = lda.fit_transform (tf_vectors)\n",
        "h1 = lda.components_"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "91PQhE4TluZI",
        "outputId": "ce8e636d-8730-4b6f-d036-3edd141327f9"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ],
      "source": [
        "import pickle\n",
        "with open(\"/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/lda_patent.pk\",\"wb\") as f1:\n",
        "    pickle.dump (lda, f1)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "TTughGF6luck",
        "outputId": "93321074-1501-4cbb-e560-a82868a1dd6c"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ],
      "source": [
        "import pickle\n",
        "lda = decomposition.LatentDirichletAllocation (n_components=8, learning_method='online', learning_offset=50, n_jobs=-1, random_state=111)\n",
        "with open(\"/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/lda_patent.pk\",\"rb\") as f1:\n",
        "    lda = pickle.load (f1)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "JGyDq4fpj5os",
        "outputId": "f540b075-248f-483a-f640-3eb5159b3948"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ],
      "source": [
        "#pyLDAvis.enable_notebook()\n",
        "#pyLDAvis.sklearn.prepare(lda, tf_vectors, vectorizer_tf, mds='tsne')"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "WIs07MaqhJsG"
      },
      "source": [
        "What did I do to make this work?\n",
        "\n",
        "I installed pyLDAvis, but didn't import it!\n",
        "\n",
        "I went to usr/local/lib/python3.10/dist-packages/pyLDAvis/sklearn.py\n",
        "and changed get_feature_names() to get_feature_names_out()\n",
        "\n",
        "saved it!\n",
        "Then imported pyLDAvis and pyLDAvis.sklearn"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "f5j2MPpArouO",
        "outputId": "1ba29fa2-2ed8-4c7a-98a1-1a52f0c1990f"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ],
      "source": [
        "w1 = lda.transform (tf_vectors)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "KyVJSp5XrpAE",
        "outputId": "d327aa1f-60a2-40ad-e30a-3812cbbd6d5b"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(5108, 8)"
            ]
          },
          "metadata": {},
          "execution_count": 44
        }
      ],
      "source": [
        "w1.shape"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "-2VMWHDNtO_v",
        "outputId": "6065a6c9-2fed-488b-da86-4d45dc1de6b9"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ],
      "source": [
        "text = []\n",
        "topic = []\n",
        "probabilit = []\n",
        "for i in range(len(idx)):\n",
        "  text.append (str(data[idx[i]]))\n",
        "  t = np.argmax (w1[i,:])\n",
        "  topic.append (t)\n",
        "  probabilit.append (w1[i,t])\n",
        "probabilities = pd.DataFrame (data= {'Text':text,'Topic':topic,'Probability':probabilit})"
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "0lbr7iWjFPbp"
      },
      "execution_count": 2,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "6skxozvjtPgQ",
        "outputId": "b5bd6fee-db38-491e-9bc0-7a198c76f6dd"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Topic: Number:\n",
            "topic 0      266\n",
            "topic 1      391\n",
            "topic 2      1310\n",
            "topic 3      596\n",
            "topic 4      260\n",
            "topic 5      1512\n",
            "topic 6      175\n",
            "topic 7      598\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ],
      "source": [
        "print('Topic:','Number:')\n",
        "for i in range(8):\n",
        "  print('topic',i,'    ',list(probabilities['Topic']).count(i))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "kqzUegLQtJlC",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "99201441-ceb7-410a-883c-bbaeb986f67c"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ],
      "source": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "PUi5wtePiGJj",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "5549010f-6442-4521-f778-ba3a9dc2ce4c"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ],
      "source": [
        "# topic similarity matrix"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import numpy as np\n",
        "import matplotlib.pyplot as plt\n",
        "import seaborn as sns\n",
        "from sklearn.metrics.pairwise import cosine_similarity\n",
        "\n",
        "# Assuming lda_model is your trained LDA model\n",
        "# Normalize the topic-word distribution\n",
        "topic_word_distributions = lda.components_ / lda.components_.sum(axis=1)[:, np.newaxis]\n",
        "\n",
        "# Compute the cosine similarity matrix\n",
        "topic_similarity_matrix = cosine_similarity(topic_word_distributions)\n",
        "\n",
        "# Create a heatmap\n",
        "plt.figure(figsize=(25, 15))\n",
        "sns.set(font_scale=1)\n",
        "sns.heatmap(\n",
        "    topic_similarity_matrix,\n",
        "    annot=True,\n",
        "    fmt=\".2f\",\n",
        "    cmap=\"coolwarm\",\n",
        "    cbar=True,\n",
        "    square=True,\n",
        "    annot_kws={\"size\": 8},\n",
        ")\n",
        "plt.title(\"Topic Similarity Matrix\")\n",
        "plt.xlabel(\"Topic ID\")\n",
        "plt.ylabel(\"Topic ID\")\n",
        "\n",
        "# Save the figure\n",
        "plt.savefig(f'/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/topic_similarity_matrix_patent.png', dpi=600)\n",
        "\n",
        "plt.show()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 626
        },
        "id": "2uevrgCwh9Ys",
        "outputId": "e1dbc124-2e18-4c7f-e784-fe919134a14a"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 2500x1500 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "7TQVuAlzh9bj"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import numpy as np\n",
        "import matplotlib.pyplot as plt\n",
        "import seaborn as sns\n",
        "from scipy.cluster.hierarchy import linkage, dendrogram, fcluster\n",
        "from sklearn.metrics.pairwise import cosine_similarity\n",
        "\n",
        "# Assuming lda_model is your trained LDA model\n",
        "topic_word_distributions = lda.components_ / lda.components_.sum(axis=1)[:, np.newaxis]\n",
        "\n",
        "# Compute the cosine similarity matrix\n",
        "topic_similarity_matrix = cosine_similarity(topic_word_distributions)\n",
        "\n",
        "# Perform hierarchical clustering\n",
        "linkage_matrix = linkage(1 - topic_similarity_matrix, method=\"average\")\n",
        "\n",
        "# Plot the dendrogram\n",
        "plt.figure(figsize=(15, 10))\n",
        "dendrogram(linkage_matrix, color_threshold=0.5)\n",
        "plt.title(\"Hierarchical Clustering of Topics\")\n",
        "plt.xlabel(\"Topic\")\n",
        "plt.ylabel(\"Distance\")\n",
        "plt.tight_layout()\n",
        "\n",
        "# Save the figure in high resolution\n",
        "plt.savefig(f'/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/topic_clustering_dendrogram_patent.png', dpi=600)\n",
        "\n",
        "plt.show()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 489
        },
        "id": "Jxzf-GUoh9fU",
        "outputId": "a9321163-e9da-45c2-aceb-789ddae96dd3"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1500x1000 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "MeqPAIGziGLK"
      },
      "outputs": [],
      "source": []
    },
    {
      "cell_type": "code",
      "source": [
        "# get_top_keywords"
      ],
      "metadata": {
        "id": "YLvp3I17jJcJ"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def get_top_keywords(lda_model, vectorizer, n_words=50):\n",
        "    terms = vectorizer.get_feature_names_out()\n",
        "    topic_keywords = []\n",
        "\n",
        "    for topic_idx, topic in enumerate(lda.components_):\n",
        "        top_keywords_idx = topic.argsort()[::-1][:n_words]\n",
        "        top_keywords = [(terms[i], topic[i]) for i in top_keywords_idx]\n",
        "        topic_keywords.append(top_keywords)\n",
        "\n",
        "    return topic_keywords\n",
        "\n",
        "top_keywords = get_top_keywords(lda, vectorizer_tf, n_words=50)\n",
        "\n",
        "# To display the topics with their keywords and scores\n",
        "with open(f\"/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/top_keywords_patent.txt\", \"w\") as f:\n",
        "    for idx, keywords in enumerate(top_keywords):\n",
        "        f.write(f\"Topic {idx}:\\n\")\n",
        "        print(f\"Topic {idx}:\")\n",
        "        for word, score in keywords:\n",
        "            f.write(f\"{word}, \")\n",
        "            print(f\"{word}\", end=\", \")\n",
        "        f.write(\"\\n\\n\")\n",
        "        print(\"\\n\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "QbvhB8uijJhu",
        "outputId": "95bf8f32-811b-4a19-d47d-64ee538dc927"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Topic 0:\n",
            "detection, method, sample, detect, bacteriophage, use, test, invention, kit, reaction, probe, fluorescent, specific, microorganism, control, nano, base, positive, enzyme, result, identification, material, mixture, determine, biological, m13, label, signal, time, presence, phage, sensitivity, concentration, contain, carry, rapid, reagent, internal, assay, agent, amplification, relate, substrate, accord, primer, animal, sensor, cross, fragment, measure, \n",
            "\n",
            "Topic 1:\n",
            "device, model, air, water, filter, utility, body, arrange, bacteriophage, plate, connect, provide, disclose, end, box, include, pipe, tank, equip, fix, set, use, layer, support, cover, shell, gas, inner, structure, surface, ion, tube, storage, disinfection, membrane, case, frame, rod, control, comprise, inlet, base, upper, second, outer, place, wall, form, purification, seal, \n",
            "\n",
            "Topic 2:\n",
            "protein, phage, peptide, cell, method, gene, polypeptide, target, invention, bind, use, recombinant, display, expression, vector, provide, sequence, library, screen, molecule, express, obtain, relate, present, site, cancer, application, plasmid, specific, construct, comprise, disclose, high, fusion, base, contain, identify, escherichia, coli, produce, affinity, tumor, acid, amino, domain, activity, prepare, ligand, molecular, encode, \n",
            "\n",
            "Topic 3:\n",
            "method, phage, preparation, high, invention, culture, material, disclose, solution, low, obtain, step, prepare, powder, temperature, follow, water, effect, application, improve, use, efficiency, liquid, field, comprise, process, time, medium, add, carry, provide, production, good, layer, cost, technical, reduce, cavity, bacteriophage, biological, dry, separation, simple, medicine, fermentation, environment, adopt, advantage, heat, weight, \n",
            "\n",
            "Topic 4:\n",
            "sequence, acid, nucleic, genome, dna, comprise, gene, method, polymerase, bacteriophage, amino, phage, nucleotide, use, fragment, invention, encode, host, control, provide, bacterium, contain, rna, recombination, strand, amplification, bacterial, product, present, produce, mutant, derive, type, pcr, select, second, specific, step, include, polynucleotide, primer, genomic, isolate, protein, disclose, group, reaction, artificial, relate, enzyme, \n",
            "\n",
            "Topic 5:\n",
            "bacteriophage, invention, composition, bacteria, use, phage, method, strain, present, application, relate, bacterial, treat, disease, prevent, infection, provide, treatment, antibiotic, salmonella, comprise, coli, cause, escherichia, number, activity, resistant, agent, novel, host, pathogenic, antibacterial, food, effect, staphylococcus, specific, disclose, kill, preparation, contain, feed, control, lytic, include, prevention, culture, infectious, infect, preservation, active, \n",
            "\n",
            "Topic 6:\n",
            "virus, particle, say, comprise, protein, composition, bacteriophage, method, like, vaccine, invention, surface, present, provide, modify, capsid, type, influenza, non, viral, include, form, peptide, antigen, nanoparticle, use, bind, relate, group, component, embodiment, contain, response, substance, accord, polymer, coat, immune, select, delivery, produce, complex, consist, carrier, link, standard, epitope, cell, process, attach, \n",
            "\n",
            "Topic 7:\n",
            "antibody, chain, human, anti, single, library, invention, application, phage, sequence, monoclonal, region, method, use, screen, display, antigen, obtain, variable, preparation, heavy, cell, high, specific, technology, disclose, affinity, amino, provide, acid, humanize, light, domain, nano, bind, drug, neutralize, prepare, construct, epitope, fragment, tumor, relate, scfv, disease, field, mouse, comprise, immune, combine, \n",
            "\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "YwKFu0VbjJkc"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Emergent topics"
      ],
      "metadata": {
        "id": "XOHiCtECjJnK"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from wordcloud import WordCloud\n",
        "import numpy as np\n",
        "import matplotlib.pyplot as plt\n",
        "\n",
        "# Word Clouds for topics\n",
        "def plot_wordcloud(lda, topic_id, ax, n_words=50):\n",
        "    terms = vectorizer_tf.get_feature_names_out()\n",
        "    word_probs = {terms[i]: prob for i, prob in enumerate(lda.components_[topic_id])}\n",
        "    wc = WordCloud(background_color='white', max_words=n_words).generate_from_frequencies(word_probs)\n",
        "    ax.imshow(wc, interpolation='bilinear')\n",
        "    ax.axis('off')\n",
        "    ax.set_title(f\"Topic {topic_id}\", fontweight='bold')  # Bold title for each subplot\n",
        "\n",
        "# Assuming n_topics to be the number of topics you've chosen\n",
        "n_topics = 8  # Make sure this matches the number of topics in lda_model\n",
        "\n",
        "# Calculate the number of rows needed\n",
        "n_rows = int(np.ceil(n_topics / 4))\n",
        "\n",
        "fig, axes = plt.subplots(n_rows, 4, figsize=(20, 4 * n_rows))\n",
        "\n",
        "# Flatten the array and truncate it to match the number of topics\n",
        "axes_flat = axes.flatten()[:n_topics]\n",
        "\n",
        "for ax, topic_id in zip(axes_flat, range(n_topics)):\n",
        "    plot_wordcloud(lda, topic_id, ax)\n",
        "\n",
        "# Remove extra subplots\n",
        "for idx in range(n_topics, len(axes.flatten())):\n",
        "    fig.delaxes(axes.flatten()[idx])\n",
        "\n",
        "plt.suptitle(\"Word Clouds for LDA Topics\", fontweight='bold')  # Bold main title\n",
        "plt.tight_layout()\n",
        "plt.savefig(f'/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/wordclouds_patent.png', dpi=600)  # Use raw string for path\n",
        "plt.show()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 579
        },
        "id": "QWyTazRCjJp-",
        "outputId": "35437cf3-6ec5-446c-cc5d-dfb816a02b92"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n",
            "/usr/local/lib/python3.10/dist-packages/wordcloud/wordcloud.py:106: MatplotlibDeprecationWarning: The get_cmap function was deprecated in Matplotlib 3.7 and will be removed two minor releases later. Use ``matplotlib.colormaps[name]`` or ``matplotlib.colormaps.get_cmap(obj)`` instead.\n",
            "  self.colormap = plt.cm.get_cmap(colormap)\n",
            "/usr/local/lib/python3.10/dist-packages/wordcloud/wordcloud.py:106: MatplotlibDeprecationWarning: The get_cmap function was deprecated in Matplotlib 3.7 and will be removed two minor releases later. Use ``matplotlib.colormaps[name]`` or ``matplotlib.colormaps.get_cmap(obj)`` instead.\n",
            "  self.colormap = plt.cm.get_cmap(colormap)\n",
            "/usr/local/lib/python3.10/dist-packages/wordcloud/wordcloud.py:106: MatplotlibDeprecationWarning: The get_cmap function was deprecated in Matplotlib 3.7 and will be removed two minor releases later. Use ``matplotlib.colormaps[name]`` or ``matplotlib.colormaps.get_cmap(obj)`` instead.\n",
            "  self.colormap = plt.cm.get_cmap(colormap)\n",
            "/usr/local/lib/python3.10/dist-packages/wordcloud/wordcloud.py:106: MatplotlibDeprecationWarning: The get_cmap function was deprecated in Matplotlib 3.7 and will be removed two minor releases later. Use ``matplotlib.colormaps[name]`` or ``matplotlib.colormaps.get_cmap(obj)`` instead.\n",
            "  self.colormap = plt.cm.get_cmap(colormap)\n",
            "/usr/local/lib/python3.10/dist-packages/wordcloud/wordcloud.py:106: MatplotlibDeprecationWarning: The get_cmap function was deprecated in Matplotlib 3.7 and will be removed two minor releases later. Use ``matplotlib.colormaps[name]`` or ``matplotlib.colormaps.get_cmap(obj)`` instead.\n",
            "  self.colormap = plt.cm.get_cmap(colormap)\n",
            "/usr/local/lib/python3.10/dist-packages/wordcloud/wordcloud.py:106: MatplotlibDeprecationWarning: The get_cmap function was deprecated in Matplotlib 3.7 and will be removed two minor releases later. Use ``matplotlib.colormaps[name]`` or ``matplotlib.colormaps.get_cmap(obj)`` instead.\n",
            "  self.colormap = plt.cm.get_cmap(colormap)\n",
            "/usr/local/lib/python3.10/dist-packages/wordcloud/wordcloud.py:106: MatplotlibDeprecationWarning: The get_cmap function was deprecated in Matplotlib 3.7 and will be removed two minor releases later. Use ``matplotlib.colormaps[name]`` or ``matplotlib.colormaps.get_cmap(obj)`` instead.\n",
            "  self.colormap = plt.cm.get_cmap(colormap)\n",
            "/usr/local/lib/python3.10/dist-packages/wordcloud/wordcloud.py:106: MatplotlibDeprecationWarning: The get_cmap function was deprecated in Matplotlib 3.7 and will be removed two minor releases later. Use ``matplotlib.colormaps[name]`` or ``matplotlib.colormaps.get_cmap(obj)`` instead.\n",
            "  self.colormap = plt.cm.get_cmap(colormap)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 2000x800 with 8 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "t4jXPXETjJ_z"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Attach Discovered Topic Labels to Original scholar publications"
      ],
      "metadata": {
        "id": "TQt994bCjKCg"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "final_topics = lda.transform(tf_vectors)\n",
        "final_topics.shape"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "mYbNmPEnjKF_",
        "outputId": "43e3b3df-2001-41ce-9062-4f94044aaebc"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "(5108, 8)"
            ]
          },
          "metadata": {},
          "execution_count": 58
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_filtered[\"Topic N°\"] = final_topics.argmax(axis=1)\n",
        "df_filtered.head()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "qbPdazntuHNg",
        "outputId": "af0ea181-4dc0-406b-892d-b451c1957cd7"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                         # Jurisdiction Kind  \\\n",
              "Lens ID             Publication Year                           \n",
              "088-886-194-310-021 2006              6343           FR   A1   \n",
              "147-331-231-570-922 2007              2680           WO   A1   \n",
              "148-164-161-664-368 2007               111           WO   A1   \n",
              "161-684-752-020-329 2004              3085           JP    A   \n",
              "089-102-410-621-069 2004              3892           JP    A   \n",
              "...                                    ...          ...  ...   \n",
              "179-151-089-030-564 2019              6156           CZ   U1   \n",
              "014-594-233-943-253 2020              6024           CZ   U1   \n",
              "115-179-292-453-581 2006              6234           AU   A1   \n",
              "069-774-923-021-970 2005              6214           AU   A1   \n",
              "125-476-374-578-517 2017              4736           GB   D0   \n",
              "\n",
              "                                            Display Key Publication Date  \\\n",
              "Lens ID             Publication Year                                       \n",
              "088-886-194-310-021 2006                  FR 2878165 A1       26/05/2006   \n",
              "147-331-231-570-922 2007              WO 2007/083793 A1       26/07/2007   \n",
              "148-164-161-664-368 2007              WO 2007/114139 A1       11/10/2007   \n",
              "161-684-752-020-329 2004                JP 2004097032 A       02/04/2004   \n",
              "089-102-410-621-069 2004                JP 2004099465 A       02/04/2004   \n",
              "...                                                 ...              ...   \n",
              "179-151-089-030-564 2019                    CZ 33381 U1       12/11/2019   \n",
              "014-594-233-943-253 2020                    CZ 33918 U1       14/04/2020   \n",
              "115-179-292-453-581 2006              AU 2006/201041 A1       06/04/2006   \n",
              "069-774-923-021-970 2005              AU 2005/227384 A1       24/11/2005   \n",
              "125-476-374-578-517 2017                GB 201709104 D0       19/07/2017   \n",
              "\n",
              "                                     Application Number Application Date  \\\n",
              "Lens ID             Publication Year                                       \n",
              "088-886-194-310-021 2006                   FR 0412364 A       22/11/2004   \n",
              "147-331-231-570-922 2007                JP 2007050890 W       22/01/2007   \n",
              "148-164-161-664-368 2007                JP 2007056579 W       28/03/2007   \n",
              "161-684-752-020-329 2004                JP 2002260418 A       05/09/2002   \n",
              "089-102-410-621-069 2004                JP 2002260419 A       05/09/2002   \n",
              "...                                                 ...              ...   \n",
              "179-151-089-030-564 2019                 CZ 201936608 U       09/09/2019   \n",
              "014-594-233-943-253 2020                 CZ 202037223 U       06/02/2020   \n",
              "115-179-292-453-581 2006               AU 2006/201041 A       10/03/2006   \n",
              "069-774-923-021-970 2005               AU 2005/227384 A       27/10/2005   \n",
              "125-476-374-578-517 2017                 GB 201709104 A       07/06/2017   \n",
              "\n",
              "                                                        Priority Numbers  \\\n",
              "Lens ID             Publication Year                                       \n",
              "088-886-194-310-021 2006                                    FR 0412364 A   \n",
              "147-331-231-570-922 2007                                 JP 2006014314 A   \n",
              "148-164-161-664-368 2007                                 JP 2006105143 A   \n",
              "161-684-752-020-329 2004                                 JP 2002260418 A   \n",
              "089-102-410-621-069 2004                                 JP 2002260419 A   \n",
              "...                                                                  ...   \n",
              "179-151-089-030-564 2019                                  CZ 201936608 U   \n",
              "014-594-233-943-253 2020                                  CZ 202037223 U   \n",
              "115-179-292-453-581 2006              AU 2001/027834 A;;AU 2006/201041 A   \n",
              "069-774-923-021-970 2005              AU 2000/077021 A;;AU 2005/227384 A   \n",
              "125-476-374-578-517 2017                                  GB 201709104 A   \n",
              "\n",
              "                                     Earliest Priority Date  \\\n",
              "Lens ID             Publication Year                          \n",
              "088-886-194-310-021 2006                         22/11/2004   \n",
              "147-331-231-570-922 2007                         23/01/2006   \n",
              "148-164-161-664-368 2007                         06/04/2006   \n",
              "161-684-752-020-329 2004                         05/09/2002   \n",
              "089-102-410-621-069 2004                         05/09/2002   \n",
              "...                                                     ...   \n",
              "179-151-089-030-564 2019                         09/09/2019   \n",
              "014-594-233-943-253 2020                         06/02/2020   \n",
              "115-179-292-453-581 2006                         12/01/2001   \n",
              "069-774-923-021-970 2005                         14/09/2000   \n",
              "125-476-374-578-517 2017                         07/06/2017   \n",
              "\n",
              "                                                                                  Title  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              New (mutant) netrin-4, netrin-1, netrin-3, ant...   \n",
              "147-331-231-570-922 2007              PANNING METHOD UTILIZING PHOTOREACTIVE GROUP A...   \n",
              "148-164-161-664-368 2007               PHAGE DISPLAY BY NOVEL FILAMENTOUS BACTERIOPHAGE   \n",
              "161-684-752-020-329 2004              METHOD FOR MONITORING BACTERIUM UTILIZING CHIT...   \n",
              "089-102-410-621-069 2004              METHOD FOR CONTROLLING INSECT PEST WITH ALGINA...   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019              System for preparing samples and identifying a...   \n",
              "014-594-233-943-253 2020              Test kit to determine the antimicrobial biolog...   \n",
              "115-179-292-453-581 2006              The parenteral use of bacterial phage associat...   \n",
              "069-774-923-021-970 2005              The use of bacterial phage associated lysing e...   \n",
              "125-476-374-578-517 2017              Use of Bacteriophages to control blackleg and ...   \n",
              "\n",
              "                                                                               Abstract  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              (Mutant) netrin-4 protein (I) comprising at le...   \n",
              "147-331-231-570-922 2007              [PROBLEMS] To provide a method for ensuring th...   \n",
              "148-164-161-664-368 2007              [PROBLEMS] To provide a phage display vector w...   \n",
              "161-684-752-020-329 2004              <P>PROBLEM TO BE SOLVED: To develop a method f...   \n",
              "089-102-410-621-069 2004              <P>PROBLEM TO BE SOLVED: To develop a new defo...   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                                              .   \n",
              "014-594-233-943-253 2020                                                              .   \n",
              "115-179-292-453-581 2006                                                              .   \n",
              "069-774-923-021-970 2005                                                              .   \n",
              "125-476-374-578-517 2017                                                              .   \n",
              "\n",
              "                                                                             Applicants  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              CENTRE NAT RECH SCIENT;;I V S INST DES VAISSEA...   \n",
              "147-331-231-570-922 2007              UNIV TOYAMA NAT UNIV CORP;;HATANAKA YASUMARU;;...   \n",
              "148-164-161-664-368 2007                                               UCHIYAMA FUMIAKI   \n",
              "161-684-752-020-329 2004                                                      UNIV KOBE   \n",
              "089-102-410-621-069 2004                                                      UNIV KOBE   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                                UNIV MASARYKOVA   \n",
              "014-594-233-943-253 2020                                                MB PHARMA S R O   \n",
              "115-179-292-453-581 2006              NEW HORIZONS DIAGNOSTICS CORPORATION;;UNIV ROC...   \n",
              "069-774-923-021-970 2005                                   NEW HORIZONS DIAGNOSTICS INC   \n",
              "125-476-374-578-517 2017                                 AGRI-FOOD AND BIOSCIENCES INST   \n",
              "\n",
              "                                                                              Inventors  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006                                    PLOUET JEAN;;ALEMANY MONICA   \n",
              "147-331-231-570-922 2007                             HATANAKA YASUMARU;;SADAKANE YUTAKA   \n",
              "148-164-161-664-368 2007                                               UCHIYAMA FUMIAKI   \n",
              "161-684-752-020-329 2004              MAYAMA SHIGEYUKI;;TOSA YUKIO;;OTSU YASUNARI;;T...   \n",
              "089-102-410-621-069 2004              MAYAMA SHIGEYUKI;;TOSA YUKIO;;OTSU YASUNARI;;T...   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019              PANTŮČEK ROMAN;;ŠTVERÁKOVÁ DANA;;ŠEDO ONDREJ;;...   \n",
              "014-594-233-943-253 2020                                     MOŠA MAREK;;BENEŠÍK MARTIN   \n",
              "115-179-292-453-581 2006                             FISCHETTI VINCENT;;LOOMIS LAWRENCE   \n",
              "069-774-923-021-970 2005                             LOOMIS LAWRENCE;;FISCHETTI VINCENT   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                     Owners  \\\n",
              "Lens ID             Publication Year          \n",
              "088-886-194-310-021 2006                NaN   \n",
              "147-331-231-570-922 2007                NaN   \n",
              "148-164-161-664-368 2007                NaN   \n",
              "161-684-752-020-329 2004                NaN   \n",
              "089-102-410-621-069 2004                NaN   \n",
              "...                                     ...   \n",
              "179-151-089-030-564 2019                NaN   \n",
              "014-594-233-943-253 2020                NaN   \n",
              "115-179-292-453-581 2006                NaN   \n",
              "069-774-923-021-970 2005                NaN   \n",
              "125-476-374-578-517 2017                NaN   \n",
              "\n",
              "                                                                       URL  \\\n",
              "Lens ID             Publication Year                                         \n",
              "088-886-194-310-021 2006              https://lens.org/088-886-194-310-021   \n",
              "147-331-231-570-922 2007              https://lens.org/147-331-231-570-922   \n",
              "148-164-161-664-368 2007              https://lens.org/148-164-161-664-368   \n",
              "161-684-752-020-329 2004              https://lens.org/161-684-752-020-329   \n",
              "089-102-410-621-069 2004              https://lens.org/089-102-410-621-069   \n",
              "...                                                                    ...   \n",
              "179-151-089-030-564 2019              https://lens.org/179-151-089-030-564   \n",
              "014-594-233-943-253 2020              https://lens.org/014-594-233-943-253   \n",
              "115-179-292-453-581 2006              https://lens.org/115-179-292-453-581   \n",
              "069-774-923-021-970 2005              https://lens.org/069-774-923-021-970   \n",
              "125-476-374-578-517 2017              https://lens.org/125-476-374-578-517   \n",
              "\n",
              "                                           Document Type Has Full Text  \\\n",
              "Lens ID             Publication Year                                     \n",
              "088-886-194-310-021 2006              Patent Application            no   \n",
              "147-331-231-570-922 2007              Patent Application           yes   \n",
              "148-164-161-664-368 2007              Patent Application           yes   \n",
              "161-684-752-020-329 2004              Patent Application            no   \n",
              "089-102-410-621-069 2004              Patent Application            no   \n",
              "...                                                  ...           ...   \n",
              "179-151-089-030-564 2019                  Limited Patent            no   \n",
              "014-594-233-943-253 2020                  Limited Patent            no   \n",
              "115-179-292-453-581 2006              Patent Application            no   \n",
              "069-774-923-021-970 2005              Patent Application            no   \n",
              "125-476-374-578-517 2017              Patent Application            no   \n",
              "\n",
              "                                      Cites Patent Count  \\\n",
              "Lens ID             Publication Year                       \n",
              "088-886-194-310-021 2006                               1   \n",
              "147-331-231-570-922 2007                               1   \n",
              "148-164-161-664-368 2007                               1   \n",
              "161-684-752-020-329 2004                               0   \n",
              "089-102-410-621-069 2004                               0   \n",
              "...                                                  ...   \n",
              "179-151-089-030-564 2019                               0   \n",
              "014-594-233-943-253 2020                               0   \n",
              "115-179-292-453-581 2006                               0   \n",
              "069-774-923-021-970 2005                               0   \n",
              "125-476-374-578-517 2017                               0   \n",
              "\n",
              "                                      Cited by Patent Count  \\\n",
              "Lens ID             Publication Year                          \n",
              "088-886-194-310-021 2006                                  7   \n",
              "147-331-231-570-922 2007                                  2   \n",
              "148-164-161-664-368 2007                                  0   \n",
              "161-684-752-020-329 2004                                  1   \n",
              "089-102-410-621-069 2004                                  0   \n",
              "...                                                     ...   \n",
              "179-151-089-030-564 2019                                  0   \n",
              "014-594-233-943-253 2020                                  1   \n",
              "115-179-292-453-581 2006                                  1   \n",
              "069-774-923-021-970 2005                                  0   \n",
              "125-476-374-578-517 2017                                  0   \n",
              "\n",
              "                                      Simple Family Size  \\\n",
              "Lens ID             Publication Year                       \n",
              "088-886-194-310-021 2006                               1   \n",
              "147-331-231-570-922 2007                               2   \n",
              "148-164-161-664-368 2007                               5   \n",
              "161-684-752-020-329 2004                               2   \n",
              "089-102-410-621-069 2004                               2   \n",
              "...                                                  ...   \n",
              "179-151-089-030-564 2019                               1   \n",
              "014-594-233-943-253 2020                               1   \n",
              "115-179-292-453-581 2006                               1   \n",
              "069-774-923-021-970 2005                               1   \n",
              "125-476-374-578-517 2017                               1   \n",
              "\n",
              "                                      Extended Family Size  Sequence Count  \\\n",
              "Lens ID             Publication Year                                         \n",
              "088-886-194-310-021 2006                                21               0   \n",
              "147-331-231-570-922 2007                                 2               4   \n",
              "148-164-161-664-368 2007                                 5              38   \n",
              "161-684-752-020-329 2004                                 2               0   \n",
              "089-102-410-621-069 2004                                 2               0   \n",
              "...                                                    ...             ...   \n",
              "179-151-089-030-564 2019                                 1               0   \n",
              "014-594-233-943-253 2020                                 1               0   \n",
              "115-179-292-453-581 2006                                 1               0   \n",
              "069-774-923-021-970 2005                                 1               0   \n",
              "125-476-374-578-517 2017                                 1               0   \n",
              "\n",
              "                                                                    CPC Classifications  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006                      A61K38/18;;A61P9/00;;A61P19/00;;A61P25/00   \n",
              "147-331-231-570-922 2007                             C07D229/02;;G01N33/582;;G01N33/554   \n",
              "148-164-161-664-368 2007              C07K14/005;;C12N15/1037;;C12N2795/14122;;C12N1...   \n",
              "161-684-752-020-329 2004                                                      Y02A50/30   \n",
              "089-102-410-621-069 2004                                                            NaN   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                             C12N7/02;;C12Q1/70   \n",
              "014-594-233-943-253 2020                              C12N1/205;;C12Q1/70;;C12R2001/445   \n",
              "115-179-292-453-581 2006                                                      Y02A50/30   \n",
              "069-774-923-021-970 2005                                                      Y02A50/30   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                                                   IPCR Classifications  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              A61K38/17;;A61K39/395;;A61K48/00;;A61P9/00;;A6...   \n",
              "147-331-231-570-922 2007              G01N33/53;;C07D229/02;;G01N33/15;;G01N33/543;;...   \n",
              "148-164-161-664-368 2007              C12N15/09;;C07K14/005;;C12N1/21;;C12N7/00;;C12...   \n",
              "161-684-752-020-329 2004                                  C12N15/09;;C12Q1/04;;C12Q1/34   \n",
              "089-102-410-621-069 2004              C12N15/09;;A01N25/28;;A01N63/00;;C12N1/20;;C12...   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                             C12Q1/70;;C12N7/02   \n",
              "014-594-233-943-253 2020                                             C12Q1/70;;C12R1/44   \n",
              "115-179-292-453-581 2006                                                      A61K38/00   \n",
              "069-774-923-021-970 2005                                                      A61K38/00   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                     US Classifications  NPL Citation Count  \\\n",
              "Lens ID             Publication Year                                          \n",
              "088-886-194-310-021 2006                            NaN                   1   \n",
              "147-331-231-570-922 2007                            NaN                   2   \n",
              "148-164-161-664-368 2007                            NaN                  24   \n",
              "161-684-752-020-329 2004                            NaN                   0   \n",
              "089-102-410-621-069 2004                            NaN                   0   \n",
              "...                                                 ...                 ...   \n",
              "179-151-089-030-564 2019                            NaN                   0   \n",
              "014-594-233-943-253 2020                            NaN                   0   \n",
              "115-179-292-453-581 2006                            NaN                   0   \n",
              "069-774-923-021-970 2005                            NaN                   0   \n",
              "125-476-374-578-517 2017                            NaN                   0   \n",
              "\n",
              "                                      NPL Resolved Citation Count  \\\n",
              "Lens ID             Publication Year                                \n",
              "088-886-194-310-021 2006                                        1   \n",
              "147-331-231-570-922 2007                                        1   \n",
              "148-164-161-664-368 2007                                       22   \n",
              "161-684-752-020-329 2004                                        0   \n",
              "089-102-410-621-069 2004                                        0   \n",
              "...                                                           ...   \n",
              "179-151-089-030-564 2019                                        0   \n",
              "014-594-233-943-253 2020                                        0   \n",
              "115-179-292-453-581 2006                                        0   \n",
              "069-774-923-021-970 2005                                        0   \n",
              "125-476-374-578-517 2017                                        0   \n",
              "\n",
              "                                                                NPL Resolved Lens ID(s)  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006                                            085-906-838-714-934   \n",
              "147-331-231-570-922 2007                                            016-994-266-998-256   \n",
              "148-164-161-664-368 2007              050-417-296-901-112;;051-984-368-264-261;;058-...   \n",
              "161-684-752-020-329 2004                                                            NaN   \n",
              "089-102-410-621-069 2004                                                            NaN   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                                            NaN   \n",
              "014-594-233-943-253 2020                                                            NaN   \n",
              "115-179-292-453-581 2006                                                            NaN   \n",
              "069-774-923-021-970 2005                                                            NaN   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                                            NPL Resolved External ID(s)  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006                    11038171;;pmc2192657;;10.1083/jcb.151.2.221   \n",
              "147-331-231-570-922 2007                             10.2174/1568026023394182;;11944820   \n",
              "148-164-161-664-368 2007              16277371;;10.1021/cr000261r;;10.1006/jmbi.1999...   \n",
              "161-684-752-020-329 2004                                                            NaN   \n",
              "089-102-410-621-069 2004                                                            NaN   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                                            NaN   \n",
              "014-594-233-943-253 2020                                                            NaN   \n",
              "115-179-292-453-581 2006                                                            NaN   \n",
              "069-774-923-021-970 2005                                                            NaN   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                                                          NPL Citations  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              KOCH M ET AL: \"A NOVEL MEMBER OF THE NETRIN FA...   \n",
              "147-331-231-570-922 2007              HATANAKA Y. ET AL.: \"Photoaffinity Labeling in...   \n",
              "148-164-161-664-368 2007              KEHOE J.W. ET AL.: \"Filamentous phage display ...   \n",
              "161-684-752-020-329 2004                                                            NaN   \n",
              "089-102-410-621-069 2004                                                            NaN   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019                                                            NaN   \n",
              "014-594-233-943-253 2020                                                            NaN   \n",
              "115-179-292-453-581 2006                                                            NaN   \n",
              "069-774-923-021-970 2005                                                            NaN   \n",
              "125-476-374-578-517 2017                                                            NaN   \n",
              "\n",
              "                                      Legal Status  \\\n",
              "Lens ID             Publication Year                 \n",
              "088-886-194-310-021 2006              DISCONTINUED   \n",
              "147-331-231-570-922 2007                   PENDING   \n",
              "148-164-161-664-368 2007                   PENDING   \n",
              "161-684-752-020-329 2004                   EXPIRED   \n",
              "089-102-410-621-069 2004                   EXPIRED   \n",
              "...                                            ...   \n",
              "179-151-089-030-564 2019                    ACTIVE   \n",
              "014-594-233-943-253 2020                    ACTIVE   \n",
              "115-179-292-453-581 2006              DISCONTINUED   \n",
              "069-774-923-021-970 2005              DISCONTINUED   \n",
              "125-476-374-578-517 2017              DISCONTINUED   \n",
              "\n",
              "                                                                           Cleaned_Text  \\\n",
              "Lens ID             Publication Year                                                      \n",
              "088-886-194-310-021 2006              new (mutant) netrin-4, netrin-1, netrin-3, ant...   \n",
              "147-331-231-570-922 2007              panning method utilizing photoreactive group k...   \n",
              "148-164-161-664-368 2007              phage display novel filamentous bacteriophage[...   \n",
              "161-684-752-020-329 2004              method monitoring bacterium utilizing chitinou...   \n",
              "089-102-410-621-069 2004              method controlling insect pest alginate microb...   \n",
              "...                                                                                 ...   \n",
              "179-151-089-030-564 2019              system preparing samples identifying least one...   \n",
              "014-594-233-943-253 2020              test kit determine antimicrobial biological ac...   \n",
              "115-179-292-453-581 2006              parenteral use bacterial phage associated lysi...   \n",
              "069-774-923-021-970 2005              use bacterial phage associated lysing enzymes ...   \n",
              "125-476-374-578-517 2017                  use bacteriophages control blackleg soft rot.   \n",
              "\n",
              "                                      Topic N°  \n",
              "Lens ID             Publication Year            \n",
              "088-886-194-310-021 2006                     4  \n",
              "147-331-231-570-922 2007                     2  \n",
              "148-164-161-664-368 2007                     2  \n",
              "161-684-752-020-329 2004                     0  \n",
              "089-102-410-621-069 2004                     5  \n",
              "...                                        ...  \n",
              "179-151-089-030-564 2019                     0  \n",
              "014-594-233-943-253 2020                     5  \n",
              "115-179-292-453-581 2006                     5  \n",
              "069-774-923-021-970 2005                     5  \n",
              "125-476-374-578-517 2017                     5  \n",
              "\n",
              "[5108 rows x 33 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-cee12963-4820-454e-9698-b9942666d302\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th>#</th>\n",
              "      <th>Jurisdiction</th>\n",
              "      <th>Kind</th>\n",
              "      <th>Display Key</th>\n",
              "      <th>Publication Date</th>\n",
              "      <th>Application Number</th>\n",
              "      <th>Application Date</th>\n",
              "      <th>Priority Numbers</th>\n",
              "      <th>Earliest Priority Date</th>\n",
              "      <th>Title</th>\n",
              "      <th>Abstract</th>\n",
              "      <th>Applicants</th>\n",
              "      <th>Inventors</th>\n",
              "      <th>Owners</th>\n",
              "      <th>URL</th>\n",
              "      <th>Document Type</th>\n",
              "      <th>Has Full Text</th>\n",
              "      <th>Cites Patent Count</th>\n",
              "      <th>Cited by Patent Count</th>\n",
              "      <th>Simple Family Size</th>\n",
              "      <th>Extended Family Size</th>\n",
              "      <th>Sequence Count</th>\n",
              "      <th>CPC Classifications</th>\n",
              "      <th>IPCR Classifications</th>\n",
              "      <th>US Classifications</th>\n",
              "      <th>NPL Citation Count</th>\n",
              "      <th>NPL Resolved Citation Count</th>\n",
              "      <th>NPL Resolved Lens ID(s)</th>\n",
              "      <th>NPL Resolved External ID(s)</th>\n",
              "      <th>NPL Citations</th>\n",
              "      <th>Legal Status</th>\n",
              "      <th>Cleaned_Text</th>\n",
              "      <th>Topic N°</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Lens ID</th>\n",
              "      <th>Publication Year</th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>088-886-194-310-021</th>\n",
              "      <th>2006</th>\n",
              "      <td>6343</td>\n",
              "      <td>FR</td>\n",
              "      <td>A1</td>\n",
              "      <td>FR 2878165 A1</td>\n",
              "      <td>26/05/2006</td>\n",
              "      <td>FR 0412364 A</td>\n",
              "      <td>22/11/2004</td>\n",
              "      <td>FR 0412364 A</td>\n",
              "      <td>22/11/2004</td>\n",
              "      <td>New (mutant) netrin-4, netrin-1, netrin-3, ant...</td>\n",
              "      <td>(Mutant) netrin-4 protein (I) comprising at le...</td>\n",
              "      <td>CENTRE NAT RECH SCIENT;;I V S INST DES VAISSEA...</td>\n",
              "      <td>PLOUET JEAN;;ALEMANY MONICA</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/088-886-194-310-021</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>1</td>\n",
              "      <td>7</td>\n",
              "      <td>1</td>\n",
              "      <td>21</td>\n",
              "      <td>0</td>\n",
              "      <td>A61K38/18;;A61P9/00;;A61P19/00;;A61P25/00</td>\n",
              "      <td>A61K38/17;;A61K39/395;;A61K48/00;;A61P9/00;;A6...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>085-906-838-714-934</td>\n",
              "      <td>11038171;;pmc2192657;;10.1083/jcb.151.2.221</td>\n",
              "      <td>KOCH M ET AL: \"A NOVEL MEMBER OF THE NETRIN FA...</td>\n",
              "      <td>DISCONTINUED</td>\n",
              "      <td>new (mutant) netrin-4, netrin-1, netrin-3, ant...</td>\n",
              "      <td>4</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>147-331-231-570-922</th>\n",
              "      <th>2007</th>\n",
              "      <td>2680</td>\n",
              "      <td>WO</td>\n",
              "      <td>A1</td>\n",
              "      <td>WO 2007/083793 A1</td>\n",
              "      <td>26/07/2007</td>\n",
              "      <td>JP 2007050890 W</td>\n",
              "      <td>22/01/2007</td>\n",
              "      <td>JP 2006014314 A</td>\n",
              "      <td>23/01/2006</td>\n",
              "      <td>PANNING METHOD UTILIZING PHOTOREACTIVE GROUP A...</td>\n",
              "      <td>[PROBLEMS] To provide a method for ensuring th...</td>\n",
              "      <td>UNIV TOYAMA NAT UNIV CORP;;HATANAKA YASUMARU;;...</td>\n",
              "      <td>HATANAKA YASUMARU;;SADAKANE YUTAKA</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/147-331-231-570-922</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>yes</td>\n",
              "      <td>1</td>\n",
              "      <td>2</td>\n",
              "      <td>2</td>\n",
              "      <td>2</td>\n",
              "      <td>4</td>\n",
              "      <td>C07D229/02;;G01N33/582;;G01N33/554</td>\n",
              "      <td>G01N33/53;;C07D229/02;;G01N33/15;;G01N33/543;;...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>2</td>\n",
              "      <td>1</td>\n",
              "      <td>016-994-266-998-256</td>\n",
              "      <td>10.2174/1568026023394182;;11944820</td>\n",
              "      <td>HATANAKA Y. ET AL.: \"Photoaffinity Labeling in...</td>\n",
              "      <td>PENDING</td>\n",
              "      <td>panning method utilizing photoreactive group k...</td>\n",
              "      <td>2</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>148-164-161-664-368</th>\n",
              "      <th>2007</th>\n",
              "      <td>111</td>\n",
              "      <td>WO</td>\n",
              "      <td>A1</td>\n",
              "      <td>WO 2007/114139 A1</td>\n",
              "      <td>11/10/2007</td>\n",
              "      <td>JP 2007056579 W</td>\n",
              "      <td>28/03/2007</td>\n",
              "      <td>JP 2006105143 A</td>\n",
              "      <td>06/04/2006</td>\n",
              "      <td>PHAGE DISPLAY BY NOVEL FILAMENTOUS BACTERIOPHAGE</td>\n",
              "      <td>[PROBLEMS] To provide a phage display vector w...</td>\n",
              "      <td>UCHIYAMA FUMIAKI</td>\n",
              "      <td>UCHIYAMA FUMIAKI</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/148-164-161-664-368</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>yes</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>5</td>\n",
              "      <td>5</td>\n",
              "      <td>38</td>\n",
              "      <td>C07K14/005;;C12N15/1037;;C12N2795/14122;;C12N1...</td>\n",
              "      <td>C12N15/09;;C07K14/005;;C12N1/21;;C12N7/00;;C12...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>24</td>\n",
              "      <td>22</td>\n",
              "      <td>050-417-296-901-112;;051-984-368-264-261;;058-...</td>\n",
              "      <td>16277371;;10.1021/cr000261r;;10.1006/jmbi.1999...</td>\n",
              "      <td>KEHOE J.W. ET AL.: \"Filamentous phage display ...</td>\n",
              "      <td>PENDING</td>\n",
              "      <td>phage display novel filamentous bacteriophage[...</td>\n",
              "      <td>2</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>161-684-752-020-329</th>\n",
              "      <th>2004</th>\n",
              "      <td>3085</td>\n",
              "      <td>JP</td>\n",
              "      <td>A</td>\n",
              "      <td>JP 2004097032 A</td>\n",
              "      <td>02/04/2004</td>\n",
              "      <td>JP 2002260418 A</td>\n",
              "      <td>05/09/2002</td>\n",
              "      <td>JP 2002260418 A</td>\n",
              "      <td>05/09/2002</td>\n",
              "      <td>METHOD FOR MONITORING BACTERIUM UTILIZING CHIT...</td>\n",
              "      <td>&lt;P&gt;PROBLEM TO BE SOLVED: To develop a method f...</td>\n",
              "      <td>UNIV KOBE</td>\n",
              "      <td>MAYAMA SHIGEYUKI;;TOSA YUKIO;;OTSU YASUNARI;;T...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/161-684-752-020-329</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>2</td>\n",
              "      <td>2</td>\n",
              "      <td>0</td>\n",
              "      <td>Y02A50/30</td>\n",
              "      <td>C12N15/09;;C12Q1/04;;C12Q1/34</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>EXPIRED</td>\n",
              "      <td>method monitoring bacterium utilizing chitinou...</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>089-102-410-621-069</th>\n",
              "      <th>2004</th>\n",
              "      <td>3892</td>\n",
              "      <td>JP</td>\n",
              "      <td>A</td>\n",
              "      <td>JP 2004099465 A</td>\n",
              "      <td>02/04/2004</td>\n",
              "      <td>JP 2002260419 A</td>\n",
              "      <td>05/09/2002</td>\n",
              "      <td>JP 2002260419 A</td>\n",
              "      <td>05/09/2002</td>\n",
              "      <td>METHOD FOR CONTROLLING INSECT PEST WITH ALGINA...</td>\n",
              "      <td>&lt;P&gt;PROBLEM TO BE SOLVED: To develop a new defo...</td>\n",
              "      <td>UNIV KOBE</td>\n",
              "      <td>MAYAMA SHIGEYUKI;;TOSA YUKIO;;OTSU YASUNARI;;T...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/089-102-410-621-069</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>2</td>\n",
              "      <td>2</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>C12N15/09;;A01N25/28;;A01N63/00;;C12N1/20;;C12...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>EXPIRED</td>\n",
              "      <td>method controlling insect pest alginate microb...</td>\n",
              "      <td>5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>179-151-089-030-564</th>\n",
              "      <th>2019</th>\n",
              "      <td>6156</td>\n",
              "      <td>CZ</td>\n",
              "      <td>U1</td>\n",
              "      <td>CZ 33381 U1</td>\n",
              "      <td>12/11/2019</td>\n",
              "      <td>CZ 201936608 U</td>\n",
              "      <td>09/09/2019</td>\n",
              "      <td>CZ 201936608 U</td>\n",
              "      <td>09/09/2019</td>\n",
              "      <td>System for preparing samples and identifying a...</td>\n",
              "      <td>.</td>\n",
              "      <td>UNIV MASARYKOVA</td>\n",
              "      <td>PANTŮČEK ROMAN;;ŠTVERÁKOVÁ DANA;;ŠEDO ONDREJ;;...</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/179-151-089-030-564</td>\n",
              "      <td>Limited Patent</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>C12N7/02;;C12Q1/70</td>\n",
              "      <td>C12Q1/70;;C12N7/02</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>ACTIVE</td>\n",
              "      <td>system preparing samples identifying least one...</td>\n",
              "      <td>0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>014-594-233-943-253</th>\n",
              "      <th>2020</th>\n",
              "      <td>6024</td>\n",
              "      <td>CZ</td>\n",
              "      <td>U1</td>\n",
              "      <td>CZ 33918 U1</td>\n",
              "      <td>14/04/2020</td>\n",
              "      <td>CZ 202037223 U</td>\n",
              "      <td>06/02/2020</td>\n",
              "      <td>CZ 202037223 U</td>\n",
              "      <td>06/02/2020</td>\n",
              "      <td>Test kit to determine the antimicrobial biolog...</td>\n",
              "      <td>.</td>\n",
              "      <td>MB PHARMA S R O</td>\n",
              "      <td>MOŠA MAREK;;BENEŠÍK MARTIN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/014-594-233-943-253</td>\n",
              "      <td>Limited Patent</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>C12N1/205;;C12Q1/70;;C12R2001/445</td>\n",
              "      <td>C12Q1/70;;C12R1/44</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>ACTIVE</td>\n",
              "      <td>test kit determine antimicrobial biological ac...</td>\n",
              "      <td>5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>115-179-292-453-581</th>\n",
              "      <th>2006</th>\n",
              "      <td>6234</td>\n",
              "      <td>AU</td>\n",
              "      <td>A1</td>\n",
              "      <td>AU 2006/201041 A1</td>\n",
              "      <td>06/04/2006</td>\n",
              "      <td>AU 2006/201041 A</td>\n",
              "      <td>10/03/2006</td>\n",
              "      <td>AU 2001/027834 A;;AU 2006/201041 A</td>\n",
              "      <td>12/01/2001</td>\n",
              "      <td>The parenteral use of bacterial phage associat...</td>\n",
              "      <td>.</td>\n",
              "      <td>NEW HORIZONS DIAGNOSTICS CORPORATION;;UNIV ROC...</td>\n",
              "      <td>FISCHETTI VINCENT;;LOOMIS LAWRENCE</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/115-179-292-453-581</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>Y02A50/30</td>\n",
              "      <td>A61K38/00</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DISCONTINUED</td>\n",
              "      <td>parenteral use bacterial phage associated lysi...</td>\n",
              "      <td>5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>069-774-923-021-970</th>\n",
              "      <th>2005</th>\n",
              "      <td>6214</td>\n",
              "      <td>AU</td>\n",
              "      <td>A1</td>\n",
              "      <td>AU 2005/227384 A1</td>\n",
              "      <td>24/11/2005</td>\n",
              "      <td>AU 2005/227384 A</td>\n",
              "      <td>27/10/2005</td>\n",
              "      <td>AU 2000/077021 A;;AU 2005/227384 A</td>\n",
              "      <td>14/09/2000</td>\n",
              "      <td>The use of bacterial phage associated lysing e...</td>\n",
              "      <td>.</td>\n",
              "      <td>NEW HORIZONS DIAGNOSTICS INC</td>\n",
              "      <td>LOOMIS LAWRENCE;;FISCHETTI VINCENT</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/069-774-923-021-970</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>Y02A50/30</td>\n",
              "      <td>A61K38/00</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DISCONTINUED</td>\n",
              "      <td>use bacterial phage associated lysing enzymes ...</td>\n",
              "      <td>5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>125-476-374-578-517</th>\n",
              "      <th>2017</th>\n",
              "      <td>4736</td>\n",
              "      <td>GB</td>\n",
              "      <td>D0</td>\n",
              "      <td>GB 201709104 D0</td>\n",
              "      <td>19/07/2017</td>\n",
              "      <td>GB 201709104 A</td>\n",
              "      <td>07/06/2017</td>\n",
              "      <td>GB 201709104 A</td>\n",
              "      <td>07/06/2017</td>\n",
              "      <td>Use of Bacteriophages to control blackleg and ...</td>\n",
              "      <td>.</td>\n",
              "      <td>AGRI-FOOD AND BIOSCIENCES INST</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>https://lens.org/125-476-374-578-517</td>\n",
              "      <td>Patent Application</td>\n",
              "      <td>no</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>1</td>\n",
              "      <td>1</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>0</td>\n",
              "      <td>0</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>NaN</td>\n",
              "      <td>DISCONTINUED</td>\n",
              "      <td>use bacteriophages control blackleg soft rot.</td>\n",
              "      <td>5</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>5108 rows × 33 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-cee12963-4820-454e-9698-b9942666d302')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-cee12963-4820-454e-9698-b9942666d302 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-cee12963-4820-454e-9698-b9942666d302');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-83b197f8-a45f-48e0-b0b1-ec947bea73a7\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-83b197f8-a45f-48e0-b0b1-ec947bea73a7')\"\n",
              "            title=\"Suggest charts.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-83b197f8-a45f-48e0-b0b1-ec947bea73a7 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ]
          },
          "metadata": {},
          "execution_count": 59
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Save data to CSV and Pickle formats\n",
        "df_filtered.to_csv(f'/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/topic_probability_patent.csv', index=False)\n",
        "df_filtered.to_pickle(f'/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/topic_probability_patent.pkl')\n",
        "\n",
        "df_filtered.head()"
      ],
      "metadata": {
        "id": "wgl1pPqUvSsH"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_filtered['Topic N°'].value_counts()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "w2YM_CRFuSL2",
        "outputId": "02d574a0-5294-4c17-f23a-f07246bb9b09"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "5    1512\n",
              "2    1310\n",
              "7     598\n",
              "3     596\n",
              "1     391\n",
              "0     266\n",
              "4     260\n",
              "6     175\n",
              "Name: Topic N°, dtype: int64"
            ]
          },
          "metadata": {},
          "execution_count": 60
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "b8FNvESuuHRW"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Frequency Counting"
      ],
      "metadata": {
        "id": "523ItiHxuHU0"
      },
      "execution_count": 1,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Step 1: Group data by 'Publication Year' and 'topic', then count occurrences\n",
        "topic_counts_by_year = df_filtered.reset_index().groupby(['Publication Year', 'Topic N°']).size().unstack(fill_value=0)\n",
        "\n",
        "# Step 2: Calculate the total count of each topic\n",
        "total_counts = topic_counts_by_year.sum()\n",
        "\n",
        "# Step 3: Sort columns by total count\n",
        "sorted_columns = total_counts.sort_values(ascending=False).index\n",
        "topic_counts_by_year = topic_counts_by_year[sorted_columns]\n",
        "\n",
        "# Step 4: Add a row with the total count of each topic\n",
        "topic_counts_by_year.loc['Total'] = total_counts.loc[sorted_columns]\n",
        "\n",
        "# Save the DataFrame to CSV and pickle files\n",
        "topic_counts_by_year.to_csv(f'/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/topic_counts_by_year_patent.csv')\n",
        "topic_counts_by_year.to_pickle(f'/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/topic_counts_by_year_patent.pkl')\n",
        "\n",
        "# This will give you a DataFrame where each row is a year (plus a 'Total' row at the bottom),\n",
        "# and each column is the count of documents associated with a topic for that year (and the total count).\n",
        "\n",
        "# Display the updated DataFrame\n",
        "topic_counts_by_year"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 826
        },
        "id": "bH7Nrjr1uHZL",
        "outputId": "54c88c1f-360b-4e5f-8882-ba224feb61ff"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Topic N°             5     2    7    3    1    0    4    6\n",
              "Publication Year                                          \n",
              "2003                28    52    6    6    2    6   11    1\n",
              "2004                29    73   10    9    1    8   16   10\n",
              "2005                18    62   10    8    0    4    7    6\n",
              "2006                20    56   16   12    2    5   11    4\n",
              "2007                21    49   11    5    4   12   11    6\n",
              "2008                22    42   16   16    1    4    7    6\n",
              "2009                64    53   11   20    4    7    7    6\n",
              "2010                37    54   16   18    2    8   10   11\n",
              "2011                53    61   25   19    0    3   17   14\n",
              "2012                43    65   34   15    2    5    7    5\n",
              "2013                45    46   32   32    5   11   10    9\n",
              "2014                59    59   31   45    2    6   12    9\n",
              "2015                64    74   30   50   28    9    3    8\n",
              "2016                65    54   34   38   67    9   15    5\n",
              "2017                66    56   28   34   48   16   11   11\n",
              "2018               142    73   27   45   74   13   15    6\n",
              "2019               142    78   40   47   31   48   16   10\n",
              "2020               146    76   64   46   20   33   23    8\n",
              "2021               196    98   77   49   54   23   17   12\n",
              "2022               190   102   61   61   30   27   26   19\n",
              "2023                62    27   19   21   14    9    8    9\n",
              "Total             1512  1310  598  596  391  266  260  175"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-d05e69cf-867d-4732-b8b2-d58a5c2be719\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th>Topic N°</th>\n",
              "      <th>5</th>\n",
              "      <th>2</th>\n",
              "      <th>7</th>\n",
              "      <th>3</th>\n",
              "      <th>1</th>\n",
              "      <th>0</th>\n",
              "      <th>4</th>\n",
              "      <th>6</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Publication Year</th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>2003</th>\n",
              "      <td>28</td>\n",
              "      <td>52</td>\n",
              "      <td>6</td>\n",
              "      <td>6</td>\n",
              "      <td>2</td>\n",
              "      <td>6</td>\n",
              "      <td>11</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2004</th>\n",
              "      <td>29</td>\n",
              "      <td>73</td>\n",
              "      <td>10</td>\n",
              "      <td>9</td>\n",
              "      <td>1</td>\n",
              "      <td>8</td>\n",
              "      <td>16</td>\n",
              "      <td>10</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2005</th>\n",
              "      <td>18</td>\n",
              "      <td>62</td>\n",
              "      <td>10</td>\n",
              "      <td>8</td>\n",
              "      <td>0</td>\n",
              "      <td>4</td>\n",
              "      <td>7</td>\n",
              "      <td>6</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2006</th>\n",
              "      <td>20</td>\n",
              "      <td>56</td>\n",
              "      <td>16</td>\n",
              "      <td>12</td>\n",
              "      <td>2</td>\n",
              "      <td>5</td>\n",
              "      <td>11</td>\n",
              "      <td>4</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2007</th>\n",
              "      <td>21</td>\n",
              "      <td>49</td>\n",
              "      <td>11</td>\n",
              "      <td>5</td>\n",
              "      <td>4</td>\n",
              "      <td>12</td>\n",
              "      <td>11</td>\n",
              "      <td>6</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2008</th>\n",
              "      <td>22</td>\n",
              "      <td>42</td>\n",
              "      <td>16</td>\n",
              "      <td>16</td>\n",
              "      <td>1</td>\n",
              "      <td>4</td>\n",
              "      <td>7</td>\n",
              "      <td>6</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2009</th>\n",
              "      <td>64</td>\n",
              "      <td>53</td>\n",
              "      <td>11</td>\n",
              "      <td>20</td>\n",
              "      <td>4</td>\n",
              "      <td>7</td>\n",
              "      <td>7</td>\n",
              "      <td>6</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2010</th>\n",
              "      <td>37</td>\n",
              "      <td>54</td>\n",
              "      <td>16</td>\n",
              "      <td>18</td>\n",
              "      <td>2</td>\n",
              "      <td>8</td>\n",
              "      <td>10</td>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2011</th>\n",
              "      <td>53</td>\n",
              "      <td>61</td>\n",
              "      <td>25</td>\n",
              "      <td>19</td>\n",
              "      <td>0</td>\n",
              "      <td>3</td>\n",
              "      <td>17</td>\n",
              "      <td>14</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2012</th>\n",
              "      <td>43</td>\n",
              "      <td>65</td>\n",
              "      <td>34</td>\n",
              "      <td>15</td>\n",
              "      <td>2</td>\n",
              "      <td>5</td>\n",
              "      <td>7</td>\n",
              "      <td>5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2013</th>\n",
              "      <td>45</td>\n",
              "      <td>46</td>\n",
              "      <td>32</td>\n",
              "      <td>32</td>\n",
              "      <td>5</td>\n",
              "      <td>11</td>\n",
              "      <td>10</td>\n",
              "      <td>9</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2014</th>\n",
              "      <td>59</td>\n",
              "      <td>59</td>\n",
              "      <td>31</td>\n",
              "      <td>45</td>\n",
              "      <td>2</td>\n",
              "      <td>6</td>\n",
              "      <td>12</td>\n",
              "      <td>9</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2015</th>\n",
              "      <td>64</td>\n",
              "      <td>74</td>\n",
              "      <td>30</td>\n",
              "      <td>50</td>\n",
              "      <td>28</td>\n",
              "      <td>9</td>\n",
              "      <td>3</td>\n",
              "      <td>8</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2016</th>\n",
              "      <td>65</td>\n",
              "      <td>54</td>\n",
              "      <td>34</td>\n",
              "      <td>38</td>\n",
              "      <td>67</td>\n",
              "      <td>9</td>\n",
              "      <td>15</td>\n",
              "      <td>5</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2017</th>\n",
              "      <td>66</td>\n",
              "      <td>56</td>\n",
              "      <td>28</td>\n",
              "      <td>34</td>\n",
              "      <td>48</td>\n",
              "      <td>16</td>\n",
              "      <td>11</td>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2018</th>\n",
              "      <td>142</td>\n",
              "      <td>73</td>\n",
              "      <td>27</td>\n",
              "      <td>45</td>\n",
              "      <td>74</td>\n",
              "      <td>13</td>\n",
              "      <td>15</td>\n",
              "      <td>6</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2019</th>\n",
              "      <td>142</td>\n",
              "      <td>78</td>\n",
              "      <td>40</td>\n",
              "      <td>47</td>\n",
              "      <td>31</td>\n",
              "      <td>48</td>\n",
              "      <td>16</td>\n",
              "      <td>10</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2020</th>\n",
              "      <td>146</td>\n",
              "      <td>76</td>\n",
              "      <td>64</td>\n",
              "      <td>46</td>\n",
              "      <td>20</td>\n",
              "      <td>33</td>\n",
              "      <td>23</td>\n",
              "      <td>8</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2021</th>\n",
              "      <td>196</td>\n",
              "      <td>98</td>\n",
              "      <td>77</td>\n",
              "      <td>49</td>\n",
              "      <td>54</td>\n",
              "      <td>23</td>\n",
              "      <td>17</td>\n",
              "      <td>12</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2022</th>\n",
              "      <td>190</td>\n",
              "      <td>102</td>\n",
              "      <td>61</td>\n",
              "      <td>61</td>\n",
              "      <td>30</td>\n",
              "      <td>27</td>\n",
              "      <td>26</td>\n",
              "      <td>19</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2023</th>\n",
              "      <td>62</td>\n",
              "      <td>27</td>\n",
              "      <td>19</td>\n",
              "      <td>21</td>\n",
              "      <td>14</td>\n",
              "      <td>9</td>\n",
              "      <td>8</td>\n",
              "      <td>9</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>Total</th>\n",
              "      <td>1512</td>\n",
              "      <td>1310</td>\n",
              "      <td>598</td>\n",
              "      <td>596</td>\n",
              "      <td>391</td>\n",
              "      <td>266</td>\n",
              "      <td>260</td>\n",
              "      <td>175</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-d05e69cf-867d-4732-b8b2-d58a5c2be719')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-d05e69cf-867d-4732-b8b2-d58a5c2be719 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-d05e69cf-867d-4732-b8b2-d58a5c2be719');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-200bd599-72a7-4a2f-bf8c-40871ea1d2bf\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-200bd599-72a7-4a2f-bf8c-40871ea1d2bf')\"\n",
              "            title=\"Suggest charts.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-200bd599-72a7-4a2f-bf8c-40871ea1d2bf button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ]
          },
          "metadata": {},
          "execution_count": 61
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "CJD35-VmvEt_"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Evolution Curve for Each Topic"
      ],
      "metadata": {
        "id": "NoSWY_VxvEeB"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import matplotlib.pyplot as plt\n",
        "import pandas as pd\n",
        "\n",
        "# Read the DataFrame from the CSV file (assuming it's stored as 'topic_counts_by_year.csv')\n",
        "# Replace this line with your actual data if it's not in a CSV\n",
        "#topic_counts_by_year = pd.read_csv('topic_counts_by_year.csv', index_col='Publication Year')\n",
        "\n",
        "# Remove the 'Total' row if it exists\n",
        "if 'Total' in topic_counts_by_year.index:\n",
        "    topic_counts_by_year = topic_counts_by_year.drop(index=['Total'])\n",
        "\n",
        "# Sort columns by topic name\n",
        "topic_counts_by_year = topic_counts_by_year.sort_index(axis=1)\n",
        "\n",
        "# Define the number of topics (make sure this matches your data)\n",
        "n_topics = len(topic_counts_by_year.columns)\n",
        "\n",
        "# Calculate the number of rows needed for subplots\n",
        "n_rows = (n_topics + 3) // 4  # +4 for rounding up\n",
        "\n",
        "# Create a grid of subplots\n",
        "fig, axes = plt.subplots(n_rows, 4, figsize=(20, n_rows * 3.5))\n",
        "\n",
        "# Flatten the array to easily iterate over it\n",
        "axes_flat = axes.flatten()\n",
        "\n",
        "# Loop through each topic and plot its curve on a separate subplot\n",
        "for i, topic in enumerate(topic_counts_by_year.columns):\n",
        "    axes_flat[i].plot(\n",
        "        topic_counts_by_year.index,\n",
        "        topic_counts_by_year[topic]\n",
        "    )\n",
        "    axes_flat[i].set_title(f'Topic {topic}')\n",
        "    axes_flat[i].set_xlabel('Year')\n",
        "    axes_flat[i].set_ylabel('Frequency')\n",
        "    axes_flat[i].grid(True, which='both', linestyle='--', linewidth=0.5)\n",
        "\n",
        "# Remove extra subplots\n",
        "for i in range(n_topics, len(axes_flat)):\n",
        "    fig.delaxes(axes_flat[i])\n",
        "\n",
        "# Add a main title for the entire figure\n",
        "fig.suptitle('Evolution Curve for Each Topic', fontsize=16, fontweight='bold')\n",
        "\n",
        "# Save the figure\n",
        "plt.tight_layout(rect=[0, 0, 1, 0.96])  # Make room for the main title\n",
        "plt.savefig(f'/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/topic_evolution_curves_subplot_ordered_patent.png', dpi=600)\n",
        "\n",
        "# Show the figure\n",
        "plt.show()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 291
        },
        "id": "3GptximmvEAS",
        "outputId": "0a4d6a13-ba5b-4653-cf29-cc6863974711"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 2000x700 with 8 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "g_30fTTfuHc2"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Temporal Heatmaps: Display how topic proportions change over time."
      ],
      "metadata": {
        "id": "5NFfs0DfyENS"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import matplotlib.pyplot as plt\n",
        "import pandas as pd\n",
        "import seaborn as sns\n",
        "\n",
        "# Assume you already have topic_counts_by_year DataFrame\n",
        "\n",
        "# Remove the 'Total' row if it exists\n",
        "if 'Total' in topic_counts_by_year.index:\n",
        "    topic_counts_by_year = topic_counts_by_year.drop(index=['Total'])\n",
        "\n",
        "# Sort columns by topic name\n",
        "topic_counts_by_year = topic_counts_by_year.sort_index(axis=1)\n",
        "\n",
        "# Calculate the total count for each year (row-wise sum)\n",
        "total_counts_by_year = topic_counts_by_year.sum(axis=1)\n",
        "\n",
        "# Normalize frequencies to get proportions\n",
        "proportions_by_year = topic_counts_by_year.divide(total_counts_by_year, axis=0)\n",
        "\n",
        "# Create the heatmap\n",
        "plt.figure(figsize=(25, 10))\n",
        "sns.heatmap(proportions_by_year.fillna(0), annot=True, cmap=\"coolwarm\", cbar=True, xticklabels=True, yticklabels=True)\n",
        "\n",
        "# Add labels and title\n",
        "plt.title('Temporal Heatmap of Topic Proportions')\n",
        "plt.xlabel('Topics')\n",
        "plt.ylabel('Publication Year')\n",
        "\n",
        "# Save the figure\n",
        "plt.tight_layout()\n",
        "plt.savefig(f\"/content/drive/MyDrive/YORKU PROJECT/JUDE/BACTERIOPHAGE/temporal_heatmap_topic_proportions_patent.png\")  # Save the plot to a PNG file\n",
        "\n",
        "# Show the plot\n",
        "plt.show()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 353
        },
        "id": "mQsuGEqMyEPw",
        "outputId": "1c614d04-b158-45b8-9216-dc4631e44287"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/ipykernel/ipkernel.py:283: DeprecationWarning: `should_run_async` will not call `transform_cell` automatically in the future. Please pass the result to `transformed_cell` argument and any exception that happen during thetransform in `preprocessing_exc_tuple` in IPython 7.17 and above.\n",
            "  and should_run_async(code)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 2500x1000 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "vP4BEzb7yESP"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "nIrPnpeayEVy"
      },
      "execution_count": null,
      "outputs": []
    }
  ],
  "metadata": {
    "colab": {
      "provenance": [],
      "include_colab_link": true
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}